



US009181632B1

(12) **United States Patent**
Murgolo et al.

(10) **Patent No.:** US 9,181,632 B1
(45) **Date of Patent:** Nov. 10, 2015

(54) **C.DIFFICILE TOXIN B CROP DOMAIN PEPTIDES, ANTIBODIES AND COMPLEXES THEREOF**

(2013.01); **C12N 9/1051** (2013.01); **C30B 7/04** (2013.01); **C07K 2299/00** (2013.01); **C07K 2317/55** (2013.01)

(71) Applicant: **Merck Sharp & Dohme Corp.**, Rahway, NJ (US)

(72) Inventors: **Nicholas Murgolo**, Millington, NJ (US); **Lorraine Hernandez**, Warren, NJ (US); **Payal Sheth**, Somerset, NJ (US); **Corey Strickland**, Martinsville, NJ (US); **Peter Orth**, Bronxville, NY (US); **Alex Therien**, Fanwood, NJ (US); **Paul Reichert**, Montville, NJ (US); **Li Xiao**, Cranbury, NJ (US)

(73) Assignee: **MERCK SHARP & DOHME CORP.**, Rahway, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/479,735**

(22) Filed: **Sep. 8, 2014**

Related U.S. Application Data

(60) Provisional application No. 61/875,266, filed on Sep. 9, 2013.

(51) **Int. Cl.**

C30B 29/58 (2006.01)
C07K 16/12 (2006.01)
C12N 9/10 (2006.01)
C30B 7/04 (2006.01)

(52) **U.S. Cl.**

CPC **C30B 29/58** (2013.01); **C07K 16/1282**

(58) **Field of Classification Search**

None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,625,559 B2	12/2009	Ambrosino et al.
8,236,311 B2	8/2012	Ambrosino et al.
8,257,709 B2	9/2012	Ambrosino et al.
8,609,111 B2	12/2013	Ambrosino et al.

FOREIGN PATENT DOCUMENTS

WO	WO2006/121422	11/2006
WO	WO2013/130981	9/2013

OTHER PUBLICATIONS


Orth P, Xiao L, Hernandez LD, Reichert P, Sheth PR, Beaumont M, Yang X, Murgolo N, Ermakov G, DiNunzio E, Racine F, Karczewski J, Secore S, Ingram RN, Mayhood T, Strickland C, Therien AG. Mechanism of Action and Epitopes of *Clostridium difficile* B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography. *J Biol Chem*. Jun. 27, 2014;289 (26):18008-21. doi: 10.1074/jbc.M114.560748. Epub May 12, 2014.

Primary Examiner — Suzanne M Noakes

(57) **ABSTRACT**

The present invention provides polypeptide domains of *C. difficile* toxin B (B1, B2, B3, B4) and complexes between the polypeptides and antibodies that bind specifically for the polypeptide. Methods of using the polypeptides to generate antibodies are also provided.

4 Claims, 4 Drawing Sheets






Fig. 2




Fig. 3



Fig. 4

1

**C.DIFFICILE TOXIN B CROP DOMAIN
PEPTIDES, ANTIBODIES AND COMPLEXES
THEREOF**

This Application claims the benefit of U.S. Provisional Patent Application No. 61/875,266; filed Sep. 9, 2013; which is herein incorporated by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to *C. difficile* polypeptides and complexes thereof with antibodies that bind specifically thereto.

BACKGROUND OF THE INVENTION

Clostridium difficile is an anaerobic pathogenic bacterium that causes infection of the colon typified by severe diarrhea, pseudomembranous colitis, and, in extreme cases, colonic rupture, sepsis and death. The symptoms of *C. difficile* infection (CDI) are caused by two exotoxins, toxin A (TcdA) and toxin B (TcdB) that are thought to target colonocytes via similar mechanisms involving glucosylation of small GTPases such as Rac and Rho. Inactivation of these important enzymes leads to morphological changes and eventually cell death, disruption of the colonic trans-epithelial resistance and the initiation and propagation of deleterious inflammatory events. Entry of the toxins into cells occurs through binding of the toxins to receptors on the cell surface, internalization via endocytosis, pH-induced conformational changes including formation of a trans-membrane pore that allows for transport and release (via autoproteolytic cleavage) of the glucosyltransferase domain of the toxins into the cytoplasm.

Bezlotoxumab is an anti-*C. difficile* toxin B human monoclonal antibody useful for the treatment and prevention of *C. difficile* infection. Understanding the nature of the bezlotoxumab interaction with the toxin B is important to the design of further therapeutic antibodies and vaccines for treating *C. difficile* infection.

SUMMARY OF THE INVENTION

The present invention provides an isolated polynucleotide (e.g., in a vector) encoding a polypeptide that comprises an amino acid sequence that is at least 80% identical or similar to an amino acid sequence that is selected from the group consisting of: *C. difficile* toxin B amino acids 1834-2367; *C. difficile* toxin B amino acids 1834-2101; *C. difficile* toxin B amino acids 1949-2275; *C. difficile* toxin B amino acids 2102-2367; *C. difficile* toxin B amino acids 1855-1971; *C. difficile* toxin B amino acids 1988-2103; *C. difficile* toxin B amino acids 2120-2237; SEQ ID NO: 14; *C. difficile* toxin B amino acids 2254-2366; EDGFKYFAPANTL (SEQ ID NO: 3); ENGEM (SEQ ID NO: 4); EDGFKY (SEQ ID NO: 5); and ENGEMQIGVFNTEDGFKY (SEQ ID NO: 6). Also provided is an isolated host cell comprising the polynucleotide or vector. The present invention also provides an isolated polypeptide (e.g., in a composition, such as a vaccine, having a carrier, e.g., a pharmaceutically acceptable carrier) comprising an amino acid sequence that is at least 80% identical or similar to an amino acid sequence that is selected from the group consisting of: *C. difficile* toxin B amino acids 1834-2367; *C. difficile* toxin B amino acids 1834-2101; *C. difficile* toxin B amino acids 1949-2275; *C. difficile* toxin B amino acids 2102-2367; *C. difficile* toxin B amino acids 1855-1971; *C. difficile* toxin B amino acids 1988-2103; *C. difficile* toxin B amino acids 2120-2237; *C. difficile* toxin B amino acids 2254-2366; SEQ ID NO: 14; EDGFKYFA-

2

PANTL (SEQ ID NO: 3); ENGEM (SEQ ID NO: 4); EDGFKY (SEQ ID NO: 5); and ENGEMQIGVFNTEDGFKY (SEQ ID NO: 6). The present invention encompasses a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2-10. Complexes between any such and an antibody (e.g., bezlotoxumab) or antigen-binding fragment thereof which binds specifically to the polypeptide are part of the present invention. In an embodiment of the invention, the complex (e.g., crystalline or non-crystalline) comprises bezlotoxumab, which comprises a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 11 and a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 12; and/or the *C. difficile* toxin B amino acids 1834-2101 comprises the amino acid sequence set forth in SEQ ID NO: 1 which optionally further comprises the C-terminal amino acid sequence LEHHHHHH (SEQ ID NO: 13).

The present invention provides an isolated crystal comprising a bezlotoxumab Fab fragment complexed with *C. difficile* toxin B amino acids 1834-2101 wherein the crystal is characterized by: space group: P21; and unit cell dimensions: a=79.413, b=134.659, c=102.579, $\alpha=\gamma=90^\circ$, $\beta=112.559^\circ$; optionally, wherein said complex is characterized by structure coordinates comprising a root mean square deviation (RMSD) of conserved residue backbone atoms of less than about 2.0 angstroms when superimposed on backbone atoms described by structural coordinates of Table 1.

The present invention also provides a method for producing a crystalline complex of the present invention (discussed herein) comprising incubating a first solution (e.g., in a drop, hanging or sitting on a surface) comprising 10 mg/ml of the complex, 5 mM phosphate, pH 7.4, 68.5 mM sodium chloride, 1.35 mM potassium chloride and 2.2% polyethylene glycol 4000 in a sealed container in close proximity to a second solution comprising 4.4% polyethylene glycol 4000.

The present invention also provides a method for immunizing an animal or for making an antibody or antigen-binding fragment thereof comprising administering a therapeutically effective amount of any of the polypeptides or vaccines of the present invention, e.g., as discussed herein, to a host animal and, optionally: (i) isolating the antibody or fragment from the host animal; (ii) humanizing the antibody or fragment; (iii) combining the antibody or fragment with a pharmaceutically acceptable carrier; (iv) isolating a splenocyte from the host animal; (v) fusing a splenocyte from the host animal with a myeloma cell; and/or (vi) fusing the light chain immunoglobulin variable region and/or heavy chain immunoglobulin variable region of the antibody or fragment with a human immunoglobulin light chain constant domain and/or human immunoglobulin heavy chain constant domain, respectively.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. Crystal structure of the N-terminal half of the TcdB CROP domain (peptide BC2) bound to two bezlotoxumab Fab fragments. A) Side view showing parallel binding of the two Fab fragments (Fab1 and Fab2) to their respective epitopes (referred to herein as E1 and E2). Heavy chains are colored light grey, light chains are colored black. B) bottom-up view showing the Fab fragments bound perpendicularly to the curvature of the CROP domain. Residues of the CROP domain that directly interact with the heavy chains (grey) or light chains (black) of the Fab fragments are also highlighted.

FIG. 2. Map of the regions within the B2 peptide shown to interact with bezlotoxumab by X-ray crystallography (diagonal lines from top left to bottom right) or by HDX-MS (diagonal lines from top right to bottom left), or putatively involved

in carbohydrate binding (vertical lines). Overlapping regions are shown as diamonds (X-ray and HDX-MS), dots (X-ray and carbohydrate binding), horizontal lines (HDX-MS and carbohydrate binding) or squares (X-ray, HDX-MS and carbohydrate binding).

FIG. 3. Model of the TcdB CROP domain bound to a full-length molecule of bezlotoxumab. The C-terminal (left) half of the CROP domain was modeled based on the structure of the B2 peptide and the Fc region of bezlotoxumab is based on published high-resolution structures of human IgG1. The four putative carbohydrate binding regions are shown in dark grey. Heavy chains of bezlotoxumab are colored light grey, light chains are colored black.

FIG. 4. Photomicrograph of anti-TcdB antibody bezlotoxumab Fab-C. *difficile* Toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex. Crystal characteristics: 20 mg/ml; 4.4% PEG 4000; 1 month @ 4° C.; 300× magnification.

DETAILED DESCRIPTION OF THE INVENTION

Crystals and crystallization conditions were discovered for an engineered *Clostridium difficile* toxin B (TcdB) construct and a Fab fragment from a monoclonal antibody specific for Toxin TcdB, bezlotoxumab. An *E. coli* expression system was established for the expression and purification of toxin TcdB B construct (*Clostridium difficile* toxin B (TcdB1834-2101)) that was suitable for complexing with the Fab fragment of bezlotoxumab which resulted in the structure determination of toxin *C difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complexed with the Fab fragment. Novel methods are disclosed to engineer a *C. difficile* toxin B TcdB (1834-2101) construct that crystallized and resulted in the three-dimensional structure determination. The present invention also provides a novel crystal form that is a suitable reagent for structure assisted drug design and methods of preparation.

X-ray crystallography and other analyses demonstrated that one molecule of bezlotoxumab bound to two distinct homologous regions within the TcdB CROP domain, partially occluding two of the four putative carbohydrate binding sites. The present method also provides *C. difficile* toxin B immunogenic polypeptide antigens encompassing the binding sites of bezlotoxumab and methods of immunizing an animal with such polypeptide antigens.

Molecular Biology

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (herein "Sambrook, et al., 1989"); DNA Cloning: A Practical Approach, Volumes I and II (DN. Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. (1985)); Transcription And Translation (B. D. Hames & S. J. Higgins, eds. (1984)); Animal Cell Culture (R. I. Freshney, ed. (1986)); Immobilized Cells And Enzymes (IRL Press, (1986)); B. Perbal, A Practical Guide To Molecular Cloning (1984); F. M. Ausubel, et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994).

A "polynucleotide", "nucleic acid" or "nucleic acid molecule" DNA and RNA (e.g., mRNA), single or double stranded.

An "endogenous" polynucleotide or polypeptide is present normally in a wild-type host cell such as a CHO cell.

A "nucleotide sequence" is a series of nucleotide bases (also called "nucleotides") in a nucleic acid, such as DNA or RNA, and means any chain of two or more nucleotides.

An "amino acid sequence" refers to a series of two or more amino acids in a protein, peptide or polypeptide.

A "protein", "peptide" or "polypeptide" includes a contiguous string of two or more amino acids.

The terms "isolated polynucleotide" or "isolated polypeptide" include a polynucleotide (e.g., RNA or DNA molecule, or a mixed polymer) or a polypeptide, respectively, which are partially (to any degree) or fully separated from other components that are normally found in cells or in recombinant DNA expression systems. These components include, but are not limited to, cell membranes, cell walls, ribosomes, polymerases, serum components and extraneous genomic sequences.

The term "host cell" includes any cell of any organism (e.g., a prokaryotic (such as a bacterial cell such as *E. coli*, e.g., BL21DE3) or eukaryotic cell (such as a fungal, insect or mammalian cells) that is selected, modified, transfected, transformed, grown, or used or manipulated in any way, for the production of a substance by the cell, for example the expression or replication, by the cell, of a gene, a DNA or RNA sequence or a protein. Fungal host cells include *Saccharomyces* cells and *Pichia* cells such as *Pichia pastoris*. Mammalian cells include Chinese hamster ovary cells. Insect cells include *Spodoptera frugiperda* cells, SF-900, SF9, SF21 or *Trichoplusia ni* cells.

The nucleic acids herein may be flanked by natural regulatory (expression control) sequences, or may be associated with heterologous sequences, including promoters, internal ribosome entry sites (IRES) and other ribosome binding site sequences, enhancers, response elements, suppressors, signal sequences, polyadenylation sequences, introns, 5'- and 3'-non-coding regions, and the like.

A coding sequence, such as Bx or E_x, is "operably linked to" transcriptional and translational control sequences in a cell when the sequences direct RNA polymerase mediated transcription of the coding sequence into RNA, preferably mRNA, which then may be RNA spliced (if it contains introns) and, optionally, translated into a protein encoded by the coding sequence.

The terms "express" and "expression" mean allowing or causing the information in a gene, RNA or DNA sequence to become manifest; for example, producing a protein by activating the cellular functions involved in transcription and translation of a corresponding gene. A DNA sequence is expressed in or by a cell to form an "expression product" such as an RNA (e.g., mRNA) or a protein. The expression product itself may also be said to be "expressed" by the cell.

The term "vector" includes a vehicle (e.g., a plasmid) by which a DNA or RNA sequence, e.g., encoding a Bx or E_x, can be introduced into a host cell, so as to transform the host and, optionally, promote expression and/or replication of the introduced sequence.

Vectors that can be used in this invention include plasmids, viruses, bacteriophage, integratable DNA fragments, and other vehicles that may facilitate introduction of the nucleic acids into the genome of the host. Plasmids are the most commonly used form of vector but all other forms of vectors which serve a similar function and which are, or become, known in the art are suitable for use herein. See, e.g., Pouwels, et al., Cloning Vectors: A Laboratory Manual, 1985 and Supplements, Elsevier, N.Y., and Rodriguez et al., (eds.),

Vectors: A Survey of Molecular Cloning Vectors and Their Uses, 1988, Butterworth, Boston, Mass.

The present invention includes *C. difficile* toxin B Bx or E_x polypeptides having the amino acid sequence of any of SEQ ID NOs: 2-10 as well as such polypeptides having superficial or slight modifications to the amino acid sequences; as well as methods of making and using thereof (as discussed herein). Function-conservative variants of the *C. difficile* toxin B Bx or E_x polypeptides of the invention are also part of the present invention. "Function-conservative variants" are those in which one or more amino acid residues in the protein have been changed without altering the overall conformation and function of the polypeptide, including, but, by no means, limited to, replacement of an amino acid with one having similar properties. Amino acids with similar properties are well known in the art. For example, polar/hydrophilic amino acids which may be interchangeable include asparagine, glutamine, serine, cysteine, threonine, lysine, arginine, histidine, aspartic acid and glutamic acid; nonpolar/hydrophobic amino acids which may be interchangeable include glycine, alanine, valine, leucine, isoleucine, proline, tyrosine, phenylalanine, tryptophan and methionine; acidic amino acids, which may be interchangeable include aspartic acid and glutamic acid and basic amino acids, which may be interchangeable include histidine, lysine and arginine.

Sequence identity refers to exact matches between the amino acids of two sequences which are being compared. Sequence similarity or homology refers to both exact matches between the amino acids of two polypeptides which are being compared in addition to matches between nonidentical, biochemically related amino acids. Biochemically related amino acids which share similar properties and may be interchangeable are discussed herein.

The following references regarding the BLAST algorithm are herein incorporated by reference: BLAST ALGORITHMS: Altschul, S. F., et al., (1990) J. Mol. Biol. 215:403-410; Gish, W., et al., (1993) Nature Genet. 3:266-272; Madden, T. L., et al., (1996) Meth. Enzymol. 266:131-141; Altschul, S. F., et al., (1997) Nucleic Acids Res. 25:3389-3402; Zhang, J., et al., (1997) Genome Res. 7:649-656; Wootton, J. C., et al., (1993) Comput. Chem. 17:149-163; Hancock, J. M., et al., (1994) Comput. Appl. Biosci. 10:67-70; ALIGNMENT SCORING SYSTEMS: Dayhoff, M. O., et al., "A model of evolutionary change in proteins." in Atlas of Protein Sequence and Structure, (1978) vol. 5, suppl. 3. M. O. Dayhoff (ed.), pp. 345-352, Natl. Biomed. Res. Found., Washington, D.C.; Schwartz, R. M., et al., "Matrices for detecting distant relationships." in Atlas of Protein Sequence and Structure, (1978) vol. 5, suppl. 3." M. O. Dayhoff (ed.), pp. 353-358, Natl. Biomed. Res. Found., Washington, D.C.; Altschul, S. F., (1991) J. Mol. Biol. 219:555-565; States, D. J., et al., (1991) Methods 3:66-70; Henikoff, S., et al., (1992) Proc. Natl. Acad. Sci. USA 89:10915-10919; Altschul, S. F., et al., (1993) J. Mol. Evol. 36:290-300; ALIGNMENT STATISTICS: Karlin, S., et al., (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268; Karlin, S., et al., (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877; Dembo, A., et al., (1994) Ann. Prob. 22:2022-2039; and Altschul, S. F. "Evaluating the statistical significance of multiple distinct local alignments." in Theoretical and Computational Methods in Genome Research (S. Suhai, ed.), (1997) pp. 1-14, Plenum, New York.

A "heterologous" amino acid sequence, as it relates to a polypeptide comprising, consisting of or consisting essentially of a *C. difficile* toxin B polypeptide fused to a heterologous polypeptide, refers to an amino acid sequence which is not contiguous with adjacent amino acid sequences in the *C.*

difficile toxin B polypeptide. Such fusions and methods of using and making the same are part of the present invention.

Bezlotoxumab is an antibody known in the art. See e.g. CAS registry no. 1246264-45-8. In an embodiment of the invention, a bezlotoxumab Fab comprises the light and heavy chain immunoglobulin amino acid sequences:

Light chain:

(SEQ ID NO: 11)
EIVLTQSPGTLSSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYG
ASSRATGIPDRFSGSGSGTDFLTISRLEPEDFAVYYCQQYGSSTWTFQGQG
TKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCNNNEYPREAKVQWKVDN
ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS
PVTKSFNRG;

Heavy chain:

(SEQ ID NO: 12)
EVQLVQSGAEVKKSGESLKISKCGSGSFTSYWIGWVRQMPKGLEWMGIF
YPGDSSTRYSPSFQGQVTISADKSVNTAYLQSSLKASDTAMYYCARRRNW
GNAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKTSGGTAALGCLVKDYPFP
EPVTWSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNV
NHKPSNTKVDKRVEPKS .

C. difficile Toxin B

Polypeptides (e.g., immunogenic polypeptides) comprising various fragments of the *C. difficile* toxin B are part of the present invention as well as method of use thereof and methods of making such polypeptides. The present invention includes the *C. difficile* toxin B fragment B1 which comprises, consists of or consists essentially of amino acids 1834-2367 of *C. difficile* toxin B; the *C. difficile* toxin B fragment B2 which comprises, consists of or consists essentially of amino acids 1834-2101 or 1834-2099 of *C. difficile* toxin B; the *C. difficile* toxin B fragment B3 which comprises, consists of or consists essentially of amino acids 1949-2275 of *C. difficile* toxin B; and, the *C. difficile* toxin B fragment B4 which comprises, consists of or consists essentially of amino acids 2102-2367 of *C. difficile* toxin B; or any 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279,

US 9,181,632 B1

7

280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291,
292, 293, 294, 295, 296, 297, 298, 299 or 300 contiguous
amino acids of a B1, B2, B3 or B4 polypeptide. *C. difficile*
toxin B fragments B1, B2, B3 and B4 may be referred to

8

herein, collectively, as "Bx"; thus, Bx refers to B1, B2, B3
and/or B4.

In an embodiment of the invention, *C. difficile* toxin B
polypeptide comprises the amino acid sequence:

(SEQ ID NO: 1)
MSLVNRKQLE KMANVRFRTO EDEYVAILDA LEEYHNMSEN TVVEKYLKLK DINSLTDIYI
DTYKKSGRNK ALKKFKEYLV TEVLELKNNN LTPVEKNLHF VWIGGQINDT AINYINQWKD
VNSDYNVNVF YDSNAFLINT LKKTVVESAI NDTLESFREN LNDPREFDYNK FFRKRMEIIY
DKQKNFINYY KAQREENPEL IIDDIVKTYL SNEYSKEIDE LNTYIEESLN KITQNSGNDV
RNFEEFKNGE SFNLYEQELV ERWNLAASD ILRISALKEI GGMYLDVDM PGIQPDFLES
IEKPSSVTVD FWEMTKLEAI MKYKEYIPEY TSEHFDMLDE EVQSSFESVL ASKSDKSEIF
SSLGDMEASP LEVKIAFNSK GIINQGLISV KDSYCSNLIV KQIENRYKIL NNSLNPAISE
DNDFTTTNT FIDSIMAEAN ADNGRFMME GKYLVRGFFF DVKTINLSG PEAYAAAYQD
LLMPKEGSMN IHЛИEADLRN FEISKTNISQ STEQEMASLW SFDDARAKAQ FEEYKRNYFE
GSLGEDDNLD FSQNIVVDKE YLLEKISSLA RSSERGYIH IVQLQGDKIS YEAACNLFAK
TPYDSVLFQK NIEDSEIAYY YNPGDGEIQE IDKYKIPSIID DRPKIKLTF IGHGKDEFNT
DIFAGFDVDS LSTEIEAAID LAKEDISPKS IEINLLGCNM FSYSINVEET YPGKLLLKVK
DKISELMPSI SQDSIIVSAN QYEVRINSEG RRELLDHSGE WINKEESIIK DISSKEYISF
NPKENKITVK SKNLPELSTL LQEIRNNNSNS SDIEEEKVM LTECEINVIS NIDTQIVEER
IEEAKNLTSQD SINYIKDEFK LIESISDALC DLKQQNELED SHFISFEDIS ETDEGFSIRF
INKETGESIF VETEKTIPISE YANHITEEIS KIKGTIFDTV NGKLVKVNL DTTHEVNTLN
AAFFIQSLIE YNSSKESLSN LSVAMKVQVY AQLFSTGLNT ITDAAKVVEL VSTALDETID
LLPTLSEGLP IIATIIDGVs LGAAIKELSE TSDPLLRQEI EAKIGIMAVN LTTATTAAIT
SSLGIASGFS ILLVPLAGIS AGIPSLVNNE LVLRDKATKV VDYPFKHVSLV ETEGVFTLLD
DKIMMPQDDL VISEIDFNNSN SIVLGKCEIW RMEGGSHTV TDDIDHFFSA PSITYREPHL
SIYDVLEVQK EELDLSKDLM VLPNAPNRVF AWETGWTPGL RSLENDGTLK LDRIRDNYEG
EFYWRYFAFI ADALITTLKP RYEDTNIRIN LDSNTRSFIV PIITTEYIRE KLSYSFYGSG
GTYALSLSQY NMGINIELSE SDVWIIDVDN VVRDVTIESD KIKKGDLIEG ILSTLSIEEN
KIIILNSHEIN FSGEVNGSNG FVSLTFSILE GINAIIEVDL LSKSYKLLIS GELKILMLNS
NHIQQKIDYI GFNSELQKNI PYSFVDSEGK ENGFINGSTK EGLFVSELPD VVLISKVYMD
DSKPSFGYYS NNLKDVKVI KDNVNILTGY YLKDDIKISL SLTLQDEKTI KLNSVHLDES
GVAEILKFMN RKGNNTNTSDS LMSFLESMMI KSIFVNFLQS NIKFILDANF IISGTTSIGQ
FEFIGDENDN IQPYFIKFNT LETNYTLYVG NRQNMIVEPN YDLDDSGDIS STVINFSQKY
LYGIDSCVNK VVISPNIYTD EINITPVYET NNTYPEVIVL DANYINEKIN VNINDLSIRY
VWSNDGNDPI LMSTSEENKV SQVKIRFVNV FKDKTLANKL SFNFSDKQDV PVSEIILSFT
PSYYEDGLIG YDGLGLVSLYN EKFYINNFGM MVSGLIYIND SLYYFKPPVN NLITGFVTVG
DDKYYFNPIN GGAASIGETI IDDKNYYFNQ SGVLQTCVFS TEDGFKYFAP ANTLDENLEG
EAIDFTGKLI IDENIIYYFD NYRGAVEWKE LDGEMHYFSP ETGKAFKGLN QIGDYKYYFN
SDGVMQKGTV SINDNKHYFD DSGVMKVGYT EIDGKHFYFA ENGEMQIGVF NTEDGFKYFA
HHNEDLGNEE GEEISYSGIL NFNNKIYYFD DSFTAVVGWK DLEDGSKYYF DEDTAEAYIG

- continued

LSLINDGQYY FNDDGIMQVG FVTINDKVFY FSDSGIIESG VQNIDDNYFY IDDNGIVQIG
 VFDTSDGYKY FAPANTVNDN IYGQAVEYSG LVRVGEDVYY FGETYTIETG WIYDMENESD
 KYYFNPETKK ACKGINLIID IKYFDEKG MRTGLISFEN NYFFNENGE MQFGYINIED
 KMFYFGEDGV MQIGVFNTPD GFKYFAHQNT LDENFEGESI NYTGWLDLDE KRYYFTDEYI
 AATGSVIIDG EEEYFPDPDTA QLVISE

In an embodiment of the invention, the *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾), also referred to herein as B2, comprises the amino acid sequence:

¹⁰ (SEQ ID NO: 8); wherein, putative carbohydrate binding residues are bracketed and underscored residues are protected by bezlotoxumab in hydrogen-deuterium exchange (HDX-MS) experiments.

(SEQ ID NO: 14)
 GLIYINDSLY YFKPPVNNLI TGFVTVGDDK YYFNPINGGA ASIGETIIDD KNYYFNQSGV
 LQTGVFSTED GFKYFAPANT LDENLEGEAI DFTGKLIIDE NIYYFDNNYR GAVEWKELDG
 EMHYFSPETG KAFKGLNQIG DYKYYFNSDG VMQKGFVSIN DNKHYFDDSG VMKVGYTEID
 GKHFYFAENG EMQIGVFNTD DGFKYFAHHN EDLGNEEGEE ISYSGILNPN NKIYYFDDSF
 TAVVGWKDLE DGSKYYFDED TAEAYIGL;

or

(SEQ ID NO: 2)
 MGLIYINDSLYYFKPPVNNLITGFVTVGDDKYYFNPINGGAASIGETIIDD
 KNYYFNQSGVLQTGVFSTEDGFKYFAPANTLDENLEGEAIDFTGKLIIDEN
 IYYFDDNYRGAVEWKELDGEMHYFS PETGKAKGLNQIGDYKYYFNSDGVM
 QKGFVSIINDNKHYFDDSGVMKVGYTEIDGKHFYFAENGEMQIGVFNTEDGF
 KYFAHHNEDLGNEEGEEISYSGILNPNNKIYYFDDSTAVVGWKDLEDGSK
 YYFDED TAEAYILEHHHHHH;

or amino acids 2-267 thereof.

The present invention also includes polypeptides comprising, consisting of or consisting essentially of the *C. difficile* toxin B E1, E2, E3 and E4 fragments (which may be collectively referred to, herein, as E_x or *C. difficile* toxin B E_x; such that, for example, E_x refers to E1, E2, E3 and/or E4) which comprise, consist of or consist essentially of amino acid sequences as set forth below or any 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300

C. difficile toxin B E1 domain: GFVTVGDDKYYFNPING-GAASIGETIIDDKNYYFNQSGVL QTGVESTE[D]GF[K]YFAPANTLDENLEGEAID-FTGKLIIDENIYYFDDNYRGAVEWKELDGEMHYFSPE TGAKFKGLNQ
 (SEQ ID NO: 7); wherein, putative carbohydrate binding residues are bracketed and underscored residues are protected by bezlotoxumab in hydrogen-deuterium exchange (HDX-MS) experiments.

C. difficile toxin B E2 domain: GETSINDNKHYFDDS-GVMKVGYTEIDGKHFYFAENGEM QIGVFNT[D]GF[K]YFAHHNEDLGNEE-GEEISYSGILNENNKIYYFDDSTAVVGWKDLEDGSKYYFDED TAEAYIGL

²⁵ C. difficile toxin B E3 domain: GFVTINDKVYFSDSGIIESGVQNID-DNYFYIDNGIV QIGVFDTSDGYKYFAPANTVND-NIYQQAVEYSGLVRVGEDVYYFGETYTIETGWIYDMENESDKYYFNPE TKAACK-GINL

(SEQ ID NO: 9)
 C. difficile toxin B E4 domain: GLISFENNYYFNENGEMQFGY-INIEDKMFYFGEDGVM QIGVENTPDGEKYFAHQNTLDENFEGES-INYTGWLDLDEKRYYFTDEYIAATGSVIIDGEYYPDPDTAQLVISE
 (SEQ ID NO: 10)

E_x polypeptide also refers to fragments of E1 and E2 comprising, consisting of or consisting essentially of:

C. difficile toxin B amino acids 1855-2103;
 EDGFKYFAPANTL (SEQ ID NO: 3);
 ENGEM (SEQ ID NO: 4);
 EDGFKY (SEQ ID NO: 5); and/or
 ENGM (SEQ ID NO: 6);

optionally, wherein any of such E_x polypeptide fragments further include, at the N-terminus, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300

contiguous N-terminal amino acids of the *C. difficile* toxin B polypeptide or a heterologous polypeptide and/or, at the C-terminus, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,

11

17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300 contiguous C-terminal amino acids of the *C. difficile* toxin B polypeptide or a heterologous polypeptide.

In an embodiment of the invention, a *C. difficile* toxin B_x or E_x polypeptide comprises an amino acid sequence that is at least about 80-99.9% (e.g., 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5, 99.9%) identical or similar to an amino acid sequence set forth in any of SEQ ID NOs: 2-10 or a fragment thereof, as discussed herein; when the comparison is performed by a BLAST algorithm wherein the parameters of the algorithm are selected to give the largest match between the respective sequences over the entire length of the respective reference sequences; or any polynucleotide that encodes such a polypeptide. In an embodiment of the invention, the polypeptide binds to bezlotoxumab.

The present invention also includes methods for making a *C. difficile* toxin B_x or E_x polypeptide comprising introducing a polynucleotide encoding the polypeptide into a host cell and culturing the host cell under conditions favorable to expression of the polypeptide. See e.g., U.S. Pat. No. 4,816,567 (Cabilly et al.).

Polynucleotides encoding *C. difficile* toxin B_x or E_x polypeptides are, in an embodiment of the invention, introduced or transformed into an appropriate host cell by various techniques well known in the art, e.g., electroporation, protoplast fusion, calcium phosphate precipitation, cell fusion with enveloped DNA, microinjection, and infection with intact virus (see, e.g., Ridgway, 1973, Vectors: Mammalian Expression Vectors, Chapter 24.2, pp. 470-472, Rodriguez and Denhardt eds., Butterworths, Boston, Mass.; Graham et al., 1973, Virology 52:456; Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, New York; Davis et al., 1986, Basic Methods in Molecular Biology, Elsevier; and Chu et al., 1981, Gene 13:197).

Cells used in the present invention can be cultured according to standard cell culture techniques, e.g., they can be fixed to a solid surface or grown in suspension in appropriate nutrient media.

The present invention further provides a *C. difficile* toxin B_x or E_x polypeptide which is immobilized to a solid substrate, e.g., a bead or particle (e.g., glass, silica, plastic, sepharose or agarose).

The present invention further provides fusions of a *C. difficile* toxin B_x or E_x polypeptide of the present invention,

12

e.g., to a heterologous protein such as a "tag" (e.g., glutathione-S-transferase, (histidine)₆, maltose binding protein, chitin binding protein, thioredoxin, green fluorescent protein, hemeagglutinin, myc, FLAG) or an immunoglobulin (IgG, e.g., IgG1, IgG2, IgG3, IgG4).

In an embodiment of the invention, a B_x and/or E_x polypeptide excludes full length wild-type *C. difficile* toxin B, e.g., SEQ ID NO: 1.

Embodiments of the invention include but are not limited to:

1. An isolated polynucleotide encoding a polypeptide that comprises an amino acid sequence that is at least 80% identical or similar to an amino acid sequence that is selected from the group consisting of:

C. difficile toxin B amino acids 1834-2367;
C. difficile toxin B amino acids 1834-2101;
C. difficile toxin B amino acids 1949-2275;
C. difficile toxin B amino acids 2102-2367;
C. difficile toxin B amino acids 1855-1971;
C. difficile toxin B amino acids 1988-2103;
C. difficile toxin B amino acids 2120-2237;
C. difficile toxin B amino acids 2254-2366;

SEQ ID NO:14;
EDGFKYFAPNTL (SEQ ID NO: 3);

ENGEM (SEQ ID NO: 4);
EDGFKY (SEQ ID NO: 5); and
ENGEMQIGVFNTEDEGFKY (SEQ ID NO: 6).

2. The polynucleotide of embodiment 1 in a vector.
3. An isolated host cell comprising the polynucleotide or vector of any of embodiments 1-2.

4. An isolated polypeptide comprising an amino acid sequence that is at least 80% identical or similar to an amino acid sequence that is selected from the group consisting of:
C. difficile toxin B amino acids 1834-2367;

C. difficile toxin B amino acids 1834-2101;
C. difficile toxin B amino acids 1949-2275;
C. difficile toxin B amino acids 2102-2367;
C. difficile toxin B amino acids 1855-1971;
C. difficile toxin B amino acids 1988-2103;
C. difficile toxin B amino acids 2120-2237;
C. difficile toxin B amino acids 2254-2366;

SEQ ID NO: 14;
EDGFKYFAPNTL (SEQ ID NO: 3);

ENGEM (SEQ ID NO: 4);
EDGFKY (SEQ ID NO: 5); and
ENGEMQIGVFNTEDEGFKY (SEQ ID NO: 6).

5. The polypeptide of embodiment 4 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-10 and 14.

6. A vaccine comprising the polypeptide of any of embodiments 4-5 and a pharmaceutically acceptable carrier.

7. A complex between the polypeptide of any of embodiments 4-5 and an antibody or antigen-binding fragment thereof which binds specifically to the polypeptide.

8. The complex of embodiment 7 wherein the antibody or fragment is an antibody which is bezlotoxumab.

9. The complex of any of embodiments 7-8 wherein the bezlotoxumab comprises a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 11 and a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 12; and/or the *C. difficile* toxin B amino acids 1834-2101 comprises the amino acid sequence set forth in SEQ ID NO: 2 which optionally further comprises the C-terminal amino acid sequence HHHHHH (SEQ ID NO: 13).

10. A method for immunizing an animal or for making an antibody or antigen-binding fragment thereof comprising administering a therapeutically effective amount of an iso-

13

lated polypeptide comprising an amino acid sequence that is at least 80% identical or similar to an amino acid sequence that is selected from the group consisting of:

C. difficile toxin B amino acids 1834-2367;
C. difficile toxin B amino acids 1834-2101;
C. difficile toxin B amino acids 1949-2275;
C. difficile toxin B amino acids 2102-2367;
C. difficile toxin B amino acids 1855-1971;
C. difficile toxin B amino acids 1988-2103;
C. difficile toxin B amino acids 2120-2237;
C. difficile toxin B amino acids 2254-2366;

SEQ ID NO: 14;

EDGFKYFAPNTL (SEQ ID NO: 3);

ENGEM (SEQ ID NO: 4);

EDGFKY (SEQ ID NO: 5); and

ENGEMQIGVFNTEDGFKY (SEQ ID NO: 6);

or an amino acid sequence selected from the group consisting of SEQ ID NOS: 2-10 and 14; or a vaccine comprising any of said polypeptides and a pharmaceutically acceptable carrier to a host animal and, optionally:

- (i) isolating the antibody or fragment from the host animal;
- (ii) humanizing the antibody or fragment;
- (iii) combining the antibody or fragment with a pharmaceutically acceptable carrier;
- (iv) isolating a splenocyte from the host animal;
- (v) fusing a splenocyte from the host animal with a myeloma cell; and/or
- (vi) fusing the light chain immunoglobulin variable region and/or heavy chain immunoglobulin variable region of the antibody or fragment with a human immunoglobulin light chain constant domain and/or human immunoglobulin heavy chain constant domain, respectively.

Crystals and Crystallization

The present invention comprises crystalline or soluble, non-crystalline complexes between bezlotoxumab or an antigen-binding fragment thereof and *C. difficile* toxin B (e.g., B_x or E_x) as well as crystallizable compositions or solutions comprising such a complex.

For example, the present invention provides a method for producing crystals of the bezlotoxumab (or an antigen-binding fragment thereof, e.g., a Fab)-*C. difficile* toxin B (e.g., B_x or E_x) complex, comprising crystallizing aqueous buffered solution comprising about 20 mg/ml of the complex, 5 mM phosphate, pH 7.4, 68.5 mM sodium chloride, 1.35 mM potassium chloride buffer and 4.4% polyethylene glycol 4000 (Jena Biosciences JBS Single stock (CSS-253)). In an embodiment of the invention, the aqueous solution (e.g., a drop) is crystallized by sealing in a container in close proximity to 4.4% polyethylene glycol 4000 (e.g., 1 microliter aqueous solution and about 0.08 mL of the 4.4% polyethylene glycol 4000 solution). In an embodiment of the invention, the drop is incubated at about 4° C.

Crystallization of a bezlotoxumab (or an antigen-binding fragment thereof, e.g., a Fab)-*C. difficile* toxin B (e.g., SEQ ID NO: 2) complex may be accomplished by using known methods in the art (Giege, et al. (1994) *Acta Crystallogr. D50*: 339-350; McPherson, (1990) *Eur. J. Biochem.* 189: 1-23). Such techniques include hanging drop vapor diffusion, sitting drop vapor diffusion, microbatch and dialysis. In an embodiment of the invention, hanging-drop vapor diffusion (see e.g., McPherson, (1976) *J. Biol. Chem.* 251: 6300-6303) is used. Both hanging drop and sitting drop vapor diffusion entail a droplet containing purified protein, buffer, and precipitant being allowed to equilibrate with a larger reservoir containing similar buffers and precipitants in higher concentrations. Ini-

14

tially, the droplet of protein solution contains an insufficient concentration of precipitant for crystallization, but as water and other volatile organic components vaporize from the drop and transfers to the reservoir, the precipitant concentration increases to a level optimal for crystallization. This may occur prior to or after reaching equilibrium. Once the system is in equilibrium, these optimum conditions are maintained until the crystallization is complete. The hanging drop method differs from the sitting drop method in the vertical orientation

- 5 of the protein solution drop within the system. In the microbatch method, protein is mixed with precipitants to achieve supersaturation, the vessel is sealed and set aside until crystals appear. In the dialysis method, protein is retained in a sealed dialysis membrane which is placed into a solution 10 containing precipitant. Equilibration across the membrane increases the precipitant concentration thereby causing the protein to reach supersaturation levels.
- 15

The present invention also comprises methods for using the bezlotoxumab (or an antigen-binding fragment thereof, e.g., a

- 20 Fab)-*C. difficile* toxin B (e.g., SEQ ID NO: 2) complex crystals of the present invention to make a crystalline complex with a compound comprising soaking, in a liquid medium, a crystalline composition comprising a *C. difficile* toxin B (e.g., SEQ ID NO: 2) polypeptide complexed with a first compound 25 (e.g., bezlotoxumab or an antigen-binding fragment thereof, e.g., a Fab) with a second compound, e.g., at a molar excess of the second compound (e.g., 2 mM) relative to the bezlotoxumab or antigen-binding fragment thereof, such that a complex forms between *C. difficile* toxin B (e.g., SEQ ID NO: 2) and the second compound.

The crystals of the present invention have a wide range of uses. For example, high quality crystals are suitable for X-ray or neutron diffraction analysis to determine the three dimensional structure of bezlotoxumab (or an antigen-binding fragment thereof, e.g., a Fab)-*C. difficile* toxin B (e.g., SEQ ID NO: 2) complexes. Knowledge of these structures and solvent accessible residues allow structure-based design and construction of inhibitors and antagonists for *C. difficile* toxin B (e.g., SEQ ID NO: 2).

- 30
 - 35
 - 40
 - 45
 - 50
 - 55
- In addition, crystallization itself can be used as a purification method. In some instances, a polypeptide or protein crystallizes from a heterogeneous mixture into crystals. Isolation of such crystals by filtration and/or centrifugation, followed by redissolving the protein affords a purified solution suitable for use in growing high-quality crystals which are preferred for diffraction analysis.

Once a crystal of the present invention is grown, X-ray diffraction data can be collected. One method for determining a structure with X-ray diffraction data includes use of synchrotron radiation, under standard cryogenic condition; however, alternative methods may also be used. For example, crystals can be characterized by using X-rays produced by a conventional source, such as a sealed tube or a rotating anode. Methods of characterization include, but are not limited to, precession photography, oscillation photography and diffractometer data collection.

The crystallizable compositions provided by this invention are amenable to X-ray crystallography for providing the three-dimensional structure of a bezlotoxumab (or an antigen-binding fragment thereof, e.g., a Fab)-*C. difficile* toxin B (e.g., SEQ ID NO: 2) complex. The present invention includes crystals which effectively diffract X-rays for the determination of the atomic coordinates of bezlotoxumab (or an antigen-binding fragment thereof, e.g., a Fab)-*C. difficile* toxin B (e.g., SEQ ID NO: 2) complexes to a resolution of greater than about 5.0 Ångströms (e.g., about 4.5 Å, about 4.0 Å, about 3 Å, about 2.5 Å, about 2 Å, about 1 Å, about 0.5 Å),

preferably greater than about 4.0 Ångströms (e.g., about 3 Å, about 2.5 Å, about 2 Å, about 1 Å, about 0.5 Å), more preferably greater than about 2.8 Ångströms (e.g., about 2.5 Å, about 2 Å, about 1 Å, about 0.5 Å) and most preferably greater than about 2.0 Ångströms (e.g., about 1.5 Å, about 1.0 Å, about 0.5 Å).

The present invention includes bezlotoxumab (or an anti-gen-binding fragment thereof, e.g., a Fab)-*C. difficile* toxin B (e.g., SEQ ID NO: 2) soluble (non-crystalline) or crystalline complexes whose three-dimensional structure is described by the structure coordinates set forth in Table 1. The scope of the present invention also includes crystals which possess structural coordinates which are similar, but not identical, to those set forth in Table 1.

The term "structure coordinates" refers to Cartesian coordinates derived from mathematical equations related to the patterns obtained on diffraction of a beam of X-rays by the atoms (scattering centers) of a molecule. The diffraction data are used to calculate electron density maps and to establish the positions of the individual atoms of the molecule.

Those of skill in the art will understand that a set of structure coordinates, for a polypeptide or an polypeptide-complex or a portion thereof, is a relative set of points that define a shape in three dimensions.

The present invention includes crystals exhibiting structural coordinates which are similar to those set forth in Table 1 but for crystallographic permutations of the structure coordinates, fractionalization of the structure coordinates, additions, subtractions, rotations or translations to sets of the structure coordinates or any combinations of the above.

Alternatively, modifications in the crystal structure due to mutations, additions, substitutions, and/or deletions of amino acids, or other changes in any of the components that make up the crystal may also account for variations in structure coordinates. If such variations are within an acceptable standard error as compared to the coordinates of Table 1, the resulting three-dimensional shape is considered to be the same and, accordingly, the modified crystal is considered to be within the scope of the present invention.

Various computational analyses may be necessary to determine whether a crystal is sufficiently similar to the crystals whose structural coordinates are set forth in Table 1 as to be considered the same. Such analyses may be carried out in current software applications, such as the Molecular Similarity application of QUANTA (Molecular Simulations Inc., San Diego, Calif.) version 4.1, and as described in the accompanying User's Guide.

The Molecular Similarity application permits comparisons between different structures, different conformations of the same structure, and different parts of the same structure. In general, the procedure used in Molecular Similarity to compare structures is, in general, divided into four steps: 1) input the structures to be compared; 2) define the atom equivalencies in these structures; 3) perform a fitting operation; and 4) analyze the results.

Generally, each structure is identified by a name. One structure is identified as the target (i.e., the fixed structure); all remaining structures are working structures (i.e., moving structures). Since atom equivalency within QUANTA is defined by user input, for the purpose of this invention we will define equivalent atoms as protein backbone atoms (N, Cα, C and O) or alpha carbon atoms (Cα) only for all conserved residues between the two structures being compared.

When a rigid fitting method is used, the working structure is translated and rotated to obtain an optimum fit with the target structure. The fitting operation uses a least squares fitting algorithm that computes the optimum translation and

rotation to be applied to the moving structure, such that the root mean square difference of the fit over the specified pairs of equivalent atom is an absolute minimum. This number, given in Ångströms, is reported by QUANTA.

5 The term "root mean square deviation" (RMSD) is a commonly known term in the art which, in general, means the square root of the arithmetic mean of the squares of the deviations from the mean distance of corresponding atoms. It is a way to express the deviation or variation from a trend or object.

10 For the purpose of this invention, any set of structure coordinates of a molecule that has a RMSD of conserved residue backbone atoms (N, Cα, C, O) or alpha carbon atoms (Cα) only of less than about 1.5 Å when superimposed—using backbone atoms or alpha carbon atoms—on the relevant structure coordinates of Table 1 are considered identical and the crystals which they characterize are both within the scope of the present invention. In an embodiment of the invention, the root mean square deviation is less than about 1.0 Å, e.g., less than about 0.5 Å, e.g., less than about 0.1 Å.

15 The term "least squares" refers to a method based on the principle that the best estimate of a value is that in which the sum of the squares of the deviations of observed values is a minimum.

25 Antibodies and Immunization

The present invention provides a method for making an antibody or antigen-binding fragment thereof that specifically binds to *C. difficile* toxin B (e.g., Bx or E_x) comprising immunizing a host animal with a therapeutically effective amount of immunogenic polypeptide which is a fragment of the *C. difficile* toxin B polypeptide (e.g., Bx or E_x); e.g., wherein the immunogenic polypeptide includes two carbohydrate binding residues of the toxin B CROP domain that are located in the E1 and E2 domains of said toxin B. For example, wherein the immunogenic polypeptide comprises the structure as depicted in FIG. 2.

20 *C. difficile* toxin B Bx or E_x polypeptides are, in an embodiment of the invention, used to immunize a host animal (e.g., mammal, rabbit, mouse, rat, dromedary, camel or llama) for the purposes of generating an antibody or antigen-binding fragment thereof (e.g., humanized antibody, a monoclonal antibody, a labeled antibody, a bivalent antibody, a polyclonal antibody, a bispecific antibody, a chimeric antibody, a recombinant antibody, an anti-idiotypic antibody, a humanized antibody, a bispecific antibody, a camelized single domain antibody, a diabody, an scfv, an scfv dimer, a dsfv, a (dsfv)₂, a dsFv-dsfv', a bispecific ds diabody, an Fv, an Fab, an Fab', an F(ab')₂, or a domain antibody, e.g., which, in an embodiment of the invention, is linked to an immunoglobulin constant region, e.g., a kappa or lambda light chain, gamma-1 heavy chain, gamma-2 heavy chain, gamma-3 heavy chain or gamma-4 heavy chain) that specifically binds to the polypeptide. In an embodiment of the invention, a host animal is not a human.

25 The present invention also provides a method for immunizing a host animal with a *C. difficile* toxin B Bx or E_x immunogenic polypeptide; or for producing an antibody or antigen-binding fragment thereof that binds specifically to a *C. difficile* toxin B Bx or E_x polypeptide comprising: administering a therapeutically effective amount of a *C. difficile* toxin B Bx or E_x immunogenic polypeptide to the host animal. In an embodiment of the invention, the *C. difficile* toxin B Bx or E_x immunogenic polypeptide is in a vaccine. For example, in an embodiment of the invention, the *C. difficile* toxin B Bx or E_x immunogenic polypeptide is prepared as an injectable

composition (e.g., liquid solutions or suspensions) or as a solid form suitable for dissolution or suspension in a liquid vehicle prior to injection. The present invention includes methods wherein the compositions are administered parenterally, e.g., by injection (e.g., subcutaneously or intramuscularly), orally, (e.g., by inhalation), by suppository, or transdermally.

In an embodiment of the invention, a hybridoma is produced from an antibody-producing B-cell of the host animal. In an embodiment of the invention, the method comprises administering a therapeutically effective amount of a *C. difficile* toxin B_{Bx} or E_x polypeptide to a host animal, isolating an antibody-producing B-cell from the immunized host animal (e.g., by isolating splenocytes from the spleen of the animal) and fusing the B-cell with a myeloma cell (e.g., rat or mouse myeloma), thereby producing the hybridoma; and, optionally, isolating the antibody or antigen-binding fragment thereof from the hybridoma. In an embodiment of the invention, the hybridoma is cultured in a growth medium, such as HAT medium (i.e., medium containing hypoxanthine, aminopterin and thymidine). See e.g., Stites et al. (eds.) *Basic and Clinical Immunology* (4th ed.), Lange Medical Publications, Los Altos, Calif., and references cited therein; Harlow and Lane (1988) *Antibodies: A Laboratory Manual*, CSH Press; Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed.), Academic Press, New York; and Kohler and Milstein (1975) in *Nature* 256:495-497.

In an embodiment of the invention, a non-human antibody that binds specifically to a *C. difficile* toxin B polypeptide which is produced by a method as set forth herein (e.g., isolated from a non-human host animal that was immunized with the immunogenic polypeptide) is humanized. Typically, the sequence of the humanized immunoglobulin heavy chain variable region framework is 65% to 95% identical to the sequence of the donor immunoglobulin heavy chain variable region framework. Each humanized immunoglobulin chain will usually comprise, in addition to the CDRs, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDRs to affect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 angstroms as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

Various methods for humanizing and modifying antibodies have been described in the art. In an embodiment of the invention, a method for making a humanized anti-*C. difficile* toxin B_{Bx} or E_x antibody or antigen-binding fragment thereof comprises humanizing the antibody or fragment, e.g., by any of the several methods known in the art. For example, U.S. Pat. No. 5,530,101 (Queen et al.) describes methods to produce humanized antibodies. See also, related methods in U.S. Pat. No. 5,693,761 (Queen et al); U.S. Pat. No. 5,693,762 (Queen et al); U.S. Pat. No. 5,585,089 (Queen et al).

In one example, U.S. Pat. No. 5,565,332 (Hoogenboom et al.) describes methods for the production of antibodies, and antibody fragments which have similar binding specificity as a parent antibody but which have increased human characteristics. In an embodiment of the invention, anti-*C. difficile* toxin B polypeptide humanized antibodies are obtained by chain shuffling, using, for example, phage display technology, and a polypeptide comprising a heavy or light chain

variable domain of a non-human antibody specific for an antigen of interest is combined with a repertoire of human complementary (light or heavy) chain variable domains. Hybrid pairings that are specific for the antigen of interest are identified and human chains from the selected pairings are combined with a repertoire of human complementary variable domains (heavy or light). In another embodiment of the invention, a component of a CDR from a non-human antibody is combined with a repertoire of component parts of CDRs from human antibodies. From the resulting library of antibody polypeptide dimers, hybrids are selected and used in a second humanizing shuffling step. Alternatively, this second step is eliminated if the hybrid is already of sufficient human character to be of therapeutic value. Methods of modification to increase human character are also described. See also Winter, FEBS Letts 430:92-92 (1998).

As another example, U.S. Pat. No. 6,054,297 (Carter et al.) describes a method for making humanized antibodies by substituting a CDR amino acid sequence for the corresponding human CDR amino acid sequence and/or substituting a FR amino acid sequence for the corresponding human FR amino acid sequences.

As another example, U.S. Pat. No. 5,766,886 (Studnicka et al.) describes methods for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the antigen binding domain while reducing its immunogenicity with respect to a heterologous species and methods for preparing these modified antibody variable domains which are useful for administration to heterologous species. See also U.S. Pat. No. 5,869,619 (Studnicka).

As discussed, modification of an antibody by any of the methods known in the art is typically designed to achieve increased binding affinity for an antigen and/or reduce immunogenicity of the antibody in the recipient. In one approach, humanized antibodies can be modified to eliminate glycosylation sites in order to increase affinity of the antibody for its cognate antigen (Co et al., Mol Immunol 30:1361-1367 (1993)). Techniques such as "reshaping," "hyperchimerization," and "veeneering/resurfacing" have produced humanized antibodies with greater therapeutic potential. (Vaswani et al., Annals of Allergy, Asthma, & Immunol 81:105 (1998); Roguska et al., Prot Engineer 9:895-904 (1996)). See also U.S. Pat. No. 6,072,035 to Hardman et al., which describes methods for reshaping antibodies. While these techniques diminish antibody immunogenicity by reducing the number of foreign residues, they do not prevent anti-idiotypic and anti-allotypic responses following repeated administration of the antibodies. Alternatives to these methods for reducing immunogenicity are described in Gilliland et al., J Immunol 62(6): 3663-71 (1999).

In many instances, humanizing antibodies results in a loss of antigen binding capacity. It is therefore preferable to "back mutate" the humanized antibody to include one or more of the amino acid residues found in the original (most often rodent) antibody in an attempt to restore binding affinity of the antibody. See, for example, Saldanha et al., Mol Immunol 36:709-19 (1999).

In an embodiment of the invention, a *C. difficile* toxin B_{Bx} or E_x polypeptide is used with an antibody phage display library to isolate an antibody or antigen-binding fragment thereof (e.g., ScFv, Fab or nanobody) that binds specifically to polypeptide. In an embodiment of the invention, the method comprises displaying a library of phage molecules (e.g., M13 or Fd) on the surfaces of host cells (e.g., bacterial cells such as *E. coli*), wherein each phage displays an antibody or antigen-binding fragment thereof on its surface, and

selecting the host cells displaying phages having binding specificity for the *C. difficile* toxin B Bx or E_x polypeptide; isolating the host cell and phage from the other host cells and phages and determining the sequence of the antibody or fragment immunoglobulin chains displayed on the phage surface (e.g., by isolating phage genomic DNA and determining the sequence of the portion of the phage genome encoding the antibody or fragment immunoglobulin chains), and, optionally, isolating the antibody or fragment from the phage and/or host cell. See e.g., *Methods in Molecular Biology, Antibody Phage Display Methods and Protocols*, Philippa M. O'Brien & Robert Aitken (eds.), Humana Press, Inc. Totowa, N.J. USA, 2002.

The present invention provides a vaccine or pharmaceutical composition comprising a *C. difficile* toxin B Bx or E_x immunogenic polypeptide and a pharmaceutically acceptable carrier as well as methods of making and using such vaccines and pharmaceutical compositions. For example, the present invention provide a method for making a vaccine or pharmaceutical composition comprising combining a *C. difficile* toxin B Bx or E_x immunogenic polypeptide with a pharmaceutically acceptable carrier and, optionally, other components that are appropriate for use in a vaccine or pharmaceutical composition (e.g., as discussed herein).

Pharmaceutically acceptable carriers which can be included in a pharmaceutical composition or vaccine of the present invention include, for example, large, slowly metabolized, macromolecules, such as proteins, polysaccharides such as latex functionalized sepharose, agarose, cellulose, cellulose beads and the like, polyalactic acids, polyglycolic acids, polymeric amino acids such as polyglutamic acid, polylysine, and the like, amino acid copolymers, and inactive virus particles.

Pharmaceutically acceptable salts can be included in a pharmaceutical composition or vaccine of the present invention. For example, such salts can be mineral salts such as hydrochlorides, hydrobromides, phosphates, or sulfates, as well as salts of organic acids such as acetates, propionates, malonates, or benzoates.

Proteins can be included in a pharmaceutical composition or vaccine of the present invention; e.g., serum albumins (e.g., human serum albumin), keyhole limpet hemocyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, tetanus toxoid, and other proteins well known to those of skill in the art.

Liquids or excipients can be included in a pharmaceutical composition or vaccine of the present invention, e.g., water, saline, glycerol, dextrose, ethanol, as well as substances such as wetting agents, emulsifying agents, or pH buffering agents.

Liposomes which act as a carrier can be included in a pharmaceutical composition or vaccine of the present invention.

Co-stimulatory molecules which improve immunogen presentation to lymphocytes, such as B7-1 or B7-2, or cytokines such as GM-CSF, IL-2, and IL-12, can be included in a pharmaceutical composition or vaccine of the present invention. Optionally, adjuvants can also be included in a composition. Adjuvants which can be used include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc.; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides or bacterial cell wall components), such as for example (a) MF59 (U.S. Pat. No. 6,299,884, incorporated herein by reference in its entirety; Chapter 10 in Vaccine design: the sub-unit and adjuvant approach, eds. Powell & Newman, Plenum Press 1995), containing 5% squalene, 0.5% TWEEN 80, and 0.5% SPAN 85 (optionally containing various amounts of

MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, Mass.), (b) SAF, containing 10% squalane, 0.4% TWEEN-80, 5% pluronic-blocked polymer L121, and thr-MDP either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) RIBI adjuvant system (RAS), (Ribi Immunochem, Hamilton, Mont.) containing 2% squalene, 0.2% TWEEN-80, and one or more bacterial cell wall components from the group consisting of monophosphoryl lipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+CWS (DETOX); (3) saponin adjuvants, such as QS21 or STIMULON (Cambridge Bioscience, Worcester, Mass.) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes), which ISCOMs may be devoid of additional detergent, see, e.g., WO00/07621; (4) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as interleukins (IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (WO99/44636), etc.), interferons (e.g., gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; (6) detoxified mutants of a bacterial ADP-ribosylating toxin such as a cholera toxin (CT), a pertussis toxin (PT), or an *E. coli* heat-labile toxin (LT), particularly LT-K63 (where lysine is substituted for the wild-type amino acid at position 63) LT-R72 (where arginine is substituted for the wild-type amino acid at position 72), CT-S109 (where serine is substituted for the wild-type amino acid at position 109), and PT-K9/G129 (where lysine is substituted for the wild-type amino acid at position 9 and glycine substituted at position 129) (see, e.g., WO93/13202 and WO92/19265); (7) MPL or 3-O-deacylated MPL (3dMPL) (see, e.g., GB 2220221), EP-A-0689454, optionally in the substantial absence of alum when used with pneumococcal saccharides (see, e.g., WO 00/56358); (8) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions (see, e.g., EP-A-0835318, EP-A-0735898, EP-A-0761231; (9) oligonucleotides comprising CpG motifs (see, e.g., Roman et al. (1997) Nat. Med. 3:849-854; Weiner et al. (1997) Proc. Natl. Acad. Sci. USA 94:10833-10837; Davis et al. (1998) J. Immunol. 160:870-876; Chu et al. (1997) J. Exp. Med. 186:1623-1631; Lipford et al. (1997) Eur. J. Immunol. 27:2340-2344; Moldoveanu et al. (1988) Vaccine 16:1216-1224; Krieg et al. (1995) Nature 374:546-549; Klinman et al. (1996) Proc. Natl. Acad. Sci. USA 93:2879-2883; Belles et al. (1996) J. Immunol. 157:1840-1845; Cowdery et al. (1996) J. Immunol. 156:4570-4575; Halpern et al. (1996) Cell Immunol. 167:72-78; Yamamoto et al. (1988) Jpn. J. Cancer Res. 79:866-873; Stacey et al. (1996) J. Immunol. 157:2116-2122; Messina et al. (1991) J. Immunol. 147:1759-1764; Yi et al. (1996) J. Immunol. 157:4918-4925; Yi et al. (1996) J. Immunol. 157:5394-5402; Yi et al. (1998) J. Immunol. 160:4755-4761; Yi et al. (1998) J. Immunol. 160:5898-5906; WO96/02555, WO98/16247, WO98/18810, WO98/40100, WO98/55495, WO98/37919 and WO 98/52581), such as those containing at least one CG dinucleotide, with cytosine optionally replaced with 5-methylcytosine; (10) a polyoxyethylene ether or a polyoxyethylene ester (see, e.g., WO99/52549); (11) a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol (see, e.g., WO01/21207) or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional non-ionic surfactant such as an octoxynol (see e.g., WO01/21152); (12) a saponin and an immunostimulatory oligonucleotide such as a CpG oligonucleotide (see, e.g., WO00/62800); (13) an immunostimulant and a particle of metal salt

21

(see, e.g., WO00/23105); and (14) other substances that act as immunostimulating agents to enhance the effectiveness of the composition.

Muramyl peptides can be included in a pharmaceutical composition or vaccine of the present invention, e.g., N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isogluatme (nor-MDP), -acetyl muramyl-L-alanyl-D-isogluatminyl-L-alanine-2-(1'-2'-dipahlitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.

Other adjuvants can be included in a pharmaceutical composition or vaccine of the present invention, e.g., submicron oil-in-water emulsions, e.g., squalene/water emulsions. Submicron oil-in-water emulsions, methods of making the same and immunostimulating agents, such as muramyl peptides, for use in the compositions, are described in detail in WO90/14837 and U.S. Pat. Nos. 6,299,884 and 6,451,325, incorporated herein by reference in their entirieties.

Other agents that can, in an embodiment of the invention, be included in a pharmaceutical composition or vaccine of the present invention include immunostimulatory molecules such as immunostimulatory nucleic acid sequences (ISS), including but not limited to, unmethylated CpG motifs, such as CpG oligonucleotides. Oligonucleotides containing unmethylated CpG motifs have been shown to induce activation of B cells, NK cells and antigen-presenting cells (APCs), such as monocytes and macrophages. See, e.g., U.S. Pat. No. 6,207,646. Moreover, the CpG oligonucleotides for use herein may be double- or single-stranded. Double-stranded molecules are more stable in vivo while single-stranded molecules display enhanced immune activity. Additionally, the phosphate backbone may be modified, such as phosphorodithioate-modified, in order to enhance the immunostimulatory activity of the CpG molecule. As described in U.S. Pat. No. 6,207,646, CpG molecules with phosphorothioate backbones preferentially activate B-cells, while those having phosphodiester backbones preferentially activate monocytic (macrophages, dendritic cells and monocytes) and NK cells. CpG molecules can readily be tested for their ability to stimulate an immune response using standard techniques, well known in the art. For example, the ability of the molecule to stimulate a humoral and/or cellular immune response is readily determined using the immunoassays described above. Moreover, the immunogenic compositions can be administered with and without the CpG molecule to determine whether an immune response is enhanced.

A *C. difficile* toxin B Bx or E_x immunogenic polypeptide is, in an embodiment of the invention, encapsulated, adsorbed to, or associated with, particulate carriers. Examples of particulate carriers include those derived from polymethyl methacrylate polymers, as well as microparticles derived from poly(lactides) and poly(lactide-co-glycolides), known as PLG. See, e.g., Jeffery et al., Pharm. Res. (1993) 10:362-368; and McGee et al., J. Microencap. (1996). One preferred method for adsorbing macromolecules onto prepared microparticles is described in WO00/050006, incorporated herein by reference in its entirety.

Methods for immunizing a host animal or for making an antibody or antigen-binding fragment thereof that binds specifically to a *C. difficile* toxin B polypeptide include the step of administering a therapeutically effective amount of *C. difficile* toxin B Bx or E_x immunogenic polypeptide to the host animal. By "therapeutically effective amount" is meant an amount of a *C. difficile* toxin B Bx or E_x immunogenic polypeptide or DNA encoding the *C. difficile* toxin B Bx or E_x polypeptide which will induce an immunological response in the individual to which it is administered, if the composition

22

is to be used as a vaccine or in an immunization. Such a response will generally result in the development in the subject of an antibody-mediated and/or a secretory or cellular immune response to the composition. Such a response may include the production of antibodies from any of the immunological classes, such as immunoglobulins A, D, E, G or M; the proliferation of B and T lymphocytes; the provision of activation, growth and differentiation signals to immunological cells; expansion of helper T cell, suppressor T cell, and/or cytotoxic T cell and/or gamma delta T cell populations. In an embodiment of the invention, the therapeutically effective amount is about 0.1 micrograms to about 200 mg of the polypeptide. An "immunogenic" polypeptide is generally capable of inducing such a response in an individual to whom the polypeptide is administered.

EXAMPLES

The following information is provided for more clearly describing the present invention and should not be construed to limit the present invention. Any and all of the compositions and methods described below fall within the scope of the present invention.

Example 1

The Cloning, Expression and Purification of *C. difficile* Toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾)

The CROP domain fragments (B1 (1834-2367), B2 (1834-2101), B3 (1949-2275) and B4 (2102-2367)) from *C. difficile* were cloned into vector pET28a(+) (EMD Biosciences), which encodes a C-terminal His₆ tag. The nucleotide sequence was confirmed by DNA sequencing (Genewiz). Bx fragments including B2 (1834-2101) were expressed in *E. coli* BL21(DE3) (Novagen) in Terrific Broth supplemented with 50 µg ml⁻¹ kanamycin for 18 hours at 16° C. with 1 mM IPTG. The cells were harvested by centrifugation for 15 minutes at 6000×g, pellets were resuspended in 50 mM Tris pH 8.0, 0.3 M NaCl, 1 mM DTT, 1 mg ml⁻¹ protease inhibitor cocktail III (EMD Biosciences), and then lysed with a microfluidizer. Cell lysate was clarified by centrifugation at 100, 000×g for 1 hour at 4° C. The supernatant was filtered and loaded onto a Ni²⁺-IMAC (Qiagen) column equilibrated with 50 mM Tris pH 8.0, 0.3 M NaCl, 10% glycerol and 1 mM DTT. The protein was eluted using an imidazole gradient (0-0.25 M) containing 50 mM Tris pH 8.0, 0.3 M NaCl, 10% glycerol and 1 mM DTT. Fractions containing Bx proteins were pooled, diluted to 50 mM NaCl and further purified by ion exchange chromatography using a Source 15Q column (GE Healthcare). The final storage buffer for Bx proteins was 50 mM Hepes pH 7.5, 0.15 M NaCl. Fractions with >95% pure Bx (as monitored by SDS-PAGE electrophoresis) were collected and concentrated to 5 mg ml⁻¹ using a centrifugal concentrator. The molecular weight of Bx was confirmed by ESI-Ion-Trap-MS using a LTQ-XL mass spectrometer and the Xcalibur software platform (Thermo-Fisher Scientific).

The *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) comprises the amino acid sequence:

(SEQ ID NO: 2)
 MGLIYINDSLYYFKPPVNNLITGFVTVGDDKYYFNPINGGAASIGETIID
 DKNYYFNQSGVLQTGVFSTEDGFKYFAPANTLDENLEGEAIDFTGKLIIID
 ENIYYFDDNYRGAVEWKELDGEHMHYFSPETGKAFKGLNQIGDYKYYFPNSD

23

- continued

GVMQKGFVSINDNKHYFDDSGVMKVGYTEIDGKHFYFAENGEMQIGVFNT
 EDGFKYFAHHNEDLGNNEEGEEISYSGILNFFNNKIYYFDDSFATAVVGWKL
 5 EDGSKYYFDEDTAEAYILEHHHHHH

Example 2

Preparation of Anti-TcdB Antibody Bezlotoxumab Fab

Fab from bezlotoxumab was generated using the Pierce Fab Preparation Kit (Catalog #44985) following the manufacturer's instructions. Briefly, prepared antibody was incubated with immobilized papain resin at 37° C. for 5 hours. Following the protease digestion, undigested IgG and Fc fragments were removed by running sample through a protein A column. The resulting Fab-containing flow-through was collected and further purified by size exclusion chromatography. N-terminal sequencing was used to confirm the Fab fragment identity.

The anti-TcdB antibody, bezlotoxumab, Fab chains comprise the following amino acid sequences:

Light chain:

(SEQ ID NO: 11)
 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAZYQQKPGQAPRLLIYG
 ASSRATGIPDRFSGSGSGTDFTLTI SRLEPEDFAVYYCQQYGSSTWTFGQG
 TKVEIKRTVAAPSVFIEPPSDEQLKSGTASVVCLLNFYPREAKVQWKVDN
 ALQSGNSQESVTEQDSKDSTYSLSSLTLS KADYEHKHVYACEVTHQGLSS
 PVTKSFNRG

Heavy chain:

(SEQ ID NO: 12)
 EVQLVQSGAEVKKGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIF
 YPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNW
 GNAFDIWGQGTMVTVSSASTKGPSVPLAPSSSTAALGCLVKDYFPEPVTWS
 WNSGALTSGVHTFPALQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN
 TKVDKRVEPKS

Example 3

Complex Between Anti-TcdB Antibody Bezlotoxumab Fab and *C. difficile* Toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) and Preparation for Crystallization

Purified B2 and Fab fragments were mixed in 1:3 molar ratios and excess Fab was separated by size exclusion chromatography (S200 26/60 column from GE Healthcare). The complex was concentrated to >15 mgs/mL for crystallization trials.

Direct binding with Bx and bezlotoxumab

(a) Temperature-Dependent Fluorescence (TdF)

166 µM Bx in 25 mM HEPES pH 7.5, 0.15 M NaCl was thawed on ice, centrifuged for 5 minutes to remove insoluble material, and diluted 100-fold. Sypro orange (Invitrogen) was prepared with 100% DMSO. To the 1 µM protein solution, Sypro orange was added to a final concentration of 5×. For the

24

TdF experiments with the complex, bezlotoxumab was added at 1:1 stoichiometric amount to 1 µM B2 protein. 10 µl of 'apo' B2 and B2-bezlotoxumab samples were pipetted into a white 384-well PCR plate (Abgene) and sealed with flat ultra clear caps (BioRad).

A TdF assay was conducted with a Roche-PCR instrument (Roche) equipped with a CCD camera for fluorescence detection. The temperature was increased from 20° C. to 80° C. in 0.2° C. increments using a 200 millisecond stabilization delay before reading.

Fluorescence signals were acquired with excitation and emission wavelengths of 490 nm and 560 nm, respectively. A customized analysis program using a non-linear least square method based on the Generalized Reduced Gradient algorithm was used to fit the protein unfolding model (reference). The fluorescence intensity of Sypro Orange dye is generally linearly dependent with temperature. The following parameters were floated during the fitting process: Y intercepts for the intensity of Sypro Orange in both the native and denatured proteins (Y_n and Y_d); the associated slopes (M_n and M_d); the midpoint of melting (T_m); and the enthalpy at the T_m (ΔH_m).

25 (b) Kinetics of Binding of Toxins Fragments to Bezlotoxumab

The binding of toxin fragments to the antibodies was studied by surface plasmon resonance using BioRad's ProteOn instrument. Surface plasmon resonance is an optical phenomenon that is used in the ProteOn system to monitor binding of two unlabeled molecules in real time. The SPR signal is based on changes in the refractive index at the surface of a gold sensor chip as an analyte flows in a microfluidic channel and binds to a ligand immobilized on the sensor chip. Monitoring the changes in the SPR signal over time produced a sensogram, a plot of the binding response versus time.

For these experiments, the antibody molecules were immobilized to the sensor chip surface as manufacturer recommendations. ProteOn GLC Sensor chip was docked to the system, and after standard cleaning, a mixture of 1×EDC+sNHS was injected over the chip to activate the chip surface. A 5 µg/mL solution of antibody in ProteOn immobilization buffer was injected for 1 min. 1M Ethanolamine HCl was injected for 5 mins to 'cap' any unoccupied reactive sites on the chip surface. Once the immobilization is confirmed, the interaction of the toxins to antibody was measured as a change in the refractive index over time. The ProteOn's 6×6 array allowed for multiple simultaneous injections of different toxin concentrations to obtain a full kinetic profile and equilibrium binding. Toxin fragments were diluted to 100 nM in ProteOn Running Buffer and then serially diluted five times 2-fold for a concentration-range experiment. Following dilution, the toxin molecules were injected in horizontal orientation for 2 minutes (flow rate 25 µl/min) and dissociation was monitored for 1 hour post-injection. Buffer was injected onto channel A6 for use as a reference. The data analyses was carried out using the ProteOn instrument software, with ligand injections corrected using referencing to the Interspot and channel A6. Data was fit using standard equilibrium fitting to determine Kd with steady-state assumptions. For individual toxin fragment-antibody interactions, distinct immobilization experiments were performed.

25

Results

Selection of Toxin 82 Fragment for Complex Formation Studies

C. difficile toxin B CROP domain fragments were overexpressed in *E. coli* as described herein. The toxin B proteins were confirmed to be >95% pure as shown by SDS-PAGE and the identity of the constructs were confirmed by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry and sequencing. Direct binding experiments using thermal-shift assay and SPR confirmed the bezlotoxumab epitope to be retained within the B2 (1834-2101) region of the toxin B CROP domain. Interestingly, no binding was observed in the region C-terminal to B2, B4 (amino acids 2102-2367). The dissociation constant ($K_d=25$ nM) for B2 (1834-2101) fragment and bezlotoxumab interaction was representative of the full-length toxin B and bezlotoxumab interaction ($K_d=12$ nM). B2-bezlotoxumab Fab complex formation was performed at 50% excess of Fab followed by separation of excess Fab from the complex by gel-filtration. The B2-bezlotoxumab Fab complex was concentrated to >15 mgs/mL and confirmed to be monodispersed by dynamic light scattering. Purity was greater than 95% as determined by SDS-PAGE and sequence analysis.

26

Example 5

Photomicrograph of Anti-TcdB Antibody Bezlotoxumab Fab-C. difficile Toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) Complex

An image of the crystal is set forth in FIG. 4.

Example 6

X-Ray Crystallographic Characterization Anti-TcdB Antibody Bezlotoxumab Fab-C. difficile Toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) Complex

Prior to data collection, crystals were harvested at 4°C and transferred into the reservoir solution with 20% ethyleneglycol added. After a 20 second exposure to this cryoprotectant, the crystals were fished using a cryo-loop and frozen in liquid nitrogen. The frozen crystals were then mounted onto the goniometer at the IMCA-CAT beamline 171D at the Argonne National Laboratory equipped with a nitrogen cooled stream.

X-ray diffraction was collected using a PILATUS 6M detector. Data were integrated and scaled using the XDS as part of the Global Phasing package. The crystal and its analysis are characterized below.

Space Group	P21			
Unit cell	a = 79.413	b = 134.659	c = 102.579	$\alpha = \gamma = 90^\circ$ $\beta = 112.559^\circ$
Low resolution limit	47.365	47.365	2.900	
High resolution limit	2.890	13.316	2.890	
Rmerge	0.056	0.020	0.547	
Ranom	0.048	0.017	0.481	
Rmeas (within I+I-)	0.068	0.023	0.669	
Rmeas (all I+ & I-)	0.066	0.024	0.645	
Rpim (within I+I-)	0.047	0.016	0.464	
Rpim (all I+ & I-)	0.036	0.014	0.340	
Total number of observations	150967	1548	1563	
Total number unique	44417	457	455	
Mean(I)/sd(I)	17.3	47.3	2.1	
Completeness	99.5	97.4	100.0	
Multiplicity	3.4	3.4	3.4	

Example 4

Crystallization of Anti-TcdB Antibody Bezlotoxumab Fab-C. difficile Toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) Complex

The anti-TcdB antibody bezlotoxumab Fab-C. difficile Toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex as described above was crystallized using a sitting-drop vapor diffusion method setup using a Oryx crystallization-robot (Douglas Instruments, LTD) in a MRC-2 (Innovadyne SD-2) crystallization plate. The anti-TcdB antibody bezlotoxumab Fab-C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex (0.5 μ L; 20 mg/mL) in 10 mM phosphate, pH 7.4, 137 mM sodium chloride, 2.7 mM potassium chloride buffer was mixed with an equal volume of precipitant solution containing 4.4% PEG 4000 (Jena Biosciences JBS Single stock (CSS-253)) and sealed in close proximity to 0.08 mL of the precipitant solution. Crystallization plates were incubated at 4°C and crystals (0.025 \times 0.015 mm) grew over a period of 5-60 days.

Example 7

Structure Determination of Anti-TcdB Antibody Bezlotoxumab Fab-C. difficile Toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) Complex

The crystal structure was solved using molecular replacement package MOLREP using the PDB entry 1 HZH as the search model for the FAB as well as a manually build toxin B model based on the PDB entry 2G7C. Refinement was done using the program autoBUSTER as part of the Global Phasing package. A pictorial representation of the complex is set forth in FIGS. 1-3.

Resolution Limits	42.31-2 \AA
Number of observed reflections	44385 (99.37%)
Number of reflections in test set	931 (2.1%)
Number of protein residues	1126
Number of solvent atoms	None
R-factor	0.2055
R-free	0.2404
RMSD bond length	0.010 \AA
RMSD bond angles	1.35°

TABLE I

Three-dimensional crystal coordinate for anti-TcdB antibody beziotuxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

CISPEP	1	GLU	A	2083	ASP	A	2084	0	5.88			
CISPEP	2	SER	A	75	VAL	H	76	0	10.99			
CISPEP	3	TRP	H	102	GLY	H	103	0	-4.24			
CISPEP	4	PHE	H	152	PRO	H	153	0	-6.82			
CISPEP	5	GLU	H	154	PRO	H	155	0	8.85			
CISPEP	6	VAL	I	76	ASN	I	77	0	-5.33			
CISPEP	7	TRP	I	102	GLY	I	103	0	-4.56			
CISPEP	8	PHE	I	152	PRO	I	153	0	-5.39			
CISPEP	9	GLU	I	154	PRO	I	155	0	8.45			
CISPEP	10	ASN	I	161	SER	I	162	0	-10.18			
CISPEP	11	SER	L	7	PRO	L	8	0	-7.19			
CISPEP	12	TYR	L	92	GLY	L	93	0	-5.59			
CISPEP	13	SER	L	95	THR	L	96	0	-28.90			
CISPEP	14	TYR	L	141	PRO	L	142	0	-3.90			
CISPEP	15	SER	M	7	PRO	M	8	0	9.05			
CISPEP	16	TYR	M	141	PRO	M	142	0	-2.24			
SSBOND	1	CYS	H	22	CYS	H	96			1555	1555	2.03
SSBOND	2	CYS	H	146	CYS	H	202			1555	1555	2.03
SSBOND	3	CYS	I	22	CYS	I	96			1555	1555	2.03
SSBOND	4	CYS	I	146	CYS	I	202			1555	1555	2.03
SSBOND	5	CYS	L	23	CYS	L	89			1555	1555	2.09
SSBOND	6	CYS	L	135	CYS	L	195			1555	1555	2.05
SSBOND	7	CYS	M	23	CYS	M	89			1555	1555	2.06
SSBOND	8	CYS	M	135	CYS	M	195			1555	1555	2.04
CRYST1	79.413		134.659	102.579		90.00	112.56	90.00 P	1 21 1			
ATOM	1	N	GLY	A1834		-8.663	-68.265	21.493	1.00	71.52	N	
ATOM	2	CA	GLY	A1834		-7.890	-67.334	20.687	1.00	71.59	C	
ATOM	3	C	GLY	A1834		-7.753	-65.946	21.273	1.00	75.58	C	
ATOM	4	O	GLY	A1834		-8.122	-65.723	22.430	1.00	75.39	O	
ATOM	5	N	LEU	A1835		-7.217	-64.995	20.476	1.00	72.14	N	
ATOM	6	CA	LEU	A1835		-7.009	-63.628	20.962	1.00	71.92	C	
ATOM	7	C	LEU	A1835		-8.319	-62.810	20.958	1.00	73.85	C	
ATOM	8	O	LEU	A1835		-9.008	-62.745	19.953	1.00	72.10	O	
ATOM	9	CB	LEU	A1835		-5.816	-62.901	20.276	1.00	71.99	C	
ATOM	10	CG	LEU	A1835		-5.878	-62.422	18.839	1.00	76.89	C	
ATOM	11	CD1	LEU	A1835		-4.532	-62.004	18.407	1.00	76.64	C	
ATOM	12	CD2	LEU	A1835		-6.332	-63.515	17.877	1.00	81.95	C	
ATOM	13	N	ILE	A1836		-8.680	-62.273	22.144	1.00	71.06	N	
ATOM	14	CA	ILE	A1836		-9.912	-61.524	22.456	1.00	71.53	C	
ATOM	15	C	ILE	A1836		-9.593	-60.140	23.032	1.00	77.30	C	
ATOM	16	O	ILE	A1836		-8.656	-60.012	23.821	1.00	77.60	O	
ATOM	17	CB	ILE	A1836		-10.781	-62.315	23.497	1.00	74.59	C	
ATOM	18	CG1	ILE	A1836		-10.917	-63.816	23.149	1.00	75.42	C	
ATOM	19	CG2	ILE	A1836		-12.152	-61.674	23.718	1.00	74.56	C	
ATOM	20	CD1	ILE	A1836		-10.742	-64.761	24.329	1.00	79.98	C	
ATOM	21	N	TYR	A1837		-10.451	-59.143	22.731	1.00	74.41	N	
ATOM	22	CA	TYR	A1837		-10.353	-57.777	23.233	1.00	74.39	C	
ATOM	23	C	TYR	A1837		-11.206	-57.501	24.472	1.00	80.35	C	
ATOM	24	O	TYR	A1837		-12.421	-57.377	24.354	1.00	79.52	O	
ATOM	25	CB	TYR	A1837		-10.749	-56.800	22.135	1.00	75.37	C	
ATOM	26	CG	TYR	A1837		-9.577	-56.306	21.328	1.00	77.69	C	
ATOM	27	CD1	TYR	A1837		-8.759	-55.281	21.805	1.00	80.05	C	
ATOM	28	CD2	TYR	A1837		-9.299	-56.835	20.072	1.00	78.10	C	
ATOM	29	CE1	TYR	A1837		-7.681	-54.811	21.059	1.00	81.52	C	
ATOM	30	CE2	TYR	A1837		-8.218	-56.380	19.319	1.00	79.02	C	
ATOM	31	CZ	TYR	A1837		-7.408	-55.372	19.819	1.00	88.34	C	
ATOM	32	OH	TYR	A1837		-6.342	-54.919	19.081	1.00	90.72	O	
ATOM	33	N	ILE	A1838		-10.577	-57.362	25.655	1.00	79.82	N	
ATOM	34	CA	ILE	A1838		-11.298	-56.987	26.890	1.00	80.48	C	
ATOM	35	C	ILE	A1838		-10.876	-55.557	27.249	1.00	86.46	C	
ATOM	36	O	ILE	A1838		-9.738	-55.339	27.675	1.00	86.14	O	
ATOM	37	CB	ILE	A1838		-11.146	-57.930	28.141	1.00	83.26	C	
ATOM	38	CG1	ILE	A1838		-10.946	-59.440	27.794	1.00	83.92	C	
ATOM	39	CG2	ILE	A1838		-12.296	-57.741	29.132	1.00	82.79	C	
ATOM	40	CD1	ILE	A1838		-12.025	-60.155	27.042	1.00	93.93	C	
ATOM	41	N	ASN	A1839		-11.798	-54.597	27.067	1.00	84.06	N	
ATOM	42	CA	ASN	A1839		-11.639	-53.190	27.407	1.00	84.25	C	

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	43	C	ASN	A1839	-10.470	-52.500	26.701	1.00	88.67	C
ATOM	44	O	ASN	A1839	-9.507	-52.077	27.365	1.00	89.38	O
ATOM	45	CB	ASN	A1839	-11.556	-52.998	28.940	1.00	86.89	C
ATOM	46	CG	ASN	A1839	-12.743	-52.279	29.527	1.00	122.69	C
ATOM	47	ND2	ASN	A1839	-12.805	-50.956	29.340	1.00	115.96	N
ATOM	48	OD1	ASN	A1839	-13.613	-52.893	30.155	1.00	119.16	O
ATOM	49	N	ASP	A1840	-10.562	-52.362	25.352	1.00	83.79	N
ATOM	50	CA	ASP	A1840	-9.580	-51.647	24.503	1.00	82.70	C
ATOM	51	C	ASP	A1840	-8.159	-52.258	24.499	1.00	81.64	C
ATOM	52	O	ASP	A1840	-7.329	-51.871	23.670	1.00	81.83	O
ATOM	53	CB	ASP	A1840	-9.515	-50.140	24.869	1.00	85.53	C
ATOM	54	CG	ASP	A1840	-10.856	-49.478	25.189	1.00	103.13	C
ATOM	55	OD1	ASP	A1840	-11.661	-49.273	24.246	1.00	105.05	O
ATOM	56	OD2	ASP	A1840	-11.091	-49.151	26.381	1.00	108.87	O
ATOM	57	N	SER	A1841	-7.901	-53.209	25.423	1.00	73.02	N
ATOM	58	CA	SER	A1841	-6.675	-53.973	25.654	1.00	69.92	C
ATOM	59	C	SER	A1841	-6.860	-55.435	25.110	1.00	70.40	C
ATOM	60	O	SER	A1841	-7.950	-56.008	25.239	1.00	71.35	O
ATOM	61	CB	SER	A1841	-6.370	-53.960	27.148	1.00	70.40	C
ATOM	62	OG	SER	A1841	-5.463	-54.978	27.524	1.00	76.29	O
ATOM	63	N	LEU	A1842	-5.805	-56.027	24.515	1.00	61.96	N
ATOM	64	CA	LEU	A1842	-5.867	-57.356	23.891	1.00	59.80	C
ATOM	65	C	LEU	A1842	-5.308	-58.523	24.756	1.00	62.98	C
ATOM	66	O	LEU	A1842	-4.245	-58.411	25.372	1.00	62.17	O
ATOM	67	CB	LEU	A1842	-5.170	-57.281	22.530	1.00	59.12	C
ATOM	68	CG	LEU	A1842	-5.031	-58.541	21.719	1.00	62.71	C
ATOM	69	CD1	LEU	A1842	-6.296	-58.873	21.002	1.00	62.29	C
ATOM	70	CD2	LEU	A1842	-3.946	-58.377	20.724	1.00	65.67	C
ATOM	71	N	TYR	A1843	-6.037	-59.661	24.764	1.00	58.59	N
ATOM	72	CA	TYR	A1843	-5.719	-60.839	25.573	1.00	57.40	C
ATOM	73	C	TYR	A1843	-5.747	-62.129	24.754	1.00	61.57	C
ATOM	74	O	TYR	A1843	-6.229	-62.110	23.635	1.00	59.90	O
ATOM	75	CB	TYR	A1843	-6.706	-60.932	26.748	1.00	57.07	C
ATOM	76	CG	TYR	A1843	-6.666	-59.756	27.701	1.00	58.91	C
ATOM	77	CD1	TYR	A1843	-7.421	-58.609	27.462	1.00	60.82	C
ATOM	78	CD2	TYR	A1843	-5.935	-59.817	28.880	1.00	60.17	C
ATOM	79	CE1	TYR	A1843	-7.420	-57.538	28.358	1.00	61.23	C
ATOM	80	CE2	TYR	A1843	-5.936	-58.757	29.792	1.00	61.32	C
ATOM	81	CZ	TYR	A1843	-6.682	-57.620	29.528	1.00	69.70	C
ATOM	82	OH	TYR	A1843	-6.666	-56.579	30.430	1.00	72.08	O
ATOM	83	N	TYR	A1844	-5.255	-63.252	25.318	1.00	59.99	N
ATOM	84	CA	TYR	A1844	-5.271	-64.558	24.648	1.00	60.51	C
ATOM	85	C	TYR	A1844	-5.772	-65.643	25.594	1.00	67.14	C
ATOM	86	O	TYR	A1844	-5.310	-65.713	26.736	1.00	68.13	O
ATOM	87	CB	TYR	A1844	-3.880	-64.921	24.099	1.00	61.04	C
ATOM	88	CG	TYR	A1844	-3.878	-66.085	23.136	1.00	62.55	C
ATOM	89	CD1	TYR	A1844	-4.183	-65.904	21.790	1.00	64.94	C
ATOM	90	CD2	TYR	A1844	-3.559	-67.365	23.564	1.00	63.53	C
ATOM	91	CE1	TYR	A1844	-4.208	-66.981	20.902	1.00	66.23	C
ATOM	92	CE2	TYR	A1844	-3.585	-68.452	22.688	1.00	64.49	C
ATOM	93	CZ	TYR	A1844	-3.906	-68.256	21.356	1.00	71.49	C
ATOM	94	OH	TYR	A1844	-3.915	-69.331	20.496	1.00	71.96	O
ATOM	95	N	PHE	A1845	-6.713	-66.489	25.120	1.00	64.37	N
ATOM	96	CA	PHE	A1845	-7.290	-67.587	25.912	1.00	64.42	C
ATOM	97	C	PHE	A1845	-7.306	-68.893	25.156	1.00	71.28	C
ATOM	98	O	PHE	A1845	-7.541	-68.895	23.949	1.00	69.30	O
ATOM	99	CB	PHE	A1845	-8.713	-67.265	26.381	1.00	65.17	C
ATOM	100	CG	PHE	A1845	-8.836	-66.312	27.544	1.00	65.15	C
ATOM	101	CD1	PHE	A1845	-8.897	-64.936	27.334	1.00	66.34	C
ATOM	102	CD2	PHE	A1845	-8.965	-66.788	28.841	1.00	65.75	C
ATOM	103	CE1	PHE	A1845	-9.064	-64.054	28.403	1.00	66.30	C
ATOM	104	CE2	PHE	A1845	-9.135	-65.902	29.910	1.00	68.03	C
ATOM	105	CZ	PHE	A1845	-9.185	-64.540	29.681	1.00	65.33	C
ATOM	106	N	LYS	A1846	-7.092	-70.009	25.883	1.00	72.31	N
ATOM	107	CA	LYS	A1846	-7.094	-71.349	25.305	1.00	74.59	C
ATOM	108	C	LYS	A1846	-8.277	-72.231	25.843	1.00	82.22	C
ATOM	109	O	LYS	A1846	-8.858	-71.933	26.906	1.00	79.73	O
ATOM	110	CB	LYS	A1846	-5.716	-72.033	25.439	1.00	78.13	C
ATOM	111	CG	LYS	A1846	-4.827	-71.861	24.197	1.00	90.10	C
ATOM	112	CD	LYS	A1846	-3.338	-72.215	24.442	1.00	94.27	C
ATOM	113	CE	LYS	A1846	-2.981	-73.680	24.316	1.00	95.69	C
ATOM	114	NZ	LYS	A1846	-2.682	-74.069	22.913	1.00	98.48	N
ATOM	115	O	PRO	A1847	-11.447	-74.500	26.924	1.00	91.84	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab – *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	116	N	PRO	A1847	-8.628	-73.295	25.048	1.00	82.98	N
ATOM	117	CA	PRO	A1847	-9.787	-74.156	25.344	1.00	83.46	C
ATOM	118	C	PRO	A1847	-10.221	-74.448	26.782	1.00	88.45	C
ATOM	119	CB	PRO	A1847	-9.427	-75.486	24.666	1.00	85.33	C
ATOM	120	CG	PRO	A1847	-8.192	-75.192	23.779	1.00	90.07	C
ATOM	121	CD	PRO	A1847	-8.050	-73.699	23.749	1.00	85.36	C
ATOM	122	O	PRO	A1848	-12.126	-74.959	30.041	1.00	81.38	O
ATOM	123	N	PRO	A1848	-9.383	-74.707	27.820	1.00	80.46	N
ATOM	124	CA	PRO	A1848	-9.959	-75.113	29.131	1.00	79.21	C
ATOM	125	C	PRO	A1848	-11.151	-74.301	29.697	1.00	80.53	C
ATOM	126	CB	PRO	A1848	-8.765	-75.073	30.065	1.00	81.09	C
ATOM	127	CG	PRO	A1848	-7.618	-75.446	29.157	1.00	85.72	C
ATOM	128	CD	PRO	A1848	-7.908	-74.807	27.830	1.00	80.87	C
ATOM	129	O	VAL	A1849	-10.758	-71.636	32.202	1.00	75.47	O
ATOM	130	N	VAL	A1849	-11.106	-72.926	29.739	1.00	73.01	N
ATOM	131	CA	VAL	A1849	-12.061	-71.894	30.252	1.00	71.58	C
ATOM	132	C	VAL	A1849	-11.339	-71.074	31.270	1.00	74.54	C
ATOM	133	CB	VAL	A1849	-13.531	-72.232	30.727	1.00	75.25	C
ATOM	134	CG1	VAL	A1849	-13.562	-73.024	32.039	1.00	75.61	C
ATOM	135	CG2	VAL	A1849	-14.378	-70.959	30.889	1.00	74.26	C
ATOM	136	O	ASN	A1850	-8.478	-68.740	33.031	1.00	70.85	O
ATOM	137	N	ASN	A1850	-11.383	-69.739	31.106	1.00	68.40	N
ATOM	138	CA	ASN	A1850	-10.705	-68.792	31.973	1.00	66.36	C
ATOM	139	C	ASN	A1850	-9.171	-69.110	32.071	1.00	70.25	C
ATOM	140	CB	ASN	A1850	-11.430	-68.717	33.304	1.00	61.37	C
ATOM	141	CG	ASN	A1850	-12.517	-67.674	33.314	1.00	72.74	C
ATOM	142	OD1	ASN	A1850	-12.399	-66.611	32.681	1.00	73.75	O
ATOM	143	ND2	ASN	A1850	-13.554	-67.903	34.113	1.00	47.82	N
ATOM	144	N	ASN	A1851	-8.664	-69.801	31.032	1.00	64.86	N
ATOM	145	CA	ASN	A1851	-7.279	-70.174	30.890	1.00	64.33	C
ATOM	146	C	ASN	A1851	-6.547	-69.045	30.141	1.00	72.69	C
ATOM	147	O	ASN	A1851	-6.299	-69.152	28.926	1.00	74.39	O
ATOM	148	CB	ASN	A1851	-7.164	-71.525	30.172	1.00	57.72	C
ATOM	149	CG	ASN	A1851	-5.754	-72.004	29.913	1.00	76.78	C
ATOM	150	ND2	ASN	A1851	-5.584	-72.760	28.845	1.00	69.89	N
ATOM	151	OD1	ASN	A1851	-4.799	-71.692	30.641	1.00	72.87	O
ATOM	152	N	LEU	A1852	-6.221	-67.941	30.870	1.00	69.27	N
ATOM	153	CA	LEU	A1852	-5.447	-66.798	30.341	1.00	68.84	C
ATOM	154	C	LEU	A1852	-4.069	-67.364	29.973	1.00	77.18	C
ATOM	155	O	LEU	A1852	-3.567	-68.246	30.688	1.00	78.22	O
ATOM	156	CB	LEU	A1852	-5.344	-65.696	31.397	1.00	67.66	C
ATOM	157	CG	LEU	A1852	-4.730	-64.390	30.982	1.00	71.13	C
ATOM	158	CD1	LEU	A1852	-5.687	-63.554	30.164	1.00	70.52	C
ATOM	159	CD2	LEU	A1852	-4.314	-63.606	32.198	1.00	73.66	C
ATOM	160	N	ILE	A1853	-3.502	-66.963	28.826	1.00	74.70	N
ATOM	161	CA	ILE	A1853	-2.284	-67.638	28.414	1.00	74.56	C
ATOM	162	C	ILE	A1853	-0.994	-66.980	28.935	1.00	79.05	C
ATOM	163	O	ILE	A1853	-0.241	-67.698	29.616	1.00	81.36	O
ATOM	164	CB	ILE	A1853	-2.292	-67.903	26.905	1.00	77.62	C
ATOM	165	CG1	ILE	A1853	-3.211	-69.119	26.603	1.00	78.25	C
ATOM	166	CG2	ILE	A1853	-0.902	-68.105	26.309	1.00	78.23	C
ATOM	167	CD1	ILE	A1853	-2.977	-70.436	27.458	1.00	87.48	C
ATOM	168	N	THR	A1854	-0.734	-65.679	28.666	1.00	71.97	N
ATOM	169	CA	THR	A1854	0.491	-64.942	29.106	1.00	71.36	C
ATOM	170	C	THR	A1854	1.848	-65.465	28.474	1.00	72.73	C
ATOM	171	O	THR	A1854	2.093	-66.670	28.313	1.00	71.18	O
ATOM	172	CB	THR	A1854	0.676	-64.754	30.664	1.00	77.14	C
ATOM	173	CG2	THR	A1854	-0.609	-64.449	31.415	1.00	72.66	C
ATOM	174	OG1	THR	A1854	1.357	-65.865	31.249	1.00	75.95	O
ATOM	175	N	GLY	A1855	2.715	-64.514	28.145	1.00	67.78	N
ATOM	176	CA	GLY	A1855	4.001	-64.815	27.544	1.00	67.60	C
ATOM	177	C	GLY	A1855	3.966	-64.693	26.040	1.00	72.77	C
ATOM	178	O	GLY	A1855	2.986	-64.208	25.459	1.00	72.33	O
ATOM	179	N	PHE	A1856	5.058	-65.109	25.404	1.00	69.65	N
ATOM	180	CA	PHE	A1856	5.191	-65.047	23.960	1.00	69.07	C
ATOM	181	C	PHE	A1856	4.313	-66.079	23.277	1.00	73.60	C
ATOM	182	O	PHE	A1856	4.402	-67.267	23.574	1.00	74.09	O
ATOM	183	CB	PHE	A1856	6.661	-65.213	23.536	1.00	70.48	C
ATOM	184	CG	PHE	A1856	7.478	-63.951	23.667	1.00	71.79	C
ATOM	185	CD1	PHE	A1856	7.430	-62.965	22.685	1.00	74.20	C
ATOM	186	CD2	PHE	A1856	8.295	-63.743	24.773	1.00	73.52	C
ATOM	187	CE1	PHE	A1856	8.175	-61.793	22.816	1.00	74.58	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	188	CE2	PHE	A1856	9.033	-62.565	24.905	1.00	76.00	C
ATOM	189	CZ	PHE	A1856	8.961	-61.596	23.928	1.00	73.75	C
ATOM	190	N	VAL	A1857	3.425	-65.614	22.402	1.00	69.56	N
ATOM	191	CA	VAL	A1857	2.554	-66.475	21.615	1.00	69.00	C
ATOM	192	C	VAL	A1857	2.622	-66.025	20.154	1.00	74.12	C
ATOM	193	O	VAL	A1857	2.829	-64.841	19.889	1.00	72.25	O
ATOM	194	CB	VAL	A1857	1.101	-66.660	22.168	1.00	71.79	C
ATOM	195	CG1	VAL	A1857	0.999	-66.304	23.642	1.00	71.49	C
ATOM	196	CG2	VAL	A1857	0.061	-65.900	21.358	1.00	71.27	C
ATOM	197	N	THR	A1858	2.487	-66.967	19.216	1.00	72.85	N
ATOM	198	CA	THR	A1858	2.505	-66.629	17.803	1.00	73.09	C
ATOM	199	C	THR	A1858	1.136	-66.930	17.245	1.00	77.82	C
ATOM	200	O	THR	A1858	0.745	-68.094	17.196	1.00	78.22	O
ATOM	201	CB	THR	A1858	3.658	-67.336	17.052	1.00	82.38	C
ATOM	202	CG2	THR	A1858	4.071	-66.584	15.785	1.00	81.73	C
ATOM	203	OG1	THR	A1858	4.793	-67.483	17.916	1.00	81.55	O
ATOM	204	N	VAL	A1859	0.377	-65.879	16.905	1.00	74.20	N
ATOM	205	CA	VAL	A1859	-0.944	-66.015	16.306	1.00	73.98	C
ATOM	206	C	VAL	A1859	-0.694	-65.872	14.805	1.00	79.64	C
ATOM	207	O	VAL	A1859	-0.603	-64.765	14.280	1.00	79.51	O
ATOM	208	CB	VAL	A1859	-1.986	-65.006	16.880	1.00	77.80	C
ATOM	209	CG1	VAL	A1859	-3.305	-65.037	16.098	1.00	77.42	C
ATOM	210	CG2	VAL	A1859	-2.237	-65.242	18.376	1.00	77.35	C
ATOM	211	N	GLY	A1860	-0.478	-67.006	14.156	1.00	77.73	N
ATOM	212	CA	GLY	A1860	-0.186	-67.065	12.732	1.00	78.39	C
ATOM	213	C	GLY	A1860	1.223	-66.623	12.390	1.00	84.94	C
ATOM	214	O	GLY	A1860	2.210	-67.268	12.767	1.00	85.02	O
ATOM	215	N	ASP	A1861	1.329	-65.520	11.662	1.00	82.76	N
ATOM	216	CA	ASP	A1861	2.636	-65.022	11.273	1.00	82.97	C
ATOM	217	C	ASP	A1861	3.300	-64.234	12.384	1.00	84.29	C
ATOM	218	O	ASP	A1861	4.401	-64.578	12.825	1.00	84.69	O
ATOM	219	CB	ASP	A1861	2.532	-64.203	9.979	1.00	85.77	C
ATOM	220	CG	ASP	A1861	2.592	-65.083	8.748	1.00	102.92	C
ATOM	221	OD2	ASP	A1861	1.670	-64.987	7.906	1.00	111.73	O
ATOM	222	OD1	ASP	A1861	3.561	-65.890	8.635	1.00	103.30	O
ATOM	223	N	ASP	A1862	2.591	-63.210	12.867	1.00	76.83	N
ATOM	224	CA	ASP	A1862	3.035	-62.267	13.876	1.00	74.17	C
ATOM	225	C	ASP	A1862	2.974	-62.795	15.325	1.00	71.89	C
ATOM	226	O	ASP	A1862	1.999	-63.436	15.688	1.00	70.54	O
ATOM	227	CB	ASP	A1862	2.236	-60.964	13.702	1.00	75.37	C
ATOM	228	CG	ASP	A1862	0.772	-61.165	13.370	1.00	76.57	C
ATOM	229	OD2	ASP	A1862	0.275	-60.493	12.444	1.00	77.05	O
ATOM	230	OD1	ASP	A1862	0.112	-61.939	14.075	1.00	77.16	O
ATOM	231	N	LYS	A1863	4.046	-62.524	16.136	1.00	65.81	N
ATOM	232	CA	LYS	A1863	4.187	-62.892	17.560	1.00	64.25	C
ATOM	233	C	LYS	A1863	3.707	-61.748	18.467	1.00	69.08	C
ATOM	234	O	LYS	A1863	3.855	-60.582	18.111	1.00	69.36	O
ATOM	235	CB	LYS	A1863	5.633	-63.303	17.943	1.00	63.59	C
ATOM	236	N	TYR	A1864	3.138	-62.091	19.639	1.00	64.51	N
ATOM	237	CA	TYR	A1864	2.639	-61.160	20.654	1.00	63.59	C
ATOM	238	C	TYR	A1864	3.286	-61.500	22.009	1.00	65.98	C
ATOM	239	O	TYR	A1864	3.877	-62.577	22.156	1.00	66.29	O
ATOM	240	CB	TYR	A1864	1.116	-61.322	20.827	1.00	64.84	C
ATOM	241	CG	TYR	A1864	0.244	-60.972	19.640	1.00	66.13	C
ATOM	242	CD1	TYR	A1864	0.040	-61.886	18.607	1.00	67.87	C
ATOM	243	CD2	TYR	A1864	-0.508	-59.801	19.626	1.00	66.14	C
ATOM	244	CE1	TYR	A1864	-0.802	-61.591	17.537	1.00	68.04	C
ATOM	245	CE2	TYR	A1864	-1.357	-59.500	18.564	1.00	66.68	C
ATOM	246	CZ	TYR	A1864	-1.498	-60.396	17.518	1.00	73.21	C
ATOM	247	OH	TYR	A1864	-2.323	-60.101	16.458	1.00	74.89	O
ATOM	248	N	TYR	A1865	3.158	-60.600	23.001	1.00	59.38	N
ATOM	249	CA	TYR	A1865	3.615	-60.908	24.343	1.00	57.99	C
ATOM	250	C	TYR	A1865	2.545	-60.444	25.293	1.00	62.72	C
ATOM	251	O	TYR	A1865	2.267	-59.250	25.371	1.00	63.59	O
ATOM	252	CB	TYR	A1865	5.003	-60.339	24.667	1.00	58.19	C
ATOM	253	CG	TYR	A1865	5.423	-60.549	26.107	1.00	58.94	C
ATOM	254	CD1	TYR	A1865	5.927	-61.775	26.539	1.00	60.23	C
ATOM	255	CD2	TYR	A1865	5.319	-59.523	27.038	1.00	60.16	C
ATOM	256	CE1	TYR	A1865	6.303	-61.976	27.870	1.00	61.15	C
ATOM	257	CE2	TYR	A1865	5.697	-59.708	28.370	1.00	61.41	C
ATOM	258	CZ	TYR	A1865	6.191	-60.934	28.784	1.00	69.35	C
ATOM	259	OH	TYR	A1865	6.581	-61.071	30.101	1.00	70.47	O
ATOM	260	N	PHE	A1866	1.892	-61.400	25.958	1.00	59.16	N
ATOM	261	CA	PHE	A1866	0.809	-61.127	26.887	1.00	59.65	C
ATOM	262	C	PHE	A1866	1.418	-61.002	28.268	1.00	67.40	C
ATOM	263	O	PHE	A1866	1.775	-62.003	28.904	1.00	66.45	O
ATOM	264	CB	PHE	A1866	-0.298	-62.196	26.768	1.00	61.07	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	265	CG	PHE	A1866	-0.898	-62.232	25.384	1.00	61.63	C
ATOM	266	CD1	PHE	A1866	-1.846	-61.292	24.995	1.00	65.28	C
ATOM	267	CD2	PHE	A1866	-0.451	-63.144	24.440	1.00	62.36	C
ATOM	268	CE1	PHE	A1866	-2.356	-61.287	23.688	1.00	66.05	C
ATOM	269	CE2	PHE	A1866	-0.934	-63.115	23.128	1.00	64.85	C
ATOM	270	CZ	PHE	A1866	-1.894	-62.200	22.764	1.00	63.36	C
ATOM	271	N	ASN	A1867	1.627	-59.734	28.677	1.00	66.33	N
ATOM	272	CA	ASN	A1867	2.314	-59.331	29.895	1.00	67.21	C
ATOM	273	C	ASN	A1867	1.739	-59.948	31.179	1.00	74.67	C
ATOM	274	O	ASN	A1867	0.698	-59.487	31.670	1.00	74.69	O
ATOM	275	CB	ASN	A1867	2.390	-57.807	29.984	1.00	67.84	C
ATOM	276	CG	ASN	A1867	3.632	-57.330	30.678	1.00	94.56	C
ATOM	277	ND2	ASN	A1867	3.788	-56.022	30.728	1.00	89.24	N
ATOM	278	OD1	ASN	A1867	4.466	-58.121	31.158	1.00	88.28	O
ATOM	279	N	PRO	A1868	2.426	-60.971	31.754	1.00	73.85	N
ATOM	280	CA	PRO	A1868	1.918	-61.601	32.990	1.00	74.61	C
ATOM	281	C	PRO	A1868	1.896	-60.683	34.203	1.00	81.70	C
ATOM	282	O	PRO	A1868	1.280	-61.034	35.214	1.00	81.84	O
ATOM	283	CB	PRO	A1868	2.818	-62.824	33.187	1.00	76.13	C
ATOM	284	CG	PRO	A1868	4.006	-62.574	32.399	1.00	80.49	C
ATOM	285	CD	PRO	A1868	3.679	-61.604	31.305	1.00	76.02	C
ATOM	286	N	ILE	A1869	2.518	-59.485	34.075	1.00	80.41	N
ATOM	287	CA	ILE	A1869	2.542	-58.432	35.095	1.00	81.34	C
ATOM	288	C	ILE	A1869	1.217	-57.685	35.001	1.00	87.89	C
ATOM	289	O	ILE	A1869	0.644	-57.322	36.033	1.00	88.86	O
ATOM	290	CB	ILE	A1869	3.704	-57.400	34.898	1.00	84.82	C
ATOM	291	CG1	ILE	A1869	5.064	-58.055	34.515	1.00	85.61	C
ATOM	292	CG2	ILE	A1869	3.844	-56.495	36.131	1.00	85.09	C
ATOM	293	CD1	ILE	A1869	6.080	-57.089	33.792	1.00	90.65	C
ATOM	294	N	ASN	A1870	0.763	-57.406	33.755	1.00	85.01	N
ATOM	295	CA	ASN	A1870	-0.437	-56.608	33.490	1.00	84.98	C
ATOM	296	C	ASN	A1870	-1.664	-57.423	33.072	1.00	87.40	C
ATOM	297	O	ASN	A1870	-2.346	-57.071	32.106	1.00	87.47	O
ATOM	298	CB	ASN	A1870	-0.126	-55.506	32.480	1.00	87.00	C
ATOM	299	CG	ASN	A1870	0.983	-54.597	32.941	1.00	113.46	C
ATOM	300	ND2	ASN	A1870	1.807	-54.156	31.999	1.00	106.17	N
ATOM	301	OD1	ASN	A1870	1.123	-54.298	34.141	1.00	106.07	O
ATOM	302	N	GLY	A1871	-1.963	-58.451	33.867	1.00	81.65	N
ATOM	303	CA	GLY	A1871	-3.103	-59.338	33.686	1.00	80.57	C
ATOM	304	C	GLY	A1871	-3.179	-60.078	32.365	1.00	83.08	C
ATOM	305	O	GLY	A1871	-4.275	-60.409	31.915	1.00	83.22	O
ATOM	306	N	GLY	A1872	-2.026	-60.347	31.756	1.00	77.90	N
ATOM	307	CA	GLY	A1872	-1.933	-61.030	30.469	1.00	76.30	C
ATOM	308	C	GLY	A1872	-2.242	-60.125	29.289	1.00	75.57	C
ATOM	309	O	GLY	A1872	-2.570	-60.623	28.204	1.00	75.56	O
ATOM	310	N	ALA	A1873	-2.165	-58.790	29.491	1.00	67.70	N
ATOM	311	CA	ALA	A1873	-2.443	-57.844	28.415	1.00	66.62	C
ATOM	312	C	ALA	A1873	-1.271	-57.745	27.410	1.00	73.48	C
ATOM	313	O	ALA	A1873	-0.093	-57.743	27.810	1.00	72.79	O
ATOM	314	CB	ALA	A1873	-2.802	-56.482	28.972	1.00	66.27	C
ATOM	315	N	ALA	A1874	-1.611	-57.707	26.093	1.00	70.95	N
ATOM	316	CA	ALA	A1874	-0.633	-57.601	25.007	1.00	70.39	C
ATOM	317	C	ALA	A1874	0.125	-56.319	25.204	1.00	75.02	C
ATOM	318	O	ALA	A1874	-0.477	-55.281	25.529	1.00	76.22	O
ATOM	319	CB	ALA	A1874	-1.317	-57.603	23.651	1.00	70.85	C
ATOM	320	N	SER	A1875	1.460	-56.424	25.118	1.00	69.26	N
ATOM	321	CA	SER	A1875	2.382	-55.316	25.310	1.00	66.55	C
ATOM	322	C	SER	A1875	2.413	-54.486	24.054	1.00	68.80	C
ATOM	323	O	SER	A1875	2.480	-55.034	22.955	1.00	68.22	O
ATOM	324	CB	SER	A1875	3.780	-55.844	25.605	1.00	67.15	C
ATOM	325	OG	SER	A1875	3.798	-56.715	26.723	1.00	68.69	O
ATOM	326	N	ILE	A1876	2.297	-53.168	24.211	1.00	65.36	N
ATOM	327	CA	ILE	A1876	2.428	-52.226	23.098	1.00	64.64	C
ATOM	328	C	ILE	A1876	3.671	-51.377	23.382	1.00	66.43	C
ATOM	329	O	ILE	A1876	4.035	-51.197	24.554	1.00	65.11	O
ATOM	330	CB	ILE	A1876	1.146	-51.424	22.677	1.00	67.37	C
ATOM	331	CG1	ILE	A1876	0.735	-50.374	23.707	1.00	67.29	C
ATOM	332	CG2	ILE	A1876	-0.027	-52.364	22.339	1.00	68.45	C
ATOM	333	CD1	ILE	A1876	0.230	-49.078	23.070	1.00	73.82	C
ATOM	334	N	GLY	A1877	4.356	-50.961	22.316	1.00	61.86	N
ATOM	335	CA	GLY	A1877	5.582	-50.181	22.414	1.00	60.49	C
ATOM	336	C	GLY	A1877	6.751	-51.016	22.885	1.00	63.28	C
ATOM	337	O	GLY	A1877	6.664	-52.248	22.914	1.00	63.02	O
ATOM	338	N	GLU	A1878	7.844	-50.340	23.288	1.00	58.99	N
ATOM	339	CA	GLU	A1878	9.086	-50.965	23.734	1.00	57.81	C
ATOM	340	C	GLU	A1878	8.942	-51.536	25.127	1.00	63.28	C
ATOM	341	O	GLU	A1878	8.601	-50.800	26.060	1.00	64.45	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.							
ATOM	342	CB	GLU	A1878	10.212	-49.948	23.681
ATOM	343	CG	GLU	A1878	11.595	-50.553	23.786
ATOM	344	CD	GLU	A1878	12.634	-49.623	24.376
ATOM	345	OE1	GLU	A1878	12.278	-48.505	24.825
ATOM	346	OE2	GLU	A1878	13.811	-50.043	24.422
ATOM	347	N	THR	A1879	9.203	-52.839	25.282
ATOM	348	CA	THR	A1879	9.028	-53.507	26.578
ATOM	349	C	THR	A1879	10.169	-54.495	26.906
ATOM	350	O	THR	A1879	10.710	-55.164	26.014
ATOM	351	CB	THR	A1879	7.606	-54.155	26.672
ATOM	352	CG2	THR	A1879	6.534	-53.151	27.121
ATOM	353	OG1	THR	A1879	7.209	-54.610	25.382
ATOM	354	N	ILE	A1880	10.522	-54.577	28.207
ATOM	355	CA	ILE	A1880	11.587	-55.452	28.726
ATOM	356	C	ILE	A1880	11.050	-56.808	29.172
ATOM	357	O	ILE	A1880	10.144	-56.881	30.003
ATOM	358	CB	ILE	A1880	12.449	-54.758	29.828
ATOM	359	CG1	ILE	A1880	13.458	-53.797	29.186
ATOM	360	CG2	ILE	A1880	13.189	-55.760	30.739
ATOM	361	CD1	ILE	A1880	12.977	-52.396	29.045
ATOM	362	N	ILE	A1881	11.630	-57.879	28.610
ATOM	363	CA	ILE	A1881	11.281	-59.259	28.917
ATOM	364	C	ILE	A1881	12.591	-60.015	29.101
ATOM	365	O	ILE	A1881	13.359	-60.139	28.141
ATOM	366	CB	ILE	A1881	10.385	-59.879	27.809
ATOM	367	CG1	ILE	A1881	9.169	-58.992	27.502
ATOM	368	CG2	ILE	A1881	9.952	-61.307	28.192
ATOM	369	CD1	ILE	A1881	8.960	-58.742	26.190
ATOM	370	N	ASP	A1882	12.845	-60.525	30.337
ATOM	371	CA	ASP	A1882	14.063	-61.274	30.728
ATOM	372	C	ASP	A1882	15.321	-60.453	30.397
ATOM	373	O	ASP	A1882	16.195	-60.927	29.673
ATOM	374	CB	ASP	A1882	14.122	-62.684	30.067
ATOM	375	CG	ASP	A1882	12.839	-63.506	30.117
ATOM	376	OD1	ASP	A1882	11.987	-63.238	31.004
ATOM	377	OD2	ASP	A1882	12.703	-64.444	29.293
ATOM	378	N	ASP	A1883	15.354	-59.190	30.867
ATOM	379	CA	ASP	A1883	16.416	-58.185	30.678
ATOM	380	C	ASP	A1883	16.635	-57.704	29.196
ATOM	381	O	ASP	A1883	17.345	-56.708	28.995
ATOM	382	CB	ASP	A1883	17.748	-58.632	31.309
ATOM	383	CG	ASP	A1883	17.810	-58.451	32.812
ATOM	384	OD2	ASP	A1883	18.558	-57.550	33.272
ATOM	385	OD1	ASP	A1883	17.142	-59.236	33.534
ATOM	386	N	LYS	A1884	15.994	-58.355	28.193
ATOM	387	CA	LYS	A1884	16.064	-57.986	26.770
ATOM	388	C	LYS	A1884	15.012	-56.933	26.405
ATOM	389	O	LYS	A1884	13.956	-56.873	27.059
ATOM	390	CB	LYS	A1884	15.865	-59.215	25.897
ATOM	391	CG	LYS	A1884	17.037	-60.172	25.941
ATOM	392	CD	LYS	A1884	16.600	-61.608	25.748
ATOM	393	CE	LYS	A1884	17.743	-62.522	26.041
ATOM	394	NZ	LYS	A1884	18.806	-62.430	24.991
ATOM	395	N	ASN	A1885	15.283	-56.108	25.350
ATOM	396	CA	ASN	A1885	14.340	-55.076	24.889
ATOM	397	C	ASN	A1885	13.714	-55.477	23.561
ATOM	398	O	ASN	A1885	14.438	-55.852	22.637
ATOM	399	CB	ASN	A1885	15.022	-53.723	24.721
ATOM	400	CG	ASN	A1885	15.505	-53.075	25.979
ATOM	401	ND2	ASN	A1885	16.577	-53.601	26.572
ATOM	402	OD1	ASN	A1885	14.989	-52.034	26.376
ATOM	403	N	TYR	A1886	12.381	-55.362	23.450
ATOM	404	CA	TYR	A1886	11.613	-55.677	22.231
ATOM	405	C	TYR	A1886	10.644	-54.535	21.937
ATOM	406	O	TYR	A1886	10.346	-53.742	22.822
ATOM	407	CB	TYR	A1886	10.827	-57.010	22.370
ATOM	408	CG	TYR	A1886	11.664	-58.213	22.749
ATOM	409	CD2	TYR	A1886	12.133	-59.092	21.780
ATOM	410	CD1	TYR	A1886	11.958	-58.493	24.082
ATOM	411	CE2	TYR	A1886	12.903	-60.205	22.121
ATOM	412	CE1	TYR	A1886	12.734	-59.594	24.436
ATOM	413	CZ	TYR	A1886	13.218	-60.441	23.449
ATOM	414	OH	TYR	A1886	13.989	-61.530	23.783
ATOM	415	N	TYR	A1887	10.136	-54.462	20.708
ATOM	416	CA	TYR	A1887	9.196	-53.424	20.303
ATOM	417	C	TYR	A1887	8.019	-54.059	19.648
ATOM	418	O	TYR	A1887	8.181	-54.892	18.755

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	419	CB	TYR	A1887	9.838	-52.411	19.346	1.00	56.49	C
ATOM	420	CG	TYR	A1887	8.982	-51.182	19.111	1.00	58.05	C
ATOM	421	CD1	TYR	A1887	8.040	-51.149	18.083	1.00	60.72	C
ATOM	422	CD2	TYR	A1887	9.104	-50.054	19.922	1.00	57.29	C
ATOM	423	CE1	TYR	A1887	7.225	-50.039	17.881	1.00	60.64	C
ATOM	424	CE2	TYR	A1887	8.317	-48.926	19.710	1.00	58.22	C
ATOM	425	CZ	TYR	A1887	7.376	-48.925	18.685	1.00	66.58	C
ATOM	426	OH	TYR	A1887	6.577	-47.836	18.444	1.00	64.12	O
ATOM	427	N	PHE	A1888	6.827	-53.636	20.080	1.00	59.77	N
ATOM	428	CA	PHE	A1888	5.524	-54.088	19.604	1.00	59.31	C
ATOM	429	C	PHE	A1888	4.746	-52.906	19.005	1.00	64.78	C
ATOM	430	O	PHE	A1888	4.715	-51.827	19.608	1.00	66.47	O
ATOM	431	CB	PHE	A1888	4.751	-54.678	20.790	1.00	60.58	C
ATOM	432	CG	PHE	A1888	5.426	-55.869	21.425	1.00	61.36	C
ATOM	433	CD2	PHE	A1888	6.249	-55.713	22.532	1.00	63.36	C
ATOM	434	CD1	PHE	A1888	5.216	-57.152	20.932	1.00	63.62	C
ATOM	435	CE2	PHE	A1888	6.893	-56.817	23.106	1.00	66.20	C
ATOM	436	CE1	PHE	A1888	5.858	-58.254	21.502	1.00	64.17	C
ATOM	437	CZ	PHE	A1888	6.701	-58.078	22.577	1.00	64.05	C
ATOM	438	N	ASN	A1889	4.090	-53.095	17.855	1.00	61.08	N
ATOM	439	CA	ASN	A1889	3.314	-51.995	17.269	1.00	61.86	C
ATOM	440	C	ASN	A1889	2.036	-51.668	18.069	1.00	69.87	C
ATOM	441	O	ASN	A1889	1.759	-52.326	19.076	1.00	70.54	O
ATOM	442	CB	ASN	A1889	3.021	-52.217	15.787	1.00	59.59	C
ATOM	443	CG	ASN	A1889	2.092	-53.343	15.422	1.00	71.11	C
ATOM	444	OD1	ASN	A1889	1.299	-53.867	16.226	1.00	65.39	O
ATOM	445	ND2	ASN	A1889	2.112	-53.662	14.144	1.00	56.43	N
ATOM	446	N	GLN	A1890	1.260	-50.652	17.626	1.00	67.79	N
ATOM	447	CA	GLN	A1890	0.021	-50.236	18.296	1.00	67.56	C
ATOM	448	C	GLN	A1890	-0.958	-51.402	18.518	1.00	72.76	C
ATOM	449	O	GLN	A1890	-1.818	-51.329	19.405	1.00	73.34	O
ATOM	450	CB	GLN	A1890	-0.649	-49.116	17.493	1.00	68.82	C
ATOM	451	N	SER	A1891	-0.787	-52.497	17.741	1.00	68.98	N
ATOM	452	CA	SER	A1891	-1.667	-53.669	17.744	1.00	68.00	C
ATOM	453	C	SER	A1891	-1.138	-54.878	18.562	1.00	70.42	C
ATOM	454	O	SER	A1891	-1.822	-55.903	18.650	1.00	69.57	O
ATOM	455	CB	SER	A1891	-2.003	-54.062	16.305	1.00	69.19	C
ATOM	456	OG	SER	A1891	-2.623	-52.982	15.615	1.00	70.47	O
ATOM	457	N	GLY	A1892	0.033	-54.728	19.176	1.00	65.41	N
ATOM	458	CA	GLY	A1892	0.640	-55.760	20.011	1.00	64.37	C
ATOM	459	C	GLY	A1892	1.575	-56.749	19.338	1.00	66.80	C
ATOM	460	O	GLY	A1892	2.164	-57.581	20.040	1.00	66.46	O
ATOM	461	N	VAL	A1893	1.731	-56.674	17.985	1.00	62.32	N
ATOM	462	CA	VAL	A1893	2.606	-57.595	17.248	1.00	62.36	C
ATOM	463	C	VAL	A1893	4.053	-57.120	17.292	1.00	67.97	C
ATOM	464	O	VAL	A1893	4.328	-55.941	17.025	1.00	68.39	O
ATOM	465	CB	VAL	A1893	2.168	-58.004	15.797	1.00	65.99	C
ATOM	466	CG1	VAL	A1893	0.691	-58.336	15.714	1.00	65.48	C
ATOM	467	CG2	VAL	A1893	2.503	-56.953	14.773	1.00	66.53	C
ATOM	468	N	LEU	A1894	4.977	-58.061	17.626	1.00	64.08	N
ATOM	469	CA	LEU	A1894	6.436	-57.873	17.703	1.00	62.79	C
ATOM	470	C	LEU	A1894	6.907	-57.440	16.348	1.00	65.80	C
ATOM	471	O	LEU	A1894	6.507	-58.007	15.326	1.00	66.04	O
ATOM	472	CB	LEU	A1894	7.116	-59.192	18.169	1.00	62.74	C
ATOM	473	CG	LEU	A1894	8.652	-59.374	18.362	1.00	67.28	C
ATOM	474	CD1	LEU	A1894	9.280	-60.058	17.180	1.00	67.06	C
ATOM	475	CD2	LEU	A1894	9.403	-58.092	18.824	1.00	71.88	C
ATOM	476	N	GLN	A1895	7.661	-56.354	16.344	1.00	61.58	N
ATOM	477	CA	GLN	A1895	8.201	-55.736	15.141	1.00	60.00	C
ATOM	478	C	GLN	A1895	9.731	-55.806	15.081	1.00	62.59	C
ATOM	479	O	GLN	A1895	10.382	-55.992	16.098	1.00	61.21	O
ATOM	480	CB	GLN	A1895	7.663	-54.302	14.996	1.00	60.32	C
ATOM	481	CG	GLN	A1895	7.241	-53.991	13.575	1.00	68.33	C
ATOM	482	CD	GLN	A1895	5.788	-54.234	13.354	1.00	96.97	C
ATOM	483	NE2	GLN	A1895	5.142	-53.272	12.700	1.00	97.50	N
ATOM	484	OE1	GLN	A1895	5.232	-55.274	13.746	1.00	91.26	O
ATOM	485	N	THR	A1896	10.288	-55.715	13.871	1.00	61.86	N
ATOM	486	CA	THR	A1896	11.730	-55.733	13.581	1.00	62.37	C
ATOM	487	C	THR	A1896	12.125	-54.414	12.866	1.00	67.69	C
ATOM	488	O	THR	A1896	11.273	-53.746	12.247	1.00	68.05	O
ATOM	489	CB	THR	A1896	12.111	-57.045	12.854	1.00	67.73	C
ATOM	490	CG2	THR	A1896	13.481	-57.000	12.204	1.00	64.65	C
ATOM	491	OG1	THR	A1896	12.113	-58.093	13.825	1.00	71.17	O
ATOM	492	N	GLY	A1897	13.393	-54.040	13.017	1.00	63.08	N
ATOM	493	CA	GLY	A1897	13.956	-52.842	12.415	1.00	62.21	C
ATOM	494	C	GLY	A1897	14.335	-51.752	13.397	1.00	64.94	C
ATOM	495	O	GLY	A1897	14.475	-51.988	14.608	1.00	64.74	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody beziotoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	496	N	VAL	A1898	14.503	-50.539	12.843	1.00	59.23	N
ATOM	497	CA	VAL	A1898	14.913	-49.328	13.544	1.00	57.72	C
ATOM	498	C	VAL	A1898	13.697	-48.545	13.997	1.00	61.42	C
ATOM	499	O	VAL	A1898	12.803	-48.274	13.195	1.00	60.71	O
ATOM	500	CB	VAL	A1898	15.934	-48.492	12.725	1.00	60.37	C
ATOM	501	CG1	VAL	A1898	16.603	-47.435	13.600	1.00	60.26	C
ATOM	502	CG2	VAL	A1898	16.998	-49.396	12.106	1.00	59.60	C
ATOM	503	N	PHE	A1899	13.635	-48.243	15.313	1.00	58.94	N
ATOM	504	CA	PHE	A1899	12.507	-47.533	15.939	1.00	58.21	C
ATOM	505	C	PHE	A1899	12.960	-46.506	16.962	1.00	62.24	C
ATOM	506	O	PHE	A1899	13.967	-46.726	17.657	1.00	62.02	O
ATOM	507	CB	PHE	A1899	11.595	-48.529	16.656	1.00	59.26	C
ATOM	508	CG	PHE	A1899	10.878	-49.505	15.764	1.00	59.74	C
ATOM	509	CD2	PHE	A1899	9.600	-49.238	15.307	1.00	61.76	C
ATOM	510	CD1	PHE	A1899	11.455	-50.719	15.433	1.00	61.31	C
ATOM	511	CE2	PHE	A1899	8.927	-50.150	14.510	1.00	61.93	C
ATOM	512	CE1	PHE	A1899	10.783	-51.628	14.631	1.00	63.49	C
ATOM	513	CZ	PHE	A1899	9.530	-51.332	14.167	1.00	61.24	C
ATOM	514	N	SER	A1900	12.186	-45.401	17.084	1.00	57.98	N
ATOM	515	CA	SER	A1900	12.449	-44.382	18.084	1.00	57.34	C
ATOM	516	C	SER	A1900	12.085	-44.935	19.461	1.00	64.83	C
ATOM	517	O	SER	A1900	11.059	-45.608	19.626	1.00	63.72	O
ATOM	518	CB	SER	A1900	11.690	-43.100	17.808	1.00	57.97	C
ATOM	519	OG	SER	A1900	12.234	-42.163	18.722	1.00	66.38	O
ATOM	520	N	THR	A1901	12.974	-44.664	20.434	1.00	63.94	N
ATOM	521	CA	THR	A1901	12.954	-45.110	21.822	1.00	63.70	C
ATOM	522	C	THR	A1901	13.285	-43.932	22.728	1.00	69.76	C
ATOM	523	O	THR	A1901	13.767	-42.915	22.240	1.00	70.08	O
ATOM	524	CB	THR	A1901	14.024	-46.186	21.939	1.00	70.66	C
ATOM	525	CG2	THR	A1901	14.336	-46.555	23.348	1.00	72.84	C
ATOM	526	OG1	THR	A1901	13.599	-47.333	21.207	1.00	70.45	O
ATOM	527	N	GLU	A1902	13.047	-44.071	24.054	1.00	67.81	N
ATOM	528	CA	GLU	A1902	13.373	-43.061	25.076	1.00	67.53	C
ATOM	529	C	GLU	A1902	14.879	-42.732	25.101	1.00	72.11	C
ATOM	530	O	GLU	A1902	15.254	-41.637	25.508	1.00	71.70	O
ATOM	531	CB	GLU	A1902	12.877	-43.501	26.464	1.00	68.81	C
ATOM	532	CG	GLU	A1902	13.235	-44.933	26.838	1.00	82.07	C
ATOM	533	CD	GLU	A1902	13.328	-45.249	28.320	1.00	109.27	C
ATOM	534	OE1	GLU	A1902	13.980	-46.264	28.660	1.00	99.07	O
ATOM	535	OE2	GLU	A1902	12.772	-44.478	29.139	1.00	106.72	O
ATOM	536	N	ASP	A1903	15.712	-43.688	24.619	1.00	69.63	N
ATOM	537	CA	ASP	A1903	17.178	-43.740	24.477	1.00	68.69	C
ATOM	538	C	ASP	A1903	17.666	-43.207	23.130	1.00	71.70	C
ATOM	539	O	ASP	A1903	18.848	-42.904	22.988	1.00	72.09	O
ATOM	540	CB	ASP	A1903	17.596	-45.215	24.504	1.00	70.00	C
ATOM	541	CG	ASP	A1903	18.228	-45.678	25.786	1.00	90.58	C
ATOM	542	OD2	ASP	A1903	17.844	-46.772	26.278	1.00	102.30	O
ATOM	543	OD1	ASP	A1903	19.139	-44.982	26.281	1.00	92.70	O
ATOM	544	N	GLY	A1904	16.786	-43.243	22.133	1.00	66.37	N
ATOM	545	CA	GLY	A1904	17.064	-42.882	20.746	1.00	64.86	C
ATOM	546	C	GLY	A1904	16.708	-44.016	19.799	1.00	65.06	C
ATOM	547	O	GLY	A1904	15.890	-44.873	20.139	1.00	64.85	O
ATOM	548	N	PHE	A1905	17.348	-44.062	18.617	1.00	57.91	N
ATOM	549	CA	PHE	A1905	17.062	-45.104	17.640	1.00	55.37	C
ATOM	550	C	PHE	A1905	17.712	-46.429	17.974	1.00	60.44	C
ATOM	551	O	PHE	A1905	18.927	-45.573	17.885	1.00	59.00	O
ATOM	552	CB	PHE	A1905	17.393	-44.668	16.205	1.00	55.37	C
ATOM	553	CG	PHE	A1905	16.589	-43.488	15.730	1.00	54.99	C
ATOM	554	CD2	PHE	A1905	17.209	-42.288	15.417	1.00	56.57	C
ATOM	555	CD1	PHE	A1905	15.210	-43.573	15.598	1.00	56.50	C
ATOM	556	CE2	PHE	A1905	16.462	-41.202	14.960	1.00	59.54	C
ATOM	557	CE1	PHE	A1905	14.460	-42.473	15.183	1.00	56.98	C
ATOM	558	CZ	PHE	A1905	15.090	-41.303	14.843	1.00	56.95	C
ATOM	559	N	LYS	A1906	16.877	-47.416	18.324	1.00	58.02	N
ATOM	560	CA	LYS	A1906	17.339	-48.760	18.623	1.00	57.25	C
ATOM	561	C	LYS	A1906	17.108	-49.675	17.420	1.00	59.68	C
ATOM	562	O	LYS	A1906	16.198	-49.420	16.623	1.00	58.99	O
ATOM	563	CB	LYS	A1906	16.591	-49.286	19.843	1.00	59.40	C
ATOM	564	CG	LYS	A1906	17.508	-49.809	20.930	1.00	64.38	C
ATOM	565	CD	LYS	A1906	16.812	-49.920	22.280	1.00	63.20	C
ATOM	566	CE	LYS	A1906	16.690	-48.589	22.962	1.00	55.76	C
ATOM	567	NZ	LYS	A1906	16.250	-48.738	24.368	1.00	64.36	N
ATOM	568	N	TYR	A1907	17.937	-50.737	17.298	1.00	54.80	N
ATOM	569	CA	TYR	A1907	17.815	-51.762	16.265	1.00	53.34	C
ATOM	570	C	TYR	A1907	17.262	-53.059	16.919	1.00	59.25	C
ATOM	571	O	TYR	A1907	17.987	-53.765	17.643	1.00	59.25	O
ATOM	572	CB	TYR	A1907	19.152	-52.023	15.515	1.00	53.04	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.							
ATOM	573	CG	TYR	A1907	19.053	-53.034	14.381
ATOM	574	CD1	TYR	A1907	17.870	-53.190	13.655
ATOM	575	CD2	TYR	A1907	20.150	-53.808	14.009
ATOM	576	CE1	TYR	A1907	17.759	-54.138	12.639
ATOM	577	CE2	TYR	A1907	20.054	-54.752	12.979
ATOM	578	CZ	TYR	A1907	18.860	-54.896	12.280
ATOM	579	OH	TYR	A1907	18.722	-55.803	11.246
ATOM	580	N	PHE	A1908	15.966	-53.346	16.667
ATOM	581	CA	PHE	A1908	15.296	-54.549	17.135
ATOM	582	C	PHE	A1908	15.496	-55.483	15.985
ATOM	583	O	PHE	A1908	14.709	-55.518	15.038
ATOM	584	CB	PHE	A1908	13.807	-54.288	17.429
ATOM	585	CG	PHE	A1908	13.612	-53.280	18.529
ATOM	586	CD2	PHE	A1908	13.427	-51.934	18.234
ATOM	587	CD1	PHE	A1908	13.674	-53.663	19.862
ATOM	588	CE2	PHE	A1908	13.302	-50.992	19.250
ATOM	589	CE1	PHE	A1908	13.541	-52.721	20.880
ATOM	590	CZ	PHE	A1908	13.358	-51.389	20.567
ATOM	591	N	ALA	A1909	16.637	-56.154	16.029
ATOM	592	CA	ALA	A1909	17.185	-57.017	14.995
ATOM	593	C	ALA	A1909	16.456	-58.322	14.769
ATOM	594	O	ALA	A1909	16.041	-58.939	15.751
ATOM	595	CB	ALA	A1909	18.638	-57.320	15.334
ATOM	596	N	PRO	A1910	16.435	-58.871	13.525
ATOM	597	CA	PRO	A1910	15.935	-60.244	13.360
ATOM	598	C	PRO	A1910	16.856	-61.237	14.119
ATOM	599	O	PRO	A1910	17.949	-60.857	14.567
ATOM	600	CB	PRO	A1910	15.978	-60.463	11.835
ATOM	601	CG	PRO	A1910	16.955	-59.521	11.335
ATOM	602	CD	PRO	A1910	16.949	-58.336	12.246
ATOM	603	N	ALA	A1911	16.403	-62.496	14.294
ATOM	604	CA	ALA	A1911	17.157	-63.520	15.019
ATOM	605	C	ALA	A1911	18.538	-63.798	14.421
ATOM	606	O	ALA	A1911	18.711	-63.776	13.192
ATOM	607	CB	ALA	A1911	16.352	-64.789	15.113
ATOM	608	N	ASN	A1912	19.527	-63.987	15.323
ATOM	609	CA	ASN	A1912	20.942	-64.302	15.081
ATOM	610	C	ASN	A1912	21.699	-63.223	14.232
ATOM	611	O	ASN	A1912	22.658	-63.541	13.510
ATOM	612	CB	ASN	A1912	21.095	-65.727	14.496
ATOM	613	CG	ASN	A1912	20.648	-66.840	15.436
ATOM	614	ND2	ASN	A1912	19.560	-67.510	15.088
ATOM	615	OD1	ASN	A1912	21.288	-67.144	16.453
ATOM	616	N	THR	A1913	21.313	-61.936	14.401
ATOM	617	CA	THR	A1913	21.941	-60.802	13.717
ATOM	618	C	THR	A1913	23.300	-60.465	14.375
ATOM	619	O	THR	A1913	24.255	-60.157	13.669
ATOM	620	CB	THR	A1913	20.936	-59.639	13.603
ATOM	621	CG2	THR	A1913	21.586	-58.295	13.389
ATOM	622	OG1	THR	A1913	20.072	-59.895	12.497
ATOM	623	N	LEU	A1914	23.396	-60.561	15.693
ATOM	624	CA	LEU	A1914	24.619	-60.266	16.433
ATOM	625	C	LEU	A1914	24.519	-61.083	17.719
ATOM	626	O	LEU	A1914	23.462	-61.043	18.358
ATOM	627	CB	LEU	A1914	24.589	-58.773	16.783
ATOM	628	CO	LEU	A1914	25.866	-57.951	17.017
ATOM	629	CD1	LEU	A1914	25.559	-56.742	17.879
ATOM	630	CD2	LEU	A1914	26.959	-58.722	17.711
ATOM	631	N	ASP	A1915	25.594	-61.808	18.115
ATOM	632	CA	ASP	A1915	25.647	-62.649	19.333
ATOM	633	C	ASP	A1915	24.364	-63.499	19.582
ATOM	634	O	ASP	A1915	23.699	-63.358	20.619
ATOM	635	CB	ASP	A1915	26.008	-61.834	20.591
ATOM	636	CG	ASP	A1915	27.307	-61.050	20.546
ATOM	637	OD1	ASP	A1915	28.378	-61.679	20.348
ATOM	638	OD2	ASP	A1915	27.268	-59.823	20.810
ATOM	639	N	GLU	A1916	24.016	-64.354	18.591
ATOM	640	CA	GLU	A1916	22.882	-65.292	18.582
ATOM	641	C	GLU	A1916	21.619	-64.737	19.254
ATOM	642	O	GLU	A1916	20.993	-65.423	20.058
ATOM	643	CB	GLU	A1916	23.291	-66.650	19.170
ATOM	644	N	ASN	A1917	21.242	-63.491	18.898
ATOM	645	CA	ASN	A1917	20.077	-62.792	19.444
ATOM	646	C	ASN	A1917	18.757	-63.404	18.987
ATOM	647	O	ASN	A1917	18.728	-64.141	18.004
ATOM	648	CB	ASN	A1917	20.127	-61.293	19.113
ATOM	649	CG	ASN	A1917	19.918	-60.946	17.657

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.							
ATOM	650	ND2	ASN	A1917	18.668	-60.741	17.260
ATOM	651	OD1	ASN	A1917	20.875	-60.770	16.901
ATOM	652	N	LEU	A1918	17.671	-63.071	19.694
ATOM	653	CA	LEU	A1918	16.313	-63.536	19.414
ATOM	654	C	LEU	A1918	15.588	-62.541	18.518
ATOM	655	O	LEU	A1918	16.040	-61.401	18.405
ATOM	656	CB	LEU	A1918	15.539	-63.693	20.737
ATOM	657	CG	LEU	A1918	16.213	-64.507	21.860
ATOM	658	CD1	LEU	A1918	15.495	-64.305	23.193
ATOM	659	CD2	LEU	A1918	16.326	-65.980	21.501
ATOM	660	N	GLU	A1919	14.463	-62.947	17.899
ATOM	661	CA	GLU	A1919	13.703	-62.054	17.014
ATOM	662	C	GLU	A1919	13.240	-60.794	17.724
ATOM	663	O	GLU	A1919	12.594	-60.872	18.778
ATOM	664	CB	GLU	A1919	12.490	-62.749	16.365
ATOM	665	CG	GLU	A1919	12.766	-63.353	15.008
ATOM	666	CD	GLU	A1919	12.792	-62.425	13.814
ATOM	667	OE1	GLU	A1919	13.758	-62.525	13.025
ATOM	668	OE2	GLU	A1919	11.789	-61.707	13.589
ATOM	669	N	GLY	A1920	13.570	-59.656	17.121
ATOM	670	CA	GLY	A1920	13.178	-58.334	17.582
ATOM	671	C	GLY	A1920	13.893	-57.834	18.815
ATOM	672	O	GLY	A1920	13.463	-56.837	19.399
ATOM	673	N	GLU	A1921	14.976	-58.511	19.217
ATOM	674	CA	GLU	A1921	15.777	-58.120	20.365
ATOM	675	C	GLU	A1921	16.627	-56.922	19.971
ATOM	676	O	GLU	A1921	17.268	-56.933	18.908
ATOM	677	CB	GLU	A1921	16.691	-59.295	20.826
ATOM	678	CG	GLU	A1921	17.593	-58.999	22.028
ATOM	679	CD	GLU	A1921	18.591	-60.056	22.487
ATOM	680	OE1	GLU	A1921	18.486	-61.229	22.054
ATOM	681	OE2	GLU	A1921	19.449	-59.718	23.336
ATOM	682	N	ALA	A1922	16.653	-55.894	20.833
ATOM	683	CA	ALA	A1922	17.526	-54.747	20.630
ATOM	684	C	ALA	A1922	18.970	-55.240	20.790
ATOM	685	O	ALA	A1922	19.304	-55.851	21.813
ATOM	686	CB	ALA	A1922	17.229	-53.679	21.660
ATOM	687	N	ILE	A1923	19.799	-55.041	19.758
ATOM	688	CA	ILE	A1923	21.204	-55.474	19.782
ATOM	689	C	ILE	A1923	22.204	-54.305	19.951
ATOM	690	O	ILE	A1923	21.921	-53.150	19.580
ATOM	691	CB	ILE	A1923	21.559	-56.350	18.565
ATOM	692	CG1	ILE	A1923	21.255	-55.627	17.249
ATOM	693	CG2	ILE	A1923	20.863	-57.685	18.653
ATOM	694	CD1	ILE	A1923	22.091	-56.049	16.166
ATOM	695	N	ASP	A1924	23.388	-54.634	20.502
ATOM	696	CA	ASP	A1924	24.448	-53.656	20.711
ATOM	697	C	ASP	A1924	25.238	-53.494	19.408
ATOM	698	O	ASP	A1924	26.407	-53.895	19.294
ATOM	699	CB	ASP	A1924	25.316	-54.012	21.938
ATOM	700	CG	ASP	A1924	24.688	-53.642	23.277
ATOM	701	OD2	ASP	A1924	25.161	-54.171	24.320
ATOM	702	OD1	ASP	A1924	23.751	-52.776	23.292
ATOM	703	N	PHE	A1925	24.556	-52.894	18.415
ATOM	704	CA	PHE	A1925	25.019	-52.683	17.051
ATOM	705	C	PHE	A1925	25.735	-51.355	16.855
ATOM	706	O	PHE	A1925	25.402	-50.360	17.503
ATOM	707	CB	PHE	A1925	23.814	-52.786	16.102
ATOM	708	CG	PHE	A1925	24.138	-52.742	14.632
ATOM	709	CD1	PHE	A1925	24.711	-53.838	13.997
ATOM	710	CD2	PHE	A1925	23.876	-51.605	13.880
ATOM	711	CE1	PHE	A1925	25.032	-53.789	12.642
ATOM	712	CE2	PHE	A1925	24.194	-51.560	12.524
ATOM	713	CZ	PHE	A1925	24.772	-52.651	11.917
ATOM	714	N	THR	A1926	26.721	-51.350	15.937
ATOM	715	CA	THR	A1926	27.499	-50.187	15.510
ATOM	716	C	THR	A1926	27.755	-50.325	14.020
ATOM	717	O	THR	A1926	27.757	-51.443	13.483
ATOM	718	CB	THR	A1926	28.800	-49.969	16.325
ATOM	719	CG2	THR	A1926	28.566	-49.263	17.643
ATOM	720	OG1	THR	A1926	29.470	-51.207	16.555
ATOM	721	N	GLY	A1927	27.904	-49.172	13.361
ATOM	722	CA	GLY	A1927	28.178	-49.089	11.929
ATOM	723	C	GLY	A1927	26.982	-48.868	11.029
ATOM	724	O	GLY	A1927	25.857	-48.695	11.503
ATOM	725	N	LYS	A1928	27.239	-48.864	9.701
ATOM	726	CA	LYS	A1928	26.218	-48.721	8.658

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	727	C	LYS	A1928	25.210	-49.864	8.763	1.00	61.78	C
ATOM	728	O	LYS	A1928	25.538	-50.940	9.270	1.00	60.25	O
ATOM	729	CB	LYS	A1928	26.839	-48.666	7.245	1.00	60.39	C
ATOM	730	N	LEU	A1929	23.976	-49.617	8.296	1.00	57.89	N
ATOM	731	CA	LEU	A1929	22.897	-50.592	8.348	1.00	56.42	C
ATOM	732	C	LEU	A1929	21.923	-50.268	7.284	1.00	59.09	C
ATOM	733	O	LEU	A1929	21.335	-49.195	7.310	1.00	58.56	O
ATOM	734	CB	LEU	A1929	22.198	-50.530	9.728	1.00	55.83	C
ATOM	735	CG	LEU	A1929	21.041	-51.480	9.959	1.00	58.31	C
ATOM	736	CD1	LEU	A1929	21.545	-52.881	10.187	1.00	57.78	C
ATOM	737	CD2	LEU	A1929	20.225	-51.027	11.131	1.00	58.04	C
ATOM	738	N	ILE	A1930	21.719	-51.192	6.363	1.00	57.06	N
ATOM	739	CA	ILE	A1930	20.741	-50.991	5.293	1.00	57.30	C
ATOM	740	C	ILE	A1930	19.595	-51.942	5.465	1.00	65.34	C
ATOM	741	O	ILE	A1930	19.820	-53.149	5.577	1.00	65.98	O
ATOM	742	CB	ILE	A1930	21.339	-51.081	3.860	1.00	59.05	C
ATOM	743	CG1	ILE	A1930	22.521	-50.122	3.683	1.00	57.50	C
ATOM	744	CG2	ILE	A1930	20.259	-50.831	2.791	1.00	59.96	C
ATOM	745	CD1	ILE	A1930	23.672	-50.776	3.340	1.00	50.54	C
ATOM	746	N	ILE	A1931	18.371	-51.403	5.465	1.00	64.55	N
ATOM	747	CA	ILE	A1931	17.152	-52.191	5.517	1.00	66.37	C
ATOM	748	C	ILE	A1931	16.215	-51.653	4.420	1.00	72.16	C
ATOM	749	O	ILE	A1931	15.583	-50.616	4.590	1.00	72.05	O
ATOM	750	CB	ILE	A1931	16.516	-52.379	6.951	1.00	70.51	C
ATOM	751	CG1	ILE	A1931	15.271	-53.281	6.933	1.00	72.45	C
ATOM	752	CG2	ILE	A1931	16.206	-51.085	7.663	1.00	72.18	C
ATOM	753	CD1	ILE	A1931	15.537	-54.844	7.202	1.00	90.03	C
ATOM	754	N	ASP	A1932	16.234	-52.321	3.254	1.00	71.07	N
ATOM	755	CA	ASP	A1932	15.409	-52.040	2.068	1.00	72.94	C
ATOM	756	C	ASP	A1932	15.519	-50.582	1.582	1.00	77.63	C
ATOM	757	O	ASP	A1932	14.544	-49.814	1.658	1.00	77.05	O
ATOM	758	CB	ASP	A1932	13.935	-52.471	2.310	1.00	75.94	C
ATOM	759	CG	ASP	A1932	13.762	-53.912	2.800	1.00	96.89	C
ATOM	760	OD2	ASP	A1932	12.701	-54.212	3.395	1.00	109.09	O
ATOM	761	OD1	ASP	A1932	14.693	-54.745	2.581	1.00	97.27	O
ATOM	762	N	GLU	A1933	16.732	-50.215	1.080	1.00	74.60	N
ATOM	763	CA	GLU	A1933	17.115	-48.867	0.616	1.00	74.59	C
ATOM	764	C	GLU	A1933	17.523	-47.908	1.761	1.00	74.85	C
ATOM	765	O	GLU	A1933	18.496	-47.166	1.613	1.00	74.64	O
ATOM	766	CB	GLU	A1933	16.040	-48.211	-0.284	1.00	76.74	C
ATOM	767	CG	GLU	A1933	16.442	-48.100	-1.751	1.00	94.61	C
ATOM	768	CD	GLU	A1933	16.270	-49.365	-2.574	1.00	116.46	C
ATOM	769	OE1	GLU	A1933	15.106	-49.727	-2.864	1.00	106.09	O
ATOM	770	OE2	GLU	A1933	17.296	-49.984	-2.945	1.00	107.14	O
ATOM	771	N	ASN	A1934	16.773	-47.915	2.882	1.00	67.82	N
ATOM	772	CA	ASN	A1934	17.004	-47.072	4.052	1.00	65.96	C
ATOM	773	C	ASN	A1934	18.382	-47.359	4.640	1.00	67.21	C
ATOM	774	O	ASN	A1934	18.728	-48.534	4.779	1.00	68.53	O
ATOM	775	CB	ASN	A1934	15.912	-47.303	5.086	1.00	65.88	C
ATOM	776	CG	ASN	A1934	14.507	-47.134	4.537	1.00	85.69	C
ATOM	777	ND2	ASN	A1934	13.757	-48.232	4.509	1.00	73.05	N
ATOM	778	OD1	ASN	A1934	14.084	-46.035	4.123	1.00	76.06	O
ATOM	779	N	ILE	A1935	19.199	-46.295	4.903	1.00	58.46	N
ATOM	780	CA	ILE	A1935	20.565	-46.424	5.426	1.00	55.97	C
ATOM	781	C	ILE	A1935	20.652	-45.697	6.729	1.00	58.93	C
ATOM	782	O	ILE	A1935	20.264	-44.537	6.813	1.00	58.82	O
ATOM	783	CB	ILE	A1935	21.685	-45.943	4.444	1.00	58.08	C
ATOM	784	CG1	ILE	A1935	21.525	-46.529	3.043	1.00	58.18	C
ATOM	785	CG2	ILE	A1935	23.080	-46.230	4.984	1.00	56.84	C
ATOM	786	CD1	ILE	A1935	21.604	-45.522	1.966	1.00	63.59	C
ATOM	787	N	TYR	A1936	21.179	-46.375	7.745	1.00	55.49	N
ATOM	788	CA	TYR	A1936	21.345	-45.838	9.088	1.00	54.87	C
ATOM	789	C	TYR	A1936	22.789	-46.027	9.496	1.00	60.31	C
ATOM	790	O	TYR	A1936	23.436	-46.975	9.050	1.00	60.14	O
ATOM	791	CB	TYR	A1936	20.465	-46.628	10.095	1.00	55.07	C
ATOM	792	CG	TYR	A1936	18.974	-46.663	9.813	1.00	55.90	C
ATOM	793	CD1	TYR	A1936	18.406	-47.704	9.086	1.00	57.65	C
ATOM	794	CD2	TYR	A1936	18.116	-45.721	10.374	1.00	56.74	C
ATOM	795	CE1	TYR	A1936	17.030	-47.768	8.865	1.00	58.95	C
ATOM	796	CE2	TYR	A1936	16.741	-45.770	10.155	1.00	57.39	C
ATOM	797	CZ	TYR	A1936	16.202	-46.794	9.397	1.00	66.98	C
ATOM	798	OH	TYR	A1936	14.850	-46.850	9.182	1.00	71.95	O
ATOM	799	N	TYR	A1937	23.288	-45.158	10.373	1.00	57.35	N
ATOM	800	CA	TYR	A1937	24.595	-45.359	10.979	1.00	57.23	C
ATOM	801	C	TYR	A1937	24.379	-45.388	12.482	1.00	62.50	C
ATOM	802	O	TYR	A1937	23.817	-44.438	13.049	1.00	62.48	O
ATOM	803	CB	TYR	A1937	25.678	-44.347	10.565	1.00	57.90	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.							
ATOM	804	CG	TYR	A1937	26.976	-44.546	11.325
ATOM	805	CD1	TYR	A1937	27.904	-45.508	10.926
ATOM	806	CD2	TYR	A1937	27.245	-43.823	12.484
ATOM	807	CE1	TYR	A1937	29.083	-45.722	11.647
ATOM	808	CE2	TYR	A1937	28.419	-44.026	13.213
ATOM	809	CZ	TYR	A1937	29.337	-44.976	12.790
ATOM	810	OH	TYR	A1937	30.494	-45.170	13.519
ATOM	811	N	PHE	A1938	24.788	-46.503	13.111
ATOM	812	CA	PHE	A1938	24.672	-46.708	14.527
ATOM	813	C	PHE	A1938	25.935	-46.315	15.225
ATOM	814	O	PHE	A1938	26.971	-46.976	15.071
ATOM	815	CB	PHE	A1938	24.277	-48.143	14.805
ATOM	816	CG	PHE	A1938	22.783	-48.288	14.923
ATOM	817	CD1	PHE	A1938	21.948	-47.978	13.850
ATOM	818	CD2	PHE	A1938	22.202	-48.707	16.113
ATOM	819	CE1	PHE	A1938	20.565	-48.086	13.967
ATOM	820	CE2	PHE	A1938	20.814	-48.823	16.225
ATOM	821	CZ	PHE	A1938	20.006	-48.516	15.152
ATOM	822	N	ASP	A1939	25.851	-45.216	15.990
ATOM	823	CA	ASP	A1939	26.935	-44.651	16.795
ATOM	824	C	ASP	A1939	27.442	-45.610	17.884
ATOM	825	O	ASP	A1939	26.796	-46.607	18.193
ATOM	826	CB	ASP	A1939	26.512	-43.304	17.412
ATOM	827	CG	ASP	A1939	27.519	-42.187	17.177
ATOM	828	OD1	ASP	A1939	27.451	-41.536	16.092
ATOM	829	OD2	ASP	A1939	28.383	-41.961	18.073
ATOM	830	N	ASP	A1940	28.593	-45.273	18.485
ATOM	831	CA	ASP	A1940	29.284	-46.041	19.533
ATOM	832	C	ASP	A1940	28.426	-46.436	20.735
ATOM	833	O	ASP	A1940	28.767	-47.410	21.407
ATOM	834	CB	ASP	A1940	30.540	-45.292	20.001
ATOM	835	CG	ASP	A1940	31.658	-45.343	18.972
ATOM	836	OD2	ASP	A1940	32.188	-44.264	18.619
ATOM	837	OD1	ASP	A1940	32.001	-46.467	18.515
ATOM	838	N	ASN	A1941	27.312	-45.705	20.987
ATOM	839	CA	ASN	A1941	26.387	-45.966	22.090
ATOM	840	C	ASN	A1941	25.300	-47.012	21.715
ATOM	841	O	ASN	A1941	24.380	-47.263	22.497
ATOM	842	CB	ASN	A1941	25.798	-44.648	22.641
ATOM	843	CG	ASN	A1941	24.805	-43.906	21.770
ATOM	844	ND2	ASN	A1941	23.974	-43.089	22.412
ATOM	845	OD1	ASN	A1941	24.795	-44.000	20.537
ATOM	846	N	TYR	A1942	25.484	-47.688	20.551
ATOM	847	CA	TYR	A1942	24.599	-48.703	19.964
ATOM	848	C	TYR	A1942	23.232	-48.123	19.553
ATOM	849	O	TYR	A1942	22.220	-48.839	19.528
ATOM	850	CB	TYR	A1942	24.462	-49.937	20.866
ATOM	851	CG	TYR	A1942	25.752	-50.370	21.524
ATOM	852	CD1	TYR	A1942	26.825	-50.833	20.766
ATOM	853	CD2	TYR	A1942	25.890	-50.354	22.908
ATOM	854	CE1	TYR	A1942	28.007	-51.264	21.368
ATOM	855	CE2	TYR	A1942	27.063	-50.792	23.524
ATOM	856	CZ	TYR	A1942	28.127	-51.235	22.748
ATOM	857	OH	TYR	A1942	29.299	-51.645	23.343
ATOM	858	N	ARG	A1943	23.224	-46.817	19.213
ATOM	859	CA	ARG	A1943	22.045	-46.080	18.795
ATOM	860	C	ARG	A1943	22.272	-45.255	17.523
ATOM	861	O	ARG	A1943	23.375	-44.797	17.268
ATOM	862	CB	ARG	A1943	21.502	-45.241	19.944
ATOM	863	CG	ARG	A1943	20.426	-45.994	20.729
ATOM	864	CD	ARG	A1943	20.663	-45.808	22.199
ATOM	865	NE	ARG	A1943	20.002	-46.794	23.064
ATOM	866	CZ	ARG	A1943	20.379	-48.055	23.251
ATOM	867	NH1	ARG	A1943	19.755	-48.812	24.139
ATOM	868	NH2	ARG	A1943	21.360	-48.582	22.523
ATOM	869	N	GLY	A1944	21.232	-45.138	16.711
ATOM	870	CA	GLY	A1944	21.253	-44.435	15.439
ATOM	871	C	GLY	A1944	21.615	-42.971	15.552
ATOM	872	O	GLY	A1944	21.069	-42.234	16.394
ATOM	873	N	ALA	A1945	22.558	-42.559	14.688
ATOM	874	CA	ALA	A1945	23.054	-41.183	14.604
ATOM	875	C	ALA	A1945	22.162	-40.359	13.696
ATOM	876	O	ALA	A1945	21.486	-40.906	12.816
ATOM	877	CB	ALA	A1945	24.486	-41.163	14.084
ATOM	878	N	VAL	A1946	22.147	-39.045	13.938
ATOM	879	CA	VAL	A1946	21.400	-38.055	13.157
ATOM	880	C	VAL	A1946	22.370	-36.957	12.668

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	881	O	VAL	A1946	23.464	-36.775	13.232	1.00	62.98	O
ATOM	882	CB	VAL	A1946	20.125	-37.483	13.864	1.00	64.42	C
ATOM	883	CG1	VAL	A1946	19.070	-38.563	14.084	1.00	64.21	C
ATOM	884	CG2	VAL	A1946	20.458	-36.788	15.177	1.00	64.08	C
ATOM	885	N	GLU	A1947	21.978	-36.270	11.599	1.00	56.36	N
ATOM	886	CA	GLU	A1947	22.704	-35.178	10.982	1.00	55.60	C
ATOM	887	C	GLU	A1947	24.022	-35.648	10.307	1.00	60.50	C
ATOM	888	O	GLU	A1947	24.061	-36.765	9.783	1.00	59.87	O
ATOM	889	CB	GLU	A1947	22.884	-34.021	11.970	1.00	56.84	C
ATOM	890	CG	GLU	A1947	21.532	-33.481	12.425	1.00	66.55	C
ATOM	891	CD	GLU	A1947	21.506	-32.272	13.338	1.00	87.79	C
ATOM	892	OE1	GLU	A1947	22.580	-31.859	13.834	1.00	101.28	O
ATOM	893	OE2	GLU	A1947	20.394	-31.748	13.572	1.00	74.60	O
ATOM	894	N	TRP	A1948	25.059	-34.779	10.241	1.00	57.19	N
ATOM	895	CA	TRP	A1948	26.324	-35.059	9.549	1.00	56.03	C
ATOM	896	C	TRP	A1948	27.208	-36.088	10.210	1.00	60.67	C
ATOM	897	O	TRP	A1948	27.673	-35.894	11.329	1.00	61.10	O
ATOM	898	CB	TRP	A1948	27.136	-33.789	9.299	1.00	54.14	C
ATOM	899	CG	TRP	A1948	26.423	-32.747	8.495	1.00	55.11	C
ATOM	900	CD1	TRP	A1948	25.843	-31.605	8.962	1.00	57.99	C
ATOM	901	CD2	TRP	A1948	26.254	-32.732	7.073	1.00	55.01	C
ATOM	902	CE2	TRP	A1948	25.581	-31.538	6.744	1.00	58.85	C
ATOM	903	CE3	TRP	A1948	26.594	-33.621	6.043	1.00	56.30	C
ATOM	904	NE1	TRP	A1948	25.323	-30.879	7.919	1.00	57.63	N
ATOM	905	CZ2	TRP	A1948	25.211	-31.230	5.435	1.00	58.04	C
ATOM	906	CZ3	TRP	A1948	26.284	-33.277	4.740	1.00	57.66	C
ATOM	907	CH2	TRP	A1948	25.596	-32.098	4.447	1.00	58.07	C
ATOM	908	N	LYS	A1949	27.484	-37.162	9.485	1.00	57.22	N
ATOM	909	CA	LYS	A1949	28.391	-38.205	9.911	1.00	56.77	C
ATOM	910	C	LYS	A1949	29.356	-38.479	8.744	1.00	61.49	C
ATOM	911	O	LYS	A1949	28.903	-38.602	7.601	1.00	60.78	O
ATOM	912	CB	LYS	A1949	27.623	-39.474	10.332	1.00	58.12	C
ATOM	913	CG	LYS	A1949	28.504	-40.512	11.039	1.00	67.04	C
ATOM	914	CD	LYS	A1949	28.648	-40.230	12.530	1.00	73.58	C
ATOM	915	CE	LYS	A1949	30.039	-40.476	13.051	1.00	76.23	C
ATOM	916	NZ	LYS	A1949	30.104	-40.205	14.514	1.00	79.46	N
ATOM	917	N	GLU	A1950	30.678	-38.519	9.032	1.00	58.48	N
ATOM	918	CA	GLU	A1950	31.712	-38.827	8.049	1.00	58.74	C
ATOM	919	C	GLU	A1950	32.032	-40.311	8.144	1.00	65.36	C
ATOM	920	O	GLU	A1950	32.503	-40.799	9.183	1.00	64.40	O
ATOM	921	CB	GLU	A1950	32.967	-37.958	8.202	1.00	59.95	C
ATOM	922	CG	GLU	A1950	33.998	-38.274	7.133	1.00	71.81	C
ATOM	923	CD	GLU	A1950	35.020	-37.210	6.790	1.00	96.69	C
ATOM	924	OE1	GLU	A1950	35.476	-37.195	5.623	1.00	97.28	O
ATOM	925	OE2	GLU	A1950	35.386	-36.410	7.680	1.00	90.81	O
ATOM	926	N	LEU	A1951	31.714	-41.034	7.061	1.00	64.06	N
ATOM	927	CA	LEU	A1951	31.875	-42.482	6.976	1.00	64.41	C
ATOM	928	C	LEU	A1951	32.839	-42.836	5.889	1.00	72.03	C
ATOM	929	O	LEU	A1951	32.583	-42.607	4.708	1.00	72.77	O
ATOM	930	CB	LEU	A1951	30.516	-43.151	6.798	1.00	64.02	C
ATOM	931	CG	LEU	A1951	29.559	-42.933	7.945	1.00	68.17	C
ATOM	932	CD1	LEU	A1951	28.242	-43.590	7.679	1.00	68.46	C
ATOM	933	CD2	LEU	A1951	30.168	-43.391	9.245	1.00	70.31	C
ATOM	934	N	ASP	A1952	33.977	-43.381	6.296	1.00	71.11	N
ATOM	935	CA	ASP	A1952	35.114	-43.616	5.409	1.00	71.53	C
ATOM	936	C	ASP	A1952	35.607	-42.201	5.062	1.00	76.90	C
ATOM	937	O	ASP	A1952	35.871	-41.423	5.997	1.00	77.33	O
ATOM	938	CB	ASP	A1952	34.792	-44.575	4.232	1.00	72.08	C
ATOM	939	CG	ASP	A1952	34.624	-46.006	4.748	1.00	72.73	C
ATOM	940	OD2	ASP	A1952	33.837	-46.787	4.121	1.00	71.67	O
ATOM	941	OD1	ASP	A1952	35.272	-46.350	5.796	1.00	70.63	O
ATOM	942	N	GLY	A1953	35.636	-41.824	3.805	1.00	73.37	N
ATOM	943	CA	GLY	A1953	36.056	-40.456	3.512	1.00	73.97	C
ATOM	944	C	GLY	A1953	34.922	-39.589	3.009	1.00	76.92	C
ATOM	945	O	GLY	A1953	35.159	-38.497	2.473	1.00	77.71	O
ATOM	946	N	GLU	A1954	33.686	-40.087	3.188	1.00	69.62	N
ATOM	947	CA	GLU	A1954	32.462	-39.528	2.640	1.00	68.37	C
ATOM	948	C	GLU	A1954	31.540	-38.906	3.670	1.00	69.92	C
ATOM	949	O	GLU	A1954	31.475	-39.376	4.799	1.00	70.58	O
ATOM	950	CB	GLU	A1954	31.701	-40.645	1.899	1.00	69.92	C
ATOM	951	CG	GLU	A1954	32.551	-41.568	1.022	1.00	78.86	C
ATOM	952	CD	GLU	A1954	31.921	-42.914	0.684	1.00	105.90	C
ATOM	953	OE1	GLU	A1954	31.576	-43.683	1.617	1.00	93.59	O
ATOM	954	OE2	GLU	A1954	31.818	-43.216	-0.529	1.00	98.86	O
ATOM	955	N	MET	A1955	30.786	-37.887	3.267	1.00	63.73	N
ATOM	956	CA	MET	A1955	29.840	-37.248	4.154	1.00	62.76	C
ATOM	957	C	MET	A1955	28.462	-37.738	3.881	1.00	64.75	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	958 O	MET	A1955	28.035	-37.816	2.730	1.00	63.58 O
ATOM	959 CB	MET	A1955	29.889	-35.731	4.028	1.00	65.81 C
ATOM	960 CG	MET	A1955	30.971	-35.128	4.839	1.00	70.52 C
ATOM	961 SD	MET	A1955	30.495	-35.065	6.561	1.00	75.31 S
ATOM	962 CE	MET	A1955	31.954	-34.368	7.225	1.00	71.92 C
ATOM	963 N	HIS	A1956	27.751	-38.043	4.958	1.00	61.88 N
ATOM	964 CA	HIS	A1956	26.376	-38.524	4.965	1.00	61.82 C
ATOM	965 C	HIS	A1956	25.523	-37.616	5.866	1.00	66.45 C
ATOM	966 O	HIS	A1956	26.061	-37.039	6.818	1.00	66.19 O
ATOM	967 CB	HIS	A1956	26.352	-39.956	5.528	1.00	62.47 C
ATOM	968 CG	HIS	A1956	27.010	-40.966	4.642	1.00	65.48 C
ATOM	969 CD2	HIS	A1956	26.457	-41.819	3.750	1.00	66.88 C
ATOM	970 ND1	HIS	A1956	28.380	-41.166	4.667	1.00	66.97 N
ATOM	971 CE1	HIS	A1956	28.612	-42.122	3.790	1.00	66.43 C
ATOM	972 NE2	HIS	A1956	27.482	-42.541	3.208	1.00	66.74 N
ATOM	973 N	TYR	A1957	24.194	-37.510	5.589	1.00	62.09 N
ATOM	974 CA	TYR	A1957	23.285	-36.736	6.441	1.00	60.53 C
ATOM	975 C	TYR	A1957	22.072	-37.566	6.793	1.00	62.47 C
ATOM	976 O	TYR	A1957	21.194	-37.773	5.961	1.00	63.68 O
ATOM	977 CB	TYR	A1957	22.897	-35.371	5.845	1.00	61.07 C
ATOM	978 CG	TYR	A1957	22.155	-34.471	6.816	1.00	62.96 C
ATOM	979 CD1	TYR	A1957	22.842	-33.604	7.665	1.00	63.44 C
ATOM	980 CD2	TYR	A1957	20.769	-34.470	6.875	1.00	65.36 C
ATOM	981 CE1	TYR	A1957	22.163	-32.764	8.548	1.00	63.18 C
ATOM	982 CE2	TYR	A1957	20.080	-33.647	7.767	1.00	65.86 C
ATOM	983 CZ	TYR	A1957	20.781	-32.794	8.597	1.00	67.45 C
ATOM	984 OH	TYR	A1957	20.077	-31.986	9.446	1.00	66.78 O
ATOM	985 N	PHE	A1958	22.027	-38.039	8.032	1.00	55.34 N
ATOM	986 CA	PHE	A1958	20.937	-38.837	8.571	1.00	52.89 C
ATOM	987 C	PHE	A1958	19.818	-37.931	9.071	1.00	54.94 C
ATOM	988 O	PHE	A1958	20.089	-36.950	9.739	1.00	53.78 O
ATOM	989 CB	PHE	A1958	21.485	-39.771	9.672	1.00	54.02 C
ATOM	990 CG	PHE	A1958	22.501	-40.749	9.112	1.00	54.43 C
ATOM	991 CD1	PHE	A1958	22.093	-41.877	8.411	1.00	56.86 C
ATOM	992 CD2	PHE	A1958	23.859	-40.501	9.221	1.00	56.10 C
ATOM	993 CE1	PHE	A1958	23.024	-42.753	7.858	1.00	58.09 C
ATOM	994 CE2	PHE	A1958	24.795	-41.366	8.639	1.00	59.25 C
ATOM	995 CZ	PHE	A1958	24.372	-42.482	7.959	1.00	57.43 C
ATOM	996 N	SER	A1959	18.565	-38.232	8.709	1.00	52.58 N
ATOM	997 CA	SER	A1959	17.379	-37.464	9.082	1.00	52.44 C
ATOM	998 C	SER	A1959	17.233	-37.319	10.599	1.00	57.28 C
ATOM	999 O	SER	A1959	17.209	-38.334	11.297	1.00	55.50 O
ATOM	1000 CB	SER	A1959	16.124	-38.120	8.510	1.00	56.50 C
ATOM	1001 OG	SER	A1959	14.919	-37.533	8.981	1.00	67.89 O
ATOM	1002 N	PRO	A1960	17.091	-36.069	11.127	1.00	55.78 N
ATOM	1003 CA	PRO	A1960	16.858	-35.897	12.567	1.00	55.22 C
ATOM	1004 C	PRO	A1960	15.485	-36.436	12.967	1.00	58.25 C
ATOM	1005 O	PRO	A1960	15.249	-36.684	14.145	1.00	58.44 O
ATOM	1006 CB	PRO	A1960	16.929	-34.373	12.754	1.00	56.75 C
ATOM	1007 CG	PRO	A1960	17.540	-33.839	11.503	1.00	60.76 C
ATOM	1008 CD	PRO	A1960	17.063	-34.758	10.445	1.00	57.24 C
ATOM	1009 N	GLU	A1961	14.603	-36.653	11.977	1.00	54.12 N
ATOM	1010 CA	GLU	A1961	13.259	-37.171	12.197	1.00	54.74 C
ATOM	1011 C	GLU	A1961	13.237	-38.716	12.289	1.00	63.20 C
ATOM	1012 O	GLU	A1961	12.618	-39.259	13.208	1.00	63.29 O
ATOM	1013 CB	GLU	A1961	12.249	-36.646	11.141	1.00	55.66 C
ATOM	1014 CG	GLU	A1961	12.643	-35.377	10.385	1.00	67.10 C
ATOM	1015 CD	GLU	A1961	12.185	-34.037	10.938	1.00	99.33 C
ATOM	1016 OE1	GLU	A1961	13.026	-33.113	11.053	1.00	97.73 O
ATOM	1017 OE2	GLU	A1961	10.970	-33.885	11.194	1.00	103.38 O
ATOM	1018 N	THR	A1962	13.931	-39.424	11.354	1.00	62.21 N
ATOM	1019 CA	THR	A1962	13.921	-40.900	11.250	1.00	61.85 C
ATOM	1020 C	THR	A1962	15.266	-41.649	11.424	1.00	67.03 C
ATOM	1021 O	THR	A1962	15.248	-42.865	11.625	1.00	68.89 O
ATOM	1022 CB	THR	A1962	13.330	-41.302	9.902	1.00	67.88 C
ATOM	1023 CG2	THR	A1962	11.909	-40.811	9.714	1.00	65.44 C
ATOM	1024 OG1	THR	A1962	14.147	-40.761	8.865	1.00	74.94 O
ATOM	1025 N	GLY	A1963	16.394	-40.953	11.310	1.00	61.48 N
ATOM	1026 CA	GLY	A1963	17.717	-41.569	11.417	1.00	60.32 C
ATOM	1027 C	GLY	A1963	18.251	-42.138	10.106	1.00	60.23 C
ATOM	1028 O	GLY	A1963	19.367	-42.681	10.068	1.00	60.11 O
ATOM	1029 N	LYS	A1964	17.441	-41.999	9.028	1.00	50.80 N
ATOM	1030 CA	LYS	A1964	17.669	-42.444	7.666	1.00	48.24 C
ATOM	1031 C	LYS	A1964	18.485	-41.436	6.888	1.00	52.23 C
ATOM	1032 O	LYS	A1964	18.111	-40.256	6.819	1.00	51.68 O
ATOM	1033 CB	LYS	A1964	16.312	-42.580	6.942	1.00	49.00 C
ATOM	1034 CG	LYS	A1964	15.472	-43.743	7.379	1.00	52.42 C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	1035	CD	LYS	A1964	14.155	-43.689	6.697	1.00	55.61	C
ATOM	1036	CE	LYS	A1964	13.155	-44.590	7.367	1.00	55.85	C
ATOM	1037	NZ	LYS	A1964	11.824	-44.471	6.729	1.00	63.14	N
ATOM	1038	N	ALA	A1965	19.528	-41.925	6.192	1.00	48.75	N
ATOM	1039	CA	ALA	A1965	20.402	-41.133	5.322	1.00	47.45	C
ATOM	1040	C	ALA	A1965	19.583	-40.494	4.233	1.00	54.84	C
ATOM	1041	O	ALA	A1965	18.696	-41.135	3.664	1.00	57.63	O
ATOM	1042	CB	ALA	A1965	21.470	-42.016	4.699	1.00	47.30	C
ATOM	1043	N	PHE	A1966	19.838	-39.211	3.997	1.00	49.76	N
ATOM	1044	CA	PHE	A1966	19.226	-38.399	2.971	1.00	48.42	C
ATOM	1045	C	PHE	A1966	19.803	-38.834	1.619	1.00	56.89	C
ATOM	1046	O	PHE	A1966	21.003	-39.141	1.522	1.00	56.73	O
ATOM	1047	CB	PHE	A1966	19.627	-36.944	3.211	1.00	49.18	C
ATOM	1048	CG	PHE	A1966	18.771	-36.081	4.102	1.00	50.07	C
ATOM	1049	CD1	PHE	A1966	17.919	-36.645	5.041	1.00	52.82	C
ATOM	1050	CD2	PHE	A1966	18.838	-34.693	4.021	1.00	51.50	C
ATOM	1051	CE1	PHE	A1966	17.127	-35.834	5.864	1.00	53.51	C
ATOM	1052	CE2	PHE	A1966	18.043	-33.887	4.839	1.00	53.25	C
ATOM	1053	CZ	PHE	A1966	17.218	-34.461	5.772	1.00	51.54	C
ATOM	1054	N	LYS	A1967	18.955	-38.799	0.565	1.00	55.58	N
ATOM	1055	CA	LYS	A1967	19.298	-39.134	-0.828	1.00	54.35	C
ATOM	1056	C	LYS	A1967	18.771	-38.019	-1.751	1.00	57.80	C
ATOM	1057	O	LYS	A1967	17.715	-37.440	-1.471	1.00	57.71	O
ATOM	1058	CB	LYS	A1967	18.698	-40.501	-1.226	1.00	54.73	C
ATOM	1059	CG	LYS	A1967	19.312	-41.715	-0.526	1.00	47.74	C
ATOM	1060	CD	LYS	A1967	18.557	-42.976	-0.903	1.00	58.24	C
ATOM	1061	CE	LYS	A1967	18.648	-44.150	0.052	1.00	69.10	C
ATOM	1062	NZ	LYS	A1967	17.442	-45.042	-0.050	1.00	77.82	N
ATOM	1063	N	GLY	A1968	19.512	-37.724	-2.819	1.00	53.39	N
ATOM	1064	CA	GLY	A1968	19.159	-36.674	-3.768	1.00	53.50	C
ATOM	1065	C	GLY	A1968	19.364	-35.289	-3.186	1.00	59.43	C
ATOM	1066	O	GLY	A1968	19.989	-35.154	-2.128	1.00	61.08	O
ATOM	1067	N	LEU	A1969	18.852	-34.249	-3.878	1.00	54.94	N
ATOM	1068	CA	LEU	A1969	78.935	-32.837	-3.462	1.00	54.72	C
ATOM	1069	C	LEU	A1969	18.147	-32.589	-2.159	1.00	60.33	C
ATOM	1070	O	LEU	A1969	16.982	-32.975	-2.057	1.00	60.48	O
ATOM	1071	CB	LEU	A1969	18.363	-31.919	-4.566	1.00	54.29	C
ATOM	1072	CG	LEU	A1969	19.156	-30.677	-4.984	1.00	56.57	C
ATOM	1073	CD1	LEU	A1969	18.439	-29.954	-6.032	1.00	55.76	C
ATOM	1074	CD2	LEU	A1969	19.327	-29.724	-3.861	1.00	58.24	C
ATOM	1075	N	ASN	A1970	18.770	-31.934	-1.178	1.00	57.17	N
ATOM	1076	CA	ASN	A1970	18.112	-31.685	0.099	1.00	57.22	C
ATOM	1077	C	ASN	A1970	18.538	-30.394	0.744	1.00	63.19	C
ATOM	1078	O	ASN	A1970	19.727	-30.060	0.730	1.00	63.28	O
ATOM	1079	CB	ASN	A1970	18.446	-32.801	1.067	1.00	56.06	C
ATOM	1080	CG	ASN	A1970	17.595	-34.017	0.942	1.00	78.85	C
ATOM	1081	ND2	ASN	A1970	18.194	-35.120	0.467	1.00	71.39	N
ATOM	1082	OD1	ASN	A1970	16.439	-34.010	1.371	1.00	68.46	O
ATOM	1083	N	GLN	A1971	17.590	-29.708	1.400	1.00	60.17	N
ATOM	1084	CA	GLN	A1971	17.959	-28.517	2.144	1.00	59.00	C
ATOM	1085	C	GLN	A1971	18.320	-28.902	3.566	1.00	63.99	C
ATOM	1086	O	GLN	A1971	17.560	-29.609	4.253	1.00	64.68	O
ATOM	1087	CB	GLN	A1971	16.874	-27.464	2.142	1.00	59.28	C
ATOM	1088	CG	GLN	A1971	17.493	-26.170	2.543	1.00	65.24	C
ATOM	1089	CD	GLN	A1971	16.698	-24.963	2.241	1.00	79.09	C
ATOM	1090	NE2	GLN	A1971	16.838	-23.995	3.116	1.00	68.56	N
ATOM	1091	OE1	GLN	A1971	16.026	-24.857	1.211	1.00	79.57	O
ATOM	1092	N	ILE	A1972	19.514	-28.470	3.984	1.00	58.99	N
ATOM	1093	CA	ILE	A1972	20.054	-28.679	5.328	1.00	57.39	C
ATOM	1094	C	ILE	A1972	20.467	-27.289	5.775	1.00	62.78	C
ATOM	1095	O	ILE	A1972	21.468	-26.750	5.280	1.00	63.51	O
ATOM	1096	CB	ILE	A1972	21.219	-29.690	5.348	1.00	58.90	C
ATOM	1097	CG1	ILE	A1972	20.735	-31.093	4.900	1.00	59.14	C
ATOM	1098	CG2	ILE	A1972	21.877	-29.712	6.728	1.00	57.48	C
ATOM	1099	CD1	ILE	A1972	21.789	-31.994	4.331	1.00	62.82	C
ATOM	1100	N	GLY	A1973	19.646	-26.692	6.638	1.00	58.12	N
ATOM	1101	CA	GLY	A1973	19.877	-25.336	7.091	1.00	57.82	C
ATOM	1102	C	GLY	A1973	19.663	-24.352	5.956	1.00	62.88	C
ATOM	1103	O	GLY	A1973	18.745	-24.521	5.143	1.00	62.80	O
ATOM	1104	N	ASP	A1974	20.523	-23.342	5.862	1.00	59.68	N
ATOM	1105	CA	ASP	A1974	20.354	-22.348	4.811	1.00	60.93	C
ATOM	1106	C	ASP	A1974	20.836	-22.821	3.421	1.00	64.59	C
ATOM	1107	O	ASP	A1974	20.687	-22.074	2.448	1.00	65.53	O
ATOM	1108	CB	ASP	A1974	21.017	-21.011	5.217	1.00	63.96	C
ATOM	1109	CG	ASP	A1974	20.853	-20.625	6.680	1.00	80.43	C
ATOM	1110	OD1	ASP	A1974	19.726	-20.806	7.228	1.00	82.68	O
ATOM	1111	OD2	ASP	A1974	21.852	-20.161	7.286	1.00	84.93	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	1112 N	TYR	A1975	21.395	-24.042	3.315	1.00	58.47	N
ATOM	1113 CA	TYR	A1975	21.939	-24.503	2.049	1.00	57.57	C
ATOM	1114 C	TYR	A1975	21.387	-25.814	1.566	1.00	60.11	C
ATOM	1115 O	TYR	A1975	20.805	-26.591	2.334	1.00	58.70	O
ATOM	1116 CB	TYR	A1975	23.476	-24.569	2.077	1.00	59.21	C
ATOM	1117 CG	TYR	A1975	24.150	-23.375	2.707	1.00	61.66	C
ATOM	1118 CD1	TYR	A1975	24.360	-22.205	1.982	1.00	64.47	C
ATOM	1119 CD2	TYR	A1975	24.637	-23.433	4.008	1.00	62.16	C
ATOM	1120 CE1	TYR	A1975	24.994	-21.101	2.555	1.00	66.69	C
ATOM	1121 CE2	TYR	A1975	25.294	-22.347	4.584	1.00	63.50	C
ATOM	1122 CZ	TYR	A1975	25.465	-21.178	3.857	1.00	75.07	C
ATOM	1123 OH	TYR	A1975	26.083	-20.090	4.429	1.00	78.62	O
ATOM	1124 N	LYS	A1976	21.621	-26.059	0.261	1.00	56.35	N
ATOM	1125 CA	LYS	A1976	21.221	-27.257	-0.448	1.00	55.88	C
ATOM	1126 C	LYS	A1976	22.430	-28.119	-0.836	1.00	59.15	C
ATOM	1127 O	LYS	A1976	23.495	-27.605	-1.195	1.00	58.02	O
ATOM	1128 CB	LYS	A1976	20.311	-26.921	-1.634	1.00	57.41	C
ATOM	1129 CG	LYS	A1976	18.927	-26.466	-1.177	1.00	72.70	C
ATOM	1130 CD	LYS	A1976	17.898	-26.531	-2.305	1.00	85.66	C
ATOM	1131 CE	LYS	A1976	17.365	-25.184	-2.745	1.00	95.27	C
ATOM	1132 NZ	LYS	A1976	16.474	-25.320	-3.932	1.00	101.46	N
ATOM	1133 N	TYR	A1977	22.273	-29.435	-0.670	1.00	56.15	N
ATOM	1134 CA	TYR	A1977	23.313	-30.425	-0.941	1.00	56.55	C
ATOM	1135 C	TYR	A1977	22.739	-31.568	-1.748	1.00	61.20	C
ATOM	1136 O	TYR	A1977	21.550	-31.882	-1.617	1.00	60.82	O
ATOM	1137 CB	TYR	A1977	23.855	-31.017	0.377	1.00	57.55	C
ATOM	1138 CG	TYR	A1977	24.322	-29.998	1.389	1.00	59.61	C
ATOM	1139 CD1	TYR	A1977	23.410	-29.307	2.186	1.00	62.52	C
ATOM	1140 CD2	TYR	A1977	25.675	-29.772	1.604	1.00	59.80	C
ATOM	1141 CE1	TYR	A1977	23.832	-28.355	3.113	1.00	63.57	C
ATOM	1142 CE2	TYR	A1977	26.110	-28.833	2.538	1.00	61.22	C
ATOM	1143 CZ	TYR	A1977	25.184	-28.129	3.298	1.00	70.47	C
ATOM	1144 OH	TYR	A1977	25.591	-27.203	4.233	1.00	73.27	O
ATOM	1145 N	TYR	A1978	23.591	-32.229	-2.538	1.00	57.72	N
ATOM	1146 CA	TYR	A1978	23.170	-33.413	-3.260	1.00	57.97	C
ATOM	1147 C	TYR	A1978	23.860	-34.628	-2.700	1.00	64.39	C
ATOM	1148 O	TYR	A1978	25.093	-34.639	-2.530	1.00	64.75	O
ATOM	1149 CB	TYR	A1978	23.400	-33.319	-4.757	1.00	58.79	C
ATOM	1150 CG	TYR	A1978	22.932	-34.534	-5.534	1.00	61.35	C
ATOM	1151 CD1	TYR	A1978	21.624	-34.633	-5.991	1.00	63.50	C
ATOM	1152 CD2	TYR	A1978	23.815	-35.562	-5.859	1.00	62.47	C
ATOM	1153 CE1	TYR	A1978	21.200	-35.731	-6.738	1.00	65.59	C
ATOM	1154 CE2	TYR	A1978	23.403	-36.665	-6.606	1.00	63.23	C
ATOM	1155 CZ	TYR	A1978	22.098	-36.738	-7.057	1.00	70.87	C
ATOM	1156 OH	TYR	A1978	21.693	-37.812	-7.810	1.00	71.32	O
ATOM	1157 N	PHE	A1979	23.049	-35.674	-2.468	1.00	60.07	N
ATOM	1158 CA	PHE	A1979	23.514	-36.951	-1.988	1.00	60.15	C
ATOM	1159 C	PHE	A1979	23.181	-38.060	-3.008	1.00	64.56	C
ATOM	1160 O	PHE	A1979	22.139	-38.015	-3.660	1.00	64.99	O
ATOM	1161 CB	PHE	A1979	22.874	-37.249	-0.625	1.00	62.31	C
ATOM	1162 CG	PHE	A1979	23.205	-36.268	0.479	1.00	63.21	C
ATOM	1163 CD2	PHE	A1979	22.394	-35.163	0.717	1.00	64.74	C
ATOM	1164 CD1	PHE	A1979	24.305	-36.466	1.302	1.00	64.84	C
ATOM	1165 CE2	PHE	A1979	22.687	-34.269	1.747	1.00	65.94	C
ATOM	1166 CE1	PHE	A1979	24.600	-35.564	2.328	1.00	64.68	C
ATOM	1167 CZ	PHE	A1979	23.781	-34.482	2.547	1.00	63.26	C
ATOM	1168 N	ASN	A1980	24.075	-39.050	-3.132	1.00	60.41	N
ATOM	1169 CA	ASN	A1980	24.001	-40.271	-3.951	1.00	59.45	C
ATOM	1170 C	ASN	A1980	22.751	-41.067	-3.662	1.00	64.68	C
ATOM	1171 O	ASN	A1980	22.052	-40.814	-2.682	1.00	65.46	O
ATOM	1172 CB	ASN	A1980	25.092	-41.207	-3.430	1.00	56.24	C
ATOM	1173 CG	ASN	A1980	26.274	-41.404	-4.274	1.00	71.50	C
ATOM	1174 ND2	ASN	A1980	27.107	-42.326	-3.838	1.00	61.50	N
ATOM	1175 OD1	ASN	A1980	26.473	-40.736	-5.288	1.00	73.16	O
ATOM	1176 N	SER	A1981	22.609	-42.180	-4.375	1.00	60.78	N
ATOM	1177 CA	SER	A1981	21.596	-43.190	-4.125	1.00	59.49	C
ATOM	1178 C	SER	A1981	22.025	-43.942	-2.840	1.00	63.66	C
ATOM	1179 O	SER	A1981	21.195	-44.585	-2.190	1.00	63.35	O
ATOM	1180 CB	SER	A1981	21.559	-44.163	-5.289	1.00	62.19	C
ATOM	1181 OG	SER	A1981	20.384	-44.943	-5.192	1.00	77.10	O
ATOM	1182 N	ASP	A1982	23.340	-43.850	-2.489	1.00	60.12	N
ATOM	1183 CA	ASP	A1982	23.975	-44.436	-1.309	1.00	60.12	C
ATOM	1184 C	ASP	A1982	24.109	-43.426	-0.160	1.00	66.41	C
ATOM	1185 O	ASP	A1982	24.637	-43.778	0.902	1.00	67.97	O
ATOM	1186 CB	ASP	A1982	25.361	-44.972	-1.654	1.00	62.27	C
ATOM	1187 CG	ASP	A1982	25.401	-46.157	-2.607	1.00	81.10	C
ATOM	1188 OD2	ASP	A1982	26.427	-46.307	-3.323	1.00	88.48	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	1189	OD1	ASP	A1982	24.428	-46.974	-2.601	1.00	82.62	O
ATOM	1190	N	GLY	A1983	23.646	-42.190	-0.379	1.00	60.76	N
ATOM	1191	CA	GLY	A1983	23.690	-41.126	0.614	1.00	58.72	C
ATOM	1192	C	GLY	A1983	25.035	-40.453	0.792	1.00	59.54	C
ATOM	1193	O	GLY	A1983	25.289	-39.857	1.836	1.00	60.99	O
ATOM	1194	N	VAL	A1984	25.889	-40.508	-0.220	1.00	52.51	N
ATOM	1195	CA	VAL	A1984	27.206	-39.891	-0.176	1.00	51.03	C
ATOM	1196	C	VAL	A1984	27.046	-38.491	-0.733	1.00	56.04	C
ATOM	1197	O	VAL	A1984	26.511	-38.312	-1.829	1.00	56.02	O
ATOM	1198	CB	VAL	A1984	28.263	-40.707	-0.975	1.00	53.26	C
ATOM	1199	CG1	VAL	A1984	29.603	-39.986	-1.028	1.00	52.17	C
ATOM	1200	CG2	VAL	A1984	28.432	-42.114	-0.408	1.00	52.88	C
ATOM	1201	N	MET	A1985	27.524	-37.498	0.008	1.00	52.34	N
ATOM	1202	CA	MET	A1985	27.436	-36.122	-0.449	1.00	51.55	C
ATOM	1203	C	MET	A1985	28.354	-35.889	-1.650	1.00	53.34	C
ATOM	1204	O	MET	A1985	29.502	-36.321	-1.638	1.00	51.51	O
ATOM	1205	CB	MET	A1985	27.715	-35.162	0.703	1.00	53.44	C
ATOM	1206	CG	MET	A1985	27.456	-33.711	0.377	1.00	55.57	C
ATOM	1207	SD	MET	A1985	28.437	-32.760	1.530	1.00	58.50	S
ATOM	1208	CE	MET	A1985	30.038	-33.014	0.873	1.00	54.51	C
ATOM	1209	N	GLN	A1986	27.819	-35.209	-2.683	1.00	49.94	N
ATOM	1210	CA	GLN	A1986	28.498	-34.955	-3.954	1.00	49.35	C
ATOM	1211	C	GLN	A1986	29.116	-33.563	-4.080	1.00	50.60	C
ATOM	1212	O	GLN	A1986	28.587	-32.594	-3.551	1.00	52.36	O
ATOM	1213	CB	GLN	A1986	27.539	-35.250	-5.131	1.00	51.02	C
ATOM	1214	CG	GLN	A1986	27.141	-36.728	-5.263	1.00	56.10	C
ATOM	1215	CD	GLN	A1986	28.352	-37.610	-5.385	1.00	70.58	C
ATOM	1216	NE2	GLN	A1986	28.572	-38.441	-4.389	1.00	64.30	N
ATOM	1217	OE1	GLN	A1986	29.140	-37.493	-6.323	1.00	66.71	O
ATOM	1218	N	LYS	A1987	30.246	-33.479	-4.769	1.00	44.53	N
ATOM	1219	CA	LYS	A1987	31.031	-32.258	-4.985	1.00	43.02	C
ATOM	1220	C	LYS	A1987	31.318	-32.179	-6.476	1.00	48.88	C
ATOM	1221	O	LYS	A1987	31.735	-33.184	-7.052	1.00	48.45	O
ATOM	1222	CB	LYS	A1987	32.365	-32.313	-4.223	1.00	41.77	C
ATOM	1223	CG	LYS	A1987	32.227	-32.293	-2.710	1.00	44.36	C
ATOM	1224	CD	LYS	A1987	33.579	-32.454	-2.020	1.00	45.79	C
ATOM	1225	CE	LYS	A1987	33.416	-32.706	-0.544	1.00	57.88	C
ATOM	1226	NZ	LYS	A1987	34.595	-32.224	0.242	1.00	79.76	N
ATOM	1227	N	GLY	A1988	31.075	-30.999	-7.071	1.00	44.69	N
ATOM	1228	CA	GLY	A1988	31.255	-30.711	-8.487	1.00	43.03	C
ATOM	1229	C	GLY	A1988	29.933	-30.548	-9.189	1.00	47.96	C
ATOM	1230	O	GLY	A1988	28.918	-30.256	-8.556	1.00	47.75	O
ATOM	1231	N	PHE	A1989	29.940	-30.720	-10.505	1.00	46.88	N
ATOM	1232	CA	PHE	A1989	28.749	-30.607	-11.354	1.00	46.99	C
ATOM	1233	C	PHE	A1989	27.952	-31.899	-11.294	1.00	54.23	C
ATOM	1234	O	PHE	A1989	28.528	-32.985	-11.349	1.00	55.04	O
ATOM	1235	CB	PHE	A1989	29.131	-30.253	-12.795	1.00	47.90	C
ATOM	1236	CG	PHE	A1989	29.634	-28.846	-13.014	1.00	48.70	C
ATOM	1237	CD1	PHE	A1989	30.985	-28.543	-12.885	1.00	49.98	C
ATOM	1238	CD2	PHE	A1989	28.752	-27.816	-13.360	1.00	51.27	C
ATOM	1239	CE1	PHE	A1989	31.452	-27.232	-13.126	1.00	53.01	C
ATOM	1240	CE2	PHE	A1989	29.214	-26.509	-13.585	1.00	50.91	C
ATOM	1241	CZ	PHE	A1989	30.559	-26.225	-13.473	1.00	50.31	C
ATOM	1242	N	VAL	A1990	26.637	-31.773	-11.074	1.00	52.56	N
ATOM	1243	CA	VAL	A1990	25.676	-32.875	-10.951	1.00	52.79	C
ATOM	1244	C	VAL	A1990	24.517	-32.563	-11.908	1.00	59.35	C
ATOM	1245	O	VAL	A1990	24.055	-31.418	-11.974	1.00	58.03	O
ATOM	1246	CB	VAL	A1990	25.145	-33.092	-9.493	1.00	56.28	C
ATOM	1247	CG1	VAL	A1990	24.225	-34.307	-9.407	1.00	56.36	C
ATOM	1248	CG2	VAL	A1990	26.271	-33.242	-8.487	1.00	55.94	C
ATOM	1249	N	SER	A1991	24.066	-33.587	-12.658	1.00	58.11	N
ATOM	1250	CA	SER	A1991	22.920	-33.474	-13.527	1.00	58.79	C
ATOM	1251	C	SER	A1991	21.741	-33.971	-12.719	1.00	65.84	C
ATOM	1252	O	SER	A1991	21.716	-35.124	-12.282	1.00	65.62	O
ATOM	1253	CB	SER	A1991	23.109	-34.275	-14.809	1.00	64.13	C
ATOM	1254	OG	SER	A1991	22.845	-33.473	-15.955	1.00	81.21	O
ATOM	1255	N	ILE	A1992	20.827	-33.049	-12.401	1.00	65.42	N
ATOM	1256	CA	ILE	A1992	19.593	-33.322	-11.662	1.00	65.97	C
ATOM	1257	C	ILE	A1992	18.467	-32.852	-12.583	1.00	74.02	C
ATOM	1258	O	ILE	A1992	18.419	-31.657	-12.942	1.00	74.46	O
ATOM	1259	CB	ILE	A1992	19.518	-32.622	-10.276	1.00	68.37	C
ATOM	1260	CG1	ILE	A1992	20.753	-32.892	-9.400	1.00	68.18	C
ATOM	1261	CG2	ILE	A1992	18.232	-33.017	-9.561	1.00	68.94	C
ATOM	1262	CD1	ILE	A1992	20.990	-31.867	-8.335	1.00	71.68	C
ATOM	1263	N	ASN	A1993	17.586	-33.811	-12.983	1.00	71.62	N
ATOM	1264	CA	ASN	A1993	16.425	-33.628	-13.862	1.00	71.23	C
ATOM	1265	C	ASN	A1993	16.765	-32.879	-15.150	1.00	74.25	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	1266 O	ASN	A1993	16.075	-31.937	-15.538	1.00	73.64 O
ATOM	1267 CB	ASN	A1993	15.267	-32.978	-13.099	1.00	73.82 C
ATOM	1268 CG	ASN	A1993	14.856	-33.735	-11.859	1.00	103.95 C
ATOM	1269 ND2	ASN	A1993	14.037	-33.098	-11.031	1.00	95.36 N
ATOM	1270 OD1	ASN	A1993	15.271	-34.881	-11.625	1.00	101.60 O
ATOM	1271 N	ASP	A1994	17.857	-33.297	-15.791	1.00	71.81 N
ATOM	1272 CA	ASP	A1994	18.366	-32.739	-17.044	1.00	73.11 C
ATOM	1273 C	ASP	A1994	18.680	-31.214	-16.955	1.00	75.92 C
ATOM	1274 O	ASP	A1994	18.411	-30.448	-17.884	1.00	75.92 O
ATOM	1275 CB	ASP	A1994	17.438	-33.094	-18.220	1.00	76.25 C
ATOM	1276 CG	ASP	A1994	17.441	-34.587	-18.511	1.00	95.12 C
ATOM	1277 OD1	ASP	A1994	18.409	-35.064	-19.164	1.00	97.40 O
ATOM	1278 OD2	ASP	A1994	16.495	-35.294	-18.048	1.00	99.30 O
ATOM	1279 N	ASN	A1995	19.294	-30.813	-15.826	1.00	70.56 N
ATOM	1280 CA	ASN	A1995	19.778	-29.470	-15.509	1.00	69.14 C
ATOM	1281 C	ASN	A1995	21.062	-29.671	-14.726	1.00	70.06 C
ATOM	1282 O	ASN	A1995	21.159	-30.650	-13.984	1.00	70.02 O
ATOM	1283 CB	ASN	A1995	18.759	-28.669	-14.684	1.00	68.41 C
ATOM	1284 CG	ASN	A1995	17.487	-28.339	-15.440	1.00	87.19 C
ATOM	1285 ND2	ASN	A1995	16.373	-28.927	-14.988	1.00	74.42 N
ATOM	1286 OD1	ASN	A1995	17.485	-27.566	-16.424	1.00	74.73 O
ATOM	1287 N	LYS	A1996	22.064	-28.786	-14.925	1.00	62.84 N
ATOM	1288 CA	LYS	A1996	23.339	-28.878	-14.232	1.00	60.41 C
ATOM	1289 C	LYS	A1996	23.355	-27.958	-12.992	1.00	63.76 C
ATOM	1290 O	LYS	A1996	23.006	-26.783	-13.095	1.00	62.93 O
ATOM	1291 CB	LYS	A1996	24.524	-28.622	-15.183	1.00	60.20 C
ATOM	1292 N	HIS	A1997	23.719	-28.532	-11.809	1.00	59.65 N
ATOM	1293 CA	HIS	A1997	23.864	-27.860	-10.504	1.00	58.31 C
ATOM	1294 C	HIS	A1997	25.324	-27.939	-10.057	1.00	58.88 C
ATOM	1295 O	HIS	A1997	26.064	-28.771	-10.563	1.00	57.87 O
ATOM	1296 CB	HIS	A1997	22.954	-28.490	-9.441	1.00	58.78 C
ATOM	1297 CG	HIS	A1997	21.486	-28.368	-9.714	1.00	62.26 C
ATOM	1298 CD2	HIS	A1997	20.735	-28.929	-10.691	1.00	64.39 C
ATOM	1299 ND1	HIS	A1997	20.654	-27.660	-8.864	1.00	64.28 N
ATOM	1300 CE1	HIS	A1997	19.433	-27.790	-9.362	1.00	63.82 C
ATOM	1301 NE2	HIS	A1997	19.429	-28.546	-10.461	1.00	64.22 N
ATOM	1302 N	TYR	A1998	25.766	-27.051	-9.162	1.00	54.09 N
ATOM	1303 CA	TYR	A1998	27.161	-27.109	-8.764	1.00	52.35 C
ATOM	1304 C	TYR	A1998	27.300	-27.093	-7.279	1.00	56.73 C
ATOM	1305 O	TYR	A1998	26.832	-26.174	-6.627	1.00	56.28 O
ATOM	1306 CB	TYR	A1998	27.972	-25.979	-9.389	1.00	52.59 C
ATOM	1307 CG	TYR	A1998	29.436	-26.056	-9.036	1.00	53.78 C
ATOM	1308 CD1	TYR	A1998	30.309	-26.841	-9.779	1.00	57.12 C
ATOM	1309 CD2	TYR	A1998	29.944	-25.379	-7.937	1.00	53.27 C
ATOM	1310 CE1	TYR	A1998	31.661	-26.919	-9.459	1.00	58.19 C
ATOM	1311 CE2	TYR	A1998	31.275	-25.507	-7.565	1.00	54.15 C
ATOM	1312 CZ	TYR	A1998	32.140	-26.245	-8.353	1.00	64.24 C
ATOM	1313 OH	TYR	A1998	33.469	-26.332	-8.033	1.00	67.81 O
ATOM	1314 N	PHE	A1999	28.040	-28.057	-6.745	1.00	52.94 N
ATOM	1315 CA	PHE	A1999	28.250	-28.189	-5.317	1.00	51.51 C
ATOM	1316 C	PHE	A1999	29.718	-27.975	-5.070	1.00	56.70 C
ATOM	1317 O	PHE	A1999	30.545	-28.648	-5.681	1.00	57.56 O
ATOM	1318 CB	PHE	A1999	27.737	-29.573	-4.862	1.00	52.72 C
ATOM	1319 CG	PHE	A1999	26.289	-29.804	-5.248	1.00	52.20 C
ATOM	1320 CD2	PHE	A1999	25.267	-29.575	-4.338	1.00	53.67 C
ATOM	1321 CD1	PHE	A1999	25.950	-30.196	-6.540	1.00	53.52 C
ATOM	1322 CE2	PHE	A1999	23.929	-29.719	-4.718	1.00	56.91 C
ATOM	1323 CE1	PHE	A1999	24.617	-30.333	-6.922	1.00	54.44 C
ATOM	1324 CZ	PHE	A1999	23.610	-30.095	-6.011	1.00	54.30 C
ATOM	1325 N	ASP	A2000	30.049	-26.976	-4.247	1.00	53.98 N
ATOM	1326 CA	ASP	A2000	31.421	-26.571	-3.943	1.00	54.57 C
ATOM	1327 C	ASP	A2000	32.178	-27.614	-3.113	1.00	60.61 C
ATOM	1328 O	ASP	A2000	31.686	-28.726	-2.934	1.00	60.58 O
ATOM	1329 CB	ASP	A2000	31.446	-25.159	-3.291	1.00	57.24 C
ATOM	1330 CG	ASP	A2000	30.997	-25.001	-1.834	1.00	68.98 C
ATOM	1331 OD1	ASP	A2000	30.540	-25.995	-1.236	1.00	68.76 O
ATOM	1332 OD2	ASP	A2000	31.135	-23.882	-1.289	1.00	77.15 O
ATOM	1333 N	ASP	A2001	33.360	-27.256	-2.573	1.00	57.91 N
ATOM	1334 CA	ASP	A2001	34.137	-28.202	-1.802	1.00	57.49 C
ATOM	1335 C	ASP	A2001	33.529	-28.602	-0.466	1.00	65.27 C
ATOM	1336 O	ASP	A2001	34.077	-29.475	0.218	1.00	66.85 O
ATOM	1337 CB	ASP	A2001	35.547	-27.707	-1.608	1.00	58.99 C
ATOM	1338 CG	ASP	A2001	36.490	-28.883	-1.506	1.00	71.35 C
ATOM	1339 OD1	ASP	A2001	36.484	-29.737	-2.445	1.00	74.58 O
ATOM	1340 OD2	ASP	A2001	37.203	-28.985	-0.475	1.00	67.55 O
ATOM	1341 N	SER	A2002	32.393	-27.997	-0.102	1.00	62.53 N
ATOM	1342 CA	SER	A2002	31.705	-28.273	1.154	1.00	62.55 C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.							
ATOM	1343 C	SER	A2002	30.396	-28.991	0.878	1.00
ATOM	1344 O	SER	A2002	29.693	-29.374	1.826	1.00
ATOM	1345 CB	SER	A2002	31.442	-26.974	1.913	1.00
ATOM	1346 OG	SER	A2002	32.510	-26.048	1.793	1.00
ATOM	1347 N	GLY	A2003	30.089	-29.161	-0.414	1.00
ATOM	1348 CA	GLY	A2003	28.876	-29.796	-0.916	1.00
ATOM	1349 C	GLY	A2003	27.717	-28.842	-1.115	1.00
ATOM	1350 O	GLY	A2003	26.656	-29.278	-1.544	1.00
ATOM	1351 N	VAL	A2004	27.897	-27.541	-0.832	1.00
ATOM	1352 CA	VAL	A2004	26.822	-26.553	-0.914	1.00
ATOM	1353 C	VAL	A2004	26.615	-26.089	-2.364	1.00
ATOM	1354 O	VAL	A2004	27.537	-25.697	-3.079	1.00
ATOM	1355 CB	VAL	A2004	26.879	-25.376	0.132	1.00
ATOM	1356 CG2	VAL	A2004	26.527	-24.016	-0.458	1.00
ATOM	1357 CG1	VAL	A2004	28.170	-25.332	0.938	1.00
ATOM	1358 N	MET	A2005	25.339	-26.133	-2.738	1.00
ATOM	1359 CA	MET	A2005	24.693	-25.899	-4.017	1.00
ATOM	1360 C	MET	A2005	25.060	-24.701	-4.869	1.00
ATOM	1361 O	MET	A2005	24.745	-24.787	-6.061	1.00
ATOM	1362 CB	MET	A2005	23.208	-25.838	-3.826	1.00
ATOM	1363 CG	MET	A2005	22.484	-26.799	-4.698	1.00
ATOM	1364 SD	MET	A2005	21.570	-25.980	-5.969	1.00
ATOM	1365 CE	MET	A2005	20.450	-24.961	-5.015	1.00
ATOM	1366 N	LYS	A2006	25.639	-23.601	-4.350	1.00
ATOM	1367 CA	LYS	A2006	26.096	-22.465	-5.202	1.00
ATOM	1368 C	LYS	A2006	25.085	-21.880	-6.229	1.00
ATOM	1369 O	LYS	A2006	24.940	-22.385	-7.331	1.00
ATOM	1370 CB	LYS	A2006	27.389	-22.831	-5.930	1.00
ATOM	1371 CG	LYS	A2006	28.579	-22.037	-5.438	1.00
ATOM	1372 CD	LYS	A2006	28.780	-22.114	-3.944	1.00
ATOM	1373 CE	LYS	A2006	30.004	-21.381	-3.461	1.00
ATOM	1374 NZ	LYS	A2006	29.702	-19.957	-3.194	1.00
ATOM	1375 N	VAL	A2007	24.455	-20.757	-5.865	1.00
ATOM	1376 CA	VAL	A2007	23.468	-20.032	-6.665	1.00
ATOM	1377 C	VAL	A2007	24.056	-18.665	-7.101	1.00
ATOM	1378 O	VAL	A2007	24.925	-18.126	-6.421	1.00
ATOM	1379 CB	VAL	A2007	22.144	-19.870	-5.866	1.00
ATOM	1380 CG2	VAL	A2007	22.391	-19.285	-4.485	1.00
ATOM	1381 CG1	VAL	A2007	21.390	-21.194	-5.746	1.00
ATOM	1382 N	GLY	A2008	23.590	-18.137	-8.223	1.00
ATOM	1383 CA	GLY	A2008	24.062	-16.874	-8.763	1.00
ATOM	1384 C	GLY	A2008	25.352	-17.009	-9.545	1.00
ATOM	1385 O	GLY	A2008	25.707	-18.102	-9.995	1.00
ATOM	1386 N	TYR	A2009	26.068	-15.879	-9.717	1.00
ATOM	1387 CA	TYR	A2009	27.341	-15.738	-10.430	1.00
ATOM	1388 C	TYR	A2009	28.410	-16.339	-9.547	1.00
ATOM	1389 O	TYR	A2009	28.648	-15.841	-8.439	1.00
ATOM	1390 CB	TYR	A2009	27.586	-14.248	-10.655	1.00
ATOM	1391 CG	TYR	A2009	28.829	-13.852	-11.409	1.00
ATOM	1392 CD1	TYR	A2009	29.105	-14.384	-12.662	1.00
ATOM	1393 CD2	TYR	A2009	29.629	-12.803	-10.962	1.00
ATOM	1394 CE1	TYR	A2009	30.204	-13.945	-13.414	1.00
ATOM	1395 CE2	TYR	A2009	30.741	-12.374	-11.686	1.00
ATOM	1396 CZ	TYR	A2009	31.031	-12.950	-12.912	1.00
ATOM	1397 OH	TYR	A2009	32.146	-12.525	-13.611	1.00
ATOM	1398 N	THR	A2010	29.021	-17.441	-10.017	1.00
ATOM	1399 CA	THR	A2010	30.020	-18.228	-9.291	1.00
ATOM	1400 C	THR	A2010	31.345	-18.335	-10.052	1.00
ATOM	1401 O	THR	A2010	31.318	-18.590	-11.262	1.00
ATOM	1402 CB	THR	A2010	29.416	-19.655	-9.035	1.00
ATOM	1403 CG2	THR	A2010	30.334	-20.552	-8.246	1.00
ATOM	1404 OG1	THR	A2010	28.143	-19.583	-8.371	1.00
ATOM	1405 N	GLU	A2011	32.500	-18.205	-9.336	1.00
ATOM	1406 CA	GLU	A2011	33.842	-18.430	-9.903	1.00
ATOM	1407 C	GLU	A2011	34.207	-19.873	-9.590	1.00
ATOM	1408 O	GLU	A2011	34.321	-20.221	-8.412	1.00
ATOM	1409 CB	GLU	A2011	34.911	-17.514	-9.288	1.00
ATOM	1410 CG	GLU	A2011	36.294	-17.634	-9.940	1.00
ATOM	1411 CD	GLU	A2011	37.394	-18.423	-9.230	1.00
ATOM	1412 OE1	GLU	A2011	37.086	-19.373	-8.471	1.00
ATOM	1413 OE2	GLU	A2011	38.582	-18.110	-9.477	1.00
ATOM	1414 N	ILE	A2012	34.357	-20.715	-10.630	1.00
ATOM	1415 CA	ILE	A2012	34.729	-22.126	-10.517	1.00
ATOM	1416 C	ILE	A2012	36.109	-22.344	-11.192	1.00
ATOM	1417 O	ILE	A2012	36.208	-22.620	-12.408	1.00
ATOM	1418 CB	ILE	A2012	33.618	-23.075	-11.045	1.00
ATOM	1419 CG1	ILE	A2012	32.301	-22.880	-10.287	1.00

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	1420	CG2	ILE	A2012	34.065	-24.552	-11.005	1.00	56.87	C
ATOM	1421	CD1	ILE	A2012	31.135	-23.462	-10.993	1.00	44.20	C
ATOM	1422	N	ASP	A2013	37.165	-22.219	-10.358	1.00	59.32	N
ATOM	1423	CA	ASP	A2013	38.574	-22.370	-10.685	1.00	60.74	C
ATOM	1424	C	ASP	A2013	39.045	-21.477	-11.870	1.00	65.45	C
ATOM	1425	O	ASP	A2013	39.682	-21.951	-12.825	1.00	65.72	O
ATOM	1426	CB	ASP	A2013	38.949	-23.851	-10.885	1.00	64.13	C
ATOM	1427	CG	ASP	A2013	40.096	-24.305	-9.984	1.00	92.25	C
ATOM	1428	OD1	ASP	A2013	41.087	-23.522	-9.818	1.00	91.95	O
ATOM	1429	OD2	ASP	A2013	40.011	-25.437	-9.435	1.00	109.31	O
ATOM	1430	N	GLY	A2014	38.767	-20.180	-11.756	1.00	61.81	N
ATOM	1431	CA	GLY	A2014	39.149	-19.185	-12.759	1.00	61.01	C
ATOM	1432	C	GLY	A2014	38.155	-18.948	-13.883	1.00	62.02	C
ATOM	1433	O	GLY	A2014	38.334	-18.017	-14.678	1.00	61.86	O
ATOM	1434	N	LYS	A2015	37.114	-19.794	-13.966	1.00	56.00	N
ATOM	1435	CA	LYS	A2015	36.048	-19.668	-14.959	1.00	55.04	C
ATOM	1436	C	LYS	A2015	34.822	-19.201	-14.200	1.00	58.63	C
ATOM	1437	O	LYS	A2015	34.727	-19.486	-13.004	1.00	58.83	O
ATOM	1438	CB	LYS	A2015	35.769	-21.012	-15.681	1.00	56.51	C
ATOM	1439	CG	LYS	A2015	36.985	-21.611	-16.408	1.00	59.92	C
ATOM	1440	CD	LYS	A2015	36.581	-22.580	-17.534	1.00	63.81	C
ATOM	1441	CE	LYS	A2015	37.687	-23.513	-17.997	1.00	67.98	C
ATOM	1442	NZ	LYS	A2015	38.984	-22.812	-18.259	1.00	76.06	N
ATOM	1443	N	HIS	A2016	33.903	-18.451	-14.865	1.00	53.30	N
ATOM	1444	CA	HIS	A2016	32.662	-17.982	-14.241	1.00	51.20	C
ATOM	1445	C	HIS	A2016	31.429	-18.582	-14.864	1.00	55.01	C
ATOM	1446	O	HIS	A2016	31.392	-18.767	-16.077	1.00	54.60	O
ATOM	1447	CB	HIS	A2016	32.570	-16.483	-14.263	1.00	51.00	C
ATOM	1448	CG	HIS	A2016	33.468	-15.830	-13.284	1.00	53.82	C
ATOM	1449	CD2	HIS	A2016	33.213	-15.434	-12.017	1.00	55.64	C
ATOM	1450	ND1	HIS	A2016	34.773	-15.505	-13.614	1.00	55.25	N
ATOM	1451	CE1	HIS	A2016	35.269	-14.910	-12.545	1.00	55.26	C
ATOM	1452	NE2	HIS	A2016	34.369	-14.857	-11.548	1.00	55.83	N
ATOM	1453	N	PHE	A2017	30.413	-18.882	-14.037	1.00	51.43	N
ATOM	1454	CA	PHE	A2017	29.160	-19.503	-14.471	1.00	52.05	C
ATOM	1455	C	PHE	A2017	27.963	-18.835	-13.768	1.00	56.92	C
ATOM	1456	O	PHE	A2017	28.147	-18.140	-12.771	1.00	58.36	O
ATOM	1457	CB	PHE	A2017	29.186	-21.020	-14.141	1.00	54.58	C
ATOM	1458	CG	PHE	A2017	30.335	-21.795	-14.760	1.00	57.05	C
ATOM	1459	CD1	PHE	A2017	31.587	-21.833	-14.146	1.00	60.08	C
ATOM	1460	CD2	PHE	A2017	30.170	-22.482	-15.959	1.00	59.03	C
ATOM	1461	CE1	PHE	A2017	32.658	-22.520	-14.740	1.00	60.49	C
ATOM	1462	CE2	PHE	A2017	31.223	-23.223	-16.513	1.00	61.17	C
ATOM	1463	CZ	PHE	A2017	32.471	-23.206	-15.920	1.00	58.50	C
ATOM	1464	N	TYR	A2018	26.741	-19.059	-14.251	1.00	51.09	N
ATOM	1465	CA	TYR	A2018	25.609	-18.458	-13.587	1.00	49.77	C
ATOM	1466	C	TYR	A2018	24.544	-19.490	-13.273	1.00	54.72	C
ATOM	1467	O	TYR	A2018	24.000	-20.101	-14.188	1.00	55.73	O
ATOM	1468	CB	TYR	A2018	25.042	-17.269	-14.390	1.00	51.12	C
ATOM	1469	CG	TYR	A2018	23.863	-16.609	-13.701	1.00	54.10	C
ATOM	1470	CD2	TYR	A2018	24.052	-15.567	-12.799	1.00	53.76	C
ATOM	1471	CD1	TYR	A2018	22.568	-17.097	-13.870	1.00	57.03	C
ATOM	1472	CE2	TYR	A2018	22.982	-15.005	-12.115	1.00	54.74	C
ATOM	1473	CE1	TYR	A2018	21.491	-16.547	-13.182	1.00	57.35	C
ATOM	1474	CZ	TYR	A2018	21.700	-15.490	-12.317	1.00	65.48	C
ATOM	1475	OH	TYR	A2018	20.627	-14.948	-11.640	1.00	71.11	O
ATOM	1476	N	PHE	A2019	24.195	-19.633	-11.981	1.00	50.87	N
ATOM	1477	CA	PHE	A2019	23.170	-20.555	-11.513	1.00	50.88	C
ATOM	1478	C	PHE	A2019	21.922	-19.796	-11.083	1.00	57.13	C
ATOM	1479	O	PHE	A2019	22.044	-18.755	-10.447	1.00	56.70	O
ATOM	1480	CB	PHE	A2019	23.719	-21.390	-10.347	1.00	52.60	C
ATOM	1481	CG	PHE	A2019	24.998	-22.101	-10.704	1.00	53.40	C
ATOM	1482	CD2	PHE	A2019	26.230	-21.552	-10.376	1.00	55.07	C
ATOM	1483	CD1	PHE	A2019	24.973	-23.297	-11.414	1.00	55.70	C
ATOM	1484	CE2	PHE	A2019	27.418	-22.179	-10.776	1.00	58.00	C
ATOM	1485	CE1	PHE	A2019	26.158	-23.925	-11.801	1.00	56.06	C
ATOM	1486	CZ	PHE	A2019	27.370	-23.358	-11.488	1.00	55.56	C
ATOM	1487	N	ALA	A2020	20.715	-20.323	-11.415	1.00	55.88	N
ATOM	1488	CA	ALA	A2020	19.416	-19.725	-11.045	1.00	56.10	C
ATOM	1489	C	ALA	A2020	19.248	-19.822	-9.514	1.00	61.31	C
ATOM	1490	O	ALA	A2020	20.113	-20.425	-8.884	1.00	59.62	O
ATOM	1491	CB	ALA	A2020	18.283	-20.439	-11.766	1.00	56.52	C
ATOM	1492	N	GLU	A2021	18.191	-19.223	-8.893	1.00	60.13	N
ATOM	1493	CA	GLU	A2021	18.134	-19.300	-7.423	1.00	60.62	C
ATOM	1494	C	GLU	A2021	17.702	-20.688	-6.910	1.00	63.96	C
ATOM	1495	O	GLU	A2021	17.698	-20.924	-5.702	1.00	63.66	O
ATOM	1496	CB	GLU	A2021	17.354	-18.149	-6.762	1.00	62.04	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	1497	CG	GLU	A2021	15.842	-18.168	-6.807	1.00	74.70	C
ATOM	1498	CD	GLU	A2021	15.238	-16.983	-6.077	1.00	90.33	C
ATOM	1499	OE1	GLU	A2021	15.370	-16.927	-4.830	1.00	67.45	O
ATOM	1500	OE2	GLU	A2021	14.650	-16.105	-6.754	1.00	82.90	O
ATOM	1501	N	ASN	A2022	17.443	-21.613	-7.829	1.00	60.89	N
ATOM	1502	CA	ASN	A2022	17.120	-22.998	-7.507	1.00	60.88	C
ATOM	1503	C	ASN	A2022	18.357	-23.882	-7.768	1.00	64.92	C
ATOM	1504	O	ASN	A2022	18.326	-25.070	-7.458	1.00	66.81	O
ATOM	1505	CB	ASN	A2022	15.899	-23.470	-8.295	1.00	60.88	C
ATOM	1506	CG	ASN	A2022	16.121	-23.807	-9.750	1.00	86.77	C
ATOM	1507	ND2	ASN	A2022	15.368	-24.796	-10.203	1.00	83.79	N
ATOM	1508	OD1	ASN	A2022	16.891	-23.165	-10.486	1.00	75.47	O
ATOM	1509	N	GLY	A2023	19.413	-23.281	-8.329	1.00	57.99	N
ATOM	1510	CA	GLY	A2023	20.695	-23.913	-8.590	1.00	56.88	C
ATOM	1511	C	GLY	A2023	21.037	-24.233	-10.024	1.00	61.57	C
ATOM	1512	O	GLY	A2023	22.215	-24.451	-10.331	1.00	61.44	O
ATOM	1513	N	GLU	A2024	20.006	-24.280	-10.902	1.00	58.19	N
ATOM	1514	CA	GLU	A2024	20.085	-24.645	-12.327	1.00	56.90	C
ATOM	1515	C	GLU	A2024	20.930	-23.699	-13.135	1.00	57.03	C
ATOM	1516	O	GLU	A2024	20.601	-22.520	-13.244	1.00	56.08	O
ATOM	1517	CB	GLU	A2024	18.682	-24.743	-12.957	1.00	58.47	C
ATOM	1518	CG	GLU	A2024	17.756	-25.789	-12.355	1.00	70.33	C
ATOM	1519	CD	GLU	A2024	16.353	-25.849	-12.944	1.00	101.74	C
ATOM	1520	OE1	GLU	A2024	15.974	-24.927	-13.707	1.00	91.90	O
ATOM	1521	OE2	GLU	A2024	15.617	-26.806	-12.605	1.00	99.51	O
ATOM	1522	N	MET	A2025	22.002	-24.223	-13.731	1.00	52.80	N
ATOM	1523	CA	MET	A2025	22.935	-23.453	-14.560	1.00	52.18	C
ATOM	1524	C	MET	A2025	22.229	-22.905	-15.799	1.00	58.49	C
ATOM	1525	O	MET	A2025	21.576	-23.661	-16.529	1.00	59.99	O
ATOM	1526	CB	MET	A2025	24.141	-24.306	-14.952	1.00	53.72	C
ATOM	1527	CG	MET	A2025	25.019	-23.652	-15.963	1.00	56.59	C
ATOM	1528	SD	MET	A2025	26.216	-24.784	-16.674	1.00	59.75	S
ATOM	1529	CE	MET	A2025	27.612	-24.133	-15.961	1.00	56.08	C
ATOM	1530	N	GLN	A2026	22.377	-21.592	-16.026	1.00	52.73	N
ATOM	1531	CA	GLN	A2026	21.732	-20.869	-17.105	1.00	51.12	C
ATOM	1532	C	GLN	A2026	22.687	-20.387	-18.197	1.00	56.02	C
ATOM	1533	O	GLN	A2026	23.882	-20.179	-17.960	1.00	55.67	O
ATOM	1534	CB	GLN	A2026	20.971	-19.673	-16.518	1.00	51.69	C
ATOM	1535	CG	GLN	A2026	19.884	-20.039	-15.513	1.00	59.35	C
ATOM	1536	CD	GLN	A2026	18.726	-20.755	-16.156	1.00	77.86	C
ATOM	1537	NE2	GLN	A2026	18.340	-21.893	-15.589	1.00	57.18	N
ATOM	1538	OE1	GLN	A2026	18.176	-20.312	-17.173	1.00	81.68	O
ATOM	1539	N	ILE	A2027	22.125	-20.208	-19.409	1.00	53.56	N
ATOM	1540	CA	ILE	A2027	22.773	-19.658	-20.589	1.00	53.00	C
ATOM	1541	C	ILE	A2027	21.945	-18.423	-20.981	1.00	58.58	C
ATOM	1542	O	ILE	A2027	20.712	-18.467	-21.033	1.00	58.66	O
ATOM	1543	CB	ILE	A2027	22.995	-20.710	-21.737	1.00	55.74	C
ATOM	1544	CG1	ILE	A2027	24.256	-21.568	-21.470	1.00	55.57	C
ATOM	1545	CG2	ILE	A2027	23.160	-20.039	-23.114	1.00	56.49	C
ATOM	1546	CD1	ILE	A2027	24.050	-22.784	-20.698	1.00	57.16	C
ATOM	1547	N	GLY	A2028	22.635	-17.314	-21.153	1.00	56.57	N
ATOM	1548	CA	GLY	A2028	22.018	-16.039	-21.484	1.00	57.09	C
ATOM	1549	C	GLY	A2028	22.673	-14.902	-20.742	1.00	61.11	C
ATOM	1550	O	GLY	A2028	23.735	-15.099	-20.139	1.00	62.34	O
ATOM	1551	N	VAL	A2029	22.060	-13.701	-20.775	1.00	55.04	N
ATOM	1552	CA	VAL	A2029	22.668	-12.599	-20.050	1.00	53.03	C
ATOM	1553	C	VAL	A2029	21.885	-12.372	-18.772	1.00	55.07	C
ATOM	1554	O	VAL	A2029	20.651	-12.395	-18.776	1.00	55.33	O
ATOM	1555	CB	VAL	A2029	22.987	-11.321	-20.860	1.00	55.71	C
ATOM	1556	CG1	VAL	A2029	22.980	-11.571	-22.365	1.00	54.71	C
ATOM	1557	CG2	VAL	A2029	22.115	-10.149	-20.467	1.00	55.20	C
ATOM	1558	N	PHE	A2030	22.617	-12.292	-17.655	1.00	49.75	N
ATOM	1559	CA	PHE	A2030	22.011	-12.156	-16.335	1.00	48.74	C
ATOM	1560	C	PHE	A2030	22.700	-11.071	-15.515	1.00	53.55	C
ATOM	1561	O	PHE	A2030	23.837	-10.675	-15.836	1.00	52.44	O
ATOM	1562	CB	PHE	A2030	22.039	-13.509	-15.586	1.00	49.74	C
ATOM	1563	CG	PHE	A2030	21.358	-14.633	-16.326	1.00	50.78	C
ATOM	1564	CD1	PHE	A2030	19.991	-14.849	-16.195	1.00	52.80	C
ATOM	1565	CD2	PHE	A2030	22.081	-15.478	-17.162	1.00	52.35	C
ATOM	1566	CE1	PHE	A2030	19.362	-15.887	-16.882	1.00	52.55	C
ATOM	1567	CE2	PHE	A2030	21.443	-16.501	-17.865	1.00	53.90	C
ATOM	1568	CZ	PHE	A2030	20.092	-16.700	-17.715	1.00	51.62	C
ATOM	1569	N	ASN	A2031	22.006	-10.621	-14.439	1.00	51.25	N
ATOM	1570	CA	ASN	A2031	22.436	-9.573	-13.508	1.00	52.19	C
ATOM	1571	C	ASN	A2031	23.408	-10.080	-12.432	1.00	61.49	C
ATOM	1572	O	ASN	A2031	23.061	-10.752	-11.446	1.00	62.97	O
ATOM	1573	CB	ASN	A2031	21.246	-8.872	-12.903	1.00	48.83	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.									
ATOM	1574 CG	ASN	A2031	21.309	-7.382	-12.873	1.00	63.49	C
ATOM	1575 ND2	ASN	A2031	20.138	-6.761	-12.977	1.00	57.32	N
ATOM	1576 OD1	ASN	A2031	22.364	-6.778	-12.677	1.00	58.47	O
ATOM	1577 N	THR	A2032	24.647	-9.747	-12.675	1.00	59.40	N
ATOM	1578 CA	THR	A2032	25.826	-10.109	-11.934	1.00	59.17	C
ATOM	1579 C	THR	A2032	26.256	-8.871	-11.134	1.00	65.21	C
ATOM	1580 O	THR	A2032	25.952	-7.743	-11.542	1.00	65.60	O
ATOM	1581 CB	THR	A2032	26.774	-10.554	-13.040	1.00	61.72	C
ATOM	1582 CG2	THR	A2032	28.187	-10.124	-12.864	1.00	57.19	C
ATOM	1583 OG1	THR	A2032	26.629	-11.952	-13.235	1.00	66.21	O
ATOM	1584 N	GLU	A2033	26.973	-9.062	-10.017	1.00	60.74	N
ATOM	1585 CA	GLU	A2033	27.479	-7.929	-9.236	1.00	59.29	C
ATOM	1586 C	GLU	A2033	28.185	-6.920	-10.132	1.00	60.70	C
ATOM	1587 O	GLU	A2033	28.059	-5.727	-9.884	1.00	61.77	O
ATOM	1588 CB	GLU	A2033	28.451	-8.362	-8.138	1.00	60.63	C
ATOM	1589 CG	GLU	A2033	28.022	-9.580	-7.363	1.00	77.29	C
ATOM	1590 CD	GLU	A2033	28.534	-10.868	-7.963	1.00	98.43	C
ATOM	1591 OE1	GLU	A2033	27.720	-11.606	-8.569	1.00	91.79	O
ATOM	1592 OE2	GLU	A2033	29.760	-11.112	-7.865	1.00	89.49	O
ATOM	1593 N	ASP	A2034	28.906	-7.386	-11.167	1.00	55.03	N
ATOM	1594 CA	ASP	A2034	29.652	-6.534	-12.109	1.00	54.84	C
ATOM	1595 C	ASP	A2034	28.755	-5.823	-13.153	1.00	57.65	C
ATOM	1596 O	ASP	A2034	29.201	-4.880	-13.808	1.00	55.98	O
ATOM	1597 CB	ASP	A2034	30.715	-7.364	-12.853	1.00	56.76	C
ATOM	1598 CG	ASP	A2034	31.616	-8.283	-12.036	1.00	68.24	C
ATOM	1599 OD2	ASP	A2034	32.416	-9.022	-12.648	1.00	76.50	O
ATOM	1600 OD1	ASP	A2034	31.553	-8.234	-10.790	1.00	68.79	O
ATOM	1601 N	GLY	A2035	27.539	-6.342	-13.331	1.00	54.71	N
ATOM	1602 CA	GLY	A2035	26.542	-5.874	-14.291	1.00	54.30	C
ATOM	1603 C	GLY	A2035	25.942	-7.007	-15.103	1.00	56.42	C
ATOM	1604 O	GLY	A2035	25.994	-8.162	-14.681	1.00	55.59	O
ATOM	1605 N	PHE	A2036	25.379	-6.702	-16.282	1.00	51.80	N
ATOM	1606 CA	PHE	A2036	24.822	-7.763	-17.125	1.00	50.49	C
ATOM	1607 C	PHE	A2036	25.938	-8.487	-17.889	1.00	52.45	C
ATOM	1608 O	PHE	A2036	26.704	-7.838	-18.594	1.00	50.60	O
ATOM	1609 CB	PHE	A2036	23.726	-7.231	-18.067	1.00	51.72	C
ATOM	1610 CG	PHE	A2036	22.364	-7.099	-17.433	1.00	52.34	C
ATOM	1611 CD2	PHE	A2036	21.934	-5.884	-16.920	1.00	54.07	C
ATOM	1612 CD1	PHE	A2036	21.507	-8.187	-17.357	1.00	54.49	C
ATOM	1613 CE2	PHE	A2036	20.669	-5.760	-16.342	1.00	56.53	C
ATOM	1614 CE1	PHE	A2036	20.238	-8.059	-16.791	1.00	55.23	C
ATOM	1615 CZ	PHE	A2036	19.822	-6.843	-16.296	1.00	54.62	C
ATOM	1616 N	LYS	A2037	26.045	-9.820	-17.720	1.00	49.18	N
ATOM	1617 CA	LYS	A2037	27.099	-10.632	-18.345	1.00	48.90	C
ATOM	1618 C	LYS	A2037	26.552	-11.821	-19.136	1.00	53.95	C
ATOM	1619 O	LYS	A2037	25.505	-12.397	-18.782	1.00	53.62	O
ATOM	1620 CB	LYS	A2037	28.120	-11.105	-17.282	1.00	50.19	C
ATOM	1621 CG	LYS	A2037	29.103	-9.998	-16.888	1.00	54.68	C
ATOM	1622 CD	LYS	A2037	30.203	-10.460	-15.960	1.00	57.32	C
ATOM	1623 CE	LYS	A2037	31.232	-9.376	-15.746	1.00	56.56	C
ATOM	1624 NZ	LYS	A2037	32.540	-9.641	-16.409	1.00	58.66	N
ATOM	1625 N	TYR	A2038	27.305	-12.220	-20.173	1.00	48.94	N
ATOM	1626 CA	TYR	A2038	26.933	-13.309	-21.072	1.00	47.53	C
ATOM	1627 C	TYR	A2038	27.591	-14.631	-20.699	1.00	53.99	C
ATOM	1628 O	TYR	A2038	28.812	-14.712	-20.557	1.00	54.38	O
ATOM	1629 CB	TYR	A2038	27.237	-12.900	-22.516	1.00	46.82	C
ATOM	1630 CG	TYR	A2038	26.824	-13.861	-23.606	1.00	45.39	C
ATOM	1631 CD1	TYR	A2038	25.682	-14.647	-23.479	1.00	46.81	C
ATOM	1632 CD2	TYR	A2038	27.522	-13.917	-24.804	1.00	45.68	C
ATOM	1633 CE1	TYR	A2038	25.295	-15.524	-24.487	1.00	47.15	C
ATOM	1634 CE2	TYR	A2038	27.149	-14.789	-25.818	1.00	46.48	C
ATOM	1635 CZ	TYR	A2038	26.036	-15.592	-25.656	1.00	55.01	C
ATOM	1636 OH	TYR	A2038	25.692	-16.462	-26.660	1.00	58.61	O
ATOM	1637 N	PHE	A2039	26.749	-15.662	-20.534	1.00	51.20	N
ATOM	1638 CA	PHE	A2039	27.067	-17.037	-20.162	1.00	51.09	C
ATOM	1639 C	PHE	A2039	26.639	-17.843	-21.367	1.00	57.37	C
ATOM	1640 O	PHE	A2039	25.468	-18.157	-21.537	1.00	57.49	O
ATOM	1641 CB	PHE	A2039	26.299	-17.408	-18.856	1.00	52.58	C
ATOM	1642 CG	PHE	A2039	26.731	-16.547	-17.689	1.00	53.21	C
ATOM	1643 CD2	PHE	A2039	26.020	-15.407	-17.349	1.00	55.74	C
ATOM	1644 CD1	PHE	A2039	27.914	-16.812	-17.008	1.00	54.65	C
ATOM	1645 CE2	PHE	A2039	26.474	-14.556	-16.334	1.00	58.16	C
ATOM	1646 CE1	PHE	A2039	28.359	-15.967	-15.993	1.00	55.14	C
ATOM	1647 CZ	PHE	A2039	27.642	-14.840	-15.674	1.00	55.21	C
ATOM	1648 N	ALA	A2040	27.580	-18.058	-22.269	1.00	57.25	N
ATOM	1649 CA	ALA	A2040	27.351	-18.628	-23.585	1.00	58.93	C
ATOM	1650 C	ALA	A2040	27.348	-20.149	-23.665	1.00	69.55	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	1651	O	ALA	A2040	27.836	-20.833	-22.754	1.00	69.74	O
ATOM	1652	CB	ALA	A2040	28.376	-18.054	-24.551	1.00	59.26	C
ATOM	1653	N	HIS	A2041	26.845	-20.677	-24.818	1.00	69.60	N
ATOM	1654	CA	HIS	A2041	26.827	-22.108	-25.135	1.00	69.71	C
ATOM	1655	C	HIS	A2041	28.253	-22.575	-25.465	1.00	78.41	C
ATOM	1656	O	HIS	A2041	29.195	-21.971	-24.975	1.00	78.55	O
ATOM	1657	CB	HIS	A2041	25.832	-22.428	-26.262	1.00	69.44	C
ATOM	1658	CG	HIS	A2041	24.449	-22.735	-25.780	1.00	72.46	C
ATOM	1659	CD2	HIS	A2041	24.031	-23.619	-24.841	1.00	74.28	C
ATOM	1660	ND1	HIS	A2041	23.347	-22.064	-26.281	1.00	74.22	N
ATOM	1661	CE1	HIS	A2041	22.297	-22.566	-25.645	1.00	73.72	C
ATOM	1662	NE2	HIS	A2041	22.660	-23.504	-24.765	1.00	74.05	N
ATOM	1663	N	HIS	A2042	28.442	-23.644	-26.241	1.00	78.40	N
ATOM	1664	CA	HIS	A2042	29.804	-24.063	-26.496	1.00	79.37	C
ATOM	1665	C	HIS	A2042	30.466	-23.253	-27.639	1.00	86.02	C
ATOM	1666	O	HIS	A2042	31.318	-22.428	-27.334	1.00	86.23	O
ATOM	1667	CB	HIS	A2042	29.925	-25.579	-26.681	1.00	80.54	C
ATOM	1668	CG	HIS	A2042	31.335	-26.012	-26.932	1.00	84.40	C
ATOM	1669	CD2	HIS	A2042	32.464	-25.717	-26.244	1.00	86.40	C
ATOM	1670	ND1	HIS	A2042	31.676	-26.740	-28.061	1.00	86.52	N
ATOM	1671	CE1	HIS	A2042	32.991	-26.885	-28.009	1.00	86.11	C
ATOM	1672	NE2	HIS	A2042	33.508	-26.286	-26.933	1.00	86.46	N
ATOM	1673	N	ASN	A2043	30.101	-23.473	-28.919	1.00	84.63	N
ATOM	1674	CA	ASN	A2043	30.678	-22.804	-30.118	1.00	86.18	C
ATOM	1675	C	ASN	A2043	32.185	-23.079	-30.374	1.00	95.12	C
ATOM	1676	O	ASN	A2043	32.958	-23.346	-29.436	1.00	94.58	O
ATOM	1677	CB	ASN	A2043	30.426	-21.280	-30.147	1.00	82.89	C
ATOM	1678	N	GLU	A2044	32.591	-22.950	-31.682	1.00	94.34	N
ATOM	1679	CA	GLU	A2044	33.960	-23.058	-32.240	1.00	94.43	C
ATOM	1680	C	GLU	A2044	34.916	-22.103	-31.498	1.00	98.22	C
ATOM	1681	O	GLU	A2044	36.140	-22.279	-31.555	1.00	96.29	O
ATOM	1682	CB	GLU	A2044	33.941	-22.688	-33.741	1.00	95.83	C
ATOM	1683	N	ASP	A2045	34.314	-21.078	-30.806	1.00	95.46	N
ATOM	1684	CA	ASP	A2045	34.942	-20.066	-29.950	1.00	94.81	C
ATOM	1685	C	ASP	A2045	35.804	-20.752	-28.920	1.00	96.43	C
ATOM	1686	O	ASP	A2045	35.414	-21.810	-28.392	1.00	94.58	O
ATOM	1687	CB	ASP	A2045	33.879	-19.226	-29.223	1.00	96.76	C
ATOM	1688	N	LEU	A2046	36.974	-20.133	-28.652	1.00	92.60	N
ATOM	1689	CA	LEU	A2046	38.051	-20.557	-27.751	1.00	92.31	C
ATOM	1690	C	LEU	A2046	37.578	-21.417	-26.559	1.00	96.73	C
ATOM	1691	O	LEU	A2046	37.399	-20.900	-25.446	1.00	96.85	O
ATOM	1692	CB	LEU	A2046	38.886	-19.355	-27.276	1.00	92.15	C
ATOM	1693	N	GLY	A2047	37.387	-22.720	-26.848	1.00	91.70	N
ATOM	1694	CA	GLY	A2047	36.957	-23.799	-25.962	1.00	90.32	C
ATOM	1695	C	GLY	A2047	36.295	-23.375	-24.672	1.00	91.31	C
ATOM	1696	O	GLY	A2047	36.737	-23.758	-23.577	1.00	92.59	O
ATOM	1697	N	ASN	A2048	35.252	-22.540	-24.802	1.00	82.26	N
ATOM	1698	CA	ASN	A2048	34.511	-22.042	-23.662	1.00	78.89	C
ATOM	1699	C	ASN	A2048	33.560	-23.124	-23.248	1.00	78.66	C
ATOM	1700	O	ASN	A2048	32.809	-23.646	-24.077	1.00	78.93	O
ATOM	1701	CB	ASN	A2048	33.782	-20.747	-23.989	1.00	74.45	C
ATOM	1702	CG	ASN	A2048	32.869	-20.845	-25.174	1.00	73.75	C
ATOM	1703	ND2	ASN	A2048	31.602	-20.802	-24.917	1.00	51.21	N
ATOM	1704	OD1	ASN	A2048	33.292	-20.986	-26.323	1.00	78.62	O
ATOM	1705	N	GLU	A2049	33.639	-23.512	-21.978	1.00	71.19	N
ATOM	1706	CA	GLU	A2049	32.793	-24.542	-21.411	1.00	69.30	C
ATOM	1707	C	GLU	A2049	31.297	-24.131	-21.508	1.00	67.03	C
ATOM	1708	O	GLU	A2049	30.999	-22.948	-21.713	1.00	67.99	O
ATOM	1709	CB	GLU	A2049	33.220	-24.772	-19.954	1.00	71.26	C
ATOM	1710	CG	GLU	A2049	34.386	-25.741	-19.771	1.00	87.40	C
ATOM	1711	CD	GLU	A2049	34.532	-26.247	-18.342	1.00	122.54	C
ATOM	1712	OE1	GLU	A2049	33.518	-26.701	-17.759	1.00	113.07	O
ATOM	1713	OE2	GLU	A2049	35.659	-26.182	-17.800	1.00	125.24	O
ATOM	1714	N	GLU	A2050	30.361	-25.098	-21.404	1.00	57.39	N
ATOM	1715	CA	GLU	A2050	28.934	-24.781	-21.410	1.00	54.94	C
ATOM	1716	C	GLU	A2050	28.683	-23.799	-20.282	1.00	60.40	C
ATOM	1717	O	GLU	A2050	29.255	-23.971	-19.194	1.00	61.58	O
ATOM	1718	CB	GLU	A2050	28.097	-26.011	-21.096	1.00	55.07	C
ATOM	1719	CG	GLU	A2050	27.261	-26.559	-22.231	1.00	59.19	C
ATOM	1720	CD	GLU	A2050	26.291	-25.646	-22.941	1.00	66.58	C
ATOM	1721	OE1	GLU	A2050	25.131	-25.505	-22.483	1.00	51.21	O
ATOM	1722	OE2	GLU	A2050	26.670	-25.162	-24.031	1.00	59.83	O
ATOM	1723	N	GLY	A2051	27.871	-22.773	-20.554	1.00	55.18	N
ATOM	1724	CA	GLY	A2051	27.479	-21.767	-19.570	1.00	53.81	C
ATOM	1725	C	GLY	A2051	28.583	-20.945	-18.939	1.00	55.28	C
ATOM	1726	O	GLY	A2051	28.332	-20.268	-17.944	1.00	57.39	O
ATOM	1727	N	GLU	A2052	29.795	-21.003	-19.491	1.00	49.04	N

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	1728	CA	GLU	A2052	30.956	-20.231	-19.039	1.00	48.53	C
ATOM	1729	C	GLU	A2052	30.761	-18.768	-19.496	1.00	53.55	C
ATOM	1730	O	GLU	A2052	30.354	-18.571	-20.643	1.00	53.48	O
ATOM	1731	CB	GLU	A2052	32.277	-20.790	-19.659	1.00	48.83	C
ATOM	1732	CG	GLU	A2052	33.540	-20.228	-19.013	1.00	53.12	C
ATOM	1733	CD	GLU	A2052	34.844	-20.317	-19.789	1.00	80.75	C
ATOM	1734	OE1	GLU	A2052	35.006	-21.255	-20.601	1.00	72.05	O
ATOM	1735	OE2	GLU	A2052	35.735	-19.474	-19.536	1.00	85.77	O
ATOM	1736	N	GLU	A2053	31.085	-17.767	-18.613	1.00	49.25	N
ATOM	1737	CA	GLU	A2053	31.023	-16.322	-18.867	1.00	48.79	C
ATOM	1738	C	GLU	A2053	31.973	-15.989	-19.997	1.00	54.85	C
ATOM	1739	O	GLU	A2053	33.162	-16.296	-19.880	1.00	54.27	O
ATOM	1740	CB	GLU	A2053	31.470	-15.529	-17.628	1.00	49.78	C
ATOM	1741	CG	GLU	A2053	31.486	-14.022	-17.856	1.00	56.36	C
ATOM	1742	CD	GLU	A2053	32.534	-13.210	-17.123	1.00	72.13	C
ATOM	1743	OE1	GLU	A2053	32.831	-13.545	-15.956	1.00	50.90	O
ATOM	1744	OE2	GLU	A2053	33.029	-12.212	-17.698	1.00	77.64	O
ATOM	1745	N	ILE	A2054	31.481	-15.368	-21.085	1.00	53.07	N
ATOM	1746	CA	ILE	A2054	32.410	-15.079	-22.164	1.00	53.82	C
ATOM	1747	C	ILE	A2054	32.631	-13.594	-22.232	1.00	61.55	C
ATOM	1748	O	ILE	A2054	31.673	-12.840	-22.169	1.00	63.50	O
ATOM	1749	CB	ILE	A2054	32.120	-15.759	-23.553	1.00	56.84	C
ATOM	1750	CG1	ILE	A2054	31.230	-14.930	-24.458	1.00	57.18	C
ATOM	1751	CG2	ILE	A2054	31.593	-17.196	-23.445	1.00	57.39	C
ATOM	1752	CD1	ILE	A2054	32.075	-14.260	-25.543	1.00	62.65	C
ATOM	1753	N	SER	A2055	33.905	-13.175	-22.342	1.00	59.96	N
ATOM	1754	CA	SER	A2055	34.335	-11.779	-22.448	1.00	59.70	C
ATOM	1755	C	SER	A2055	33.942	-11.184	-23.812	1.00	64.58	C
ATOM	1756	O	SER	A2055	34.769	-10.931	-24.700	1.00	64.01	O
ATOM	1757	CB	SER	A2055	35.812	-11.645	-22.105	1.00	60.27	C
ATOM	1758	OG	SER	A2055	35.922	-11.878	-20.709	1.00	65.22	O
ATOM	1759	N	TYR	A2056	32.624	-10.970	-23.940	1.00	61.34	N
ATOM	1760	CA	TYR	A2056	31.946	-10.463	-25.117	1.00	61.91	C
ATOM	1761	C	TYR	A2056	32.020	-8.959	-25.218	1.00	66.88	C
ATOM	1762	O	TYR	A2056	31.973	-8.245	-24.205	1.00	66.36	O
ATOM	1763	CB	TYR	A2056	30.472	-10.870	-25.075	1.00	62.94	C
ATOM	1764	CG	TYR	A2056	29.842	-10.952	-26.445	1.00	64.16	C
ATOM	1765	CD2	TYR	A2056	29.638	-12.181	-27.065	1.00	64.25	C
ATOM	1766	CD1	TYR	A2056	29.385	-9.810	-27.094	1.00	66.09	C
ATOM	1767	CE2	TYR	A2056	29.029	-12.268	-28.314	1.00	65.00	C
ATOM	1768	CE1	TYR	A2056	28.789	-9.882	-28.352	1.00	67.34	C
ATOM	1769	CZ	TYR	A2056	28.613	-11.115	-28.959	1.00	73.06	C
ATOM	1770	OH	TYR	A2056	27.989	-11.194	-30.184	1.00	74.69	O
ATOM	1771	N	SER	A2057	32.097	-8.478	-26.459	1.00	63.01	N
ATOM	1772	CA	SER	A2057	32.101	-7.056	-26.774	1.00	62.33	C
ATOM	1773	C	SER	A2057	31.394	-6.850	-28.119	1.00	65.29	C
ATOM	1774	O	SER	A2057	31.535	-7.668	-29.035	1.00	65.93	O
ATOM	1775	CB	SER	A2057	33.514	-6.501	-26.780	1.00	65.10	C
ATOM	1776	OG	SER	A2057	34.270	-7.194	-27.757	1.00	80.09	O
ATOM	1777	N	GLY	A2058	30.591	-5.801	-28.194	1.00	59.38	N
ATOM	1778	CA	GLY	A2058	29.808	-5.506	-29.377	1.00	58.93	C
ATOM	1779	C	GLY	A2058	28.388	-5.981	-29.210	1.00	63.73	C
ATOM	1780	O	GLY	A2058	28.019	-6.417	-28.113	1.00	64.99	O
ATOM	1781	N	ILE	A2059	27.568	-5.887	-30.283	1.00	59.38	N
ATOM	1782	CA	ILE	A2059	26.173	-6.285	-30.159	1.00	59.08	C
ATOM	1783	C	ILE	A2059	26.064	-7.803	-30.090	1.00	61.17	C
ATOM	1784	O	ILE	A2059	26.842	-8.508	-30.733	1.00	62.33	O
ATOM	1785	CB	ILE	A2059	25.125	-5.640	-31.144	1.00	62.47	C
ATOM	1786	CG1	ILE	A2059	24.787	-6.532	-32.329	1.00	63.33	C
ATOM	1787	CG2	ILE	A2059	25.471	-4.247	-31.606	1.00	63.15	C
ATOM	1788	CD1	ILE	A2059	23.285	-6.985	-32.315	1.00	77.57	C
ATOM	1789	N	LEU	A2060	25.120	-8.285	-29.263	1.00	55.07	N
ATOM	1790	CA	LEU	A2060	24.798	-9.692	-29.085	1.00	54.31	C
ATOM	1791	C	LEU	A2060	23.331	-9.907	-29.445	1.00	60.14	C
ATOM	1792	O	LEU	A2060	22.453	-9.235	-28.904	1.00	61.14	O
ATOM	1793	CB	LEU	A2060	25.107	-10.195	-27.626	1.00	53.48	C
ATOM	1794	CG	LEU	A2060	24.395	-11.509	-27.151	1.00	56.04	C
ATOM	1795	CD1	LEU	A2060	24.847	-12.725	-27.948	1.00	56.01	C
ATOM	1796	CD2	LEU	A2060	24.614	-11.765	-25.712	1.00	53.84	C
ATOM	1797	N	ASN	A2061	23.061	-10.845	-30.336	1.00	57.14	N
ATOM	1798	CA	ASN	A2061	21.679	-11.156	-30.643	1.00	57.87	C
ATOM	1799	C	ASN	A2061	21.464	-12.550	-30.106	1.00	62.73	C
ATOM	1800	O	ASN	A2061	22.072	-13.500	-30.608	1.00	65.30	O
ATOM	1801	CB	ASN	A2061	21.378	-11.036	-32.145	1.00	62.04	C
ATOM	1802	CG	ASN	A2061	19.912	-10.789	-32.432	1.00	100.04	C
ATOM	1803	ND2	ASN	A2061	19.660	-9.712	-33.162	1.00	94.49	N
ATOM	1804	OD1	ASN	A2061	19.001	-11.542	-32.005	1.00	94.34	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	1805	N	PHE	A2062	20.696	-12.662	-29.021	1.00	56.77	N
ATOM	1806	CA	PHE	A2062	20.481	-13.919	-28.312	1.00	55.60	C
ATOM	1807	C	PHE	A2062	19.048	-14.051	-27.856	1.00	60.61	C
ATOM	1808	O	PHE	A2062	18.583	-13.161	-27.174	1.00	60.36	O
ATOM	1809	CB	PHE	A2062	21.409	-13.953	-27.075	1.00	56.92	C
ATOM	1810	CG	PHE	A2062	21.288	-15.201	-26.238	1.00	57.34	C
ATOM	1811	CD1	PHE	A2062	20.316	-15.302	-25.248	1.00	58.43	C
ATOM	1812	CD2	PHE	A2062	22.129	-16.290	-26.459	1.00	58.63	C
ATOM	1813	CE1	PHE	A2062	20.148	-16.484	-24.532	1.00	59.32	C
ATOM	1814	CE2	PHE	A2062	21.977	-17.468	-25.728	1.00	61.03	C
ATOM	1815	CZ	PHE	A2062	20.988	-17.557	-24.766	1.00	59.03	C
ATOM	1816	N	ASN	A2063	18.389	-15.196	-28.138	1.00	59.47	N
ATOM	1817	CA	ASN	A2063	17.010	-15.535	-27.756	1.00	60.63	C
ATOM	1818	C	ASN	A2063	16.006	-14.424	-28.140	1.00	66.22	C
ATOM	1819	O	ASN	A2063	15.152	-14.008	-27.340	1.00	64.09	O
ATOM	1820	CB	ASN	A2063	16.905	-15.950	-26.264	1.00	65.36	C
ATOM	1821	CG	ASN	A2063	15.553	-16.538	-25.853	1.00	97.76	C
ATOM	1822	ND2	ASN	A2063	15.025	-16.086	-24.719	1.00	86.96	N
ATOM	1823	OD1	ASN	A2063	14.945	-17.361	-26.561	1.00	93.60	O
ATOM	1824	N	ASN	A2064	16.144	-13.938	-29.393	1.00	65.50	N
ATOM	1825	CA	ASN	A2064	15.310	-12.880	-29.972	1.00	66.06	C
ATOM	1826	C	ASN	A2064	15.412	-11.544	-29.165	1.00	67.17	C
ATOM	1827	O	ASN	A2064	14.497	-10.713	-29.206	1.00	66.48	O
ATOM	1828	CB	ASN	A2064	13.845	-13.382	-30.163	1.00	71.34	C
ATOM	1829	CG	ASN	A2064	13.016	-12.592	-31.164	1.00	113.83	C
ATOM	1830	ND2	ASN	A2064	11.693	-12.576	-30.958	1.00	106.61	N
ATOM	1831	OD1	ASN	A2064	13.536	-11.991	-32.126	1.00	112.24	O
ATOM	1832	N	LYS	A2065	16.557	-11.347	-28.455	1.00	61.04	N
ATOM	1833	CA	LYS	A2065	16.868	-10.163	-27.643	1.00	59.46	C
ATOM	1834	C	LYS	A2065	18.179	-9.556	-28.149	1.00	64.53	C
ATOM	1835	O	LYS	A2065	19.040	-10.289	-28.639	1.00	65.18	O
ATOM	1836	CB	LYS	A2065	16.983	-10.522	-26.153	1.00	59.86	C
ATOM	1837	CG	LYS	A2065	15.662	-10.876	-25.461	1.00	64.04	C
ATOM	1838	CD	LYS	A2065	15.863	-11.853	-24.293	1.00	68.00	C
ATOM	1839	CE	LYS	A2065	14.628	-12.007	-23.428	1.00	75.09	C
ATOM	1840	NZ	LYS	A2065	14.728	-13.178	-22.494	1.00	74.89	N
ATOM	1841	N	ILE	A2066	18.316	-8.218	-28.071	1.00	59.83	N
ATOM	1842	CA	ILE	A2066	19.514	-7.498	-28.531	1.00	58.49	C
ATOM	1843	C	ILE	A2066	20.179	-6.776	-27.363	1.00	61.05	C
ATOM	1844	O	ILE	A2066	19.520	-6.070	-26.599	1.00	60.81	O
ATOM	1845	CB	ILE	A2066	19.209	-6.544	-29.710	1.00	60.84	C
ATOM	1846	CG1	ILE	A2066	18.666	-7.315	-30.897	1.00	60.69	C
ATOM	1847	CG2	ILE	A2066	20.420	-5.672	-30.094	1.00	60.44	C
ATOM	1848	CD1	ILE	A2066	17.610	-6.595	-31.579	1.00	68.04	C
ATOM	1849	N	TYR	A2067	21.494	-6.951	-27.253	1.00	55.38	N
ATOM	1850	CA	TYR	A2067	22.321	-6.415	-26.185	1.00	53.14	C
ATOM	1851	C	TYR	A2067	23.532	-5.796	-26.804	1.00	55.62	C
ATOM	1852	O	TYR	A2067	23.903	-6.160	-27.907	1.00	55.49	O
ATOM	1853	CB	TYR	A2067	22.790	-7.576	-25.283	1.00	52.53	C
ATOM	1854	CG	TYR	A2067	21.682	-8.269	-24.524	1.00	53.20	C
ATOM	1855	CD2	TYR	A2067	21.152	-9.478	-24.970	1.00	54.25	C
ATOM	1856	CD1	TYR	A2067	21.185	-7.737	-23.340	1.00	54.66	C
ATOM	1857	CE2	TYR	A2067	20.164	-10.152	-24.238	1.00	55.23	C
ATOM	1858	CE1	TYR	A2067	20.172	-8.375	-22.626	1.00	54.79	C
ATOM	1859	CZ	TYR	A2067	19.680	-9.595	-23.062	1.00	62.01	C
ATOM	1860	OH	TYR	A2067	18.701	-10.218	-22.318	1.00	63.89	O
ATOM	1861	N	TYR	A2068	24.180	-4.896	-26.095	1.00	50.45	N
ATOM	1862	CA	TYR	A2068	25.425	-4.353	-26.581	1.00	49.42	C
ATOM	1863	C	TYR	A2068	26.318	-4.429	-25.395	1.00	56.65	C
ATOM	1864	O	TYR	A2068	25.900	-4.051	-24.295	1.00	57.17	O
ATOM	1865	CB	TYR	A2068	25.302	-2.905	-27.088	1.00	48.92	C
ATOM	1866	CG	TYR	A2068	26.630	-2.317	-27.534	1.00	48.01	C
ATOM	1867	CD1	TYR	A2068	27.130	-2.554	-28.819	1.00	48.44	C
ATOM	1868	CD2	TYR	A2068	27.416	-1.578	-26.655	1.00	48.17	C
ATOM	1869	CE1	TYR	A2068	28.373	-2.060	-29.211	1.00	46.14	C
ATOM	1870	CE2	TYR	A2068	28.661	-1.080	-27.038	1.00	48.20	C
ATOM	1871	CZ	TYR	A2068	29.134	-1.321	-28.312	1.00	52.91	C
ATOM	1872	OH	TYR	A2068	30.353	-0.788	-28.647	1.00	56.94	O
ATOM	1873	N	PHE	A2069	27.546	-4.917	-25.611	1.00	53.68	N
ATOM	1874	CA	PHE	A2069	28.531	-5.043	-24.561	1.00	53.54	C
ATOM	1875	C	PHE	A2069	29.737	-4.152	-24.848	1.00	62.22	C
ATOM	1876	O	PHE	A2069	30.226	-4.125	-25.976	1.00	62.56	O
ATOM	1877	CB	PHE	A2069	28.948	-6.514	-24.435	1.00	54.36	C
ATOM	1878	CG	PHE	A2069	27.947	-7.464	-23.795	1.00	54.40	C
ATOM	1879	CD1	PHE	A2069	26.835	-7.910	-24.501	1.00	55.73	C
ATOM	1880	CD2	PHE	A2069	28.193	-8.019	-22.541	1.00	54.98	C
ATOM	1881	CE1	PHE	A2069	25.939	-8.824	-23.931	1.00	55.97	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	1882	CE2	PHE	A2069	27.298	-8.931	-21.973	1.00	57.48	C
ATOM	1883	CZ	PHE	A2069	26.173	-9.325	-22.672	1.00	55.23	C
ATOM	1884	N	ASP	A2070	30.212	-3.412	-23.842	1.00	62.07	N
ATOM	1885	CA	ASP	A2070	31.406	-2.570	-23.988	1.00	63.50	C
ATOM	1886	C	ASP	A2070	32.645	-3.370	-23.551	1.00	70.43	C
ATOM	1887	O	ASP	A2070	32.528	-4.543	-23.241	1.00	71.45	O
ATOM	1888	CB	ASP	A2070	31.258	-1.269	-23.168	1.00	65.93	C
ATOM	1889	CG	ASP	A2070	31.175	-1.461	-21.663	1.00	76.66	C
ATOM	1890	OD2	ASP	A2070	31.665	-0.579	-20.924	1.00	78.26	O
ATOM	1891	OD1	ASP	A2070	30.660	-2.514	-21.226	1.00	79.11	O
ATOM	1892	N	ASP	A2071	33.807	-2.731	-23.466	1.00	68.46	N
ATOM	1893	CA	ASP	A2071	35.085	-3.346	-23.075	1.00	68.77	C
ATOM	1894	C	ASP	A2071	35.109	-3.818	-21.616	1.00	69.53	C
ATOM	1895	O	ASP	A2071	36.113	-4.350	-21.147	1.00	68.95	O
ATOM	1896	CB	ASP	A2071	36.223	-2.360	-23.352	1.00	72.22	C
ATOM	1897	CG	ASP	A2071	35.870	-1.391	-24.469	1.00	96.52	C
ATOM	1898	OD1	ASP	A2071	35.166	-0.379	-24.181	1.00	106.90	O
ATOM	1899	OD2	ASP	A2071	36.170	-1.710	-25.652	1.00	97.80	O
ATOM	1900	N	SER	A2072	33.997	-3.623	-20.913	1.00	64.73	N
ATOM	1901	CA	SER	A2072	33.796	-4.023	-19.527	1.00	64.45	C
ATOM	1902	C	SER	A2072	33.249	-5.444	-19.574	1.00	68.07	C
ATOM	1903	O	SER	A2072	33.173	-6.114	-18.547	1.00	67.77	O
ATOM	1904	CB	SER	A2072	32.761	-3.103	-18.881	1.00	68.10	C
ATOM	1905	OG	SER	A2072	33.175	-2.524	-17.655	1.00	81.11	O
ATOM	1906	N	PHE	A2073	32.871	-5.895	-20.798	1.00	63.76	N
ATOM	1907	CA	PHE	A2073	32.233	-7.167	-21.142	1.00	62.58	C
ATOM	1908	C	PHE	A2073	30.941	-7.322	-20.351	1.00	64.09	C
ATOM	1909	O	PHE	A2073	30.649	-8.401	-19.813	1.00	64.48	O
ATOM	1910	CB	PHE	A2073	33.171	-8.373	-20.987	1.00	64.87	C
ATOM	1911	CG	PHE	A2073	34.588	-8.163	-21.452	1.00	66.60	C
ATOM	1912	CD1	PHE	A2073	34.879	-8.011	-22.802	1.00	69.24	C
ATOM	1913	CD2	PHE	A2073	35.637	-8.141	-20.541	1.00	68.81	C
ATOM	1914	CE1	PHE	A2073	36.190	-7.818	-23.229	1.00	69.89	C
ATOM	1915	CE2	PHE	A2073	36.951	-7.940	-20.969	1.00	71.22	C
ATOM	1916	CZ	PHE	A2073	37.217	-7.781	-22.310	1.00	68.93	C
ATOM	1917	N	THR	A2074	30.202	-6.186	-20.233	1.00	57.06	N
ATOM	1918	CA	THR	A2074	28.932	-6.041	-19.535	1.00	54.37	C
ATOM	1919	C	THR	A2074	28.005	-5.322	-20.463	1.00	56.48	C
ATOM	1920	O	THR	A2074	28.450	-4.503	-21.263	1.00	55.26	O
ATOM	1921	CB	THR	A2074	29.079	-5.237	-18.246	1.00	58.68	C
ATOM	1922	CG2	THR	A2074	29.879	-5.951	-17.174	1.00	54.46	C
ATOM	1923	OG1	THR	A2074	29.692	-3.995	-18.554	1.00	66.60	O
ATOM	1924	N	ALA	A2075	26.717	-5.634	-20.391	1.00	53.92	N
ATOM	1925	CA	ALA	A2075	25.736	-4.946	-21.221	1.00	53.69	C
ATOM	1926	C	ALA	A2075	25.427	-3.529	-20.688	1.00	57.07	C
ATOM	1927	O	ALA	A2075	25.344	-3.289	-19.465	1.00	56.01	O
ATOM	1928	CB	ALA	A2075	24.459	-5.762	-21.340	1.00	54.26	C
ATOM	1929	N	VAL	A2076	25.258	-2.607	-21.650	1.00	52.92	N
ATOM	1930	CA	VAL	A2076	24.934	-1.180	-21.473	1.00	51.22	C
ATOM	1931	C	VAL	A2076	23.413	-0.936	-21.400	1.00	56.59	C
ATOM	1932	O	VAL	A2076	22.619	-1.682	-21.978	1.00	56.50	O
ATOM	1933	CB	VAL	A2076	25.598	-0.300	-22.555	1.00	51.50	C
ATOM	1934	CG1	VAL	A2076	27.108	-0.345	-22.443	1.00	50.30	C
ATOM	1935	CG2	VAL	A2076	25.165	-0.724	-23.942	1.00	50.86	C
ATOM	1936	N	VAL	A2077	23.024	0.106	-20.673	1.00	53.73	N
ATOM	1937	CA	VAL	A2077	21.631	0.522	-20.489	1.00	53.05	C
ATOM	1938	C	VAL	A2077	21.425	1.987	-20.997	1.00	58.01	C
ATOM	1939	O	VAL	A2077	22.398	2.735	-21.108	1.00	57.41	O
ATOM	1940	CB	VAL	A2077	21.193	0.319	-19.024	1.00	56.04	C
ATOM	1941	CG1	VAL	A2077	21.149	-1.163	-18.654	1.00	55.46	C
ATOM	1942	CG2	VAL	A2077	22.090	1.093	-18.068	1.00	55.94	C
ATOM	1943	N	GLY	A2078	20.191	2.347	-21.354	1.00	55.45	N
ATOM	1944	CA	GLY	A2078	19.857	3.672	-21.876	1.00	55.85	C
ATOM	1945	C	GLY	A2078	20.126	3.833	-23.360	1.00	61.29	C
ATOM	1946	O	GLY	A2078	20.129	2.841	-24.098	1.00	60.92	O
ATOM	1947	N	TRP	A2079	20.365	5.084	-23.808	1.00	59.21	N
ATOM	1948	CA	TRP	A2079	20.641	5.395	-25.230	1.00	60.01	C
ATOM	1949	C	TRP	A2079	22.073	5.122	-25.626	1.00	63.95	C
ATOM	1950	O	TRP	A2079	22.979	5.535	-24.890	1.00	63.88	O
ATOM	1951	CB	TRP	A2079	20.304	6.872	-25.555	1.00	58.90	C
ATOM	1952	CG	TRP	A2079	18.842	7.151	-25.507	1.00	59.68	C
ATOM	1953	CD1	TRP	A2079	18.134	7.604	-24.436	1.00	62.25	C
ATOM	1954	CD2	TRP	A2079	17.880	6.793	-26.506	1.00	60.07	C
ATOM	1955	CE2	TRP	A2079	16.607	7.110	-25.992	1.00	63.24	C
ATOM	1956	CE3	TRP	A2079	17.970	6.223	-27.793	1.00	62.13	C
ATOM	1957	NE1	TRP	A2079	16.791	7.597	-24.722	1.00	61.87	N
ATOM	1958	CZ2	TRP	A2079	15.434	6.888	-26.716	1.00	62.33	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	1959	CZ3	TRP	A2079	16.799	5.996	-28.509	1.00	63.52	C
ATOM	1960	CH2	TRP	A2079	15.552	6.322	-27.966	1.00	63.81	C
ATOM	1961	N	LYS	A2080	22.289	4.516	-26.818	1.00	60.52	N
ATOM	1962	CA	LYS	A2080	23.634	4.224	-27.347	1.00	61.35	C
ATOM	1963	C	LYS	A2080	23.671	4.391	-28.859	1.00	69.22	C
ATOM	1964	O	LYS	A2080	22.810	3.853	-29.554	1.00	66.66	O
ATOM	1965	CB	LYS	A2080	24.097	2.794	-26.926	1.00	63.99	C
ATOM	1966	CG	LYS	A2080	25.468	2.314	-27.455	1.00	66.19	C
ATOM	1967	CD	LYS	A2080	26.578	2.429	-26.410	1.00	73.46	C
ATOM	1968	CE	LYS	A2080	27.714	3.350	-26.814	1.00	72.44	C
ATOM	1969	NZ	LYS	A2080	28.158	4.179	-25.656	1.00	68.42	N
ATOM	1970	N	ASP	A2081	24.741	5.055	-29.364	1.00	72.69	N
ATOM	1971	CA	ASP	A2081	25.006	5.356	-30.779	1.00	75.11	C
ATOM	1972	C	ASP	A2081	25.994	4.377	-31.467	1.00	82.89	C
ATOM	1973	O	ASP	A2081	25.734	3.178	-31.478	1.00	82.73	O
ATOM	1974	CB	ASP	A2081	25.465	6.827	-30.905	1.00	78.11	C
ATOM	1975	CG	ASP	A2081	24.332	7.843	-30.776	1.00	94.06	C
ATOM	1976	OD1	ASP	A2081	23.405	7.820	-31.636	1.00	95.77	O
ATOM	1977	OD2	ASP	A2081	24.372	8.665	-29.822	1.00	98.52	O
ATOM	1978	N	LEU	A2082	27.077	4.897	-32.095	1.00	83.84	N
ATOM	1979	CA	LEU	A2082	28.175	4.203	-32.812	1.00	85.38	C
ATOM	1980	C	LEU	A2082	28.173	4.476	-34.327	1.00	91.49	C
ATOM	1981	O	LEU	A2082	28.414	5.613	-34.733	1.00	92.46	O
ATOM	1982	CB	LEU	A2082	28.272	2.685	-32.523	1.00	85.58	C
ATOM	1983	N	GLU	A2083	27.959	3.421	-35.145	1.00	87.24	N
ATOM	1984	CA	GLU	A2083	27.933	3.396	-36.607	1.00	86.27	C
ATOM	1985	C	GLU	A2083	27.537	1.954	-37.017	1.00	92.11	C
ATOM	1986	O	GLU	A2083	27.919	1.020	-36.321	1.00	92.17	O
ATOM	1987	CB	GLU	A2083	29.294	3.795	-37.190	1.00	87.13	C
ATOM	1988	O	ASP	A2084	23.845	3.161	-38.725	1.00	93.05	O
ATOM	1989	N	ASP	A2084	26.728	1.735	-38.061	1.00	89.74	N
ATOM	1990	CA	ASP	A2084	26.206	2.709	-39.013	1.00	89.96	C
ATOM	1991	C	ASP	A2084	25.011	3.515	-38.481	1.00	93.76	C
ATOM	1992	CB	ASP	A2084	25.878	2.016	-40.346	1.00	91.96	C
ATOM	1993	O	GLY	A2085	23.283	5.800	-35.057	1.00	91.47	O
ATOM	1994	N	GLY	A2085	25.343	4.589	-37.748	1.00	89.99	N
ATOM	1995	CA	GLY	A2085	24.420	5.551	-37.145	1.00	89.20	C
ATOM	1996	C	GLY	A2085	23.559	5.045	-36.003	1.00	91.12	C
ATOM	1997	N	SER	A2086	23.125	3.759	-36.114	1.00	84.59	N
ATOM	1998	CA	SER	A2086	22.292	2.943	-35.227	1.00	82.40	C
ATOM	1999	C	SER	A2086	22.191	3.466	-33.791	1.00	83.23	C
ATOM	2000	O	SER	A2086	23.167	3.458	-33.030	1.00	83.63	O
ATOM	2001	CB	SER	A2086	22.749	1.487	-35.254	1.00	84.96	C
ATOM	2002	OG	SER	A2086	22.613	0.943	-36.558	1.00	93.25	O
ATOM	2003	N	LYS	A2087	21.008	4.010	-33.471	1.00	75.98	N
ATOM	2004	CA	LYS	A2087	20.668	4.548	-32.167	1.00	73.37	C
ATOM	2005	C	LYS	A2087	19.809	3.482	-31.512	1.00	71.45	C
ATOM	2006	O	LYS	A2087	18.855	2.996	-32.107	1.00	70.41	O
ATOM	2007	CB	LYS	A2087	19.951	5.905	-32.293	1.00	76.25	C
ATOM	2008	CG	LYS	A2087	19.922	6.736	-30.999	1.00	90.36	C
ATOM	2009	CD	LYS	A2087	19.641	8.229	-31.270	1.00	94.79	C
ATOM	2010	CE	LYS	A2087	19.492	9.068	-30.016	1.00	99.70	C
ATOM	2011	NZ	LYS	A2087	20.737	9.120	-29.194	1.00	107.51	N
ATOM	2012	N	TYR	A2088	20.246	3.019	-30.345	1.00	65.07	N
ATOM	2013	CA	TYR	A2088	19.580	1.981	-29.569	1.00	62.40	C
ATOM	2014	C	TYR	A2088	19.152	2.535	-28.228	1.00	60.35	C
ATOM	2015	O	TYR	A2088	19.806	3.447	-27.674	1.00	59.54	O
ATOM	2016	CB	TYR	A2088	20.559	0.829	-29.276	1.00	63.26	C
ATOM	2017	CG	TYR	A2088	20.725	-0.230	-30.350	1.00	64.60	C
ATOM	2018	CD2	TYR	A2088	21.809	-0.195	-31.227	1.00	65.33	C
ATOM	2019	CD1	TYR	A2088	19.876	-1.333	-30.407	1.00	65.93	C
ATOM	2020	CE2	TYR	A2088	22.010	-1.199	-32.171	1.00	66.18	C
ATOM	2021	CE1	TYR	A2088	20.056	-2.335	-31.361	1.00	66.44	C
ATOM	2022	CZ	TYR	A2088	21.125	-2.260	-32.244	1.00	77.85	C
ATOM	2023	OH	TYR	A2088	21.319	-3.227	-33.206	1.00	85.83	O
ATOM	2024	N	TYR	A2089	18.067	1.959	-27.689	1.00	52.18	N
ATOM	2025	CA	TYR	A2089	17.656	2.228	-26.327	1.00	50.48	C
ATOM	2026	C	TYR	A2089	17.566	0.884	-25.654	1.00	53.59	C
ATOM	2027	O	TYR	A2089	16.722	0.051	-26.031	1.00	54.50	O
ATOM	2028	CB	TYR	A2089	16.379	3.059	-26.158	1.00	50.76	C
ATOM	2029	CG	TYR	A2089	16.021	3.246	-24.690	1.00	51.35	C
ATOM	2030	CD2	TYR	A2089	16.493	4.339	-23.970	1.00	52.15	C
ATOM	2031	CD1	TYR	A2089	15.302	2.274	-23.995	1.00	52.10	C
ATOM	2032	CE2	TYR	A2089	16.209	4.490	-22.610	1.00	51.10	C
ATOM	2033	CE1	TYR	A2089	15.046	2.398	-22.626	1.00	52.69	C
ATOM	2034	CZ	TYR	A2089	15.466	3.528	-21.948	1.00	56.77	C
ATOM	2035	OH	TYR	A2089	15.158	3.681	-20.619	1.00	57.70	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody beziotoxumab Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	2036 N	PHE	A2090	18.458	0.667	-24.662	1.00	47.49	N
ATOM	2037 CA	PHE	A2090	18.549	-0.582	-23.927	1.00	46.41	C
ATOM	2038 C	PHE	A2090	17.883	-0.471	-22.584	1.00	50.34	C
ATOM	2039 O	PHE	A2090	18.292	0.339	-21.765	1.00	50.39	O
ATOM	2040 CB	PHE	A2090	20.010	-0.967	-23.796	1.00	47.76	C
ATOM	2041 CG	PHE	A2090	20.690	-1.290	-25.106	1.00	47.12	C
ATOM	2042 CD1	PHE	A2090	20.357	-2.435	-25.816	1.00	48.56	C
ATOM	2043 CD2	PHE	A2090	21.695	-0.472	-25.603	1.00	46.56	C
ATOM	2044 CE1	PHE	A2090	21.005	-2.743	-27.006	1.00	49.39	C
ATOM	2045 CE2	PHE	A2090	22.346	-0.786	-26.792	1.00	48.70	C
ATOM	2046 CZ	PHE	A2090	21.994	-1.912	-27.490	1.00	46.86	C
ATOM	2047 N	ASP	A2091	16.831	-1.248	-22.378	1.00	48.15	N
ATOM	2048 CA	ASP	A2091	15.997	-1.197	-21.183	1.00	50.03	C
ATOM	2049 C	ASP	A2091	16.815	-1.132	-19.907	1.00	59.30	C
ATOM	2050 O	ASP	A2091	17.703	-1.940	-19.702	1.00	58.92	O
ATOM	2051 CB	ASP	A2091	14.966	-2.353	-21.164	1.00	51.76	C
ATOM	2052 CG	ASP	A2091	13.989	-2.319	-20.009	1.00	66.74	C
ATOM	2053 OD1	ASP	A2091	13.698	-1.211	-19.509	1.00	69.97	O
ATOM	2054 OD2	ASP	A2091	13.521	-3.403	-19.593	1.00	72.94	O
ATOM	2055 N	GLU	A2092	16.538	-0.147	-19.064	1.00	60.29	N
ATOM	2056 CA	GLU	A2092	17.279	0.024	-17.805	1.00	61.71	C
ATOM	2057 C	GLU	A2092	17.215	-1.218	-16.895	1.00	65.40	C
ATOM	2058 O	GLU	A2092	18.191	-1.481	-16.197	1.00	66.25	O
ATOM	2059 CB	GLU	A2092	16.796	1.265	-17.018	1.00	63.75	C
ATOM	2060 CG	GLU	A2092	16.464	2.507	-17.848	1.00	79.34	C
ATOM	2061 CD	GLU	A2092	17.583	3.488	-18.181	1.00	97.47	C
ATOM	2062 OE1	GLU	A2092	17.430	4.224	-19.186	1.00	102.41	O
ATOM	2063 OE2	GLU	A2092	18.571	3.577	-17.412	1.00	68.33	O
ATOM	2064 N	ASP	A2093	16.084	-1.980	-16.911	1.00	59.47	N
ATOM	2065 CA	ASP	A2093	15.873	-3.140	-16.035	1.00	57.72	C
ATOM	2066 C	ASP	A2093	16.498	-4.420	-16.505	1.00	61.66	C
ATOM	2067 O	ASP	A2093	16.951	-5.220	-15.676	1.00	61.40	O
ATOM	2068 CB	ASP	A2093	14.381	-3.415	-15.828	1.00	58.57	C
ATOM	2069 CG	ASP	A2093	13.492	-2.216	-15.598	1.00	60.96	C
ATOM	2070 OD2	ASP	A2093	12.366	-2.205	-16.134	1.00	66.69	O
ATOM	2071 OD1	ASP	A2093	13.902	-1.313	-14.849	1.00	58.84	O
ATOM	2072 N	THR	A2094	16.451	-4.656	-17.831	1.00	57.93	N
ATOM	2073 CA	THR	A2094	16.866	-5.911	-18.465	1.00	56.63	C
ATOM	2074 C	THR	A2094	18.075	-5.821	-19.350	1.00	58.47	C
ATOM	2075 O	THR	A2094	18.606	-6.866	-19.745	1.00	59.66	O
ATOM	2076 CB	THR	A2094	15.710	-6.450	-19.316	1.00	64.58	C
ATOM	2077 CG2	THR	A2094	14.436	-6.707	-18.497	1.00	61.31	C
ATOM	2078 OG1	THR	A2094	15.455	-5.535	-20.391	1.00	65.58	O
ATOM	2079 N	ALA	A2095	18.464	-4.593	-19.724	1.00	51.76	N
ATOM	2080 CA	ALA	A2095	19.566	-4.248	-20.624	1.00	50.90	C
ATOM	2081 C	ALA	A2095	19.343	-4.701	-22.052	1.00	55.54	C
ATOM	2082 O	ALA	A2095	20.277	-4.600	-22.843	1.00	55.71	O
ATOM	2083 CB	ALA	A2095	20.904	-4.728	-20.098	1.00	51.76	C
ATOM	2084 N	GLU	A2096	18.082	-5.100	-22.414	1.00	52.19	N
ATOM	2085 CA	GLU	A2096	17.679	-5.528	-23.765	1.00	52.56	C
ATOM	2086 C	GLU	A2096	17.224	-4.337	-24.590	1.00	58.55	C
ATOM	2087 O	GLU	A2096	16.564	-3.447	-24.045	1.00	56.53	O
ATOM	2088 CB	GLU	A2096	16.482	-6.479	-23.727	1.00	54.29	C
ATOM	2089 CG	GLU	A2096	16.570	-7.699	-22.842	1.00	67.16	C
ATOM	2090 CD	GLU	A2096	15.224	-8.358	-22.621	1.00	91.71	C
ATOM	2091 OE1	GLU	A2096	14.327	-8.212	-23.486	1.00	85.70	O
ATOM	2092 OE2	GLU	A2096	15.072	-9.028	-21.576	1.00	90.57	O
ATOM	2093 N	ALA	A2097	17.494	-4.360	-25.926	1.00	59.20	N
ATOM	2094 CA	ALA	A2097	17.083	-3.289	-26.851	1.00	60.27	C
ATOM	2095 C	ALA	A2097	15.582	-3.292	-27.020	1.00	65.84	C
ATOM	2096 O	ALA	A2097	14.979	-4.350	-27.290	1.00	65.60	O
ATOM	2097 CB	ALA	A2097	17.751	-3.438	-28.206	1.00	60.82	C
ATOM	2098 N	TYR	A2098	14.984	-2.105	-26.802	1.00	61.97	N
ATOM	2099 CA	TYR	A2098	13.550	-1.860	-26.921	1.00	61.43	C
ATOM	2100 C	TYR	A2098	13.248	-0.998	-28.142	1.00	66.78	C
ATOM	2101 O	TYR	A2098	12.184	-1.167	-28.726	1.00	66.84	O
ATOM	2102 CB	TYR	A2098	13.002	-1.239	-25.629	1.00	62.09	C
ATOM	2103 CG	TYR	A2098	12.564	-2.265	-24.598	1.00	65.22	C
ATOM	2104 CD2	TYR	A2098	11.453	-2.040	-23.790	1.00	65.91	C
ATOM	2105 CD1	TYR	A2098	13.280	-3.450	-24.405	1.00	67.72	C
ATOM	2106 CE2	TYR	A2098	11.054	-2.971	-22.826	1.00	66.78	C
ATOM	2107 CE1	TYR	A2098	12.886	-4.392	-23.451	1.00	68.73	C
ATOM	2108 CZ	TYR	A2098	11.772	-4.147	-22.660	1.00	72.92	C
ATOM	2109 OH	TYR	A2098	11.367	-5.063	-21.712	1.00	69.55	O
ATOM	2110 O	ILE	A2099	16.568	0.599	-29.909	1.00	75.12	O
ATOM	2111 N	ILE	A2099	14.215	-0.118	-28.548	1.00	63.58	N
ATOM	2112 CA	ILE	A2099	14.178	0.826	-29.675	1.00	63.43	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.									
ATOM	2113 C	ILE	A2099	15.487	0.712	-30.492	1.00	73.91 C	
ATOM	2114 CB	ILE	A2099	14.000	2.285	-29.123	1.00	65.17 C	
ATOM	2115 CG1	ILE	A2099	12.685	2.473	-28.388	1.00	64.48 C	
ATOM	2116 CG2	ILE	A2099	14.184	3.385	-30.179	1.00	65.56 C	
ATOM	2117 CD1	ILE	A2099	12.772	3.517	-27.319	1.00	70.37 C	
ATOM	2118 O	LEU	A2100	15.513	1.231	-34.999	1.00	82.54 O	
ATOM	2119 N	LEU	A2100	15.384	0.790	-31.838	1.00	73.77 N	
ATOM	2120 CA	LEU	A2100	16.511	0.814	-32.786	1.00	74.45 C	
ATOM	2121 C	LEU	A2100	16.196	1.669	-34.059	1.00	83.81 C	
ATOM	2122 CB	LEU	A2100	17.060	-0.592	-33.147	1.00	73.42 C	
ATOM	2123 CG	LEU	A2100	18.096	-0.687	-34.305	1.00	75.70 C	
ATOM	2124 CD1	LEU	A2100	19.351	0.160	-34.051	1.00	74.84 C	
ATOM	2125 CD2	LEU	A2100	18.409	-2.124	-34.652	1.00	74.46 C	
ATOM	2126 O	GLU	A2101	19.045	3.781	-35.419	1.00	95.82 O	
ATOM	2127 N	GLU	A2101	16.730	2.892	-34.051	1.00	84.83 N	
ATOM	2128 CA	GLU	A2101	16.661	3.859	-35.137	1.00	86.55 C	
ATOM	2129 C	GLU	A2101	17.950	3.701	-35.973	1.00	96.39 C	
ATOM	2130 CB	GLU	A2101	16.573	5.292	-34.567	1.00	87.63 C	
ATOM	2131 CG	GLU	A2101	15.215	5.643	-33.983	1.00	96.91 C	
ATOM	2132 CD	GLU	A2101	15.177	6.724	-32.916	1.00	115.46 C	
ATOM	2133 OE1	GLU	A2101	16.050	7.627	-32.929	1.00	88.08 O	
ATOM	2134 OE2	GLU	A2101	14.242	6.681	-32.080	1.00	113.17 O	
ATOM	2135 O	HIS	A2102	18.365	5.315	-39.400	1.00	106.98 O	
ATOM	2136 N	HIS	A2102	17.818	3.442	-37.289	1.00	97.56 N	
ATOM	2137 CA	HIS	A2102	18.954	3.317	-38.207	1.00	99.18 C	
ATOM	2138 C	HIS	A2102	19.240	4.719	-38.765	1.00	106.52 C	
ATOM	2139 CB	HIS	A2102	18.623	2.362	-39.365	1.00	100.25 C	
ATOM	2140 CG	HIS	A2102	18.061	1.038	-38.952	1.00	103.99 C	
ATOM	2141 ND1	HIS	A2102	18.876	-0.070	-38.778	1.00	105.93 N	
ATOM	2142 CD2	HIS	A2102	16.774	0.676	-38.736	1.00	105.97 C	
ATOM	2143 CE1	HIS	A2102	18.063	-1.063	-38.448	1.00	105.42 C	
ATOM	2144 NE2	HIS	A2102	16.788	-0.662	-38.408	1.00	105.73 N	
ATOM	2145 O	HIS	A2103	22.285	5.476	-40.517	1.00	108.48 O	
ATOM	2146 N	HIS	A2103	20.432	5.265	-38.499	1.00	104.51 N	
ATOM	2147 CA	HIS	A2103	20.784	5.594	-39.004	1.00	105.00 C	
ATOM	2148 C	HIS	A2103	21.654	6.511	-40.267	1.00	109.03 C	
ATOM	2149 CB	HIS	A2103	21.403	7.477	-37.903	1.00	106.15 C	
ATOM	2150 CG	HIS	A2103	20.434	7.954	-36.856	1.00	109.71 C	
ATOM	2151 ND1	HIS	A2103	19.149	7.428	-36.747	1.00	111.56 N	
ATOM	2152 CD2	HIS	A2103	20.602	8.892	-35.892	1.00	111.46 C	
ATOM	2153 CE1	HIS	A2103	18.582	8.072	-35.737	1.00	110.98 C	
ATOM	2154 NE2	HIS	A2103	19.417	8.958	-35.187	1.00	111.25 N	
ATOM	2155 O	HIS	A2104	20.666	6.345	-43.445	1.00	111.19 O	
ATOM	2156 N	HIS	A2104	21.641	7.594	-41.081	1.00	1105.95 N	
ATOM	2157 CA	HIS	A2104	22.322	7.738	-42.381	1.00	139.50 C	
ATOM	2158 C	HIS	A2104	21.852	6.690	-43.402	1.00	157.82 C	
ATOM	2159 CB	HIS	A2104	23.843	7.707	-42.224	1.00	140.23 C	
TER	2160	HIS	A2104						
ATOM	2161 O	GLU	H	1	9.441	7.033	-7.636	1.00	68.44 O
ATOM	2162 N	GLU	H	1	7.969	8.930	-9.008	1.00	68.19 N
ATOM	2163 CA	GLU	H	1	9.431	8.911	-9.148	1.00	67.28 C
ATOM	2164 C	GLU	H	1	10.071	7.710	-8.458	1.00	69.17 C
ATOM	2165 CB	GLU	H	1	10.106	10.237	-8.691	1.00	68.58 C
ATOM	2166 CG	GLU	H	1	9.363	11.054	-7.643	1.00	82.60 C
ATOM	2167 CD	GLU	H	1	10.014	11.265	-6.287	1.00	113.13 C
ATOM	2168 OE1	GLU	H	1	9.309	11.074	-5.270	1.00	125.63 O
ATOM	2169 OE2	GLU	H	1	11.191	11.693	-6.234	1.00	101.83 O
ATOM	2170 N	VAL	H	2	11.331	7.443	-8.805	1.00	63.79 N
ATOM	2171 CA	VAL	H	2	12.091	6.362	-8.194	1.00	61.56 C
ATOM	2172 C	VAL	H	2	12.544	6.894	-6.846	1.00	65.29 C
ATOM	2173 O	VAL	H	2	13.154	7.972	-6.778	1.00	65.35 O
ATOM	2174 CB	VAL	H	2	13.299	5.957	-9.059	1.00	63.73 C
ATOM	2175 CG1	VAL	H	2	14.048	4.784	-8.445	1.00	63.00 C
ATOM	2176 CG2	VAL	H	2	12.874	5.655	-10.486	1.00	63.34 C
ATOM	2177 N	GLN	H	3	12.216	6.163	-5.772	1.00	60.82 N
ATOM	2178 CA	GLN	H	3	12.610	6.554	-4.428	1.00	59.79 C
ATOM	2179 C	GLN	H	3	12.730	5.389	-3.489	1.00	61.97 C
ATOM	2180 O	GLN	H	3	11.982	4.425	-3.631	1.00	63.13 O
ATOM	2181 CB	GLN	H	3	11.698	7.652	-3.851	1.00	61.27 C
ATOM	2182 CG	GLN	H	3	10.215	7.315	-3.740	1.00	83.59 C
ATOM	2183 CD	GLN	H	3	9.364	8.550	-3.520	1.00	89.95 C
ATOM	2184 OE1	GLN	H	3	9.693	9.435	-2.709	1.00	74.58 O
ATOM	2185 NE2	GLN	H	3	8.246	8.635	-4.251	1.00	80.78 N
ATOM	2186 N	LEU	H	4	13.693	5.468	-2.541	1.00	56.35 N
ATOM	2187 CA	LEU	H	4	13.906	4.478	-1.486	1.00	55.57 C
ATOM	2188 C	LEU	H	4	13.626	5.214	-0.175	1.00	62.48 C
ATOM	2189 O	LEU	H	4	14.271	6.235	0.114	1.00	64.53 O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	2190	CB	LEU	H	4	15.329	3.873	-1.489
ATOM	2191	CG	LEU	H	4	15.823	3.193	-2.786
ATOM	2192	CD1	LEU	H	4	17.290	2.963	-2.736
ATOM	2193	CD2	LEU	H	4	15.148	1.884	-3.032
ATOM	2194	N	VAL	H	5	12.607	4.743	0.583
ATOM	2195	CA	VAL	H	5	12.200	5.370	1.838
ATOM	2196	C	VAL	H	5	12.589	4.477	3.011
ATOM	2197	O	VAL	H	5	12.166	3.332	3.085
ATOM	2198	CB	VAL	H	5	10.703	5.759	1.831
ATOM	2199	CG1	VAL	H	5	10.307	6.468	3.122
ATOM	2200	CG2	VAL	H	5	10.354	6.611	0.605
ATOM	2201	N	GLN	H	6	13.400	5.001	3.919
ATOM	2202	CA	GLN	H	6	13.873	4.204	5.030
ATOM	2203	C	GLN	H	6	13.094	4.392	6.329
ATOM	2204	O	GLN	H	6	12.399	5.400	6.533
ATOM	2205	CB	GLN	H	6	15.368	4.443	5.249
ATOM	2206	CG	GLN	H	6	16.197	4.111	4.028
ATOM	2207	CD	GLN	H	6	17.652	4.304	4.277
ATOM	2208	OE1	GLN	H	6	18.307	5.104	3.612
ATOM	2209	NE2	GLN	H	6	18.197	3.551	5.212
ATOM	2210	N	SER	H	7	13.222	3.389	7.219
ATOM	2211	CA	SER	H	7	12.592	3.393	8.532
ATOM	2212	C	SER	H	7	13.193	4.522	9.391
ATOM	2213	O	SER	H	7	14.302	4.993	9.111
ATOM	2214	CB	SER	H	7	12.706	2.025	9.205
ATOM	2215	OG	SER	H	7	14.022	1.507	9.244
ATOM	2216	N	GLY	H	8	12.419	4.987	10.375
ATOM	2217	CA	GLY	H	8	12.773	6.079	11.275
ATOM	2218	C	GLY	H	8	13.988	5.811	12.128
ATOM	2219	O	GLY	H	8	14.497	4.681	12.181
ATOM	2220	N	ALA	H	9	14.455	6.887	12.795
ATOM	2221	CA	ALA	H	9	15.615	6.887	13.687
ATOM	2222	C	ALA	H	9	15.439	5.887	14.837
ATOM	2223	O	ALA	H	9	14.362	5.800	15.432
ATOM	2224	CB	ALA	H	9	15.843	8.280	14.234
ATOM	2225	N	GLU	H	10	16.488	5.122	15.122
ATOM	2226	CA	GLU	H	10	16.446	4.115	16.158
ATOM	2227	C	GLU	H	10	17.409	4.408	17.300
ATOM	2228	O	GLU	H	10	18.581	4.721	17.080
ATOM	2229	CB	GLU	H	10	16.725	2.723	15.570
ATOM	2230	CG	GLU	H	10	15.697	2.274	14.549
ATOM	2231	CD	GLU	H	10	14.412	1.656	15.054
ATOM	2232	OE1	GLU	H	10	13.431	1.637	14.277
ATOM	2233	OE2	GLU	H	10	14.385	1.164	16.205
ATOM	2234	N	VAL	H	11	16.899	4.309	18.525
ATOM	2235	CA	VAL	H	11	17.698	4.432	19.739
ATOM	2236	C	VAL	H	11	17.509	3.113	20.482
ATOM	2237	O	VAL	H	11	16.382	2.778	20.876
ATOM	2238	CB	VAL	H	11	17.399	5.664	20.626
ATOM	2239	CG1	VAL	H	11	18.572	5.925	21.569
ATOM	2240	CG2	VAL	H	11	17.099	6.917	19.789
ATOM	2241	N	LYS	H	12	18.602	2.329	20.580
ATOM	2242	CA	LYS	H	12	18.602	0.994	21.157
ATOM	2243	C	LYS	H	12	19.650	0.868	22.223
ATOM	2244	O	LYS	H	12	20.685	1.527	22.124
ATOM	2245	CB	LYS	H	12	18.894	-0.065	20.060
ATOM	2246	CG	LYS	H	12	17.949	-0.091	18.843
ATOM	2247	CD	LYS	H	12	16.439	-0.171	19.166
ATOM	2248	CE	LYS	H	12	15.908	-1.576	19.293
ATOM	2249	NZ	LYS	H	12	14.679	-1.599	20.125
ATOM	2250	N	LYS	H	13	19.413	-0.010	23.232
ATOM	2251	CA	LYS	H	13	20.407	-0.311	24.274
ATOM	2252	C	LYS	H	13	21.344	-1.360	23.668
ATOM	2253	O	LYS	H	13	20.920	-2.080	22.773
ATOM	2254	CB	LYS	H	13	19.737	-0.819	25.562
ATOM	2255	N	SER	H	14	22.620	-1.417	24.090
ATOM	2256	CA	SER	H	14	23.605	-2.388	23.556
ATOM	2257	C	SER	H	14	23.115	-3.845	23.748
ATOM	2258	O	SER	H	14	22.226	-4.096	24.567
ATOM	2259	CB	SER	H	14	24.971	-2.213	24.216
ATOM	2260	OG	SER	H	14	25.329	-0.851	24.373
ATOM	2261	N	GLY	H	15	23.645	-4.777	22.963
ATOM	2262	CA	GLY	H	15	23.243	-6.180	23.053
ATOM	2263	C	GLY	H	15	21.885	-6.552	22.467
ATOM	2264	O	GLY	H	15	21.621	-7.746	22.266
ATOM	2265	N	GLU	H	16	21.001	-5.542	22.199
ATOM	2266	CA	GLU	H	16	19.663	-5.719	21.602

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	2267	C	GLU	H	16	19.776	-6.104	20.100	1.00	75.61	C
ATOM	2268	O	GLU	H	16	20.870	-6.065	19.520	1.00	74.97	O
ATOM	2269	CB	GLU	H	16	18.824	-4.430	21.733	1.00	70.58	C
ATOM	2270	CG	GLU	H	16	18.231	-4.168	23.108	1.00	80.41	C
ATOM	2271	CD	GLU	H	16	17.276	-2.988	23.212	1.00	103.68	C
ATOM	2272	OE1	GLU	H	16	16.532	-2.730	22.242	1.00	88.29	O
ATOM	2273	OE2	GLU	H	16	17.235	-2.346	24.286	1.00	111.46	O
ATOM	2274	N	SER	H	17	18.646	-6.456	19.469	1.00	72.15	N
ATOM	2275	CA	SER	H	17	18.651	-6.766	18.051	1.00	71.86	C
ATOM	2276	C	SER	H	17	17.794	-5.781	17.278	1.00	74.46	C
ATOM	2277	O	SER	H	17	16.800	-5.270	17.814	1.00	75.96	O
ATOM	2278	CB	SER	H	17	18.285	-8.218	17.805	1.00	77.34	C
ATOM	2279	OG	SER	H	17	19.415	-8.987	18.190	1.00	94.80	O
ATOM	2280	N	LEU	H	18	18.229	-5.436	16.051	1.00	66.54	N
ATOM	2281	CA	LEU	H	18	17.551	-4.428	15.229	1.00	63.63	C
ATOM	2282	C	LEU	H	18	17.471	-4.889	13.776	1.00	64.48	C
ATOM	2283	O	LEU	H	18	18.416	-5.509	13.295	1.00	63.78	O
ATOM	2284	CB	LEU	H	18	18.438	-3.173	15.296	1.00	62.90	C
ATOM	2285	CG	LEU	H	18	17.902	-1.755	15.236	1.00	65.49	C
ATOM	2286	CD1	LEU	H	18	18.713	-0.963	14.286	1.00	65.60	C
ATOM	2287	CD2	LEU	H	18	16.439	-1.656	14.927	1.00	65.00	C
ATOM	2288	N	LYS	H	19	16.343	-4.600	13.099	1.00	60.02	N
ATOM	2289	CA	LYS	H	19	16.083	-4.842	11.675	1.00	60.42	C
ATOM	2290	C	LYS	H	19	15.557	-3.526	11.152	1.00	67.13	C
ATOM	2291	O	LYS	H	19	14.552	-2.988	11.667	1.00	66.65	O
ATOM	2292	CB	LYS	H	19	15.067	-5.971	11.391	1.00	62.90	C
ATOM	2293	N	ILE	H	20	16.292	-2.974	10.163	1.00	64.32	N
ATOM	2294	CA	ILE	H	20	16.016	-1.697	9.547	1.00	63.02	C
ATOM	2295	C	ILE	H	20	15.558	-1.913	8.110	1.00	64.87	C
ATOM	2296	O	ILE	H	20	16.033	-2.819	7.432	1.00	63.63	O
ATOM	2297	CB	ILE	H	20	17.232	-0.772	9.778	1.00	66.79	C
ATOM	2298	CG1	ILE	H	20	16.763	0.514	10.392	1.00	68.23	C
ATOM	2299	CG2	ILE	H	20	18.194	-0.546	8.603	1.00	68.02	C
ATOM	2300	CD1	ILE	H	20	16.786	0.491	11.823	1.00	77.59	C
ATOM	2301	N	SER	H	21	14.543	-1.155	7.701	1.00	61.50	N
ATOM	2302	CA	SER	H	21	13.936	-1.315	6.393	1.00	61.51	C
ATOM	2303	C	SER	H	21	14.263	-0.173	5.429	1.00	66.48	C
ATOM	2304	O	SER	H	21	14.742	0.889	5.849	1.00	67.71	O
ATOM	2305	CB	SER	H	21	12.431	-1.548	6.528	1.00	65.02	C
ATOM	2306	OG	SER	H	21	11.619	-0.393	6.388	1.00	78.17	O
ATOM	2307	N	CYS	H	22	14.000	-0.417	4.136	1.00	60.91	N
ATOM	2308	CA	CYS	H	22	14.254	0.461	3.007	1.00	60.47	C
ATOM	2309	C	CYS	H	22	13.241	0.063	1.937	1.00	63.20	C
ATOM	2310	O	CYS	H	22	13.403	-0.979	1.291	1.00	62.84	O
ATOM	2311	CB	CYS	H	22	15.692	0.247	2.532	1.00	61.32	C
ATOM	2312	SG	CYS	H	22	16.074	0.895	0.878	1.00	65.44	S
ATOM	2313	N	LYS	H	23	12.173	0.860	1.783	1.00	58.45	N
ATOM	2314	CA	LYS	H	23	11.125	0.584	0.815	1.00	57.56	C
ATOM	2315	C	LYS	H	23	11.333	1.296	-0.523	1.00	62.13	C
ATOM	2316	O	LYS	H	23	11.323	2.540	-0.603	1.00	62.72	O
ATOM	2317	CB	LYS	H	23	9.730	0.883	1.379	1.00	58.80	C
ATOM	2318	CG	LYS	H	23	8.681	-0.127	0.880	1.00	58.77	C
ATOM	2319	CD	LYS	H	23	7.306	0.469	0.601	1.00	63.19	C
ATOM	2320	CE	LYS	H	23	6.226	-0.587	0.460	1.00	72.87	C
ATOM	2321	NZ	LYS	H	23	4.926	-0.152	1.079	1.00	76.82	N
ATOM	2322	N	GLY	H	24	11.515	0.487	-1.554	1.00	56.07	N
ATOM	2323	CA	GLY	H	24	11.652	0.965	-2.915	1.00	55.44	C
ATOM	2324	C	GLY	H	24	10.310	1.089	-3.610	1.00	57.32	C
ATOM	2325	O	GLY	H	24	9.408	0.268	-3.393	1.00	55.25	O
ATOM	2326	N	SER	H	25	10.195	2.119	-4.474	1.00	53.78	N
ATOM	2327	CA	SER	H	25	8.997	2.467	-5.240	1.00	54.35	C
ATOM	2328	C	SER	H	25	9.354	3.241	-6.504	1.00	60.55	C
ATOM	2329	O	SER	H	25	10.353	3.961	-6.514	1.00	61.37	O
ATOM	2330	CB	SER	H	25	8.039	3.301	-4.381	1.00	58.01	C
ATOM	2331	OG	SER	H	25	8.699	4.179	-3.479	1.00	66.40	O
ATOM	2332	N	GLY	H	26	8.505	3.140	-7.531	1.00	57.46	N
ATOM	2333	CA	GLY	H	26	8.700	3.858	-8.795	1.00	57.24	C
ATOM	2334	C	GLY	H	26	9.492	3.096	-9.849	1.00	60.98	C
ATOM	2335	O	GLY	H	26	9.643	3.566	-10.988	1.00	60.24	O
ATOM	2336	N	TYR	H	27	10.000	1.902	-9.470	1.00	55.67	N
ATOM	2337	CA	TYR	H	27	10.812	1.069	-10.337	1.00	54.96	C
ATOM	2338	C	TYR	H	27	10.496	-0.415	-10.080	1.00	60.43	C
ATOM	2339	O	TYR	H	27	9.761	-0.743	-9.131	1.00	60.95	O
ATOM	2340	CB	TYR	H	27	12.304	1.403	-10.110	1.00	55.20	C
ATOM	2341	CG	TYR	H	27	12.912	0.802	-8.851	1.00	56.09	C
ATOM	2342	CD1	TYR	H	27	12.695	1.376	-7.604	1.00	57.54	C
ATOM	2343	CD2	TYR	H	27	13.719	-0.326	-8.913	1.00	57.30	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	2344	CE1	TYR	H	27	13.229	0.816	-6.443	1.00	56.87	C
ATOM	2345	CE2	TYR	H	27	14.280	-0.881	-7.763	1.00	58.91	C
ATOM	2346	CZ	TYR	H	27	14.020	-0.314	-6.525	1.00	65.82	C
ATOM	2347	OH	TYR	H	27	14.570	-0.851	-5.384	1.00	69.33	O
ATOM	2348	N	SER	H	28	11.068	-1.307	-10.931	1.00	55.75	N
ATOM	2349	CA	SER	H	28	10.945	-2.760	-10.822	1.00	54.83	C
ATOM	2350	C	SER	H	28	11.942	-3.278	-9.754	1.00	55.58	C
ATOM	2351	O	SER	H	28	13.132	-3.430	-10.018	1.00	54.31	O
ATOM	2352	CB	SER	H	28	11.199	-3.412	-12.173	1.00	59.57	C
ATOM	2353	OG	SER	H	28	11.370	-4.813	-12.006	1.00	76.32	O
ATOM	2354	N	PHE	H	29	11.442	-3.545	-8.563	1.00	50.96	N
ATOM	2355	CA	PHE	H	29	12.256	-3.913	-7.420	1.00	50.91	C
ATOM	2356	C	PHE	H	29	13.189	-5.116	-7.636	1.00	58.02	C
ATOM	2357	O	PHE	H	29	14.333	-5.080	-7.164	1.00	59.90	O
ATOM	2358	CB	PHE	H	29	11.361	-4.117	-6.195	1.00	51.98	C
ATOM	2359	CG	PHE	H	29	12.085	-4.430	-4.909	1.00	52.70	C
ATOM	2360	CD2	PHE	H	29	12.130	-5.735	-4.416	1.00	54.22	C
ATOM	2361	CD1	PHE	H	29	12.697	-3.419	-4.173	1.00	54.84	C
ATOM	2362	CE2	PHE	H	29	12.775	-6.024	-3.213	1.00	56.91	C
ATOM	2363	CE1	PHE	H	29	13.346	-3.705	-2.969	1.00	55.68	C
ATOM	2364	CZ	PHE	H	29	13.386	-5.009	-2.498	1.00	55.40	C
ATOM	2365	N	THR	H	30	12.714	-6.163	-8.325	1.00	54.16	N
ATOM	2366	CA	THR	H	30	13.475	-7.407	-8.591	1.00	52.91	C
ATOM	2367	C	THR	H	30	14.475	-7.295	-9.736	1.00	55.68	C
ATOM	2368	O	THR	H	30	15.079	-8.308	-10.076	1.00	58.41	O
ATOM	2369	CB	THR	H	30	12.514	-8.548	-8.953	1.00	55.28	C
ATOM	2370	OG1	THR	H	30	11.783	-8.182	-10.136	1.00	56.25	O
ATOM	2371	CG2	THR	H	30	11.562	-8.897	-7.826	1.00	50.65	C
ATOM	2372	N	SER	H	31	14.608	-6.116	-10.372	1.00	47.98	N
ATOM	2373	CA	SER	H	31	15.487	-5.898	-11.521	1.00	46.50	C
ATOM	2374	C	SER	H	31	16.756	-5.141	-11.166	1.00	52.73	C
ATOM	2375	O	SER	H	31	17.583	-4.884	-12.052	1.00	52.49	O
ATOM	2376	CB	SER	H	31	14.745	-5.103	-12.589	1.00	47.37	C
ATOM	2377	OG	SER	H	31	13.676	-5.822	-13.173	1.00	53.09	O
ATOM	2378	N	TYR	H	32	16.891	-4.727	-9.885	1.00	50.47	N
ATOM	2379	CA	TYR	H	32	18.000	-3.889	-9.423	1.00	50.57	C
ATOM	2380	C	TYR	H	32	18.594	-4.385	-8.161	1.00	57.62	C
ATOM	2381	O	TYR	H	32	17.856	-4.837	-7.291	1.00	57.77	O
ATOM	2382	CB	TYR	H	32	17.498	-2.452	-9.180	1.00	50.48	C
ATOM	2383	CZ	TYR	H	32	17.120	-1.753	-10.464	1.00	50.56	C
ATOM	2384	CD2	TYR	H	32	18.041	-0.961	-11.145	1.00	50.15	C
ATOM	2385	CD1	TYR	H	32	15.856	-1.924	-11.032	1.00	51.97	C
ATOM	2386	CE2	TYR	H	32	17.707	-0.335	-12.344	1.00	50.84	C
ATOM	2387	CE1	TYR	H	32	15.527	-1.339	-12.253	1.00	52.50	C
ATOM	2388	CZ	TYR	H	32	16.454	-0.537	-12.902	1.00	58.94	C
ATOM	2389	OH	TYR	H	32	16.153	0.048	-14.107	1.00	58.77	O
ATOM	2390	N	TRP	H	33	19.918	-4.235	-8.017	1.00	55.75	N
ATOM	2391	CA	TRP	H	33	20.571	-4.568	-6.762	1.00	56.20	C
ATOM	2392	C	TRP	H	33	20.353	-3.399	-5.833	1.00	61.22	C
ATOM	2393	O	TRP	H	33	20.250	-2.256	-6.289	1.00	61.04	O
ATOM	2394	CB	TRP	H	33	22.063	-4.760	-6.948	1.00	55.63	C
ATOM	2395	CG	TRP	H	33	22.424	-5.974	-7.738	1.00	57.32	C
ATOM	2396	CD1	TRP	H	33	22.225	-6.178	-9.070	1.00	60.27	C
ATOM	2397	CD2	TRP	H	33	23.120	-7.119	-7.256	1.00	57.62	C
ATOM	2398	NE1	TRP	H	33	22.745	-7.388	-9.444	1.00	59.87	N
ATOM	2399	CE2	TRP	H	33	23.302	-7.990	-8.351	1.00	61.59	C
ATOM	2400	CE3	TRP	H	33	23.585	-7.513	-5.991	1.00	59.67	C
ATOM	2401	CZ2	TRP	H	33	23.938	-9.227	-8.226	1.00	61.65	C
ATOM	2402	CZ3	TRP	H	33	24.210	-8.746	-5.865	1.00	61.52	C
ATOM	2403	CH2	TRP	H	33	24.382	-9.587	-6.972	1.00	62.17	C
ATOM	2404	N	ILE	H	34	20.264	-3.682	-4.539	1.00	59.13	N
ATOM	2405	CA	ILE	H	34	20.089	-2.677	-3.501	1.00	59.66	C
ATOM	2406	C	ILE	H	34	21.189	-2.909	-2.433	1.00	63.18	C
ATOM	2407	O	ILE	H	34	21.386	-4.033	-1.981	1.00	61.66	O
ATOM	2408	CB	ILE	H	34	18.614	-2.549	-2.978	1.00	63.07	C
ATOM	2409	CG1	ILE	H	34	18.532	-2.011	-1.562	1.00	64.04	C
ATOM	2410	CG2	ILE	H	34	17.814	-3.822	-3.103	1.00	65.26	C
ATOM	2411	CD1	ILE	H	34	18.374	-0.604	-1.517	1.00	80.43	C
ATOM	2412	N	GLY	H	35	21.961	-1.860	-2.156	1.00	60.18	N
ATOM	2413	CA	GLY	H	35	23.084	-1.909	-1.228	1.00	59.97	C
ATOM	2414	C	GLY	H	35	22.938	-1.094	0.035	1.00	62.93	C
ATOM	2415	O	GLY	H	35	22.070	-0.226	0.112	1.00	63.93	O
ATOM	2416	N	TRP	H	36	23.781	-1.399	1.046	1.00	56.44	N
ATOM	2417	CA	TRP	H	36	23.800	-0.732	2.349	1.00	54.56	C
ATOM	2418	C	TRP	H	36	25.182	-0.123	2.609	1.00	58.10	C
ATOM	2419	O	TRP	H	36	26.206	-0.800	2.472	1.00	58.81	O
ATOM	2420	CB	TRP	H	36	23.342	-1.657	3.498	1.00	52.55	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	2421	CG	TRP	H	36	21.892	-2.049	3.427	1.00	53.02	C
ATOM	2422	CD1	TRP	H	36	21.364	-3.121	2.768	1.00	55.61	C
ATOM	2423	CD2	TRP	H	36	20.783	-1.361	4.028	1.00	52.72	C
ATOM	2424	NE1	TRP	H	36	19.993	-3.130	2.900	1.00	54.49	N
ATOM	2425	CE2	TRP	H	36	19.611	-2.056	3.661	1.00	55.76	C
ATOM	2426	CE3	TRP	H	36	20.664	-0.219	4.837	1.00	54.02	C
ATOM	2427	CZ2	TRP	H	36	18.345	-1.650	4.075	1.00	55.32	C
ATOM	2428	CZ3	TRP	H	36	19.404	0.183	5.249	1.00	55.26	C
ATOM	2429	CH2	TRP	H	36	18.266	-0.537	4.887	1.00	55.85	C
ATOM	2430	N	VAL	H	37	25.192	1.191	2.912	1.00	51.87	N
ATOM	2431	CA	VAL	H	37	26.370	2.012	3.168	1.00	49.53	C
ATOM	2432	C	VAL	H	37	26.251	2.587	4.580	1.00	55.24	C
ATOM	2433	O	VAL	H	37	25.180	3.074	4.971	1.00	56.25	O
ATOM	2434	CB	VAL	H	37	26.501	3.134	2.098	1.00	51.25	C
ATOM	2435	CG1	VAL	H	37	27.745	3.991	2.319	1.00	49.80	C
ATOM	2436	CG2	VAL	H	37	26.479	2.553	0.682	1.00	50.75	C
ATOM	2437	N	ARG	H	38	27.357	2.516	5.341	1.00	51.89	N
ATOM	2438	CA	ARG	H	38	27.479	3.048	6.698	1.00	51.31	C
ATOM	2439	C	ARG	H	38	28.301	4.323	6.685	1.00	55.75	C
ATOM	2440	O	ARG	H	38	29.363	4.389	6.037	1.00	55.51	O
ATOM	2441	CB	ARG	H	38	28.137	2.020	7.656	1.00	50.27	C
ATOM	2442	CG	ARG	H	38	28.292	2.516	9.104	1.00	50.25	C
ATOM	2443	CD	ARG	H	38	28.785	1.469	10.061	1.00	53.59	C
ATOM	2444	NE	ARG	H	38	30.222	1.203	9.938	1.00	59.32	N
ATOM	2445	CZ	ARG	H	38	30.904	0.404	10.760	1.00	72.57	C
ATOM	2446	NH1	ARG	H	38	30.286	-0.208	11.773	1.00	60.22	N
ATOM	2447	NH2	ARG	H	38	32.205	0.208	10.576	1.00	53.44	N
ATOM	2448	N	GLN	H	39	27.829	5.307	7.470	1.00	51.93	N
ATOM	2449	CA	GLN	H	39	28.522	6.564	7.661	1.00	52.00	C
ATOM	2450	C	GLN	H	39	28.567	6.896	9.152	1.00	61.29	C
ATOM	2451	O	GLN	H	39	27.618	7.481	9.706	1.00	62.88	O
ATOM	2452	CB	GLN	H	39	27.879	7.681	6.831	1.00	52.11	C
ATOM	2453	CG	GLN	H	39	28.608	9.006	6.962	1.00	43.61	C
ATOM	2454	CD	GLN	H	39	28.047	10.086	6.094	1.00	59.96	C
ATOM	2455	OE1	GLN	H	39	26.848	10.383	6.113	1.00	56.09	O
ATOM	2456	NE2	GLN	H	39	28.924	10.758	5.383	1.00	50.75	N
ATOM	2457	N	MET	H	40	29.675	6.527	9.799	1.00	59.50	N
ATOM	2458	CA	MET	H	40	29.901	6.807	11.220	1.00	61.32	C
ATOM	2459	C	MET	H	40	29.869	8.318	11.482	1.00	64.80	C
ATOM	2460	O	MET	H	40	30.218	9.075	10.578	1.00	64.20	O
ATOM	2461	CB	MET	H	40	31.258	6.264	11.655	1.00	65.13	C
ATOM	2462	CG	MET	H	40	31.505	4.878	11.201	1.00	71.02	C
ATOM	2463	SD	MET	H	40	31.765	3.838	12.628	1.00	77.86	S
ATOM	2464	CE	MET	H	40	33.483	3.232	12.241	1.00	74.91	C
ATOM	2465	N	PRO	H	41	29.495	8.798	12.692	1.00	60.82	N
ATOM	2466	CA	PRO	H	41	29.471	10.249	12.925	1.00	59.95	C
ATOM	2467	C	PRO	H	41	30.777	10.967	12.605	1.00	64.00	C
ATOM	2468	O	PRO	H	41	31.866	10.566	13.056	1.00	63.16	O
ATOM	2469	CB	PRO	H	41	29.076	10.358	14.391	1.00	61.50	C
ATOM	2470	CG	PRO	H	41	28.335	9.092	14.668	1.00	65.78	C
ATOM	2471	CD	PRO	H	41	29.092	8.069	13.908	1.00	61.71	C
ATOM	2472	N	GLY	H	42	30.643	11.967	11.733	1.00	61.01	N
ATOM	2473	CA	GLY	H	42	31.735	12.808	11.249	1.00	60.46	C
ATOM	2474	C	GLY	H	42	32.790	12.131	10.394	1.00	62.34	C
ATOM	2475	O	GLY	H	42	33.863	12.697	10.181	1.00	62.89	O
ATOM	2476	N	LYS	H	43	32.501	10.917	9.910	1.00	57.21	N
ATOM	2477	CA	LYS	H	43	33.393	10.127	9.064	1.00	55.28	C
ATOM	2478	C	LYS	H	43	32.757	10.019	7.654	1.00	57.04	C
ATOM	2479	O	LYS	H	43	31.705	10.628	7.396	1.00	53.08	O
ATOM	2480	CB	LYS	H	43	33.698	8.751	9.726	1.00	55.93	C
ATOM	2481	N	GLY	H	44	33.417	9.274	6.760	1.00	56.02	N
ATOM	2482	CA	GLY	H	44	32.989	9.099	5.372	1.00	55.82	C
ATOM	2483	C	GLY	H	44	32.047	7.943	5.128	1.00	58.04	C
ATOM	2484	O	GLY	H	44	31.316	7.550	6.030	1.00	59.70	O
ATOM	2485	N	LEU	H	45	32.070	7.377	3.911	1.00	51.28	N
ATOM	2486	CA	LEU	H	45	31.171	6.286	3.517	1.00	48.71	C
ATOM	2487	C	LEU	H	45	31.873	4.933	3.445	1.00	54.84	C
ATOM	2488	O	LEU	H	45	32.986	4.829	2.900	1.00	54.23	O
ATOM	2489	CB	LEU	H	45	30.469	6.608	2.176	1.00	46.95	C
ATOM	2490	CG	LEU	H	45	29.746	7.963	2.059	1.00	48.50	C
ATOM	2491	CD1	LEU	H	45	29.328	8.237	0.624	1.00	46.80	C
ATOM	2492	CD2	LEU	H	45	28.564	8.079	3.023	1.00	47.06	C
ATOM	2493	N	GLU	H	46	31.224	3.898	4.028	1.00	52.47	N
ATOM	2494	CA	GLU	H	46	31.732	2.525	4.047	1.00	53.12	C
ATOM	2495	C	GLU	H	46	30.701	1.608	3.429	1.00	56.86	C
ATOM	2496	O	GLU	H	46	29.576	1.527	3.936	1.00	56.42	O
ATOM	2497	CB	GLU	H	46	31.984	2.026	5.490	1.00	55.08	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.											
ATOM	2498	CG	GLU	H	46	33.140	2.640	6.256	1.00	67.11	C
ATOM	2499	CD	GLU	H	46	32.983	2.385	7.743	1.00	89.57	C
ATOM	2500	OE1	GLU	H	46	32.098	3.016	8.364	1.00	87.79	O
ATOM	2501	OE2	GLU	H	46	33.691	1.498	8.271	1.00	81.48	O
ATOM	2502	N	TRP	H	47	31.083	0.865	2.375	1.00	53.24	N
ATOM	2503	CA	TRP	H	47	30.141	-0.102	1.808	1.00	52.30	C
ATOM	2504	C	TRP	H	47	30.090	-1.385	2.690	1.00	56.24	C
ATOM	2505	O	TRP	H	47	31.138	-1.940	3.072	1.00	55.85	O
ATOM	2506	CB	TRP	H	47	30.453	-0.395	0.333	1.00	50.57	C
ATOM	2507	CG	TRP	H	47	29.639	-1.515	-0.245	1.00	51.38	C
ATOM	2508	CD1	TRP	H	47	28.318	-1.486	-0.581	1.00	54.23	C
ATOM	2509	CD2	TRP	H	47	30.095	-2.847	-0.514	1.00	51.35	C
ATOM	2510	NE1	TRP	H	47	27.918	-2.723	-1.037	1.00	53.85	N
ATOM	2511	CE2	TRP	H	47	28.988	-3.581	-0.995	1.00	55.80	C
ATOM	2512	CE3	TRP	H	47	31.324	-3.504	-0.357	1.00	52.98	C
ATOM	2513	CZ2	TRP	H	47	29.078	-4.947	-1.323	1.00	55.73	C
ATOM	2514	CZ3	TRP	H	47	31.413	-4.850	-0.687	1.00	54.99	C
ATOM	2515	CH2	TRP	H	47	30.309	-5.551	-1.192	1.00	55.79	C
ATOM	2516	N	MET	H	48	28.857	-1.819	3.022	1.00	51.19	N
ATOM	2517	CA	MET	H	48	28.566	-2.978	3.859	1.00	49.51	C
ATOM	2518	C	MET	H	48	28.257	-4.212	3.031	1.00	54.55	C
ATOM	2519	O	MET	H	48	28.913	-5.239	3.225	1.00	55.50	O
ATOM	2520	CB	MET	H	48	27.394	-2.675	4.814	1.00	51.28	C
ATOM	2521	CG	MET	H	48	27.659	-1.535	5.759	1.00	54.07	C
ATOM	2522	SD	MET	H	48	26.240	-1.136	6.789	1.00	57.69	S
ATOM	2523	CE	MET	H	48	26.269	-2.410	7.920	1.00	54.01	C
ATOM	2524	N	GLY	H	49	27.261	-4.104	2.143	1.00	51.30	N
ATOM	2525	CA	GLY	H	49	26.807	-5.183	1.274	1.00	51.77	C
ATOM	2526	C	GLY	H	49	25.760	-4.765	0.266	1.00	59.10	C
ATOM	2527	O	GLY	H	49	25.304	-3.619	0.298	1.00	60.65	O
ATOM	2528	N	ILE	H	50	25.418	-5.679	-0.682	1.00	55.41	N
ATOM	2529	CA	ILE	H	50	24.382	-5.520	-1.741	1.00	54.25	C
ATOM	2530	C	ILE	H	50	23.522	-6.754	-1.707	1.00	55.49	C
ATOM	2531	O	ILE	H	50	23.985	-7.823	-1.315	1.00	54.59	O
ATOM	2532	CB	ILE	H	50	24.898	-5.405	-3.216	1.00	56.97	C
ATOM	2533	CG1	ILE	H	50	26.309	-5.869	-3.337	1.00	59.41	C
ATOM	2534	CG2	ILE	H	50	24.699	-4.056	-3.873	1.00	55.22	C
ATOM	2535	CD1	ILE	H	50	26.430	-7.316	-3.666	1.00	78.35	C
ATOM	2536	N	PHE	H	51	22.346	-6.643	-2.305	1.00	50.94	N
ATOM	2537	CA	PHE	H	51	21.419	-7.736	-2.451	1.00	50.64	C
ATOM	2538	C	PHE	H	51	20.737	-7.656	-3.831	1.00	55.90	C
ATOM	2539	O	PHE	H	51	20.255	-6.586	-4.189	1.00	56.60	O
ATOM	2540	CB	PHE	H	51	20.373	-7.610	-1.332	1.00	52.20	C
ATOM	2541	CG	PHE	H	51	19.392	-8.749	-1.239	1.00	53.05	C
ATOM	2542	CD1	PHE	H	51	18.193	-8.714	-1.937	1.00	54.41	C
ATOM	2543	CD2	PHE	H	51	19.650	-9.841	-0.424	1.00	55.24	C
ATOM	2544	CE1	PHE	H	51	17.299	-9.765	-1.854	1.00	55.14	C
ATOM	2545	CE2	PHE	H	51	18.747	-10.900	-0.343	1.00	57.19	C
ATOM	2546	CZ	PHE	H	51	17.574	-10.847	-1.049	1.00	54.62	C
ATOM	2547	N	TYR	H	52	20.627	-8.775	-4.571	1.00	52.26	N
ATOM	2548	CA	TYR	H	52	19.871	-8.778	-5.826	1.00	52.78	C
ATOM	2549	C	TYR	H	52	18.499	-9.389	-5.534	1.00	61.77	C
ATOM	2550	O	TYR	H	52	18.454	-10.593	-5.302	1.00	64.26	O
ATOM	2551	CB	TYR	H	52	20.577	-9.578	-6.952	1.00	53.66	C
ATOM	2552	CG	TYR	H	52	19.887	-9.413	-8.293	1.00	55.12	C
ATOM	2553	CD1	TYR	H	52	19.063	-8.319	-8.545	1.00	57.69	C
ATOM	2554	CD2	TYR	H	52	20.058	-10.346	-9.312	1.00	55.14	C
ATOM	2555	CE1	TYR	H	52	18.389	-8.181	-9.753	1.00	59.82	C
ATOM	2556	CE2	TYR	H	52	19.372	-10.226	-10.524	1.00	55.70	C
ATOM	2557	CZ	TYR	H	52	18.542	-9.134	-10.740	1.00	65.25	C
ATOM	2558	OH	TYR	H	52	17.888	-8.921	-11.928	1.00	67.27	O
ATOM	2559	N	PRO	H	53	17.366	-8.648	-5.525	1.00	59.45	N
ATOM	2560	CA	PRO	H	53	16.087	-9.286	-5.173	1.00	59.33	C
ATOM	2561	C	PRO	H	53	15.568	-10.339	-6.152	1.00	67.52	C
ATOM	2562	O	PRO	H	53	14.889	-11.275	-5.739	1.00	69.35	O
ATOM	2563	CB	PRO	H	53	15.121	-8.115	-5.040	1.00	60.33	C
ATOM	2564	CG	PRO	H	53	15.950	-6.920	-4.943	1.00	65.07	C
ATOM	2565	CD	PRO	H	53	17.187	-7.202	-5.716	1.00	61.24	C
ATOM	2566	O	GLY	H	54	15.624	-13.419	-9.172	1.00	70.10	O
ATOM	2567	N	GLY	H	54	15.891	-10.213	-7.425	1.00	64.49	N
ATOM	2568	CA	GLY	H	54	15.397	-11.179	-8.400	1.00	64.95	C
ATOM	2569	C	GLY	H	54	16.051	-12.545	-8.414	1.00	69.41	C
ATOM	2570	N	ASP	H	55	17.042	-12.756	-7.541	1.00	65.90	N
ATOM	2571	CA	ASP	H	55	17.928	-13.918	-7.457	1.00	65.98	C
ATOM	2572	C	ASP	H	55	18.178	-14.317	-5.987	1.00	72.33	C
ATOM	2573	O	ASP	H	55	18.671	-15.417	-5.707	1.00	72.95	O
ATOM	2574	CB	ASP	H	55	19.275	-13.422	-8.019	1.00	67.86	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.											
ATOM	2575	CG	ASP	H	55	20.245	-14.412	-8.612	1.00	88.21	C
ATOM	2576	OD1	ASP	H	55	19.926	-15.623	-8.634	1.00	92.27	O
ATOM	2577	OD2	ASP	H	55	21.318	-13.968	-9.103	1.00	94.99	O
ATOM	2578	N	SER	H	56	17.941	-13.358	-5.065	1.00	68.85	N
ATOM	2579	CA	SER	H	56	18.182	-13.436	-3.632	1.00	68.85	C
ATOM	2580	C	SER	H	56	19.688	-13.578	-3.305	1.00	70.75	C
ATOM	2581	O	SER	H	56	20.043	-13.877	-2.159	1.00	71.61	O
ATOM	2582	CB	SER	H	56	17.314	-14.502	-2.955	1.00	75.57	C
ATOM	2583	OG	SER	H	56	17.719	-15.829	-3.251	1.00	91.78	O
ATOM	2584	N	SER	H	57	20.578	-13.292	-4.288	1.00	64.86	N
ATOM	2585	CA	SER	H	57	22.019	-13.346	-4.037	1.00	63.11	C
ATOM	2586	C	SER	H	57	22.478	-12.123	-3.285	1.00	66.50	C
ATOM	2587	O	SER	H	57	22.041	-10.999	-3.548	1.00	67.19	O
ATOM	2588	CB	SER	H	57	22.855	-13.580	-5.295	1.00	62.90	C
ATOM	2589	OG	SER	H	57	22.193	-13.245	-6.495	1.00	66.77	O
ATOM	2590	N	THR	H	58	23.305	-12.360	-2.287	1.00	61.53	N
ATOM	2591	CA	THR	H	58	23.832	-11.311	-1.435	1.00	60.91	C
ATOM	2592	C	THR	H	58	25.350	-11.429	-1.430	1.00	64.49	C
ATOM	2593	O	THR	H	58	25.858	-12.534	-1.600	1.00	65.49	O
ATOM	2594	CB	THR	H	58	23.173	-11.329	-0.029	1.00	67.27	C
ATOM	2595	OG1	THR	H	58	24.161	-11.548	0.976	1.00	74.17	O
ATOM	2596	CG2	THR	H	58	22.068	-12.374	0.130	1.00	61.48	C
ATOM	2597	N	ARG	H	59	26.070	-10.299	-1.295	1.00	59.51	N
ATOM	2598	CA	ARG	H	59	27.538	-10.247	-1.217	1.00	59.08	C
ATOM	2599	C	ARG	H	59	27.913	-9.134	-0.241	1.00	63.75	C
ATOM	2600	O	ARG	H	59	27.375	-8.030	-0.342	1.00	65.31	O
ATOM	2601	CB	ARG	H	59	28.254	-10.070	-2.588	1.00	56.56	C
ATOM	2602	CG	ARG	H	59	27.836	-10.964	-3.771	1.00	61.15	C
ATOM	2603	CD	ARG	H	59	28.314	-12.422	-3.818	1.00	64.78	C
ATOM	2604	NE	ARG	H	59	27.883	-13.056	-5.066	1.00	72.85	N
ATOM	2605	CZ	ARG	H	59	27.029	-14.075	-5.168	1.00	97.07	C
ATOM	2606	NH1	ARG	H	59	26.421	-14.554	-4.089	1.00	86.62	N
ATOM	2607	NH2	ARG	H	59	26.683	-14.539	-6.361	1.00	93.15	N
ATOM	2608	N	TYR	H	60	28.794	-9.434	0.721	1.00	58.80	N
ATOM	2609	CA	TYR	H	60	29.175	-8.503	1.778	1.00	58.15	C
ATOM	2610	C	TYR	H	60	30.574	-8.003	1.644	1.00	64.40	C
ATOM	2611	O	TYR	H	60	31.367	-8.561	0.884	1.00	64.95	O
ATOM	2612	CB	TYR	H	60	29.052	-9.185	3.144	1.00	58.41	C
ATOM	2613	CG	TYR	H	60	27.660	-9.657	3.478	1.00	59.47	C
ATOM	2614	CD1	TYR	H	60	26.706	-8.775	3.985	1.00	61.16	C
ATOM	2615	CD2	TYR	H	60	27.302	-10.995	3.331	1.00	59.67	C
ATOM	2616	CE1	TYR	H	60	25.424	-9.212	4.328	1.00	61.11	C
ATOM	2617	CE2	TYR	H	60	26.014	-11.440	3.650	1.00	60.32	C
ATOM	2618	CZ	TYR	H	60	25.079	-10.543	4.150	1.00	66.87	C
ATOM	2619	OH	TYR	H	60	23.811	-10.962	4.457	1.00	64.63	O
ATOM	2620	N	SER	H	61	30.890	-6.950	2.410	1.00	61.78	N
ATOM	2621	CA	SER	H	61	32.240	-6.432	2.513	1.00	62.68	C
ATOM	2622	C	SER	H	61	32.901	-7.370	3.512	1.00	70.07	C
ATOM	2623	O	SER	H	61	32.273	-7.661	4.535	1.00	71.48	O
ATOM	2624	CB	SER	H	61	32.228	-5.021	3.085	1.00	66.24	C
ATOM	2625	OG	SER	H	61	33.534	-4.481	3.193	1.00	71.95	O
ATOM	2626	N	PRO	H	62	34.126	-7.885	3.267	1.00	66.67	N
ATOM	2627	CA	PRO	H	62	34.754	-8.777	4.262	1.00	66.83	C
ATOM	2628	C	PRO	H	62	34.744	-8.223	5.698	1.00	72.86	C
ATOM	2629	O	PRO	H	62	34.664	-8.999	6.657	1.00	75.15	O
ATOM	2630	CB	PRO	H	62	36.165	-9.009	3.716	1.00	68.15	C
ATOM	2631	CG	PRO	H	62	36.342	-8.040	2.626	1.00	72.46	C
ATOM	2632	CD	PRO	H	62	35.005	-7.672	2.106	1.00	67.89	C
ATOM	2633	N	SER	H	63	34.718	-6.887	5.837	1.00	67.24	N
ATOM	2634	CA	SER	H	63	34.651	-6.192	7.121	1.00	66.52	C
ATOM	2635	C	SER	H	63	33.244	-6.223	7.801	1.00	68.13	C
ATOM	2636	O	SER	H	63	33.131	-5.919	8.989	1.00	67.98	O
ATOM	2637	CB	SER	H	63	35.153	-4.764	6.960	1.00	71.41	C
ATOM	2638	OG	SER	H	63	34.513	-4.143	5.856	1.00	85.45	O
ATOM	2639	N	PHE	H	64	32.191	-6.590	7.058	1.00	62.90	N
ATOM	2640	CA	PHE	H	64	30.810	-6.691	7.565	1.00	61.82	C
ATOM	2641	C	PHE	H	64	30.241	-8.132	7.520	1.00	65.04	C
ATOM	2642	O	PHE	H	64	29.173	-8.408	8.076	1.00	62.75	O
ATOM	2643	CB	PHE	H	64	29.889	-5.694	6.845	1.00	62.66	C
ATOM	2644	CG	PHE	H	64	30.190	-4.258	7.206	1.00	62.68	C
ATOM	2645	CD2	PHE	H	64	29.542	-3.642	8.270	1.00	62.88	C
ATOM	2646	CD1	PHE	H	64	31.126	-3.524	6.487	1.00	63.96	C
ATOM	2647	CE2	PHE	H	64	29.830	-2.323	8.611	1.00	64.49	C
ATOM	2648	CE1	PHE	H	64	31.413	-2.205	6.835	1.00	63.26	C
ATOM	2649	CZ	PHE	H	64	30.768	-1.618	7.897	1.00	61.65	C
ATOM	2650	N	GLN	H	65	31.003	-9.042	6.895	1.00	63.04	N
ATOM	2651	CA	GLN	H	65	30.706	-10.460	6.768	1.00	63.66	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab - <i>C. difficile</i> toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	2652	C	GLN	H	65	30.537	-11.073	8.164
ATOM	2653	O	GLN	H	65	31.476	-11.049	8.971
ATOM	2654	CB	GLN	H	65	31.851	-11.151	5.993
ATOM	2655	CG	GLN	H	65	31.544	-12.568	5.523
ATOM	2656	CD	GLN	H	65	30.409	-12.643	4.533
ATOM	2657	OE1	GLN	H	65	29.301	-13.061	4.879
ATOM	2658	NE2	GLN	H	65	30.670	-12.252	3.281
ATOM	2659	N	GLY	H	66	29.328	-11.552	8.448
ATOM	2660	CA	GLY	H	66	29.002	-12.164	9.736
ATOM	2661	C	GLY	H	66	28.348	-11.241	10.749
ATOM	2662	O	GLY	H	66	27.380	-11.632	11.405
ATOM	2663	N	GLN	H	67	28.862	-9.998	10.866
ATOM	2664	CA	GLN	H	67	28.392	-8.948	11.789
ATOM	2665	C	GLN	H	67	26.958	-8.442	11.528
ATOM	2666	O	GLN	H	67	26.299	-7.923	12.444
ATOM	2667	CB	GLN	H	67	29.381	-7.761	11.812
ATOM	2668	CG	GLN	H	67	30.613	-7.991	12.692
ATOM	2669	CD	GLN	H	67	31.752	-8.628	11.945
ATOM	2670	OE1	GLN	H	67	32.648	-7.945	11.429
ATOM	2671	NE2	GLN	H	67	31.760	-9.951	11.893
ATOM	2672	N	VAL	H	68	26.483	-8.594	10.285
ATOM	2673	CA	VAL	H	68	25.163	-8.116	9.840
ATOM	2674	C	VAL	H	68	24.595	-9.072	8.764
ATOM	2675	O	VAL	H	68	25.365	-9.856	8.199
ATOM	2676	CB	VAL	H	68	25.356	-6.634	9.334
ATOM	2677	CG1	VAL	H	68	25.635	-6.533	7.835
ATOM	2678	CG2	VAL	H	68	24.207	-5.745	9.742
ATOM	2679	N	THR	H	69	23.264	-9.041	8.494
ATOM	2680	CA	THR	H	69	22.678	-9.843	7.385
ATOM	2681	C	THR	H	69	21.687	-8.984	6.578
ATOM	2682	O	THR	H	69	20.882	-8.246	7.158
ATOM	2683	CB	THR	H	69	22.091	-11.270	7.745
ATOM	2684	OG1	THR	H	69	20.793	-11.173	8.338
ATOM	2685	CG2	THR	H	69	23.020	-12.145	8.609
ATOM	2686	N	ILE	H	70	21.769	-9.084	5.238
ATOM	2687	CA	ILE	H	70	20.895	-8.365	4.305
ATOM	2688	C	ILE	H	70	19.870	-9.335	3.687
ATOM	2689	O	ILE	H	70	20.199	-10.458	3.298
ATOM	2690	CB	ILE	H	70	21.683	-7.522	3.260
ATOM	2691	CG1	ILE	H	70	22.740	-6.639	3.950
ATOM	2692	CG2	ILE	H	70	20.732	-6.659	2.408
ATOM	2693	CD1	ILE	H	70	23.706	-5.934	3.032
ATOM	2694	N	SER	H	71	18.623	-8.910	3.659
ATOM	2695	CA	SER	H	71	17.513	-9.707	3.182
ATOM	2696	C	SER	H	71	16.553	-8.761	2.533
ATOM	2697	O	SER	H	71	16.791	-7.548	2.541
ATOM	2698	CB	SER	H	71	16.828	-10.377	4.368
ATOM	2699	OG	SER	H	71	16.503	-9.432	5.378
ATOM	2700	N	ALA	H	72	15.472	-9.303	1.954
ATOM	2701	CA	ALA	H	72	14.458	-8.470	1.347
ATOM	2702	C	ALA	H	72	13.091	-9.101	1.225
ATOM	2703	O	ALA	H	72	12.908	-10.304	1.288
ATOM	2704	CB	ALA	H	72	14.911	-7.955	-0.013
ATOM	2705	N	ASP	H	73	12.145	-8.189	1.204
ATOM	2706	CA	ASP	H	73	10.754	-8.079	0.844
ATOM	2707	C	ASP	H	73	9.951	-9.262	0.662
ATOM	2708	O	ASP	H	73	10.169	-9.994	-0.321
ATOM	2709	CB	ASP	H	73	10.686	-7.353	-0.495
ATOM	2710	N	LYS	H	74	8.841	-9.307	1.450
ATOM	2711	CA	LYS	H	74	7.728	-10.244	1.274
ATOM	2712	C	LYS	H	74	6.974	-9.688	-0.014
ATOM	2713	O	LYS	H	74	5.834	-10.048	-0.331
ATOM	2714	CB	LYS	H	74	6.826	-10.197	2.525
ATOM	2715	N	SER	H	75	7.705	-8.774	-0.717
ATOM	2716	CA	SER	H	75	7.452	-7.959	-1.889
ATOM	2717	C	SER	H	75	5.988	-7.502	-1.875
ATOM	2718	O	SER	H	75	5.155	-8.270	-2.317
ATOM	2719	CB	SER	H	75	7.951	-8.650	-3.155
ATOM	2720	OG	SER	H	75	9.320	-9.026	-3.009
ATOM	2721	N	VAL	H	76	5.611	-6.361	-1.187
ATOM	2722	CA	VAL	H	76	6.339	-5.221	-0.526
ATOM	2723	C	VAL	H	76	7.784	-5.052	-0.977
ATOM	2724	O	VAL	H	76	8.632	-5.845	-0.599
ATOM	2725	CB	VAL	H	76	6.266	-5.162	1.023
ATOM	2726	CG1	VAL	H	76	4.931	-4.596	1.478
ATOM	2727	CG2	VAL	H	76	6.558	-6.507	1.681
ATOM	2728	N	ASN	H	77	8.067	-4.032	-1.781

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	2729	CA	ASN	H	77	9.408	-3.797	-2.311	1.00	66.86	C
ATOM	2730	C	ASN	H	77	10.298	-3.243	-1.188	1.00	66.33	C
ATOM	2731	O	ASN	H	77	10.584	-2.050	-1.183	1.00	66.18	O
ATOM	2732	CB	ASN	H	77	9.312	-2.784	-3.437	1.00	65.77	C
ATOM	2733	CG	ASN	H	77	8.323	-3.041	-4.539	1.00	80.85	C
ATOM	2734	OD1	ASN	H	77	7.832	-2.089	-5.159	1.00	85.12	O
ATOM	2735	ND2	ASN	H	77	8.133	-4.293	-4.921	1.00	63.18	N
ATOM	2736	N	THR	H	78	10.739	-4.098	-0.252	1.00	59.82	N
ATOM	2737	CA	THR	H	78	11.460	-3.677	0.943	1.00	59.85	C
ATOM	2738	C	THR	H	78	12.766	-4.412	1.212	1.00	64.29	C
ATOM	2739	O	THR	H	78	12.760	-5.623	1.347	1.00	62.62	O
ATOM	2740	CB	THR	H	78	10.520	-3.786	2.169	1.00	67.62	C
ATOM	2741	OG1	THR	H	78	9.257	-3.209	1.846	1.00	72.02	O
ATOM	2742	CG2	THR	H	78	11.074	-3.109	3.401	1.00	62.57	C
ATOM	2743	N	ALA	H	79	13.882	-3.665	1.377	1.00	60.90	N
ATOM	2744	CA	ALA	H	79	15.157	-4.292	1.721	1.00	60.00	C
ATOM	2745	C	ALA	H	79	15.382	-4.167	3.228	1.00	61.88	C
ATOM	2746	O	ALA	H	79	14.929	-3.197	3.847	1.00	60.57	O
ATOM	2747	CB	ALA	H	79	16.296	-3.653	0.951	1.00	60.60	C
ATOM	2748	N	TYR	H	80	16.092	-5.147	3.813	1.00	57.35	N
ATOM	2749	CA	TYR	H	80	16.364	-5.172	5.245	1.00	56.14	C
ATOM	2750	C	TYR	H	80	17.854	-5.303	5.616	1.00	57.58	C
ATOM	2751	O	TYR	H	80	18.601	-6.028	4.966	1.00	55.12	O
ATOM	2752	CB	TYR	H	80	15.534	-6.285	5.936	1.00	57.24	C
ATOM	2753	CG	TYR	H	80	14.025	-6.150	5.780	1.00	59.46	C
ATOM	2754	CD1	TYR	H	80	13.304	-5.239	6.545	1.00	61.18	C
ATOM	2755	CD2	TYR	H	80	13.315	-6.966	4.902	1.00	60.81	C
ATOM	2756	CE1	TYR	H	80	11.920	-5.110	6.414	1.00	60.32	C
ATOM	2757	CE2	TYR	H	80	11.926	-6.854	4.768	1.00	61.96	C
ATOM	2758	CZ	TYR	H	80	11.232	-5.922	5.530	1.00	69.32	C
ATOM	2759	OH	TYR	H	80	9.867	-5.768	5.410	1.00	69.55	O
ATOM	2760	N	LEU	H	81	18.264	-4.601	6.690	1.00	54.99	N
ATOM	2761	CA	LEU	H	81	19.584	-4.696	7.312	1.00	54.90	C
ATOM	2762	C	LEU	H	81	19.346	-5.062	8.766	1.00	60.74	C
ATOM	2763	O	LEU	H	81	18.605	-4.359	9.452	1.00	59.61	O
ATOM	2764	CB	LEU	H	81	20.375	-3.386	7.222	1.00	54.90	C
ATOM	2765	CG	LEU	H	81	21.837	-3.443	7.690	1.00	57.77	C
ATOM	2766	CD1	LEU	H	81	22.673	-4.302	6.772	1.00	58.61	C
ATOM	2767	CD2	LEU	H	81	22.425	-2.093	7.706	1.00	55.35	C
ATOM	2768	N	GLN	H	82	19.937	-6.165	9.235	1.00	61.13	N
ATOM	2769	CA	GLN	H	82	19.699	-6.582	10.610	1.00	63.15	C
ATOM	2770	C	GLN	H	82	20.955	-7.069	11.351	1.00	71.51	C
ATOM	2771	O	GLN	H	82	21.883	-7.637	10.752	1.00	71.27	O
ATOM	2772	CB	GLN	H	82	18.547	-7.612	10.724	1.00	64.76	C
ATOM	2773	CG	GLN	H	82	18.800	-8.973	10.070	1.00	89.64	C
ATOM	2774	CD	GLN	H	82	18.028	-10.067	10.760	1.00	108.55	C
ATOM	2775	OE1	GLN	H	82	18.530	-10.721	11.689	1.00	109.00	O
ATOM	2776	NE2	GLN	H	82	16.797	-10.294	10.310	1.00	90.25	N
ATOM	2777	N	TRP	H	83	20.958	-6.810	12.673	1.00	70.63	N
ATOM	2778	CA	TRP	H	83	22.002	-7.182	13.621	1.00	71.87	C
ATOM	2779	C	TRP	H	83	21.386	-8.066	14.708	1.00	80.04	C
ATOM	2780	O	TRP	H	83	20.257	-7.824	15.162	1.00	79.90	O
ATOM	2781	CB	TRP	H	83	22.587	-5.932	14.336	1.00	69.80	C
ATOM	2782	CG	TRP	H	83	23.252	-4.909	13.463	1.00	70.04	C
ATOM	2783	CD1	TRP	H	83	24.591	-4.765	13.233	1.00	72.80	C
ATOM	2784	CD2	TRP	H	83	22.611	-3.822	12.788	1.00	69.67	C
ATOM	2785	NE1	TRP	H	83	24.817	-3.674	12.419	1.00	71.75	N
ATOM	2786	CE2	TRP	H	83	23.617	-3.084	12.126	1.00	72.76	C
ATOM	2787	CE3	TRP	H	83	21.269	-3.415	12.652	1.00	71.01	C
ATOM	2788	CZ2	TRP	H	83	23.322	-1.983	11.323	1.00	72.02	C
ATOM	2789	CZ3	TRP	H	83	20.980	-2.307	11.879	1.00	72.22	C
ATOM	2790	CH2	TRP	H	83	21.998	-1.601	11.229	1.00	72.92	C
ATOM	2791	N	SER	H	84	22.154	-9.058	15.145	1.00	78.78	N
ATOM	2792	CA	SER	H	84	21.818	-9.923	16.266	1.00	79.55	C
ATOM	2793	C	SER	H	84	22.892	-9.502	17.273	1.00	85.26	C
ATOM	2794	O	SER	H	84	24.087	-9.822	17.073	1.00	86.47	O
ATOM	2795	CB	SER	H	84	21.964	-11.396	15.883	1.00	84.03	C
ATOM	2796	OG	SER	H	84	20.924	-11.822	15.015	1.00	95.49	O
ATOM	2797	N	SER	H	85	22.488	-8.660	18.268	1.00	79.09	N
ATOM	2798	CA	SER	H	85	23.340	-8.040	19.311	1.00	77.27	C
ATOM	2799	C	SER	H	85	24.213	-6.859	18.778	1.00	77.19	C
ATOM	2800	O	SER	H	85	25.351	-7.047	18.316	1.00	75.18	O
ATOM	2801	CB	SER	H	85	24.181	-9.058	20.086	1.00	78.84	C
ATOM	2802	OG	SER	H	85	24.768	-8.480	21.243	1.00	82.84	O
ATOM	2803	N	LEU	H	86	23.637	-5.636	18.892	1.00	72.21	N
ATOM	2804	CA	LEU	H	86	24.193	-4.333	18.509	1.00	71.76	C
ATOM	2805	C	LEU	H	86	25.289	-3.852	19.477	1.00	76.64	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	2806 O	LEU H	86	25.010	-3.685	20.666	1.00	76.71 O
ATOM	2807 CB	LEU H	86	23.075	-3.272	18.531	1.00	71.26 C
ATOM	2808 CG	LEU H	86	22.085	-3.222	17.395	1.00	75.90 C
ATOM	2809 CD1	LEU H	86	20.850	-2.455	17.824	1.00	76.18 C
ATOM	2810 CD2	LEU H	86	22.690	-2.557	16.180	1.00	78.29 C
ATOM	2811 N	LYS H	87	26.517	-3.583	18.969	1.00	72.41 N
ATOM	2812 CA	LYS H	87	27.610	-3.005	19.768	1.00	70.71 C
ATOM	2813 C	LYS H	87	27.382	-1.441	19.768	1.00	74.48 C
ATOM	2814 O	LYS H	87	26.676	-0.937	18.889	1.00	74.24 O
ATOM	2815 CB	LYS H	87	28.984	-3.417	19.178	1.00	70.76 C
ATOM	2816 N	ALA H	88	27.918	-0.685	20.755	1.00	70.72 N
ATOM	2817 CA	ALA H	88	27.765	0.792	20.739	1.00	70.52 C
ATOM	2818 C	ALA H	88	28.508	1.360	19.502	1.00	73.06 C
ATOM	2819 O	ALA H	88	28.102	2.368	18.915	1.00	71.60 O
ATOM	2820 CB	ALA H	88	28.333	1.404	22.009	1.00	71.21 C
ATOM	2821 N	SER H	89	29.563	0.626	19.090	1.00	67.91 N
ATOM	2822 CA	SER H	89	30.421	0.784	17.935	1.00	67.22 C
ATOM	2823 C	SER H	89	29.619	0.891	16.613	1.00	71.98 C
ATOM	2824 O	SER H	89	30.172	1.295	15.593	1.00	73.38 O
ATOM	2825 CB	SER H	89	31.319	-0.443	17.860	1.00	72.28 C
ATOM	2826 OG	SER H	89	32.534	-0.146	17.198	1.00	90.02 O
ATOM	2827 N	ASP H	90	28.339	0.475	16.625	1.00	67.85 N
ATOM	2828 CA	ASP H	90	27.408	0.478	15.492	1.00	66.48 C
ATOM	2829 C	ASP H	90	26.618	1.782	15.391	1.00	68.65 C
ATOM	2830 O	ASP H	90	25.804	1.906	14.465	1.00	68.47 O
ATOM	2831 CB	ASP H	90	26.429	-0.717	15.575	1.00	67.84 C
ATOM	2832 CG	ASP H	90	27.041	-2.110	15.569	1.00	77.99 C
ATOM	2833 OD1	ASP H	90	28.230	-2.253	15.142	1.00	77.78 O
ATOM	2834 OD2	ASP H	90	26.335	-3.066	15.970	1.00	85.82 O
ATOM	2835 N	THR H	91	26.829	2.745	16.344	1.00	63.50 N
ATOM	2836 CA	THR H	91	26.184	4.070	16.308	1.00	62.14 C
ATOM	2837 C	THR H	91	26.731	4.787	15.050	1.00	63.73 C
ATOM	2838 O	THR H	91	27.914	5.153	15.024	1.00	62.31 O
ATOM	2839 CB	THR H	91	26.448	4.867	17.592	1.00	65.24 C
ATOM	2840 OG1	THR H	91	26.072	4.078	18.709	1.00	64.85 O
ATOM	2841 CG2	THR H	91	25.705	6.206	17.624	1.00	60.37 C
ATOM	2842 N	ALA H	92	25.891	4.846	13.971	1.00	58.43 N
ATOM	2843 CA	ALA H	92	26.186	5.406	12.644	1.00	56.37 C
ATOM	2844 C	ALA H	92	24.908	5.644	11.832	1.00	58.35 C
ATOM	2845 O	ALA H	92	23.818	5.247	12.259	1.00	56.99 O
ATOM	2846 CB	ALA H	92	27.094	4.457	11.887	1.00	56.89 C
ATOM	2847 N	MET H	93	25.048	6.322	10.678	1.00	55.58 N
ATOM	2848 CA	MET H	93	23.964	6.584	9.726	1.00	55.97 C
ATOM	2849 C	MET H	93	23.995	5.485	8.716	1.00	59.98 C
ATOM	2850 O	MET H	93	25.077	5.120	8.228	1.00	60.68 O
ATOM	2851 CB	MET H	93	24.150	7.910	9.010	1.00	58.86 C
ATOM	2852 CG	MET H	93	23.171	8.941	9.442	1.00	63.86 C
ATOM	2853 SD	MET H	93	21.581	8.687	8.679	1.00	68.93 S
ATOM	2854 CE	MET H	93	20.775	10.130	9.179	1.00	65.34 C
ATOM	2855 N	TYR H	94	22.829	4.917	8.425	1.00	54.82 N
ATOM	2856 CA	TYR H	94	22.748	3.817	7.482	1.00	52.98 C
ATOM	2857 C	TYR H	94	21.902	4.193	6.315	1.00	55.89 C
ATOM	2858 O	TYR H	94	20.760	4.634	6.468	1.00	53.38 O
ATOM	2859 CB	TYR H	94	22.277	2.521	8.162	1.00	53.06 C
ATOM	2860 CG	TYR H	94	23.258	2.005	9.202	1.00	51.98 C
ATOM	2861 CD1	TYR H	94	24.342	1.217	8.833	1.00	52.51 C
ATOM	2862 CD2	TYR H	94	23.115	2.330	10.551	1.00	51.91 C
ATOM	2863 CE1	TYR H	94	25.257	0.763	9.777	1.00	52.51 C
ATOM	2864 CE2	TYR H	94	24.021	1.865	11.508	1.00	52.16 C
ATOM	2865 CZ	TYR H	94	25.106	1.105	11.113	1.00	56.25 C
ATOM	2866 OH	TYR H	94	26.025	0.670	12.045	1.00	56.69 O
ATOM	2867 N	TYR H	95	22.516	4.092	5.133	1.00	53.56 N
ATOM	2868 CA	TYR H	95	21.888	4.411	3.862	1.00	52.33 C
ATOM	2869 C	TYR H	95	21.728	3.163	3.020	1.00	56.95 C
ATOM	2870 O	TYR H	95	22.621	2.320	2.997	1.00	55.53 O
ATOM	2871 CB	TYR H	95	22.763	5.406	3.086	1.00	52.04 C
ATOM	2872 CG	TYR H	95	22.903	6.775	3.710	1.00	52.21 C
ATOM	2873 CD1	TYR H	95	21.867	7.706	3.636	1.00	53.99 C
ATOM	2874 CD2	TYR H	95	24.108	7.180	4.292	1.00	51.79 C
ATOM	2875 CE1	TYR H	95	22.002	8.978	4.183	1.00	55.27 C
ATOM	2876 CE2	TYR H	95	24.260	8.459	4.823	1.00	52.19 C
ATOM	2877 CZ	TYR H	95	23.206	9.361	4.756	1.00	63.06 C
ATOM	2878 OH	TYR H	95	23.338	10.631	5.276	1.00	68.00 O
ATOM	2879 N	CYS H	96	20.606	3.056	2.311	1.00	55.60 N
ATOM	2880 CA	CYS H	96	20.410	2.015	1.324	1.00	56.73 C
ATOM	2881 C	CYS H	96	20.346	2.796	0.021	1.00	56.54 C
ATOM	2882 O	CYS H	96	19.775	3.886	-0.042	1.00	54.02 O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab - <i>C. difficile</i> toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	2883	CB	CYS H	96	19.137	1.205	1.552	1.00
ATOM	2884	SG	CYS H	96	17.625	2.153	1.265	1.00
ATOM	2885	N	ALA H	97	20.937	2.247	-1.012	1.00
ATOM	2886	CA	ALA H	97	20.941	2.839	-2.324	1.00
ATOM	2887	C	ALA H	97	20.675	1.735	-3.347	1.00
ATOM	2888	O	ALA H	97	21.040	0.583	-3.104	1.00
ATOM	2889	CB	ALA H	97	22.297	3.456	-2.578	1.00
ATOM	2890	N	ARG H	98	20.065	2.051	-4.489	1.00
ATOM	2891	CA	ARG H	98	19.927	0.999	-5.477	1.00
ATOM	2892	C	ARG H	98	20.966	1.213	-6.513	1.00
ATOM	2893	O	ARG H	98	21.307	2.361	-6.785	1.00
ATOM	2894	CB	ARG H	98	18.522	0.825	-6.053	1.00
ATOM	2895	CG	ARG H	98	18.113	1.890	-7.012	1.00
ATOM	2896	CD	ARG H	98	17.599	1.280	-8.258	1.00
ATOM	2897	NE	ARG H	98	17.756	2.262	-9.316	1.00
ATOM	2898	CZ	ARG H	98	16.781	2.625	-10.127	1.00
ATOM	2899	NH1	ARG H	98	15.583	2.068	-10.023	1.00
ATOM	2900	NH2	ARG H	98	16.997	3.537	-11.064	1.00
ATOM	2901	O	ARG H	99	21.089	-0.334	-9.744	1.00
ATOM	2902	N	ARG H	99	21.539	0.106	-7.020	1.00
ATOM	2903	CA	ARG H	99	22.639	0.089	-7.972	1.00
ATOM	2904	C	ARG H	99	22.132	0.218	-9.402	1.00
ATOM	2905	CB	ARG H	99	23.414	-1.227	-7.803	1.00
ATOM	2906	CG	ARG H	99	24.800	-1.254	-8.449	1.00
ATOM	2907	CD	ARG H	99	25.209	-2.638	-8.910	1.00
ATOM	2908	NE	ARG H	99	24.451	-3.067	-10.085	1.00
ATOM	2909	CZ	ARG H	99	24.508	-4.291	-10.594	1.00
ATOM	2910	NH1	ARG H	99	25.285	-5.210	-10.040	1.00
ATOM	2911	NH2	ARG H	99	23.768	-4.614	-11.649	1.00
ATOM	2912	O	ARG H	100	23.880	-0.930	-11.839	1.00
ATOM	2913	N	ARG H	100	22.892	0.922	-10.238	1.00
ATOM	2914	CA	ARG H	100	22.633	1.089	-11.667	1.00
ATOM	2915	C	ARG H	100	22.986	-0.223	-12.338	1.00
ATOM	2916	CB	ARG H	100	23.556	2.162	-12.229	1.00
ATOM	2917	CG	ARG H	100	22.880	3.509	-12.375	1.00
ATOM	2918	CD	ARG H	100	23.698	4.479	-13.189	1.00
ATOM	2919	NE	ARG H	100	23.878	4.031	-14.571	1.00
ATOM	2920	CZ	ARG H	100	23.111	4.393	-15.597	1.00
ATOM	2921	NH1	ARG H	100	22.075	5.209	-15.410	1.00
ATOM	2922	NH2	ARG H	100	23.367	3.937	-16.815	1.00
ATOM	2923	O	ASN H	101	23.929	-2.575	-16.093	1.00
ATOM	2924	N	ASN H	101	22.328	-0.564	-13.467	1.00
ATOM	2925	CA	ASN H	101	22.645	-1.840	-14.135	1.00
ATOM	2926	C	ASN H	101	23.793	-1.717	-15.213	1.00
ATOM	2927	CB	ASN H	101	21.388	-2.523	-14.675	1.00
ATOM	2928	CG	ASN H	101	20.420	-3.054	-13.628	1.00
ATOM	2929	OD1	ASN H	101	20.798	-3.548	-12.530	1.00
ATOM	2930	ND2	ASN H	101	19.130	-2.997	-13.981	1.00
ATOM	2931	O	TRP H	102	25.609	2.000	-15.151	1.00
ATOM	2932	N	TRP H	102	24.674	-0.699	-15.027	1.00
ATOM	2933	CA	TRP H	102	25.924	-0.317	-15.707	1.00
ATOM	2934	C	TRP H	102	26.353	1.028	-15.049	1.00
ATOM	2935	CB	TRP H	102	25.700	-0.121	-17.213	1.00
ATOM	2936	CG	TRP H	102	26.982	-0.021	-17.993	1.00
ATOM	2937	CD1	TRP H	102	27.575	-1.015	-18.731	1.00
ATOM	2938	CD2	TRP H	102	27.900	1.095	-18.007	1.00
ATOM	2939	NE1	TRP H	102	28.800	-0.590	-19.194	1.00
ATOM	2940	CE2	TRP H	102	29.007	0.714	-18.796	1.00
ATOM	2941	CE3	TRP H	102	27.887	2.389	-17.437	1.00
ATOM	2942	CZ2	TRP H	102	30.069	1.589	-19.058	1.00
ATOM	2943	CZ3	TRP H	102	28.954	3.239	-17.667	1.00
ATOM	2944	CH2	TRP H	102	30.023	2.844	-18.481	1.00
ATOM	2945	O	GLY H	103	29.744	1.033	-12.185	1.00
ATOM	2946	N	GLY H	103	27.516	1.167	-14.422	1.00
ATOM	2947	CA	GLY H	103	28.560	0.210	-14.122	1.00
ATOM	2948	C	GLY H	103	28.816	0.355	-12.631	1.00
ATOM	2949	O	ASN H	104	27.676	0.693	-8.355	1.00
ATOM	2950	N	ASN H	104	27.838	-0.115	-11.887	1.00
ATOM	2951	CA	ASN H	104	27.773	-0.328	-10.469	1.00
ATOM	2952	C	ASN H	104	27.691	0.886	-9.569	1.00
ATOM	2953	CB	ASN H	104	28.901	-1.223	-10.046	1.00
ATOM	2954	CG	ASN H	104	28.707	-2.654	-10.494	1.00
ATOM	2955	OD1	ASN H	104	27.653	-3.072	-11.013	1.00
ATOM	2956	ND2	ASN H	104	29.719	-3.442	-10.274	1.00
ATOM	2957	N	ALA H	105	27.454	2.090	-10.101	1.00
ATOM	2958	CA	ALA H	105	27.250	3.267	-9.237	1.00
ATOM	2959	C	ALA H	105	25.881	3.187	-8.565	1.00

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	2960	O	ALA	H	105	25.002	2.520	-9.104	1.00	50.66	O
ATOM	2961	CB	ALA	H	105	27.371	4.539	-10.044	1.00	45.67	C
ATOM	2962	N	PHE	H	106	25.692	3.812	-7.380	1.00	46.97	N
ATOM	2963	CA	PHE	H	106	24.393	3.791	-6.688	1.00	46.47	C
ATOM	2964	C	PHE	H	106	23.676	5.029	-7.079	1.00	51.03	C
ATOM	2965	O	PHE	H	106	24.028	6.103	-6.586	1.00	52.54	O
ATOM	2966	CB	PHE	H	106	24.573	3.732	-5.168	1.00	48.38	C
ATOM	2967	CG	PHE	H	106	25.256	2.471	-4.689	1.00	49.81	C
ATOM	2968	CD1	PHE	H	106	24.666	1.224	-4.883	1.00	50.41	C
ATOM	2969	CD2	PHE	H	106	26.519	2.523	-4.107	1.00	50.74	C
ATOM	2970	CE1	PHE	H	106	25.310	0.059	-4.464	1.00	49.97	C
ATOM	2971	CE2	PHE	H	106	27.166	1.353	-3.705	1.00	52.62	C
ATOM	2972	CZ	PHE	H	106	26.556	0.130	-3.891	1.00	49.76	C
ATOM	2973	N	ASP	H	107	22.703	4.908	-8.000	1.00	47.06	N
ATOM	2974	CA	ASP	H	107	22.003	6.065	-8.555	1.00	47.41	C
ATOM	2975	C	ASP	H	107	20.910	6.680	-7.648	1.00	55.81	C
ATOM	2976	O	ASP	H	107	20.735	7.909	-7.701	1.00	57.59	O
ATOM	2977	CB	ASP	H	107	21.445	5.764	-9.954	1.00	48.51	C
ATOM	2978	CG	ASP	H	107	20.383	4.689	-10.054	1.00	58.36	C
ATOM	2979	OD1	ASP	H	107	20.173	3.966	-9.061	1.00	61.37	O
ATOM	2980	OD2	ASP	H	107	19.763	4.564	-11.137	1.00	61.48	O
ATOM	2981	N	ILE	H	108	20.169	5.863	-6.845	1.00	51.61	N
ATOM	2982	CA	ILE	H	108	19.117	6.391	-5.962	1.00	50.68	C
ATOM	2983	C	ILE	H	108	19.441	6.044	-4.534	1.00	52.42	C
ATOM	2984	O	ILE	H	108	19.818	4.913	-4.286	1.00	51.92	O
ATOM	2985	CB	ILE	H	108	17.676	6.014	-6.406	1.00	53.67	C
ATOM	2986	CG1	ILE	H	108	17.118	7.092	-7.359	1.00	52.54	C
ATOM	2987	CG2	ILE	H	108	16.713	5.847	-5.233	1.00	55.16	C
ATOM	2988	CD1	ILE	H	108	17.330	6.843	-8.722	1.00	56.19	C
ATOM	2989	N	TRP	H	109	19.379	7.048	-3.617	1.00	48.02	N
ATOM	2990	CA	TRP	H	109	19.720	6.892	-2.196	1.00	47.47	C
ATOM	2991	C	TRP	H	109	18.511	7.099	-1.266	1.00	53.80	C
ATOM	2992	O	TRP	H	109	17.601	7.856	-1.586	1.00	55.48	O
ATOM	2993	CB	TRP	H	109	20.903	7.829	-1.793	1.00	44.39	C
ATOM	2994	CG	TRP	H	109	22.235	7.481	-2.403	1.00	44.39	C
ATOM	2995	CD1	TRP	H	109	22.600	7.612	-3.715	1.00	47.24	C
ATOM	2996	CD2	TRP	H	109	23.396	6.980	-1.715	1.00	43.92	C
ATOM	2997	NE1	TRP	H	109	23.915	7.238	-3.890	1.00	46.25	N
ATOM	2998	CE2	TRP	H	109	24.416	6.806	-2.682	1.00	47.79	C
ATOM	2999	CE3	TRP	H	109	23.677	6.644	-0.373	1.00	44.28	C
ATOM	3000	CZ2	TRP	H	109	25.699	6.318	-2.344	1.00	46.31	C
ATOM	3001	CZ3	TRP	H	109	24.940	6.152	-0.052	1.00	44.72	C
ATOM	3002	CH2	TRP	H	109	25.934	6.001	-1.029	1.00	45.00	C
ATOM	3003	N	GLY	H	110	18.520	6.425	-0.129	1.00	50.34	N
ATOM	3004	CA	GLY	H	110	17.496	6.594	0.890	1.00	50.70	C
ATOM	3005	C	GLY	H	110	17.844	7.788	1.754	1.00	56.66	C
ATOM	3006	O	GLY	H	110	18.992	8.232	1.747	1.00	58.25	O
ATOM	3007	N	GLN	H	111	16.873	8.344	2.485	1.00	53.44	N
ATOM	3008	CA	GLN	H	111	17.126	9.507	3.357	1.00	53.30	C
ATOM	3009	C	GLN	H	111	18.123	9.216	4.493	1.00	59.37	C
ATOM	3010	O	GLN	H	111	18.797	10.126	4.968	1.00	61.40	O
ATOM	3011	CB	GLN	H	111	15.811	10.095	3.905	1.00	54.40	C
ATOM	3012	CG	GLN	H	111	15.213	9.393	5.136	1.00	47.13	C
ATOM	3013	CD	GLN	H	111	14.240	8.264	4.865	1.00	64.42	C
ATOM	3014	OE1	GLN	H	111	14.043	7.796	3.738	1.00	62.66	O
ATOM	3015	NE2	GLN	H	111	13.624	7.784	5.922	1.00	62.40	N
ATOM	3016	N	GLY	H	112	18.221	7.952	4.873	1.00	56.18	N
ATOM	3017	CA	GLY	H	112	19.090	7.480	5.932	1.00	56.09	C
ATOM	3018	C	GLY	H	112	18.306	7.101	7.164	1.00	61.49	C
ATOM	3019	O	GLY	H	112	17.174	7.558	7.355	1.00	61.44	O
ATOM	3020	N	THR	H	113	18.898	6.224	7.984	1.00	58.70	N
ATOM	3021	CA	THR	H	113	18.331	5.787	9.252	1.00	58.80	C
ATOM	3022	C	THR	H	113	19.420	5.985	10.308	1.00	63.64	C
ATOM	3023	O	THR	H	113	20.469	5.330	10.219	1.00	63.23	O
ATOM	3024	CB	THR	H	113	17.823	4.324	9.211	1.00	65.82	C
ATOM	3025	OG1	THR	H	113	16.766	4.171	8.257	1.00	69.38	O
ATOM	3026	CG2	THR	H	113	17.347	3.849	10.572	1.00	61.52	C
ATOM	3027	N	MET	H	114	19.179	6.882	11.303	1.00	60.14	N
ATOM	3028	CA	MET	H	114	20.161	7.106	12.353	1.00	59.89	C
ATOM	3029	C	MET	H	114	20.014	6.022	13.374	1.00	65.10	C
ATOM	3030	O	MET	H	114	18.925	5.819	13.908	1.00	66.14	O
ATOM	3031	CB	MET	H	114	20.051	8.515	12.979	1.00	62.50	C
ATOM	3032	CG	MET	H	114	21.186	8.852	13.943	1.00	66.89	C
ATOM	3033	SD	MET	H	114	22.837	8.929	13.167	1.00	72.90	S
ATOM	3034	CE	MET	H	114	23.888	8.121	14.438	1.00	68.92	C
ATOM	3035	N	VAL	H	115	21.093	5.282	13.610	1.00	61.55	N
ATOM	3036	CA	VAL	H	115	21.094	4.198	14.589	1.00	61.01	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody beziotuxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	3037 C	VAL	H	115	22.055	4.570	15.724	1.00	68.25	C
ATOM	3038 O	VAL	H	115	23.281	4.527	15.552	1.00	68.88	O
ATOM	3039 CB	VAL	H	115	21.376	2.811	13.951	1.00	63.65	C
ATOM	3040 CG1	VAL	H	115	21.498	1.720	15.012	1.00	62.84	C
ATOM	3041 CG2	VAL	H	115	20.295	2.449	12.938	1.00	63.40	C
ATOM	3042 N	THR	H	116	21.467	5.004	16.862	1.00	65.55	N
ATOM	3043 CA	THR	H	116	22.152	5.401	18.105	1.00	65.09	C
ATOM	3044 C	THR	H	116	22.114	4.179	19.047	1.00	66.36	C
ATOM	3045 O	THR	H	116	21.013	3.706	19.333	1.00	65.25	O
ATOM	3046 CB	THR	H	116	21.468	6.656	18.723	1.00	70.15	C
ATOM	3047 OG1	THR	H	116	20.847	7.462	17.704	1.00	67.81	O
ATOM	3048 CG2	THR	H	116	22.423	7.498	19.545	1.00	66.81	C
ATOM	3049 N	VAL	H	117	23.302	3.634	19.458	1.00	61.95	N
ATOM	3050 CA	VAL	H	117	23.472	2.448	20.340	1.00	62.42	C
ATOM	3051 C	VAL	H	117	24.314	2.742	21.624	1.00	68.67	C
ATOM	3052 O	VAL	H	117	25.547	2.810	21.543	1.00	68.02	O
ATOM	3053 CB	VAL	H	117	24.058	1.192	19.623	1.00	66.34	C
ATOM	3054 CG1	VAL	H	117	23.986	-0.036	20.533	1.00	66.42	C
ATOM	3055 CG2	VAL	H	117	23.376	0.913	18.290	1.00	66.07	C
ATOM	3056 N	SER	H	118	23.657	2.782	22.810	1.00	66.45	N
ATOM	3057 CA	SER	H	118	24.306	3.052	24.108	1.00	65.78	C
ATOM	3058 C	SER	H	118	23.777	2.191	25.263	1.00	70.89	C
ATOM	3059 O	SER	H	118	22.569	1.911	25.316	1.00	71.47	O
ATOM	3060 CB	SER	H	118	24.085	4.519	24.485	1.00	65.29	C
ATOM	3061 OG	SER	H	118	24.907	4.959	25.555	1.00	68.49	O
ATOM	3062 N	SER	H	119	24.650	1.904	26.266	1.00	66.28	N
ATOM	3063 CA	SER	H	119	24.219	1.259	27.532	1.00	64.79	C
ATOM	3064 C	SER	H	119	23.426	2.272	28.411	1.00	63.69	C
ATOM	3065 O	SER	H	119	22.745	1.874	29.351	1.00	63.41	O
ATOM	3066 CB	SER	H	119	25.419	0.692	28.297	1.00	68.73	C
ATOM	3067 OG	SER	H	119	26.358	1.693	28.659	1.00	79.39	O
ATOM	3068 N	ALA	H	120	23.510	3.572	28.066	1.00	57.76	N
ATOM	3069 CA	ALA	H	120	22.864	4.686	28.742	1.00	56.97	C
ATOM	3070 C	ALA	H	120	21.349	4.650	28.627	1.00	63.07	C
ATOM	3071 O	ALA	H	120	20.804	4.003	27.725	1.00	63.69	O
ATOM	3072 CB	ALA	H	120	23.391	6.005	28.204	1.00	57.12	C
ATOM	3073 N	SER	H	121	20.683	5.391	29.527	1.00	59.50	N
ATOM	3074 CA	SER	H	121	19.240	5.499	29.604	1.00	60.12	C
ATOM	3075 C	SER	H	121	18.842	6.961	29.473	1.00	63.89	C
ATOM	3076 O	SER	H	121	19.634	7.829	29.842	1.00	65.66	O
ATOM	3077 CB	SER	H	121	18.762	4.950	30.946	1.00	66.07	C
ATOM	3078 OG	SER	H	121	19.551	3.838	31.340	1.00	81.48	O
ATOM	3079 N	THR	H	122	17.621	7.233	28.989	1.00	58.12	N
ATOM	3080 CA	THR	H	122	17.087	8.574	28.817	1.00	58.48	C
ATOM	3081 C	THR	H	122	17.198	9.442	30.084	1.00	68.58	C
ATOM	3082 O	THR	H	122	16.421	9.279	31.044	1.00	71.19	O
ATOM	3083 CB	THR	H	122	15.643	8.543	28.293	1.00	60.77	C
ATOM	3084 OG1	THR	H	122	15.516	7.588	27.248	1.00	61.19	O
ATOM	3085 CG2	THR	H	122	15.172	9.903	27.821	1.00	55.16	C
ATOM	3086 N	LYS	H	123	18.194	10.348	30.078	1.00	66.00	N
ATOM	3087 CA	LYS	H	123	18.456	11.334	31.125	1.00	65.83	C
ATOM	3088 C	LYS	H	123	18.253	12.707	30.500	1.00	72.08	C
ATOM	3089 O	LYS	H	123	18.637	12.929	29.352	1.00	72.25	O
ATOM	3090 CB	LYS	H	123	19.873	11.185	31.738	1.00	66.63	C
ATOM	3091 N	GLY	H	124	17.584	13.587	31.223	1.00	70.52	N
ATOM	3092 CA	GLY	H	124	17.344	14.958	30.782	1.00	70.71	C
ATOM	3093 C	GLY	H	124	18.552	15.852	31.021	1.00	75.03	C
ATOM	3094 O	GLY	H	124	19.391	15.555	31.891	1.00	74.65	O
ATOM	3095 N	PRO	H	125	18.660	16.966	30.257	1.00	71.42	N
ATOM	3096 CA	PRO	H	125	19.816	17.870	30.421	1.00	71.26	C
ATOM	3097 C	PRO	H	125	19.812	18.710	31.697	1.00	78.29	C
ATOM	3098 O	PRO	H	125	18.749	18.989	32.268	1.00	79.33	O
ATOM	3099 CB	PRO	H	125	19.693	18.800	29.213	1.00	72.37	C
ATOM	3100 CG	PRO	H	125	18.226	18.842	28.909	1.00	76.30	C
ATOM	3101 CD	PRO	H	125	17.743	17.447	29.198	1.00	72.35	C
ATOM	3102 N	SER	H	126	21.009	19.153	32.111	1.00	74.62	N
ATOM	3103 CA	SER	H	126	21.216	20.084	33.221	1.00	73.97	C
ATOM	3104 C	SER	H	126	21.532	21.396	32.512	1.00	79.67	C
ATOM	3105 O	SER	H	126	22.214	21.370	31.487	1.00	81.18	O
ATOM	3106 CB	SER	H	126	22.423	19.669	34.059	1.00	75.14	C
ATOM	3107 OG	SER	H	126	22.330	18.357	34.583	1.00	77.89	O
ATOM	3108 N	VAL	H	127	21.021	22.524	32.992	1.00	75.65	N
ATOM	3109 CA	VAL	H	127	21.315	23.807	32.336	1.00	75.07	C
ATOM	3110 C	VAL	H	127	22.026	24.731	33.319	1.00	82.70	C
ATOM	3111 O	VAL	H	127	21.512	25.023	34.408	1.00	83.14	O
ATOM	3112 CB	VAL	H	127	20.107	24.478	31.616	1.00	76.83	C
ATOM	3113 CG1	VAL	H	127	20.518	25.791	30.956	1.00	76.16	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody beziotuxumab Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	3114	CG2	VAL	H	127	19.480	23.537	30.587	1.00	76.11	C
ATOM	3115	N	PHE	H	128	23.240	25.135	32.945	1.00	80.69	N
ATOM	3116	CA	PHE	H	128	24.086	26.029	33.728	1.00	81.26	C
ATOM	3117	C	PHE	H	128	24.387	27.283	32.921	1.00	88.81	C
ATOM	3118	O	PHE	H	128	24.598	27.175	31.711	1.00	89.76	O
ATOM	3119	CB	PHE	H	128	25.389	25.327	34.120	1.00	82.93	C
ATOM	3120	CG	PHE	H	128	25.164	24.003	34.812	1.00	84.36	C
ATOM	3121	CD1	PHE	H	128	24.499	23.941	36.031	1.00	87.04	C
ATOM	3122	CD2	PHE	H	128	25.612	22.816	34.243	1.00	86.57	C
ATOM	3123	CE1	PHE	H	128	24.277	22.713	36.663	1.00	87.59	C
ATOM	3124	CE2	PHE	H	128	25.397	21.587	34.882	1.00	89.02	C
ATOM	3125	CZ	PHE	H	128	24.743	21.547	36.094	1.00	86.48	C
ATOM	3126	N	PRO	H	129	24.426	28.489	33.529	1.00	86.52	N
ATOM	3127	CA	PRO	H	129	24.707	29.679	32.717	1.00	86.26	C
ATOM	3128	C	PRO	H	129	26.193	29.893	32.433	1.00	89.67	C
ATOM	3129	O	PRO	H	129	27.058	29.434	33.182	1.00	89.25	O
ATOM	3130	CB	PRO	H	129	24.091	30.821	33.534	1.00	88.01	C
ATOM	3131	CG	PRO	H	129	24.188	30.352	34.954	1.00	92.58	C
ATOM	3132	CD	PRO	H	129	24.220	28.840	34.953	1.00	88.16	C
ATOM	3133	N	LEU	H	130	26.470	30.577	31.315	1.00	85.74	N
ATOM	3134	CA	LEU	H	130	27.801	30.989	30.898	1.00	85.11	C
ATOM	3135	C	LEU	H	130	27.711	32.523	30.964	1.00	91.81	C
ATOM	3136	O	LEU	H	130	27.365	33.184	29.984	1.00	91.69	O
ATOM	3137	CB	LEU	H	130	28.149	30.449	29.484	1.00	84.16	C
ATOM	3138	CG	LEU	H	130	28.257	28.919	29.307	1.00	86.33	C
ATOM	3139	CD1	LEU	H	130	28.333	28.554	27.861	1.00	85.71	C
ATOM	3140	CD2	LEU	H	130	29.463	28.352	30.014	1.00	85.49	C
ATOM	3141	N	ALA	H	131	27.897	33.059	32.188	1.00	89.95	N
ATOM	3142	CA	ALA	H	131	27.756	34.478	32.532	1.00	90.15	C
ATOM	3143	C	ALA	H	131	28.803	35.397	31.906	1.00	93.97	C
ATOM	3144	O	ALA	H	131	29.988	35.015	31.848	1.00	93.16	O
ATOM	3145	CB	ALA	H	131	27.773	34.646	34.039	1.00	91.09	C
ATOM	3146	N	PRO	H	132	28.399	36.646	31.520	1.00	90.34	N
ATOM	3147	CA	PRO	H	132	29.376	37.615	30.980	1.00	91.03	C
ATOM	3148	C	PRO	H	132	30.303	38.209	32.064	1.00	99.48	C
ATOM	3149	O	PRO	H	132	30.061	37.985	33.257	1.00	99.35	O
ATOM	3150	CB	PRO	H	132	28.491	38.688	30.324	1.00	92.23	C
ATOM	3151	CG	PRO	H	132	27.077	38.207	30.439	1.00	95.50	C
ATOM	3152	CD	PRO	H	132	27.047	37.235	31.557	1.00	91.00	C
ATOM	3153	O	SER	H	133	32.071	41.764	33.467	1.00	107.94	O
ATOM	3154	N	SER	H	133	31.361	38.971	31.664	1.00	99.36	N
ATOM	3155	CA	SER	H	133	32.331	39.534	32.621	1.00	100.73	C
ATOM	3156	C	SER	H	133	32.524	41.073	32.548	1.00	107.55	C
ATOM	3157	CB	SER	H	133	33.680	38.814	32.531	1.00	104.49	C
ATOM	3158	OG	SER	H	133	34.106	38.576	31.200	1.00	112.57	O
ATOM	3159	O	SER	H	134	33.829	44.431	29.316	1.00	96.01	O
ATOM	3160	N	SER	H	134	33.238	41.595	31.505	1.00	105.12	N
ATOM	3161	CA	SER	H	134	33.543	43.031	31.291	1.00	126.89	C
ATOM	3162	C	SER	H	134	33.995	43.320	29.837	1.00	146.61	C
ATOM	3163	CB	SER	H	134	34.609	43.516	32.274	1.00	129.10	C
ATOM	3164	OG	SER	H	134	35.794	42.740	32.190	1.00	134.95	O
ATOM	3165	N	THR	H	141	31.455	44.601	22.588	1.00	89.53	N
ATOM	3166	CA	THR	H	141	30.603	43.413	22.715	1.00	89.60	C
ATOM	3167	C	THR	H	141	31.096	42.413	23.779	1.00	92.55	C
ATOM	3168	O	THR	H	141	32.304	42.268	24.025	1.00	91.21	O
ATOM	3169	CB	THR	H	141	30.363	42.682	21.363	1.00	99.87	C
ATOM	3170	OG1	THR	H	141	31.518	41.931	21.007	1.00	102.71	O
ATOM	3171	CG2	THR	H	141	29.944	43.614	20.221	1.00	98.70	C
ATOM	3172	N	ALA	H	142	30.124	41.695	24.367	1.00	87.95	N
ATOM	3173	CA	ALA	H	142	30.302	40.658	25.378	1.00	86.26	C
ATOM	3174	C	ALA	H	142	29.690	39.325	24.876	1.00	87.16	C
ATOM	3175	O	ALA	H	142	28.817	39.326	23.991	1.00	85.84	O
ATOM	3176	CB	ALA	H	142	29.614	41.091	26.663	1.00	86.79	C
ATOM	3177	N	ALA	H	143	30.138	38.198	25.458	1.00	81.75	N
ATOM	3178	CA	ALA	H	143	29.597	36.882	25.135	1.00	81.00	C
ATOM	3179	C	ALA	H	143	29.012	36.208	26.361	1.00	83.96	C
ATOM	3180	O	ALA	H	143	29.586	36.295	27.450	1.00	83.50	O
ATOM	3181	CB	ALA	H	143	30.662	35.994	24.526	1.00	81.71	C
ATOM	3182	N	LEU	H	144	27.873	35.522	26.167	1.00	79.59	N
ATOM	3183	CA	LEU	H	144	27.148	34.731	27.169	1.00	78.46	C
ATOM	3184	C	LEU	H	144	26.520	33.490	26.511	1.00	82.83	C
ATOM	3185	O	LEU	H	144	26.336	33.469	25.292	1.00	83.73	O
ATOM	3186	CB	LEU	H	144	26.078	35.573	27.889	1.00	78.01	C
ATOM	3187	CG	LEU	H	144	24.996	36.224	27.033	1.00	81.78	C
ATOM	3188	CD1	LEU	H	144	23.726	35.431	27.089	1.00	81.89	C
ATOM	3189	CD2	LEU	H	144	24.715	37.611	27.507	1.00	83.50	C
ATOM	3190	N	GLY	H	145	26.172	32.489	27.312	1.00	78.11	N

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	3191	CA	GLY	H	145	25.542	31.281	26.798	1.00	77.45	C
ATOM	3192	C	GLY	H	145	24.984	30.346	27.842	1.00	81.68	C
ATOM	3193	O	GLY	H	145	24.836	30.718	29.003	1.00	81.48	O
ATOM	3194	N	CYS	H	146	24.654	29.127	27.423	1.00	78.83	N
ATOM	3195	CA	CYS	H	146	24.119	28.079	28.285	1.00	78.72	C
ATOM	3196	C	CYS	H	146	24.900	26.821	28.114	1.00	77.01	C
ATOM	3197	O	CYS	H	146	25.276	26.481	27.003	1.00	77.28	O
ATOM	3198	CB	CYS	H	146	22.645	27.838	27.994	1.00	80.70	C
ATOM	3199	SG	CYS	H	146	21.536	28.956	28.873	1.00	85.97	S
ATOM	3200	N	LEU	H	147	25.102	26.105	29.194	1.00	69.65	N
ATOM	3201	CA	LEU	H	147	25.778	24.840	29.156	1.00	68.83	C
ATOM	3202	C	LEU	H	147	24.713	23.723	29.319	1.00	74.59	C
ATOM	3203	O	LEU	H	147	24.180	23.536	30.410	1.00	75.30	O
ATOM	3204	CB	LEU	H	147	26.867	24.808	30.240	1.00	68.22	C
ATOM	3205	CG	LEU	H	147	27.623	23.500	30.450	1.00	72.37	C
ATOM	3206	CD1	LEU	H	147	28.478	23.146	29.264	1.00	72.45	C
ATOM	3207	CD2	LEU	H	147	28.477	23.568	31.684	1.00	74.09	C
ATOM	3208	N	VAL	H	148	24.355	23.041	28.209	1.00	70.28	N
ATOM	3209	CA	VAL	H	148	23.395	21.918	28.162	1.00	68.93	C
ATOM	3210	C	VAL	H	148	24.225	20.633	28.457	1.00	72.54	C
ATOM	3211	O	VAL	H	148	24.805	20.045	27.545	1.00	72.00	O
ATOM	3212	CB	VAL	H	148	22.674	21.866	26.782	1.00	71.15	C
ATOM	3213	CG1	VAL	H	148	21.662	20.735	26.725	1.00	70.59	C
ATOM	3214	CG2	VAL	H	148	22.017	23.199	26.445	1.00	70.27	C
ATOM	3215	N	LYS	H	149	24.340	20.254	29.738	1.00	68.84	N
ATOM	3216	CA	LYS	H	149	25.184	19.134	30.151	1.00	68.19	C
ATOM	3217	C	LYS	H	149	24.443	17.871	30.568	1.00	76.07	C
ATOM	3218	O	LYS	H	149	23.331	17.936	31.087	1.00	76.54	O
ATOM	3219	CB	LYS	H	149	26.129	19.574	31.280	1.00	68.22	C
ATOM	3220	CG	LYS	H	149	27.496	18.927	31.191	1.00	55.28	C
ATOM	3221	CD	LYS	H	149	28.135	18.700	32.539	1.00	51.22	C
ATOM	3222	CE	LYS	H	149	29.423	17.918	32.429	1.00	51.45	C
ATOM	3223	NZ	LYS	H	149	29.618	16.939	33.545	1.00	59.13	N
ATOM	3224	N	ASP	H	150	25.103	16.715	30.338	1.00	74.79	N
ATOM	3225	CA	ASP	H	150	24.751	15.339	30.697	1.00	74.86	C
ATOM	3226	C	ASP	H	150	23.357	14.832	30.253	1.00	78.06	C
ATOM	3227	O	ASP	H	150	22.677	14.153	31.024	1.00	76.98	O
ATOM	3228	CB	ASP	H	150	24.941	15.128	32.201	1.00	76.59	C
ATOM	3229	CG	ASP	H	150	26.391	15.010	32.603	1.00	89.20	C
ATOM	3230	OD1	ASP	H	150	27.109	14.158	32.011	1.00	88.80	O
ATOM	3231	OD2	ASP	H	150	26.804	15.731	33.543	1.00	98.73	O
ATOM	3232	N	TYR	H	151	22.985	15.063	28.987	1.00	74.57	N
ATOM	3233	CA	TYR	H	151	21.716	14.534	28.480	1.00	74.16	C
ATOM	3234	C	TYR	H	151	21.904	13.240	27.662	1.00	75.20	C
ATOM	3235	O	TYR	H	151	23.030	12.824	27.396	1.00	73.73	O
ATOM	3236	CB	TYR	H	151	20.929	15.599	27.699	1.00	76.05	C
ATOM	3237	CG	TYR	H	151	21.560	16.032	26.396	1.00	79.09	C
ATOM	3238	CD2	TYR	H	151	21.238	15.399	25.199	1.00	80.28	C
ATOM	3239	CD1	TYR	H	151	22.450	17.105	26.351	1.00	81.22	C
ATOM	3240	CE2	TYR	H	151	21.812	15.801	23.992	1.00	81.62	C
ATOM	3241	CE1	TYR	H	151	23.040	17.509	25.153	1.00	81.21	C
ATOM	3242	CZ	TYR	H	151	22.707	16.861	23.974	1.00	87.75	C
ATOM	3243	OH	TYR	H	151	23.237	17.277	22.782	1.00	86.37	O
ATOM	3244	N	PHE	H	152	20.786	12.604	27.287	1.00	70.84	N
ATOM	3245	CA	PHE	H	152	20.708	11.382	26.481	1.00	69.36	C
ATOM	3246	C	PHE	H	152	19.234	11.050	26.169	1.00	71.84	C
ATOM	3247	O	PHE	H	152	18.400	11.082	27.066	1.00	70.50	O
ATOM	3248	CB	PHE	H	152	21.380	10.176	27.183	1.00	70.73	C
ATOM	3249	CG	PHE	H	152	21.396	8.934	26.323	1.00	72.19	C
ATOM	3250	CD1	PHE	H	152	22.417	8.719	25.404	1.00	75.60	C
ATOM	3251	CD2	PHE	H	152	20.361	8.007	26.390	1.00	73.06	C
ATOM	3252	CE1	PHE	H	152	22.395	7.607	24.567	1.00	75.83	C
ATOM	3253	CE2	PHE	H	152	20.342	6.901	25.553	1.00	75.59	C
ATOM	3254	CZ	PHE	H	152	21.355	6.712	24.642	1.00	73.98	C
ATOM	3255	N	PRO	H	153	18.893	10.652	24.936	1.00	69.10	N
ATOM	3256	CA	PRO	H	153	19.730	10.603	23.736	1.00	68.69	C
ATOM	3257	C	PRO	H	153	19.643	11.932	22.973	1.00	71.75	C
ATOM	3258	O	PRO	H	153	18.919	12.853	23.369	1.00	69.85	O
ATOM	3259	CB	PRO	H	153	19.108	9.436	22.961	1.00	70.19	C
ATOM	3260	CG	PRO	H	153	17.617	9.555	23.273	1.00	75.00	C
ATOM	3261	CD	PRO	H	153	17.505	10.256	24.621	1.00	70.77	C
ATOM	3262	N	GLU	H	154	20.370	12.015	21.859	1.00	69.05	N
ATOM	3263	CA	GLU	H	154	20.359	13.190	21.001	1.00	68.46	C
ATOM	3264	C	GLU	H	154	18.979	13.255	20.327	1.00	73.33	C
ATOM	3265	O	GLU	H	154	18.406	12.188	20.054	1.00	72.74	O
ATOM	3266	CB	GLU	H	154	21.462	13.074	19.942	1.00	69.41	C
ATOM	3267	CG	GLU	H	154	22.778	13.698	20.364	1.00	79.20	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	3268	CD	GLU H	154	22.945	15.158	19.992	1.00 105.78 C
ATOM	3269	OE1	GLU H	154	23.837	15.439	19.160	1.00 97.73 O
ATOM	3270	OE2	GLU H	154	22.213	16.020	20.537	1.00 100.70 O
ATOM	3271	N	PRO H	155	18.360	14.448	20.138	1.00 69.72 N
ATOM	3272	CA	PRO H	155	18.873	15.810	20.330	1.00 69.14 C
ATOM	3273	C	PRO H	155	18.205	16.685	21.408	1.00 73.87 C
ATOM	3274	O	PRO H	155	17.149	16.360	21.950	1.00 74.02 O
ATOM	3275	CB	PRO H	155	18.560	16.426	18.963	1.00 70.32 C
ATOM	3276	CG	PRO H	155	17.237	15.755	18.539	1.00 74.28 C
ATOM	3277	CD	PRO H	155	17.085	14.506	19.400	1.00 70.56 C
ATOM	3278	N	VAL H	156	18.821	17.850	21.651	1.00 70.69 N
ATOM	3279	CA	VAL H	156	18.317	18.965	22.452	1.00 70.00 C
ATOM	3280	C	VAL H	156	18.158	20.126	21.451	1.00 75.36 C
ATOM	3281	O	VAL H	156	18.849	20.145	20.419	1.00 74.45 O
ATOM	3282	CB	VAL H	156	19.198	19.385	23.666	1.00 73.08 C
ATOM	3283	CG1	VAL H	156	19.208	18.327	24.748	1.00 73.12 C
ATOM	3284	CG2	VAL H	156	20.614	19.753	23.259	1.00 72.48 C
ATOM	3285	N	THR H	157	17.240	21.069	21.732	1.00 72.99 N
ATOM	3286	CA	THR H	157	17.048	22.253	20.889	1.00 72.39 C
ATOM	3287	C	THR H	157	17.204	23.493	21.748	1.00 74.74 C
ATOM	3288	O	THR H	157	16.537	23.610	22.774	1.00 75.08 O
ATOM	3289	CB	THR H	157	15.699	22.244	20.156	1.00 81.78 C
ATOM	3290	OG1	THR H	157	14.644	22.471	21.092	1.00 79.43 O
ATOM	3291	CG2	THR H	157	15.463	20.969	19.356	1.00 83.70 C
ATOM	3292	N	VAL H	158	18.077	24.417	21.336	1.00 69.87 N
ATOM	3293	CA	VAL H	158	18.273	25.671	22.057	1.00 69.47 C
ATOM	3294	C	VAL H	158	17.803	26.853	21.210	1.00 75.77 C
ATOM	3295	O	VAL H	158	17.971	26.854	19.988	1.00 75.40 O
ATOM	3296	CB	VAL H	158	19.708	25.877	22.631	1.00 72.60 C
ATOM	3297	CG1	VAL H	158	19.704	26.959	23.709	1.00 72.36 C
ATOM	3298	CG2	VAL H	158	20.291	24.576	23.197	1.00 72.01 C
ATOM	3299	N	SER H	159	17.158	27.828	21.869	1.00 74.83 N
ATOM	3300	CA	SER H	159	16.663	29.097	21.313	1.00 75.25 C
ATOM	3301	C	SER H	159	16.941	30.177	22.369	1.00 81.84 C
ATOM	3302	O	SER H	159	17.260	29.834	23.528	1.00 80.85 O
ATOM	3303	CB	SER H	159	15.172	29.018	21.011	1.00 77.68 C
ATOM	3304	OG	SER H	159	14.429	28.732	22.183	1.00 86.05 O
ATOM	3305	N	TRP H	160	16.907	31.469	21.972	1.00 79.51 N
ATOM	3306	CA	TRP H	160	17.243	32.417	23.010	1.00 79.36 C
ATOM	3307	C	TRP H	160	16.004	33.134	23.534	1.00 88.25 C
ATOM	3308	O	TRP H	160	15.286	32.485	24.287	1.00 89.93 O
ATOM	3309	CB	TRP H	160	18.415	33.311	22.635	1.00 76.85 C
ATOM	3310	CG	TRP H	160	19.680	32.554	22.920	1.00 76.82 C
ATOM	3311	CD1	TRP H	160	20.275	31.635	22.104	1.00 79.34 C
ATOM	3312	CD2	TRP H	160	20.328	32.427	24.201	1.00 76.15 C
ATOM	3313	NE1	TRP H	160	21.292	30.989	22.776	1.00 77.99 N
ATOM	3314	CE2	TRP H	160	21.367	31.480	24.054	1.00 79.11 C
ATOM	3315	CE3	TRP H	160	20.151	33.045	25.449	1.00 76.92 C
ATOM	3316	CZ2	TRP H	160	22.249	31.169	25.092	1.00 78.05 C
ATOM	3317	CZ3	TRP H	160	21.033	32.743	26.473	1.00 78.16 C
ATOM	3318	CH2	TRP H	160	22.065	31.811	26.291	1.00 78.67 C
ATOM	3319	N	ASN H	161	15.749	34.411	23.248	1.00 85.68 N
ATOM	3320	CA	ASN H	161	14.580	35.045	23.865	1.00 85.17 C
ATOM	3321	C	ASN H	161	13.296	34.618	23.120	1.00 90.52 C
ATOM	3322	O	ASN H	161	12.770	35.343	22.273	1.00 90.27 O
ATOM	3323	CB	ASN H	161	14.790	36.564	24.008	1.00 82.54 C
ATOM	3324	CG	ASN H	161	15.999	36.973	24.861	1.00 89.87 C
ATOM	3325	OD1	ASN H	161	16.390	36.325	25.857	1.00 65.77 O
ATOM	3326	ND2	ASN H	161	16.608	38.091	24.494	1.00 86.31 N
ATOM	3327	N	SER H	162	12.836	33.381	23.444	1.00 88.08 N
ATOM	3328	CA	SER H	162	11.733	32.590	22.880	1.00 88.26 C
ATOM	3329	C	SER H	162	12.031	32.234	21.433	1.00 93.81 C
ATOM	3330	O	SER H	162	12.178	31.059	21.102	1.00 94.35 O
ATOM	3331	CB	SER H	162	10.380	33.237	23.110	1.00 91.08 C
ATOM	3332	OG	SER H	162	10.114	33.057	24.492	1.00 98.80 O
ATOM	3333	O	GLY H	163	14.831	34.107	19.763	1.00 96.22 O
ATOM	3334	N	GLY H	163	12.199	33.256	20.621	1.00 91.08 N
ATOM	3335	CA	GLY H	163	12.683	33.215	19.253	1.00 91.28 C
ATOM	3336	C	GLY H	163	13.708	34.321	19.295	1.00 95.65 C
ATOM	3337	N	ALA H	164	13.218	35.538	18.990	1.00 90.91 N
ATOM	3338	CA	ALA H	164	13.774	36.894	19.026	1.00 90.33 C
ATOM	3339	C	ALA H	164	15.279	37.038	18.737	1.00 91.85 C
ATOM	3340	O	ALA H	164	15.641	37.711	17.761	1.00 92.21 O
ATOM	3341	CB	ALA H	164	13.431	37.555	20.352	1.00 91.23 C
ATOM	3342	N	LEU H	165	16.140	36.463	19.595	1.00 85.44 N
ATOM	3343	CA	LEU H	165	17.588	36.482	19.437	1.00 83.74 C
ATOM	3344	C	LEU H	165	18.066	35.277	18.593	1.00 84.83 C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TedB antibody beziotoxumab
Fab -C. difficile toxin B (TedB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	3345 O	LEU	H	165	17.984	34.123	19.027	1.00	83.89	O
ATOM	3346 CB	LEU	H	165	18.253	36.527	20.818	1.00	83.32	C
ATOM	3347 CG	LEU	H	165	19.754	36.722	20.872	1.00	87.57	C
ATOM	3348 CD1	LEU	H	165	20.174	38.058	20.271	1.00	87.39	C
ATOM	3349 CD2	LEU	H	165	20.230	36.626	22.290	1.00	89.82	C
ATOM	3350 N	THR	H	166	18.501	35.571	17.359	1.00	80.20	N
ATOM	3351 CA	THR	H	166	19.012	34.612	16.364	1.00	79.60	C
ATOM	3352 C	THR	H	166	20.417	35.030	15.885	1.00	81.42	C
ATOM	3353 O	THR	H	166	21.260	34.168	15.624	1.00	80.32	O
ATOM	3354 CB	THR	H	166	18.048	34.478	15.164	1.00	87.84	C
ATOM	3355 OG1	THR	H	166	17.753	35.768	14.632	1.00	93.24	O
ATOM	3356 CG2	THR	H	166	16.767	33.781	15.519	1.00	85.45	C
ATOM	3357 N	SER	H	167	20.641	36.360	15.761	1.00	76.92	N
ATOM	3358 CA	SER	H	167	21.887	36.986	15.331	1.00	76.18	C
ATOM	3359 C	SER	H	167	23.020	36.727	16.331	1.00	79.38	C
ATOM	3360 O	SER	H	167	22.868	36.963	17.536	1.00	79.58	O
ATOM	3361 CB	SER	H	167	21.693	38.487	15.122	1.00	78.74	C
ATOM	3362 OG	SER	H	167	21.902	38.882	13.771	1.00	88.18	O
ATOM	3363 N	GLY	H	168	24.133	36.216	15.809	1.00	73.96	N
ATOM	3364 CA	GLY	H	168	25.330	35.937	16.592	1.00	72.77	C
ATOM	3365 C	GLY	H	168	25.236	34.769	17.548	1.00	74.46	C
ATOM	3366 O	GLY	H	168	26.099	34.632	18.427	1.00	72.98	O
ATOM	3367 N	VAL	H	169	24.195	33.912	17.370	1.00	69.82	N
ATOM	3368 CA	VAL	H	169	23.971	32.718	18.187	1.00	68.77	C
ATOM	3369 C	VAL	H	169	24.753	31.581	17.557	1.00	71.88	C
ATOM	3370 O	VAL	H	169	24.715	31.402	16.329	1.00	71.03	O
ATOM	3371 CB	VAL	H	169	22.468	32.344	18.358	1.00	72.62	C
ATOM	3372 CG1	VAL	H	169	22.298	31.075	19.194	1.00	72.13	C
ATOM	3373 CG2	VAL	H	169	21.663	33.489	18.959	1.00	72.61	C
ATOM	3374 N	HIS	H	170	25.467	30.825	18.407	1.00	68.09	N
ATOM	3375 CA	HIS	H	170	26.250	29.664	18.025	1.00	67.18	C
ATOM	3376 C	HIS	H	170	25.915	28.479	18.913	1.00	69.53	C
ATOM	3377 O	HIS	H	170	26.428	28.387	20.034	1.00	69.70	O
ATOM	3378 CB	HIS	H	170	27.760	29.954	18.057	1.00	68.04	C
ATOM	3379 CG	HIS	H	170	28.263	30.834	16.953	1.00	71.41	C
ATOM	3380 ND1	HIS	H	170	28.010	30.547	15.630	1.00	73.27	N
ATOM	3381 CD2	HIS	H	170	29.044	31.939	17.022	1.00	72.88	C
ATOM	3382 CE1	HIS	H	170	28.614	31.502	14.939	1.00	72.75	C
ATOM	3383 NE2	HIS	H	170	29.251	32.358	15.736	1.00	72.78	N
ATOM	3384 N	THR	H	171	25.030	27.580	18.425	1.00	64.33	N
ATOM	3385 CA	THR	H	171	24.702	26.359	19.161	1.00	63.69	C
ATOM	3386 C	THR	H	171	25.667	25.318	18.619	1.00	65.99	C
ATOM	3387 O	THR	H	171	25.764	25.131	17.410	1.00	65.78	O
ATOM	3388 CB	THR	H	171	23.208	25.998	19.100	1.00	69.19	C
ATOM	3389 OG1	THR	H	171	22.428	27.122	19.532	1.00	67.31	O
ATOM	3390 CG2	THR	H	171	22.873	24.809	19.979	1.00	66.43	C
ATOM	3391 N	PHE	H	172	26.466	24.742	19.495	1.00	61.93	N
ATOM	3392 CA	PHE	H	172	27.509	23.831	19.079	1.00	61.74	C
ATOM	3393 C	PHE	H	172	27.040	22.408	18.940	1.00	68.65	C
ATOM	3394 O	PHE	H	172	26.147	21.976	19.676	1.00	69.26	O
ATOM	3395 CB	PHE	H	172	28.685	23.895	20.060	1.00	63.30	C
ATOM	3396 CG	PHE	H	172	29.523	25.136	19.929	1.00	64.97	C
ATOM	3397 CD1	PHE	H	172	30.565	25.197	19.014	1.00	68.24	C
ATOM	3398 CD2	PHE	H	172	29.285	26.245	20.736	1.00	67.16	C
ATOM	3399 CE1	PHE	H	172	31.354	26.345	18.906	1.00	68.83	C
ATOM	3400 CE2	PHE	H	172	30.074	27.395	20.624	1.00	70.07	C
ATOM	3401 CZ	PHE	H	172	31.103	27.436	19.708	1.00	68.09	C
ATOM	3402 N	PRO	H	173	27.692	21.626	18.047	1.00	65.16	N
ATOM	3403 CA	PRO	H	173	27.370	20.196	17.947	1.00	63.80	C
ATOM	3404 C	PRO	H	173	27.667	19.498	19.267	1.00	65.74	C
ATOM	3405 O	PRO	H	173	28.674	19.837	19.915	1.00	65.25	O
ATOM	3406 CB	PRO	H	173	28.343	19.702	16.875	1.00	65.28	C
ATOM	3407 CG	PRO	H	173	28.699	20.897	16.101	1.00	70.29	C
ATOM	3408 CD	PRO	H	173	28.775	21.983	17.109	1.00	66.61	C
ATOM	3409 N	ALA	H	174	26.792	18.548	19.677	1.00	60.29	N
ATOM	3410 CA	ALA	H	174	26.978	17.828	20.935	1.00	59.85	C
ATOM	3411 C	ALA	H	174	28.227	16.968	20.924	1.00	67.21	C
ATOM	3412 O	ALA	H	174	28.643	16.492	19.872	1.00	67.94	O
ATOM	3413 CB	ALA	H	174	25.778	16.981	21.234	1.00	60.18	C
ATOM	3414 N	VAL	H	175	28.846	16.803	22.090	1.00	65.32	N
ATOM	3415 CA	VAL	H	175	30.056	15.995	22.242	1.00	65.82	C
ATOM	3416 C	VAL	H	175	29.686	14.890	23.210	1.00	69.04	C
ATOM	3417 O	VAL	H	175	29.086	15.171	24.252	1.00	72.23	O
ATOM	3418 CB	VAL	H	175	31.285	16.809	22.751	1.00	70.88	C
ATOM	3419 CG1	VAL	H	175	32.566	16.005	22.594	1.00	71.09	C
ATOM	3420 CG2	VAL	H	175	31.426	18.146	22.028	1.00	70.98	C
ATOM	3421 N	LEU	H	176	29.999	13.646	22.865	1.00	60.13	N

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.											
ATOM	3422	CA	LEU	H	176	29.682	12.528	23.717	1.00	57.94	C
ATOM	3423	C	LEU	H	176	30.787	12.359	24.720	1.00	63.95	C
ATOM	3424	O	LEU	H	176	31.928	12.094	24.345	1.00	64.11	O
ATOM	3425	CB	LEU	H	176	29.472	11.245	22.904	1.00	56.99	C
ATOM	3426	CG	LEU	H	176	29.234	9.971	23.719	1.00	58.82	C
ATOM	3427	CD1	LEU	H	176	27.830	9.933	24.300	1.00	58.05	C
ATOM	3428	CD2	LEU	H	176	29.536	8.780	22.912	1.00	55.10	C
ATOM	3429	N	GLN	H	177	30.432	12.491	26.002	1.00	62.62	N
ATOM	3430	CA	GLN	H	177	31.341	12.389	27.148	1.00	63.25	C
ATOM	3431	C	GLN	H	177	31.619	10.916	27.444	1.00	69.03	C
ATOM	3432	O	GLN	H	177	30.870	10.064	26.984	1.00	69.16	O
ATOM	3433	CB	GLN	H	177	30.718	13.082	28.374	1.00	64.11	C
ATOM	3434	CG	GLN	H	177	30.239	14.501	28.105	1.00	58.48	C
ATOM	3435	CD	GLN	H	177	29.434	15.027	29.265	1.00	81.68	C
ATOM	3436	OE1	GLN	H	177	29.980	15.561	30.232	1.00	85.33	O
ATOM	3437	NE2	GLN	H	177	28.121	14.887	29.209	1.00	63.59	N
ATOM	3438	N	SER	H	178	32.678	10.619	28.218	1.00	66.60	N
ATOM	3439	CA	SER	H	178	33.075	9.261	28.613	1.00	66.89	C
ATOM	3440	C	SER	H	178	31.994	8.599	29.474	1.00	72.73	C
ATOM	3441	O	SER	H	178	31.926	7.369	29.537	1.00	73.01	O
ATOM	3442	CB	SER	H	178	34.385	9.312	29.389	1.00	71.67	C
ATOM	3443	OG	SER	H	178	34.293	10.201	30.493	1.00	85.01	O
ATOM	3444	N	SER	H	179	31.148	9.433	30.138	1.00	69.53	N
ATOM	3445	CA	SER	H	179	30.018	9.043	30.989	1.00	68.56	C
ATOM	3446	C	SER	H	179	28.893	8.325	30.215	1.00	72.76	C
ATOM	3447	O	SER	H	179	28.038	7.686	30.833	1.00	73.86	O
ATOM	3448	CB	SER	H	179	29.439	10.279	31.673	1.00	70.45	C
ATOM	3449	OG	SER	H	179	28.756	11.135	30.774	1.00	75.20	O
ATOM	3450	N	GLY	H	180	28.883	8.476	28.888	1.00	67.26	N
ATOM	3451	CA	GLY	H	180	27.863	7.932	27.996	1.00	65.57	C
ATOM	3452	C	GLY	H	180	26.788	8.953	27.663	1.00	66.65	C
ATOM	3453	O	GLY	H	180	25.941	8.717	26.792	1.00	67.40	O
ATOM	3454	N	LEU	H	181	26.811	10.089	28.368	1.00	60.09	N
ATOM	3455	CA	LEU	H	181	25.891	11.201	28.189	1.00	59.38	C
ATOM	3456	C	LEU	H	181	26.507	12.278	27.299	1.00	64.34	C
ATOM	3457	O	LEU	H	181	27.737	12.393	27.233	1.00	65.19	O
ATOM	3458	CB	LEU	H	181	25.555	11.805	29.552	1.00	59.07	C
ATOM	3459	CG	LEU	H	181	24.991	10.847	30.569	1.00	62.24	C
ATOM	3460	CD1	LEU	H	181	25.261	11.323	31.946	1.00	61.54	C
ATOM	3461	CD2	LEU	H	181	23.531	10.612	30.327	1.00	63.54	C
ATOM	3462	N	TYR	H	182	25.658	13.055	26.617	1.00	60.27	N
ATOM	3463	CA	TYR	H	182	26.072	14.142	25.737	1.00	61.36	C
ATOM	3464	C	TYR	H	182	26.000	15.487	26.462	1.00	68.94	C
ATOM	3465	O	TYR	H	182	25.169	15.703	27.368	1.00	69.01	O
ATOM	3466	CB	TYR	H	182	25.160	14.234	24.498	1.00	63.71	C
ATOM	3467	CG	TYR	H	182	25.165	13.029	23.581	1.00	68.44	C
ATOM	3468	CD1	TYR	H	182	26.160	12.863	22.620	1.00	70.58	C
ATOM	3469	CD2	TYR	H	182	24.127	12.105	23.608	1.00	70.09	C
ATOM	3470	CE1	TYR	H	182	26.136	11.792	21.729	1.00	71.24	C
ATOM	3471	CE2	TYR	H	182	24.096	11.024	22.729	1.00	71.99	C
ATOM	3472	CZ	TYR	H	182	25.103	10.872	21.786	1.00	82.39	C
ATOM	3473	OH	TYR	H	182	25.072	9.812	20.899	1.00	85.40	O
ATOM	3474	N	SER	H	183	26.838	16.416	25.995	1.00	65.76	N
ATOM	3475	CA	SER	H	183	26.928	17.789	26.456	1.00	64.58	C
ATOM	3476	C	SER	H	183	27.215	18.699	25.246	1.00	66.50	C
ATOM	3477	O	SER	H	183	27.839	18.266	24.269	1.00	65.55	O
ATOM	3478	CB	SER	H	183	28.011	17.904	27.525	1.00	68.41	C
ATOM	3479	OG	SER	H	183	28.627	19.178	27.587	1.00	81.74	O
ATOM	3480	N	LEU	H	184	26.718	19.944	25.313	1.00	61.74	N
ATOM	3481	CA	LEU	H	184	26.912	21.015	24.339	1.00	60.15	C
ATOM	3482	C	LEU	H	184	26.682	22.385	24.968	1.00	63.45	C
ATOM	3483	O	LEU	H	184	25.995	22.483	25.989	1.00	62.38	O
ATOM	3484	CB	LEU	H	184	26.026	20.843	23.074	1.00	59.77	C
ATOM	3485	CG	LEU	H	184	24.479	21.010	23.120	1.00	63.36	C
ATOM	3486	CD1	LEU	H	184	24.055	22.451	23.213	1.00	62.92	C
ATOM	3487	CD2	LEU	H	184	23.880	20.540	21.828	1.00	64.40	C
ATOM	3488	N	SER	H	185	27.187	23.454	24.305	1.00	59.82	N
ATOM	3489	CA	SER	H	185	26.926	24.839	24.700	1.00	58.06	C
ATOM	3490	C	SER	H	185	26.310	25.601	23.560	1.00	63.53	C
ATOM	3491	O	SER	H	185	26.613	25.358	22.390	1.00	62.49	O
ATOM	3492	CB	SER	H	185	28.188	25.561	25.156	1.00	56.76	C
ATOM	3493	OG	SER	H	185	28.759	24.990	26.319	1.00	61.77	O
ATOM	3494	N	SER	H	186	25.419	26.513	23.914	1.00	62.53	N
ATOM	3495	CA	SER	H	186	24.832	27.485	23.004	1.00	63.12	C
ATOM	3496	C	SER	H	186	25.291	28.842	23.546	1.00	66.60	C
ATOM	3497	O	SER	H	186	25.088	29.140	24.724	1.00	62.93	O
ATOM	3498	CB	SER	H	186	23.315	27.408	22.985	1.00	66.48	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	3499	OG	SER	H	186	22.789	28.512	22.266	1.00	72.86	O
ATOM	3500	N	VAL	H	187	25.969	29.621	22.692	1.00	65.49	N
ATOM	3501	CA	VAL	H	187	26.527	30.931	23.032	1.00	65.67	C
ATOM	3502	C	VAL	H	187	25.975	32.019	22.111	1.00	72.63	C
ATOM	3503	O	VAL	H	187	25.458	31.700	21.039	1.00	72.76	O
ATOM	3504	CB	VAL	H	187	28.082	30.908	23.053	1.00	68.21	C
ATOM	3505	CG1	VAL	H	187	28.610	29.903	24.069	1.00	67.25	C
ATOM	3506	CG2	VAL	H	187	28.659	30.630	21.670	1.00	68.02	C
ATOM	3507	N	VAL	H	188	26.073	33.300	22.537	1.00	70.67	N
ATOM	3508	CA	VAL	H	188	25.628	34.476	21.776	1.00	71.01	C
ATOM	3509	C	VAL	H	188	26.442	35.705	22.173	1.00	78.69	C
ATOM	3510	O	VAL	H	188	26.671	35.942	23.362	1.00	78.75	O
ATOM	3511	CB	VAL	H	188	24.081	34.716	21.825	1.00	74.53	C
ATOM	3512	CG1	VAL	H	188	23.588	35.065	23.234	1.00	74.55	C
ATOM	3513	CG2	VAL	H	188	23.627	35.756	20.800	1.00	73.89	C
ATOM	3514	N	THR	H	189	26.916	36.456	21.164	1.00	78.31	N
ATOM	3515	CA	THR	H	189	27.648	37.710	21.357	1.00	78.94	C
ATOM	3516	C	THR	H	189	26.647	38.836	21.253	1.00	85.28	C
ATOM	3517	O	THR	H	189	25.874	38.908	20.283	1.00	83.52	O
ATOM	3518	CB	THR	H	189	28.855	37.862	20.410	1.00	84.05	C
ATOM	3519	OG1	THR	H	189	28.505	37.464	19.078	1.00	84.59	O
ATOM	3520	CG2	THR	H	189	30.076	37.099	20.902	1.00	78.76	C
ATOM	3521	N	VAL	H	190	26.614	39.674	22.296	1.00	85.83	N
ATOM	3522	CA	VAL	H	190	25.699	40.820	22.407	1.00	87.45	C
ATOM	3523	C	VAL	H	190	26.463	42.114	22.750	1.00	94.58	C
ATOM	3524	O	VAL	H	190	27.584	42.005	23.269	1.00	93.70	O
ATOM	3525	CB	VAL	H	190	24.571	40.552	23.440	1.00	91.39	C
ATOM	3526	CG1	VAL	H	190	23.501	39.637	22.867	1.00	91.33	C
ATOM	3527	CG2	VAL	H	190	25.122	40.012	24.759	1.00	91.21	C
ATOM	3528	N	PRO	H	191	25.882	43.336	22.525	1.00	93.59	N
ATOM	3529	CA	PRO	H	191	26.590	44.569	22.945	1.00	93.87	C
ATOM	3530	C	PRO	H	191	26.706	44.656	24.478	1.00	98.30	C
ATOM	3531	O	PRO	H	191	25.755	44.290	25.172	1.00	96.93	O
ATOM	3532	CB	PRO	H	191	25.705	45.700	22.389	1.00	95.48	C
ATOM	3533	CG	PRO	H	191	24.738	45.043	21.443	1.00	99.50	C
ATOM	3534	CD	PRO	H	191	24.563	43.653	21.930	1.00	94.99	C
ATOM	3535	N	SER	H	192	27.871	45.113	25.005	1.00	96.49	N
ATOM	3536	CA	SER	H	192	28.133	45.255	26.451	1.00	97.24	C
ATOM	3537	C	SER	H	192	27.137	46.192	27.165	1.00	103.72	C
ATOM	3538	O	SER	H	192	26.878	46.021	28.361	1.00	103.11	O
ATOM	3539	CB	SER	H	192	29.561	45.727	26.697	1.00	100.57	C
ATOM	3540	OG	SER	H	192	30.490	44.681	26.477	1.00	108.92	O
ATOM	3541	N	SER	H	193	26.573	47.165	26.412	1.00	101.84	N
ATOM	3542	CA	SER	H	193	25.578	48.139	26.862	1.00	101.96	C
ATOM	3543	C	SER	H	193	24.220	47.489	27.214	1.00	109.48	C
ATOM	3544	O	SER	H	193	23.465	48.050	28.015	1.00	110.43	O
ATOM	3545	CB	SER	H	193	25.386	49.224	25.804	1.00	103.28	C
ATOM	3546	OG	SER	H	193	24.898	48.714	24.574	1.00	106.17	O
ATOM	3547	N	SER	H	194	23.914	46.320	26.607	1.00	106.99	N
ATOM	3548	CA	SER	H	194	22.672	45.555	26.793	1.00	107.18	C
ATOM	3549	C	SER	H	194	22.581	44.876	28.162	1.00	111.78	C
ATOM	3550	O	SER	H	194	21.481	44.692	28.672	1.00	110.97	O
ATOM	3551	CB	SER	H	194	22.518	44.515	25.689	1.00	110.81	C
ATOM	3552	OG	SER	H	194	22.818	45.053	24.410	1.00	118.86	O
ATOM	3553	N	LEU	H	195	23.731	44.495	28.743	1.00	109.85	N
ATOM	3554	CA	LEU	H	195	23.857	43.836	30.052	1.00	110.40	C
ATOM	3555	C	LEU	H	195	23.241	44.725	31.155	1.00	116.52	C
ATOM	3556	O	LEU	H	195	23.771	45.797	31.474	1.00	117.26	O
ATOM	3557	CB	LEU	H	195	25.350	43.558	30.332	1.00	110.26	C
ATOM	3558	CG	LEU	H	195	26.015	42.313	29.704	1.00	114.47	C
ATOM	3559	CD1	LEU	H	195	25.876	42.264	28.195	1.00	114.70	C
ATOM	3560	CD2	LEU	H	195	27.483	42.295	30.014	1.00	116.29	C
ATOM	3561	N	GLY	H	196	22.100	44.292	31.680	1.00	112.85	N
ATOM	3562	CA	GLY	H	196	21.354	45.053	32.675	1.00	112.46	C
ATOM	3563	C	GLY	H	196	20.040	45.544	32.100	1.00	115.92	C
ATOM	3564	O	GLY	H	196	18.991	45.374	32.728	1.00	116.50	O
ATOM	3565	N	THR	H	197	20.087	46.128	30.879	1.00	110.80	N
ATOM	3566	CA	THR	H	197	18.918	46.611	30.124	1.00	109.86	C
ATOM	3567	C	THR	H	197	18.097	45.402	29.616	1.00	111.00	C
ATOM	3568	O	THR	H	197	16.924	45.260	29.978	1.00	110.52	O
ATOM	3569	CB	THR	H	197	19.373	47.511	28.946	1.00	119.84	C
ATOM	3570	OG1	THR	H	197	20.330	48.471	29.405	1.00	120.80	O
ATOM	3571	CG2	THR	H	197	18.207	48.206	28.236	1.00	117.23	C
ATOM	3572	N	GLN	H	198	18.735	44.538	28.785	1.00	105.39	N
ATOM	3573	CA	GLN	H	198	18.157	43.336	28.181	1.00	103.86	C
ATOM	3574	C	GLN	H	198	18.371	42.056	28.975	1.00	104.53	C
ATOM	3575	O	GLN	H	198	19.450	41.819	29.532	1.00	102.56	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	3576	CB	GLN	H	198	18.635	43.138	26.733	1.00	104.95	C
ATOM	3577	CG	GLN	H	198	17.526	43.291	25.689	1.00	116.31	C
ATOM	3578	CD	GLN	H	198	16.363	42.345	25.903	1.00	133.91	C
ATOM	3579	OE1	GLN	H	198	16.426	41.159	25.568	1.00	128.86	O
ATOM	3580	NE2	GLN	H	198	15.279	42.849	26.485	1.00	126.96	N
ATOM	3581	N	THR	H	199	17.323	41.217	28.985	1.00	100.21	N
ATOM	3582	CA	THR	H	199	17.286	39.926	29.670	1.00	98.85	C
ATOM	3583	C	THR	H	199	17.563	38.817	28.670	1.00	98.22	C
ATOM	3584	O	THR	H	199	16.967	38.791	27.583	1.00	97.55	O
ATOM	3585	CB	THR	H	199	15.949	39.722	30.405	1.00	108.82	C
ATOM	3586	OG1	THR	H	199	15.412	40.988	30.809	1.00	111.77	O
ATOM	3587	CG2	THR	H	199	16.086	38.794	31.610	1.00	106.28	C
ATOM	3588	N	TYR	H	200	18.478	37.905	29.044	1.00	91.51	N
ATOM	3589	CA	TYR	H	200	18.890	36.777	28.213	1.00	89.21	C
ATOM	3590	C	TYR	H	200	18.540	35.434	28.852	1.00	89.00	C
ATOM	3591	O	TYR	H	200	19.100	35.062	29.883	1.00	87.67	O
ATOM	3592	CB	TYR	H	200	20.383	36.892	27.845	1.00	89.85	C
ATOM	3593	CG	TYR	H	200	20.690	38.141	27.038	1.00	91.63	C
ATOM	3594	CD1	TYR	H	200	20.245	38.276	25.724	1.00	93.42	C
ATOM	3595	CD2	TYR	H	200	21.371	39.214	27.607	1.00	92.54	C
ATOM	3596	CE1	TYR	H	200	20.486	39.439	24.991	1.00	93.61	C
ATOM	3597	CE2	TYR	H	200	21.617	40.386	26.881	1.00	93.46	C
ATOM	3598	CZ	TYR	H	200	21.176	40.490	25.569	1.00	101.76	C
ATOM	3599	OH	TYR	H	200	21.414	41.622	24.817	1.00	104.21	O
ATOM	3600	N	ILE	H	201	17.567	34.736	28.255	1.00	84.11	N
ATOM	3601	CA	ILE	H	201	17.109	33.420	28.708	1.00	83.70	C
ATOM	3602	C	ILE	H	201	17.265	32.437	27.555	1.00	86.26	C
ATOM	3603	O	ILE	H	201	16.851	32.749	26.437	1.00	85.36	O
ATOM	3604	CB	ILE	H	201	15.630	33.423	29.214	1.00	86.75	C
ATOM	3605	CG1	ILE	H	201	15.337	34.583	30.177	1.00	87.36	C
ATOM	3606	CG2	ILE	H	201	15.263	32.076	29.851	1.00	86.33	C
ATOM	3607	CD1	ILE	H	201	13.954	35.106	30.054	1.00	93.78	C
ATOM	3608	N	CYS	H	202	17.848	31.254	27.822	1.00	81.72	N
ATOM	3609	CA	CYS	H	202	17.963	30.222	26.798	1.00	81.35	C
ATOM	3610	C	CYS	H	202	16.877	29.175	27.005	1.00	84.05	C
ATOM	3611	O	CYS	H	202	16.646	28.744	28.140	1.00	83.61	O
ATOM	3612	CB	CYS	H	202	19.355	29.601	26.772	1.00	81.81	C
ATOM	3613	SG	CYS	H	202	19.696	28.481	28.149	1.00	85.97	S
ATOM	3614	N	ASN	H	203	16.194	28.780	25.921	1.00	79.41	N
ATOM	3615	CA	ASN	H	203	15.147	27.764	26.016	1.00	78.12	C
ATOM	3616	C	ASN	H	203	15.636	26.429	25.460	1.00	77.93	C
ATOM	3617	O	ASN	H	203	15.749	26.242	24.240	1.00	76.12	O
ATOM	3618	CB	ASN	H	203	13.849	28.217	25.356	1.00	81.94	C
ATOM	3619	CG	ASN	H	203	13.629	29.709	25.309	1.00	101.25	C
ATOM	3620	OD1	ASN	H	203	13.490	30.278	24.232	1.00	89.90	O
ATOM	3621	ND2	ASN	H	203	13.564	30.367	26.465	1.00	94.35	N
ATOM	3622	N	VAL	H	204	15.968	25.528	26.390	1.00	73.17	N
ATOM	3623	CA	VAL	H	204	16.489	24.188	26.148	1.00	73.22	C
ATOM	3624	C	VAL	H	204	15.335	23.184	26.234	1.00	77.20	C
ATOM	3625	O	VAL	H	204	14.699	23.064	27.282	1.00	76.50	O
ATOM	3626	CB	VAL	H	204	17.643	23.826	27.135	1.00	77.03	C
ATOM	3627	CG1	VAL	H	204	18.255	22.460	26.799	1.00	76.89	C
ATOM	3628	CG2	VAL	H	204	18.717	24.916	27.165	1.00	76.33	C
ATOM	3629	N	ASN	H	205	15.079	22.463	25.125	1.00	73.54	N
ATOM	3630	CA	ASN	H	205	14.018	21.458	25.006	1.00	72.14	C
ATOM	3631	C	ASN	H	205	14.626	20.106	24.648	1.00	72.33	C
ATOM	3632	O	ASN	H	205	15.451	20.040	23.744	1.00	72.16	O
ATOM	3633	CB	ASN	H	205	12.988	21.894	23.955	1.00	74.82	C
ATOM	3634	CG	ASN	H	205	11.641	21.249	24.137	1.00	108.35	C
ATOM	3635	OD1	ASN	H	205	10.876	21.605	25.043	1.00	106.08	O
ATOM	3636	ND2	ASN	H	205	11.326	20.277	23.286	1.00	100.19	N
ATOM	3637	N	HIS	H	206	14.254	19.047	25.384	1.00	67.46	N
ATOM	3638	CA	HIS	H	206	14.729	17.671	25.191	1.00	67.14	C
ATOM	3639	C	HIS	H	206	13.544	16.726	25.287	1.00	71.23	C
ATOM	3640	O	HIS	H	206	13.201	16.214	26.367	1.00	69.57	O
ATOM	3641	CB	HIS	H	206	15.833	17.296	26.188	1.00	67.72	C
ATOM	3642	CG	HIS	H	206	16.373	15.901	26.017	1.00	71.21	C
ATOM	3643	ND1	HIS	H	206	16.412	15.008	27.075	1.00	73.23	N
ATOM	3644	CD2	HIS	H	206	16.917	15.305	24.932	1.00	72.61	C
ATOM	3645	CE1	HIS	H	206	16.950	13.898	26.594	1.00	72.31	C
ATOM	3646	NE2	HIS	H	206	17.276	14.031	25.313	1.00	72.43	N
ATOM	3647	N	LYS	H	207	12.900	16.546	24.121	1.00	67.38	N
ATOM	3648	CA	LYS	H	207	11.699	15.736	23.910	1.00	65.82	C
ATOM	3649	C	LYS	H	207	11.820	14.300	24.459	1.00	69.89	C
ATOM	3650	O	LYS	H	207	10.898	13.884	25.181	1.00	68.86	O
ATOM	3651	CB	LYS	H	207	11.272	15.745	22.434	1.00	65.83	C
ATOM	3652	CG	LYS	H	207	10.854	17.101	21.909	1.00	69.85	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	3653	CD	LYS	H	207	10.315	16.932	20.505	1.00	82.99	C
ATOM	3654	CE	LYS	H	207	9.934	18.235	19.852	1.00	97.08	C
ATOM	3655	NZ	LYS	H	207	9.336	17.995	18.511	1.00	106.00	N
ATOM	3656	N	PRO	H	208	12.936	13.547	24.207	1.00	66.82	N
ATOM	3657	CA	PRO	H	208	13.037	12.179	24.751	1.00	67.05	C
ATOM	3658	C	PRO	H	208	12.805	12.021	26.262	1.00	73.14	C
ATOM	3659	O	PRO	H	208	12.263	11.008	26.666	1.00	72.32	O
ATOM	3660	CB	PRO	H	208	14.445	11.749	24.351	1.00	68.42	C
ATOM	3661	CG	PRO	H	208	14.754	12.528	23.146	1.00	72.65	C
ATOM	3662	CD	PRO	H	208	14.124	13.862	23.383	1.00	68.20	C
ATOM	3663	N	SER	H	209	13.200	13.002	27.083	1.00	73.44	N
ATOM	3664	CA	SER	H	209	12.984	12.982	28.537	1.00	74.50	C
ATOM	3665	C	SER	H	209	11.890	13.992	28.930	1.00	81.53	C
ATOM	3666	O	SER	H	209	11.545	14.101	30.108	1.00	80.71	O
ATOM	3667	CB	SER	H	209	14.286	13.284	29.276	1.00	77.35	C
ATOM	3668	OG	SER	H	209	14.671	14.645	29.166	1.00	83.97	O
ATOM	3669	N	ASN	H	210	11.339	14.709	27.924	1.00	81.27	N
ATOM	3670	CA	ASN	H	210	10.331	15.768	28.051	1.00	82.68	C
ATOM	3671	C	ASN	H	210	10.757	16.843	29.082	1.00	86.20	C
ATOM	3672	O	ASN	H	210	10.043	17.125	30.051	1.00	86.37	O
ATOM	3673	CB	ASN	H	210	8.923	15.215	28.306	1.00	88.32	C
ATOM	3674	CG	ASN	H	210	7.836	16.233	28.050	1.00	117.12	C
ATOM	3675	OD1	ASN	H	210	7.195	16.731	28.987	1.00	111.93	O
ATOM	3676	ND2	ASN	H	210	7.645	16.605	26.783	1.00	108.25	N
ATOM	3677	N	THR	H	211	11.962	17.409	28.861	1.00	81.24	N
ATOM	3678	CA	THR	H	211	12.576	18.449	29.688	1.00	79.78	C
ATOM	3679	C	THR	H	211	12.536	19.769	28.921	1.00	82.66	C
ATOM	3680	O	THR	H	211	13.063	19.849	27.815	1.00	81.53	O
ATOM	3681	CB	THR	H	211	14.022	18.042	30.072	1.00	81.62	C
ATOM	3682	OG1	THR	H	211	14.014	16.786	30.735	1.00	80.25	O
ATOM	3683	CG2	THR	H	211	14.704	19.048	30.963	1.00	77.41	C
ATOM	3684	N	LYS	H	212	11.872	20.782	29.495	1.00	79.85	N
ATOM	3685	CA	LYS	H	212	11.787	22.141	28.961	1.00	79.58	C
ATOM	3686	C	LYS	H	212	12.298	23.057	30.080	1.00	84.68	C
ATOM	3687	O	LYS	H	212	11.655	23.194	31.126	1.00	84.13	O
ATOM	3688	CB	LYS	H	212	10.365	22.502	28.491	1.00	80.88	C
ATOM	3689	N	VAL	H	213	13.519	23.587	29.892	1.00	81.98	N
ATOM	3690	CA	VAL	H	213	14.231	24.468	30.827	1.00	81.76	C
ATOM	3691	C	VAL	H	213	14.367	25.865	30.203	1.00	87.76	C
ATOM	3692	O	VAL	H	213	14.467	25.995	28.983	1.00	88.45	O
ATOM	3693	CB	VAL	H	213	15.633	23.898	31.194	1.00	84.86	C
ATOM	3694	CG1	VAL	H	213	16.292	24.694	32.318	1.00	84.42	C
ATOM	3695	CG2	VAL	H	213	15.559	22.426	31.566	1.00	84.38	C
ATOM	3696	N	ASP	H	214	14.363	26.900	31.045	1.00	85.23	N
ATOM	3697	CA	ASP	H	214	14.567	28.292	30.646	1.00	85.23	C
ATOM	3698	C	ASP	H	214	15.474	28.918	31.733	1.00	90.42	C
ATOM	3699	O	ASP	H	214	14.973	29.335	32.788	1.00	91.23	O
ATOM	3700	CB	ASP	H	214	13.228	29.051	30.487	1.00	86.86	C
ATOM	3701	CG	ASP	H	214	12.209	28.383	29.585	1.00	100.37	C
ATOM	3702	OD1	ASP	H	214	12.330	28.520	28.355	1.00	101.22	O
ATOM	3703	OD2	ASP	H	214	11.280	27.735	30.115	1.00	109.12	O
ATOM	3704	N	LYS	H	215	16.815	28.880	31.529	1.00	85.82	N
ATOM	3705	CA	LYS	H	215	17.777	29.456	32.482	1.00	85.11	C
ATOM	3706	C	LYS	H	215	18.098	30.897	32.099	1.00	91.42	C
ATOM	3707	O	LYS	H	215	18.388	31.182	30.934	1.00	91.39	O
ATOM	3708	CB	LYS	H	215	19.064	28.628	32.605	1.00	86.08	C
ATOM	3709	N	ARG	H	216	17.993	31.815	33.074	1.00	89.40	N
ATOM	3710	CA	ARG	H	216	18.306	33.224	32.866	1.00	89.14	C
ATOM	3711	C	ARG	H	216	19.809	33.379	33.079	1.00	91.83	C
ATOM	3712	O	ARG	H	216	20.343	32.990	34.136	1.00	90.26	O
ATOM	3713	CB	ARG	H	216	17.501	34.152	33.804	1.00	90.12	C
ATOM	3714	CG	ARG	H	216	17.921	35.622	33.696	1.00	105.64	C
ATOM	3715	CD	ARG	H	216	17.318	36.491	34.770	1.00	122.84	C
ATOM	3716	NE	ARG	H	216	15.952	36.871	34.419	1.00	138.90	N
ATOM	3717	CZ	ARG	H	216	15.175	37.649	35.162	1.00	157.20	C
ATOM	3718	NH1	ARG	H	216	15.619	38.137	36.315	1.00	148.31	N
ATOM	3719	NH2	ARG	H	216	13.945	37.945	34.760	1.00	142.54	N
ATOM	3720	N	VAL	H	217	20.485	33.892	32.029	1.00	87.94	N
ATOM	3721	CA	VAL	H	217	21.917	34.161	32.021	1.00	87.62	C
ATOM	3722	C	VAL	H	217	22.040	35.636	32.386	1.00	92.65	C
ATOM	3723	O	VAL	H	217	21.584	36.529	31.645	1.00	92.05	O
ATOM	3724	CB	VAL	H	217	22.614	33.791	30.682	1.00	91.18	C
ATOM	3725	CG1	VAL	H	217	24.131	33.955	30.782	1.00	90.91	C
ATOM	3726	CG2	VAL	H	217	22.261	32.369	30.254	1.00	90.75	C
ATOM	3727	N	GLU	H	218	22.571	35.858	33.593	1.00	90.11	N
ATOM	3728	CA	GLU	H	218	22.759	37.161	34.209	1.00	90.36	C
ATOM	3729	C	GLU	H	218	24.234	37.321	34.562	1.00	94.71	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	3730	O	GLU	H	218	24.889	36.308	34.841
ATOM	3731	CB	GLU	H	218	21.899	37.255	35.484
ATOM	3732	N	PRO	H	219	24.778	38.569	34.574
ATOM	3733	CA	PRO	H	219	26.189	38.737	34.949
ATOM	3734	C	PRO	H	219	26.394	38.372	36.419
ATOM	3735	O	PRO	H	219	25.557	38.730	37.261
ATOM	3736	CB	PRO	H	219	26.447	40.233	34.710
ATOM	3737	CG	PRO	H	219	25.277	40.739	33.922
ATOM	3738	CD	PRO	H	219	24.139	39.876	34.295
ATOM	3739	N	LYS	H	220	27.486	37.629	36.725
ATOM	3740	CA	LYS	H	220	27.826	37.213	38.099
ATOM	3741	C	LYS	H	220	28.246	38.436	38.943
ATOM	3742	O	LYS	H	220	29.038	39.264	38.463
ATOM	3743	CB	LYS	H	220	28.952	36.162	38.092
ATOM	3744	N	SER	H	221	27.705	38.567	40.177
ATOM	3745	CA	SER	H	221	28.023	39.699	41.062
ATOM	3746	C	SER	H	221	29.202	39.401	42.014
ATOM	3747	O	SER	H	221	30.343	39.807	41.761
ATOM	3748	CB	SER	H	221	26.786	40.130	41.845
ATOM	3749	OG	SER	H	221	25.775	40.642	40.993
TER	3750		SER	H	221			
ATOM	3751	O	GLU	I	1	9.402	-22.914	13.399
ATOM	3752	N	GLU	I	1	10.278	-21.223	11.441
ATOM	3753	CA	GLU	I	1	11.266	-21.823	12.342
ATOM	3754	C	GLU	I	1	10.631	-22.865	13.249
ATOM	3755	CB	GLU	I	1	12.000	-20.745	13.184
ATOM	3756	N	VAL	I	2	11.484	-23.701	13.857
ATOM	3757	CA	VAL	I	2	11.051	-24.715	14.806
ATOM	3758	C	VAL	I	2	10.766	-23.993	16.117
ATOM	3759	O	VAL	I	2	11.646	-23.293	16.639
ATOM	3760	CB	VAL	I	2	12.108	-25.810	14.997
ATOM	3761	CG1	VAL	I	2	11.591	-26.891	15.934
ATOM	3762	CG2	VAL	I	2	12.510	-26.402	13.659
ATOM	3763	N	GLN	I	3	9.533	-24.136	16.626
ATOM	3764	CA	GLN	I	3	9.146	-23.514	17.882
ATOM	3765	C	GLN	I	3	8.023	-24.252	18.592
ATOM	3766	O	GLN	I	3	7.176	-24.860	17.947
ATOM	3767	CB	GLN	I	3	8.824	-22.005	17.713
ATOM	3768	CG	GLN	I	3	7.703	-21.651	16.755
ATOM	3769	CD	GLN	I	3	7.731	-20.181	16.430
ATOM	3770	OE1	GLN	I	3	7.912	-19.324	17.306
ATOM	3771	NE2	GLN	I	3	7.561	-19.856	15.153
ATOM	3772	N	LEU	I	4	8.051	-24.202	19.929
ATOM	3773	CA	LEU	I	4	7.028	-24.744	20.823
ATOM	3774	C	LEU	I	4	6.432	-23.534	21.557
ATOM	3775	O	LEU	I	4	7.163	-22.794	22.219
ATOM	3776	CB	LEU	I	4	7.597	-25.778	21.828
ATOM	3777	CG	LEU	I	4	8.328	-27.001	21.257
ATOM	3778	CD1	LEU	I	4	9.067	-27.723	22.331
ATOM	3779	CD2	LEU	I	4	7.378	-27.977	20.611
ATOM	3780	N	VAL	I	5	5.126	-23.288	21.370
ATOM	3781	CA	VAL	I	5	4.427	-22.147	21.967
ATOM	3782	C	VAL	I	5	3.497	-22.633	23.072
ATOM	3783	O	VAL	I	5	2.596	-23.432	22.835
ATOM	3784	CB	VAL	I	5	3.708	-21.282	20.901
ATOM	3785	CG1	VAL	I	5	3.070	-20.053	21.529
ATOM	3786	CG2	VAL	I	5	4.660	-20.886	19.775
ATOM	3787	N	GLN	I	6	3.714	-22.154	24.274
ATOM	3788	CA	GLN	I	6	2.917	-22.605	25.396
ATOM	3789	C	GLN	I	6	1.739	-21.688	25.760
ATOM	3790	O	GLN	I	6	1.696	-20.499	25.403
ATOM	3791	CB	GLN	I	6	3.812	-22.852	26.602
ATOM	3792	CG	GLN	I	6	4.881	-23.871	26.318
ATOM	3793	CD	GLN	I	6	5.727	-24.133	27.510
ATOM	3794	OE1	GLN	I	6	6.938	-23.936	27.478
ATOM	3795	NE2	GLN	I	6	5.108	-24.620	28.574
ATOM	3796	N	SER	I	7	0.766	-22.278	26.479
ATOM	3797	CA	SER	I	7	-0.410	-21.578	26.945
ATOM	3798	C	SER	I	7	0.007	-20.487	27.963
ATOM	3799	O	SER	I	7	1.099	-20.576	28.558
ATOM	3800	CB	SER	I	7	-1.437	-22.558	27.518
ATOM	3801	OG	SER	I	7	-0.911	-23.449	28.487
ATOM	3802	N	GLY	I	8	-0.843	-19.455	28.094
ATOM	3803	CA	GLY	I	8	-0.654	-18.320	28.986
ATOM	3804	C	GLY	I	8	-0.525	-18.675	30.456
ATOM	3805	O	GLY	I	8	-0.791	-19.812	30.873
ATOM	3806	N	ALA	I	9	-0.098	-17.675	31.243

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	3807	CA	ALA	I	9	0.088	-17.766	32.688	1.00	72.69	C
ATOM	3808	C	ALA	I	9	-1.219	-18.156	33.386	1.00	78.61	C
ATOM	3809	O	ALA	I	9	-2.294	-17.644	33.048	1.00	78.66	O
ATOM	3810	CB	ALA	I	9	0.594	-16.437	33.222	1.00	73.25	C
ATOM	3811	N	GLU	I	10	-1.120	-19.077	34.341	1.00	75.84	N
ATOM	3812	CA	GLU	I	10	-2.277	-19.558	35.063	1.00	76.46	C
ATOM	3813	C	GLU	I	10	-2.225	-19.221	36.539	1.00	82.81	C
ATOM	3814	O	GLU	I	10	-1.209	-19.429	37.205	1.00	82.16	O
ATOM	3815	CB	GLU	I	10	-2.450	-21.072	34.865	1.00	78.04	C
ATOM	3816	CG	GLU	I	10	-2.709	-21.476	33.424	1.00	90.94	C
ATOM	3817	CD	GLU	I	10	-4.126	-21.368	32.896	1.00	116.83	C
ATOM	3818	OE1	GLU	I	10	-4.283	-21.290	31.655	1.00	111.63	O
ATOM	3819	OE2	GLU	I	10	-5.078	-21.393	33.712	1.00	115.99	O
ATOM	3820	N	VAL	I	11	-3.338	-18.690	37.047	1.00	81.59	N
ATOM	3821	CA	VAL	I	11	-3.521	-18.408	38.470	1.00	81.14	C
ATOM	3822	C	VAL	I	11	-4.732	-19.235	38.892	1.00	83.64	C
ATOM	3823	O	VAL	I	11	-5.846	-19.016	38.390	1.00	82.52	O
ATOM	3824	CB	VAL	I	11	-3.662	-16.914	38.858	1.00	84.07	C
ATOM	3825	CG1	VAL	I	11	-3.321	-16.734	40.333	1.00	83.20	C
ATOM	3826	CG2	VAL	I	11	-2.801	-16.005	37.973	1.00	83.77	C
ATOM	3827	N	LYS	I	12	-4.484	-20.237	39.745	1.00	79.43	N
ATOM	3828	CA	LYS	I	12	-5.497	-21.172	40.203	1.00	79.84	C
ATOM	3829	C	LYS	I	12	-5.524	-21.237	41.706	1.00	86.22	C
ATOM	3830	O	LYS	I	12	-4.474	-21.081	42.333	1.00	87.01	O
ATOM	3831	CB	LYS	I	12	-5.198	-22.597	39.661	1.00	82.18	C
ATOM	3832	CG	LYS	I	12	-5.085	-22.749	38.125	1.00	91.72	C
ATOM	3833	CD	LYS	I	12	-6.256	-22.187	37.303	1.00	97.26	C
ATOM	3834	CE	LYS	I	12	-7.395	-23.155	37.094	1.00	102.17	C
ATOM	3835	NZ	LYS	I	12	-8.669	-22.427	36.838	1.00	111.39	N
ATOM	3836	N	LYS	I	13	-6.712	-21.512	42.290	1.00	82.90	N
ATOM	3837	CA	LYS	I	13	-6.845	-21.715	43.735	1.00	82.79	C
ATOM	3838	C	LYS	I	13	-6.412	-23.169	44.011	1.00	85.28	C
ATOM	3839	O	LYS	I	13	-6.502	-23.995	43.109	1.00	84.54	O
ATOM	3840	CB	LYS	I	13	-8.285	-21.435	44.225	1.00	85.23	C
ATOM	3841	N	SER	I	14	-5.895	-23.467	45.211	1.00	81.97	N
ATOM	3842	CA	SER	I	14	-5.435	-24.814	45.579	1.00	82.20	C
ATOM	3843	C	SER	I	14	-6.560	-25.878	45.400	1.00	86.66	C
ATOM	3844	O	SER	I	14	-7.744	-25.513	45.383	1.00	87.74	O
ATOM	3845	CB	SER	I	14	-4.881	-24.814	47.008	1.00	85.78	C
ATOM	3846	OG	SER	I	14	-4.119	-23.651	47.316	1.00	93.93	O
ATOM	3847	N	GLY	I	15	-6.173	-27.145	45.187	1.00	81.09	N
ATOM	3848	CA	GLY	I	15	-7.084	-28.276	44.989	1.00	79.61	C
ATOM	3849	C	GLY	I	15	-7.796	-28.382	43.643	1.00	79.62	C
ATOM	3850	O	GLY	I	15	-8.335	-29.452	43.322	1.00	77.38	O
ATOM	3851	N	GLU	I	16	-7.858	-27.252	42.867	1.00	74.66	N
ATOM	3852	CA	GLU	I	16	-8.456	-27.159	41.525	1.00	74.04	C
ATOM	3853	C	GLU	I	16	-7.691	-28.067	40.525	1.00	81.04	C
ATOM	3854	O	GLU	I	16	-6.645	-28.630	40.867	1.00	81.55	O
ATOM	3855	CB	GLU	I	16	-8.413	-25.705	41.000	1.00	74.78	C
ATOM	3856	CG	GLU	I	16	-9.461	-24.761	41.568	1.00	81.12	C
ATOM	3857	CD	GLU	I	16	-9.541	-23.385	40.920	1.00	108.65	C
ATOM	3858	OE1	GLU	I	16	-9.329	-23.281	39.691	1.00	113.72	O
ATOM	3859	OE2	GLU	I	16	-9.875	-22.414	41.635	1.00	106.73	O
ATOM	3860	N	SER	I	17	-8.199	-28.193	39.281	1.00	77.41	N
ATOM	3861	CA	SER	I	17	-7.521	-28.991	38.265	1.00	76.16	C
ATOM	3862	C	SER	I	17	-7.120	-28.151	37.079	1.00	78.93	C
ATOM	3863	O	SER	I	17	-7.802	-27.169	36.761	1.00	80.06	O
ATOM	3864	CB	SER	I	17	-8.342	-30.208	37.884	1.00	79.27	C
ATOM	3865	OG	SER	I	17	-8.252	-31.116	38.972	1.00	86.97	O
ATOM	3866	N	LEU	I	18	-5.972	-28.489	36.457	1.00	72.35	N
ATOM	3867	CA	LEU	I	18	-5.428	-27.702	35.338	1.00	69.83	C
ATOM	3868	C	LEU	I	18	-4.777	-28.559	34.237	1.00	67.70	C
ATOM	3869	O	LEU	I	18	-4.134	-29.561	34.540	1.00	64.52	O
ATOM	3870	CB	LEU	I	18	-4.416	-26.680	35.920	1.00	69.44	C
ATOM	3871	CG	LEU	I	18	-3.584	-25.779	35.008	1.00	73.20	C
ATOM	3872	CD2	LEU	I	18	-2.568	-25.059	35.815	1.00	76.20	C
ATOM	3873	CD1	LEU	I	18	-4.442	-24.750	34.275	1.00	72.76	C
ATOM	3874	N	LYS	I	19	-4.966	-28.142	32.964	1.00	62.41	N
ATOM	3875	CA	LYS	I	19	-4.369	-28.749	31.776	1.00	62.11	C
ATOM	3876	C	LYS	I	19	-3.697	-27.616	31.026	1.00	66.97	C
ATOM	3877	O	LYS	I	19	-4.342	-26.609	30.694	1.00	66.47	O
ATOM	3878	CB	LYS	I	19	-5.390	-29.481	30.872	1.00	64.31	C
ATOM	3879	N	ILE	I	20	-2.381	-27.773	30.804	1.00	63.63	N
ATOM	3880	CA	ILE	I	20	-1.539	-26.799	30.149	1.00	63.55	C
ATOM	3881	C	ILE	I	20	-1.067	-27.353	28.808	1.00	65.55	C
ATOM	3882	O	ILE	I	20	-0.819	-28.551	28.678	1.00	64.15	O
ATOM	3883	CB	ILE	I	20	-0.442	-26.336	31.156	1.00	68.03	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	3884	CG1	ILE	I	20	-0.426	-24.851	31.233
ATOM	3885	CG2	ILE	I	20	0.972	-26.910	30.992
ATOM	3886	CD1	ILE	I	20	-1.289	-24.363	32.284
ATOM	3887	N	SER	I	21	-1.042	-26.495	27.793
ATOM	3888	CA	SER	I	21	-0.704	-26.892	26.436
ATOM	3889	C	SER	I	21	0.663	-26.366	25.981
ATOM	3890	O	SER	I	21	1.248	-25.476	26.610
ATOM	3891	CB	SER	I	21	-1.832	-26.509	25.473
ATOM	3892	OG	SER	I	21	-1.657	-25.282	24.780
ATOM	3893	N	CYS	I	22	1.160	-26.950	24.881
ATOM	3894	CA	CYS	I	22	2.448	-26.693	24.249
ATOM	3895	C	CYS	I	22	2.267	-27.046	22.773
ATOM	3896	O	CYS	I	22	2.194	-28.225	22.438
ATOM	3897	CB	CYS	I	22	3.500	-27.573	24.925
ATOM	3898	SG	CYS	I	22	5.059	-27.755	24.020
ATOM	3899	N	LYS	I	23	2.137	-26.035	21.909
ATOM	3900	CA	LYS	I	23	1.926	-26.220	20.479
ATOM	3901	C	LYS	I	23	3.233	-26.174	19.670
ATOM	3902	O	LYS	I	23	3.928	-25.161	19.651
ATOM	3903	CB	LYS	I	23	0.901	-25.199	19.938
ATOM	3904	CG	LYS	I	23	0.077	-25.702	18.764
ATOM	3905	CD	LYS	I	23	-0.371	-24.564	17.894
ATOM	3906	CE	LYS	I	23	-1.320	-24.994	16.807
ATOM	3907	NZ	LYS	I	23	-1.823	-23.816	16.052
ATOM	3908	N	GLY	I	24	3.505	-27.251	18.952
ATOM	3909	CA	GLY	I	24	4.680	-27.368	18.098
ATOM	3910	C	GLY	I	24	4.390	-27.033	16.647
ATOM	3911	O	GLY	I	24	3.400	-27.505	16.079
ATOM	3912	N	SER	I	25	5.277	-26.228	16.037
ATOM	3913	CA	SER	I	25	5.206	-25.773	14.649
ATOM	3914	C	SER	I	25	6.621	-25.687	14.053
ATOM	3915	O	SER	I	25	7.578	-25.457	14.789
ATOM	3916	CB	SER	I	25	4.525	-24.408	14.582
ATOM	3917	OG	SER	I	25	5.121	-23.460	15.456
ATOM	3918	N	GLY	I	26	6.743	-25.868	12.739
ATOM	3919	CA	GLY	I	26	8.012	-25.783	12.019
ATOM	3920	C	GLY	I	26	8.717	-27.103	11.808
ATOM	3921	O	GLY	I	26	9.726	-27.162	11.095
ATOM	3922	N	TYR	I	27	8.183	-28.173	12.424
ATOM	3923	CA	TYR	I	27	8.761	-29.511	12.367
ATOM	3924	C	TYR	I	27	7.659	-30.580	12.355
ATOM	3925	O	TYR	I	27	6.483	-30.263	12.554
ATOM	3926	CB	TYR	I	27	9.745	-29.693	13.560
ATOM	3927	CG	TYR	I	27	9.088	-30.010	14.892
ATOM	3928	CD1	TYR	I	27	8.610	-28.998	15.719
ATOM	3929	CD2	TYR	I	27	8.952	-31.325	15.326
ATOM	3930	CE1	TYR	I	27	8.001	-29.293	16.939
ATOM	3931	CE2	TYR	I	27	8.348	-31.630	16.542
ATOM	3932	CZ	TYR	I	27	7.869	-30.614	17.341
ATOM	3933	OH	TYR	I	27	7.249	-30.949	18.512
ATOM	3934	N	SER	I	28	8.054	-31.848	12.125
ATOM	3935	CA	SER	I	28	7.151	-32.997	12.117
ATOM	3936	C	SER	I	28	6.896	-33.464	13.571
ATOM	3937	O	SER	I	28	7.731	-34.153	14.163
ATOM	3938	CB	SER	I	28	7.740	-34.114	11.257
ATOM	3939	OG	SER	I	28	7.169	-35.378	11.552
ATOM	3940	N	PHE	I	29	5.749	-33.073	14.134
ATOM	3941	CA	PHE	I	29	5.377	-33.349	15.519
ATOM	3942	C	PHE	I	29	5.447	-34.816	15.943
ATOM	3943	O	PHE	I	29	5.705	-35.084	17.116
ATOM	3944	CB	PHE	I	29	3.990	-32.768	15.821
ATOM	3945	CG	PHE	I	29	3.525	-32.852	17.266
ATOM	3946	CD2	PHE	I	29	2.613	-33.828	17.668
ATOM	3947	CD1	PHE	I	29	3.952	-31.920	18.209
ATOM	3948	CE2	PHE	I	29	2.152	-33.875	18.985
ATOM	3949	CE1	PHE	I	29	3.508	-31.986	19.532
ATOM	3950	CZ	PHE	I	29	2.621	-32.971	19.910
ATOM	3951	N	THR	I	30	5.211	-35.756	15.019
ATOM	3952	CA	THR	I	30	5.167	-37.199	15.327
ATOM	3953	C	THR	I	30	6.518	-37.852	15.354
ATOM	3954	O	THR	I	30	6.626	-38.999	15.792
ATOM	3955	CB	THR	I	30	4.231	-37.949	14.363
ATOM	3956	OG1	THR	I	30	4.363	-37.412	13.044
ATOM	3957	CG2	THR	I	30	2.780	-37.893	14.802
ATOM	3958	N	SER	I	31	7.542	-37.141	14.858
ATOM	3959	CA	SER	I	31	8.915	-37.628	14.748
ATOM	3960	C	SER	I	31	9.814	-37.329	15.968

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.											
ATOM	3961	O	SER	I	31	10.944	-37.854	16.043	1.00	66.52	O
ATOM	3962	CB	SER	I	31	9.555	-37.060	13.493	1.00	64.19	C
ATOM	3963	OG	SER	I	31	8.801	-37.401	12.345	1.00	74.65	O
ATOM	3964	N	TYR	I	32	9.316	-36.502	16.920	1.00	58.86	N
ATOM	3965	CA	TYR	I	32	10.090	-36.116	18.091	1.00	57.29	C
ATOM	3966	C	TYR	I	32	9.369	-36.328	19.391	1.00	61.91	C
ATOM	3967	O	TYR	I	32	8.208	-35.940	19.497	1.00	62.97	O
ATOM	3968	CB	TYR	I	32	10.501	-34.643	18.000	1.00	56.76	C
ATOM	3969	CG	TYR	I	32	11.403	-34.317	16.840	1.00	57.85	C
ATOM	3970	CD2	TYR	I	32	12.788	-34.266	16.998	1.00	57.52	C
ATOM	3971	CD1	TYR	I	32	10.877	-34.015	15.586	1.00	60.39	C
ATOM	3972	CE2	TYR	I	32	13.626	-33.949	15.930	1.00	57.30	C
ATOM	3973	CE1	TYR	I	32	11.704	-33.673	14.517	1.00	61.02	C
ATOM	3974	CZ	TYR	I	32	13.078	-33.659	14.690	1.00	65.11	C
ATOM	3975	OH	TYR	I	32	13.873	-33.299	13.636	1.00	69.43	O
ATOM	3976	N	TRP	I	33	10.086	-36.846	20.413	1.00	57.69	N
ATOM	3977	CA	TRP	I	33	9.588	-36.962	21.783	1.00	57.15	C
ATOM	3978	C	TRP	I	33	9.554	-35.550	22.368	1.00	62.63	C
ATOM	3979	O	TRP	I	33	10.367	-34.703	21.987	1.00	61.83	O
ATOM	3980	CB	TRP	I	33	10.513	-37.817	22.645	1.00	55.19	C
ATOM	3981	CG	TRP	I	33	10.500	-39.265	22.287	1.00	55.50	C
ATOM	3982	CD1	TRP	I	33	10.896	-39.822	21.106	1.00	58.27	C
ATOM	3983	CD2	TRP	I	33	10.176	-40.351	23.156	1.00	55.17	C
ATOM	3984	NE1	TRP	I	33	10.823	-41.189	21.182	1.00	57.64	N
ATOM	3985	CE2	TRP	I	33	10.373	-41.543	22.429	1.00	59.21	C
ATOM	3986	CE3	TRP	I	33	9.683	-40.435	24.469	1.00	56.43	C
ATOM	3987	CZ2	TRP	I	33	10.064	-42.803	22.963	1.00	58.66	C
ATOM	3988	CZ3	TRP	I	33	9.405	-41.686	25.007	1.00	57.70	C
ATOM	3989	CH2	TRP	I	33	9.596	-42.850	24.259	1.00	58.37	C
ATOM	3990	N	ILE	I	34	8.615	-35.293	23.281	1.00	60.52	N
ATOM	3991	CA	ILE	I	34	8.423	-33.968	23.861	1.00	60.27	C
ATOM	3992	C	ILE	I	34	8.280	-34.103	25.379	1.00	64.45	C
ATOM	3993	O	ILE	I	34	7.510	-34.935	25.851	1.00	64.21	O
ATOM	3994	CB	ILE	I	34	7.283	-33.214	23.114	1.00	63.07	C
ATOM	3995	CG1	ILE	I	34	6.979	-31.864	23.725	1.00	64.36	C
ATOM	3996	CG2	ILE	I	34	6.025	-34.033	22.956	1.00	64.11	C
ATOM	3997	CD1	ILE	I	34	6.790	-30.832	22.682	1.00	76.51	C
ATOM	3998	N	GLY	I	35	9.114	-33.362	26.113	1.00	60.99	N
ATOM	3999	CA	GLY	I	35	9.191	-33.446	27.570	1.00	60.47	C
ATOM	4000	C	GLY	I	35	8.761	-32.221	28.343	1.00	61.90	C
ATOM	4001	O	GLY	I	35	8.635	-31.135	27.775	1.00	60.92	O
ATOM	4002	N	TRP	I	36	8.515	-32.407	29.650	1.00	57.98	N
ATOM	4003	CA	TRP	I	36	8.080	-31.354	30.577	1.00	58.04	C
ATOM	4004	C	TRP	I	36	9.080	-31.215	31.731	1.00	64.17	C
ATOM	4005	O	TRP	I	36	9.437	-32.203	32.392	1.00	63.35	O
ATOM	4006	CB	TRP	I	36	6.636	-31.574	31.076	1.00	56.24	C
ATOM	4007	CG	TRP	I	36	5.591	-31.424	30.002	1.00	57.43	C
ATOM	4008	CD1	TRP	I	36	5.118	-32.405	29.179	1.00	60.28	C
ATOM	4009	CD2	TRP	I	36	4.902	-30.211	29.619	1.00	57.34	C
ATOM	4010	NE1	TRP	I	36	4.195	-31.877	28.290	1.00	59.51	N
ATOM	4011	CE2	TRP	I	36	4.057	-30.533	28.529	1.00	60.44	C
ATOM	4012	CE3	TRP	I	36	4.920	-28.882	30.092	1.00	58.90	C
ATOM	4013	CZ2	TRP	I	36	3.244	-29.579	27.901	1.00	59.80	C
ATOM	4014	CZ3	TRP	I	36	4.101	-27.937	29.477	1.00	60.39	C
ATOM	4015	CH2	TRP	I	36	3.264	-28.290	28.405	1.00	60.79	C
ATOM	4016	N	VAL	I	37	9.572	-29.976	31.916	1.00	62.07	N
ATOM	4017	CA	VAL	I	37	10.571	-29.593	32.912	1.00	62.56	C
ATOM	4018	C	VAL	I	37	9.962	-28.517	33.810	1.00	67.37	C
ATOM	4019	O	VAL	I	37	9.327	-27.573	33.307	1.00	64.75	O
ATOM	4020	CB	VAL	I	37	11.883	-29.092	32.223	1.00	66.31	C
ATOM	4021	CG1	VAL	I	37	12.956	-28.723	33.234	1.00	65.80	C
ATOM	4022	CG2	VAL	I	37	12.429	-30.116	31.234	1.00	66.10	C
ATOM	4023	N	ARG	I	38	10.157	-28.676	35.138	1.00	66.86	N
ATOM	4024	CA	ARG	I	38	9.701	-27.747	36.169	1.00	68.05	C
ATOM	4025	C	ARG	I	38	10.889	-26.940	36.707	1.00	74.93	C
ATOM	4026	O	ARG	I	38	11.946	-27.507	36.999	1.00	74.31	O
ATOM	4027	CB	ARG	I	38	9.006	-28.504	37.331	1.00	67.75	C
ATOM	4028	CG	ARG	I	38	8.500	-27.591	38.452	1.00	71.79	C
ATOM	4029	CD	ARG	I	38	7.694	-28.311	39.504	1.00	87.98	C
ATOM	4030	NE	ARG	I	38	8.525	-29.075	40.437	1.00	100.56	N
ATOM	4031	CZ	ARG	I	38	8.054	-29.690	41.517	1.00	112.67	C
ATOM	4032	NH1	ARG	I	38	6.762	-29.636	41.809	1.00	101.01	N
ATOM	4033	NH2	ARG	I	38	8.869	-30.374	42.308	1.00	97.53	N
ATOM	4034	N	GLN	I	39	10.703	-25.624	36.855	1.00	73.42	N
ATOM	4035	CA	GLN	I	39	11.682	-24.716	37.435	1.00	74.06	C
ATOM	4036	C	GLN	I	39	11.002	-23.972	38.608	1.00	83.18	C
ATOM	4037	O	GLN	I	39	10.327	-22.944	38.388	1.00	83.31	O

TABLE 1-continued

Three-dimensional crystal coordinate for anti-TedB antibody beziotoxumab
Fab -C. difficile toxin B (TedB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	4038	CB	GLN	I	39	12.246	-23.750	36.367	1.00	74.63	C
ATOM	4039	CG	GLN	I	39	13.290	-22.773	36.912	1.00	81.64	C
ATOM	4040	CD	GLN	I	39	13.967	-21.958	35.847	1.00	95.43	C
ATOM	4041	OE1	GLN	I	39	13.371	-21.058	35.237	1.00	91.60	O
ATOM	4042	NE2	GLN	I	39	15.249	-22.221	35.649	1.00	82.03	N
ATOM	4043	N	MET	I	40	11.159	-24.510	39.852	1.00	82.05	N
ATOM	4044	CA	MET	I	40	10.600	-23.892	41.073	1.00	83.44	C
ATOM	4045	C	MET	I	40	11.135	-22.454	41.172	1.00	89.91	C
ATOM	4046	O	MET	I	40	12.262	-22.245	40.727	1.00	90.05	O
ATOM	4047	CB	MET	I	40	11.000	-24.685	42.324	1.00	86.17	C
ATOM	4048	CG	MET	I	40	10.386	-26.071	42.395	1.00	90.46	C
ATOM	4049	SD	MET	I	40	9.331	-26.351	43.842	1.00	95.11	S
ATOM	4050	CE	MET	I	40	7.983	-25.267	43.468	1.00	91.89	C
ATOM	4051	N	PRO	I	41	10.384	-21.431	41.659	1.00	88.42	N
ATOM	4052	CA	PRO	I	41	10.936	-20.055	41.652	1.00	88.60	C
ATOM	4053	C	PRO	I	41	12.289	-19.910	42.350	1.00	89.80	C
ATOM	4054	O	PRO	I	41	12.505	-20.447	43.450	1.00	87.55	O
ATOM	4055	CB	PRO	I	41	9.831	-19.203	42.292	1.00	90.37	C
ATOM	4056	CG	PRO	I	41	8.598	-19.985	42.082	1.00	94.63	C
ATOM	4057	CD	PRO	I	41	9.015	-21.437	42.206	1.00	90.21	C
ATOM	4058	N	GLY	I	42	13.212	-19.290	41.614	1.00	85.86	N
ATOM	4059	CA	GLY	I	42	14.593	-19.060	42.029	1.00	85.71	C
ATOM	4060	C	GLY	I	42	15.470	-20.295	42.163	1.00	88.60	C
ATOM	4061	O	GLY	I	42	16.568	-20.208	42.715	1.00	88.65	O
ATOM	4062	N	LYS	I	43	14.988	-21.456	41.693	1.00	83.66	N
ATOM	4063	CA	LYS	I	43	15.708	-22.733	41.730	1.00	81.93	C
ATOM	4064	C	LYS	I	43	16.029	-23.146	40.266	1.00	83.54	C
ATOM	4065	O	LYS	I	43	15.772	-22.366	39.329	1.00	83.06	O
ATOM	4066	CB	LYS	I	43	14.909	-23.799	42.518	1.00	83.00	C
ATOM	4067	N	GLY	I	44	16.620	-24.326	40.096	1.00	77.42	N
ATOM	4068	CA	GLY	I	44	17.028	-24.838	38.793	1.00	75.70	C
ATOM	4069	C	GLY	I	44	15.974	-25.633	38.052	1.00	75.88	C
ATOM	4070	O	GLY	I	44	14.783	-25.391	38.224	1.00	76.37	O
ATOM	4071	N	LEU	I	45	16.410	-26.622	37.244	1.00	68.72	N
ATOM	4072	CA	LEU	I	45	15.530	-27.436	36.393	1.00	65.41	C
ATOM	4073	C	LEU	I	45	15.316	-28.859	36.907	1.00	71.62	C
ATOM	4074	O	LEU	I	45	16.273	-29.523	37.316	1.00	71.65	O
ATOM	4075	CB	LEU	I	45	16.043	-27.435	34.940	1.00	63.32	C
ATOM	4076	CG	LEU	I	45	16.360	-26.055	34.318	1.00	65.48	C
ATOM	4077	CD1	LEU	I	45	17.107	-26.170	33.009	1.00	64.91	C
ATOM	4078	CD2	LEU	I	45	15.141	-25.202	34.150	1.00	65.18	C
ATOM	4079	N	GLU	I	46	14.043	-29.309	36.917	1.00	69.73	N
ATOM	4080	CA	GLU	I	46	13.634	-30.671	37.326	1.00	69.90	C
ATOM	4081	C	GLU	I	46	12.877	-31.347	36.191	1.00	71.66	C
ATOM	4082	O	GLU	I	46	11.846	-30.824	35.746	1.00	69.77	O
ATOM	4083	CB	GLU	I	46	12.688	-30.654	38.528	1.00	71.45	C
ATOM	4084	CG	GLU	I	46	13.263	-30.217	39.854	1.00	82.95	C
ATOM	4085	CD	GLU	I	46	12.143	-29.855	40.810	1.00	108.09	C
ATOM	4086	OE1	GLU	I	46	11.545	-28.765	40.631	1.00	91.03	O
ATOM	4087	OE2	GLU	I	46	11.807	-30.700	41.677	1.00	104.43	O
ATOM	4088	N	TRP	I	47	13.349	-32.522	35.755	1.00	67.36	N
ATOM	4089	CA	TRP	I	47	12.620	-33.231	34.705	1.00	66.61	C
ATOM	4090	C	TRP	I	47	11.404	-33.988	35.303	1.00	70.00	C
ATOM	4091	O	TRP	I	47	11.537	-34.680	36.325	1.00	67.96	O
ATOM	4092	CB	TRP	I	47	13.546	-34.135	33.888	1.00	64.48	C
ATOM	4093	CG	TRP	I	47	12.815	-35.022	32.933	1.00	64.76	C
ATOM	4094	CD1	TRP	I	47	12.229	-34.663	31.751	1.00	67.48	C
ATOM	4095	CD2	TRP	I	47	12.584	-36.427	33.091	1.00	64.21	C
ATOM	4096	NE1	TRP	I	47	11.644	-35.764	31.163	1.00	66.79	N
ATOM	4097	CE2	TRP	I	47	11.837	-36.858	31.972	1.00	68.07	C
ATOM	4098	CE3	TRP	I	47	12.916	-37.362	34.087	1.00	64.98	C
ATOM	4099	CZ2	TRP	I	47	11.417	-38.181	31.827	1.00	67.32	C
ATOM	4100	CZ3	TRP	I	47	12.500	-38.674	33.939	1.00	66.41	C
ATOM	4101	CH2	TRP	I	47	11.784	-39.080	32.813	1.00	67.15	C
ATOM	4102	N	MET	I	48	10.221	-33.807	34.663	1.00	66.56	N
ATOM	4103	CA	MET	I	48	8.934	-34.386	35.070	1.00	65.76	C
ATOM	4104	C	MET	I	48	8.604	-35.648	34.291	1.00	67.95	C
ATOM	4105	O	MET	I	48	8.364	-36.680	34.904	1.00	65.85	O
ATOM	4106	CB	MET	I	48	7.806	-33.361	34.903	1.00	68.05	C
ATOM	4107	CG	MET	I	48	7.995	-32.120	35.739	1.00	71.63	C
ATOM	4108	SD	MET	I	48	6.733	-30.878	35.446	1.00	75.98	S
ATOM	4109	CE	MET	I	48	5.403	-31.584	36.272	1.00	72.85	C
ATOM	4110	N	GLY	I	49	8.593	-35.541	32.955	1.00	65.12	N
ATOM	4111	CA	GLY	I	49	8.310	-36.636	32.028	1.00	64.44	C
ATOM	4112	C	GLY	I	49	8.508	-36.285	30.563	1.00	66.69	C
ATOM	4113	O	GLY	I	49	8.785	-35.129	30.237	1.00	64.21	O
ATOM	4114	N	ILE	I	50	8.412	-37.304	29.672	1.00	64.86	N

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	4115	CA	ILE	I	50	8.520	-37.213	28.193	1.00	64.38	C
ATOM	4116	C	ILE	I	50	7.363	-37.980	27.644	1.00	67.11	C
ATOM	4117	O	ILE	I	50	6.898	-38.938	28.260	1.00	65.22	O
ATOM	4118	CB	ILE	I	50	9.803	-37.841	27.526	1.00	67.39	C
ATOM	4119	CG1	ILE	I	50	10.525	-38.798	28.470	1.00	69.16	C
ATOM	4120	CG2	ILE	I	50	10.759	-36.834	26.901	1.00	65.25	C
ATOM	4121	CD1	ILE	I	50	10.063	-40.199	28.364	1.00	83.75	C
ATOM	4122	N	PHE	I	51	6.991	-37.640	26.420	1.00	64.44	N
ATOM	4123	CA	PHE	I	51	5.925	-38.274	25.683	1.00	63.50	C
ATOM	4124	C	PHE	I	51	6.355	-38.474	24.231	1.00	63.70	C
ATOM	4125	O	PHE	I	51	6.980	-37.576	23.663	1.00	62.37	O
ATOM	4126	CB	PHE	I	51	4.695	-37.348	25.732	1.00	65.37	C
ATOM	4127	CG	PHE	I	51	3.470	-37.981	25.126	1.00	67.10	C
ATOM	4128	CD2	PHE	I	51	3.068	-37.659	23.836	1.00	69.71	C
ATOM	4129	CD1	PHE	I	51	2.749	-38.941	25.824	1.00	68.50	C
ATOM	4130	CE2	PHE	I	51	1.966	-38.274	23.266	1.00	70.24	C
ATOM	4131	CE1	PHE	I	51	1.638	-39.543	25.256	1.00	71.23	C
ATOM	4132	CZ	PHE	I	51	1.248	-39.197	23.984	1.00	69.49	C
ATOM	4133	N	TYR	I	52	5.971	-39.603	23.611	1.00	58.21	N
ATOM	4134	CA	TYR	I	52	6.235	-39.783	22.195	1.00	58.01	C
ATOM	4135	C	TYR	I	52	4.950	-39.632	21.401	1.00	66.37	C
ATOM	4136	O	TYR	I	52	4.136	-40.548	21.395	1.00	66.71	O
ATOM	4137	CB	TYR	I	52	6.951	-41.098	21.842	1.00	58.63	C
ATOM	4138	CG	TYR	I	52	7.366	-41.193	20.377	1.00	59.77	C
ATOM	4139	CD1	TYR	I	52	7.748	-40.060	19.662	1.00	62.49	C
ATOM	4140	CD2	TYR	I	52	7.463	-42.423	19.738	1.00	59.51	C
ATOM	4141	CE1	TYR	I	52	8.151	-40.144	18.332	1.00	64.97	C
ATOM	4142	CE2	TYR	I	52	7.826	-42.517	18.398	1.00	60.69	C
ATOM	4143	CZ	TYR	I	52	8.184	-41.375	17.699	1.00	71.54	C
ATOM	4144	OH	TYR	I	52	8.568	-41.453	16.379	1.00	71.88	O
ATOM	4145	N	PRO	I	53	4.764	-38.501	20.685	1.00	65.38	N
ATOM	4146	CA	PRO	I	53	3.547	-38.323	19.869	1.00	65.71	C
ATOM	4147	C	PRO	I	53	3.180	-39.459	18.887	1.00	71.34	C
ATOM	4148	O	PRO	I	53	2.002	-39.755	18.747	1.00	72.34	O
ATOM	4149	CB	PRO	I	53	3.843	-37.019	19.118	1.00	67.04	C
ATOM	4150	CG	PRO	I	53	4.716	-36.270	20.047	1.00	70.50	C
ATOM	4151	CD	PRO	I	53	5.620	-37.298	20.614	1.00	66.14	C
ATOM	4152	O	GLY	I	54	3.940	-43.426	16.809	1.00	74.29	O
ATOM	4153	N	GLY	I	54	4.161	-40.071	18.226	1.00	68.35	N
ATOM	4154	CA	GLY	I	54	3.907	-41.088	17.212	1.00	68.65	C
ATOM	4155	C	GLY	I	54	3.895	-42.534	17.661	1.00	73.95	C
ATOM	4156	N	ASP	I	55	3.794	-42.775	18.986	1.00	69.60	N
ATOM	4157	CA	ASP	I	55	3.792	-44.083	19.659	1.00	69.20	C
ATOM	4158	C	ASP	I	55	2.867	-44.029	20.885	1.00	75.40	C
ATOM	4159	O	ASP	I	55	2.448	-45.070	21.412	1.00	75.17	O
ATOM	4160	CB	ASP	I	55	5.213	-44.324	20.180	1.00	71.13	C
ATOM	4161	CG	ASP	I	55	5.700	-45.734	20.429	1.00	88.45	C
ATOM	4162	OD1	ASP	I	55	4.920	-46.678	20.218	1.00	93.48	O
ATOM	4163	OD2	ASP	I	55	6.888	-45.896	20.805	1.00	94.33	O
ATOM	4164	N	SER	I	56	2.623	-42.801	21.387	1.00	72.73	N
ATOM	4165	CA	SER	I	56	1.876	-42.466	22.594	1.00	72.43	C
ATOM	4166	C	SER	I	56	2.561	-43.002	23.863	1.00	75.15	C
ATOM	4167	O	SER	I	56	1.942	-42.996	24.925	1.00	75.21	O
ATOM	4168	CB	SER	I	56	0.404	-42.866	22.490	1.00	77.56	C
ATOM	4169	OG	SER	I	56	-0.340	-41.817	21.886	1.00	89.97	O
ATOM	4170	N	SER	I	57	3.860	-43.398	23.778	1.00	71.33	N
ATOM	4171	CA	SER	I	57	4.591	-43.900	24.957	1.00	71.28	C
ATOM	4172	C	SER	I	57	5.001	-42.765	25.835	1.00	75.85	C
ATOM	4173	O	SER	I	57	5.425	-41.715	25.349	1.00	75.79	O
ATOM	4174	CB	SER	I	57	5.780	-44.804	24.612	1.00	74.12	C
ATOM	4175	OG	SER	I	57	6.242	-44.661	23.281	1.00	80.60	O
ATOM	4176	N	THR	I	58	4.794	-42.943	27.127	1.00	73.23	N
ATOM	4177	CA	THR	I	58	5.115	-41.931	28.115	1.00	73.74	C
ATOM	4178	C	THR	I	58	5.986	-42.571	29.178	1.00	79.05	C
ATOM	4179	O	THR	I	58	5.844	-43.767	29.415	1.00	79.82	O
ATOM	4180	CB	THR	I	58	3.820	-41.188	28.645	1.00	81.60	C
ATOM	4181	OG1	THR	I	58	3.703	-41.330	30.054	1.00	80.87	O
ATOM	4182	CG2	THR	I	58	2.514	-41.666	28.004	1.00	78.87	C
ATOM	4183	N	ARG	I	59	6.899	-41.788	29.793	1.00	75.67	N
ATOM	4184	CA	ARG	I	59	7.758	-42.183	30.921	1.00	75.09	C
ATOM	4185	C	ARG	I	59	7.927	-40.978	31.834	1.00	77.95	C
ATOM	4186	O	ARG	I	59	8.230	-39.889	31.347	1.00	76.23	O
ATOM	4187	CB	ARG	I	59	9.091	-42.807	30.482	1.00	75.50	C
ATOM	4188	CG	ARG	I	59	8.906	-44.279	30.145	1.00	90.00	C
ATOM	4189	CD	ARG	I	59	9.430	-44.684	28.783	1.00	99.22	C
ATOM	4190	NE	ARG	I	59	8.887	-45.985	28.360	1.00	100.63	N
ATOM	4191	CZ	ARG	I	59	8.870	-46.443	27.113	1.00	118.22	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	4192	NH	ARG	I	59	8.317	-47.617	26.839	1.00	104.68	N
ATOM	4193	NH2	ARG	I	59	9.531	-45.805	26.153	1.00	113.99	N
ATOM	4194	N	TYR	I	60	7.595	-41.149	33.138	1.00	75.39	N
ATOM	4195	CA	TYR	I	60	7.634	-40.086	34.166	1.00	74.89	C
ATOM	4196	C	TYR	I	60	8.795	-40.270	35.157	1.00	82.20	C
ATOM	4197	O	TYR	I	60	9.238	-41.409	35.400	1.00	82.64	O
ATOM	4198	CB	TYR	I	60	6.320	-40.053	34.993	1.00	73.75	C
ATOM	4199	CG	TYR	I	60	5.048	-39.877	34.196	1.00	72.22	C
ATOM	4200	CD1	TYR	I	60	4.626	-38.616	33.791	1.00	73.60	C
ATOM	4201	CD2	TYR	I	60	4.225	-40.958	33.916	1.00	72.14	C
ATOM	4202	CE1	TYR	I	60	3.440	-38.442	33.083	1.00	73.63	C
ATOM	4203	CE2	TYR	I	60	3.025	-40.794	33.226	1.00	72.67	C
ATOM	4204	CZ	TYR	I	60	2.642	-39.535	32.800	1.00	78.09	C
ATOM	4205	OH	TYR	I	60	1.502	-39.376	32.055	1.00	76.21	O
ATOM	4206	N	SER	I	61	9.234	-39.143	35.776	1.00	79.09	N
ATOM	4207	CA	SER	I	61	10.258	-39.125	36.813	1.00	79.20	C
ATOM	4208	C	SER	I	61	9.595	-39.776	38.008	1.00	84.62	C
ATOM	4209	O	SER	I	61	8.444	-39.430	38.279	1.00	84.52	O
ATOM	4210	CB	SER	I	61	10.619	-37.691	37.176	1.00	83.03	C
ATOM	4211	OG	SER	I	61	11.631	-37.628	38.168	1.00	91.50	O
ATOM	4212	N	PRO	I	62	10.238	-40.734	38.723	1.00	81.17	N
ATOM	4213	CA	PRO	I	62	9.557	-41.356	39.881	1.00	80.59	C
ATOM	4214	C	PRO	I	62	8.957	-40.341	40.864	1.00	85.77	C
ATOM	4215	O	PRO	I	62	7.941	-40.629	41.501	1.00	86.46	O
ATOM	4216	CB	PRO	I	62	10.632	-42.244	40.515	1.00	82.02	C
ATOM	4217	CG	PRO	I	62	11.914	-41.877	39.849	1.00	86.48	C
ATOM	4218	CD	PRO	I	62	11.591	-41.288	38.522	1.00	82.17	C
ATOM	4219	N	SER	I	63	9.525	-39.129	40.913	1.00	82.61	N
ATOM	4220	CA	SER	I	63	9.057	-38.024	41.757	1.00	83.30	C
ATOM	4221	C	SER	I	63	7.771	-37.317	41.236	1.00	87.98	C
ATOM	4222	O	SER	I	63	7.136	-36.574	41.989	1.00	87.96	O
ATOM	4223	CB	SER	I	63	10.182	-37.015	41.971	1.00	88.09	C
ATOM	4224	OG	SER	I	63	10.792	-36.675	40.734	1.00	100.11	O
ATOM	4225	N	PHE	I	64	7.393	-37.542	39.962	1.00	84.31	N
ATOM	4226	CA	PHE	I	64	6.191	-36.958	39.339	1.00	83.68	C
ATOM	4227	C	PHE	I	64	5.159	-38.024	38.921	1.00	90.07	C
ATOM	4228	O	PHE	I	64	4.036	-37.684	38.538	1.00	89.38	O
ATOM	4229	CB	PHE	I	64	6.567	-36.043	38.171	1.00	84.83	C
ATOM	4230	CG	PHE	I	64	7.272	-34.783	38.607	1.00	86.15	C
ATOM	4231	CD2	PHE	I	64	6.554	-33.629	38.898	1.00	87.83	C
ATOM	4232	CD1	PHE	I	64	8.656	-34.753	38.750	1.00	88.94	C
ATOM	4233	CE2	PHE	I	64	7.209	-32.466	39.319	1.00	90.51	C
ATOM	4234	CE1	PHE	I	64	9.309	-33.590	39.171	1.00	89.74	C
ATOM	4235	CZ	PHE	I	64	8.582	-32.454	39.450	1.00	88.45	C
ATOM	4236	N	GLN	I	65	5.542	-39.315	39.040	1.00	88.24	N
ATOM	4237	CA	GLN	I	65	4.721	-40.486	38.750	1.00	88.48	C
ATOM	4238	C	GLN	I	65	3.462	-40.450	39.614	1.00	93.18	C
ATOM	4239	O	GLN	I	65	3.552	-40.454	40.845	1.00	92.74	O
ATOM	4240	CB	GLN	I	65	5.539	-41.764	39.018	1.00	89.93	C
ATOM	4241	CG	GLN	I	65	4.926	-43.055	38.476	1.00	100.99	C
ATOM	4242	CD	GLN	I	65	4.786	-43.075	36.972	1.00	113.06	C
ATOM	4243	OE1	GLN	I	65	3.690	-42.909	36.432	1.00	105.20	O
ATOM	4244	NE2	GLN	I	65	5.892	-43.280	36.267	1.00	106.70	N
ATOM	4245	N	GLY	I	66	2.314	-40.341	38.954	1.00	90.49	N
ATOM	4246	CA	GLY	I	66	1.017	-40.281	39.620	1.00	90.22	C
ATOM	4247	C	GLY	I	66	0.477	-38.881	39.834	1.00	92.06	C
ATOM	4248	O	GLY	I	66	-0.707	-38.634	39.583	1.00	92.64	O
ATOM	4249	N	GLN	I	67	1.344	-37.951	40.290	1.00	85.34	N
ATOM	4250	CA	GLN	I	67	1.006	-36.550	40.590	1.00	83.34	C
ATOM	4251	C	GLN	I	67	0.558	-35.719	39.375	1.00	81.57	C
ATOM	4252	O	GLN	I	67	-0.133	-34.720	39.546	1.00	80.11	O
ATOM	4253	CB	GLN	I	67	2.182	-35.851	41.314	1.00	84.85	C
ATOM	4254	CG	GLN	I	67	2.280	-36.163	42.810	1.00	101.47	C
ATOM	4255	CD	GLN	I	67	3.123	-37.382	43.103	1.00	119.87	C
ATOM	4256	OE1	GLN	I	67	4.325	-37.291	43.374	1.00	116.31	O
ATOM	4257	NE2	GLN	I	67	2.510	-38.548	43.083	1.00	108.56	N
ATOM	4258	N	VAL	I	68	0.957	-36.127	38.162	1.00	75.55	N
ATOM	4259	CA	VAL	I	68	0.676	-35.423	36.904	1.00	73.75	C
ATOM	4260	C	VAL	I	68	0.494	-36.451	35.750	1.00	75.01	C
ATOM	4261	O	VAL	I	68	0.921	-37.607	35.907	1.00	73.95	O
ATOM	4262	CB	VAL	I	68	1.847	-34.403	36.665	1.00	76.57	C
ATOM	4263	CG1	VAL	I	68	2.977	-34.965	35.793	1.00	76.18	C
ATOM	4264	CG2	VAL	I	68	1.349	-33.083	36.128	1.00	75.91	C
ATOM	4265	N	THR	I	69	-0.159	-36.058	34.623	1.00	70.31	N
ATOM	4266	CA	THR	I	69	-0.267	-36.938	33.438	1.00	70.03	C
ATOM	4267	C	THR	I	69	0.048	-36.150	32.150	1.00	73.35	C
ATOM	4268	O	THR	I	69	-0.423	-35.019	31.978	1.00	72.58	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	4269	CB	THR	I	69	-1.579	-37.814	33.303
ATOM	4270	OG1	THR	I	69	-2.674	-37.051	32.812
ATOM	4271	CG2	THR	I	69	-1.982	-38.571	34.576
ATOM	4272	N	ILE	I	70	0.862	-36.765	31.256
ATOM	4273	CA	ILE	I	70	1.244	-36.189	29.959
ATOM	4274	C	ILE	I	70	0.493	-36.912	28.809
ATOM	4275	O	ILE	I	70	0.353	-38.147	28.813
ATOM	4276	CB	ILE	I	70	2.785	-36.136	29.760
ATOM	4277	CG1	ILE	I	70	3.463	-35.480	30.977
ATOM	4278	CG2	ILE	I	70	3.156	-35.368	28.487
ATOM	4279	CD1	ILE	I	70	4.972	-35.562	31.032
ATOM	4280	N	SER	I	71	-0.003	-36.114	27.842
ATOM	4281	CA	SER	I	71	-0.783	-36.538	26.684
ATOM	4282	C	SER	I	71	-0.490	-35.610	25.493
ATOM	4283	O	SER	I	71	0.271	-34.658	25.683
ATOM	4284	CB	SER	I	71	-2.266	-36.489	27.037
ATOM	4285	OG	SER	I	71	-2.689	-35.191	27.436
ATOM	4286	N	ALA	I	72	-1.088	-35.861	24.272
ATOM	4287	CA	ALA	I	72	-0.850	-35.010	23.087
ATOM	4288	C	ALA	I	72	-2.048	-34.852	22.081
ATOM	4289	O	ALA	I	72	-3.069	-35.519	22.203
ATOM	4290	CB	ALA	I	72	0.400	-35.458	22.346
ATOM	4291	N	ASP	I	73	-1.739	-34.108	20.979
ATOM	4292	CA	ASP	I	73	-2.323	-33.306	19.883
ATOM	4293	C	ASP	I	73	-3.846	-33.260	19.769
ATOM	4294	O	ASP	I	73	-4.319	-32.249	19.229
ATOM	4295	CB	ASP	I	73	-1.703	-33.543	18.474
ATOM	4296	CG	ASP	I	73	-2.083	-34.740	17.623
ATOM	4297	OD1	ASP	I	73	-2.609	-35.729	18.186
ATOM	4298	OD2	ASP	I	73	-1.750	-34.732	16.406
ATOM	4299	N	LYS	I	74	-4.618	-34.244	20.270
ATOM	4300	CA	LYS	I	74	-6.093	-34.212	20.158
ATOM	4301	C	LYS	I	74	-6.571	-33.798	18.710
ATOM	4302	O	LYS	I	74	-7.631	-33.167	18.555
ATOM	4303	CB	LYS	I	74	-6.710	-33.324	21.268
ATOM	4304	N	SER	I	75	-5.723	-34.163	17.671
ATOM	4305	CA	SER	I	75	-5.732	-33.966	16.191
ATOM	4306	C	SER	I	75	-4.436	-33.287	15.661
ATOM	4307	O	SER	I	75	-3.675	-33.911	14.929
ATOM	4308	CB	SER	I	75	-6.987	-33.253	15.667
ATOM	4309	OG	SER	I	75	-6.968	-31.839	15.800
ATOM	4310	N	VAL	I	76	-4.197	-32.025	16.049
ATOM	4311	CA	VAL	I	76	-3.057	-31.189	15.658
ATOM	4312	C	VAL	I	76	-2.877	-30.118	16.769
ATOM	4313	O	VAL	I	76	-3.884	-29.501	17.148
ATOM	4314	CB	VAL	I	76	-3.270	-30.523	14.251
ATOM	4315	CG1	VAL	I	76	-2.864	-31.451	13.103
ATOM	4316	CG2	VAL	I	76	-4.698	-30.009	14.059
ATOM	4317	N	ASN	I	77	-1.651	-29.845	17.300
ATOM	4318	CA	ASN	I	77	-0.302	-30.427	17.141
ATOM	4319	C	ASN	I	77	0.331	-30.008	18.471
ATOM	4320	O	ASN	I	77	1.399	-29.388	18.542
ATOM	4321	CB	ASN	I	77	0.421	-29.767	15.965
ATOM	4322	CG	ASN	I	77	0.965	-30.725	14.945
ATOM	4323	OD1	ASN	I	77	1.725	-30.334	14.059
ATOM	4324	ND2	ASN	I	77	0.582	-31.998	15.025
ATOM	4325	N	THR	I	78	-0.402	-30.342	19.536
ATOM	4326	CA	THR	I	78	-0.230	-29.856	20.877
ATOM	4327	C	THR	I	78	-0.026	-30.918	21.932
ATOM	4328	O	THR	I	78	-0.820	-31.828	22.030
ATOM	4329	CB	THR	I	78	-1.493	-29.010	21.163
ATOM	4330	OG1	THR	I	78	-1.652	-28.005	20.150
ATOM	4331	CG2	THR	I	78	-1.498	-28.387	22.530
ATOM	4332	N	ALA	I	79	0.968	-30.738	22.812
ATOM	4333	CA	ALA	I	79	1.181	-31.660	23.935
ATOM	4334	C	ALA	I	79	0.499	-31.072	25.194
ATOM	4335	O	ALA	I	79	0.217	-29.881	25.231
ATOM	4336	CB	ALA	I	79	2.668	-31.888	24.158
ATOM	4337	N	TYR	I	80	0.218	-31.901	26.194
ATOM	4338	CA	TYR	I	80	-0.475	-31.475	27.395
ATOM	4339	C	TYR	I	80	0.147	-31.978	28.709
ATOM	4340	O	TYR	I	80	0.619	-33.116	28.791
ATOM	4341	CB	TYR	I	80	-1.976	-31.907	27.331
ATOM	4342	CG	TYR	I	80	-2.766	-31.336	26.167
ATOM	4343	CD1	TYR	I	80	-3.185	-30.006	26.167
ATOM	4344	CD2	TYR	I	80	-3.133	-32.135	25.086
ATOM	4345	CE1	TYR	I	80	-3.895	-29.468	25.089

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	4346	CE2	TYR	I	80	-3.840	-31.607	24.001	1.00	63.23	C
ATOM	4347	CZ	TYR	I	80	-4.216	-30.270	24.007	1.00	70.75	C
ATOM	4348	OH	TYR	I	80	-4.901	-29.720	22.948	1.00	71.51	O
ATOM	4349	N	LEU	I	81	0.096	-31.125	29.747	1.00	58.86	N
ATOM	4350	CA	LEU	I	81	0.487	-31.450	31.116	1.00	59.81	C
ATOM	4351	C	LEU	I	81	-0.731	-31.157	31.992	1.00	67.58	C
ATOM	4352	O	LEU	I	81	-1.258	-30.042	31.938	1.00	67.30	O
ATOM	4353	CB	LEU	I	81	1.702	-30.631	31.599	1.00	59.07	C
ATOM	4354	CG	LEU	I	81	2.285	-31.027	32.970	1.00	61.30	C
ATOM	4355	CD1	LEU	I	81	2.914	-32.399	32.927	1.00	60.54	C
ATOM	4356	CD2	LEU	I	81	3.321	-30.054	33.384	1.00	63.67	C
ATOM	4357	N	GLN	I	82	-1.197	-32.147	32.772	1.00	66.44	N
ATOM	4358	CA	GLN	I	82	-2.378	-31.910	33.597	1.00	67.86	C
ATOM	4359	C	GLN	I	82	-2.291	-32.493	35.014	1.00	73.19	C
ATOM	4360	O	GLN	I	82	-1.650	-33.524	35.240	1.00	73.14	O
ATOM	4361	CB	GLN	I	82	-3.682	-32.352	32.889	1.00	69.72	C
ATOM	4362	CG	GLN	I	82	-3.837	-33.848	32.632	1.00	90.54	C
ATOM	4363	CD	GLN	I	82	-5.290	-34.258	32.627	1.00	111.89	C
ATOM	4364	OE1	GLN	I	82	-5.859	-34.640	33.661	1.00	108.87	O
ATOM	4365	NE2	GLN	I	82	-5.920	-34.195	31.461	1.00	100.24	N
ATOM	4366	N	TRP	I	83	-2.947	-31.791	35.960	1.00	70.46	N
ATOM	4367	CA	TRP	I	83	-3.041	-32.135	37.381	1.00	70.66	C
ATOM	4368	C	TRP	I	83	-4.510	-32.291	37.760	1.00	83.37	C
ATOM	4369	O	TRP	I	83	-5.361	-31.516	37.300	1.00	84.96	O
ATOM	4370	CB	TRP	I	83	-2.461	-31.011	38.286	1.00	67.04	C
ATOM	4371	CG	TRP	I	83	-1.010	-30.675	38.104	1.00	65.59	C
ATOM	4372	CD1	TRP	I	83	0.032	-31.091	38.880	1.00	67.89	C
ATOM	4373	CD2	TRP	I	83	-0.461	-29.758	37.148	1.00	64.38	C
ATOM	4374	NE1	TRP	I	83	1.203	-30.534	38.434	1.00	66.56	N
ATOM	4375	CE2	TRP	I	83	0.930	-29.705	37.374	1.00	67.50	C
ATOM	4376	CE3	TRP	I	83	-1.011	-28.988	36.101	1.00	64.98	C
ATOM	4377	CZ2	TRP	I	83	1.785	-28.932	36.579	1.00	66.36	C
ATOM	4378	CZ3	TRP	I	83	-0.168	-28.213	35.323	1.00	65.88	C
ATOM	4379	CH2	TRP	I	83	1.212	-28.187	35.565	1.00	66.44	C
ATOM	4380	N	SER	I	84	-4.792	-33.263	38.630	1.00	83.28	N
ATOM	4381	CA	SER	I	84	-6.094	-33.482	39.235	1.00	84.74	C
ATOM	4382	C	SER	I	84	-5.807	-33.129	40.692	1.00	93.19	C
ATOM	4383	O	SER	I	84	-5.148	-33.916	41.385	1.00	95.27	O
ATOM	4384	CB	SER	I	84	-6.526	-34.937	39.079	1.00	88.92	C
ATOM	4385	OG	SER	I	84	-6.876	-35.232	37.735	1.00	101.14	O
ATOM	4386	N	SER	I	85	-6.174	-31.891	41.111	1.00	89.53	N
ATOM	4387	CA	SER	I	85	-5.928	-31.286	42.444	1.00	89.26	C
ATOM	4388	C	SER	I	85	-4.475	-30.773	42.632	1.00	89.34	C
ATOM	4389	O	SER	I	85	-3.577	-31.497	43.083	1.00	86.85	O
ATOM	4390	CB	SER	I	85	-6.364	-32.178	43.613	1.00	94.50	C
ATOM	4391	OG	SER	I	85	-6.388	-31.460	44.840	1.00	105.28	O
ATOM	4392	N	LEU	I	86	-4.300	-29.472	42.306	1.00	85.26	N
ATOM	4393	CA	LEU	I	86	-3.078	-28.661	42.400	1.00	84.31	C
ATOM	4394	C	LEU	I	86	-2.733	-28.260	43.859	1.00	89.59	C
ATOM	4395	O	LEU	I	86	-3.532	-27.576	44.517	1.00	90.45	O
ATOM	4396	CB	LEU	I	86	-3.269	-27.343	41.606	1.00	83.44	C
ATOM	4397	CG	LEU	I	86	-3.192	-27.372	40.098	1.00	87.09	C
ATOM	4398	CD1	LEU	I	86	-3.835	-26.140	39.529	1.00	86.96	C
ATOM	4399	CD2	LEU	I	86	-1.753	-27.452	39.629	1.00	88.11	C
ATOM	4400	N	LYS	I	87	-1.528	-28.633	44.340	1.00	84.50	N
ATOM	4401	CA	LYS	I	87	-1.033	-28.200	45.652	1.00	83.18	C
ATOM	4402	C	LYS	I	87	-0.394	-26.771	45.458	1.00	86.42	C
ATOM	4403	O	LYS	I	87	-0.062	-26.419	44.320	1.00	85.59	O
ATOM	4404	CB	LYS	I	87	-0.021	-29.225	46.206	1.00	84.21	C
ATOM	4405	N	ALA	I	88	-0.263	-25.932	46.525	1.00	82.35	N
ATOM	4406	CA	ALA	I	88	0.391	-24.608	46.369	1.00	81.39	C
ATOM	4407	C	ALA	I	88	1.879	-24.834	45.989	1.00	83.21	C
ATOM	4408	O	ALA	I	88	2.490	-24.034	45.267	1.00	81.39	O
ATOM	4409	CB	ALA	I	88	0.297	-23.805	47.653	1.00	81.83	C
ATOM	4410	N	SER	I	89	2.405	-25.995	46.449	1.00	77.71	N
ATOM	4411	CA	SER	I	89	3.713	-26.583	46.219	1.00	76.69	C
ATOM	4412	C	SER	I	89	4.057	-26.688	44.707	1.00	79.47	C
ATOM	4413	O	SER	I	89	5.223	-26.881	44.368	1.00	78.46	O
ATOM	4414	CB	SER	I	89	3.708	-27.980	46.822	1.00	79.81	C
ATOM	4415	OG	SER	I	89	5.014	-28.405	47.163	1.00	88.15	O
ATOM	4416	N	ASP	I	90	3.034	-26.605	43.826	1.00	74.80	N
ATOM	4417	CA	ASP	I	90	3.127	-26.696	42.370	1.00	74.14	C
ATOM	4418	C	ASP	I	90	3.345	-25.336	41.713	1.00	79.15	C
ATOM	4419	O	ASP	I	90	3.435	-25.278	40.484	1.00	78.89	O
ATOM	4420	CB	ASP	I	90	1.871	-27.369	41.770	1.00	76.00	C
ATOM	4421	CG	ASP	I	90	1.555	-28.787	42.228	1.00	87.45	C
ATOM	4422	OD1	ASP	I	90	2.475	-29.472	42.755	1.00	87.05	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	4423	OD2	ASP	I	90	0.394	-29.229	42.029	1.00	93.28	O
ATOM	4424	N	THR	I	91	3.414	-24.236	42.512	1.00	76.58	N
ATOM	4425	CA	THR	I	91	3.692	-22.884	41.995	1.00	75.82	C
ATOM	4426	C	THR	I	91	5.131	-22.896	41.470	1.00	77.90	C
ATOM	4427	O	THR	I	91	6.079	-23.005	42.267	1.00	78.03	O
ATOM	4428	CB	THR	I	91	3.503	-21.808	43.081	1.00	84.76	C
ATOM	4429	OG1	THR	I	91	2.202	-21.940	43.653	1.00	85.48	O
ATOM	4430	CG2	THR	I	91	3.727	-20.383	42.555	1.00	80.94	C
ATOM	4431	N	ALA	I	92	5.271	-22.858	40.119	1.00	70.28	N
ATOM	4432	CA	ALA	I	92	6.538	-22.900	39.395	1.00	67.23	C
ATOM	4433	C	ALA	I	92	6.360	-22.529	37.932	1.00	69.35	C
ATOM	4434	O	ALA	I	92	5.259	-22.188	37.490	1.00	68.20	O
ATOM	4435	CB	ALA	I	92	7.145	-24.291	39.500	1.00	67.44	C
ATOM	4436	N	MET	I	93	7.467	-22.595	37.174	1.00	65.74	N
ATOM	4437	CA	MET	I	93	7.501	-22.346	35.742	1.00	64.17	C
ATOM	4438	C	MET	I	93	7.582	-23.684	35.076	1.00	68.18	C
ATOM	4439	O	MET	I	93	8.363	-24.555	35.498	1.00	68.24	O
ATOM	4440	CB	MET	I	93	8.719	-21.536	35.363	1.00	66.08	C
ATOM	4441	CG	MET	I	93	8.382	-20.150	34.974	1.00	69.26	C
ATOM	4442	SD	MET	I	93	7.741	-20.104	33.317	1.00	72.55	S
ATOM	4443	CE	MET	I	93	7.650	-18.368	33.068	1.00	68.53	C
ATOM	4444	N	TYR	I	94	6.735	-23.880	34.067	1.00	63.25	N
ATOM	4445	CA	TYR	I	94	6.693	-25.149	33.363	1.00	60.98	C
ATOM	4446	C	TYR	I	94	7.073	-24.959	31.937	1.00	64.06	C
ATOM	4447	O	TYR	I	94	6.514	-24.109	31.230	1.00	62.49	O
ATOM	4448	CB	TYR	I	94	5.338	-25.849	33.534	1.00	60.50	C
ATOM	4449	CG	TYR	I	94	5.063	-26.255	34.967	1.00	59.82	C
ATOM	4450	CD1	TYR	I	94	5.554	-27.448	35.479	1.00	61.25	C
ATOM	4451	CD2	TYR	I	94	4.327	-25.437	35.815	1.00	59.54	C
ATOM	4452	CE1	TYR	I	94	5.317	-27.818	36.797	1.00	62.07	C
ATOM	4453	CE2	TYR	I	94	4.081	-25.800	37.136	1.00	59.80	C
ATOM	4454	CZ	TYR	I	94	4.595	-26.983	37.630	1.00	66.38	C
ATOM	4455	OH	TYR	I	94	4.372	-27.357	38.935	1.00	68.06	O
ATOM	4456	N	TYR	I	95	8.100	-25.710	31.543	1.00	60.91	N
ATOM	4457	CA	TYR	I	95	8.634	-25.689	30.195	1.00	60.38	C
ATOM	4458	C	TYR	I	95	8.391	-27.024	29.518	1.00	65.05	C
ATOM	4459	O	TYR	I	95	8.510	-28.073	30.161	1.00	63.60	O
ATOM	4460	CB	TYR	I	95	10.160	-25.433	30.236	1.00	60.07	C
ATOM	4461	CG	TYR	I	95	10.580	-24.071	30.756	1.00	59.37	C
ATOM	4462	CD1	TYR	I	95	10.440	-22.927	29.970	1.00	59.89	C
ATOM	4463	CD2	TYR	I	95	11.193	-23.935	32.003	1.00	59.43	C
ATOM	4464	CE1	TYR	I	95	10.852	-21.676	30.431	1.00	59.09	C
ATOM	4465	CE2	TYR	I	95	11.617	-22.687	32.472	1.00	59.72	C
ATOM	4466	CZ	TYR	I	95	11.452	-21.561	31.676	1.00	67.71	C
ATOM	4467	OH	TYR	I	95	11.857	-20.323	32.114	1.00	73.56	O
ATOM	4468	N	CYS	I	96	8.071	-26.983	28.221	1.00	62.75	N
ATOM	4469	CA	CYS	I	96	8.017	-28.179	27.398	1.00	63.23	C
ATOM	4470	C	CYS	I	96	9.169	-27.978	26.438	1.00	62.49	C
ATOM	4471	O	CYS	I	96	9.415	-26.862	25.945	1.00	60.11	O
ATOM	4472	CB	CYS	I	96	6.695	-28.348	26.658	1.00	65.65	C
ATOM	4473	SG	CYS	I	96	6.422	-27.098	25.373	1.00	71.03	S
ATOM	4474	N	ALA	I	97	9.923	-29.045	26.251	1.00	57.68	N
ATOM	4475	CA	ALA	I	97	11.071	-29.060	25.372	1.00	56.23	C
ATOM	4476	C	ALA	I	97	11.038	-30.278	24.459	1.00	59.50	C
ATOM	4477	O	ALA	I	97	10.720	-31.393	24.906	1.00	58.81	O
ATOM	4478	CB	ALA	I	97	12.349	-29.049	26.192	1.00	56.36	C
ATOM	4479	N	ARG	I	98	11.357	-30.054	23.176	1.00	55.47	N
ATOM	4480	CA	ARG	I	98	11.461	-31.098	22.168	1.00	55.28	C
ATOM	4481	C	ARG	I	98	12.777	-31.812	22.431	1.00	61.66	C
ATOM	4482	O	ARG	I	98	13.764	-31.151	22.727	1.00	63.73	O
ATOM	4483	CB	ARG	I	98	11.483	-30.495	20.747	1.00	52.20	C
ATOM	4484	CG	ARG	I	98	11.349	-31.539	19.639	1.00	52.52	C
ATOM	4485	CD	ARG	I	98	11.504	-30.982	18.241	1.00	54.41	C
ATOM	4486	NE	ARG	I	98	12.901	-30.807	17.814	1.00	48.01	N
ATOM	4487	CZ	ARG	I	98	13.266	-30.458	16.581	1.00	59.84	C
ATOM	4488	NH1	ARG	I	98	12.350	-30.264	15.637	1.00	51.11	N
ATOM	4489	NH2	ARG	I	98	14.543	-30.305	16.281	1.00	45.05	N
ATOM	4490	O	ARG	I	99	13.856	-34.443	20.116	1.00	64.14	O
ATOM	4491	N	ARG	I	99	12.798	-33.139	22.308	1.00	57.21	N
ATOM	4492	CA	ARG	I	99	13.994	-33.960	22.466	1.00	56.50	C
ATOM	4493	C	ARG	I	99	14.598	-34.244	21.092	1.00	63.16	C
ATOM	4494	CB	ARG	I	99	13.627	-35.288	23.147	1.00	51.74	C
ATOM	4495	CG	ARG	I	99	14.816	-36.095	23.603	1.00	45.77	C
ATOM	4496	CD	ARG	I	99	14.501	-37.572	23.688	1.00	42.04	C
ATOM	4497	NE	ARG	I	99	14.370	-38.130	22.346	1.00	58.63	N
ATOM	4498	CZ	ARG	I	99	14.239	-39.420	22.085	1.00	61.42	C
ATOM	4499	NH1	ARG	I	99	14.217	-40.302	23.072	1.00	50.73	N

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	4500	NH2	ARG	I	99	14.132	-39.842	20.835	1.00	35.29	N
ATOM	4501	O	ARG	I	100	16.551	-36.807	20.705	1.00	64.10	O
ATOM	4502	N	ARG	I	100	15.949	-34.294	21.034	1.00	60.27	N
ATOM	4503	CA	ARG	I	100	16.763	-34.632	19.853	1.00	59.52	C
ATOM	4504	C	ARG	I	100	16.686	-36.120	19.691	1.00	63.15	C
ATOM	4505	CB	ARG	I	100	18.224	-34.262	20.103	1.00	58.50	C
ATOM	4506	CG	ARG	I	100	18.631	-32.957	19.451	1.00	64.68	C
ATOM	4507	CD	ARG	I	100	20.119	-32.753	19.529	1.00	58.81	C
ATOM	4508	NE	ARG	I	100	20.829	-33.756	18.744	1.00	47.62	N
ATOM	4509	CZ	ARG	I	100	21.323	-33.540	17.541	1.00	71.53	C
ATOM	4510	NH1	ARG	I	100	21.231	-32.333	16.987	1.00	78.73	N
ATOM	4511	NH2	ARG	I	100	21.969	-34.502	16.901	1.00	51.18	N
ATOM	4512	O	ASN	I	101	18.281	-39.914	17.759	1.00	64.71	O
ATOM	4513	N	ASN	I	101	16.786	-36.642	18.455	1.00	59.46	N
ATOM	4514	CA	ASN	I	101	16.695	-38.106	18.275	1.00	59.62	C
ATOM	4515	C	ASN	I	101	18.101	-38.828	18.321	1.00	65.32	C
ATOM	4516	CB	ASN	I	101	15.855	-38.474	17.039	1.00	56.27	C
ATOM	4517	CG	ASN	I	101	14.353	-38.221	17.174	1.00	72.37	C
ATOM	4518	OD1	ASN	I	101	13.709	-38.370	18.238	1.00	71.10	O
ATOM	4519	ND2	ASN	I	101	13.745	-37.856	16.070	1.00	57.18	N
ATOM	4520	O	TRP	I	102	21.126	-36.321	19.592	1.00	74.00	O
ATOM	4521	N	TRP	I	102	19.043	-38.219	19.094	1.00	63.87	N
ATOM	4522	CA	TRP	I	102	20.408	-38.604	19.514	1.00	64.27	C
ATOM	4523	C	TRP	I	102	20.981	-37.351	20.243	1.00	70.98	C
ATOM	4524	CB	TRP	I	102	21.310	-38.967	18.306	1.00	62.63	C
ATOM	4525	CG	TRP	I	102	22.592	-39.644	18.711	1.00	63.21	C
ATOM	4526	CD1	TRP	I	102	22.858	-40.981	18.664	1.00	65.96	C
ATOM	4527	CD2	TRP	I	102	23.739	-39.028	19.342	1.00	62.93	C
ATOM	4528	NE1	TRP	I	102	24.082	-41.244	19.247	1.00	64.91	N
ATOM	4529	CE2	TRP	I	102	24.654	-40.058	19.645	1.00	66.07	C
ATOM	4530	CE3	TRP	I	102	24.077	-37.698	19.694	1.00	63.76	C
ATOM	4531	CZ2	TRP	I	102	25.889	-39.801	20.249	1.00	64.77	C
ATOM	4532	CZ3	TRP	I	102	25.285	-37.451	20.319	1.00	64.30	C
ATOM	4533	CH2	TRP	I	102	26.181	-38.493	20.574	1.00	64.84	C
ATOM	4534	O	GLY	I	103	21.296	-37.339	24.652	1.00	71.15	O
ATOM	4535	N	GLY	I	103	21.359	-37.382	21.516	1.00	65.69	N
ATOM	4536	CA	GLY	I	103	21.271	-38.432	22.505	1.00	65.61	C
ATOM	4537	C	GLY	I	103	20.625	-37.785	23.714	1.00	70.41	C
ATOM	4538	O	ASN	I	104	17.741	-35.244	25.942	1.00	66.47	O
ATOM	4539	N	ASN	I	104	19.313	-37.585	23.585	1.00	65.24	N
ATOM	4540	CA	ASN	I	104	18.354	-37.117	24.569	1.00	63.92	C
ATOM	4541	C	ASN	I	104	18.482	-35.642	25.043	1.00	66.08	C
ATOM	4542	CB	ASN	I	104	18.337	-38.085	25.749	1.00	61.56	C
ATOM	4543	CG	ASN	I	104	17.759	-39.424	25.340	1.00	66.74	C
ATOM	4544	OD1	ASN	I	104	17.575	-39.730	24.154	1.00	66.49	O
ATOM	4545	ND2	ASN	I	104	17.453	-40.248	26.300	1.00	49.13	N
ATOM	4546	N	ALA	I	105	19.293	-34.808	24.401	1.00	60.63	N
ATOM	4547	CA	ALA	I	105	19.333	-33.405	24.827	1.00	59.30	C
ATOM	4548	C	ALA	I	105	18.075	-32.730	24.293	1.00	62.73	C
ATOM	4549	O	ALA	I	105	17.596	-33.137	23.237	1.00	63.08	O
ATOM	4550	CB	ALA	I	105	20.575	-32.714	24.283	1.00	59.60	C
ATOM	4551	N	PHE	I	106	17.527	-31.734	25.030	1.00	57.33	N
ATOM	4552	CA	PHE	I	106	16.332	-30.978	24.680	1.00	55.96	C
ATOM	4553	C	PHE	I	106	16.730	-29.821	23.824	1.00	60.51	C
ATOM	4554	O	PHE	I	106	17.249	-28.852	24.343	1.00	62.91	O
ATOM	4555	CB	PHE	I	106	15.638	-30.502	25.945	1.00	58.12	C
ATOM	4556	CG	PHE	I	106	15.087	-31.647	26.758	1.00	60.72	C
ATOM	4557	CD1	PHE	I	106	14.035	-32.422	26.276	1.00	64.19	C
ATOM	4558	CD2	PHE	I	106	15.617	-31.950	28.006	1.00	64.01	C
ATOM	4559	CE1	PHE	I	106	13.521	-33.473	27.030	1.00	65.41	C
ATOM	4560	CE2	PHE	I	106	15.113	-33.010	28.755	1.00	67.43	C
ATOM	4561	CZ	PHE	I	106	14.065	-33.761	28.263	1.00	65.76	C
ATOM	4562	N	ASP	I	107	16.499	-29.909	22.514	1.00	56.13	N
ATOM	4563	CA	ASP	I	107	16.970	-28.945	21.531	1.00	55.91	C
ATOM	4564	C	ASP	I	107	16.065	-27.739	21.278	1.00	62.29	C
ATOM	4565	O	ASP	I	107	16.569	-26.706	20.828	1.00	62.36	O
ATOM	4566	CB	ASP	I	107	17.295	-29.655	20.209	1.00	57.96	C
ATOM	4567	CG	ASP	I	107	16.159	-30.377	19.472	1.00	70.40	C
ATOM	4568	OD1	ASP	I	107	15.045	-30.505	20.050	1.00	72.67	O
ATOM	4569	OD2	ASP	I	107	16.388	-30.821	18.325	1.00	71.67	O
ATOM	4570	N	ILE	I	108	14.756	-27.853	21.498	1.00	60.10	N
ATOM	4571	CA	ILE	I	108	13.869	-26.692	21.326	1.00	60.37	C
ATOM	4572	C	ILE	I	108	13.048	-26.544	22.568	1.00	63.34	C
ATOM	4573	O	ILE	I	108	12.552	-27.553	23.042	1.00	64.00	O
ATOM	4574	CB	ILE	I	108	13.056	-26.690	19.996	1.00	64.09	C
ATOM	4575	CG1	ILE	I	108	13.851	-25.966	18.904	1.00	64.91	C
ATOM	4576	CG2	ILE	I	108	11.715	-25.991	20.145	1.00	65.36	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	4577	CD1	ILE	I	108	14.669	-26.811	18.079	1.00	71.15	C
ATOM	4578	N	TRP	I	109	12.968	-25.319	23.149	1.00	58.89	N
ATOM	4579	CA	TRP	I	109	12.229	-25.045	24.401	1.00	57.56	C
ATOM	4580	C	TRP	I	109	11.059	-24.066	24.196	1.00	63.90	C
ATOM	4581	O	TRP	I	109	11.104	-23.193	23.316	1.00	61.82	O
ATOM	4582	CB	TRP	I	109	13.177	-24.510	25.506	1.00	54.89	C
ATOM	4583	CG	TRP	I	109	14.206	-25.487	26.010	1.00	54.39	C
ATOM	4584	CD1	TRP	I	109	15.312	-25.931	25.346	1.00	57.11	C
ATOM	4585	CD2	TRP	I	109	14.250	-26.091	27.310	1.00	53.33	C
ATOM	4586	NE1	TRP	I	109	16.011	-26.824	26.132	1.00	56.23	N
ATOM	4587	CE2	TRP	I	109	15.375	-26.948	27.339	1.00	57.12	C
ATOM	4588	CE3	TRP	I	109	13.424	-26.025	28.436	1.00	53.93	C
ATOM	4589	CZ2	TRP	I	109	15.694	-27.732	28.451	1.00	55.94	C
ATOM	4590	CZ3	TRP	I	109	13.745	-26.794	29.539	1.00	55.13	C
ATOM	4591	CH2	TRP	I	109	14.884	-27.615	29.551	1.00	55.66	C
ATOM	4592	N	GLY	I	110	10.018	-24.240	25.008	1.00	64.25	N
ATOM	4593	CA	GLY	I	110	8.859	-23.355	25.007	1.00	65.21	C
ATOM	4594	C	GLY	I	110	9.153	-22.128	25.845	1.00	71.13	C
ATOM	4595	O	GLY	I	110	10.077	-22.164	26.664	1.00	70.25	O
ATOM	4596	N	GLN	I	111	8.394	-21.025	25.655	1.00	69.24	N
ATOM	4597	CA	GLN	I	111	8.612	-19.787	26.426	1.00	69.09	C
ATOM	4598	C	GLN	I	111	8.388	-19.976	27.938	1.00	74.19	C
ATOM	4599	O	GLN	I	111	8.975	-19.246	28.748	1.00	75.00	O
ATOM	4600	CB	GLN	I	111	7.775	-18.617	25.873	1.00	69.81	C
ATOM	4601	CG	GLN	I	111	6.313	-18.553	26.344	1.00	68.69	C
ATOM	4602	CD	GLN	I	111	5.304	-19.277	25.496	1.00	79.87	C
ATOM	4603	OE1	GLN	I	111	5.623	-20.009	24.562	1.00	77.58	O
ATOM	4604	NE2	GLN	I	111	4.046	-19.087	25.824	1.00	74.33	N
ATOM	4605	N	GLY	I	112	7.568	-20.965	28.282	1.00	69.18	N
ATOM	4606	CA	GLY	I	112	7.231	-21.292	29.654	1.00	68.76	C
ATOM	4607	C	GLY	I	112	5.817	-20.879	29.982	1.00	72.83	C
ATOM	4608	O	GLY	I	112	5.235	-20.009	29.317	1.00	72.62	O
ATOM	4609	N	THR	I	113	5.240	-21.543	30.984	1.00	69.37	N
ATOM	4610	CA	THR	I	113	3.898	-21.244	31.480	1.00	69.37	C
ATOM	4611	C	THR	I	113	4.031	-21.073	32.990	1.00	73.62	C
ATOM	4612	O	THR	I	113	4.402	-22.037	33.680	1.00	74.10	O
ATOM	4613	CB	THR	I	113	2.866	-22.347	31.117	1.00	75.92	C
ATOM	4614	OG1	THR	I	113	2.709	-22.448	29.703	1.00	77.02	O
ATOM	4615	CG2	THR	I	113	1.511	-22.097	31.741	1.00	71.97	C
ATOM	4616	N	MET	I	114	3.738	-19.853	33.499	1.00	68.94	N
ATOM	4617	CA	MET	I	114	3.825	-19.612	34.930	1.00	69.17	C
ATOM	4618	C	MET	I	114	2.570	-20.125	35.586	1.00	75.49	C
ATOM	4619	O	MET	I	114	1.468	-19.731	35.209	1.00	75.78	O
ATOM	4620	CB	MET	I	114	4.110	-18.125	35.267	1.00	71.15	C
ATOM	4621	CG	MET	I	114	4.394	-17.881	36.754	1.00	74.06	C
ATOM	4622	SD	MET	I	114	5.920	-18.639	37.375	1.00	77.83	S
ATOM	4623	CE	MET	I	114	5.398	-19.238	39.001	1.00	73.87	C
ATOM	4624	N	VAL	I	115	2.735	-21.053	36.518	1.00	74.20	N
ATOM	4625	CA	VAL	I	115	1.610	-21.640	37.227	1.00	75.92	C
ATOM	4626	C	VAL	I	115	1.717	-21.248	38.690	1.00	82.15	C
ATOM	4627	O	VAL	I	115	2.560	-21.770	39.430	1.00	80.62	O
ATOM	4628	CB	VAL	I	115	1.456	-23.177	36.988	1.00	80.77	C
ATOM	4629	CG1	VAL	I	115	0.340	-23.778	37.850	1.00	80.34	C
ATOM	4630	CG2	VAL	I	115	1.206	-23.481	35.507	1.00	80.85	C
ATOM	4631	N	THR	I	116	0.865	-20.299	39.082	1.00	81.34	N
ATOM	4632	CA	THR	I	116	0.771	-19.743	40.422	1.00	81.86	C
ATOM	4633	C	THR	I	116	-0.438	-20.396	41.101	1.00	87.53	C
ATOM	4634	O	THR	I	116	-1.546	-20.317	40.561	1.00	86.65	O
ATOM	4635	CB	THR	I	116	0.724	-18.204	40.327	1.00	89.20	C
ATOM	4636	OG1	THR	I	116	1.448	-17.765	39.159	1.00	84.58	O
ATOM	4637	CG2	THR	I	116	1.262	-17.527	41.582	1.00	87.40	C
ATOM	4638	N	VAL	I	117	-0.199	-21.108	42.239	1.00	86.38	N
ATOM	4639	CA	VAL	I	117	-1.211	-21.852	43.018	1.00	87.45	C
ATOM	4640	C	VAL	I	117	-1.279	-21.397	44.494	1.00	95.37	C
ATOM	4641	O	VAL	I	117	-0.450	-21.818	45.305	1.00	95.88	O
ATOM	4642	CB	VAL	I	117	-1.048	-23.410	42.956	1.00	91.11	C
ATOM	4643	CG1	VAL	I	117	-2.248	-24.109	43.587	1.00	91.00	C
ATOM	4644	CG2	VAL	I	117	-0.826	-23.917	41.537	1.00	90.87	C
ATOM	4645	N	SER	I	118	-2.286	-20.588	44.858	1.00	93.36	N
ATOM	4646	CA	SER	I	118	-2.483	-20.203	46.263	1.00	93.40	C
ATOM	4647	C	SER	I	118	-3.958	-20.006	46.607	1.00	95.19	C
ATOM	4648	O	SER	I	118	-4.772	-19.679	45.731	1.00	94.74	O
ATOM	4649	CB	SER	I	118	-1.624	-18.999	46.672	1.00	98.35	C
ATOM	4650	OG	SER	I	118	-2.147	-17.720	46.348	1.00	107.14	O
ATOM	4651	N	SER	I	119	-4.286	-20.210	47.895	1.00	89.69	N
ATOM	4652	CA	SER	I	119	-5.623	-20.049	48.473	1.00	88.21	C
ATOM	4653	C	SER	I	119	-6.121	-18.561	48.449	1.00	89.81	C

TABLE 1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody beziotuxumab Fab -C. difficile toxin B (TcdB¹⁸³⁴⁻²¹⁰¹) complex.

ATOM	4654	O	SER	I	119	-7.306	-18.295	48.673	1.00	89.99	O
ATOM	4655	CB	SER	I	119	-5.637	-20.595	49.897	1.00	90.18	C
ATOM	4656	OG	SER	I	119	-4.758	-19.868	50.737	1.00	92.44	O
ATOM	4657	N	ALA	I	120	-5.207	-17.609	48.157	1.00	83.84	N
ATOM	4658	CA	ALA	I	120	-5.442	-16.164	48.067	1.00	81.80	C
ATOM	4659	C	ALA	I	120	-6.378	-15.788	46.926	1.00	83.10	C
ATOM	4660	O	ALA	I	120	-6.582	-16.575	46.005	1.00	82.12	O
ATOM	4661	CB	ALA	I	120	-4.114	-15.432	47.916	1.00	82.06	C
ATOM	4662	N	SER	I	121	-6.927	-14.571	46.985	1.00	79.17	N
ATOM	4663	CA	SER	I	121	-7.861	-14.034	45.999	1.00	79.25	C
ATOM	4664	C	SER	I	121	-7.354	-12.700	45.489	1.00	82.86	C
ATOM	4665	O	SER	I	121	-6.668	-11.993	46.231	1.00	82.44	O
ATOM	4666	CB	SER	I	121	-9.238	-13.841	46.630	1.00	83.90	C
ATOM	4667	OG	SER	I	121	-9.490	-14.807	47.641	1.00	94.48	O
ATOM	4668	N	THR	I	122	-7.731	-12.334	44.243	1.00	79.20	N
ATOM	4669	CA	THR	I	122	-7.310	-11.096	43.585	1.00	79.37	C
ATOM	4670	C	THR	I	122	-7.609	-9.848	44.424	1.00	87.44	C
ATOM	4671	O	THR	I	122	-8.758	-9.401	44.504	1.00	88.29	O
ATOM	4672	CB	THR	I	122	-7.864	-10.992	42.154	1.00	83.93	C
ATOM	4673	OG1	THR	I	122	-7.631	-12.213	41.466	1.00	83.39	O
ATOM	4674	CG2	THR	I	122	-7.242	-9.856	41.357	1.00	83.42	C
ATOM	4675	N	LYS	I	123	-6.549	-9.310	45.063	1.00	85.28	N
ATOM	4676	CA	LYS	I	123	-6.545	-8.080	45.853	1.00	84.99	C
ATOM	4677	C	LYS	I	123	-5.632	-7.086	45.147	1.00	91.44	C
ATOM	4678	O	LYS	I	123	-4.590	-7.462	44.602	1.00	91.05	O
ATOM	4679	CB	LYS	I	123	-6.051	-8.327	47.289	1.00	86.21	C
ATOM	4680	N	GLY	I	124	-6.039	-5.830	45.145	1.00	90.07	N
ATOM	4681	CA	GLY	I	124	-5.259	-4.754	44.544	1.00	90.55	C
ATOM	4682	C	GLY	I	124	-4.180	-4.246	45.485	1.00	95.76	C
ATOM	4683	O	GLY	I	124	-4.203	-4.562	46.683	1.00	95.81	O
ATOM	4684	N	PRO	I	125	-3.228	-3.425	44.988	1.00	92.42	N
ATOM	4685	CA	PRO	I	125	-2.150	-2.935	45.871	1.00	91.97	C
ATOM	4686	C	PRO	I	125	-2.395	-1.602	46.601	1.00	95.20	C
ATOM	4687	O	PRO	I	125	-3.072	-0.705	46.083	1.00	94.78	O
ATOM	4688	CB	PRO	I	125	-0.970	-2.806	44.910	1.00	93.56	C
ATOM	4689	CG	PRO	I	125	-1.591	-2.502	43.571	1.00	97.61	C
ATOM	4690	CD	PRO	I	125	-3.022	-2.983	43.592	1.00	93.48	C
ATOM	4691	N	SER	I	126	-1.787	-1.454	47.789	1.00	91.14	N
ATOM	4692	CA	SER	I	126	-1.820	-0.215	48.565	1.00	90.71	C
ATOM	4693	C	SER	I	126	-0.483	0.475	48.253	1.00	96.04	C
ATOM	4694	O	SER	I	126	0.571	-0.082	48.571	1.00	95.98	O
ATOM	4695	CB	SER	I	126	-1.928	-0.516	50.055	1.00	93.12	C
ATOM	4696	OG	SER	I	126	-2.948	-1.451	50.362	1.00	100.72	O
ATOM	4697	N	VAL	I	127	-0.526	1.640	47.564	1.00	93.21	N
ATOM	4698	CA	VAL	I	127	0.656	2.409	47.123	1.00	93.25	C
ATOM	4699	C	VAL	I	127	0.979	3.585	48.090	1.00	96.42	C
ATOM	4700	O	VAL	I	127	0.316	4.627	48.042	1.00	96.23	O
ATOM	4701	CB	VAL	I	127	0.538	2.872	45.625	1.00	97.69	C
ATOM	4702	CG1	VAL	I	127	1.805	3.590	45.143	1.00	97.64	C
ATOM	4703	CG2	VAL	I	127	0.204	1.705	44.697	1.00	97.45	C
ATOM	4704	N	PHE	I	128	2.028	3.403	48.935	1.00	92.71	N
ATOM	4705	CA	PHE	I	128	2.544	4.343	49.946	1.00	92.43	C
ATOM	4706	C	PHE	I	128	3.824	5.035	49.464	1.00	99.28	C
ATOM	4707	O	PHE	I	128	4.641	4.378	48.807	1.00	98.69	O
ATOM	4708	CB	PHE	I	128	2.844	3.602	51.260	1.00	93.31	C
ATOM	4709	CG	PHE	I	128	1.689	2.798	51.773	1.00	93.93	C
ATOM	4710	CD1	PHE	I	128	0.482	3.411	52.094	1.00	96.22	C
ATOM	4711	CD2	PHE	I	128	1.795	1.426	51.919	1.00	95.72	C
ATOM	4712	CE1	PHE	I	128	-0.600	2.662	52.548	1.00	96.99	C
ATOM	4713	CE2	PHE	I	128	0.714	0.677	52.387	1.00	98.52	C
ATOM	4714	CZ	PHE	I	128	-0.469	1.304	52.718	1.00	96.33	C
ATOM	4715	N	PRO	I	129	4.048	6.344	49.766	1.00	97.35	N
ATOM	4716	CA	PRO	I	129	5.285	6.978	49.285	1.00	96.99	C
ATOM	4717	C	PRO	I	129	6.500	6.668	50.161	1.00	100.02	C
ATOM	4718	O	PRO	I	129	6.367	6.350	51.352	1.00	100.09	O
ATOM	4719	CB	PRO	I	129	4.938	8.469	49.266	1.00	98.62	C
ATOM	4720	CG	PRO	I	129	3.908	8.634	50.346	1.00	103.21	C
ATOM	4721	CD	PRO	I	129	3.209	7.302	50.526	1.00	98.88	C
ATOM	4722	N	LEU	I	130	7.688	6.726	49.540	1.00	94.69	N
ATOM	4723	CA	LEU	I	130	8.980	6.571	50.197	1.00	93.24	C
ATOM	4724	C	LEU	I	130	9.610	7.963	50.007	1.00	96.86	C
ATOM	4725	O	LEU	I	130	10.310	8.220	49.025	1.00	96.71	O
ATOM	4726	CB	LEU	I	130	9.812	5.425	49.567	1.00	92.58	C
ATOM	4727	CG	LEU	I	130	9.251	3.989	49.674	1.00	95.46	C
ATOM	4728	CD1	LEU	I	130	10.007	3.044	48.774	1.00	95.36	C
ATOM	4729	CD2	LEU	I	130	9.276	3.470	51.096	1.00	95.72	C
ATOM	4730	N	ALA	I	131	9.215	8.893	50.902	1.00	92.62	N

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	4731	CA	ALA	I	131	9.565	10.309	50.906	1.00	92.20	C
ATOM	4732	C	ALA	I	131	11.039	10.605	51.108	1.00	98.03	C
ATOM	4733	O	ALA	I	131	11.683	9.974	51.959	1.00	96.98	O
ATOM	4734	CB	ALA	I	131	8.737	11.053	51.942	1.00	92.74	C
ATOM	4735	N	PRO	I	132	11.577	11.597	50.344	1.00	96.54	N
ATOM	4736	CA	PRO	I	132	12.998	11.954	50.506	1.00	96.97	C
ATOM	4737	C	PRO	I	132	13.297	12.506	51.899	1.00	103.35	C
ATOM	4738	O	PRO	I	132	12.482	13.257	52.470	1.00	102.40	O
ATOM	4739	CB	PRO	I	132	13.242	13.003	49.409	1.00	98.18	C
ATOM	4740	CG	PRO	I	132	12.069	12.942	48.510	1.00	102.01	C
ATOM	4741	CD	PRO	I	132	10.924	12.448	49.325	1.00	97.63	C
ATOM	4742	O	SER	I	133	15.807	14.507	52.813	1.00	109.86	O
ATOM	4743	N	SER	I	133	14.451	12.087	52.463	1.00	101.65	N
ATOM	4744	CA	SER	I	133	14.895	12.517	53.790	1.00	101.99	C
ATOM	4745	C	SER	I	133	15.217	14.008	53.782	1.00	109.26	C
ATOM	4746	CB	SER	I	133	16.122	11.726	54.233	1.00	103.60	C
ATOM	4747	OG	SER	I	133	16.386	11.918	55.614	1.00	108.96	O
ATOM	4748	O	SER	I	134	17.179	17.419	54.952	1.00	111.11	O
ATOM	4749	N	SER	I	134	14.823	14.722	54.857	1.00	106.59	N
ATOM	4750	CA	SER	I	134	15.131	16.145	55.024	1.00	106.65	C
ATOM	4751	C	SER	I	134	16.659	16.329	55.193	1.00	111.62	C
ATOM	4752	CB	SER	I	134	14.358	16.739	56.198	1.00	109.65	C
ATOM	4753	OG	SER	I	134	14.300	15.863	57.313	1.00	117.05	O
ATOM	4754	O	LYS	I	135	20.125	16.292	54.067	1.00	119.04	O
ATOM	4755	N	LYS	I	135	17.367	15.231	55.543	1.00	109.47	N
ATOM	4756	CA	LYS	I	135	18.812	15.148	55.693	1.00	110.34	C
ATOM	4757	C	LYS	I	135	19.486	15.267	54.316	1.00	118.67	C
ATOM	4758	CB	LYS	I	135	19.208	13.841	56.402	1.00	112.25	C
ATOM	4759	O	SER	I	136	20.432	16.303	51.319	1.00	123.06	O
ATOM	4760	N	SER	I	136	19.294	14.246	53.421	1.00	117.45	N
ATOM	4761	CA	SER	I	136	19.815	14.078	52.038	1.00	118.01	C
ATOM	4762	C	SER	I	136	20.830	15.157	51.580	1.00	123.25	C
ATOM	4763	CB	SER	I	136	18.670	13.954	51.031	1.00	121.12	C
ATOM	4764	OG	SER	I	136	17.952	15.165	50.859	1.00	128.40	O
ATOM	4765	O	THR	I	137	22.882	16.248	48.894	1.00	123.47	O
ATOM	4766	N	THR	I	137	22.143	14.765	51.502	1.00	120.14	N
ATOM	4767	CA	THR	I	137	23.329	15.590	51.162	1.00	119.74	C
ATOM	4768	C	THR	I	137	23.006	16.621	50.065	1.00	123.40	C
ATOM	4769	CB	THR	I	137	24.577	14.708	50.834	1.00	127.04	C
ATOM	4770	OG1	THR	I	137	24.439	14.087	49.554	1.00	128.39	O
ATOM	4771	CG2	THR	I	137	24.866	13.645	51.900	1.00	123.70	C
ATOM	4772	O	SER	I	138	24.670	19.226	48.769	1.00	120.71	O
ATOM	4773	N	SER	I	138	22.780	17.901	50.469	1.00	119.16	N
ATOM	4774	CA	SER	I	138	22.405	18.996	49.558	1.00	118.61	C
ATOM	4775	C	SER	I	138	23.466	19.274	48.486	1.00	121.40	C
ATOM	4776	CB	SER	I	138	22.034	20.263	50.322	1.00	121.85	C
ATOM	4777	OG	SER	I	138	21.179	21.080	49.537	1.00	129.21	O
ATOM	4778	O	GLY	I	139	23.874	18.272	44.136	1.00	117.83	O
ATOM	4779	N	GLY	I	139	22.992	19.500	47.257	1.00	116.67	N
ATOM	4780	CA	GLY	I	139	23.828	19.685	46.076	1.00	115.68	C
ATOM	4781	C	GLY	I	139	23.991	18.353	45.367	1.00	117.62	C
ATOM	4782	O	GLY	I	140	22.137	15.918	44.869	1.00	106.65	O
ATOM	4783	N	GLY	I	140	24.221	17.308	46.175	1.00	110.84	N
ATOM	4784	CA	GLY	I	140	24.357	15.917	45.760	1.00	108.70	C
ATOM	4785	C	GLY	I	140	23.032	15.261	45.416	1.00	107.45	C
ATOM	4786	N	THR	I	141	22.896	13.947	45.720	1.00	100.21	N
ATOM	4787	CA	THR	I	141	21.696	13.184	45.353	1.00	97.96	C
ATOM	4788	C	THR	I	141	20.905	12.616	46.538	1.00	99.17	C
ATOM	4789	O	THR	I	141	21.464	12.258	47.580	1.00	98.05	O
ATOM	4790	CB	THR	I	141	22.007	12.056	44.327	1.00	96.77	C
ATOM	4791	OG1	THR	I	141	22.607	10.942	44.984	1.00	91.02	O
ATOM	4792	CG2	THR	I	141	22.864	12.515	43.133	1.00	92.83	C
ATOM	4793	N	ALA	I	142	19.590	12.496	46.321	1.00	94.79	N
ATOM	4794	CA	ALA	I	142	18.594	11.963	47.248	1.00	94.09	C
ATOM	4795	C	ALA	I	142	17.849	10.784	46.605	1.00	95.35	C
ATOM	4796	O	ALA	I	142	17.808	10.669	45.373	1.00	93.87	O
ATOM	4797	CB	ALA	I	142	17.596	13.060	47.606	1.00	94.93	C
ATOM	4798	N	ALA	I	143	17.246	9.918	47.442	1.00	90.67	N
ATOM	4799	CA	ALA	I	143	16.456	8.789	46.961	1.00	89.84	C
ATOM	4800	C	ALA	I	143	15.020	8.871	47.445	1.00	93.12	C
ATOM	4801	O	ALA	I	143	14.766	9.241	48.594	1.00	94.15	O
ATOM	4802	CB	ALA	I	143	17.072	7.473	47.395	1.00	90.50	C
ATOM	4803	N	LEU	I	144	14.082	8.517	46.553	1.00	87.96	N
ATOM	4804	CA	LEU	I	144	12.638	8.443	46.791	1.00	86.62	C
ATOM	4805	C	LEU	I	144	12.049	7.255	46.019	1.00	91.15	C
ATOM	4806	O	LEU	I	144	12.664	6.781	45.064	1.00	89.73	O
ATOM	4807	CB	LEU	I	144	11.928	9.756	46.413	1.00	85.89	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	4808	CG	LEU	I	144	12.065	10.252	44.984	1.00	88.65	C
ATOM	4809	CD1	LEU	I	144	10.843	9.923	44.184	1.00	88.53	C
ATOM	4810	CD2	LEU	I	144	12.255	11.719	44.964	1.00	89.24	C
ATOM	4811	N	GLY	I	145	10.871	6.801	46.425	1.00	89.47	N
ATOM	4812	CA	GLY	I	145	10.212	5.690	45.758	1.00	89.42	C
ATOM	4813	C	GLY	I	145	8.773	5.448	46.155	1.00	93.08	C
ATOM	4814	O	GLY	I	145	8.130	6.313	46.760	1.00	92.16	O
ATOM	4815	N	CYS	I	146	8.283	4.228	45.846	1.00	89.47	N
ATOM	4816	CA	CYS	I	146	6.928	3.753	46.136	1.00	88.68	C
ATOM	4817	C	CYS	I	146	6.917	2.396	46.837	1.00	87.38	C
ATOM	4818	O	CYS	I	146	7.780	1.562	46.583	1.00	86.24	O
ATOM	4819	CB	CYS	I	146	6.061	3.755	44.876	1.00	89.65	C
ATOM	4820	SG	CYS	I	146	5.636	5.415	44.309	1.00	94.46	S
ATOM	4821	N	LEU	I	147	5.960	2.199	47.747	1.00	81.04	N
ATOM	4822	CA	LEU	I	147	5.785	0.940	48.443	1.00	79.87	C
ATOM	4823	C	LEU	I	147	4.465	0.319	47.973	1.00	86.78	C
ATOM	4824	O	LEU	I	147	3.394	0.687	48.462	1.00	87.19	O
ATOM	4825	CB	LEU	I	147	5.843	1.104	49.970	1.00	78.70	C
ATOM	4826	CG	LEU	I	147	5.531	-0.144	50.779	1.00	81.69	C
ATOM	4827	CD1	LEU	I	147	6.532	-1.225	50.530	1.00	80.60	C
ATOM	4828	CD2	LEU	I	147	5.423	0.173	52.242	1.00	84.29	C
ATOM	4829	N	VAL	I	148	4.556	-0.596	46.984	1.00	83.92	N
ATOM	4830	CA	VAL	I	148	3.427	-1.328	46.402	1.00	83.30	C
ATOM	4831	C	VAL	I	148	3.204	-2.527	47.338	1.00	87.17	C
ATOM	4832	O	VAL	I	148	3.831	-3.569	47.162	1.00	86.56	O
ATOM	4833	CB	VAL	I	148	3.728	-1.740	44.928	1.00	86.52	C
ATOM	4834	CG1	VAL	I	148	2.542	-2.463	44.303	1.00	86.44	C
ATOM	4835	CG2	VAL	I	148	4.134	-0.535	44.073	1.00	85.65	C
ATOM	4836	N	LYS	I	149	2.392	-2.329	48.398	1.00	84.85	N
ATOM	4837	CA	LYS	I	149	2.137	-3.336	49.430	1.00	84.88	C
ATOM	4838	C	LYS	I	149	0.813	-4.067	49.266	1.00	91.28	C
ATOM	4839	O	LYS	I	149	-0.152	-3.507	48.742	1.00	90.02	O
ATOM	4840	CB	LYS	I	149	2.265	-2.745	50.850	1.00	86.36	C
ATOM	4841	N	ASP	I	150	0.803	-5.345	49.723	1.00	90.59	N
ATOM	4842	CA	ASP	I	150	-0.288	-6.329	49.752	1.00	90.77	C
ATOM	4843	C	ASP	I	150	-1.144	-6.368	48.449	1.00	94.40	C
ATOM	4844	O	ASP	I	150	-2.120	-5.623	48.303	1.00	93.76	O
ATOM	4845	CB	ASP	I	150	-1.149	-6.140	51.012	1.00	92.68	C
ATOM	4846	CG	ASP	I	150	-0.374	-6.310	52.307	1.00	106.15	C
ATOM	4847	OD1	ASP	I	150	0.064	-7.457	52.601	1.00	109.72	O
ATOM	4848	OD2	ASP	I	150	-0.196	-5.304	53.024	1.00	108.69	O
ATOM	4849	N	TYR	I	151	-0.739	-7.238	47.502	1.00	90.14	N
ATOM	4850	CA	TYR	I	151	-1.427	-7.431	46.224	1.00	89.25	C
ATOM	4851	C	TYR	I	151	-1.380	-8.886	45.748	1.00	89.59	C
ATOM	4852	O	TYR	I	151	-0.535	-9.670	46.183	1.00	87.99	O
ATOM	4853	CB	TYR	I	151	-0.928	-6.451	45.137	1.00	91.18	C
ATOM	4854	CG	TYR	I	151	0.427	-6.768	44.528	1.00	95.03	C
ATOM	4855	CD1	TYR	I	151	0.552	-7.695	43.491	1.00	97.94	C
ATOM	4856	CD2	TYR	I	151	1.567	-6.068	44.911	1.00	95.50	C
ATOM	4857	CE1	TYR	I	151	1.790	-7.973	42.911	1.00	98.31	C
ATOM	4858	CE2	TYR	I	151	2.809	-6.332	44.329	1.00	95.99	C
ATOM	4859	CZ	TYR	I	151	2.912	-7.279	43.325	1.00	101.86	C
ATOM	4860	OH	TYR	I	151	4.121	-7.530	42.730	1.00	101.50	O
ATOM	4861	N	PHE	I	152	-2.303	-9.232	44.845	1.00	85.38	N
ATOM	4862	CA	PHE	I	152	-2.427	-10.560	44.254	1.00	84.53	C
ATOM	4863	C	PHE	I	152	-3.239	-10.536	42.957	1.00	89.25	C
ATOM	4864	O	PHE	I	152	-4.292	-9.899	42.910	1.00	88.28	O
ATOM	4865	CB	PHE	I	152	-3.060	-11.562	45.237	1.00	85.62	C
ATOM	4866	CG	PHE	I	152	-2.835	-12.994	44.837	1.00	86.53	C
ATOM	4867	CD1	PHE	I	152	-1.678	-13.663	45.213	1.00	88.88	C
ATOM	4868	CD2	PHE	I	152	-3.762	-13.668	44.054	1.00	88.88	C
ATOM	4869	CE1	PHE	I	152	-1.455	-14.983	44.815	1.00	91.47	C
ATOM	4870	CE2	PHE	I	152	-3.534	-14.981	43.650	1.00	89.70	C
ATOM	4871	CZ	PHE	I	152	-2.381	-15.629	44.031	1.00	89.17	C
ATOM	4872	N	PRO	I	153	-2.803	-11.274	41.910	1.00	86.54	N
ATOM	4873	CA	PRO	I	153	-1.554	-12.051	41.792	1.00	86.21	C
ATOM	4874	C	PRO	I	153	-0.435	-11.203	41.165	1.00	90.56	C
ATOM	4875	O	PRO	I	153	-0.620	-9.991	40.972	1.00	90.08	O
ATOM	4876	CB	PRO	I	153	-1.989	-13.214	40.894	1.00	87.65	C
ATOM	4877	CG	PRO	I	153	-3.146	-12.648	40.034	1.00	91.68	C
ATOM	4878	CD	PRO	I	153	-3.578	-11.341	40.657	1.00	87.36	C
ATOM	4879	N	GLU	I	154	0.720	-11.829	40.838	1.00	87.04	N
ATOM	4880	CA	GLU	I	154	1.807	-11.150	40.133	1.00	86.47	C
ATOM	4881	C	GLU	I	154	1.349	-11.006	38.663	1.00	92.03	C
ATOM	4882	O	GLU	I	154	0.627	-11.887	38.187	1.00	92.57	O
ATOM	4883	CB	GLU	I	154	3.087	-12.001	40.205	1.00	87.28	C
ATOM	4884	CG	GLU	I	154	4.027	-11.624	41.337	1.00	93.92	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	4885	CD	GLU	I	154	5.041	-10.535	41.024	1.00	108.42	C
ATOM	4886	OE1	GLU	I	154	6.254	-10.849	41.050	1.00	114.38	O
ATOM	4887	OE2	GLU	I	154	4.639	-9.370	40.778	1.00	83.15	O
ATOM	4888	N	PRO	I	155	1.642	-9.908	37.935	1.00	89.32	N
ATOM	4889	CA	PRO	I	155	2.525	-8.784	38.258	1.00	89.38	C
ATOM	4890	C	PRO	I	155	1.876	-7.392	38.384	1.00	92.57	C
ATOM	4891	O	PRO	I	155	0.715	-7.173	38.011	1.00	91.20	O
ATOM	4892	CB	PRO	I	155	3.443	-8.766	37.024	1.00	90.92	C
ATOM	4893	CG	PRO	I	155	2.509	-9.189	35.863	1.00	95.18	C
ATOM	4894	CD	PRO	I	155	1.284	-9.849	36.504	1.00	90.95	C
ATOM	4895	N	VAL	I	156	2.697	-6.434	38.854	1.00	89.14	N
ATOM	4896	CA	VAL	I	156	2.415	-5.004	38.897	1.00	89.18	C
ATOM	4897	C	VAL	I	156	3.462	-4.368	37.979	1.00	93.38	C
ATOM	4898	O	VAL	I	156	4.532	-4.966	37.781	1.00	92.47	O
ATOM	4899	CB	VAL	I	156	2.429	-4.359	40.316	1.00	93.34	C
ATOM	4900	CG1	VAL	I	156	1.265	-4.847	41.173	1.00	93.11	C
ATOM	4901	CG2	VAL	I	156	3.762	-4.559	41.031	1.00	93.24	C
ATOM	4902	N	THR	I	157	3.160	-3.186	37.404	1.00	90.16	N
ATOM	4903	CA	THR	I	157	4.106	-2.453	36.554	1.00	90.00	C
ATOM	4904	C	THR	I	157	4.266	-1.044	37.094	1.00	93.54	C
ATOM	4905	O	THR	I	157	3.268	-0.349	37.283	1.00	93.08	O
ATOM	4906	CB	THR	I	157	3.686	-2.432	35.078	1.00	100.22	C
ATOM	4907	OG1	THR	I	157	2.551	-1.573	34.915	1.00	105.88	O
ATOM	4908	CG2	THR	I	157	3.422	-3.822	34.507	1.00	96.38	C
ATOM	4909	N	VAL	I	158	5.510	-0.622	37.350	1.00	90.13	N
ATOM	4910	CA	VAL	I	158	5.793	0.730	37.839	1.00	89.42	C
ATOM	4911	C	VAL	I	158	6.566	1.542	36.790	1.00	94.55	C
ATOM	4912	O	VAL	I	158	7.432	1.001	36.091	1.00	93.59	O
ATOM	4913	CB	VAL	I	158	6.458	0.782	39.235	1.00	92.29	C
ATOM	4914	CG1	VAL	I	158	6.300	2.171	39.848	1.00	92.21	C
ATOM	4915	CG2	VAL	I	158	5.887	-0.280	40.176	1.00	91.59	C
ATOM	4916	N	SER	I	159	6.202	2.833	36.664	1.00	92.98	N
ATOM	4917	CA	SER	I	159	6.797	3.847	35.774	1.00	93.53	C
ATOM	4918	C	SER	I	159	6.814	5.180	36.542	1.00	98.16	C
ATOM	4919	O	SER	I	159	6.191	5.234	37.613	1.00	96.98	O
ATOM	4920	CB	SER	I	159	5.974	3.990	34.495	1.00	97.29	C
ATOM	4921	OG	SER	I	159	4.648	4.397	34.781	1.00	107.32	O
ATOM	4922	N	TRP	I	160	7.452	6.275	36.005	1.00	95.47	N
ATOM	4923	CA	TRP	I	160	7.460	7.535	36.767	1.00	95.61	C
ATOM	4924	C	TRP	I	160	6.866	8.771	35.990	1.00	103.64	C
ATOM	4925	O	TRP	I	160	7.088	9.931	36.367	1.00	101.80	O
ATOM	4926	CB	TRP	I	160	8.847	7.798	37.370	1.00	93.26	C
ATOM	4927	CG	TRP	I	160	9.170	6.844	38.503	1.00	93.33	C
ATOM	4928	CD1	TRP	I	160	9.706	5.592	38.392	1.00	95.87	C
ATOM	4929	CD2	TRP	I	160	8.909	7.043	39.905	1.00	92.79	C
ATOM	4930	NE1	TRP	I	160	9.824	5.011	39.635	1.00	94.61	N
ATOM	4931	CE2	TRP	I	160	9.341	5.878	40.582	1.00	95.97	C
ATOM	4932	CE3	TRP	I	160	8.375	8.104	40.660	1.00	93.72	C
ATOM	4933	CZ2	TRP	I	160	9.255	5.744	41.975	1.00	94.88	C
ATOM	4934	CZ3	TRP	I	160	8.300	7.972	42.041	1.00	94.71	C
ATOM	4935	CH2	TRP	I	160	8.737	6.804	42.683	1.00	95.08	C
ATOM	4936	N	ASN	I	161	5.983	8.461	35.008	1.00	105.27	N
ATOM	4937	CA	ASN	I	161	5.127	9.302	34.143	1.00	107.48	C
ATOM	4938	C	ASN	I	161	5.781	10.452	33.359	1.00	115.17	C
ATOM	4939	O	ASN	I	161	6.446	11.309	33.954	1.00	114.89	O
ATOM	4940	CB	ASN	I	161	3.910	9.885	34.883	1.00	110.08	C
ATOM	4941	CG	ASN	I	161	2.679	9.939	33.991	1.00	131.37	C
ATOM	4942	OD1	ASN	I	161	2.298	10.998	33.481	1.00	125.82	O
ATOM	4943	ND2	ASN	I	161	2.094	8.780	33.682	1.00	120.55	N
ATOM	4944	N	SER	I	162	5.446	10.568	32.032	1.00	114.07	N
ATOM	4945	CA	SER	I	162	4.683	9.594	31.193	1.00	114.46	C
ATOM	4946	C	SER	I	162	5.747	8.600	30.683	1.00	118.36	C
ATOM	4947	O	SER	I	162	6.044	8.492	29.481	1.00	118.03	O
ATOM	4948	CB	SER	I	162	3.952	10.309	30.045	1.00	118.09	C
ATOM	4949	OG	SER	I	162	4.806	10.967	29.119	1.00	124.68	O
ATOM	4950	O	GLY	I	163	8.672	8.275	33.302	1.00	117.39	O
ATOM	4951	N	GLY	I	163	6.324	7.910	31.660	1.00	113.88	N
ATOM	4952	CA	GLY	I	163	7.543	7.146	31.547	1.00	113.35	C
ATOM	4953	C	GLY	I	163	8.516	8.181	32.079	1.00	116.16	C
ATOM	4954	N	ALA	I	164	8.975	9.112	31.175	1.00	109.50	N
ATOM	4955	CA	ALA	I	164	9.881	10.276	31.385	1.00	107.85	C
ATOM	4956	C	ALA	I	164	11.158	9.989	32.230	1.00	109.07	C
ATOM	4957	O	ALA	I	164	12.285	10.146	31.729	1.00	109.05	O
ATOM	4958	CB	ALA	I	164	9.119	11.459	31.959	1.00	108.30	C
ATOM	4959	N	LEU	I	165	10.971	9.599	33.504	1.00	102.24	N
ATOM	4960	CA	LEU	I	165	12.030	9.231	34.424	1.00	100.47	C
ATOM	4961	C	LEU	I	165	12.305	7.715	34.321	1.00	103.07	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	4962	O	LEU	I	165	11.457	6.888	34.677	1.00	101.94	O
ATOM	4963	CB	LEU	I	165	11.658	9.671	35.845	1.00	99.97	C
ATOM	4964	CG	LEU	I	165	12.689	9.497	36.941	1.00	103.60	C
ATOM	4965	CD1	LEU	I	165	13.919	10.329	36.679	1.00	103.01	C
ATOM	4966	CD2	LEU	I	165	12.100	9.883	38.262	1.00	106.28	C
ATOM	4967	N	THR	I	166	13.484	7.377	33.761	1.00	99.45	N
ATOM	4968	CA	THR	I	166	13.985	6.011	33.544	1.00	98.72	C
ATOM	4969	C	THR	I	166	15.361	5.827	34.204	1.00	100.98	C
ATOM	4970	O	THR	I	166	15.660	4.742	34.711	1.00	99.89	O
ATOM	4971	CB	THR	I	166	14.059	5.680	32.035	1.00	105.94	C
ATOM	4972	OG1	THR	I	166	14.779	6.703	31.346	1.00	106.52	O
ATOM	4973	CG2	THR	I	166	12.699	5.503	31.404	1.00	103.49	C
ATOM	4974	N	SER	I	167	16.195	6.897	34.169	1.00	97.09	N
ATOM	4975	CA	SER	I	167	17.552	6.963	34.719	1.00	96.17	C
ATOM	4976	C	SER	I	167	17.537	6.820	36.236	1.00	98.21	C
ATOM	4977	O	SER	I	167	16.808	7.543	36.930	1.00	97.76	O
ATOM	4978	CB	SER	I	167	18.224	8.281	34.327	1.00	99.05	C
ATOM	4979	OG	SER	I	167	19.375	8.112	33.518	1.00	106.96	O
ATOM	4980	N	GLY	I	168	18.327	5.867	36.725	1.00	93.26	N
ATOM	4981	CA	GLY	I	168	18.487	5.598	38.150	1.00	92.27	C
ATOM	4982	C	GLY	I	168	17.290	4.994	38.850	1.00	93.84	C
ATOM	4983	O	GLY	I	168	17.239	5.010	40.085	1.00	93.83	O
ATOM	4984	N	VAL	I	169	16.328	4.449	38.068	1.00	87.52	N
ATOM	4985	CA	VAL	I	169	15.117	3.796	38.577	1.00	85.23	C
ATOM	4986	C	VAL	I	169	15.452	2.344	38.847	1.00	86.23	C
ATOM	4987	O	VAL	I	169	16.071	1.689	37.998	1.00	86.89	O
ATOM	4988	CB	VAL	I	169	13.886	3.921	37.636	1.00	87.95	C
ATOM	4989	CG1	VAL	I	169	12.668	3.205	38.223	1.00	87.55	C
ATOM	4990	CG2	VAL	I	169	13.550	5.382	37.343	1.00	87.52	C
ATOM	4991	N	HIS	I	170	15.044	1.854	40.031	1.00	79.52	N
ATOM	4992	CA	HIS	I	170	15.216	0.483	40.473	1.00	78.66	C
ATOM	4993	C	HIS	I	170	13.893	-0.091	40.970	1.00	81.41	C
ATOM	4994	O	HIS	I	170	13.495	0.170	42.106	1.00	80.23	O
ATOM	4995	CB	HIS	I	170	16.304	0.361	41.553	1.00	79.63	C
ATOM	4996	CG	HIS	I	170	17.706	0.531	41.045	1.00	83.75	C
ATOM	4997	ND1	HIS	I	170	18.194	-0.222	39.977	1.00	85.96	N
ATOM	4998	CD2	HIS	I	170	18.703	1.321	41.510	1.00	85.58	C
ATOM	4999	CE1	HIS	I	170	19.453	0.160	39.816	1.00	85.19	C
ATOM	5000	NE2	HIS	I	170	19.805	1.082	40.716	1.00	85.39	N
ATOM	5001	N	THR	I	171	13.190	-0.853	40.105	1.00	77.41	N
ATOM	5002	CA	THR	I	171	11.955	-1.526	40.508	1.00	76.29	C
ATOM	5003	C	THR	I	171	12.399	-2.902	40.982	1.00	78.77	C
ATOM	5004	O	THR	I	171	13.127	-3.595	40.268	1.00	79.69	O
ATOM	5005	CB	THR	I	171	10.883	-1.496	39.414	1.00	82.12	C
ATOM	5006	OG1	THR	I	171	10.661	-0.144	38.993	1.00	78.45	O
ATOM	5007	CG2	THR	I	171	9.563	-2.075	39.892	1.00	83.56	C
ATOM	5008	N	PHE	I	172	12.080	-3.235	42.224	1.00	73.25	N
ATOM	5009	CA	PHE	I	172	12.551	-4.468	42.815	1.00	73.28	C
ATOM	5010	C	PHE	I	172	11.671	-5.642	42.561	1.00	80.56	C
ATOM	5011	O	PHE	I	172	10.454	-5.474	42.490	1.00	81.22	O
ATOM	5012	CB	PHE	I	172	12.757	-4.302	44.322	1.00	74.96	C
ATOM	5013	CG	PHE	I	172	13.980	-3.499	44.686	1.00	76.33	C
ATOM	5014	CD1	PHE	I	172	15.217	-4.110	44.808	1.00	79.01	C
ATOM	5015	CD2	PHE	I	172	13.890	-2.134	44.924	1.00	78.58	C
ATOM	5016	CE1	PHE	I	172	16.349	-3.363	45.116	1.00	80.34	C
ATOM	5017	CE2	PHE	I	172	15.020	-1.391	45.261	1.00	81.64	C
ATOM	5018	CZ	PHE	I	172	16.242	-2.010	45.359	1.00	79.92	C
ATOM	5019	N	PRO	I	173	12.257	-6.863	42.489	1.00	79.18	N
ATOM	5020	CA	PRO	I	173	11.428	-8.068	42.341	1.00	79.05	C
ATOM	5021	C	PRO	I	173	10.516	-8.227	43.553	1.00	82.42	C
ATOM	5022	O	PRO	I	173	10.926	-7.925	44.678	1.00	81.70	O
ATOM	5023	CB	PRO	I	173	12.457	-9.203	42.303	1.00	80.80	C
ATOM	5024	CG	PRO	I	173	13.727	-8.558	41.897	1.00	85.65	C
ATOM	5025	CD	PRO	I	173	13.692	-7.217	42.540	1.00	81.35	C
ATOM	5026	N	ALA	I	174	9.270	-8.675	43.312	1.00	78.53	N
ATOM	5027	CA	ALA	I	174	8.291	-8.874	44.366	1.00	77.80	C
ATOM	5028	C	ALA	I	174	8.696	-9.995	45.302	1.00	81.36	C
ATOM	5029	O	ALA	I	174	9.369	-10.938	44.896	1.00	80.31	O
ATOM	5030	CB	ALA	I	174	6.929	-9.157	43.769	1.00	78.45	C
ATOM	5031	N	VAL	I	175	8.318	-9.859	46.569	1.00	79.11	N
ATOM	5032	CA	VAL	I	175	8.562	-10.851	47.606	1.00	78.98	C
ATOM	5033	C	VAL	I	175	7.202	-11.259	48.130	1.00	84.62	C
ATOM	5034	O	VAL	I	175	6.365	-10.397	48.406	1.00	85.14	O
ATOM	5035	CB	VAL	I	175	9.518	-10.376	48.733	1.00	81.98	C
ATOM	5036	CG1	VAL	I	175	10.942	-10.245	48.210	1.00	81.35	C
ATOM	5037	CG2	VAL	I	175	9.049	-9.064	49.363	1.00	81.82	C
ATOM	5038	N	LEU	I	176	6.943	-12.562	48.181	1.00	81.22	N

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	5039	CA	LEU	I	176	5.679	-13.063	48.677	1.00	80.56	C
ATOM	5040	C	LEU	I	176	5.790	-13.055	50.176	1.00	84.36	C
ATOM	5041	O	LEU	I	176	6.702	-13.658	50.742	1.00	82.52	O
ATOM	5042	CB	LEU	I	176	5.375	-14.486	48.141	1.00	80.78	C
ATOM	5043	CG	LEU	I	176	4.112	-15.178	48.720	1.00	85.45	C
ATOM	5044	CD1	LEU	I	176	2.863	-14.836	47.919	1.00	85.54	C
ATOM	5045	CD2	LEU	I	176	4.309	-16.673	48.858	1.00	85.48	C
ATOM	5046	N	GLN	I	177	4.862	-12.350	50.816	1.00	83.92	N
ATOM	5047	CA	GLN	I	177	4.763	-12.236	52.279	1.00	84.30	C
ATOM	5048	C	GLN	I	177	4.141	-13.527	52.868	1.00	90.28	C
ATOM	5049	O	GLN	I	177	3.617	-14.366	52.124	1.00	90.10	O
ATOM	5050	CB	GLN	I	177	3.922	-10.992	52.664	1.00	84.92	C
ATOM	5051	CG	GLN	I	177	4.341	-9.706	51.937	1.00	88.13	C
ATOM	5052	CD	GLN	I	177	3.544	-8.508	52.367	1.00	100.73	C
ATOM	5053	OE1	GLN	I	177	3.772	-7.949	53.442	1.00	101.57	O
ATOM	5054	NE2	GLN	I	177	2.604	-8.078	51.535	1.00	82.04	N
ATOM	5055	N	SER	I	178	4.208	-13.679	54.201	1.00	88.20	N
ATOM	5056	CA	SER	I	178	3.597	-14.794	54.948	1.00	88.55	C
ATOM	5057	C	SER	I	178	2.066	-14.720	54.852	1.00	91.50	C
ATOM	5058	O	SER	I	178	1.387	-15.742	55.000	1.00	90.72	O
ATOM	5059	CB	SER	I	178	4.018	-14.737	56.415	1.00	93.39	C
ATOM	5060	OG	SER	I	178	3.822	-13.437	56.950	1.00	104.56	O
ATOM	5061	N	SER	I	179	1.544	-13.493	54.593	1.00	87.52	N
ATOM	5062	CA	SER	I	179	0.130	-13.144	54.425	1.00	87.08	C
ATOM	5063	C	SER	I	179	-0.521	-13.793	53.200	1.00	90.02	C
ATOM	5064	O	SER	I	179	-1.748	-13.856	53.123	1.00	88.99	O
ATOM	5065	CB	SER	I	179	-0.031	-11.625	54.347	1.00	90.71	C
ATOM	5066	OG	SER	I	179	0.453	-11.091	53.126	1.00	100.84	O
ATOM	5067	N	GLY	I	180	0.306	-14.222	52.247	1.00	86.83	N
ATOM	5068	CA	GLY	I	180	-0.127	-14.821	50.990	1.00	86.26	C
ATOM	5069	C	GLY	I	180	-0.163	-13.819	49.858	1.00	89.12	C
ATOM	5070	O	GLY	I	180	-0.425	-14.198	48.714	1.00	88.61	O
ATOM	5071	N	LEU	I	181	0.138	-12.529	50.172	1.00	85.62	N
ATOM	5072	CA	LEU	I	181	0.127	-11.388	49.232	1.00	85.21	C
ATOM	5073	C	LEU	I	181	1.527	-10.921	48.872	1.00	87.98	C
ATOM	5074	O	LEU	I	181	2.435	-10.997	49.693	1.00	87.94	O
ATOM	5075	CB	LEU	I	181	-0.686	-10.205	49.794	1.00	85.31	C
ATOM	5076	CG	LEU	I	181	-2.181	-10.438	50.030	1.00	89.61	C
ATOM	5077	CD1	LEU	I	181	-2.453	-10.925	51.456	1.00	89.27	C
ATOM	5078	CD2	LEU	I	181	-2.960	-9.178	49.767	1.00	92.33	C
ATOM	5079	N	TYR	I	182	1.706	-10.453	47.645	1.00	84.03	N
ATOM	5080	CA	TYR	I	182	3.004	-10.004	47.142	1.00	84.04	C
ATOM	5081	C	TYR	I	182	3.263	-8.538	47.466	1.00	87.97	C
ATOM	5082	O	TYR	I	182	2.319	-7.751	47.582	1.00	86.84	O
ATOM	5083	CB	TYR	I	182	3.094	-10.211	45.613	1.00	85.21	C
ATOM	5084	CG	TYR	I	182	3.075	-11.655	45.149	1.00	86.64	C
ATOM	5085	CD1	TYR	I	182	4.205	-12.454	45.256	1.00	88.62	C
ATOM	5086	CD2	TYR	I	182	1.961	-12.187	44.506	1.00	87.24	C
ATOM	5087	CE1	TYR	I	182	4.217	-13.763	44.775	1.00	89.74	C
ATOM	5088	CE2	TYR	I	182	1.962	-13.494	44.015	1.00	87.97	C
ATOM	5089	CZ	TYR	I	182	3.092	-14.283	44.159	1.00	92.80	C
ATOM	5090	OH	TYR	I	182	3.122	-15.579	43.693	1.00	86.97	O
ATOM	5091	N	SER	I	183	4.555	-8.164	47.571	1.00	85.19	N
ATOM	5092	CA	SER	I	183	4.973	-6.785	47.823	1.00	84.83	C
ATOM	5093	C	SER	I	183	6.319	-6.421	47.207	1.00	87.34	C
ATOM	5094	O	SER	I	183	7.255	-7.219	47.249	1.00	87.11	O
ATOM	5095	CB	SER	I	183	4.977	-6.484	49.316	1.00	89.01	C
ATOM	5096	OG	SER	I	183	3.656	-6.241	49.764	1.00	99.89	O
ATOM	5097	N	LEU	I	184	6.413	-5.205	46.648	1.00	82.67	N
ATOM	5098	CA	LEU	I	184	7.656	-4.685	46.086	1.00	82.67	C
ATOM	5099	C	LEU	I	184	7.821	-3.174	46.271	1.00	86.31	C
ATOM	5100	O	LEU	I	184	6.862	-2.484	46.639	1.00	86.20	O
ATOM	5101	CB	LEU	I	184	7.865	-5.084	44.614	1.00	82.76	C
ATOM	5102	CG	LEU	I	184	6.866	-4.630	43.548	1.00	87.40	C
ATOM	5103	CD1	LEU	I	184	7.155	-3.225	43.049	1.00	86.84	C
ATOM	5104	CD2	LEU	I	184	6.964	-5.540	42.365	1.00	91.94	C
ATOM	5105	N	SER	I	185	9.044	-2.665	45.987	1.00	81.21	N
ATOM	5106	CA	SER	I	185	9.365	-1.245	46.063	1.00	79.97	C
ATOM	5107	C	SER	I	185	10.032	-0.782	44.749	1.00	84.08	C
ATOM	5108	O	SER	I	185	10.873	-1.502	44.208	1.00	83.89	O
ATOM	5109	CB	SER	I	185	10.276	-0.953	47.259	1.00	80.99	C
ATOM	5110	OG	SER	I	185	9.792	-1.437	48.504	1.00	81.72	O
ATOM	5111	N	SER	I	186	9.612	0.390	44.214	1.00	80.23	N
ATOM	5112	CA	SER	I	186	10.243	1.037	43.056	1.00	79.94	C
ATOM	5113	C	SER	I	186	10.863	2.325	43.589	1.00	83.41	C
ATOM	5114	O	SER	I	186	10.166	3.164	44.157	1.00	81.52	O
ATOM	5115	CB	SER	I	186	9.251	1.361	41.942	1.00	82.34	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	5116	OG	SER	I	186	9.876	2.160	40.945	1.00	85.14	O
ATOM	5117	N	VAL	I	187	12.183	2.447	43.441	1.00	80.65	N
ATOM	5118	CA	VAL	I	187	12.960	3.587	43.933	1.00	80.16	C
ATOM	5119	C	VAL	I	187	13.687	4.299	42.784	1.00	85.19	C
ATOM	5120	O	VAL	I	187	13.859	3.718	41.713	1.00	84.52	O
ATOM	5121	CB	VAL	I	187	13.925	3.175	45.088	1.00	82.67	C
ATOM	5122	CG1	VAL	I	187	13.162	2.572	46.271	1.00	82.08	C
ATOM	5123	CG2	VAL	I	187	15.013	2.226	44.592	1.00	82.02	C
ATOM	5124	N	VAL	I	188	14.089	5.559	43.008	1.00	83.84	N
ATOM	5125	CA	VAL	I	188	14.817	6.386	42.040	1.00	84.15	C
ATOM	5126	C	VAL	I	188	15.692	7.406	42.782	1.00	88.55	C
ATOM	5127	O	VAL	I	188	15.230	8.045	43.733	1.00	87.29	O
ATOM	5128	CB	VAL	I	188	13.910	7.024	40.924	1.00	87.46	C
ATOM	5129	CG1	VAL	I	188	12.920	8.044	41.493	1.00	86.52	C
ATOM	5130	CG2	VAL	I	188	14.740	7.631	39.788	1.00	87.23	C
ATOM	5131	N	THR	I	189	16.968	7.508	42.365	1.00	86.26	N
ATOM	5132	CA	THR	I	189	17.916	8.484	42.891	1.00	86.21	C
ATOM	5133	C	THR	I	189	17.875	9.696	41.978	1.00	91.22	C
ATOM	5134	O	THR	I	189	18.007	9.568	40.762	1.00	89.89	O
ATOM	5135	CB	THR	I	189	19.322	7.904	43.115	1.00	90.42	C
ATOM	5136	OG1	THR	I	189	19.705	7.089	42.008	1.00	93.39	O
ATOM	5137	CG2	THR	I	189	19.428	7.114	44.413	1.00	85.93	C
ATOM	5138	N	VAL	I	190	17.611	10.863	42.570	1.00	90.14	N
ATOM	5139	CA	VAL	I	190	17.502	12.152	41.877	1.00	90.60	C
ATOM	5140	C	VAL	I	190	18.400	13.214	42.540	1.00	97.62	C
ATOM	5141	O	VAL	I	190	18.760	13.026	43.708	1.00	97.62	O
ATOM	5142	CB	VAL	I	190	16.023	12.637	41.807	1.00	94.09	C
ATOM	5143	CG1	VAL	I	190	15.246	11.891	40.728	1.00	93.88	C
ATOM	5144	CG2	VAL	I	190	15.324	12.558	43.168	1.00	93.53	C
ATOM	5145	N	PRO	I	191	18.740	14.349	41.860	1.00	96.00	N
ATOM	5146	CA	PRO	I	191	19.527	15.401	42.544	1.00	95.98	C
ATOM	5147	C	PRO	I	191	18.718	16.060	43.680	1.00	98.22	C
ATOM	5148	O	PRO	I	191	17.513	16.275	43.516	1.00	96.71	O
ATOM	5149	CB	PRO	I	191	19.835	16.414	41.420	1.00	97.89	C
ATOM	5150	CG	PRO	I	191	19.458	15.738	40.137	1.00	102.10	C
ATOM	5151	CD	PRO	I	191	18.395	14.753	40.479	1.00	97.54	C
ATOM	5152	N	SER	I	192	19.371	16.360	44.832	1.00	94.89	N
ATOM	5153	CA	SER	I	192	18.747	16.988	46.010	1.00	94.73	C
ATOM	5154	C	SER	I	192	18.123	18.352	45.705	1.00	99.92	C
ATOM	5155	O	SER	I	192	17.158	18.751	46.368	1.00	100.04	O
ATOM	5156	CB	SER	I	192	19.749	17.112	47.152	1.00	97.74	C
ATOM	5157	OG	SER	I	192	19.975	15.853	47.764	1.00	105.99	O
ATOM	5158	N	SER	I	193	18.669	19.050	44.687	1.00	97.04	N
ATOM	5159	CA	SER	I	193	18.215	20.360	44.203	1.00	97.18	C
ATOM	5160	C	SER	I	193	16.815	20.307	43.542	1.00	100.08	C
ATOM	5161	O	SER	I	193	16.111	21.319	43.519	1.00	99.79	O
ATOM	5162	CB	SER	I	193	19.239	20.949	43.232	1.00	101.65	C
ATOM	5163	OG	SER	I	193	19.431	20.148	42.075	1.00	111.92	O
ATOM	5164	N	SER	I	194	16.426	19.130	43.012	1.00	95.40	N
ATOM	5165	CA	SER	I	194	15.153	18.879	42.328	1.00	94.30	C
ATOM	5166	C	SER	I	194	13.944	18.852	43.278	1.00	97.25	C
ATOM	5167	O	SER	I	194	12.842	19.201	42.864	1.00	96.45	O
ATOM	5168	CB	SER	I	194	15.227	17.568	41.553	1.00	97.30	C
ATOM	5169	OG	SER	I	194	16.446	17.437	40.839	1.00	106.38	O
ATOM	5170	N	LEU	I	195	14.152	18.424	44.538	1.00	93.34	N
ATOM	5171	CA	LEU	I	195	13.137	18.338	45.591	1.00	93.10	C
ATOM	5172	C	LEU	I	195	12.506	19.727	45.832	1.00	97.84	C
ATOM	5173	O	LEU	I	195	13.165	20.642	46.346	1.00	97.78	O
ATOM	5174	CB	LEU	I	195	13.812	17.823	46.882	1.00	93.18	C
ATOM	5175	CG	LEU	I	195	14.048	16.320	47.074	1.00	97.71	C
ATOM	5176	CD1	LEU	I	195	14.826	15.686	45.905	1.00	97.43	C
ATOM	5177	CD2	LEU	I	195	14.804	16.080	48.373	1.00	100.80	C
ATOM	5178	N	GLY	I	196	11.257	19.880	45.413	1.00	94.64	N
ATOM	5179	CA	GLY	I	196	10.540	21.147	45.509	1.00	94.76	C
ATOM	5180	C	GLY	I	196	10.274	21.716	44.130	1.00	100.03	C
ATOM	5181	O	GLY	I	196	9.144	22.114	43.831	1.00	99.76	O
ATOM	5182	N	THR	I	197	11.314	21.722	43.266	1.00	97.57	N
ATOM	5183	CA	THR	I	197	11.245	22.177	41.867	1.00	98.16	C
ATOM	5184	C	THR	I	197	10.445	21.149	41.026	1.00	102.84	C
ATOM	5185	O	THR	I	197	9.413	21.499	40.441	1.00	102.18	O
ATOM	5186	CB	THR	I	197	12.678	22.367	41.297	1.00	109.28	C
ATOM	5187	OG1	THR	I	197	13.473	23.115	42.215	1.00	111.17	O
ATOM	5188	CG2	THR	I	197	12.695	23.025	39.914	1.00	107.72	C
ATOM	5189	N	GLN	I	198	10.944	19.884	40.979	1.00	99.80	N
ATOM	5190	CA	GLN	I	198	10.373	18.762	40.235	1.00	99.75	C
ATOM	5191	C	GLN	I	198	9.413	17.892	41.028	1.00	103.58	C
ATOM	5192	O	GLN	I	198	9.638	17.601	42.211	1.00	102.87	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	5193	CB	GLN	I	198	11.465	17.882	39.599	1.00	101.22	C
ATOM	5194	CG	GLN	I	198	11.490	17.919	38.068	1.00	118.24	C
ATOM	5195	CD	GLN	I	198	10.187	17.495	37.441	1.00	137.84	C
ATOM	5196	OE1	GLN	I	198	9.875	16.307	37.344	1.00	133.10	O
ATOM	5197	NE2	GLN	I	198	9.391	18.463	37.013	1.00	131.29	N
ATOM	5198	N	THR	I	199	8.352	17.449	40.331	1.00	100.25	N
ATOM	5199	CA	THR	I	199	7.290	16.596	40.858	1.00	100.08	C
ATOM	5200	C	THR	I	199	7.553	15.157	40.464	1.00	103.20	C
ATOM	5201	O	THR	I	199	7.827	14.873	39.293	1.00	102.49	O
ATOM	5202	CB	THR	I	199	5.903	17.074	40.393	1.00	109.09	C
ATOM	5203	OG1	THR	I	199	5.922	18.490	40.190	1.00	109.74	O
ATOM	5204	CG2	THR	I	199	4.807	16.712	41.385	1.00	108.29	C
ATOM	5205	N	TYR	I	200	7.474	14.254	41.455	1.00	99.52	N
ATOM	5206	CA	TYR	I	200	7.714	12.825	41.271	1.00	99.29	C
ATOM	5207	C	TYR	I	200	6.472	12.000	41.575	1.00	104.26	C
ATOM	5208	O	TYR	I	200	6.025	11.951	42.727	1.00	104.99	O
ATOM	5209	CB	TYR	I	200	8.939	12.368	42.092	1.00	100.04	C
ATOM	5210	CG	TYR	I	200	10.216	13.054	41.664	1.00	101.65	C
ATOM	5211	CD1	TYR	I	200	10.807	12.766	40.436	1.00	103.79	C
ATOM	5212	CD2	TYR	I	200	10.806	14.036	42.459	1.00	102.17	C
ATOM	5213	CE1	TYR	I	200	11.959	13.425	40.014	1.00	104.59	C
ATOM	5214	CE2	TYR	I	200	11.963	14.700	42.050	1.00	102.87	C
ATOM	5215	CZ	TYR	I	200	12.536	14.388	40.825	1.00	109.36	C
ATOM	5216	OH	TYR	I	200	13.680	15.015	40.404	1.00	107.27	O
ATOM	5217	N	ILE	I	201	5.879	11.397	40.520	1.00	99.44	N
ATOM	5218	CA	ILE	I	201	4.689	10.544	40.635	1.00	98.10	C
ATOM	5219	C	ILE	I	201	5.017	9.175	40.064	1.00	99.19	C
ATOM	5220	O	ILE	I	201	5.558	9.094	38.955	1.00	98.53	O
ATOM	5221	CB	ILE	I	201	3.431	11.143	39.924	1.00	101.06	C
ATOM	5222	CG1	ILE	I	201	3.221	12.639	40.253	1.00	101.01	C
ATOM	5223	CG2	ILE	I	201	2.161	10.315	40.231	1.00	101.90	C
ATOM	5224	CD1	ILE	I	201	2.652	13.423	39.137	1.00	106.55	C
ATOM	5225	N	CYS	I	202	4.677	8.105	40.803	1.00	93.61	N
ATOM	5226	CA	CYS	I	202	4.863	6.745	40.304	1.00	92.43	C
ATOM	5227	C	CYS	I	202	3.544	6.189	39.789	1.00	95.34	C
ATOM	5228	O	CYS	I	202	2.517	6.343	40.447	1.00	94.15	O
ATOM	5229	CB	CYS	I	202	5.503	5.823	41.342	1.00	91.95	C
ATOM	5230	SG	CYS	I	202	4.408	5.310	42.690	1.00	94.91	S
ATOM	5231	N	ASN	I	203	3.567	5.560	38.607	1.00	91.63	N
ATOM	5232	CA	ASN	I	203	2.357	4.973	38.035	1.00	90.93	C
ATOM	5233	C	ASN	I	203	2.388	3.456	38.167	1.00	93.62	C
ATOM	5234	O	ASN	I	203	3.119	2.765	37.443	1.00	92.60	O
ATOM	5235	CB	ASN	I	203	2.115	5.423	36.595	1.00	91.76	C
ATOM	5236	CG	ASN	I	203	2.697	6.764	36.230	1.00	101.68	C
ATOM	5237	OD1	ASN	I	203	3.525	6.854	35.320	1.00	90.18	O
ATOM	5238	ND2	ASN	I	203	2.267	7.829	36.912	1.00	89.26	N
ATOM	5239	N	VAL	I	204	1.617	2.962	39.150	1.00	90.03	N
ATOM	5240	CA	VAL	I	204	1.477	1.553	39.514	1.00	89.87	C
ATOM	5241	C	VAL	I	204	0.212	1.000	38.850	1.00	95.64	C
ATOM	5242	O	VAL	I	204	-0.892	1.490	39.109	1.00	96.06	O
ATOM	5243	CB	VAL	I	204	1.460	1.356	41.052	1.00	92.93	C
ATOM	5244	CG1	VAL	I	204	1.432	-0.124	41.417	1.00	92.58	C
ATOM	5245	CG2	VAL	I	204	2.644	2.048	41.712	1.00	92.56	C
ATOM	5246	N	ASN	I	205	0.384	-0.016	37.986	1.00	91.97	N
ATOM	5247	CA	ASN	I	205	-0.698	-0.664	37.249	1.00	90.90	C
ATOM	5248	C	ASN	I	205	-0.737	-2.149	37.606	1.00	91.48	C
ATOM	5249	O	ASN	I	205	0.305	-2.800	37.584	1.00	91.03	O
ATOM	5250	CB	ASN	I	205	-0.507	-0.456	35.739	1.00	92.29	C
ATOM	5251	CG	ASN	I	205	-1.778	-0.568	34.949	1.00	122.49	C
ATOM	5252	OD1	ASN	I	205	-2.617	0.342	34.950	1.00	118.21	O
ATOM	5253	ND2	ASN	I	205	-1.946	-1.692	34.255	1.00	115.15	N
ATOM	5254	N	HIS	I	206	-1.920	-2.659	38.001	1.00	85.66	N
ATOM	5255	CA	HIS	I	206	-2.144	-4.060	38.363	1.00	84.39	C
ATOM	5256	C	HIS	I	206	-3.400	-4.536	37.628	1.00	91.22	C
ATOM	5257	O	HIS	I	206	-4.499	-4.460	38.190	1.00	92.66	O
ATOM	5258	CB	HIS	I	206	-2.276	-4.219	39.898	1.00	83.58	C
ATOM	5259	CG	HIS	I	206	-2.454	-5.634	40.381	1.00	85.52	C
ATOM	5260	ND1	HIS	I	206	-3.532	-5.995	41.159	1.00	86.50	N
ATOM	5261	CD2	HIS	I	206	-1.665	-6.721	40.208	1.00	85.91	C
ATOM	5262	CE1	HIS	I	206	-3.373	-7.279	41.427	1.00	85.16	C
ATOM	5263	NE2	HIS	I	206	-2.261	-7.756	40.883	1.00	85.28	N
ATOM	5264	N	LYS	I	207	-3.238	-5.004	36.360	1.00	87.41	N
ATOM	5265	CA	LYS	I	207	-4.311	-5.487	35.480	1.00	86.80	C
ATOM	5266	C	LYS	I	207	-5.221	-6.568	36.119	1.00	89.94	C
ATOM	5267	O	LYS	I	207	-6.446	-6.422	36.007	1.00	89.76	O
ATOM	5268	CB	LYS	I	207	-3.764	-5.951	34.128	1.00	89.18	C
ATOM	5269	CG	LYS	I	207	-3.243	-4.803	33.269	1.00	107.36	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab - <i>C. difficile</i> toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	5270	CD	LYS I	207	-3.384	-5.089	31.763	1.00
ATOM	5271	CE	LYS I	207	-3.345	-3.841	30.909	1.00
ATOM	5272	NZ	LYS I	207	-3.882	-4.093	29.547	1.00
ATOM	5273	N	PRO I	208	-4.692	-7.588	36.857	1.00
ATOM	5274	CA	PRO I	208	-5.588	-8.593	37.468	1.00
ATOM	5275	C	PRO I	208	-6.734	-8.056	38.333	1.00
ATOM	5276	O	PRO I	208	-7.811	-8.654	38.323	1.00
ATOM	5277	CB	PRO I	208	-4.637	-9.464	38.273	1.00
ATOM	5278	CG	PRO I	208	-3.367	-9.371	37.546	1.00
ATOM	5279	CD	PRO I	208	-3.279	-7.946	37.100	1.00
ATOM	5280	N	SER I	209	-6.524	-6.945	39.058	1.00
ATOM	5281	CA	SER I	209	-7.569	-6.321	39.880	1.00
ATOM	5282	C	SER I	209	-8.039	-5.005	39.232	1.00
ATOM	5283	O	SER I	209	-8.931	-4.335	39.765	1.00
ATOM	5284	CB	SER I	209	-7.073	-6.081	41.307	1.00
ATOM	5285	OG	SER I	209	-6.133	-5.021	41.368	1.00
ATOM	5286	N	ASN I	210	-7.444	-4.661	38.065	1.00
ATOM	5287	CA	ASN I	210	-7.674	-3.434	37.289	1.00
ATOM	5288	C	ASN I	210	-7.505	-2.164	38.162	1.00
ATOM	5289	O	ASN I	210	-8.404	-1.323	38.256	1.00
ATOM	5290	CB	ASN I	210	-9.002	-3.465	36.523	1.00
ATOM	5291	CG	ASN I	210	-9.068	-2.426	35.432	1.00
ATOM	5292	OD1	ASN I	210	-9.774	-1.413	35.542	1.00
ATOM	5293	ND2	ASN I	210	-8.289	-2.626	34.377	1.00
ATOM	5294	N	THR I	211	-6.333	-2.069	38.821	1.00
ATOM	5295	CA	THR I	211	-5.926	-0.976	39.697	1.00
ATOM	5296	C	THR I	211	-4.841	-0.148	38.998	1.00
ATOM	5297	O	THR I	211	-3.792	-0.677	38.629	1.00
ATOM	5298	CB	THR I	211	-5.439	-1.534	41.048	1.00
ATOM	5299	OG1	THR I	211	-6.460	-2.342	41.623	1.00
ATOM	5300	CG2	THR I	211	-5.079	-0.449	42.036	1.00
ATOM	5301	N	LYS I	212	-5.124	1.144	38.797	1.00
ATOM	5302	CA	LYS I	212	-4.204	2.127	38.234	1.00
ATOM	5303	C	LYS I	212	-4.117	3.254	39.266	1.00
ATOM	5304	O	LYS I	212	-5.098	3.975	39.487	1.00
ATOM	5305	CB	LYS I	212	-4.668	2.627	36.853	1.00
ATOM	5306	N	VAL I	213	-2.974	3.316	39.978	1.00
ATOM	5307	CA	VAL I	213	-2.668	4.294	41.033	1.00
ATOM	5308	C	VAL I	213	-1.552	5.227	40.551	1.00
ATOM	5309	O	VAL I	213	-0.685	4.809	39.784	1.00
ATOM	5310	CB	VAL I	213	-2.257	3.591	42.357	1.00
ATOM	5311	CG1	VAL I	213	-2.139	4.585	43.509	1.00
ATOM	5312	CG2	VAL I	213	-3.225	2.478	42.717	1.00
ATOM	5313	N	ASP I	214	-1.585	6.489	40.997	1.00
ATOM	5314	CA	ASP I	214	-0.563	7.492	40.710	1.00
ATOM	5315	C	ASP I	214	-0.325	8.260	42.024	1.00
ATOM	5316	O	ASP I	214	-1.078	9.195	42.327	1.00
ATOM	5317	CB	ASP I	214	-0.982	8.428	39.551	1.00
ATOM	5318	CG	ASP I	214	-1.412	7.724	38.274	1.00
ATOM	5319	OD1	ASP I	214	-0.525	7.297	37.503	1.00
ATOM	5320	OD2	ASP I	214	-2.637	7.614	38.041	1.00
ATOM	5321	N	LYS I	215	0.654	7.797	42.852	1.00
ATOM	5322	CA	LYS I	215	0.977	8.436	44.133	1.00
ATOM	5323	C	LYS I	215	2.082	9.467	43.943	1.00
ATOM	5324	O	LYS I	215	3.107	9.164	43.328	1.00
ATOM	5325	CB	LYS I	215	1.352	7.413	45.221	1.00
ATOM	5326	N	ARG I	216	1.849	10.701	44.427	1.00
ATOM	5327	CA	ARG I	216	2.841	11.770	44.371	1.00
ATOM	5328	C	ARG I	216	3.745	11.610	45.584	1.00
ATOM	5329	O	ARG I	216	3.265	11.555	46.728	1.00
ATOM	5330	CB	ARG I	216	2.198	13.169	44.337	1.00
ATOM	5331	N	VAL I	217	5.048	11.446	45.312	1.00
ATOM	5332	CA	VAL I	217	6.097	11.308	46.315	1.00
ATOM	5333	C	VAL I	217	6.667	12.711	46.508	1.00
ATOM	5334	O	VAL I	217	7.272	13.284	45.600	1.00
ATOM	5335	CB	VAL I	217	7.180	10.251	45.955	1.00
ATOM	5336	CG1	VAL I	217	8.155	10.044	47.114	1.00
ATOM	5337	CG2	VAL I	217	6.543	8.923	45.555	1.00
ATOM	5338	N	GLU I	218	6.367	13.287	47.668	1.00
ATOM	5339	CA	GLU I	218	6.759	14.622	48.078	1.00
ATOM	5340	C	GLU I	218	7.491	14.505	49.411	1.00
ATOM	5341	O	GLU I	218	7.182	13.572	50.163	1.00
ATOM	5342	CB	GLU I	218	5.496	15.492	48.253	1.00
ATOM	5343	N	PRO I	219	8.438	15.422	49.753	1.00
ATOM	5344	CA	PRO I	219	9.084	15.349	51.085	1.00
ATOM	5345	C	PRO I	219	8.065	15.621	52.187	1.00
ATOM	5346	O	PRO I	219	7.237	16.515	52.016	1.00
							102.72	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	5347	CB	PRO	I	219	10.161	16.432	51.026
ATOM	5348	CG	PRO	I	219	10.250	16.841	49.573
ATOM	5349	CD	PRO	I	219	8.908	16.596	48.996
ATOM	5350	N	LYS	I	220	8.066	14.808	53.265
ATOM	5351	CA	LYS	I	220	7.091	14.939	54.366
ATOM	5352	C	LYS	I	220	7.249	16.261	55.136
ATOM	5353	O	LYS	I	220	8.376	16.610	55.498
ATOM	5354	CB	LYS	I	220	7.171	13.732	55.323
ATOM	5355	N	SER	I	221	6.132	16.995	55.375
ATOM	5356	CA	SER	I	221	6.155	18.268	56.115
ATOM	5357	C	SER	I	221	5.808	18.070	57.595
ATOM	5358	O	SER	I	221	6.693	18.077	58.450
ATOM	5359	CB	SER	I	221	5.214	19.290	55.479
ATOM	5360	OG	SER	I	221	5.649	19.682	54.187
TER	5361	SER	I		221			
ATOM	5362	N	GLU	L	1	43.840	-4.581	-1.942
ATOM	5363	CA	GLU	L	1	42.800	-4.307	-2.937
ATOM	5364	C	GLU	L	1	42.920	-2.883	-3.543
ATOM	5365	O	GLU	L	1	44.010	-2.286	-3.496
ATOM	5366	CB	GLU	L	1	41.389	-4.595	-2.373
ATOM	5367	CG	GLU	L	1	41.096	-3.960	-1.024
ATOM	5368	CD	GLU	L	1	39.969	-2.946	-0.986
ATOM	5369	OE1	GLU	L	1	38.918	-3.181	-1.627
ATOM	5370	OE2	GLU	L	1	40.121	-1.933	-0.266
ATOM	5371	N	ILE	L	2	41.809	-2.374	-4.139
ATOM	5372	CA	ILE	L	2	41.697	-1.070	-4.805
ATOM	5373	C	ILE	L	2	41.564	0.026	-3.741
ATOM	5374	O	ILE	L	2	40.692	-0.065	-2.882
ATOM	5375	CB	ILE	L	2	40.507	-1.020	-5.829
ATOM	5376	CG1	ILE	L	2	40.096	-2.423	-6.384
ATOM	5377	CG2	ILE	L	2	40.789	-0.051	-6.956
ATOM	5378	CD1	ILE	L	2	39.087	-3.313	-5.447
ATOM	5379	N	VAL	L	3	42.440	1.040	-3.764
ATOM	5380	CA	VAL	L	3	42.382	2.102	-2.754
ATOM	5381	C	VAL	L	3	42.274	3.458	-3.430
ATOM	5382	O	VAL	L	3	43.122	3.818	-4.246
ATOM	5383	CB	VAL	L	3	43.521	2.057	-1.693
ATOM	5384	CG1	VAL	L	3	43.314	3.123	-0.627
ATOM	5385	CG2	VAL	L	3	43.647	0.676	-1.051
ATOM	5386	N	LEU	L	4	41.221	4.205	-3.088
ATOM	5387	CA	LEU	L	4	40.953	5.517	-3.651
ATOM	5388	C	LEU	L	4	41.399	6.607	-2.699
ATOM	5389	O	LEU	L	4	40.854	6.780	-1.601
ATOM	5390	CB	LEU	L	4	39.470	5.672	-4.059
ATOM	5391	CG	LEU	L	4	38.928	4.676	-5.083
ATOM	5392	CD1	LEU	L	4	37.463	4.717	-5.106
ATOM	5393	CD2	LEU	L	4	39.444	4.957	-6.473
ATOM	5394	N	THR	L	5	42.423	7.337	-3.137
ATOM	5395	CA	THR	L	5	43.040	8.436	-2.392
ATOM	5396	C	THR	L	5	42.701	9.742	-3.093
ATOM	5397	O	THR	L	5	43.087	9.932	-4.242
ATOM	5398	CB	THR	L	5	44.542	8.162	-2.139
ATOM	5399	OG1	THR	L	5	44.999	7.070	-2.971
ATOM	5400	CG2	THR	L	5	44.812	7.788	-0.688
ATOM	5401	N	GLN	L	6	41.883	10.581	-2.435
ATOM	5402	CA	GLN	L	6	41.429	11.873	-2.944
ATOM	5403	C	GLN	L	6	42.286	13.024	-2.431
ATOM	5404	O	GLN	L	6	42.730	13.006	-1.285
ATOM	5405	CB	GLN	L	6	39.979	12.141	-2.516
ATOM	5406	CG	GLN	L	6	38.939	11.315	-3.246
ATOM	5407	CD	GLN	L	6	37.564	11.830	-2.964
ATOM	5408	OE1	GLN	L	6	36.795	11.201	-2.238
ATOM	5409	NE2	GLN	L	6	37.230	12.999	-3.528
ATOM	5410	N	SER	L	7	42.475	14.052	-3.259
ATOM	5411	CA	SER	L	7	43.252	15.224	-2.884
ATOM	5412	C	SER	L	7	42.599	16.478	-3.445
ATOM	5413	O	SER	L	7	42.052	16.429	-4.560
ATOM	5414	CB	SER	L	7	44.686	15.114	-3.374
ATOM	5415	OG	SER	L	7	44.735	15.009	-4.787
ATOM	5416	N	PRO	L	8	42.654	17.611	-2.692
ATOM	5417	CA	PRO	L	8	43.151	17.733	-1.315
ATOM	5418	C	PRO	L	8	42.048	17.250	-0.334
ATOM	5419	O	PRO	L	8	40.961	16.828	-0.759
ATOM	5420	CB	PRO	L	8	43.400	19.230	-1.199
ATOM	5421	CG	PRO	L	8	42.309	19.846	-2.023
ATOM	5422	CD	PRO	L	8	42.030	18.869	-3.147
ATOM	5423	N	GLY	L	9	42.315	17.326	0.959

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	5424	CA	GLY	L	9	41.305	16.985	1.947	1.00	59.40	C
ATOM	5425	C	GLY	L	9	40.289	18.102	2.040	1.00	64.25	C
ATOM	5426	O	GLY	L	9	39.093	17.862	2.240	1.00	64.26	O
ATOM	5427	N	THR	L	10	40.775	19.342	1.907	1.00	61.63	N
ATOM	5428	CA	THR	L	10	39.930	20.532	1.899	1.00	61.59	C
ATOM	5429	C	THR	L	10	40.382	21.483	0.814	1.00	65.77	C
ATOM	5430	O	THR	L	10	41.576	21.761	0.664	1.00	66.69	O
ATOM	5431	CB	THR	L	10	39.781	21.190	3.267	1.00	63.98	C
ATOM	5432	OG1	THR	L	10	39.617	20.174	4.254	1.00	63.13	O
ATOM	5433	CG2	THR	L	10	38.580	22.122	3.322	1.00	60.61	C
ATOM	5434	N	LEU	L	11	39.422	21.905	0.014	1.00	60.13	N
ATOM	5435	CA	LEU	L	11	39.635	22.811	-1.077	1.00	59.18	C
ATOM	5436	C	LEU	L	11	38.891	24.041	-0.718	1.00	60.46	C
ATOM	5437	O	LEU	L	11	37.663	24.015	-0.619	1.00	59.29	O
ATOM	5438	CB	LEU	L	11	39.083	22.186	-2.364	1.00	60.38	C
ATOM	5439	CG	LEU	L	11	39.413	22.861	-3.699	1.00	66.20	C
ATOM	5440	CD1	LEU	L	11	40.901	22.936	-3.927	1.00	67.21	C
ATOM	5441	CD2	LEU	L	11	38.775	22.111	-4.847	1.00	68.71	C
ATOM	5442	N	SER	L	12	39.645	25.113	-0.434	1.00	57.16	N
ATOM	5443	CA	SER	L	12	39.115	26.427	-0.070	1.00	55.56	C
ATOM	5444	C	SER	L	12	39.179	27.327	-1.302	1.00	56.24	C
ATOM	5445	O	SER	L	12	40.267	27.602	-1.805	1.00	55.47	O
ATOM	5446	CB	SER	L	12	39.910	27.018	1.088	1.00	58.46	C
ATOM	5447	OG	SER	L	12	39.908	26.104	2.171	1.00	68.18	O
ATOM	5448	N	LEU	L	13	38.008	27.673	-1.844	1.00	50.92	N
ATOM	5449	CA	LEU	L	13	37.847	28.522	-3.015	1.00	51.13	C
ATOM	5450	C	LEU	L	13	36.652	29.445	-2.765	1.00	56.65	C
ATOM	5451	O	LOU	L	13	35.786	29.135	-1.944	1.00	56.69	O
ATOM	5452	CB	LEU	L	13	37.575	27.680	-4.275	1.00	52.02	C
ATOM	5453	CG	LOU	L	13	38.497	26.496	-4.621	1.00	57.97	C
ATOM	5454	CD1	LEU	L	13	37.857	25.620	-5.658	1.00	59.35	C
ATOM	5455	CD2	LEU	L	13	39.854	26.953	-5.139	1.00	57.90	C
ATOM	5456	N	SER	L	14	36.598	30.565	-3.463	1.00	54.88	N
ATOM	5457	CA	SER	L	14	35.506	31.515	-3.311	1.00	56.51	C
ATOM	5458	C	SER	L	14	34.353	31.246	-4.311	1.00	63.77	C
ATOM	5459	O	SER	L	14	34.608	30.671	-5.370	1.00	64.16	O
ATOM	5460	CB	SER	L	14	36.028	32.942	-3.428	1.00	60.01	C
ATOM	5461	OG	SER	L	14	37.318	32.964	-4.019	1.00	66.90	O
ATOM	5462	N	PRO	L	15	33.086	31.637	-4.028	1.00	62.16	N
ATOM	5463	CA	PRO	L	15	32.007	31.355	-5.006	1.00	62.97	C
ATOM	5464	C	PRO	L	15	32.283	31.943	-6.388	1.00	69.17	C
ATOM	5465	O	PRO	L	15	32.821	33.048	-6.483	1.00	70.89	O
ATOM	5466	CB	PRO	L	15	30.742	31.942	-4.348	1.00	64.59	C
ATOM	5467	CG	PRO	L	15	31.083	32.029	-2.889	1.00	68.60	C
ATOM	5468	CD	PRO	L	15	32.561	32.305	-2.816	1.00	63.66	C
ATOM	5469	N	GLY	L	16	31.952	31.177	-7.429	1.00	65.22	N
ATOM	5470	CA	GLY	L	16	32.160	31.561	-8.819	1.00	65.61	C
ATOM	5471	C	GLY	L	16	33.429	30.983	-9.414	1.00	70.80	C
ATOM	5472	O	GLY	L	16	33.583	30.932	-10.640	1.00	71.00	O
ATOM	5473	N	GLU	L	17	34.345	30.533	-8.545	1.00	67.70	N
ATOM	5474	CA	GLU	L	17	35.628	29.948	-8.933	1.00	67.64	C
ATOM	5475	C	GLU	L	17	35.501	28.521	-9.500	1.00	71.32	C
ATOM	5476	O	GLU	L	17	34.507	27.817	-9.249	1.00	71.00	O
ATOM	5477	CB	GLU	L	17	36.580	29.970	-7.722	1.00	69.03	C
ATOM	5478	CG	GLU	L	17	37.876	30.713	-7.948	1.00	81.01	C
ATOM	5479	CD	GLU	L	17	37.761	32.213	-8.132	1.00	101.69	C
ATOM	5480	OE1	GLU	L	17	37.774	32.927	-7.105	1.00	115.11	O
ATOM	5481	OE2	GLU	L	17	37.671	32.677	-9.294	1.00	80.18	O
ATOM	5482	N	ARG	L	18	36.528	28.102	-10.252	1.00	66.65	N
ATOM	5483	CA	ARG	L	18	36.577	26.750	-10.806	1.00	65.66	C
ATOM	5484	C	ARG	L	18	37.182	25.772	-9.788	1.00	69.31	C
ATOM	5485	O	ARG	L	18	38.275	26.016	-9.254	1.00	69.79	O
ATOM	5486	CB	ARG	L	18	37.368	26.710	-12.116	1.00	63.17	C
ATOM	5487	CG	ARG	L	18	36.944	25.562	-12.998	1.00	71.89	C
ATOM	5488	CD	ARG	L	18	37.568	25.643	-14.368	1.00	78.44	C
ATOM	5489	NE	ARG	L	18	38.813	24.880	-14.439	1.00	78.79	N
ATOM	5490	CZ	ARG	L	18	39.016	23.862	-15.269	1.00	92.94	C
ATOM	5491	NH	ARG	L	18	38.061	23.486	-16.117	1.00	81.79	N
ATOM	5492	NH2	ARG	L	18	40.182	23.220	-15.270	1.00	69.25	N
ATOM	5493	N	ALA	L	19	36.470	24.655	-9.540	1.00	63.87	N
ATOM	5494	CA	ALA	L	19	36.919	23.607	-8.631	1.00	62.35	C
ATOM	5495	C	ALA	L	19	37.340	22.395	-9.410	1.00	64.04	C
ATOM	5496	O	ALA	L	19	36.640	21.974	-10.325	1.00	63.04	O
ATOM	5497	CB	ALA	L	19	35.824	23.242	-7.644	1.00	62.93	C
ATOM	5498	N	THR	L	20	38.497	21.837	-9.040	1.00	60.53	N
ATOM	5499	CA	THR	L	20	39.100	20.639	-9.615	1.00	59.52	C
ATOM	5500	C	THR	L	20	39.464	19.741	-8.441	1.00	62.35	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	5501	O	THR	L	20	40.343	20.092	-7.648	1.00	64.48	O
ATOM	5502	CB	THR	L	20	40.294	21.035	-10.504	1.00	69.04	C
ATOM	5503	OG1	THR	L	20	39.789	21.538	-11.739	1.00	65.66	O
ATOM	5504	CG2	THR	L	20	41.243	19.882	-10.774	1.00	70.57	C
ATOM	5505	N	LEU	L	21	38.759	18.602	-8.322	1.00	55.37	N
ATOM	5506	CA	LEU	L	21	38.911	17.588	-7.279	1.00	53.33	C
ATOM	5507	C	LEU	L	21	39.521	16.371	-7.901	1.00	56.28	C
ATOM	5508	O	LEU	L	21	39.085	15.965	-8.978	1.00	54.74	O
ATOM	5509	CB	LEU	L	21	37.534	17.203	-6.720	1.00	53.05	C
ATOM	5510	CG	LEU	L	21	36.842	18.161	-5.764	1.00	56.61	C
ATOM	5511	CD1	LEU	L	21	36.021	19.182	-6.513	1.00	57.81	C
ATOM	5512	CD2	LEU	L	21	35.891	17.432	-4.928	1.00	57.63	C
ATOM	5513	N	SER	L	22	40.507	15.770	-7.220	1.00	54.45	N
ATOM	5514	CA	SER	L	22	41.245	14.598	-7.691	1.00	54.75	C
ATOM	5515	C	SER	L	22	40.877	13.317	-6.941	1.00	60.88	C
ATOM	5516	O	SER	L	22	40.475	13.357	-5.775	1.00	62.48	O
ATOM	5517	CB	SER	L	22	42.745	14.854	-7.588	1.00	59.96	C
ATOM	5518	OG	SER	L	22	43.519	13.671	-7.726	1.00	77.31	O
ATOM	5519	N	CYS	L	23	41.044	12.187	-7.632	1.00	56.85	N
ATOM	5520	CA	CYS	L	23	40.812	10.829	-7.186	1.00	56.90	C
ATOM	5521	C	CYS	L	23	41.881	9.996	-7.859	1.00	64.35	C
ATOM	5522	O	CYS	L	23	41.936	9.928	-9.088	1.00	63.96	O
ATOM	5523	CB	CYS	L	23	39.418	10.364	-7.585	1.00	57.47	C
ATOM	5524	SG	CYS	L	23	38.960	8.708	-6.986	1.00	61.77	S
ATOM	5525	N	ARG	L	24	42.795	9.444	-7.056	1.00	63.39	N
ATOM	5526	CA	ARG	L	24	43.869	8.600	-7.541	1.00	63.01	C
ATOM	5527	C	ARG	L	24	43.661	7.201	-6.993	1.00	67.02	C
ATOM	5528	O	ARG	L	24	43.376	7.029	-5.806	1.00	67.83	O
ATOM	5529	CB	ARG	L	24	45.253	9.175	-7.190	1.00	63.63	C
ATOM	5530	CG	ARG	L	24	46.389	8.567	-8.024	1.00	76.92	C
ATOM	5531	CD	ARG	L	24	47.725	9.244	-7.799	1.00	91.95	C
ATOM	5532	NE	ARG	L	24	48.063	10.170	-8.885	1.00	111.61	N
ATOM	5533	CZ	ARG	L	24	49.103	11.004	-8.878	1.00	131.05	C
ATOM	5534	NH1	ARG	L	24	49.913	11.060	-7.828	1.00	118.00	N
ATOM	5535	NH2	ARG	L	24	49.334	11.796	-9.917	1.00	120.58	N
ATOM	5536	N	ALA	L	25	43.732	6.211	-7.881	1.00	63.07	N
ATOM	5537	CA	ALA	L	25	43.548	4.799	-7.555	1.00	62.13	C
ATOM	5538	C	ALA	L	25	44.897	4.116	-7.349	1.00	65.91	C
ATOM	5539	O	ALA	L	25	45.891	4.463	-8.011	1.00	65.87	O
ATOM	5540	CB	ALA	L	25	42.776	4.104	-8.659	1.00	62.30	C
ATOM	5541	N	SER	L	26	44.922	3.143	-6.421	1.00	61.59	N
ATOM	5542	CA	SER	L	26	46.098	2.351	-6.037	1.00	60.66	C
ATOM	5543	C	SER	L	26	46.623	1.470	-7.191	1.00	65.58	C
ATOM	5544	O	SER	L	26	47.784	1.042	-7.182	1.00	64.91	O
ATOM	5545	CB	SER	L	26	45.755	1.485	-4.833	1.00	61.45	C
ATOM	5546	OG	SER	L	26	44.809	0.488	-5.180	1.00	62.91	O
ATOM	5547	N	GLN	L	27	45.737	1.185	-8.161	1.00	62.63	N
ATOM	5548	CA	GLN	L	27	45.980	0.385	-9.356	1.00	61.67	C
ATOM	5549	C	GLN	L	27	45.072	0.860	-10.467	1.00	66.39	C
ATOM	5550	O	GLN	L	27	44.036	1.459	-10.185	1.00	66.06	O
ATOM	5551	CB	GLN	L	27	45.755	-1.122	-9.069	1.00	62.52	C
ATOM	5552	CG	GLN	L	27	44.336	-1.515	-8.661	1.00	68.66	C
ATOM	5553	CD	GLN	L	27	44.334	-2.805	-7.883	1.00	85.50	C
ATOM	5554	OE1	GLN	L	27	44.101	-3.885	-8.430	1.00	71.84	O
ATOM	5555	NE2	GLN	L	27	44.592	-2.718	-6.577	1.00	87.24	N
ATOM	5556	N	SER	L	28	45.457	0.592	-11.722	1.00	65.99	N
ATOM	5557	CA	SER	L	28	44.683	0.937	-12.916	1.00	67.33	C
ATOM	5558	C	SER	L	28	43.285	0.318	-12.830	1.00	71.73	C
ATOM	5559	O	SER	L	28	43.124	-0.836	-12.387	1.00	70.64	O
ATOM	5560	CB	SER	L	28	45.397	0.498	-14.193	1.00	71.59	C
ATOM	5561	OG	SER	L	28	44.675	0.917	-15.341	1.00	82.75	O
ATOM	5562	N	VAL	L	29	42.276	1.134	-13.181	1.00	68.32	N
ATOM	5563	CA	VAL	L	29	40.914	0.678	-13.048	1.00	68.37	C
ATOM	5564	C	VAL	L	29	39.982	1.186	-14.196	1.00	70.91	C
ATOM	5565	O	VAL	L	29	40.327	2.140	-14.920	1.00	72.04	O
ATOM	5566	CB	VAL	L	29	40.424	0.994	-11.614	1.00	72.10	C
ATOM	5567	CG1	VAL	L	29	40.206	2.488	-11.376	1.00	71.14	C
ATOM	5568	CG2	VAL	L	29	39.229	0.121	-11.242	1.00	72.13	C
ATOM	5569	N	SER	L	30	38.851	0.457	-14.406	1.00	63.77	N
ATOM	5570	CA	SER	L	30	37.902	0.737	-15.473	1.00	62.68	C
ATOM	5571	C	SER	L	30	37.160	2.046	-15.246	1.00	67.91	C
ATOM	5572	O	SER	L	30	36.764	2.371	-14.117	1.00	68.65	O
ATOM	5573	CB	SER	L	30	36.909	-0.406	-15.615	1.00	64.54	C
ATOM	5574	OG	SER	L	30	36.113	-0.217	-16.770	1.00	70.01	O
ATOM	5575	N	SER	L	31	36.984	2.806	-16.324	1.00	63.51	N
ATOM	5576	CA	SER	L	31	36.280	4.088	-16.287	1.00	61.49	C
ATOM	5577	C	SER	L	31	34.807	3.869	-16.060	1.00	62.45	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	5578	O	SER	L	31	34.143	4.761	-15.552	1.00	64.72	O
ATOM	5579	CB	SER	L	31	36.513	4.880	-17.566	1.00	62.63	C
ATOM	5580	OG	SER	L	31	37.832	5.396	-17.564	1.00	69.48	O
ATOM	5581	N	SER	L	32	34.319	2.659	-16.365	1.00	53.62	N
ATOM	5582	CA	SER	L	32	32.926	2.235	-16.227	1.00	51.91	C
ATOM	5583	C	SER	L	32	32.499	2.242	-14.777	1.00	56.02	C
ATOM	5584	O	SER	L	32	31.367	2.615	-14.453	1.00	55.69	O
ATOM	5585	CB	SER	L	32	32.761	0.820	-16.790	1.00	53.89	C
ATOM	5586	OG	SER	L	32	33.310	0.715	-18.100	1.00	62.45	O
ATOM	5587	N	TYR	L	33	33.429	1.841	-13.899	1.00	52.80	N
ATOM	5588	CA	TYR	L	33	33.193	1.671	-12.484	1.00	52.05	C
ATOM	5589	C	TYR	L	33	33.486	2.897	-11.640	1.00	54.87	C
ATOM	5590	O	TYR	L	33	33.274	2.844	-10.420	1.00	54.42	O
ATOM	5591	CB	TYR	L	33	33.959	0.445	-11.997	1.00	53.54	C
ATOM	5592	CG	TYR	L	33	33.426	-0.835	-12.592	1.00	55.98	C
ATOM	5593	CD1	TYR	L	33	32.096	-1.205	-12.422	1.00	58.45	C
ATOM	5594	CD2	TYR	L	33	34.234	-1.653	-13.362	1.00	57.43	C
ATOM	5595	CE1	TYR	L	33	31.590	-2.368	-12.991	1.00	60.29	C
ATOM	5596	CE2	TYR	L	33	33.752	-2.839	-13.905	1.00	59.26	C
ATOM	5597	CZ	TYR	L	33	32.427	-3.199	-13.717	1.00	69.64	C
ATOM	5598	OH	TYR	L	33	31.942	-4.381	-14.255	1.00	72.42	O
ATOM	5599	N	LEU	L	34	33.879	4.025	-12.282	1.00	50.54	N
ATOM	5600	CA	LEU	L	34	34.154	5.251	-11.546	1.00	49.35	C
ATOM	5601	C	LEU	L	34	32.950	6.173	-11.427	1.00	54.13	C
ATOM	5602	O	LEU	L	34	32.388	6.617	-12.436	1.00	56.03	O
ATOM	5603	CB	LEU	L	34	35.375	6.028	-12.053	1.00	48.74	C
ATOM	5604	CG	LEU	L	34	35.906	6.924	-10.937	1.00	52.85	C
ATOM	5605	CD1	LEU	L	34	37.155	6.412	-10.318	1.00	52.09	C
ATOM	5606	CD2	LEU	L	34	35.898	8.349	-11.302	1.00	56.62	C
ATOM	5607	N	ALA	L	35	32.595	6.500	-10.178	1.00	47.55	N
ATOM	5608	CA	ALA	L	35	31.494	7.398	-9.869	1.00	46.13	C
ATOM	5609	C	ALA	L	35	31.885	8.479	-8.850	1.00	50.63	C
ATOM	5610	O	ALA	L	35	32.807	8.283	-8.042	1.00	50.38	O
ATOM	5611	CB	ALA	L	35	30.301	6.607	-9.365	1.00	46.62	C
ATOM	5612	N	TRP	L	36	31.161	9.626	-8.886	1.00	46.06	N
ATOM	5613	CA	TRP	L	36	31.352	10.738	-7.955	1.00	44.33	C
ATOM	5614	C	TRP	L	36	30.037	11.037	-7.292	1.00	46.41	C
ATOM	5615	O	TRP	L	36	29.018	11.108	-7.972	1.00	46.88	O
ATOM	5616	CB	TRP	L	36	31.869	11.988	-8.669	1.00	42.07	C
ATOM	5617	CG	TRP	L	36	33.291	11.901	-9.126	1.00	42.39	C
ATOM	5618	CD1	TRP	L	36	33.738	11.438	-10.329	1.00	45.04	C
ATOM	5619	CD2	TRP	L	36	34.448	12.360	-8.415	1.00	42.32	C
ATOM	5620	NE1	TRP	L	36	35.105	11.567	-10.410	1.00	44.27	N
ATOM	5621	CE2	TRP	L	36	35.569	12.123	-9.243	1.00	45.94	C
ATOM	5622	CE3	TRP	L	36	34.647	12.975	-7.168	1.00	43.58	C
ATOM	5623	CZ2	TRP	L	36	36.868	12.449	-8.849	1.00	45.08	C
ATOM	5624	CZ3	TRP	L	36	35.935	13.314	-6.786	1.00	44.83	C
ATOM	5625	CH2	TRP	L	36	37.026	13.041	-7.615	1.00	45.40	C
ATOM	5626	N	TYR	L	37	30.070	11.228	-5.972	1.00	42.14	N
ATOM	5627	CA	TYR	L	37	28.914	11.547	-5.132	1.00	41.65	C
ATOM	5628	C	TYR	L	37	29.149	12.854	-4.441	1.00	45.17	C
ATOM	5629	O	TYR	L	37	30.284	13.158	-4.088	1.00	45.97	O
ATOM	5630	CB	TYR	L	37	28.646	10.449	-4.053	1.00	41.70	C
ATOM	5631	CG	TYR	L	37	28.451	9.076	-4.646	1.00	43.68	C
ATOM	5632	CD2	TYR	L	37	27.181	8.600	-4.949	1.00	44.78	C
ATOM	5633	CD1	TYR	L	37	29.538	8.272	-4.959	1.00	45.68	C
ATOM	5634	CE2	TYR	L	37	26.999	7.356	-5.548	1.00	45.08	C
ATOM	5635	CE1	TYR	L	37	29.372	7.044	-5.584	1.00	47.36	C
ATOM	5636	CZ	TYR	L	37	28.103	6.590	-5.879	1.00	51.21	C
ATOM	5637	OH	TYR	L	37	27.978	5.359	-6.462	1.00	50.20	O
ATOM	5638	N	GLN	L	38	28.066	13.588	-4.183	1.00	41.87	N
ATOM	5639	CA	GLN	L	38	28.036	14.829	-3.427	1.00	41.89	C
ATOM	5640	C	GLN	L	38	27.257	14.592	-2.153	1.00	48.12	C
ATOM	5641	O	GLN	L	38	26.209	13.962	-2.196	1.00	48.45	O
ATOM	5642	CB	GLN	L	38	27.359	15.956	-4.245	1.00	43.38	C
ATOM	5643	CG	GLN	L	38	27.344	17.326	-3.533	1.00	54.50	C
ATOM	5644	CD	GLN	L	38	26.492	18.354	-4.208	1.00	76.26	C
ATOM	5645	OE1	GLN	L	38	25.294	18.144	-4.457	1.00	70.37	O
ATOM	5646	NE2	GLN	L	38	27.094	19.500	-4.485	1.00	71.83	N
ATOM	5647	N	GLN	L	39	27.715	15.149	-1.029	1.00	46.94	N
ATOM	5648	CA	GLN	L	39	26.962	15.073	0.217	1.00	46.32	C
ATOM	5649	C	GLN	L	39	26.909	16.429	0.884	1.00	54.04	C
ATOM	5650	O	GLN	L	39	27.897	16.885	1.465	1.00	54.99	O
ATOM	5651	CB	GLN	L	39	27.549	14.033	1.151	1.00	46.93	C
ATOM	5652	CG	GLN	L	39	26.668	13.784	2.364	1.00	40.23	C
ATOM	5653	CD	GLN	L	39	27.269	12.743	3.254	1.00	54.48	C
ATOM	5654	OE1	GLN	L	39	28.505	12.635	3.425	1.00	50.09	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	5655	NE2	GLN	L	39	26.391	12.004	3.882	1.00	42.51	N
ATOM	5656	N	LYS	L	40	25.737	17.079	0.790	1.00	52.83	N
ATOM	5657	CA	LYS	L	40	25.466	18.387	1.387	1.00	52.18	C
ATOM	5658	C	LYS	L	40	25.361	18.184	2.896	1.00	59.58	C
ATOM	5659	O	LYS	L	40	25.092	17.055	3.326	1.00	59.65	O
ATOM	5660	CB	LYS	L	40	24.176	18.972	0.800	1.00	52.66	C
ATOM	5661	CG	LYS	L	40	24.402	19.761	-0.475	1.00	55.38	C
ATOM	5662	CD	LYS	L	40	23.248	19.594	-1.483	1.00	57.60	C
ATOM	5663	CE	LYS	L	40	23.528	20.411	-2.735	1.00	62.62	C
ATOM	5664	NZ	LYS	L	40	22.316	20.737	-3.542	1.00	54.05	N
ATOM	5665	N	PRO	L	41	25.588	19.216	3.744	1.00	59.16	N
ATOM	5666	CA	PRO	L	41	25.509	18.983	5.202	1.00	59.42	C
ATOM	5667	C	PRO	L	41	24.128	18.524	5.676	1.00	63.78	C
ATOM	5668	O	PRO	L	41	23.107	19.084	5.246	1.00	63.64	O
ATOM	5669	CB	PRO	L	41	25.906	20.331	5.802	1.00	60.80	C
ATOM	5670	CG	PRO	L	41	26.547	21.086	4.688	1.00	64.84	C
ATOM	5671	CD	PRO	L	41	25.904	20.625	3.446	1.00	60.22	C
ATOM	5672	N	GLY	L	42	24.119	17.469	6.489	1.00	60.54	N
ATOM	5673	CA	GLY	L	42	22.896	16.888	7.044	1.00	61.23	C
ATOM	5674	C	GLY	L	42	21.948	16.258	6.036	1.00	65.97	C
ATOM	5675	O	GLY	L	42	20.743	16.139	6.293	1.00	65.95	O
ATOM	5676	N	GLN	L	43	22.501	15.833	4.882	1.00	61.39	N
ATOM	5677	CA	GLN	L	43	21.766	15.223	3.778	1.00	59.34	C
ATOM	5678	C	GLN	L	43	22.441	13.933	3.344	1.00	58.69	C
ATOM	5679	O	GLN	L	43	23.592	13.656	3.719	1.00	58.73	O
ATOM	5680	CB	GLN	L	43	21.656	16.205	2.593	1.00	60.64	C
ATOM	5681	CG	GLN	L	43	20.802	17.437	2.883	1.00	61.94	C
ATOM	5682	CD	GLN	L	43	20.337	18.089	1.615	1.00	84.44	C
ATOM	5683	OE1	GLN	L	43	19.518	17.539	0.874	1.00	81.09	O
ATOM	5684	NE2	GLN	L	43	20.812	19.298	1.353	1.00	81.58	N
ATOM	5685	N	ALA	L	44	21.700	13.127	2.567	1.00	51.53	N
ATOM	5686	CA	ALA	L	44	22.193	11.846	2.058	1.00	49.32	C
ATOM	5687	C	ALA	L	44	23.117	12.079	0.870	1.00	48.57	C
ATOM	5688	O	ALA	L	44	22.938	13.078	0.170	1.00	45.05	O
ATOM	5689	CB	ALA	L	44	21.021	10.961	1.635	1.00	49.71	C
ATOM	5690	N	PRO	L	45	24.098	11.180	0.593	1.00	45.87	N
ATOM	5691	CA	PRO	L	45	24.909	11.348	-0.619	1.00	45.35	C
ATOM	5692	C	PRO	L	45	24.017	11.237	-1.864	1.00	51.05	C
ATOM	5693	O	PRO	L	45	22.953	10.601	-1.817	1.00	51.85	O
ATOM	5694	CB	PRO	L	45	25.882	10.155	-0.570	1.00	46.92	C
ATOM	5695	CG	PRO	L	45	25.840	9.661	0.833	1.00	51.74	C
ATOM	5696	CD	PRO	L	45	24.462	9.936	1.304	1.00	47.72	C
ATOM	5697	N	ARG	L	46	24.421	11.875	-2.965	1.00	47.06	N
ATOM	5698	CA	ARG	L	46	23.697	11.775	-4.228	1.00	47.38	C
ATOM	5699	C	ARG	L	46	24.689	11.592	-5.351	1.00	52.81	C
ATOM	5700	O	ARG	L	46	25.791	12.138	-5.283	1.00	54.12	O
ATOM	5701	CB	ARG	L	46	22.743	12.957	-4.488	1.00	49.52	C
ATOM	5702	CG	ARG	L	46	23.391	14.313	-4.715	1.00	54.55	C
ATOM	5703	CD	ARG	L	46	22.369	15.329	-5.161	1.00	58.70	C
ATOM	5704	NE	ARG	L	46	23.027	16.567	-5.584	1.00	71.05	N
ATOM	5705	CZ	ARG	L	46	22.537	17.411	-6.485	1.00	81.32	C
ATOM	5706	NH1	ARG	L	46	21.361	17.172	-7.061	1.00	71.34	N
ATOM	5707	NH2	ARG	L	46	23.217	18.501	-6.817	1.00	60.17	N
ATOM	5708	N	LEU	L	47	24.318	10.782	-6.373	1.00	46.09	N
ATOM	5709	CA	LEU	L	47	25.178	10.532	-7.523	1.00	42.81	C
ATOM	5710	C	LEU	L	47	25.216	11.791	-8.390	1.00	52.55	C
ATOM	5711	O	LEU	L	47	24.172	12.429	-8.621	1.00	54.44	O
ATOM	5712	CB	LEU	L	47	24.674	9.324	-8.334	1.00	40.60	C
ATOM	5713	CG	LEU	L	47	25.544	8.833	-9.483	1.00	42.90	C
ATOM	5714	CD1	LEU	L	47	26.797	8.194	-8.993	1.00	42.54	C
ATOM	5715	CD2	LEU	L	47	24.812	7.856	-10.319	1.00	42.71	C
ATOM	5716	N	LEU	L	48	26.436	12.161	-8.822	1.00	48.70	N
ATOM	5717	CA	LEU	L	48	26.700	13.251	-9.729	1.00	48.38	C
ATOM	5718	C	LEU	L	48	27.143	12.674	-11.070	1.00	52.68	C
ATOM	5719	O	LEU	L	48	26.590	13.049	-12.101	1.00	54.63	O
ATOM	5720	CB	LEU	L	48	27.834	14.167	-9.215	1.00	48.81	C
ATOM	5721	CG	LEU	L	48	27.633	15.004	-7.973	1.00	53.56	C
ATOM	5722	CD1	LEU	L	48	28.867	15.827	-7.710	1.00	53.53	C
ATOM	5723	CD2	LEU	L	48	26.402	15.895	-8.072	1.00	54.71	C
ATOM	5724	N	ILE	L	49	28.185	11.820	-11.067	1.00	47.45	N
ATOM	5725	CA	ILE	L	49	28.823	11.292	-12.283	1.00	46.28	C
ATOM	5726	C	ILE	L	49	28.986	9.807	-12.205	1.00	50.07	C
ATOM	5727	O	ILE	L	49	29.499	9.328	-11.203	1.00	51.65	O
ATOM	5728	CB	ILE	L	49	30.217	11.969	-12.441	1.00	48.99	C
ATOM	5729	CG1	ILE	L	49	30.131	13.515	-12.588	1.00	49.35	C
ATOM	5730	CG2	ILE	L	49	31.042	11.350	-13.540	1.00	49.62	C
ATOM	5731	CD1	ILE	L	49	29.374	14.075	-13.820	1.00	66.24	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	5732 N	TYR	L	50	28.570	9.075	-13.237	1.00
ATOM	5733 CA	TYR	L	50	28.755	7.616	-13.329	1.00
ATOM	5734 C	TYR	L	50	29.584	7.303	-14.574	1.00
ATOM	5735 O	TYR	L	50	29.579	8.107	-15.504	1.00
ATOM	5736 CB	TYR	L	50	27.423	6.865	-13.368	1.00
ATOM	5737 CG	TYR	L	50	26.556	7.168	-14.571	1.00
ATOM	5738 CD2	TYR	L	50	26.553	6.330	-15.684	1.00
ATOM	5739 CD1	TYR	L	50	25.654	8.230	-14.554	1.00
ATOM	5740 CE2	TYR	L	50	25.716	6.577	-16.774	1.00
ATOM	5741 CE1	TYR	L	50	24.830	8.499	-15.644	1.00
ATOM	5742 CZ	TYR	L	50	24.865	7.672	-16.751	1.00
ATOM	5743 OH	TYR	L	50	24.050	7.986	-17.808	1.00
ATOM	5744 N	GLY	L	51	30.305	6.180	-14.585	1.00
ATOM	5745 CA	GLY	L	51	31.108	5.790	-15.741	1.00
ATOM	5746 C	GLY	L	51	32.177	6.793	-16.123	1.00
ATOM	5747 O	GLY	L	51	32.515	6.927	-17.307	1.00
ATOM	5748 N	ALA	L	52	32.732	7.480	-15.080	1.00
ATOM	5749 CA	ALA	L	52	33.811	8.483	-15.058	1.00
ATOM	5750 C	ALA	L	52	33.456	9.829	-15.630	1.00
ATOM	5751 O	ALA	L	52	33.902	10.817	-15.068	1.00
ATOM	5752 CB	ALA	L	52	35.075	7.961	-15.725	1.00
ATOM	5753 N	SER	L	53	32.668	9.896	-16.718	1.00
ATOM	5754 CA	SER	L	53	32.327	11.139	-17.428	1.00
ATOM	5755 C	SER	L	53	30.836	11.429	-17.598	1.00
ATOM	5756 O	SER	L	53	30.489	12.578	-17.913	1.00
ATOM	5757 CB	SER	L	53	32.969	11.137	-18.811	1.00
ATOM	5758 OG	SER	L	53	32.341	10.160	-19.628	1.00
ATOM	5759 N	SER	L	54	29.969	10.402	-17.453	1.00
ATOM	5760 CA	SER	L	54	28.526	10.550	-17.656	1.00
ATOM	5761 C	SER	L	54	27.895	11.196	-16.465	1.00
ATOM	5762 O	SER	L	54	28.249	10.893	-15.335	1.00
ATOM	5763 CB	SER	L	54	27.853	9.218	-17.978	1.00
ATOM	5764 OG	SER	L	54	28.531	8.480	-18.986	1.00
ATOM	5765 N	ARG	L	55	26.993	12.117	-16.717	1.00
ATOM	5766 CA	ARG	L	55	26.343	12.922	-15.700	1.00
ATOM	5767 C	ARG	L	55	25.013	12.270	-15.298	1.00
ATOM	5768 O	ARG	L	55	24.189	11.972	-16.170	1.00
ATOM	5769 CB	ARG	L	55	26.139	14.326	-16.299	1.00
ATOM	5770 CG	ARG	L	55	26.083	15.486	-15.327	1.00
ATOM	5771 CD	ARG	L	55	26.736	16.759	-15.861	1.00
ATOM	5772 NE	ARG	L	55	26.307	17.113	-17.213	1.00
ATOM	5773 CZ	ARG	L	55	27.102	17.615	-18.155	1.00
ATOM	5774 NH1	ARG	L	55	28.388	17.847	-17.899	1.00
ATOM	5775 NH2	ARG	L	55	26.622	17.884	-19.359	1.00
ATOM	5776 N	ALA	L	56	24.806	12.039	-13.979	1.00
ATOM	5777 CA	ALA	L	56	23.572	11.452	-13.431	1.00
ATOM	5778 C	ALA	L	56	22.366	12.357	-13.728	1.00
ATOM	5779 O	ALA	L	56	22.563	13.535	-14.037	1.00
ATOM	5780 CB	ALA	L	56	23.713	11.214	-11.938	1.00
ATOM	5781 N	THR	L	57	21.127	11.808	-13.676	1.00
ATOM	5782 CA	THR	L	57	19.903	12.557	-13.994	1.00
ATOM	5783 C	THR	L	57	19.742	13.832	-13.156	1.00
ATOM	5784 O	THR	L	57	19.866	13.779	-11.932	1.00
ATOM	5785 CB	THR	L	57	18.651	11.668	-13.921	1.00
ATOM	5786 OG1	THR	L	57	18.968	10.338	-14.311	1.00
ATOM	5787 CG2	THR	L	57	17.535	12.172	-14.815	1.00
ATOM	5788 N	GLY	L	58	19.483	14.955	-13.847	1.00
ATOM	5789 CA	GLY	L	58	19.256	16.269	-13.244	1.00
ATOM	5790 C	GLY	L	58	20.476	16.915	-12.621	1.00
ATOM	5791 O	GLY	L	58	20.359	17.761	-11.716	1.00
ATOM	5792 N	ILE	L	59	21.663	16.521	-13.100	1.00
ATOM	5793 CA	ILE	L	59	22.885	17.094	-12.566	1.00
ATOM	5794 C	ILE	L	59	23.345	18.247	-13.469	1.00
ATOM	5795 O	ILE	L	59	23.663	18.001	-14.642	1.00
ATOM	5796 CB	ILE	L	59	23.990	16.028	-12.245	1.00
ATOM	5797 CG1	ILE	L	59	23.525	15.014	-11.156	1.00
ATOM	5798 CG2	ILE	L	59	25.342	16.658	-11.874	1.00
ATOM	5799 CD1	ILE	L	59	22.962	15.573	-9.830	1.00
ATOM	5800 N	PRO	L	60	23.394	19.494	-12.895	1.00
ATOM	5801 CA	PRO	L	60	23.872	20.672	-13.648	1.00
ATOM	5802 C	PRO	L	60	25.130	20.487	-14.498	1.00
ATOM	5803 O	PRO	L	60	26.055	19.774	-14.091	1.00
ATOM	5804 CB	PRO	L	60	24.161	21.679	-12.538	1.00
ATOM	5805 CG	PRO	L	60	23.224	21.328	-11.456	1.00
ATOM	5806 CD	PRO	L	60	23.037	19.861	-11.504	1.00
ATOM	5807 N	ASP	L	61	25.187	21.188	-15.653	1.00
ATOM	5808 CA	ASP	L	61	26.301	21.146	-16.612	1.00

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	5809	C	ASP	L	61	27.636	21.612	-16.034	1.00	62.99	C
ATOM	5810	O	ASP	L	61	28.684	21.305	-16.620	1.00	60.28	O
ATOM	5811	CB	ASP	L	61	25.980	21.959	-17.882	1.00	66.94	C
ATOM	5812	CG	ASP	L	61	24.605	21.701	-18.477	1.00	90.60	C
ATOM	5813	OD1	ASP	L	61	23.595	22.126	-17.852	1.00	94.51	O
ATOM	5814	OD2	ASP	L	61	24.537	21.107	-19.582	1.00	95.59	O
ATOM	5815	N	ARG	L	62	27.614	22.363	-14.901	1.00	59.82	N
ATOM	5816	CA	ARG	L	62	28.859	22.838	-14.263	1.00	59.65	C
ATOM	5817	C	ARG	L	62	29.693	21.656	-13.733	1.00	63.14	C
ATOM	5818	O	ARG	L	62	30.932	21.724	-13.693	1.00	62.83	O
ATOM	5819	CB	ARG	L	62	28.613	23.926	-13.200	1.00	56.72	C
ATOM	5820	CG	ARG	L	62	27.738	23.515	-12.033	1.00	59.13	C
ATOM	5821	CD	ARG	L	62	27.408	24.749	-11.233	1.00	59.60	C
ATOM	5822	NE	ARG	L	62	26.724	24.442	-9.982	1.00	65.52	N
ATOM	5823	CZ	ARG	L	62	25.407	24.375	-9.838	1.00	84.67	C
ATOM	5824	NH1	ARG	L	62	24.607	24.575	-10.879	1.00	76.96	N
ATOM	5825	NH2	ARG	L	62	24.877	24.105	-8.653	1.00	73.58	N
ATOM	5826	N	PHE	L	63	28.991	20.554	-13.397	1.00	57.17	N
ATOM	5827	CA	PHE	L	63	29.606	19.309	-12.972	1.00	56.22	C
ATOM	5828	C	PHE	L	63	30.072	18.514	-14.217	1.00	63.19	C
ATOM	5829	O	PHE	L	63	29.263	18.193	-15.100	1.00	64.84	O
ATOM	5830	CB	PHE	L	63	28.641	18.496	-12.099	1.00	56.29	C
ATOM	5831	CG	PHE	L	63	28.344	19.127	-10.749	1.00	56.11	C
ATOM	5832	CD1	PHE	L	63	29.298	19.118	-9.728	1.00	56.41	C
ATOM	5833	CD2	PHE	L	63	27.102	19.685	-10.482	1.00	56.25	C
ATOM	5834	CE1	PHE	L	63	29.026	19.686	-8.486	1.00	55.15	C
ATOM	5835	CE2	PHE	L	63	26.835	20.256	-9.238	1.00	57.30	C
ATOM	5836	CZ	PHE	L	63	27.800	20.242	-8.249	1.00	54.72	C
ATOM	5837	N	SER	L	64	31.389	18.258	-14.303	1.00	56.81	N
ATOM	5838	CA	SER	L	64	32.011	17.522	-15.396	1.00	54.91	C
ATOM	5839	C	SER	L	64	32.984	16.487	-14.789	1.00	58.65	C
ATOM	5840	O	SER	L	64	33.655	16.781	-13.788	1.00	57.31	O
ATOM	5841	CB	SER	L	64	32.707	18.499	-16.337	1.00	55.44	C
ATOM	5842	OG	SER	L	64	33.870	17.989	-16.966	1.00	59.84	O
ATOM	5843	N	GLY	L	65	33.005	15.279	-15.368	1.00	54.81	N
ATOM	5844	CA	GLY	L	65	33.865	14.185	-14.927	1.00	53.66	C
ATOM	5845	C	GLY	L	65	34.801	13.727	-16.011	1.00	58.15	C
ATOM	5846	O	GLY	L	65	34.396	13.640	-17.166	1.00	60.10	O
ATOM	5847	N	SER	L	66	36.057	13.430	-15.663	1.00	54.74	N
ATOM	5848	CA	SER	L	66	37.095	13.005	-16.631	1.00	54.86	C
ATOM	5849	C	SER	L	66	38.179	12.173	-15.970	1.00	58.41	C
ATOM	5850	O	SER	L	66	38.235	12.103	-14.735	1.00	59.23	O
ATOM	5851	CB	SER	L	66	37.755	14.225	-17.276	1.00	60.23	C
ATOM	5852	OG	SER	L	66	38.174	15.157	-16.286	1.00	78.66	O
ATOM	5853	N	GLY	L	67	39.038	11.583	-16.800	1.00	53.96	N
ATOM	5854	CA	GLY	L	67	40.164	10.755	-16.372	1.00	54.54	C
ATOM	5855	C	GLY	L	67	40.129	9.341	-16.915	1.00	60.66	C
ATOM	5856	O	GLY	L	67	39.127	8.936	-17.516	1.00	63.09	O
ATOM	5857	N	SER	L	68	41.224	8.586	-16.708	1.00	56.17	N
ATOM	5858	CA	SER	L	68	41.388	7.170	-17.069	1.00	57.09	C
ATOM	5859	C	SER	L	68	42.566	6.554	-16.281	1.00	63.38	C
ATOM	5860	O	SER	L	68	43.379	7.287	-15.708	1.00	62.58	O
ATOM	5861	CB	SER	L	68	41.616	6.988	-18.567	1.00	61.84	C
ATOM	5862	OG	SER	L	68	42.996	7.052	-18.902	1.00	74.23	O
ATOM	5863	N	GLY	L	69	42.651	5.224	-16.283	1.00	61.34	N
ATOM	5864	CA	GLY	L	69	43.727	4.508	-15.610	1.00	61.65	C
ATOM	5865	C	GLY	L	69	43.673	4.590	-14.101	1.00	65.89	C
ATOM	5866	O	GLY	L	69	42.922	3.841	-13.468	1.00	66.36	O
ATOM	5867	N	THR	L	70	44.465	5.506	-13.520	1.00	61.20	N
ATOM	5868	CA	THR	L	70	44.548	5.704	-12.064	1.00	60.43	C
ATOM	5869	C	THR	L	70	44.127	7.104	-11.640	1.00	63.32	C
ATOM	5870	O	THR	L	70	43.723	7.262	-10.497	1.00	63.15	O
ATOM	5871	CB	THR	L	70	45.973	5.403	-11.519	1.00	68.78	C
ATOM	5872	OG1	THR	L	70	46.935	6.230	-12.178	1.00	66.44	O
ATOM	5873	CG2	THR	L	70	46.371	3.957	-11.668	1.00	67.13	C
ATOM	5874	N	ASP	L	71	44.238	8.117	-12.527	1.00	59.61	N
ATOM	5875	CA	ASP	L	71	43.905	9.496	-12.186	1.00	59.92	C
ATOM	5876	C	ASP	L	71	42.598	9.978	-12.763	1.00	61.40	C
ATOM	5877	O	ASP	L	71	42.436	10.027	-13.979	1.00	61.27	O
ATOM	5878	CB	ASP	L	71	45.046	10.441	-12.555	1.00	63.66	C
ATOM	5879	CG	ASP	L	71	46.282	10.294	-11.669	1.00	92.94	C
ATOM	5880	OD1	ASP	L	71	46.738	9.139	-11.459	1.00	95.34	O
ATOM	5881	OD2	ASP	L	71	46.814	11.336	-11.214	1.00	106.83	O
ATOM	5882	N	PHE	L	72	41.668	10.358	-11.864	1.00	56.44	N
ATOM	5883	CA	PHE	L	72	40.316	10.845	-12.182	1.00	54.76	C
ATOM	5884	C	PHE	L	72	40.081	12.228	-11.589	1.00	58.38	C
ATOM	5885	O	PHE	L	72	40.806	12.621	-10.667	1.00	59.77	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	5886	CB	PHE	L	72	39.241	9.832	-11.761	1.00	55.16	C
ATOM	5887	CG	PHE	L	72	39.353	8.500	-12.478	1.00	55.60	C
ATOM	5888	CD1	PHE	L	72	38.709	8.290	-13.697	1.00	57.70	C
ATOM	5889	CD2	PHE	L	72	40.134	7.469	-11.956	1.00	55.85	C
ATOM	5890	CE1	PHE	L	72	38.834	7.073	-14.376	1.00	56.96	C
ATOM	5891	CE2	PHE	L	72	40.257	6.248	-12.634	1.00	57.87	C
ATOM	5892	CZ	PHE	L	72	39.615	6.066	-13.843	1.00	55.66	C
ATOM	5893	N	THR	L	73	39.144	13.005	-12.179	1.00	52.38	N
ATOM	5894	CA	THR	L	73	38.911	14.387	-11.794	1.00	51.35	C
ATOM	5895	C	THR	L	73	37.463	14.799	-11.914	1.00	55.32	C
ATOM	5896	O	THR	L	73	36.836	14.620	-12.968	1.00	57.20	O
ATOM	5897	CB	THR	L	73	39.775	15.337	-12.713	1.00	60.15	C
ATOM	5898	OG1	THR	L	73	41.135	14.918	-12.768	1.00	57.14	O
ATOM	5899	CG2	THR	L	73	39.728	16.808	-12.295	1.00	59.35	C
ATOM	5900	N	LEU	L	74	36.966	15.454	-10.870	1.00	49.47	N
ATOM	5901	CA	LEU	L	74	35.641	16.066	-10.897	1.00	47.79	C
ATOM	5902	C	LEU	L	74	35.895	17.574	-11.000	1.00	52.87	C
ATOM	5903	O	LEU	L	74	36.695	18.138	-10.235	1.00	51.22	O
ATOM	5904	CB	LEU	L	74	34.829	15.746	-9.631	1.00	46.50	C
ATOM	5905	CG	LEU	L	74	33.443	16.376	-9.546	1.00	48.05	C
ATOM	5906	CD1	LEU	L	74	32.435	15.584	-10.343	1.00	47.27	C
ATOM	5907	CD2	LEU	L	74	32.989	16.501	-8.122	1.00	47.46	C
ATOM	5908	N	THR	L	75	35.199	18.220	-11.940	1.00	50.79	N
ATOM	5909	CA	THR	L	75	35.316	19.651	-12.183	1.00	49.97	C
ATOM	5910	C	THR	L	75	33.990	20.353	-11.955	1.00	53.61	C
ATOM	5911	O	THR	L	75	32.943	19.837	-12.346	1.00	53.92	O
ATOM	5912	CB	THR	L	75	35.863	19.889	-13.607	1.00	56.93	C
ATOM	5913	OG1	THR	L	75	36.945	18.990	-13.857	1.00	60.43	O
ATOM	5914	CG2	THR	L	75	36.340	21.311	-13.821	1.00	54.29	C
ATOM	5915	N	ILE	L	76	34.031	21.522	-11.309	1.00	50.54	N
ATOM	5916	CA	ILE	L	76	32.871	22.399	-11.103	1.00	50.78	C
ATOM	5917	C	ILE	L	76	33.331	23.707	-11.737	1.00	60.08	C
ATOM	5918	O	ILE	L	76	34.189	24.385	-11.169	1.00	61.97	O
ATOM	5919	CB	ILE	L	76	32.427	22.546	-9.606	1.00	53.05	C
ATOM	5920	CG1	ILE	L	76	32.232	21.178	-8.925	1.00	53.30	C
ATOM	5921	CG2	ILE	L	76	31.145	23.342	-9.500	1.00	52.76	C
ATOM	5922	CD1	ILE	L	76	32.540	21.126	-7.447	1.00	52.48	C
ATOM	5923	N	SER	L	77	32.841	24.010	-12.959	1.00	58.65	N
ATOM	5924	CA	SER	L	77	33.228	25.199	-13.757	1.00	58.47	C
ATOM	5925	C	SER	L	77	33.037	26.554	-13.041	1.00	64.07	C
ATOM	5926	O	SER	L	77	33.833	27.482	-13.229	1.00	66.93	O
ATOM	5927	CB	SER	L	77	32.486	25.204	-15.084	1.00	60.87	C
ATOM	5928	OG	SER	L	77	31.089	25.350	-14.888	1.00	69.89	O
ATOM	5929	N	ARG	L	78	32.008	26.646	-12.211	1.00	57.66	N
ATOM	5930	CA	ARG	L	78	31.686	27.831	-11.440	1.00	58.28	C
ATOM	5931	C	ARG	L	78	30.956	27.366	-10.167	1.00	62.17	C
ATOM	5932	O	ARG	L	78	29.841	26.826	-10.263	1.00	61.13	O
ATOM	5933	CB	ARG	L	78	30.813	28.786	-12.290	1.00	61.58	C
ATOM	5934	CG	ARG	L	78	30.027	29.872	-11.530	1.00	73.53	C
ATOM	5935	CD	ARG	L	78	29.401	30.894	-12.458	1.00	89.57	C
ATOM	5936	NE	ARG	L	78	30.443	31.640	-13.163	1.00	106.08	N
ATOM	5937	CZ	ARG	L	78	30.828	32.871	-12.856	1.00	125.30	C
ATOM	5938	NH1	ARG	L	78	31.809	33.452	-13.533	1.00	108.46	N
ATOM	5939	NH2	ARG	L	78	30.200	33.553	-11.902	1.00	116.44	N
ATOM	5940	N	LEU	L	79	31.600	27.537	-8.986	1.00	56.93	N
ATOM	5941	CA	LEU	L	79	31.026	27.123	-7.707	1.00	55.62	C
ATOM	5942	C	LEU	L	79	29.865	28.015	-7.263	1.00	58.48	C
ATOM	5943	O	LEU	L	79	30.039	29.202	-7.010	1.00	57.44	O
ATOM	5944	CB	LEU	L	79	32.090	27.080	-6.595	1.00	55.43	C
ATOM	5945	CG	LEU	L	79	33.165	26.011	-6.643	1.00	59.69	C
ATOM	5946	CD1	LEU	L	79	34.273	26.353	-5.684	1.00	59.92	C
ATOM	5947	CD2	LEU	L	79	32.613	24.661	-6.268	1.00	61.04	C
ATOM	5948	N	GLU	L	80	28.692	27.425	-7.133	1.00	55.72	N
ATOM	5949	CA	GLU	L	80	27.503	28.098	-6.659	1.00	56.06	C
ATOM	5950	C	GLU	L	80	27.493	27.943	-5.117	1.00	63.06	C
ATOM	5951	O	GLU	L	80	28.318	27.187	-4.586	1.00	61.48	O
ATOM	5952	CB	GLU	L	80	26.240	27.500	-7.328	1.00	57.16	C
ATOM	5953	CG	GLU	L	80	26.093	27.786	-8.818	1.00	69.05	C
ATOM	5954	CD	GLU	L	80	26.127	29.238	-9.263	1.00	103.17	C
ATOM	5955	OE1	GLU	L	80	25.392	30.066	-8.677	1.00	117.15	O
ATOM	5956	OE2	GLU	L	80	26.874	29.542	-10.222	1.00	97.16	O
ATOM	5957	N	PRO	L	81	26.614	28.656	-4.358	1.00	62.24	N
ATOM	5958	CA	PRO	L	81	26.621	28.493	-2.889	1.00	62.76	C
ATOM	5959	C	PRO	L	81	26.330	27.055	-2.442	1.00	68.81	C
ATOM	5960	O	PRO	L	81	26.957	26.542	-1.508	1.00	69.54	O
ATOM	5961	CB	PRO	L	81	25.516	29.455	-2.431	1.00	63.90	C
ATOM	5962	CG	PRO	L	81	25.371	30.418	-3.524	1.00	67.14	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	5963	CD	PRO	L	81	25.582	29.631	-4.767	1.00	62.53	C
ATOM	5964	N	GLU	L	82	25.399	26.396	-3.154	1.00	65.21	N
ATOM	5965	CA	GLU	L	82	24.954	25.018	-2.909	1.00	64.35	C
ATOM	5966	C	GLU	L	82	26.076	23.979	-3.063	1.00	63.66	C
ATOM	5967	O	GLU	L	82	26.049	22.969	-2.366	1.00	63.43	O
ATOM	5968	CB	GLU	L	82	23.717	24.663	-3.780	1.00	65.92	C
ATOM	5969	CG	GLU	L	82	23.779	25.077	-5.250	1.00	80.48	C
ATOM	5970	CD	GLU	L	82	23.206	26.429	-5.669	1.00	109.48	C
ATOM	5971	OE1	GLU	L	82	23.019	27.319	-4.803	1.00	94.67	O
ATOM	5972	OE2	GLU	L	82	22.974	26.608	-6.889	1.00	105.83	O
ATOM	5973	N	ASP	L	83	27.091	24.281	-3.898	1.00	56.53	N
ATOM	5974	CA	ASP	L	83	28.233	23.422	-4.252	1.00	54.91	C
ATOM	5975	C	ASP	L	83	29.275	23.214	-3.152	1.00	56.94	C
ATOM	5976	O	ASP	L	83	30.140	22.350	-3.303	1.00	57.35	O
ATOM	5977	CB	ASP	L	83	28.911	23.930	-5.537	1.00	55.47	C
ATOM	5978	CG	ASP	L	83	28.005	23.903	-6.775	1.00	63.26	C
ATOM	5979	OD1	ASP	L	83	26.887	23.305	-6.706	1.00	62.97	O
ATOM	5980	OD2	ASP	L	83	28.401	24.464	-7.799	1.00	70.85	O
ATOM	5981	N	PHE	L	84	29.174	23.936	-2.037	1.00	50.62	N
ATOM	5982	CA	PHE	L	84	30.096	23.724	-0.923	1.00	48.57	C
ATOM	5983	C	PHE	L	84	29.580	22.525	-0.099	1.00	55.52	C
ATOM	5984	O	PHE	L	84	28.532	22.610	0.553	1.00	56.71	O
ATOM	5985	CB	PHE	L	84	30.321	25.019	-0.117	1.00	48.58	C
ATOM	5986	CG	PHE	L	84	31.024	26.059	-0.943	1.00	48.75	C
ATOM	5987	CD1	PHE	L	84	32.416	26.065	-1.049	1.00	49.93	C
ATOM	5988	CD2	PHE	L	84	30.299	26.991	-1.680	1.00	50.42	C
ATOM	5989	CE1	PHE	L	84	33.068	26.995	-1.857	1.00	49.13	C
ATOM	5990	CE2	PHE	L	84	30.953	27.910	-2.503	1.00	51.88	C
ATOM	5991	CZ	PHE	L	84	32.333	27.902	-2.583	1.00	48.58	C
ATOM	5992	N	ALA	L	85	30.255	21.364	-0.254	1.00	51.11	N
ATOM	5993	CA	ALA	L	85	29.882	20.091	0.366	1.00	49.42	C
ATOM	5994	C	ALA	L	85	31.048	19.100	0.284	1.00	52.28	C
ATOM	5995	O	ALA	L	85	32.154	19.460	-0.123	1.00	50.91	O
ATOM	5996	CB	ALA	L	85	28.659	19.500	-0.351	1.00	49.99	C
ATOM	5997	N	VAL	L	86	30.785	17.838	0.666	1.00	48.77	N
ATOM	5998	CA	VAL	L	86	31.790	16.787	0.590	1.00	46.99	C
ATOM	5999	C	VAL	L	86	31.569	15.972	-0.682	1.00	50.28	C
ATOM	6000	O	VAL	L	86	30.429	15.794	-1.118	1.00	48.85	O
ATOM	6001	CB	VAL	L	86	31.868	15.940	1.871	1.00	47.72	C
ATOM	6002	CG1	VAL	L	86	33.019	14.947	1.796	1.00	46.53	C
ATOM	6003	CG2	VAL	L	86	32.019	16.841	3.092	1.00	46.57	C
ATOM	6004	N	TYR	L	87	32.673	15.540	-1.300	1.00	46.90	N
ATOM	6005	CA	TYR	L	87	32.645	14.800	-2.541	1.00	46.45	C
ATOM	6006	C	TYR	L	87	33.435	13.540	-2.397	1.00	54.18	C
ATOM	6007	O	TYR	L	87	34.634	13.582	-2.062	1.00	55.29	O
ATOM	6008	CB	TYR	L	87	33.207	15.653	-3.679	1.00	46.51	C
ATOM	6009	CG	TYR	L	87	32.341	16.844	-4.008	1.00	48.00	C
ATOM	6010	CD1	TYR	L	87	31.309	16.745	-4.934	1.00	47.70	C
ATOM	6011	CD2	TYR	L	87	32.538	18.069	-3.379	1.00	50.58	C
ATOM	6012	CE1	TYR	L	87	30.501	17.835	-5.229	1.00	48.16	C
ATOM	6013	CE2	TYR	L	87	31.715	19.158	-3.644	1.00	50.45	C
ATOM	6014	CZ	TYR	L	87	30.704	19.039	-4.575	1.00	52.38	C
ATOM	6015	OH	TYR	L	87	29.915	20.116	-4.855	1.00	50.93	O
ATOM	6016	N	TYR	L	88	32.775	12.403	-2.668	1.00	49.42	N
ATOM	6017	CA	TYR	L	88	33.418	11.091	-2.596	1.00	48.12	C
ATOM	6018	C	TYR	L	88	33.500	10.462	-3.980	1.00	53.17	C
ATOM	6019	O	TYR	L	88	32.557	10.566	-4.754	1.00	52.26	O
ATOM	6020	CB	TYR	L	88	32.661	10.138	-1.635	1.00	46.86	C
ATOM	6021	CG	TYR	L	88	32.447	10.663	-0.229	1.00	46.16	C
ATOM	6022	CD1	TYR	L	88	33.352	10.378	0.790	1.00	47.49	C
ATOM	6023	CD2	TYR	L	88	31.291	11.373	0.105	1.00	46.71	C
ATOM	6024	CE1	TYR	L	88	33.153	10.853	2.093	1.00	46.28	C
ATOM	6025	CE2	TYR	L	88	31.070	11.828	1.405	1.00	47.66	C
ATOM	6026	CZ	TYR	L	88	32.004	11.563	2.395	1.00	54.38	C
ATOM	6027	OH	TYR	L	88	31.783	12.045	3.660	1.00	62.00	O
ATOM	6028	N	CYS	L	89	34.624	9.827	-4.298	1.00	53.10	N
ATOM	6029	CA	CYS	L	89	34.724	9.087	-5.543	1.00	54.58	C
ATOM	6030	C	CYS	L	89	34.578	7.629	-5.170	1.00	57.92	C
ATOM	6031	O	CYS	L	89	34.694	7.280	-3.985	1.00	57.49	O
ATOM	6032	CB	CYS	L	89	35.998	9.382	-6.333	1.00	56.37	C
ATOM	6033	SG	CYS	L	89	37.547	8.992	-5.478	1.00	61.65	S
ATOM	6034	N	GLN	L	90	34.213	6.790	-6.146	1.00	52.95	N
ATOM	6035	CA	GLN	L	90	33.928	5.385	-5.889	1.00	51.28	C
ATOM	6036	C	GLN	L	90	34.458	4.509	-7.003	1.00	54.42	C
ATOM	6037	O	GLN	L	90	34.506	4.941	-8.147	1.00	53.41	O
ATOM	6038	CB	GLN	L	90	32.404	5.208	-5.676	1.00	51.68	C
ATOM	6039	CG	GLN	L	90	31.880	3.783	-5.473	1.00	48.00	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab - <i>C. difficile</i> toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	6040	CD	GLN	L	90	31.042	3.298	-6.627
ATOM	6041	OE1	GLN	L	90	29.946	3.767	-6.847
ATOM	6042	NE2	GLN	L	90	31.511	2.335	-7.389
ATOM	6043	N	GLN	L	91	34.868	3.273	-6.657
ATOM	6044	CA	GLN	L	91	35.339	2.259	-7.600
ATOM	6045	C	GLN	L	91	34.766	0.873	-7.345
ATOM	6046	O	GLN	L	91	34.031	0.662	-6.383
ATOM	6047	CB	GLN	L	91	36.864	2.210	-7.691
ATOM	6048	CG	GLN	L	91	37.381	2.922	-8.928
ATOM	6049	CD	GLN	L	91	36.970	2.247	-10.216
ATOM	6050	OE1	GLN	L	91	36.722	1.040	-10.252
ATOM	6051	NE2	GLN	L	91	36.990	2.980	-11.330
ATOM	6052	N	TYR	L	92	35.120	-0.071	-8.247
ATOM	6053	CA	TYR	L	92	34.729	-1.489	-8.319
ATOM	6054	C	TYR	L	92	35.730	-2.301	-9.241
ATOM	6055	O	TYR	L	92	35.980	-1.927	-10.389
ATOM	6056	CB	TYR	L	92	33.270	-1.602	-8.827
ATOM	6057	CG	TYR	L	92	32.686	-2.994	-8.747
ATOM	6058	CD2	TYR	L	92	31.835	-3.355	-7.711
ATOM	6059	CD1	TYR	L	92	32.980	-3.951	-9.712
ATOM	6060	CE2	TYR	L	92	31.315	-4.639	-7.623
ATOM	6061	CE1	TYR	L	92	32.451	-5.229	-9.647
ATOM	6062	CZ	TYR	L	92	31.617	-5.568	-8.603
ATOM	6063	OH	TYR	L	92	31.097	-6.826	-8.569
ATOM	6064	N	GLY	L	93	36.266	-3.407	-8.747
ATOM	6065	CA	GLY	L	93	36.050	-3.802	-7.376
ATOM	6066	C	GLY	L	93	36.167	-5.245	-6.957
ATOM	6067	O	GLY	L	93	36.490	-5.482	-5.790
ATOM	6068	N	SER	L	94	35.865	-6.216	-7.843
ATOM	6069	CA	SER	L	94	35.790	-7.629	-7.439
ATOM	6070	C	SER	L	94	34.799	-7.801	-6.209
ATOM	6071	O	SER	L	94	35.018	-8.574	-5.276
ATOM	6072	CB	SER	L	94	37.171	-8.268	-7.238
ATOM	6073	OG	SER	L	94	37.803	-7.919	-6.016
ATOM	6074	N	SER	L	95	33.743	-6.960	-6.222
ATOM	6075	CA	SER	L	95	32.524	-6.925	-5.419
ATOM	6076	C	SER	L	95	32.588	-6.930	-3.907
ATOM	6077	O	SER	L	95	31.933	-7.816	-3.363
ATOM	6078	CB	SER	L	95	31.658	-8.127	-5.804
ATOM	6079	OG	SER	L	95	32.314	-9.366	-5.573
ATOM	6080	N	THR	L	96	33.013	-5.899	-3.167
ATOM	6081	CA	THR	L	96	33.897	-4.742	-3.157
ATOM	6082	C	THR	L	96	33.537	-3.604	-4.104
ATOM	6083	O	THR	L	96	33.762	-3.627	-5.301
ATOM	6084	CB	THR	L	96	35.338	-5.114	-3.269
ATOM	6085	OG1	THR	L	96	35.611	-6.082	-2.253
ATOM	6086	CG2	THR	L	96	36.257	-3.900	-3.077
ATOM	6087	N	TRP	L	97	32.998	-2.577	-3.444
ATOM	6088	CA	TRP	L	97	32.676	-1.235	-3.847
ATOM	6089	C	TRP	L	97	33.539	-0.471	-2.840
ATOM	6090	O	TRP	L	97	33.444	-0.707	-1.636
ATOM	6091	CB	TRP	L	97	31.186	-0.907	-3.612
ATOM	6092	CG	TRP	L	97	30.251	-1.234	-4.755
ATOM	6093	CD1	TRP	L	97	29.757	-0.364	-5.684
ATOM	6094	CD2	TRP	L	97	29.642	-2.507	-5.039
ATOM	6095	NE1	TRP	L	97	28.927	-1.027	-6.561
ATOM	6096	CE2	TRP	L	97	28.819	-2.336	-6.172
ATOM	6097	CE3	TRP	L	97	29.719	-3.776	-4.453
ATOM	6098	CZ2	TRP	L	97	28.097	-3.394	-6.738
ATOM	6099	CZ3	TRP	L	97	28.968	-4.809	-4.987
ATOM	6100	CH2	TRP	L	97	28.180	-4.619	-6.125
ATOM	6101	N	THR	L	98	34.454	0.356	-3.331
ATOM	6102	CA	THR	L	98	35.350	1.178	-2.509
ATOM	6103	C	THR	L	98	34.928	2.640	-2.670
ATOM	6104	O	THR	L	98	34.515	3.033	-3.761
ATOM	6105	CB	THR	L	98	36.823	0.923	-2.950
ATOM	6106	OG1	THR	L	98	37.243	-0.329	-2.415
ATOM	6107	CG2	THR	L	98	37.796	1.991	-2.483
ATOM	6108	N	PHE	L	99	35.071	3.436	-1.600
ATOM	6109	CA	PHE	L	99	34.848	4.894	-1.601
ATOM	6110	C	PHE	L	99	36.157	5.627	-1.260
ATOM	6111	O	PHE	L	99	37.070	5.062	-0.657
ATOM	6112	CB	PHE	L	99	33.772	5.301	-0.575
ATOM	6113	CG	PHE	L	99	32.356	5.021	-0.993
ATOM	6114	CD1	PHE	L	99	31.639	5.946	-1.745
ATOM	6115	CD2	PHE	L	99	31.736	3.829	-0.646
ATOM	6116	CE1	PHE	L	99	30.337	5.667	-2.167

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.											
ATOM	6117	CE2	PHE	L	99	30.420	3.566	-1.035	1.00	61.41	C
ATOM	6118	CZ	PHE	L	99	29.745	4.470	-1.821	1.00	59.96	C
ATOM	6119	N	GLY	L	100	36.228	6.879	-1.669	1.00	58.51	N
ATOM	6120	CA	GLY	L	100	37.328	7.773	-1.347	1.00	57.64	C
ATOM	6121	C	GLY	L	100	37.012	8.406	-0.008	1.00	59.94	C
ATOM	6122	O	GLY	L	100	35.862	8.343	0.458	1.00	59.83	O
ATOM	6123	N	GLN	L	101	38.018	9.007	0.638	1.00	55.17	N
ATOM	6124	CA	GLN	L	101	37.828	9.576	1.975	1.00	54.34	C
ATOM	6125	C	GLN	L	101	37.092	10.927	1.967	1.00	57.93	C
ATOM	6126	O	GLN	L	101	36.678	11.406	3.024	1.00	59.17	O
ATOM	6127	CB	GLN	L	101	39.156	9.631	2.746	1.00	55.71	C
ATOM	6128	CG	GLN	L	101	40.066	10.835	2.445	1.00	69.37	C
ATOM	6129	CD	GLN	L	101	40.745	10.860	1.083	1.00	79.91	C
ATOM	6130	OE1	GLN	L	101	41.001	9.825	0.414	1.00	76.02	O
ATOM	6131	NE2	GLN	L	101	41.092	12.072	0.677	1.00	51.71	N
ATOM	6132	N	GLY	L	102	36.887	11.493	0.781	1.00	53.60	N
ATOM	6133	CA	GLY	L	102	36.197	12.764	0.601	1.00	52.06	C
ATOM	6134	C	GLY	L	102	37.118	13.941	0.396	1.00	54.52	C
ATOM	6135	O	GLY	L	102	38.318	13.874	0.689	1.00	55.03	O
ATOM	6136	N	THR	L	103	36.539	15.030	-0.118	1.00	48.87	N
ATOM	6137	CA	THR	L	103	37.187	16.321	-0.301	1.00	47.59	C
ATOM	6138	C	THR	L	103	36.106	17.320	0.097	1.00	51.08	C
ATOM	6139	O	THR	L	103	35.051	17.356	-0.543	1.00	51.06	O
ATOM	6140	CB	THR	L	103	37.731	16.519	-1.759	1.00	54.47	C
ATOM	6141	OG1	THR	L	103	38.829	15.659	-2.004	1.00	56.80	O
ATOM	6142	CG2	THR	L	103	38.198	17.941	-2.042	1.00	52.92	C
ATOM	6143	N	LYS	L	104	36.342	18.092	1.173	1.00	48.45	N
ATOM	6144	CA	LYS	L	104	35.405	19.139	1.604	1.00	49.14	C
ATOM	6145	C	LYS	L	104	35.707	20.417	0.783	1.00	56.09	C
ATOM	6146	O	LYS	L	104	36.872	20.814	0.653	1.00	56.77	O
ATOM	6147	CB	LYS	L	104	35.524	19.421	3.111	1.00	49.79	C
ATOM	6148	CG	LYS	L	104	34.578	20.497	3.628	1.00	53.51	C
ATOM	6149	CD	LYS	L	104	34.998	20.975	5.009	1.00	65.37	C
ATOM	6150	CE	LYS	L	104	34.237	22.203	5.439	1.00	77.53	C
ATOM	6151	NZ	LYS	L	104	34.367	22.442	6.903	1.00	85.83	N
ATOM	6152	N	VAL	L	105	34.657	21.030	0.206	1.00	51.55	N
ATOM	6153	CA	VAL	L	105	34.817	22.240	-0.560	1.00	50.08	C
ATOM	6154	C	VAL	L	105	34.325	23.349	0.354	1.00	56.27	C
ATOM	6155	O	VAL	L	105	33.128	23.490	0.610	1.00	57.68	O
ATOM	6156	CB	VAL	L	105	34.200	22.205	-1.982	1.00	51.60	C
ATOM	6157	CG1	VAL	L	105	34.517	23.495	-2.727	1.00	50.16	C
ATOM	6158	CG2	VAL	L	105	34.712	21.007	-2.777	1.00	50.96	C
ATOM	6159	N	GLU	L	106	35.289	24.029	0.951	1.00	53.19	N
ATOM	6160	CA	GLU	L	106	35.137	25.089	1.935	1.00	53.75	C
ATOM	6161	C	GLU	L	106	35.138	26.450	1.235	1.00	59.78	C
ATOM	6162	O	GLU	L	106	35.749	26.602	0.163	1.00	60.52	O
ATOM	6163	CB	GLU	L	106	36.325	24.984	2.907	1.00	55.46	C
ATOM	6164	CG	GLU	L	106	36.236	25.818	4.165	1.00	69.29	C
ATOM	6165	CD	GLU	L	106	37.569	26.417	4.571	1.00	92.80	C
ATOM	6166	OE1	GLU	L	106	38.069	27.281	3.816	1.00	90.35	O
ATOM	6167	OE2	GLU	L	106	38.120	26.034	5.631	1.00	85.01	O
ATOM	6168	N	ILE	L	107	34.468	27.449	1.850	1.00	54.66	N
ATOM	6169	CA	ILE	L	107	34.381	28.797	1.289	1.00	53.47	C
ATOM	6170	C	ILE	L	107	35.627	29.621	1.705	1.00	58.84	C
ATOM	6171	O	ILE	L	107	35.802	29.881	2.900	1.00	60.31	O
ATOM	6172	CB	ILE	L	107	33.045	29.486	1.693	1.00	55.76	C
ATOM	6173	CG1	ILE	L	107	31.830	28.524	1.565	1.00	55.93	C
ATOM	6174	CG2	ILE	L	107	32.832	30.759	0.881	1.00	55.85	C
ATOM	6175	CD1	ILE	L	107	30.660	28.734	2.503	1.00	59.96	C
ATOM	6176	N	LYS	L	108	36.505	30.002	0.732	1.00	52.76	N
ATOM	6177	CA	LYS	L	108	37.670	30.847	1.026	1.00	50.95	C
ATOM	6178	C	LYS	L	108	37.155	32.242	1.343	1.00	55.85	C
ATOM	6179	O	LYS	L	108	36.216	32.733	0.682	1.00	58.35	O
ATOM	6180	CB	LYS	L	108	38.701	30.928	-0.132	1.00	50.65	C
ATOM	6181	N	ARG	L	109	37.748	32.858	2.395	1.00	47.76	N
ATOM	6182	CA	ARG	L	109	37.473	34.210	2.850	1.00	44.54	C
ATOM	6183	C	ARG	L	109	38.727	34.797	3.502	1.00	46.41	C
ATOM	6184	O	ARG	L	109	39.704	34.079	3.717	1.00	46.17	O
ATOM	6185	CB	ARG	L	109	36.228	34.252	3.760	1.00	37.33	C
ATOM	6186	CG	ARG	L	109	36.454	33.695	5.118	1.00	37.37	C
ATOM	6187	CD	ARG	L	109	35.762	34.516	6.178	1.00	51.21	C
ATOM	6188	NE	ARG	L	109	36.459	35.764	6.484	1.00	49.17	N
ATOM	6189	CZ	ARG	L	109	35.906	36.781	7.130	1.00	73.40	C
ATOM	6190	NH1	ARG	L	109	34.639	36.715	7.530	1.00	73.01	N
ATOM	6191	NH2	ARG	L	109	36.601	37.888	7.351	1.00	58.92	N
ATOM	6192	N	THR	L	110	38.714	36.098	3.792	1.00	42.08	N
ATOM	6193	CA	THR	L	110	39.865	36.737	4.425	1.00	42.16	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	6194	C	THR	L	110	40.116	36.211	5.827	1.00	49.30	C
ATOM	6195	O	THR	L	110	39.178	35.827	6.524	1.00	51.84	O
ATOM	6196	CB	THR	L	110	39.701	38.264	4.454	1.00	45.02	C
ATOM	6197	OG1	THR	L	110	38.435	38.626	5.031	1.00	53.95	O
ATOM	6198	CG2	THR	L	110	39.876	38.890	3.103	1.00	33.32	C
ATOM	6199	N	VAL	L	111	41.379	36.209	6.249	1.00	45.46	N
ATOM	6200	CA	VAL	L	111	41.744	35.860	7.618	1.00	45.14	C
ATOM	6201	C	VAL	L	111	40.958	36.770	8.562	1.00	52.19	C
ATOM	6202	O	VAL	L	111	40.797	37.963	8.287	1.00	53.24	O
ATOM	6203	CB	VAL	L	111	43.278	35.944	7.864	1.00	47.80	C
ATOM	6204	CG1	VAL	L	111	43.639	35.869	9.351	1.00	47.21	C
ATOM	6205	CG2	VAL	L	111	44.013	34.860	7.074	1.00	47.70	C
ATOM	6206	N	ALA	L	112	40.362	36.159	9.590	1.00	50.55	N
ATOM	6207	CA	ALA	L	112	39.587	36.781	10.657	1.00	50.77	C
ATOM	6208	C	ALA	L	112	40.098	36.152	11.944	1.00	58.85	C
ATOM	6209	O	ALA	L	112	40.272	34.934	12.008	1.00	60.33	O
ATOM	6210	CB	ALA	L	112	38.113	36.495	10.482	1.00	51.01	C
ATOM	6211	N	ALA	L	113	40.402	36.979	12.947	1.00	56.14	N
ATOM	6212	CA	ALA	L	113	40.918	36.481	14.210	1.00	56.12	C
ATOM	6213	C	ALA	L	113	39.779	36.156	15.171	1.00	61.89	C
ATOM	6214	O	ALA	L	113	38.732	36.819	15.143	1.00	62.14	O
ATOM	6215	CB	ALA	L	113	41.852	37.503	14.826	1.00	56.91	C
ATOM	6216	N	PRO	L	114	39.935	35.129	16.026	1.00	59.20	N
ATOM	6217	CA	PRO	L	114	38.862	34.830	16.975	1.00	59.32	C
ATOM	6218	C	PRO	L	114	38.744	35.866	18.083	1.00	64.01	C
ATOM	6219	O	PRO	L	114	39.744	36.462	18.472	1.00	65.36	O
ATOM	6220	CB	PRO	L	114	39.265	33.463	17.552	1.00	60.92	C
ATOM	6221	CG	PRO	L	114	40.737	33.412	17.439	1.00	65.13	C
ATOM	6222	CD	PRO	L	114	41.086	34.220	16.207	1.00	60.79	C
ATOM	6223	N	SER	L	115	37.523	36.082	18.586	1.00	58.84	N
ATOM	6224	CA	SER	L	115	37.285	36.890	19.767	1.00	57.60	C
ATOM	6225	C	SER	L	115	37.285	35.768	20.816	1.00	64.02	C
ATOM	6226	O	SER	L	115	36.490	34.834	20.689	1.00	65.48	O
ATOM	6227	CB	SER	L	115	35.920	37.569	19.714	1.00	60.35	C
ATOM	6228	OG	SER	L	115	35.370	37.672	18.409	1.00	76.28	O
ATOM	6229	N	VAL	L	116	38.241	35.770	21.759	1.00	59.89	N
ATOM	6230	CA	VAL	L	116	38.339	34.716	22.785	1.00	58.69	C
ATOM	6231	C	VAL	L	116	37.552	35.119	24.060	1.00	65.01	C
ATOM	6232	O	VAL	L	116	37.503	36.308	24.393	1.00	65.19	O
ATOM	6233	CB	VAL	L	116	39.809	34.315	23.065	1.00	60.42	C
ATOM	6234	CG1	VAL	L	116	39.906	33.133	24.040	1.00	59.87	C
ATOM	6235	CG2	VAL	L	116	40.522	33.987	21.766	1.00	59.72	C
ATOM	6236	N	PHE	L	117	36.895	34.137	24.730	1.00	61.99	N
ATOM	6237	CA	PHE	L	117	36.113	34.313	25.965	1.00	61.54	C
ATOM	6238	C	PHE	L	117	36.270	33.084	26.852	1.00	69.02	C
ATOM	6239	O	PHE	L	117	36.144	31.967	26.356	1.00	69.59	O
ATOM	6240	CB	PHE	L	117	34.618	34.513	25.668	1.00	62.32	C
ATOM	6241	CG	PHE	L	117	34.258	35.682	24.788	1.00	63.82	C
ATOM	6242	CD1	PHE	L	117	34.038	36.946	25.332	1.00	66.98	C
ATOM	6243	CD2	PHE	L	117	34.120	35.522	23.412	1.00	66.25	C
ATOM	6244	CE1	PHE	L	117	33.685	38.036	24.512	1.00	67.50	C
ATOM	6245	CE2	PHE	L	117	33.754	36.604	22.595	1.00	68.57	C
ATOM	6246	CZ	PHE	L	117	33.536	37.854	23.153	1.00	66.42	C
ATOM	6247	N	ILE	L	118	36.535	33.282	28.160	1.00	67.17	N
ATOM	6248	CA	ILE	L	118	36.626	32.198	29.153	1.00	66.92	C
ATOM	6249	C	ILE	L	118	35.419	32.326	30.105	1.00	73.10	C
ATOM	6250	O	ILE	L	118	35.011	33.460	30.443	1.00	73.63	O
ATOM	6251	CB	ILE	L	118	38.004	32.082	29.904	1.00	68.99	C
ATOM	6252	CG1	ILE	L	118	38.122	30.707	30.649	1.00	67.89	C
ATOM	6253	CG2	ILE	L	118	38.245	33.282	30.860	1.00	69.25	C
ATOM	6254	CD1	ILE	L	118	39.422	30.373	31.285	1.00	61.13	C
ATOM	6255	N	PHE	L	119	34.823	31.165	30.483	1.00	68.58	N
ATOM	6256	CA	PHE	L	119	33.676	31.092	31.391	1.00	67.30	C
ATOM	6257	C	PHE	L	119	33.994	30.148	32.542	1.00	74.85	C
ATOM	6258	O	PHE	L	119	34.381	28.995	32.310	1.00	75.06	O
ATOM	6259	CB	PHE	L	119	32.390	30.659	30.674	1.00	67.22	C
ATOM	6260	CG	PHE	L	119	31.981	31.537	29.520	1.00	67.50	C
ATOM	6261	CD2	PHE	L	119	31.054	32.555	29.696	1.00	69.53	C
ATOM	6262	CD1	PHE	L	119	32.496	31.326	28.245	1.00	69.24	C
ATOM	6263	CE2	PHE	L	119	30.659	33.356	28.618	1.00	71.50	C
ATOM	6264	CE1	PHE	L	119	32.098	32.124	27.169	1.00	69.39	C
ATOM	6265	CZ	PHE	L	119	31.189	33.136	27.365	1.00	68.80	C
ATOM	6266	N	PRO	L	120	33.865	30.633	33.797	1.00	73.31	N
ATOM	6267	CA	PRO	L	120	34.137	29.755	34.954	1.00	72.78	C
ATOM	6268	C	PRO	L	120	32.928	28.867	35.263	1.00	74.68	C
ATOM	6269	O	PRO	L	120	31.816	29.215	34.837	1.00	73.74	O
ATOM	6270	CB	PRO	L	120	34.398	30.751	36.100	1.00	74.41	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab - <i>C. difficile</i> toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	6271	CG	PRO	L	120	34.267	32.159	35.466
ATOM	6272	CD	PRO	L	120	33.447	31.979	34.244
ATOM	6273	N	PRO	L	121	33.088	27.750	36.017
ATOM	6274	CA	PRO	L	121	31.911	26.924	36.350
ATOM	6275	C	PRO	L	121	30.891	27.680	37.203
ATOM	6276	O	PRO	L	121	31.289	28.337	38.162
ATOM	6277	CB	PRO	L	121	32.512	25.733	37.114
ATOM	6278	CG	PRO	L	121	33.830	26.170	37.566
ATOM	6279	CD	PRO	L	121	34.327	27.183	36.595
ATOM	6280	N	SER	L	122	29.588	27.609	36.854
ATOM	6281	CA	SER	L	122	28.512	28.278	37.609
ATOM	6282	C	SER	L	122	28.426	27.776	39.064
ATOM	6283	O	SER	L	122	28.969	26.703	39.381
ATOM	6284	CB	SER	L	122	27.169	28.109	36.908
ATOM	6285	OG	SER	L	122	26.877	26.741	36.688
ATOM	6286	N	ASP	L	123	27.792	28.569	39.954
ATOM	6287	CA	ASP	L	123	27.646	28.187	41.367
ATOM	6288	C	ASP	L	123	26.754	26.951	41.481
ATOM	6289	O	ASP	L	123	27.108	26.014	42.216
ATOM	6290	CB	ASP	L	123	27.128	29.361	42.237
ATOM	6291	CG	ASP	L	123	28.090	30.548	42.363
ATOM	6292	OD1	ASP	L	123	29.288	30.320	42.718
ATOM	6293	OD2	ASP	L	123	27.644	31.705	42.126
ATOM	6294	N	GLU	L	124	25.642	26.920	40.674
ATOM	6295	CA	GLU	L	124	24.687	25.799	40.572
ATOM	6296	C	GLU	L	124	25.445	24.494	40.286
ATOM	6297	O	GLU	L	124	25.236	23.494	40.982
ATOM	6298	CB	GLU	L	124	23.656	26.015	39.449
ATOM	6299	CG	GLU	L	124	23.003	27.386	39.352
ATOM	6300	CD	GLU	L	124	22.039	27.576	38.186
ATOM	6301	OE1	GLU	L	124	21.899	28.732	37.720
ATOM	6302	OE2	GLU	L	124	21.431	26.575	37.731
ATOM	6303	N	GLN	L	125	26.335	24.520	39.268
ATOM	6304	CA	GLN	L	125	27.137	23.378	38.839
ATOM	6305	C	GLN	L	125	28.133	22.949	39.893
ATOM	6306	O	GLN	L	125	28.387	21.753	40.028
ATOM	6307	CB	GLN	L	125	27.856	23.670	37.512
ATOM	6308	CG	GLN	L	125	28.297	22.401	36.775
ATOM	6309	CD	GLN	L	125	29.499	22.586	35.903
ATOM	6310	OE1	GLN	L	125	29.854	23.697	35.476
ATOM	6311	NE2	GLN	L	125	30.141	21.477	35.611
ATOM	6312	N	LEU	L	126	28.698	23.912	40.631
ATOM	6313	CA	LEU	L	126	29.676	23.619	41.672
ATOM	6314	C	LEU	L	126	29.075	22.930	42.906
ATOM	6315	O	LEU	L	126	29.806	22.209	43.595
ATOM	6316	CB	LEU	L	126	30.468	24.866	42.054
ATOM	6317	CG	LEU	L	126	31.702	25.099	41.201
ATOM	6318	CD1	LEU	L	126	32.208	26.514	41.370
ATOM	6319	CD2	LEU	L	126	32.802	24.052	41.497
ATOM	6320	N	LYS	L	127	27.743	23.115	43.153
ATOM	6321	CA	LYS	L	127	27.000	22.466	44.242
ATOM	6322	C	LYS	L	127	27.098	20.937	44.038
ATOM	6323	O	LYS	L	127	27.425	20.217	44.989
ATOM	6324	CB	LYS	L	127	25.541	22.955	44.298
ATOM	6325	N	SER	L	128	26.900	20.460	42.773
ATOM	6326	CA	SER	L	128	27.112	19.056	42.393
ATOM	6327	C	SER	L	128	28.635	18.920	42.235
ATOM	6328	O	SER	L	128	29.312	19.908	41.961
ATOM	6329	CB	SER	L	128	26.376	18.717	41.102
ATOM	6330	OG	SER	L	128	26.686	19.627	40.060
ATOM	6331	N	GLY	L	129	29.171	17.732	42.461
ATOM	6332	CA	GLY	L	129	30.618	17.505	42.453
ATOM	6333	C	GLY	L	129	31.427	17.658	41.175
ATOM	6334	O	GLY	L	129	32.459	16.987	41.047
ATOM	6335	N	THR	L	130	31.008	18.555	40.240
ATOM	6336	CA	THR	L	130	31.707	18.765	38.962
ATOM	6337	C	THR	L	130	31.799	20.260	38.577
ATOM	6338	O	THR	L	130	30.885	21.047	38.852
ATOM	6339	CB	THR	L	130	31.084	17.869	37.851
ATOM	6340	OG1	THR	L	130	31.478	16.516	38.095
ATOM	6341	CG2	THR	L	130	31.515	18.260	36.424
ATOM	6342	N	ALA	L	131	32.943	20.611	37.930
ATOM	6343	CA	ALA	L	131	33.313	21.927	37.405
ATOM	6344	C	ALA	L	131	33.669	21.853	35.912
ATOM	6345	O	ALA	L	131	34.554	21.089	35.509
ATOM	6346	CB	ALA	L	131	34.485	22.493	38.191
ATOM	6347	N	SER	L	132	32.964	22.661	35.103

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	6348	CA	SER	L	132	33.152	22.766	33.660	1.00	80.65	C
ATOM	6349	C	SER	L	132	33.587	24.181	33.293	1.00	81.93	C
ATOM	6350	O	SER	L	132	32.836	25.149	33.488	1.00	81.18	O
ATOM	6351	CB	SER	L	132	31.885	22.362	32.909	1.00	83.31	C
ATOM	6352	OG	SER	L	132	31.622	20.975	33.063	1.00	90.07	O
ATOM	6353	N	VAL	L	133	34.828	24.296	32.804	1.00	76.88	N
ATOM	6354	CA	VAL	L	133	35.428	25.570	32.381	1.00	75.61	C
ATOM	6355	C	VAL	L	133	35.349	25.619	30.867	1.00	75.70	C
ATOM	6356	O	VAL	L	133	35.781	24.674	30.201	1.00	73.90	O
ATOM	6357	CB	VAL	L	133	36.881	25.770	32.885	1.00	79.61	C
ATOM	6358	CG1	VAL	L	133	37.239	27.240	32.881	1.00	79.33	C
ATOM	6359	CG2	VAL	L	133	37.088	25.179	34.278	1.00	79.43	C
ATOM	6360	N	VAL	L	134	34.779	26.708	30.329	1.00	71.56	N
ATOM	6361	CA	VAL	L	134	34.542	26.863	28.891	1.00	71.54	C
ATOM	6362	C	VAL	L	134	35.356	28.001	28.232	1.00	74.84	C
ATOM	6363	O	VAL	L	134	35.228	29.166	28.608	1.00	72.97	O
ATOM	6364	CB	VAL	L	134	33.022	27.018	28.602	1.00	75.58	C
ATOM	6365	CG1	VAL	L	134	32.738	27.052	27.105	1.00	75.54	C
ATOM	6366	CG2	VAL	L	134	32.216	25.909	29.263	1.00	75.67	C
ATOM	6367	N	CYS	L	135	36.106	27.652	27.173	1.00	72.40	N
ATOM	6368	CA	CYS	L	135	36.882	28.582	26.348	1.00	72.41	C
ATOM	6369	C	CYS	L	135	36.209	28.709	24.964	1.00	71.88	C
ATOM	6370	O	CYS	L	135	36.159	27.725	24.224	1.00	70.42	O
ATOM	6371	CB	CYS	L	135	38.321	28.096	26.227	1.00	73.93	C
ATOM	6372	SG	CYS	L	135	39.449	29.274	25.462	1.00	78.93	S
ATOM	6373	N	LEU	L	136	35.667	29.910	24.638	1.00	65.53	N
ATOM	6374	CA	LEU	L	136	34.990	30.221	23.370	1.00	63.25	C
ATOM	6375	C	LEU	L	136	35.875	31.025	22.403	1.00	67.07	C
ATOM	6376	O	LEU	L	136	36.407	32.053	22.795	1.00	68.54	O
ATOM	6377	CB	LEU	L	136	33.655	30.961	23.612	1.00	61.80	C
ATOM	6378	CG	LEU	L	136	32.977	31.578	22.385	1.00	64.05	C
ATOM	6379	CD1	LEU	L	136	32.459	30.516	21.438	1.00	64.16	C
ATOM	6380	CD2	LEU	L	136	31.852	32.496	22.780	1.00	62.75	C
ATOM	6381	N	LEU	L	137	35.981	30.568	21.131	1.00	61.13	N
ATOM	6382	CA	LEU	L	137	36.694	31.204	20.000	1.00	58.54	C
ATOM	6383	C	LEU	L	137	35.601	31.640	19.002	1.00	63.94	C
ATOM	6384	O	LEU	L	137	35.121	30.835	18.212	1.00	63.46	O
ATOM	6385	CB	LEU	L	137	37.705	30.244	19.328	1.00	56.45	C
ATOM	6386	CG	LEU	L	137	38.990	29.933	20.074	1.00	58.54	C
ATOM	6387	CD1	LEU	L	137	38.732	29.079	21.322	1.00	59.18	C
ATOM	6388	CD2	LEU	L	137	39.969	29.228	19.166	1.00	56.50	C
ATOM	6389	N	ASN	L	138	35.133	32.881	19.119	1.00	62.13	N
ATOM	6390	CA	ASN	L	138	34.027	33.362	18.295	1.00	61.99	C
ATOM	6391	C	ASN	L	138	34.486	33.835	16.902	1.00	64.53	C
ATOM	6392	O	ASN	L	138	35.542	34.444	16.758	1.00	64.06	O
ATOM	6393	CB	ASN	L	138	33.210	34.429	19.048	1.00	58.89	C
ATOM	6394	CG	ASN	L	138	31.957	34.831	18.347	1.00	89.15	C
ATOM	6395	OD1	ASN	L	138	30.934	34.147	18.432	1.00	85.10	O
ATOM	6396	ND2	ASN	L	138	32.018	35.949	17.629	1.00	87.54	N
ATOM	6397	N	ASN	L	139	33.672	33.505	15.894	1.00	59.08	N
ATOM	6398	CA	ASN	L	139	33.766	33.815	14.473	1.00	57.59	C
ATOM	6399	C	ASN	L	139	35.188	34.063	13.930	1.00	61.44	C
ATOM	6400	O	ASN	L	139	35.537	35.206	13.628	1.00	64.18	O
ATOM	6401	CB	ASN	L	139	32.831	34.977	14.140	1.00	49.62	C
ATOM	6402	CG	ASN	L	139	31.380	34.612	14.292	1.00	87.20	C
ATOM	6403	OD1	ASN	L	139	30.615	35.295	14.986	1.00	83.45	O
ATOM	6404	ND2	ASN	L	139	30.979	33.489	13.689	1.00	89.23	N
ATOM	6405	N	PHE	L	140	35.981	32.986	13.761	1.00	54.00	N
ATOM	6406	CA	PHE	L	140	37.337	33.057	13.202	1.00	52.69	C
ATOM	6407	C	PHE	L	140	37.452	32.350	11.832	1.00	53.51	C
ATOM	6408	O	PHE	L	140	36.538	31.630	11.440	1.00	51.52	O
ATOM	6409	CB	PHE	L	140	38.365	32.482	14.194	1.00	54.20	C
ATOM	6410	CG	PHE	L	140	38.276	30.989	14.439	1.00	55.05	C
ATOM	6411	CD1	PHE	L	140	38.970	30.092	13.629	1.00	56.99	C
ATOM	6412	CD2	PHE	L	140	37.518	30.483	15.496	1.00	56.38	C
ATOM	6413	CE1	PHE	L	140	38.879	28.714	13.848	1.00	57.68	C
ATOM	6414	CE2	PHE	L	140	37.409	29.107	15.709	1.00	58.67	C
ATOM	6415	CZ	PHE	L	140	38.113	28.233	14.902	1.00	57.15	C
ATOM	6416	N	TYR	L	141	38.591	32.548	11.129	1.00	48.76	N
ATOM	6417	CA	TYR	L	141	38.924	31.944	9.834	1.00	47.65	C
ATOM	6418	C	TYR	L	141	40.451	32.072	9.520	1.00	53.69	C
ATOM	6419	O	TYR	L	141	41.002	33.164	9.672	1.00	52.37	O
ATOM	6420	CB	TYR	L	141	38.080	32.542	8.680	1.00	47.33	C
ATOM	6421	CG	TYR	L	141	38.353	31.826	7.378	1.00	48.55	C
ATOM	6422	CD2	TYR	L	141	37.524	30.800	6.938	1.00	48.58	C
ATOM	6423	CD1	TYR	L	141	39.510	32.090	6.641	1.00	50.45	C
ATOM	6424	CE2	TYR	L	141	37.801	30.099	5.763	1.00	49.74	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	6425	CE1	TYR	L	141	39.815	31.371	5.486	1.00	50.02	C
ATOM	6426	CZ	TYR	L	141	38.952	30.384	5.041	1.00	59.17	C
ATOM	6427	OH	TYR	L	141	39.231	29.697	3.879	1.00	63.42	O
ATOM	6428	N	PRO	L	142	41.159	31.033	9.012	1.00	52.88	N
ATOM	6429	CA	PRO	L	142	40.727	29.652	8.740	1.00	53.77	C
ATOM	6430	C	PRO	L	142	40.507	28.821	9.992	1.00	60.99	C
ATOM	6431	O	PRO	L	142	40.750	29.309	11.105	1.00	61.31	O
ATOM	6432	CB	PRO	L	142	41.862	29.106	7.858	1.00	55.31	C
ATOM	6433	CG	PRO	L	142	43.063	29.848	8.288	1.00	58.47	C
ATOM	6434	CD	PRO	L	142	42.588	31.220	8.676	1.00	54.53	C
ATOM	6435	N	ARG	L	143	40.048	27.556	9.780	1.00	58.33	N
ATOM	6436	CA	ARG	L	143	39.730	26.553	10.793	1.00	58.12	C
ATOM	6437	C	ARG	L	143	40.911	26.213	11.779	1.00	63.25	C
ATOM	6438	O	ARG	L	143	40.651	25.835	12.932	1.00	65.09	O
ATOM	6439	CB	ARG	L	143	39.182	25.310	10.078	1.00	56.67	C
ATOM	6440	CG	ARG	L	143	38.974	24.065	10.911	1.00	61.75	C
ATOM	6441	CD	ARG	L	143	37.871	24.138	11.935	1.00	66.61	C
ATOM	6442	NE	ARG	L	143	37.641	22.796	12.470	1.00	90.33	N
ATOM	6443	CZ	ARG	L	143	36.819	21.888	11.936	1.00	103.98	C
ATOM	6444	NH1	ARG	L	143	36.714	20.680	12.478	1.00	97.32	N
ATOM	6445	NH2	ARG	L	143	36.090	22.187	10.859	1.00	71.31	N
ATOM	6446	N	GLU	L	144	42.175	26.396	11.351	1.00	58.55	N
ATOM	6447	CA	GLU	L	144	43.381	26.129	12.156	1.00	58.32	C
ATOM	6448	C	GLU	L	144	43.510	27.059	13.365	1.00	63.84	C
ATOM	6449	O	GLU	L	144	43.740	28.264	13.223	1.00	65.20	O
ATOM	6450	CB	GLU	L	144	44.667	26.117	11.311	1.00	59.58	C
ATOM	6451	CG	GLU	L	144	44.652	25.088	10.185	1.00	80.90	C
ATOM	6452	CD	GLU	L	144	43.946	25.512	8.901	1.00	108.16	C
ATOM	6453	OE1	GLU	L	144	44.386	26.511	8.288	1.00	111.55	O
ATOM	6454	OE2	GLU	L	144	42.965	24.844	8.500	1.00	97.11	O
ATOM	6455	N	ALA	L	145	43.316	26.471	14.551	1.00	59.89	N
ATOM	6456	CA	ALA	L	145	43.367	27.082	15.872	1.00	59.59	C
ATOM	6457	C	ALA	L	145	43.900	26.065	16.927	1.00	65.63	C
ATOM	6458	O	ALA	L	145	43.481	24.900	16.916	1.00	68.15	O
ATOM	6459	CB	ALA	L	145	41.973	27.557	16.258	1.00	60.04	C
ATOM	6460	N	LYS	L	146	44.823	26.495	17.818	1.00	60.77	N
ATOM	6461	CA	LYS	L	146	45.359	25.664	18.911	1.00	61.02	C
ATOM	6462	C	LYS	L	146	44.835	26.219	20.223	1.00	69.89	C
ATOM	6463	O	LYS	L	146	45.037	27.410	20.477	1.00	72.34	O
ATOM	6464	CB	LYS	L	146	46.897	25.631	18.923	1.00	62.47	C
ATOM	6465	N	VAL	L	147	44.094	25.399	21.018	1.00	66.58	N
ATOM	6466	CA	VAL	L	147	43.565	25.827	22.320	1.00	66.61	C
ATOM	6467	C	VAL	L	147	44.218	24.989	23.394	1.00	71.65	C
ATOM	6468	O	VAL	L	147	44.062	23.769	23.424	1.00	71.89	O
ATOM	6469	CB	VAL	L	147	42.025	25.819	22.435	1.00	71.09	C
ATOM	6470	CG1	VAL	L	147	41.561	26.298	23.823	1.00	71.14	C
ATOM	6471	CG2	VAL	L	147	41.406	26.666	21.339	1.00	71.13	C
ATOM	6472	N	GLN	L	148	45.002	25.640	24.240	1.00	68.80	N
ATOM	6473	CA	GLN	L	148	45.698	24.969	25.322	1.00	68.07	C
ATOM	6474	C	GLN	L	148	45.065	25.358	26.655	1.00	71.74	C
ATOM	6475	O	GLN	L	148	44.704	26.525	26.825	1.00	71.96	O
ATOM	6476	CB	GLN	L	148	47.178	25.337	25.290	1.00	69.15	C
ATOM	6477	CG	GLN	L	148	48.060	24.129	25.578	1.00	85.40	C
ATOM	6478	CD	GLN	L	148	49.078	23.920	24.496	1.00	93.41	C
ATOM	6479	OE1	GLN	L	148	50.023	24.702	24.350	1.00	82.71	O
ATOM	6480	NE2	GLN	L	148	48.964	22.806	23.780	1.00	81.20	N
ATOM	6481	N	TRP	L	149	44.865	24.374	27.577	1.00	66.93	N
ATOM	6482	CA	TRP	L	149	44.334	24.671	28.914	1.00	65.84	C
ATOM	6483	C	TRP	L	149	45.504	24.662	29.898	1.00	75.51	C
ATOM	6484	O	TRP	L	149	46.372	23.784	29.813	1.00	77.24	O
ATOM	6485	CB	TRP	L	149	43.231	23.703	29.349	1.00	62.25	C
ATOM	6486	CG	TRP	L	149	41.878	24.015	28.790	1.00	61.15	C
ATOM	6487	CD1	TRP	L	149	41.256	23.377	27.762	1.00	63.75	C
ATOM	6488	CD2	TRP	L	149	40.966	25.024	29.247	1.00	60.31	C
ATOM	6489	NE1	TRP	L	149	40.025	23.950	27.523	1.00	62.82	N
ATOM	6490	CE2	TRP	L	149	39.816	24.952	28.430	1.00	64.12	C
ATOM	6491	CE3	TRP	L	149	41.015	26.003	30.255	1.00	61.11	C
ATOM	6492	CZ2	TRP	L	149	38.704	25.789	28.620	1.00	63.31	C
ATOM	6493	CZ3	TRP	L	149	39.926	26.854	30.420	1.00	62.19	C
ATOM	6494	CH2	TRP	L	149	38.796	26.756	29.597	1.00	62.87	C
ATOM	6495	N	LYS	L	150	45.577	25.692	30.753	1.00	73.64	N
ATOM	6496	CA	LYS	L	150	46.625	25.848	31.747	1.00	75.01	C
ATOM	6497	C	LYS	L	150	45.983	26.150	33.104	1.00	84.34	C
ATOM	6498	O	LYS	L	150	45.171	27.072	33.224	1.00	82.82	O
ATOM	6499	CB	LYS	L	150	47.666	26.902	31.312	1.00	76.93	C
ATOM	6500	N	VAL	L	151	46.277	25.297	34.103	1.00	86.19	N
ATOM	6501	CA	VAL	L	151	45.734	25.411	35.463	1.00	88.08	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	6502 C	VAL	L	151	46.928	25.646	36.381	1.00	94.72	C
ATOM	6503 O	VAL	L	151	47.722	24.722	36.615	1.00	94.87	O
ATOM	6504 CB	VAL	L	151	44.905	24.152	35.844	1.00	92.46	C
ATOM	6505 CG1	VAL	L	151	44.449	24.211	37.290	1.00	92.43	C
ATOM	6506 CG2	VAL	L	151	43.707	23.980	34.919	1.00	92.04	C
ATOM	6507 N	ASP	L	152	47.075	26.901	36.854	1.00	92.52	N
ATOM	6508 CA	ASP	L	152	48.215	27.376	37.648	1.00	93.32	C
ATOM	6509 C	ASP	L	152	49.523	27.118	36.861	1.00	99.60	C
ATOM	6510 O	ASP	L	152	50.429	26.443	37.360	1.00	100.41	O
ATOM	6511 CB	ASP	L	152	48.243	26.784	39.086	1.00	94.73	C
ATOM	6512 CG	ASP	L	152	47.239	27.377	40.064	1.00	103.42	C
ATOM	6513 OD1	ASP	L	152	46.815	28.539	39.857	1.00	104.73	O
ATOM	6514 OD2	ASP	L	152	46.931	26.708	41.073	1.00	106.13	O
ATOM	6515 N	ASN	L	153	49.562	27.597	35.584	1.00	95.63	N
ATOM	6516 CA	ASN	L	153	50.672	27.505	34.611	1.00	95.12	C
ATOM	6517 C	ASN	L	153	51.069	26.058	34.203	1.00	96.90	C
ATOM	6518 O	ASN	L	153	52.105	25.875	33.550	1.00	96.75	O
ATOM	6519 CB	ASN	L	153	51.911	28.296	35.076	1.00	99.06	C
ATOM	6520 CG	ASN	L	153	51.607	29.642	35.707	1.00	135.84	C
ATOM	6521 OD1	ASN	L	153	50.819	30.450	35.190	1.00	133.75	O
ATOM	6522 ND2	ASN	L	153	52.236	29.908	36.846	1.00	128.26	N
ATOM	6523 N	ALA	L	154	50.232	25.053	34.538	1.00	91.39	N
ATOM	6524 CA	ALA	L	154	50.463	23.653	34.172	1.00	90.55	C
ATOM	6525 C	ALA	L	154	49.586	23.272	32.958	1.00	93.26	C
ATOM	6526 O	ALA	L	154	48.363	23.463	33.010	1.00	92.03	O
ATOM	6527 CB	ALA	L	154	50.149	22.750	35.357	1.00	91.22	C
ATOM	6528 N	LEU	L	155	50.208	22.759	31.864	1.00	89.26	N
ATOM	6529 CA	LEU	L	155	49.478	22.357	30.651	1.00	89.27	C
ATOM	6530 C	LEU	L	155	48.638	21.103	30.877	1.00	91.14	C
ATOM	6531 O	LEU	L	155	49.164	20.060	31.283	1.00	90.21	O
ATOM	6532 CB	LEU	L	155	50.362	22.220	29.381	1.00	89.99	C
ATOM	6533 CG	LEU	L	155	51.872	21.934	29.545	1.00	96.37	C
ATOM	6534 CD1	LEU	L	155	52.155	20.439	29.678	1.00	97.09	C
ATOM	6535 CD2	LEU	L	155	52.663	22.487	28.367	1.00	99.85	C
ATOM	6536 N	GLN	L	156	47.321	21.228	30.625	1.00	86.37	N
ATOM	6537 CA	GLN	L	156	46.323	20.176	30.788	1.00	85.57	C
ATOM	6538 C	GLN	L	156	46.213	19.278	29.573	1.00	90.15	C
ATOM	6539 O	GLN	L	156	46.221	19.776	28.442	1.00	90.24	O
ATOM	6540 CB	GLN	L	156	44.941	20.778	31.119	1.00	86.60	C
ATOM	6541 CG	GLN	L	156	44.898	21.673	32.354	1.00	95.54	C
ATOM	6542 CD	GLN	L	156	45.453	21.015	33.601	1.00	105.17	C
ATOM	6543 OE1	GLN	L	156	44.798	20.200	34.256	1.00	91.50	O
ATOM	6544 NE2	GLN	L	156	46.682	21.355	33.952	1.00	103.98	N
ATOM	6545 N	SER	L	157	46.074	17.953	29.814	1.00	87.33	N
ATOM	6546 CA	SER	L	157	45.891	16.949	28.764	1.00	87.63	C
ATOM	6547 C	SER	L	157	44.895	15.839	29.163	1.00	92.20	C
ATOM	6548 O	SER	L	157	44.918	15.366	30.302	1.00	92.53	O
ATOM	6549 CB	SER	L	157	47.226	16.378	28.293	1.00	90.25	C
ATOM	6550 OG	SER	L	157	47.550	15.160	28.942	1.00	99.31	O
ATOM	6551 N	GLY	L	158	44.043	15.458	28.204	1.00	87.36	N
ATOM	6552 CA	GLY	L	158	43.039	14.414	28.339	1.00	86.13	C
ATOM	6553 C	GLY	L	158	41.899	14.739	29.279	1.00	88.60	C
ATOM	6554 O	GLY	L	158	41.338	13.830	29.898	1.00	89.48	O
ATOM	6555 N	ASN	L	159	41.544	16.033	29.395	1.00	82.21	N
ATOM	6556 CA	ASN	L	159	40.457	16.487	30.264	1.00	80.42	C
ATOM	6557 C	ASN	L	159	39.609	17.600	29.633	1.00	80.71	C
ATOM	6558 O	ASN	L	159	38.851	18.284	30.337	1.00	80.62	O
ATOM	6559 CB	ASN	L	159	40.988	16.873	31.642	1.00	80.58	C
ATOM	6560 CG	ASN	L	159	41.974	18.008	31.680	1.00	105.23	C
ATOM	6561 OD1	ASN	L	159	42.472	18.514	30.658	1.00	108.47	O
ATOM	6562 ND2	ASN	L	159	42.281	18.435	32.887	1.00	91.62	N
ATOM	6563 N	SER	L	160	39.735	17.760	28.292	1.00	74.34	N
ATOM	6564 CA	SER	L	160	38.981	18.733	27.491	1.00	72.39	C
ATOM	6565 C	SER	L	160	38.424	18.138	26.192	1.00	72.37	C
ATOM	6566 O	SER	L	160	38.905	17.104	25.707	1.00	71.75	O
ATOM	6567 CB	SER	L	160	39.780	20.009	27.225	1.00	74.18	C
ATOM	6568 OG	SER	L	160	41.057	19.746	26.673	1.00	78.48	O
ATOM	6569 N	GLN	L	161	37.376	18.780	25.664	1.00	65.76	N
ATOM	6570 CA	GLN	L	161	36.709	18.374	24.443	1.00	64.69	C
ATOM	6571 C	GLN	L	161	36.374	19.603	23.605	1.00	68.02	C
ATOM	6572 O	GLN	L	161	35.634	20.476	24.086	1.00	67.59	O
ATOM	6573 CB	GLN	L	161	35.413	17.620	24.772	1.00	66.06	C
ATOM	6574 CG	GLN	L	161	35.575	16.176	25.233	1.00	78.85	C
ATOM	6575 CD	GLN	L	161	34.253	15.519	25.626	1.00	86.84	C
ATOM	6576 OE1	GLN	L	161	33.383	16.063	26.345	1.00	88.62	O
ATOM	6577 NE2	GLN	L	161	34.106	14.293	25.204	1.00	56.79	N
ATOM	6578 N	GLU	L	162	36.890	19.672	22.348	1.00	64.13	N

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab - <i>C. difficile</i> toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	6579 CA	GLU	L	162	36.531	20.798	21.469	1.00
ATOM	6580 C	GLU	L	162	35.373	20.413	20.515	1.00
ATOM	6581 O	GLU	L	162	35.184	19.237	20.179	1.00
ATOM	6582 CB	GLU	L	162	37.708	21.503	20.719	1.00
ATOM	6583 CG	GLU	L	162	39.087	20.877	20.806	1.00
ATOM	6584 CD	GLU	L	162	40.205	21.828	21.196	1.00
ATOM	6585 OE1	GLU	L	162	40.525	21.907	22.410	1.00
ATOM	6586 OE2	GLU	L	162	40.801	22.443	20.278	1.00
ATOM	6587 N	SER	L	163	34.574	21.428	20.143	1.00
ATOM	6588 CA	SER	L	163	33.427	21.323	19.265	1.00
ATOM	6589 C	SER	L	163	33.446	22.533	18.333	1.00
ATOM	6590 O	SER	L	163	33.529	23.665	18.793	1.00
ATOM	6591 CB	SER	L	163	32.145	21.272	20.083	1.00
ATOM	6592 OG	SER	L	163	31.008	21.198	19.244	1.00
ATOM	6593 N	VAL	L	164	33.395	22.278	17.023	1.00
ATOM	6594 CA	VAL	L	164	33.441	23.290	15.968	1.00
ATOM	6595 C	VAL	L	164	32.115	23.374	15.275	1.00
ATOM	6596 O	VAL	L	164	31.530	22.345	14.953	1.00
ATOM	6597 CB	VAL	L	164	34.532	23.007	14.897	1.00
ATOM	6598 CG1	VAL	L	164	34.982	24.303	14.233	1.00
ATOM	6599 CG2	VAL	L	164	35.719	22.244	15.478	1.00
ATOM	6600 N	THR	L	165	31.684	24.604	14.961	1.00
ATOM	6601 CA	THR	L	165	30.462	24.823	14.188	1.00
ATOM	6602 C	THR	L	165	30.814	24.650	12.712	1.00
ATOM	6603 O	THR	L	165	31.996	24.662	12.334	1.00
ATOM	6604 CB	THR	L	165	29.933	26.246	14.398	1.00
ATOM	6605 OG1	THR	L	165	30.989	27.196	14.161	1.00
ATOM	6606 CG2	THR	L	165	29.275	26.447	15.769	1.00
ATOM	6607 N	GLU	L	166	29.792	24.497	11.869	1.00
ATOM	6608 CA	GLU	L	166	30.023	24.450	10.432	1.00
ATOM	6609 C	GLU	L	166	30.223	25.916	9.982	1.00
ATOM	6610 O	GLU	L	166	29.886	26.842	10.740	1.00
ATOM	6611 CB	GLU	L	166	28.900	23.706	9.676	1.00
ATOM	6612 CG	GLU	L	166	29.029	22.185	9.754	1.00
ATOM	6613 CD	GLU	L	166	30.397	21.572	9.476	1.00
ATOM	6614 OE1	GLU	L	166	30.916	21.753	8.349	1.00
ATOM	6615 OE2	GLU	L	166	30.971	20.950	10.401	1.00
ATOM	6616 N	GLN	L	167	30.867	26.122	8.826	1.00
ATOM	6617 CA	GLN	L	167	31.153	27.428	8.270	1.00
ATOM	6618 C	GLN	L	167	29.868	28.259	8.232	1.00
ATOM	6619 O	GLN	L	167	28.850	27.781	7.726	1.00
ATOM	6620 CB	GLN	L	167	31.754	27.253	6.880	1.00
ATOM	6621 CG	GLN	L	167	32.611	28.409	6.456	1.00
ATOM	6622 CD	GLN	L	167	33.500	28.083	5.304	1.00
ATOM	6623 OE1	GLN	L	167	33.163	27.294	4.411	1.00
ATOM	6624 NE2	GLN	L	167	34.638	28.735	5.276	1.00
ATOM	6625 N	ASP	L	168	29.892	29.456	8.857	1.00
ATOM	6626 CA	ASP	L	168	28.745	30.366	8.980	1.00
ATOM	6627 C	ASP	L	168	28.143	30.791	7.651	1.00
ATOM	6628 O	ASP	L	168	28.868	31.127	6.715	1.00
ATOM	6629 CB	ASP	L	168	29.097	31.603	9.828	1.00
ATOM	6630 CG	ASP	L	168	27.874	32.314	10.377	1.00
ATOM	6631 OD1	ASP	L	168	27.349	31.873	11.423	1.00
ATOM	6632 OD2	ASP	L	168	27.409	33.274	9.731	1.00
ATOM	6633 N	SER	L	169	26.804	30.789	7.580	1.00
ATOM	6634 CA	SER	L	169	26.028	31.162	6.386	1.00
ATOM	6635 C	SER	L	169	26.210	32.635	5.998	1.00
ATOM	6636 O	SER	L	169	26.133	32.961	4.810	1.00
ATOM	6637 CB	SER	L	169	24.544	30.864	6.600	1.00
ATOM	6638 OG	SER	L	169	24.014	31.563	7.716	1.00
ATOM	6639 N	LYS	L	170	26.447	33.521	6.993	1.00
ATOM	6640 CA	LYS	L	170	26.590	34.959	6.766	1.00
ATOM	6641 C	LYS	L	170	28.036	35.398	6.444	1.00
ATOM	6642 O	LYS	L	170	28.290	35.953	5.361	1.00
ATOM	6643 CB	LYS	L	170	26.018	35.740	7.964	1.00
ATOM	6644 CG	LYS	L	170	25.252	37.003	7.601	1.00
ATOM	6645 CD	LYS	L	170	25.014	37.897	8.834	1.00
ATOM	6646 CE	LYS	L	170	23.554	38.034	9.238	1.00
ATOM	6647 NZ	LYS	L	170	23.380	38.840	10.481	1.00
ATOM	6648 N	ASP	L	171	28.980	35.126	7.381	1.00
ATOM	6649 CA	ASP	L	171	30.363	35.579	7.291	1.00
ATOM	6650 C	ASP	L	171	31.420	34.504	7.003	1.00
ATOM	6651 O	ASP	L	171	32.613	34.819	7.063	1.00
ATOM	6652 CB	ASP	L	171	30.738	36.352	8.557	1.00
ATOM	6653 CG	ASP	L	171	30.360	35.679	9.851	1.00
ATOM	6654 OD2	ASP	L	171	31.253	35.444	10.669	1.00
ATOM	6655 OD1	ASP	L	171	29.148	35.505	10.100	1.00
							100.48	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	6656 N	SER	L	172	31.001	33.271	6.640	1.00
ATOM	6657 CA	SER	L	172	31.872	32.127	6.302	1.00
ATOM	6658 C	SER	L	172	32.965	31.821	7.367	1.00
ATOM	6659 O	SER	L	172	34.056	31.361	7.031	1.00
ATOM	6660 CB	SER	L	172	32.480	32.284	4.909	1.00
ATOM	6661 OG	SER	L	172	31.459	32.266	3.932	1.00
ATOM	6662 N	THR	L	173	32.642	32.022	8.637	1.00
ATOM	6663 CA	THR	L	173	33.574	31.765	9.728	1.00
ATOM	6664 C	THR	L	173	33.192	30.540	10.562	1.00
ATOM	6665 O	THR	L	173	32.078	30.013	10.469	1.00
ATOM	6666 CB	THR	L	173	33.674	32.974	10.658	1.00
ATOM	6667 OG1	THR	L	173	32.410	33.181	11.283	1.00
ATOM	6668 CG2	THR	L	173	34.183	34.220	9.963	1.00
ATOM	6669 N	TYR	L	174	34.132	30.137	11.423	1.00
ATOM	6670 CA	TYR	L	174	34.006	29.055	12.369	1.00
ATOM	6671 C	TYR	L	174	34.004	29.575	13.798	1.00
ATOM	6672 O	TYR	L	174	34.627	30.588	14.112	1.00
ATOM	6673 CB	TYR	L	174	35.175	28.089	12.220	1.00
ATOM	6674 CG	TYR	L	174	35.269	27.466	10.848	1.00
ATOM	6675 CD1	TYR	L	174	34.445	26.399	10.485	1.00
ATOM	6676 CD2	TYR	L	174	36.186	27.938	9.905	1.00
ATOM	6677 CE1	TYR	L	174	34.510	25.836	9.213	1.00
ATOM	6678 CE2	TYR	L	174	36.278	27.361	8.636	1.00
ATOM	6679 CZ	TYR	L	174	35.437	26.311	8.297	1.00
ATOM	6680 OH	TYR	L	174	35.524	25.753	7.051	1.00
ATOM	6681 N	SER	L	175	33.314	28.852	14.667	1.00
ATOM	6682 CA	SER	L	175	33.340	29.086	16.087	1.00
ATOM	6683 C	SER	L	175	33.726	27.755	16.738	1.00
ATOM	6684 O	SER	L	175	33.520	26.688	16.139	1.00
ATOM	6685 CB	SER	L	175	32.030	29.666	16.578	1.00
ATOM	6686 OG	SER	L	175	31.867	30.923	15.942	1.00
ATOM	6687 N	LEU	L	176	34.389	27.819	17.888	1.00
ATOM	6688 CA	LEU	L	176	34.893	26.653	18.586	1.00
ATOM	6689 C	LEU	L	176	34.714	26.847	20.097	1.00
ATOM	6690 O	LEU	L	176	34.899	27.953	20.603	1.00
ATOM	6691 CB	LEU	L	176	36.380	26.445	18.211	1.00
ATOM	6692 CG	LEU	L	176	37.113	25.219	18.761	1.00
ATOM	6693 CD1	LEU	L	176	38.055	24.649	17.727	1.00
ATOM	6694 CD2	LEU	L	176	37.904	25.565	19.994	1.00
ATOM	6695 N	SER	L	177	34.337	25.770	20.804	1.00
ATOM	6696 CA	SER	L	177	34.184	25.756	22.240	0.47
ATOM	6697 C	SER	L	177	35.048	24.617	22.711	1.00
ATOM	6698 O	SER	L	177	34.929	23.531	22.162	1.00
ATOM	6699 CB	SER	L	177	32.725	25.521	22.624	0.47
ATOM	6700 OG	SER	L	177	32.306	24.179	22.439	0.47
ATOM	6701 N	SER	L	178	35.985	24.868	23.646	1.00
ATOM	6702 CA	SER	L	178	36.840	23.834	24.250	1.00
ATOM	6703 C	SER	L	178	36.444	23.760	25.730	1.00
ATOM	6704 O	SER	L	178	36.601	24.751	26.450	1.00
ATOM	6705 CB	SER	L	178	38.323	24.165	24.099	1.00
ATOM	6706 OG	SER	L	178	39.135	23.202	24.755	1.00
ATOM	6707 N	THR	L	179	35.860	22.624	26.165	1.00
ATOM	6708 CA	THR	L	179	35.390	22.481	27.544	1.00
ATOM	6709 C	THR	L	179	36.324	21.636	28.394	1.00
ATOM	6710 O	THR	L	179	36.544	20.464	28.088	1.00
ATOM	6711 CB	THR	L	179	33.941	21.978	27.591	1.00
ATOM	6712 OG1	THR	L	179	33.116	22.819	26.785	1.00
ATOM	6713 CG2	THR	L	179	33.376	21.957	28.997	1.00
ATOM	6714 N	LEU	L	180	36.849	22.239	29.487	1.00
ATOM	6715 CA	LEU	L	180	37.696	21.574	30.487	1.00
ATOM	6716 C	LEU	L	180	36.765	21.022	31.598	1.00
ATOM	6717 O	LEU	L	180	35.972	21.782	32.175	1.00
ATOM	6718 CB	LEU	L	180	38.713	22.569	31.075	1.00
ATOM	6719 CG	LEU	L	180	39.694	22.003	32.091	1.00
ATOM	6720 CD1	LEU	L	180	40.910	21.399	31.413	1.00
ATOM	6721 CD2	LEU	L	180	40.150	23.076	33.023	1.00
ATOM	6722 N	THR	L	181	36.825	19.709	31.859	1.00
ATOM	6723 CA	THR	L	181	35.957	19.127	32.889	1.00
ATOM	6724 C	THR	L	181	36.817	18.530	34.015	1.00
ATOM	6725 O	THR	L	181	37.712	17.690	33.793	1.00
ATOM	6726 CB	THR	L	181	34.873	18.171	32.302	1.00
ATOM	6727 OG1	THR	L	181	34.028	18.904	31.398	1.00
ATOM	6728 CG2	THR	L	181	33.977	17.545	33.394	1.00
ATOM	6729 N	LEU	L	182	36.530	19.024	35.224	1.00
ATOM	6730 CA	LEU	L	182	37.198	18.664	36.465	1.00
ATOM	6731 C	LEU	L	182	36.185	18.368	37.572	1.00
ATOM	6732 O	LEU	L	182	35.103	18.973	37.606	1.00

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody beziotoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	6733	CB	LEU	L	182	38.048	19.857	36.934	1.00	83.59	C
ATOM	6734	CG	LEU	L	182	39.349	20.147	36.213	1.00	88.49	C
ATOM	6735	CD1	LEU	L	182	39.821	21.554	36.530	1.00	88.95	C
ATOM	6736	CD2	LEU	L	182	40.416	19.130	36.569	1.00	90.02	C
ATOM	6737	N	SER	L	183	36.580	17.492	38.523	1.00	85.90	N
ATOM	6738	CA	SER	L	183	35.787	17.194	39.720	1.00	85.74	C
ATOM	6739	C	SER	L	183	35.922	18.398	40.676	1.00	88.65	C
ATOM	6740	O	SER	L	183	37.036	18.926	40.810	1.00	87.92	O
ATOM	6741	CB	SER	L	183	36.305	15.931	40.404	1.00	89.15	C
ATOM	6742	OG	SER	L	183	37.600	16.126	40.948	1.00	97.89	O
ATOM	6743	N	LYS	L	184	34.804	18.830	41.334	1.00	84.92	N
ATOM	6744	CA	LYS	L	184	34.775	19.950	42.303	1.00	84.70	C
ATOM	6745	C	LYS	L	184	36.019	19.944	43.207	1.00	89.80	C
ATOM	6746	O	LYS	L	184	36.568	21.004	43.474	1.00	88.98	O
ATOM	6747	CB	LYS	L	184	33.483	19.935	43.146	1.00	86.54	C
ATOM	6748	CG	LYS	L	184	33.275	21.171	44.019	1.00	90.47	C
ATOM	6749	CD	LYS	L	184	32.385	20.869	45.217	1.00	98.25	C
ATOM	6750	CE	LYS	L	184	32.277	22.059	46.141	1.00	107.40	C
ATOM	6751	NZ	LYS	L	184	31.204	21.892	47.157	1.00	114.82	N
ATOM	6752	N	ALA	L	185	36.498	18.738	43.598	1.00	87.88	N
ATOM	6753	CA	ALA	L	185	37.692	18.496	44.411	1.00	88.22	C
ATOM	6754	C	ALA	L	185	38.924	19.155	43.788	1.00	93.04	C
ATOM	6755	O	ALA	L	185	39.465	20.084	44.387	1.00	93.34	O
ATOM	6756	CB	ALA	L	185	37.921	16.996	44.566	1.00	89.04	C
ATOM	6757	N	ASP	L	186	39.314	18.718	42.559	1.00	89.22	N
ATOM	6758	CA	ASP	L	186	40.457	19.218	41.787	1.00	88.68	C
ATOM	6759	C	ASP	L	186	40.335	20.693	41.368	1.00	91.99	C
ATOM	6760	O	ASP	L	186	41.352	21.380	41.239	1.00	91.21	O
ATOM	6761	CB	ASP	L	186	40.716	18.321	40.582	1.00	90.38	C
ATOM	6762	CG	ASP	L	186	41.163	16.932	40.969	1.00	100.56	C
ATOM	6763	OD2	ASP	L	186	42.379	16.666	40.906	1.00	108.13	O
ATOM	6764	OD1	ASP	L	186	40.300	16.120	41.357	1.00	100.27	O
ATOM	6765	N	TYR	L	187	39.103	21.181	41.181	1.00	88.60	N
ATOM	6766	CA	TYR	L	187	38.869	22.583	40.856	1.00	88.50	C
ATOM	6767	C	TYR	L	187	39.218	23.501	42.046	1.00	94.44	C
ATOM	6768	O	TYR	L	187	39.849	24.539	41.825	1.00	94.88	O
ATOM	6769	CB	TYR	L	187	37.430	22.815	40.373	1.00	88.86	C
ATOM	6770	CG	TYR	L	187	37.092	24.268	40.121	1.00	89.12	C
ATOM	6771	CD1	TYR	L	187	37.641	24.956	39.044	1.00	90.63	C
ATOM	6772	CD2	TYR	L	187	36.219	24.954	40.957	1.00	89.71	C
ATOM	6773	CE1	TYR	L	187	37.342	26.300	38.816	1.00	90.87	C
ATOM	6774	CE2	TYR	L	187	35.898	26.291	40.729	1.00	90.40	C
ATOM	6775	CZ	TYR	L	187	36.470	26.964	39.664	1.00	96.75	C
ATOM	6776	OH	TYR	L	187	36.116	28.268	39.426	1.00	96.71	O
ATOM	6777	N	GLU	L	188	38.820	23.119	43.299	1.00	91.05	N
ATOM	6778	CA	GLU	L	188	39.104	23.879	44.540	1.00	90.43	C
ATOM	6779	C	GLU	L	188	40.627	23.928	44.857	1.00	94.06	C
ATOM	6780	O	GLU	L	188	41.096	24.889	45.486	1.00	94.03	O
ATOM	6781	CB	GLU	L	188	38.358	23.308	45.763	1.00	91.70	C
ATOM	6782	CG	GLU	L	188	36.874	23.019	45.595	1.00	104.35	C
ATOM	6783	CD	GLU	L	188	35.883	24.140	45.834	1.00	132.32	C
ATOM	6784	OE1	GLU	L	188	35.971	25.179	45.139	1.00	141.21	O
ATOM	6785	OE2	GLU	L	188	34.963	23.940	46.661	1.00	122.04	O
ATOM	6786	N	LYS	L	189	41.381	22.883	44.411	1.00	88.77	N
ATOM	6787	CA	LYS	L	189	42.826	22.697	44.588	1.00	88.33	C
ATOM	6788	C	LYS	L	189	43.727	23.766	43.910	1.00	93.69	C
ATOM	6789	O	LYS	L	189	44.915	23.850	44.249	1.00	94.47	O
ATOM	6790	CB	LYS	L	189	43.236	21.305	44.058	1.00	90.35	C
ATOM	6791	CG	LYS	L	189	43.104	20.156	45.042	1.00	102.70	C
ATOM	6792	CD	LYS	L	189	43.736	18.882	44.466	1.00	111.79	C
ATOM	6793	CE	LYS	L	189	43.605	17.686	45.383	1.00	122.00	C
ATOM	6794	NZ	LYS	L	189	44.211	16.461	44.790	1.00	125.69	N
ATOM	6795	N	HIS	L	190	43.197	24.525	42.916	1.00	89.21	N
ATOM	6796	CA	HIS	L	190	43.964	25.506	42.130	1.00	87.90	C
ATOM	6797	C	HIS	L	190	43.277	26.872	41.997	1.00	91.03	C
ATOM	6798	O	HIS	L	190	42.061	26.942	42.179	1.00	89.21	O
ATOM	6799	CB	HIS	L	190	44.269	24.921	40.756	1.00	87.99	C
ATOM	6800	CG	HIS	L	190	45.067	23.667	40.819	1.00	90.88	C
ATOM	6801	ND1	HIS	L	190	44.455	22.429	40.900	1.00	92.40	N
ATOM	6802	CD2	HIS	L	190	46.409	23.498	40.836	1.00	93.03	C
ATOM	6803	CE1	HIS	L	190	45.438	21.546	40.949	1.00	92.25	C
ATOM	6804	NE2	HIS	L	190	46.634	22.141	40.913	1.00	92.79	N
ATOM	6805	N	LYS	L	191	44.055	27.949	41.658	1.00	88.42	N
ATOM	6806	CA	LYS	L	191	43.571	29.350	41.564	1.00	88.55	C
ATOM	6807	C	LYS	L	191	43.393	29.927	40.143	1.00	91.01	C
ATOM	6808	O	LYS	L	191	42.311	30.446	39.837	1.00	89.46	O
ATOM	6809	CB	LYS	L	191	44.477	30.300	42.381	1.00	91.03	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TedB antibody beziotoxumab
Fab -C. difficile toxin B (TedB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	6810	N	VAL	L	192	44.469	29.897	39.319	1.00	87.27	N
ATOM	6811	CA	VAL	L	192	44.497	30.447	37.955	1.00	87.31	C
ATOM	6812	C	VAL	L	192	44.122	29.416	36.882	1.00	89.67	C
ATOM	6813	O	VAL	L	192	44.802	28.398	36.704	1.00	88.82	O
ATOM	6814	CB	VAL	L	192	45.819	31.167	37.574	1.00	91.79	C
ATOM	6815	CG1	VAL	L	192	45.552	32.298	36.577	1.00	91.61	C
ATOM	6816	CG2	VAL	L	192	46.564	31.688	38.804	1.00	91.76	C
ATOM	6817	N	TYR	L	193	43.051	29.726	36.143	1.00	84.51	N
ATOM	6818	CA	TYR	L	193	42.518	28.905	35.067	1.00	83.32	C
ATOM	6819	C	TYR	L	193	42.607	29.684	33.768	1.00	83.43	C
ATOM	6820	O	TYR	L	193	41.948	30.711	33.633	1.00	83.97	O
ATOM	6821	CB	TYR	L	193	41.069	28.489	35.396	1.00	85.28	C
ATOM	6822	CG	TYR	L	193	41.000	27.402	36.446	1.00	87.51	C
ATOM	6823	CD1	TYR	L	193	41.078	26.059	36.091	1.00	89.43	C
ATOM	6824	CD2	TYR	L	193	40.925	27.717	37.799	1.00	88.78	C
ATOM	6825	CE1	TYR	L	193	41.059	25.054	37.054	1.00	90.87	C
ATOM	6826	CE2	TYR	L	193	40.929	26.719	38.775	1.00	90.10	C
ATOM	6827	CZ	TYR	L	193	41.005	25.388	38.398	1.00	97.03	C
ATOM	6828	OH	TYR	L	193	40.988	24.393	39.346	1.00	94.97	O
ATOM	6829	N	ALA	L	194	43.436	29.225	32.823	1.00	76.24	N
ATOM	6830	CA	ALA	L	194	43.638	29.950	31.574	1.00	74.87	C
ATOM	6831	C	ALA	L	194	43.592	29.118	30.311	1.00	77.60	C
ATOM	6832	O	ALA	L	194	44.122	28.010	30.283	1.00	76.42	O
ATOM	6833	CB	ALA	L	194	44.975	30.670	31.628	1.00	75.47	C
ATOM	6834	N	CYS	L	195	43.039	29.685	29.229	1.00	74.49	N
ATOM	6835	CA	CYS	L	195	43.133	29.033	27.926	1.00	73.76	C
ATOM	6836	C	CYS	L	195	43.949	29.918	26.993	1.00	72.69	C
ATOM	6837	O	CYS	L	195	43.788	31.137	27.015	1.00	71.87	O
ATOM	6838	CB	CYS	L	195	41.788	28.608	27.331	1.00	74.99	C
ATOM	6839	SG	CYS	L	195	40.642	29.965	26.973	1.00	79.53	S
ATOM	6840	N	GLU	L	196	44.894	29.312	26.268	1.00	66.50	N
ATOM	6841	CA	GLU	L	196	45.809	29.993	25.354	1.00	64.97	C
ATOM	6842	C	GLU	L	196	45.545	29.616	23.874	1.00	69.19	C
ATOM	6843	O	GLU	L	196	45.994	28.557	23.386	1.00	70.03	O
ATOM	6844	CB	GLU	L	196	47.272	29.732	25.770	1.00	65.61	C
ATOM	6845	CG	GLU	L	196	48.291	30.513	24.967	1.00	70.23	C
ATOM	6846	CD	GLU	L	196	49.729	30.195	25.306	1.00	87.02	C
ATOM	6847	OE1	GLU	L	196	50.232	30.733	26.318	1.00	89.05	O
ATOM	6848	OE2	GLU	L	196	50.367	29.442	24.538	1.00	80.82	O
ATOM	6849	N	VAL	L	197	44.834	30.532	23.169	1.00	63.00	N
ATOM	6850	CA	VAL	L	197	44.465	30.465	21.746	1.00	61.71	C
ATOM	6851	C	VAL	L	197	45.635	30.879	20.822	1.00	65.36	C
ATOM	6852	O	VAL	L	197	46.303	31.881	21.067	1.00	64.58	O
ATOM	6853	CB	VAL	L	197	43.191	31.298	21.501	1.00	65.41	C
ATOM	6854	CG1	VAL	L	197	42.908	31.516	20.011	1.00	65.24	C
ATOM	6855	CG2	VAL	L	197	41.999	30.651	22.192	1.00	65.11	C
ATOM	6856	N	THR	L	198	45.881	30.091	19.772	1.00	62.72	N
ATOM	6857	CA	THR	L	198	46.946	30.335	18.786	1.00	61.95	C
ATOM	6858	C	THR	L	198	46.322	30.320	17.366	1.00	62.72	C
ATOM	6859	O	THR	L	198	46.108	29.252	16.797	1.00	63.42	O
ATOM	6860	CB	THR	L	198	48.081	29.297	18.993	1.00	68.37	C
ATOM	6861	OG1	THR	L	198	48.479	29.287	20.370	1.00	77.57	O
ATOM	6862	CG2	THR	L	198	49.280	29.543	18.098	1.00	58.19	C
ATOM	6863	N	HIS	L	199	45.986	31.495	16.832	1.00	56.20	N
ATOM	6864	CA	HIS	L	199	45.416	31.629	15.487	1.00	55.38	C
ATOM	6865	C	HIS	L	199	46.292	32.576	14.649	1.00	59.30	C
ATOM	6866	O	HIS	L	199	46.936	33.471	15.211	1.00	60.85	O
ATOM	6867	CB	HIS	L	199	43.962	32.126	15.548	1.00	55.61	C
ATOM	6868	CG	HIS	L	199	43.226	32.059	14.237	1.00	58.46	C
ATOM	6869	ND1	HIS	L	199	43.284	33.092	13.323	1.00	59.86	N
ATOM	6870	CD2	HIS	L	199	42.440	31.079	13.732	1.00	59.81	C
ATOM	6871	CE1	HIS	L	199	42.550	32.703	12.290	1.00	59.11	C
ATOM	6872	NE2	HIS	L	199	42.007	31.506	12.500	1.00	59.41	N
ATOM	6873	N	GLN	L	200	46.323	32.376	13.317	1.00	53.39	N
ATOM	6874	CA	GLN	L	200	47.107	33.205	12.387	1.00	52.53	C
ATOM	6875	C	GLN	L	200	46.552	34.624	12.195	1.00	58.56	C
ATOM	6876	O	GLN	L	200	47.176	35.429	11.520	1.00	58.57	O
ATOM	6877	CB	GLN	L	200	47.308	32.506	11.026	1.00	53.01	C
ATOM	6878	CG	GLN	L	200	46.074	32.440	10.133	1.00	53.61	C
ATOM	6879	CD	GLN	L	200	46.193	31.319	9.157	1.00	69.13	C
ATOM	6880	OE1	GLN	L	200	46.434	31.529	7.976	1.00	62.32	O
ATOM	6881	NE2	GLN	L	200	46.057	30.098	9.639	1.00	74.77	N
ATOM	6882	N	GLY	L	201	45.391	34.908	12.768	1.00	56.22	N
ATOM	6883	CA	GLY	L	201	44.786	36.231	12.714	1.00	56.08	C
ATOM	6884	C	GLY	L	201	45.251	37.074	13.875	1.00	60.60	C
ATOM	6885	O	GLY	L	201	45.046	38.280	13.862	1.00	62.27	O
ATOM	6886	N	LEU	L	202	45.879	36.440	14.883	1.00	57.20	N

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody beziotoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	6887	CA	LEU	L	202	46.376	37.063	16.111	1.00	57.43	C
ATOM	6888	C	LEU	L	202	47.876	37.279	16.089	1.00	62.50	C
ATOM	6889	O	LEU	L	202	48.618	36.377	15.686	1.00	62.55	O
ATOM	6890	CB	LEU	L	202	45.999	36.208	17.343	1.00	57.78	C
ATOM	6891	CG	LEU	L	202	44.521	35.941	17.611	1.00	61.52	C
ATOM	6892	CD1	LEU	L	202	44.356	34.819	18.621	1.00	61.78	C
ATOM	6893	CD2	LEU	L	202	43.811	37.184	18.072	1.00	60.94	C
ATOM	6894	N	SER	L	203	48.306	38.471	16.575	1.00	60.60	N
ATOM	6895	CA	SER	L	203	49.695	38.960	16.672	1.00	61.89	C
ATOM	6896	C	SER	L	203	50.625	38.065	17.466	1.00	70.21	C
ATOM	6897	O	SER	L	203	51.813	37.935	17.126	1.00	71.14	O
ATOM	6898	CB	SER	L	203	49.746	40.375	17.234	1.00	65.21	C
ATOM	6899	OG	SER	L	203	48.744	40.591	18.212	1.00	77.85	O
ATOM	6900	N	SER	L	204	50.085	37.455	18.530	1.00	68.60	N
ATOM	6901	CA	SER	L	204	50.792	36.522	19.415	1.00	69.23	C
ATOM	6902	C	SER	L	204	49.734	35.634	20.114	1.00	73.37	C
ATOM	6903	O	SER	L	204	48.568	36.051	20.130	1.00	72.30	O
ATOM	6904	CB	SER	L	204	51.635	37.296	20.444	1.00	72.60	C
ATOM	6905	OG	SER	L	204	50.879	37.764	21.553	1.00	79.45	O
ATOM	6906	N	PRO	L	205	50.080	34.468	20.753	1.00	69.87	N
ATOM	6907	CA	PRO	L	205	49.038	33.695	21.467	1.00	69.21	C
ATOM	6908	C	PRO	L	205	48.295	34.542	22.492	1.00	73.08	C
ATOM	6909	O	PRO	L	205	48.921	35.281	23.257	1.00	73.09	O
ATOM	6910	CB	PRO	L	205	49.798	32.530	22.113	1.00	70.39	C
ATOM	6911	CG	PRO	L	205	51.226	32.887	22.016	1.00	74.78	C
ATOM	6912	CD	PRO	L	205	51.386	33.785	20.831	1.00	70.76	C
ATOM	6913	N	VAL	L	206	46.957	34.516	22.408	1.00	69.29	N
ATOM	6914	CA	VAL	L	206	46.039	35.257	23.264	1.00	69.12	C
ATOM	6915	C	VAL	L	206	45.644	34.349	24.433	1.00	75.87	C
ATOM	6916	O	VAL	L	206	45.257	33.198	24.216	1.00	76.61	O
ATOM	6917	CB	VAL	L	206	44.820	35.762	22.436	1.00	72.39	C
ATOM	6918	CG1	VAL	L	206	43.641	36.155	23.317	1.00	72.28	C
ATOM	6919	CG2	VAL	L	206	45.213	36.917	21.535	1.00	72.10	C
ATOM	6920	N	THR	L	207	45.784	34.860	25.668	1.00	72.53	N
ATOM	6921	CA	THR	L	207	45.426	34.143	26.888	1.00	71.57	C
ATOM	6922	C	THR	L	207	44.321	34.901	27.615	1.00	77.35	C
ATOM	6923	O	THR	L	207	44.395	36.117	27.836	1.00	78.07	O
ATOM	6924	CB	THR	L	207	46.656	33.864	27.755	1.00	71.78	C
ATOM	6925	OG1	THR	L	207	47.646	33.197	26.968	1.00	72.44	O
ATOM	6926	CG2	THR	L	207	46.334	33.032	28.987	1.00	67.86	C
ATOM	6927	N	LYS	L	208	43.276	34.169	27.944	1.00	73.65	N
ATOM	6928	CA	LYS	L	208	42.134	34.683	28.672	1.00	72.94	C
ATOM	6929	C	LYS	L	208	42.028	33.790	29.892	1.00	79.06	C
ATOM	6930	O	LYS	L	208	42.079	32.552	29.787	1.00	77.91	O
ATOM	6931	CB	LYS	L	208	40.859	34.722	27.806	1.00	72.93	C
ATOM	6932	CG	LYS	L	208	40.998	35.673	26.614	1.00	74.54	C
ATOM	6933	CD	LYS	L	208	39.909	36.710	26.593	1.00	83.24	C
ATOM	6934	CE	LYS	L	208	40.299	37.919	25.792	1.00	92.83	C
ATOM	6935	NZ	LYS	L	208	39.329	39.026	25.995	1.00	101.06	N
ATOM	6936	N	SER	L	209	42.039	34.434	31.064	1.00	77.32	N
ATOM	6937	CA	SER	L	209	42.032	33.708	32.317	1.00	77.31	C
ATOM	6938	C	SER	L	209	41.144	34.309	33.392	1.00	80.63	C
ATOM	6939	O	SER	L	209	40.551	35.377	33.229	1.00	79.17	O
ATOM	6940	CB	SER	L	209	43.460	33.533	32.830	1.00	81.70	C
ATOM	6941	OG	SER	L	209	43.857	34.513	33.775	1.00	95.27	O
ATOM	6942	N	PHE	L	210	41.071	33.586	34.506	1.00	79.14	N
ATOM	6943	CA	PHE	L	210	40.348	33.941	35.716	1.00	79.97	C
ATOM	6944	C	PHE	L	210	41.005	33.288	36.949	1.00	84.05	C
ATOM	6945	O	PHE	L	210	41.834	32.373	36.838	1.00	81.01	O
ATOM	6946	CB	PHE	L	210	38.829	33.612	35.614	1.00	82.01	C
ATOM	6947	CG	PHE	L	210	38.447	32.145	35.703	1.00	84.12	C
ATOM	6948	CD1	PHE	L	210	38.337	31.509	36.937	1.00	87.68	C
ATOM	6949	CD2	PHE	L	210	38.152	31.416	34.559	1.00	86.61	C
ATOM	6950	CE1	PHE	L	210	37.985	30.162	37.017	1.00	88.82	C
ATOM	6951	CE2	PHE	L	210	37.793	30.076	34.643	1.00	89.57	C
ATOM	6952	CZ	PHE	L	210	37.704	29.458	35.870	1.00	87.97	C
ATOM	6953	N	ASN	L	211	40.619	33.805	38.115	1.00	83.58	N
ATOM	6954	CA	ASN	L	211	40.987	33.364	39.448	1.00	84.77	C
ATOM	6955	C	ASN	L	211	39.637	33.266	40.144	1.00	92.29	C
ATOM	6956	O	ASN	L	211	38.712	33.998	39.770	1.00	92.16	O
ATOM	6957	CB	ASN	L	211	41.881	34.400	40.125	1.00	87.58	C
ATOM	6958	CG	ASN	L	211	43.122	34.753	39.327	1.00	121.75	C
ATOM	6959	OD1	ASN	L	211	44.135	34.041	39.342	1.00	117.29	O
ATOM	6960	ND2	ASN	L	211	43.061	35.857	38.596	1.00	114.95	N
ATOM	6961	N	ARG	L	212	39.500	32.355	41.119	1.00	91.14	N
ATOM	6962	CA	ARG	L	212	38.229	32.101	41.816	1.00	91.19	C
ATOM	6963	C	ARG	L	212	37.691	32.353	42.736	1.00	95.54	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	6964	O	ARG	L	212	37.631	33.105	43.954	1.00	95.00	O
ATOM	6965	CB	ARG	L	212	38.334	30.797	42.584	1.00	90.86	C
ATOM	6966	CG	ARG	L	212	38.161	29.595	41.676	1.00	98.37	C
ATOM	6967	CD	ARG	L	212	39.366	28.677	41.671	1.00	105.60	C
ATOM	6968	NE	ARG	L	212	39.908	28.394	43.007	1.00	110.08	N
ATOM	6969	CZ	ARG	L	212	39.338	27.611	43.920	1.00	114.15	C
ATOM	6970	NH1	ARG	L	212	38.151	27.065	43.687	1.00	100.69	N
ATOM	6971	NH2	ARG	L	212	39.926	27.413	45.092	1.00	91.15	N
ATOM	6972	N	GLY	L	213	37.213	34.333	42.113	1.00	92.58	N
ATOM	6973	CA	GLY	L	213	36.641	35.501	42.776	1.00	106.58	C
ATOM	6974	C	GLY	L	213	35.954	36.431	41.797	1.00	108.15	C
ATOM	6975	O	GLY	L	213	36.505	36.749	40.742	1.00	68.79	O
TER	6976		GLY	L	213						
ATOM	6977	N	GLU	M	1	20.740	-42.473	42.489	1.00	109.36	N
ATOM	6978	CA	GLU	M	1	20.894	-42.340	41.041	1.00	109.00	C
ATOM	6979	C	GLU	M	1	22.082	-41.418	40.663	1.00	110.75	C
ATOM	6980	O	GLU	M	1	22.995	-41.225	41.478	1.00	110.89	O
ATOM	6981	CB	GLU	M	1	19.562	-41.916	40.364	1.00	110.65	C
ATOM	6982	CG	GLU	M	1	18.878	-40.704	40.988	1.00	124.03	C
ATOM	6983	CD	GLU	M	1	18.721	-39.477	40.106	1.00	146.85	C
ATOM	6984	OE1	GLU	M	1	18.381	-39.639	38.911	1.00	130.26	O
ATOM	6985	OE2	GLU	M	1	18.897	-38.348	40.622	1.00	144.32	O
ATOM	6986	N	ILE	M	2	22.075	-40.890	39.418	1.00	104.17	N
ATOM	6987	CA	ILE	M	2	23.096	-40.011	38.833	1.00	102.39	C
ATOM	6988	C	ILE	M	2	22.924	-38.593	39.388	1.00	101.87	C
ATOM	6989	O	ILE	M	2	21.828	-38.036	39.306	1.00	101.66	O
ATOM	6990	CB	ILE	M	2	23.049	-40.023	37.271	1.00	105.84	C
ATOM	6991	CG1	ILE	M	2	22.426	-41.327	36.666	1.00	106.84	C
ATOM	6992	CG2	ILE	M	2	24.415	-39.748	36.686	1.00	105.75	C
ATOM	6993	CD1	ILE	M	2	20.802	-41.332	36.520	1.00	112.23	C
ATOM	6994	N	VAL	M	3	23.979	-38.019	39.992	1.00	94.99	N
ATOM	6995	CA	VAL	M	3	23.877	-36.670	40.569	1.00	93.13	C
ATOM	6996	C	VAL	M	3	24.926	-35.747	39.967	1.00	92.30	C
ATOM	6997	O	VAL	M	3	26.121	-36.038	40.031	1.00	92.23	O
ATOM	6998	CB	VAL	M	3	23.869	-36.648	42.127	1.00	96.75	C
ATOM	6999	CG1	VAL	M	3	23.683	-35.229	42.662	1.00	96.56	C
ATOM	7000	CG2	VAL	M	3	22.787	-37.567	42.690	1.00	96.39	C
ATOM	7001	N	LEU	M	4	24.465	-34.641	39.382	1.00	85.62	N
ATOM	7002	CA	LEU	M	4	25.331	-33.664	38.742	1.00	84.86	C
ATOM	7003	C	LEU	M	4	25.594	-32.477	39.653	1.00	87.43	C
ATOM	7004	O	LEU	M	4	24.681	-31.715	39.991	1.00	86.43	O
ATOM	7005	CB	LEU	M	4	24.788	-33.226	37.360	1.00	84.52	C
ATOM	7006	CG	LEU	M	4	24.569	-34.326	36.315	1.00	87.66	C
ATOM	7007	CD1	LEU	M	4	23.701	-33.832	35.212	1.00	87.30	C
ATOM	7008	CD2	LEU	M	4	25.873	-34.819	35.745	1.00	88.72	C
ATOM	7009	N	THR	M	5	26.859	-32.349	40.059	1.00	83.10	N
ATOM	7010	CA	THR	M	5	27.340	-31.305	40.949	1.00	81.92	C
ATOM	7011	C	THR	M	5	28.238	-30.375	40.162	1.00	83.23	C
ATOM	7012	O	THR	M	5	29.279	-30.802	39.668	1.00	82.46	O
ATOM	7013	CB	THR	M	5	27.950	-31.929	42.242	1.00	90.79	C
ATOM	7014	OG1	THR	M	5	28.160	-33.344	42.068	1.00	87.12	O
ATOM	7015	CG2	THR	M	5	27.038	-31.741	43.460	1.00	89.36	C
ATOM	7016	N	GLN	M	6	27.782	-29.130	39.965	1.00	79.61	N
ATOM	7017	CA	GLN	M	6	28.488	-28.077	39.222	1.00	79.93	C
ATOM	7018	C	GLN	M	6	29.291	-27.158	40.139	1.00	88.34	C
ATOM	7019	O	GLN	M	6	28.852	-26.842	41.237	1.00	89.23	O
ATOM	7020	CB	GLN	M	6	27.507	-27.208	38.428	1.00	80.47	C
ATOM	7021	CG	GLN	M	6	26.898	-27.886	37.222	1.00	73.52	C
ATOM	7022	CD	GLN	M	6	26.157	-26.885	36.386	1.00	85.55	C
ATOM	7023	OE1	GLN	M	6	24.924	-26.881	36.349	1.00	71.00	O
ATOM	7024	NE2	GLN	M	6	26.900	-26.001	35.703	1.00	82.93	N
ATOM	7025	N	SER	M	7	30.441	-26.683	39.666	1.00	86.67	N
ATOM	7026	CA	SER	M	7	31.301	-25.768	40.419	1.00	86.03	C
ATOM	7027	C	SER	M	7	31.875	-24.703	39.471	1.00	88.67	C
ATOM	7028	O	SER	M	7	32.178	-25.039	38.325	1.00	87.56	O
ATOM	7029	CB	SER	M	7	32.409	-26.532	41.138	1.00	89.10	C
ATOM	7030	OG	SER	M	7	33.219	-27.271	40.239	1.00	97.65	O
ATOM	7031	N	PRO	M	8	31.963	-23.407	39.848	1.00	84.59	N
ATOM	7032	CA	PRO	M	8	31.736	-22.823	41.183	1.00	83.77	C
ATOM	7033	C	PRO	M	8	30.297	-22.861	41.722	1.00	86.46	C
ATOM	7034	O	PRO	M	8	29.979	-23.612	42.641	1.00	86.52	O
ATOM	7035	CB	PRO	M	8	32.264	-21.379	41.032	1.00	85.25	C
ATOM	7036	CG	PRO	M	8	32.282	-21.095	39.562	1.00	89.48	C
ATOM	7037	CD	PRO	M	8	32.549	-22.417	38.914	1.00	85.51	C
ATOM	7038	N	GLY	M	9	29.467	-22.013	41.172	1.00	81.88	N
ATOM	7039	CA	GLY	M	9	28.107	-21.764	41.604	1.00	81.92	C
ATOM	7040	C	GLY	M	9	27.873	-20.336	41.188	1.00	86.70	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	7041 O	GLY M	9	26.759	-19.958	40.804	1.00	87.35 O
ATOM	7042 N	THR M	10	28.987	-19.550	41.235	1.00	81.97 N
ATOM	7043 CA	THR M	10	29.142	-18.172	40.765	1.00	80.78 C
ATOM	7044 C	THR M	10	30.556	-17.945	40.274	1.00	82.37 C
ATOM	7045 O	THR M	10	31.530	-18.253	40.963	1.00	81.25 O
ATOM	7046 CB	THR M	10	28.692	-17.101	41.751	1.00	84.97 C
ATOM	7047 OG1	THR M	10	27.620	-17.596	42.554	1.00	85.61 O
ATOM	7048 CG2	THR M	10	28.283	-15.803	41.036	1.00	80.10 C
ATOM	7049 N	LEU M	11	30.649	-17.396	39.078	1.00	78.41 N
ATOM	7050 CA	LEU M	11	31.906	-17.126	38.427	1.00	78.49 C
ATOM	7051 C	LEU M	11	31.871	-15.684	37.998	1.00	82.50 C
ATOM	7052 O	LEU M	11	31.060	-15.311	37.151	1.00	82.45 O
ATOM	7053 CB	LEU M	11	32.051	-18.065	37.221	1.00	78.77 C
ATOM	7054 CG	LEU M	11	33.402	-18.148	36.517	1.00	83.66 C
ATOM	7055 CD1	LEU M	11	34.494	-18.604	37.457	1.00	83.97 C
ATOM	7056 CD2	LEU M	11	33.331	-19.128	35.359	1.00	86.96 C
ATOM	7057 N	SER M	12	32.690	-14.857	38.658	1.00	78.46 N
ATOM	7058 CA	SER M	12	32.800	-13.428	38.382	1.00	77.03 C
ATOM	7059 C	SER M	12	34.056	-13.203	37.538	1.00	79.52 C
ATOM	7060 O	SER M	12	35.163	-13.492	37.979	1.00	78.87 O
ATOM	7061 CB	SER M	12	32.841	-12.626	39.682	1.00	76.93 C
ATOM	7062 OG	SER M	12	31.699	-12.921	40.468	1.00	74.57 O
ATOM	7063 N	LEU M	13	33.860	-12.809	36.288	1.00	76.26 N
ATOM	7064 CA	LEU M	13	34.912	-12.540	35.306	1.00	76.96 C
ATOM	7065 C	LEU M	13	34.506	-11.316	34.491	1.00	81.23 C
ATOM	7066 O	LEU M	13	33.327	-10.994	34.404	1.00	80.24 O
ATOM	7067 CB	LEU M	13	35.123	-13.736	34.351	1.00	77.35 C
ATOM	7068 CG	LEU M	13	35.281	-15.155	34.935	1.00	82.36 C
ATOM	7069 CD1	LEU M	13	35.102	-16.175	33.868	1.00	82.17 C
ATOM	7070 CD2	LEU M	13	36.642	-15.367	35.587	1.00	85.57 C
ATOM	7071 N	SER M	14	35.466	-10.635	33.901	1.00	80.06 N
ATOM	7072 CA	SER M	14	35.195	-9.433	33.110	1.00	81.06 C
ATOM	7073 C	SER M	14	34.999	-9.777	31.620	1.00	86.39 C
ATOM	7074 O	SER M	14	35.542	-10.790	31.171	1.00	86.28 O
ATOM	7075 CB	SER M	14	36.325	-8.413	33.297	1.00	85.12 C
ATOM	7076 OG	SER M	14	37.486	-8.974	33.888	1.00	94.25 O
ATOM	7077 N	PRO M	15	34.253	-8.964	30.824	1.00	83.07 N
ATOM	7078 CA	PRO M	15	34.113	-9.276	29.386	1.00	83.23 C
ATOM	7079 C	PRO M	15	35.468	-9.398	28.662	1.00	88.88 C
ATOM	7080 O	PRO M	15	36.391	-8.635	28.939	1.00	89.33 O
ATOM	7081 CB	PRO M	15	33.279	-8.103	28.853	1.00	84.83 C
ATOM	7082 CG	PRO M	15	32.551	-7.575	30.047	1.00	88.71 C
ATOM	7083 CD	PRO M	15	33.524	-7.724	31.172	1.00	84.26 C
ATOM	7084 N	GLY M	16	35.583	-10.383	27.780	1.00	85.84 N
ATOM	7085 CA	GLY M	16	36.804	-10.697	27.037	1.00	84.99 C
ATOM	7086 C	GLY M	16	37.590	-11.846	27.642	1.00	87.67 C
ATOM	7087 O	GLY M	16	38.390	-12.479	26.948	1.00	88.13 O
ATOM	7088 N	GLU M	17	37.347	-12.135	28.933	1.00	82.44 N
ATOM	7089 CA	GLU M	17	38.010	-13.193	29.694	1.00	81.88 C
ATOM	7090 C	GLU M	17	37.535	-14.604	29.354	1.00	85.81 C
ATOM	7091 O	GLU M	17	36.434	-14.793	28.828	1.00	86.69 O
ATOM	7092 CB	GLU M	17	37.814	-12.941	31.183	1.00	83.34 C
ATOM	7093 CG	GLU M	17	39.102	-12.767	31.963	1.00	94.74 C
ATOM	7094 CD	GLU M	17	38.880	-12.867	33.457	1.00	114.57 C
ATOM	7095 OE1	GLU M	17	38.532	-11.839	34.083	1.00	101.36 O
ATOM	7096 OE2	GLU M	17	39.055	-13.980	34.004	1.00	112.29 O
ATOM	7097 N	ARG M	18	38.368	-15.605	29.656	1.00	80.93 N
ATOM	7098 CA	ARG M	18	38.037	-17.010	29.429	1.00	78.92 C
ATOM	7099 C	ARG M	18	37.277	-17.586	30.621	1.00	80.23 C
ATOM	7100 O	ARG M	18	37.731	-17.475	31.763	1.00	79.01 O
ATOM	7101 CB	ARG M	18	39.298	-17.844	29.144	1.00	76.78 C
ATOM	7102 CG	ARG M	18	38.983	-19.069	28.314	1.00	87.41 C
ATOM	7103 CD	ARG M	18	40.215	-19.764	27.796	1.00	90.67 C
ATOM	7104 NE	ARG M	18	40.612	-20.835	28.705	1.00	95.47 N
ATOM	7105 CZ	ARG M	18	40.715	-22.114	28.360	1.00	102.41 C
ATOM	7106 NH1	ARG M	18	40.452	-22.496	27.115	1.00	85.39 N
ATOM	7107 NH2	ARG M	18	41.079	-23.024	29.260	1.00	81.19 N
ATOM	7108 N	ALA M	19	36.122	-18.218	30.348	1.00	75.55 N
ATOM	7109 CA	ALA M	19	35.290	-18.874	31.367	1.00	73.77 C
ATOM	7110 C	ALA M	19	35.384	-20.372	31.248	1.00	75.13 C
ATOM	7111 O	ALA M	19	35.306	-20.900	30.142	1.00	73.92 O
ATOM	7112 CB	ALA M	19	33.843	-18.438	31.237	1.00	74.13 C
ATOM	7113 N	THR M	20	35.570	-21.043	32.390	1.00	71.16 N
ATOM	7114 CA	THR M	20	35.669	-22.494	32.534	1.00	71.02 C
ATOM	7115 C	THR M	20	34.705	-22.906	33.647	1.00	76.77 C
ATOM	7116 O	THR M	20	34.902	-22.528	34.809	1.00	75.13 O
ATOM	7117 CB	THR M	20	37.132	-22.911	32.780	1.00	75.37 C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	7118 OG1	THR	M	20	37.850	-22.813	31.551	1.00	80.96	O
ATOM	7119 CG2	THR	M	20	37.271	-24.330	33.334	1.00	69.67	C
ATOM	7120 N	LEU	M	21	33.634	-23.640	33.262	1.00	75.20	N
ATOM	7121 CA	LEU	M	21	32.557	-24.138	34.135	1.00	74.83	C
ATOM	7122 C	LEU	M	21	32.681	-25.641	34.233	1.00	80.69	C
ATOM	7123 O	LEU	M	21	32.894	-26.292	33.218	1.00	79.75	O
ATOM	7124 CB	LEU	M	21	31.185	-23.804	33.532	1.00	74.33	C
ATOM	7125 CG	LEU	M	21	30.684	-22.369	33.601	1.00	78.00	C
ATOM	7126 CD1	LEU	M	21	31.184	-21.528	32.423	1.00	77.70	C
ATOM	7127 CD2	LEU	M	21	29.221	-22.364	33.517	1.00	80.33	C
ATOM	7128 N	SER	M	22	32.538	-26.191	35.439	1.00	80.99	N
ATOM	7129 CA	SER	M	22	32.667	-27.623	35.717	1.00	82.67	C
ATOM	7130 C	SER	M	22	31.338	-28.302	36.025	1.00	87.87	C
ATOM	7131 O	SER	M	22	30.410	-27.663	36.527	1.00	88.94	O
ATOM	7132 CB	SER	M	22	33.648	-27.856	36.868	1.00	89.27	C
ATOM	7133 OG	SER	M	22	33.588	-29.174	37.401	1.00	102.72	O
ATOM	7134 N	CYS	M	23	31.280	-29.613	35.735	1.00	83.37	N
ATOM	7135 CA	CYS	M	23	30.162	-30.518	35.950	1.00	82.62	C
ATOM	7136 C	CYS	M	23	30.785	-31.848	36.327	1.00	87.91	C
ATOM	7137 O	CYS	M	23	31.514	-32.439	35.527	1.00	87.54	O
ATOM	7138 CB	CYS	M	23	29.308	-30.634	34.687	1.00	82.16	C
ATOM	7139 SG	CYS	M	23	27.815	-31.662	34.863	1.00	85.53	S
ATOM	7140 N	ARG	M	24	30.571	-32.268	37.573	1.00	85.90	N
ATOM	7141 CA	ARG	M	24	31.072	-33.541	38.065	1.00	86.95	C
ATOM	7142 C	ARG	M	24	29.880	-34.451	38.363	1.00	91.30	C
ATOM	7143 O	ARG	M	24	28.900	-34.018	38.978	1.00	91.04	O
ATOM	7144 CB	ARG	M	24	32.003	-33.369	39.287	1.00	90.73	C
ATOM	7145 CG	ARG	M	24	32.861	-34.612	39.563	1.00	108.13	C
ATOM	7146 CD	ARG	M	24	33.897	-34.399	40.647	1.00	125.63	C
ATOM	7147 NE	ARG	M	24	35.236	-34.156	40.104	1.00	139.68	N
ATOM	7148 CZ	ARG	M	24	36.340	-34.053	40.841	1.00	159.27	C
ATOM	7149 NH1	ARG	M	24	36.281	-34.186	42.162	1.00	149.63	N
ATOM	7150 NH2	ARG	M	24	37.514	-33.830	40.262	1.00	146.24	N
ATOM	7151 N	ALA	M	25	29.948	-35.688	37.871	1.00	87.65	N
ATOM	7152 CA	ALA	M	25	28.905	-36.686	38.036	1.00	87.67	C
ATOM	7153 C	ALA	M	25	29.232	-37.618	39.186	1.00	93.12	C
ATOM	7154 O	ALA	M	25	30.407	-37.929	39.416	1.00	93.27	O
ATOM	7155 CB	ALA	M	25	28.741	-37.472	36.746	1.00	88.44	C
ATOM	7156 N	SER	M	26	28.180	-38.076	39.895	1.00	90.49	N
ATOM	7157 CA	SER	M	26	28.241	-38.985	41.044	1.00	90.94	C
ATOM	7158 C	SER	M	26	28.793	-40.370	40.665	1.00	96.44	C
ATOM	7159 O	SER	M	26	29.290	-41.097	41.528	1.00	97.79	O
ATOM	7160 CB	SER	M	26	26.859	-39.122	41.680	1.00	94.58	C
ATOM	7161 OG	SER	M	26	25.973	-39.820	40.823	1.00	105.57	O
ATOM	7162 N	GLN	M	27	28.683	-40.726	39.379	1.00	92.34	N
ATOM	7163 CA	GLN	M	27	29.154	-41.977	38.785	1.00	92.48	C
ATOM	7164 C	GLN	M	27	29.487	-41.729	37.315	1.00	96.55	C
ATOM	7165 O	GLN	M	27	29.010	-40.749	36.747	1.00	96.64	O
ATOM	7166 CB	GLN	M	27	28.104	-43.100	38.933	1.00	93.91	C
ATOM	7167 CG	GLN	M	27	26.775	-42.841	38.222	1.00	105.35	C
ATOM	7168 CD	GLN	M	27	25.645	-43.622	38.834	1.00	117.21	C
ATOM	7169 OE1	GLN	M	27	25.306	-44.710	38.378	1.00	108.04	O
ATOM	7170 NE2	GLN	M	27	25.036	-43.079	39.880	1.00	111.22	N
ATOM	7171 N	SER	M	28	30.305	-42.605	36.702	1.00	92.47	N
ATOM	7172 CA	SER	M	28	30.691	-42.520	35.285	1.00	91.75	C
ATOM	7173 C	SER	M	28	29.432	-42.507	34.384	1.00	93.80	C
ATOM	7174 O	SER	M	28	28.473	-43.244	34.656	1.00	92.75	O
ATOM	7175 CB	SER	M	28	31.626	-43.668	34.916	1.00	95.68	C
ATOM	7176 OG	SER	M	28	32.129	-43.505	33.600	1.00	104.65	O
ATOM	7177 N	VAL	M	29	29.431	-41.640	33.336	1.00	88.62	N
ATOM	7178 CA	VAL	M	29	28.316	-41.348	32.413	1.00	87.06	C
ATOM	7179 C	VAL	M	29	28.757	-41.371	30.939	1.00	89.62	C
ATOM	7180 O	VAL	M	29	29.913	-41.040	30.657	1.00	91.46	O
ATOM	7181 CB	VAL	M	29	27.770	-39.946	32.825	1.00	90.78	C
ATOM	7182 CG1	VAL	M	29	27.088	-39.189	31.687	1.00	90.47	C
ATOM	7183 CG2	VAL	M	29	26.854	-40.057	34.028	1.00	90.85	C
ATOM	7184 N	SER	M	30	27.840	-41.723	29.996	1.00	82.54	N
ATOM	7185 CA	SER	M	30	28.143	-41.671	28.558	1.00	81.04	C
ATOM	7186 C	SER	M	30	28.281	-40.209	28.120	1.00	84.28	C
ATOM	7187 O	SER	M	30	27.524	-39.344	28.578	1.00	84.52	O
ATOM	7188 CB	SER	M	30	27.065	-42.357	27.730	1.00	83.64	C
ATOM	7189 OG	SER	M	30	27.444	-42.384	26.362	1.00	92.12	O
ATOM	7190 N	SER	M	31	29.264	-39.931	27.248	1.00	79.14	N
ATOM	7191 CA	SER	M	31	29.500	-38.583	26.737	1.00	77.74	C
ATOM	7192 C	SER	M	31	28.386	-38.183	25.803	1.00	77.68	C
ATOM	7193 O	SER	M	31	28.145	-36.996	25.638	1.00	76.29	O
ATOM	7194 CB	SER	M	31	30.842	-38.504	26.025	1.00	82.29	C

TABLE 1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody beziotuxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	7195	OG	SER	M	31	31.888	-38.523	26.981	1.00	93.98	O
ATOM	7196	N	SER	M	32	27.669	-39.179	25.243	1.00	72.18	N
ATOM	7197	CA	SER	M	32	26.556	-39.007	24.313	1.00	70.62	C
ATOM	7198	C	SER	M	32	25.391	-38.279	24.976	1.00	74.12	C
ATOM	7199	O	SER	M	32	24.716	-37.458	24.345	1.00	74.35	O
ATOM	7200	CB	SER	M	32	26.092	-40.365	23.817	1.00	71.76	C
ATOM	7201	OG	SER	M	32	27.183	-41.134	23.340	1.00	82.23	O
ATOM	7202	N	TYR	M	33	25.172	-38.583	26.261	1.00	68.78	N
ATOM	7203	CA	TYR	M	33	24.057	-38.086	27.042	1.00	67.33	C
ATOM	7204	C	TYR	M	33	24.363	-36.821	27.836	1.00	72.06	C
ATOM	7205	O	TYR	M	33	23.474	-36.329	28.539	1.00	74.01	O
ATOM	7206	CB	TYR	M	33	23.508	-39.216	27.932	1.00	66.94	C
ATOM	7207	CG	TYR	M	33	22.923	-40.346	27.106	1.00	65.96	C
ATOM	7208	CD1	TYR	M	33	21.877	-40.117	26.215	1.00	67.44	C
ATOM	7209	CD2	TYR	M	33	23.452	-41.629	27.169	1.00	66.30	C
ATOM	7210	CE1	TYR	M	33	21.359	-41.141	25.418	1.00	66.28	C
ATOM	7211	CE2	TYR	M	33	22.928	-42.667	26.389	1.00	67.39	C
ATOM	7212	CZ	TYR	M	33	21.884	-42.414	25.508	1.00	70.35	C
ATOM	7213	OH	TYR	M	33	21.386	-43.403	24.696	1.00	67.62	O
ATOM	7214	N	LEU	M	34	25.569	-36.242	27.665	1.00	66.30	N
ATOM	7215	CA	LEU	M	34	25.909	-34.993	28.341	1.00	64.95	C
ATOM	7216	C	LEU	M	34	25.600	-33.755	27.518	1.00	67.28	C
ATOM	7217	O	LEU	M	34	26.126	-33.592	26.413	1.00	67.41	O
ATOM	7218	CB	LEU	M	34	27.343	-34.922	28.877	1.00	64.67	C
ATOM	7219	CG	LEU	M	34	27.445	-33.857	29.982	1.00	69.67	C
ATOM	7220	CD1	LEU	M	34	27.533	-34.465	31.363	1.00	70.32	C
ATOM	7221	CD2	LEU	M	34	28.417	-32.760	29.655	1.00	70.92	C
ATOM	7222	N	ALA	M	35	24.794	-32.850	28.104	1.00	62.26	N
ATOM	7223	CA	ALA	M	35	24.406	-31.586	27.493	1.00	61.37	C
ATOM	7224	C	ALA	M	35	24.572	-30.371	28.420	1.00	63.32	C
ATOM	7225	O	ALA	M	35	24.545	-30.506	29.636	1.00	59.47	O
ATOM	7226	CB	ALA	M	35	22.975	-31.671	26.986	1.00	62.09	C
ATOM	7227	N	TRP	M	36	24.738	-29.184	27.820	1.00	62.83	N
ATOM	7228	CA	TRP	M	36	24.858	-27.918	28.532	1.00	63.95	C
ATOM	7229	C	TRP	M	36	23.815	-26.964	27.992	1.00	66.63	C
ATOM	7230	O	TRP	M	36	23.664	-26.840	26.772	1.00	66.49	O
ATOM	7231	CB	TRP	M	36	26.257	-27.286	28.352	1.00	63.84	C
ATOM	7232	CG	TRP	M	36	27.366	-27.990	29.077	1.00	65.37	C
ATOM	7233	CD1	TRP	M	36	28.124	-29.030	28.617	1.00	68.23	C
ATOM	7234	CD2	TRP	M	36	27.873	-27.669	30.373	1.00	65.65	C
ATOM	7235	NE1	TRP	M	36	29.059	-29.390	29.560	1.00	67.59	N
ATOM	7236	CE2	TRP	M	36	28.917	-28.579	30.655	1.00	69.44	C
ATOM	7237	CE3	TRP	M	36	27.548	-26.697	31.331	1.00	67.29	C
ATOM	7238	CZ2	TRP	M	36	29.632	-28.546	31.854	1.00	69.05	C
ATOM	7239	CZ3	TRP	M	36	28.264	-26.666	32.521	1.00	68.79	C
ATOM	7240	CH2	TRP	M	36	29.284	-27.586	32.775	1.00	69.23	C
ATOM	7241	N	TYR	M	37	23.111	-26.276	28.909	1.00	60.69	N
ATOM	7242	CA	TYR	M	37	22.075	-25.287	28.605.	1.00	58.76	C
ATOM	7243	C	TYR	M	37	22.449	-23.955	29.180	1.00	61.41	C
ATOM	7244	O	TYR	M	37	23.062	-23.900	30.242	1.00	60.35	O
ATOM	7245	CB	TYR	M	37	20.709	-25.702	29.195	1.00	59.06	C
ATOM	7246	CG	TYR	M	37	20.238	-27.059	28.719	1.00	58.30	C
ATOM	7247	CD2	TYR	M	37	19.422	-27.183	27.592	1.00	57.96	C
ATOM	7248	CD1	TYR	M	37	20.657	-28.224	29.353	1.00	59.41	C
ATOM	7249	CE2	TYR	M	37	19.033	-28.433	27.120	1.00	58.14	C
ATOM	7250	CE1	TYR	M	37	20.304	-29.477	28.870	1.00	59.20	C
ATOM	7251	CZ	TYR	M	37	19.496	-29.578	27.753	1.00	62.82	C
ATOM	7252	OH	TYR	M	37	19.139	-30.822	27.323	1.00	60.93	O
ATOM	7253	N	GLN	M	38	22.046	-22.882	28.496	1.00	58.94	N
ATOM	7254	CA	GLN	M	38	22.215	-21.498	28.924	1.00	59.80	C
ATOM	7255	C	GLN	M	38	20.827	-20.924	29.230	1.00	65.13	C
ATOM	7256	O	GLN	M	38	19.893	-21.131	28.457	1.00	65.70	O
ATOM	7257	CB	GLN	M	38	22.885	-20.658	27.816	1.00	61.01	C
ATOM	7258	CG	GLN	M	38	23.111	-19.180	28.215	1.00	67.64	C
ATOM	7259	CD	GLN	M	38	23.550	-18.316	27.063	1.00	81.27	C
ATOM	7260	OE1	GLN	M	38	22.874	-18.197	26.040	1.00	71.43	O
ATOM	7261	NE2	GLN	M	38	24.696	-17.676	27.202	1.00	79.70	N
ATOM	7262	N	GLN	M	39	20.699	-20.177	30.315	1.00	62.04	N
ATOM	7263	CA	GLN	M	39	19.432	-19.548	30.640	1.00	62.53	C
ATOM	7264	C	GLN	M	39	19.651	-18.102	31.015	1.00	69.37	C
ATOM	7265	O	GLN	M	39	20.153	-17.829	32.108	1.00	68.00	O
ATOM	7266	CB	GLN	M	39	18.715	-20.312	31.759	1.00	63.51	C
ATOM	7267	CG	GLN	M	39	17.304	-19.797	31.997	1.00	71.07	C
ATOM	7268	CD	GLN	M	39	16.590	-20.538	33.082	1.00	81.21	C
ATOM	7269	OE1	GLN	M	39	17.176	-20.945	34.083	1.00	81.20	O
ATOM	7270	NE2	GLN	M	39	15.301	-20.691	32.931	1.00	66.53	N
ATOM	7271	N	LYS	M	40	19.283	-17.167	30.118	1.00	69.29	N

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	7272	CA	LYS	M	40	19.391	-15.727	30.416	1.00	70.48	C
ATOM	7273	C	LYS	M	40	18.316	-15.373	31.466	1.00	80.16	C
ATOM	7274	O	LYS	M	40	17.333	-16.102	31.558	1.00	79.45	O
ATOM	7275	CB	LYS	M	40	19.245	-14.875	29.151	1.00	71.41	C
ATOM	7276	N	PRO	M	41	18.464	-14.334	32.315	1.00	81.41	N
ATOM	7277	CA	PRO	M	41	17.404	-14.074	33.327	1.00	81.36	C
ATOM	7278	C	PRO	M	41	16.034	-13.764	32.721	1.00	85.30	C
ATOM	7279	O	PRO	M	41	15.933	-13.013	31.743	1.00	86.00	O
ATOM	7280	CB	PRO	M	41	17.951	-12.902	34.144	1.00	83.24	C
ATOM	7281	CG	PRO	M	41	19.424	-12.833	33.805	1.00	88.66	C
ATOM	7282	CD	PRO	M	41	19.563	-13.345	32.405	1.00	84.09	C
ATOM	7283	N	GLY	M	42	15.004	-14.405	33.271	1.00	80.78	N
ATOM	7284	CA	GLY	M	42	13.616	-14.258	32.825	1.00	79.73	C
ATOM	7285	C	GLY	M	42	13.315	-14.797	31.433	1.00	80.94	C
ATOM	7286	O	GLY	M	42	12.350	-14.366	30.791	1.00	80.00	O
ATOM	7287	N	GLN	M	43	14.152	-15.744	30.953	1.00	74.70	N
ATOM	7288	CA	GLN	M	43	14.050	-16.366	29.642	1.00	72.84	C
ATOM	7289	C	GLN	M	43	14.106	-17.884	29.775	1.00	73.41	C
ATOM	7290	O	GLN	M	43	14.475	-18.402	30.842	1.00	71.73	O
ATOM	7291	CB	GLN	M	43	15.177	-15.862	28.726	1.00	74.66	C
ATOM	7292	CG	GLN	M	43	15.061	-14.377	28.371	1.00	94.33	C
ATOM	7293	CD	GLN	M	43	15.837	-14.035	27.134	1.00	112.28	C
ATOM	7294	OE1	GLN	M	43	15.523	-14.487	26.024	1.00	105.82	O
ATOM	7295	NE2	GLN	M	43	16.858	-13.208	27.298	1.00	106.17	N
ATOM	7296	N	ALA	M	44	13.718	-18.597	28.699	1.00	67.78	N
ATOM	7297	CA	ALA	M	44	13.729	-20.058	28.677	1.00	66.34	C
ATOM	7298	C	ALA	M	44	15.157	-20.602	28.496	1.00	67.41	C
ATOM	7299	O	ALA	M	44	15.981	-19.931	27.842	1.00	68.14	O
ATOM	7300	CB	ALA	M	44	12.846	-20.561	27.542	1.00	66.87	C
ATOM	7301	N	PRO	M	45	15.464	-21.828	29.003	1.00	60.38	N
ATOM	7302	CA	PRO	M	45	16.788	-22.408	28.727	1.00	60.40	C
ATOM	7303	C	PRO	M	45	16.963	-22.671	27.225	1.00	66.02	C
ATOM	7304	O	PRO	M	45	15.979	-22.804	26.496	1.00	66.24	O
ATOM	7305	CB	PRO	M	45	16.760	-23.740	29.496	1.00	61.47	C
ATOM	7306	CG	PRO	M	45	15.613	-23.644	30.457	1.00	63.87	C
ATOM	7307	CD	PRO	M	45	14.626	-22.772	29.775	1.00	59.92	C
ATOM	7308	N	ARG	M	46	18.210	-22.704	26.757	1.00	63.55	N
ATOM	7309	CA	ARG	M	46	18.527	-23.038	25.370	1.00	63.30	C
ATOM	7310	C	ARG	M	46	19.717	-23.975	25.340	1.00	69.04	C
ATOM	7311	O	ARG	M	46	20.611	-23.844	26.175	1.00	68.87	O
ATOM	7312	CB	ARG	M	46	18.703	-21.813	24.453	1.00	61.48	C
ATOM	7313	CG	ARG	M	46	19.934	-20.978	24.678	1.00	66.93	C
ATOM	7314	CD	ARG	M	46	20.127	-19.978	23.558	1.00	88.00	C
ATOM	7315	NE	ARG	M	46	21.432	-19.312	23.674	1.00	113.15	N
ATOM	7316	CZ	ARG	M	46	22.121	-18.792	22.658	1.00	127.37	C
ATOM	7317	NH1	ARG	M	46	21.639	-18.844	21.422	1.00	119.94	N
ATOM	7318	NH2	ARG	M	46	23.307	-18.231	22.870	1.00	104.31	N
ATOM	7319	N	LEU	M	47	19.700	-24.957	24.426	1.00	66.83	N
ATOM	7320	CA	LEU	M	47	20.792	-25.922	24.290	1.00	65.69	C
ATOM	7321	C	LEU	M	47	21.985	-25.221	23.670	1.00	68.82	C
ATOM	7322	O	LEU	M	47	21.826	-24.437	22.722	1.00	67.73	O
ATOM	7323	CB	LEU	M	47	20.368	-27.144	23.434	1.00	64.63	C
ATOM	7324	CG	LEU	M	47	21.343	-28.316	23.330	1.00	67.32	C
ATOM	7325	CD1	LEU	M	47	21.457	-29.051	24.608	1.00	66.65	C
ATOM	7326	CD2	LEU	M	47	20.917	-29.279	22.281	1.00	69.38	C
ATOM	7327	N	LEU	M	48	23.173	-25.476	24.262	1.00	65.41	N
ATOM	7328	CA	LEU	M	48	24.474	-24.996	23.789	1.00	64.24	C
ATOM	7329	C	LEU	M	48	25.269	-26.180	23.229	1.00	66.69	C
ATOM	7330	O	LEU	M	48	25.742	-26.112	22.104	1.00	66.83	O
ATOM	7331	CB	LEU	M	48	25.307	-24.361	24.919	1.00	63.52	C
ATOM	7332	CG	LEU	M	48	24.856	-23.079	25.550	1.00	67.40	C
ATOM	7333	CD1	LEU	M	48	25.853	-22.665	26.570	1.00	67.89	C
ATOM	7334	CD2	LEU	M	48	24.640	-21.970	24.520	1.00	67.64	C
ATOM	7335	N	ILE	M	49	25.457	-27.234	24.045	1.00	62.19	N
ATOM	7336	CA	ILE	M	49	26.294	-28.379	23.715	1.00	62.09	C
ATOM	7337	C	ILE	M	49	25.569	-29.680	23.952	1.00	64.66	C
ATOM	7338	O	ILE	M	49	25.011	-29.851	25.022	1.00	64.62	O
ATOM	7339	CB	ILE	M	49	27.587	-28.307	24.600	1.00	65.60	C
ATOM	7340	CG1	ILE	M	49	28.419	-27.019	24.352	1.00	66.16	C
ATOM	7341	CG2	ILE	M	49	28.457	-29.557	24.488	1.00	66.81	C
ATOM	7342	CD1	ILE	M	49	29.009	-26.809	22.916	1.00	78.14	C
ATOM	7343	N	TYR	M	50	25.595	-30.594	22.982	1.00	60.35	N
ATOM	7344	CA	TYR	M	50	25.025	-31.930	23.121	1.00	61.08	C
ATOM	7345	C	TYR	M	50	26.135	-32.954	22.891	1.00	68.46	C
ATOM	7346	O	TYR	M	50	27.111	-32.645	22.212	1.00	68.72	O
ATOM	7347	CB	TYR	M	50	23.861	-32.173	22.144	1.00	62.02	C
ATOM	7348	CG	TYR	M	50	24.236	-32.136	20.680	1.00	63.07	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	7349	CD2	TYR	M	50	24.495	-33.312	19.973	1.00	63.14	C
ATOM	7350	CD1	TYR	M	50	24.231	-30.937	19.972	1.00	65.35	C
ATOM	7351	CE2	TYR	M	50	24.797	-33.285	18.611	1.00	64.05	C
ATOM	7352	CE1	TYR	M	50	24.550	-30.896	18.615	1.00	66.04	C
ATOM	7353	CZ	TYR	M	50	24.837	-32.071	17.939	1.00	71.13	C
ATOM	7354	OH	TYR	M	50	25.156	-32.016	16.608	1.00	71.44	O
ATOM	7355	N	GLY	M	51	25.998	-34.150	23.450	1.00	66.09	N
ATOM	7356	CA	GLY	M	51	26.990	-35.204	23.260	1.00	66.23	C
ATOM	7357	C	GLY	M	51	28.375	-34.847	23.753	1.00	72.07	C
ATOM	7358	O	GLY	M	51	29.378	-35.301	23.186	1.00	74.10	O
ATOM	7359	N	ALA	M	52	28.414	-34.029	24.835	1.00	66.83	N
ATOM	7360	CA	ALA	M	52	29.562	-33.518	25.599	1.00	65.45	C
ATOM	7361	C	ALA	M	52	30.403	-32.476	24.889	1.00	68.60	C
ATOM	7362	O	ALA	M	52	30.818	-31.533	25.550	1.00	68.68	O
ATOM	7363	CB	ALA	M	52	30.447	-34.647	26.101	1.00	65.65	C
ATOM	7364	N	SER	M	53	30.642	-32.618	23.569	1.00	64.94	N
ATOM	7365	CA	SER	M	53	31.508	-31.728	22.777	1.00	64.13	C
ATOM	7366	C	SER	M	53	30.864	-31.058	21.558	1.00	68.66	C
ATOM	7367	O	SER	M	53	31.438	-30.089	21.039	1.00	68.95	O
ATOM	7368	CB	SER	M	53	32.735	-32.496	22.310	1.00	65.66	C
ATOM	7369	OG	SER	M	53	32.358	-33.470	21.352	1.00	73.06	O
ATOM	7370	N	SER	M	54	29.723	-31.601	21.067	1.00	63.93	N
ATOM	7371	CA	SER	M	54	29.054	-31.101	19.873	1.00	62.92	C
ATOM	7372	C	SER	M	54	28.269	-29.882	20.204	1.00	66.55	C
ATOM	7373	O	SER	M	54	27.649	-29.798	21.252	1.00	65.89	O
ATOM	7374	CB	SER	M	54	28.177	-32.165	19.224	1.00	68.35	C
ATOM	7375	OG	SER	M	54	28.833	-33.418	19.075	1.00	82.57	O
ATOM	7376	N	ARG	M	55	28.333	-28.915	19.324	1.00	64.56	N
ATOM	7377	CA	ARG	M	55	27.726	-27.617	19.487	1.00	64.93	C
ATOM	7378	C	ARG	M	55	26.354	-27.598	18.822	1.00	70.90	C
ATOM	7379	O	ARG	M	55	26.241	-27.952	17.644	1.00	70.44	O
ATOM	7380	CB	ARG	M	55	28.680	-26.606	18.836	1.00	67.13	C
ATOM	7381	CG	ARG	M	55	28.663	-25.200	19.396	1.00	82.33	C
ATOM	7382	CD	ARG	M	55	30.041	-24.553	19.425	1.00	88.94	C
ATOM	7383	NE	ARG	M	55	30.782	-24.688	18.170	1.00	92.83	N
ATOM	7384	CZ	ARG	M	55	32.090	-24.920	18.087	1.00	99.82	C
ATOM	7385	NH1	ARG	M	55	32.828	-25.034	19.191	1.00	64.11	N
ATOM	7386	NH2	ARG	M	55	32.671	-25.047	16.903	1.00	97.18	N
ATOM	7387	N	ALA	M	56	25.305	-27.190	19.579	1.00	69.63	N
ATOM	7388	CA	ALA	M	56	23.921	-27.068	19.085	1.00	69.91	C
ATOM	7389	C	ALA	M	56	23.833	-26.026	17.960	1.00	74.64	C
ATOM	7390	O	ALA	M	56	24.743	-25.210	17.818	1.00	74.16	O
ATOM	7391	CB	ALA	M	56	22.986	-26.700	20.221	1.00	70.53	C
ATOM	7392	N	THR	M	57	22.772	-26.078	17.139	1.00	72.67	N
ATOM	7393	CA	THR	M	57	22.611	-25.182	15.987	1.00	73.42	C
ATOM	7394	C	THR	M	57	22.650	-23.688	16.372	1.00	77.88	C
ATOM	7395	O	THR	M	57	21.976	-23.272	17.320	1.00	76.09	O
ATOM	7396	CB	THR	M	57	21.354	-25.533	15.162	1.00	85.42	C
ATOM	7397	OG1	THR	M	57	21.072	-26.929	15.232	1.00	85.01	O
ATOM	7398	CG2	THR	M	57	21.495	-25.128	13.707	1.00	87.10	C
ATOM	7399	N	GLY	M	58	23.455	-22.922	15.635	1.00	75.65	N
ATOM	7400	CA	GLY	M	58	23.606	-21.481	15.829	1.00	76.07	C
ATOM	7401	C	GLY	M	58	24.333	-21.066	17.098	1.00	79.99	C
ATOM	7402	O	GLY	M	58	24.191	-19.928	17.565	1.00	79.15	O
ATOM	7403	N	ILE	M	59	25.135	-21.971	17.659	1.00	75.67	N
ATOM	7404	CA	ILE	M	59	25.881	-21.658	18.864	1.00	74.60	C
ATOM	7405	C	ILE	M	59	27.306	-21.219	18.486	1.00	80.18	C
ATOM	7406	O	ILE	M	59	28.073	-22.015	17.917	1.00	80.89	O
ATOM	7407	CB	ILE	M	59	25.811	-22.792	19.942	1.00	76.66	C
ATOM	7408	CG1	ILE	M	59	24.359	-23.070	20.414	1.00	77.27	C
ATOM	7409	CG2	ILE	M	59	26.735	-22.546	21.124	1.00	75.40	C
ATOM	7410	CD1	ILE	M	59	23.491	-21.867	20.865	1.00	83.72	C
ATOM	7411	N	PRO	M	60	27.647	-19.944	18.820	1.00	75.11	N
ATOM	7412	CA	PRO	M	60	29.003	-19.412	18.570	1.00	74.06	C
ATOM	7413	C	PRO	M	60	30.178	-20.318	18.935	1.00	79.41	C
ATOM	7414	O	PRO	M	60	30.122	-21.040	19.939	1.00	78.74	O
ATOM	7415	CB	PRO	M	60	29.038	-18.177	19.453	1.00	75.24	C
ATOM	7416	CG	PRO	M	60	27.658	-17.723	19.516	1.00	79.74	C
ATOM	7417	CD	PRO	M	60	26.796	-18.937	19.484	1.00	75.90	C
ATOM	7418	N	ASP	M	61	31.272	-20.222	18.142	1.00	77.58	N
ATOM	7419	CA	ASP	M	61	32.505	-21.011	18.313	1.00	78.06	C
ATOM	7420	C	ASP	M	61	33.205	-20.792	19.662	1.00	78.50	C
ATOM	7421	O	ASP	M	61	34.031	-21.630	20.051	1.00	78.43	O
ATOM	7422	CB	ASP	M	61	33.501	-20.766	17.163	1.00	81.37	C
ATOM	7423	CG	ASP	M	61	32.893	-20.787	15.777	1.00	105.70	C
ATOM	7424	OD1	ASP	M	61	32.153	-19.827	15.438	1.00	108.63	O
ATOM	7425	OD2	ASP	M	61	33.183	-21.745	15.011	1.00	115.01	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	7426	N	ARG	M	62	32.902	-19.674	20.368	1.00	71.40	N
ATOM	7427	CA	ARG	M	62	33.510	-19.403	21.678	1.00	70.23	C
ATOM	7428	C	ARG	M	62	33.081	-20.443	22.724	1.00	73.27	C
ATOM	7429	O	ARG	M	62	33.832	-20.757	23.660	1.00	72.55	O
ATOM	7430	CB	ARG	M	62	33.285	-17.965	22.140	1.00	68.39	C
ATOM	7431	CG	ARG	M	62	31.837	-17.555	22.329	1.00	73.40	C
ATOM	7432	CD	ARG	M	62	31.787	-16.068	22.516	1.00	72.20	C
ATOM	7433	NE	ARG	M	62	30.453	-15.592	22.853	1.00	77.05	N
ATOM	7434	CZ	ARG	M	62	29.561	-15.168	21.964	1.00	85.17	C
ATOM	7435	NH1	ARG	M	62	29.849	-15.171	20.671	1.00	58.18	N
ATOM	7436	NH2	ARG	M	62	28.372	-14.740	22.363	1.00	79.51	N
ATOM	7437	N	PHE	M	63	31.894	-21.033	22.499	1.00	69.13	N
ATOM	7438	CA	PHE	M	63	31.357	-22.104	23.324	1.00	67.88	C
ATOM	7439	C	PHE	M	63	31.983	-23.433	22.873	1.00	70.49	C
ATOM	7440	O	PHE	M	63	31.870	-23.819	21.706	1.00	70.37	O
ATOM	7441	CB	PHE	M	63	29.813	-22.129	23.265	1.00	69.11	C
ATOM	7442	CG	PHE	M	63	29.136	-20.946	23.916	1.00	69.80	C
ATOM	7443	CD1	PHE	M	63	29.073	-20.835	25.304	1.00	72.17	C
ATOM	7444	CD2	PHE	M	63	28.534	-19.959	23.145	1.00	71.35	C
ATOM	7445	CE1	PHE	M	63	28.437	-19.743	25.907	1.00	73.18	C
ATOM	7446	CE2	PHE	M	63	27.891	-18.869	23.749	1.00	74.57	C
ATOM	7447	CZ	PHE	M	63	27.842	-18.771	25.123	1.00	72.57	C
ATOM	7448	N	SER	M	64	32.682	-24.100	23.798	1.00	65.48	N
ATOM	7449	CA	SER	M	64	33.350	-25.374	23.577	1.00	64.30	C
ATOM	7450	C	SER	M	64	33.031	-26.306	24.760	1.00	65.76	C
ATOM	7451	O	SER	M	64	32.982	-25.856	25.911	1.00	64.40	O
ATOM	7452	CB	SER	M	64	34.853	-25.140	23.409	1.00	68.68	C
ATOM	7453	OG	SER	M	64	35.675	-26.196	23.881	1.00	81.78	O
ATOM	7454	N	GLY	M	65	32.772	-27.571	24.449	1.00	61.73	N
ATOM	7455	CA	GLY	M	65	32.459	-28.592	25.440	1.00	62.24	C
ATOM	7456	C	GLY	M	65	33.457	-29.733	25.406	1.00	68.95	C
ATOM	7457	O	GLY	M	65	33.890	-30.149	24.324	1.00	68.18	O
ATOM	7458	N	SER	M	66	33.832	-30.249	26.596	1.00	67.02	N
ATOM	7459	CA	SER	M	66	34.822	-31.327	26.729	1.00	66.91	C
ATOM	7460	C	SER	M	66	34.628	-32.113	28.002	1.00	70.38	C
ATOM	7461	O	SER	M	66	33.875	-31.684	28.886	1.00	71.07	O
ATOM	7462	CB	SER	M	66	36.235	-30.751	26.717	1.00	72.37	C
ATOM	7463	OG	SER	M	66	36.354	-29.700	27.665	1.00	87.21	O
ATOM	7464	N	GLY	M	67	35.320	-33.249	28.082	1.00	65.26	N
ATOM	7465	CA	GLY	M	67	35.294	-34.144	29.230	1.00	64.70	C
ATOM	7466	C	GLY	M	67	34.866	-35.555	28.890	1.00	69.17	C
ATOM	7467	O	GLY	M	67	34.442	-35.818	27.759	1.00	67.77	O
ATOM	7468	N	SER	M	68	35.000	-36.475	29.874	1.00	67.72	N
ATOM	7469	CA	SER	M	68	34.604	-37.891	29.823	1.00	69.00	C
ATOM	7470	C	SER	M	68	34.502	-38.469	31.243	1.00	78.38	C
ATOM	7471	O	SER	M	68	35.014	-37.869	32.197	1.00	79.74	O
ATOM	7472	CB	SER	M	68	35.590	-38.714	29.004	1.00	72.16	C
ATOM	7473	OG	SER	M	68	36.660	-39.192	29.806	1.00	83.70	O
ATOM	7474	N	GLY	M	69	33.865	-39.630	31.362	1.00	77.07	N
ATOM	7475	CA	GLY	M	69	33.696	-40.323	32.635	1.00	77.99	C
ATOM	7476	C	GLY	M	69	32.801	-39.606	33.624	1.00	84.14	C
ATOM	7477	O	GLY	M	69	31.578	-39.728	33.544	1.00	84.30	O
ATOM	7478	N	THR	M	70	33.408	-38.845	34.556	1.00	81.77	N
ATOM	7479	CA	THR	M	70	32.685	-38.104	35.598	1.00	82.14	C
ATOM	7480	C	THR	M	70	32.899	-36.598	35.509	1.00	86.96	C
ATOM	7481	O	THR	M	70	32.051	-35.852	35.994	1.00	86.99	O
ATOM	7482	CB	THR	M	70	33.048	-38.608	37.017	1.00	90.39	C
ATOM	7483	OG1	THR	M	70	34.455	-38.482	37.236	1.00	90.99	O
ATOM	7484	CG2	THR	M	70	32.612	-40.039	37.265	1.00	88.15	C
ATOM	7485	N	ASP	M	71	34.029	-36.143	34.932	1.00	83.69	N
ATOM	7486	CA	ASP	M	71	34.342	-34.706	34.861	1.00	83.48	C
ATOM	7487	C	ASP	M	71	34.156	-34.108	33.490	1.00	83.76	C
ATOM	7488	O	ASP	M	71	34.835	-34.512	32.540	1.00	83.82	O
ATOM	7489	CB	ASP	M	71	35.752	-34.408	35.401	1.00	86.12	C
ATOM	7490	CG	ASP	M	71	35.899	-34.609	36.899	1.00	105.25	C
ATOM	7491	OD1	ASP	M	71	35.437	-35.667	37.414	1.00	107.33	O
ATOM	7492	OD2	ASP	M	71	36.500	-33.733	37.558	1.00	113.57	O
ATOM	7493	N	PHE	M	72	33.248	-33.117	33.404	1.00	76.78	N
ATOM	7494	CA	PHE	M	72	32.891	-32.395	32.177	1.00	74.75	C
ATOM	7495	C	PHE	M	72	33.106	-30.889	32.348	1.00	77.36	C
ATOM	7496	O	PHE	M	72	33.150	-30.400	33.480	1.00	77.58	O
ATOM	7497	CB	PHE	M	72	31.460	-32.746	31.733	1.00	75.70	C
ATOM	7498	CG	PHE	M	72	31.277	-34.212	31.390	1.00	76.10	C
ATOM	7499	CD1	PHE	M	72	31.524	-34.681	30.100	1.00	78.31	C
ATOM	7500	CD2	PHE	M	72	30.893	-35.130	32.364	1.00	76.94	C
ATOM	7501	CE1	PHE	M	72	31.377	-36.044	29.786	1.00	78.91	C
ATOM	7502	CE2	PHE	M	72	30.743	-36.493	32.049	1.00	79.38	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab - <i>C. difficile</i> toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	7503	CZ	PHE	M	72	30.991	-36.941	30.764
ATOM	7504	N	THR	M	73	33.318	-30.168	31.238
ATOM	7505	CA	THR	M	73	33.657	-28.745	31.268
ATOM	7506	C	THR	M	73	33.076	-27.965	30.093
ATOM	7507	O	THR	M	73	33.247	-28.350	28.927
ATOM	7508	CB	THR	M	73	35.220	-28.582	31.240
ATOM	7509	OG1	THR	M	73	35.840	-29.422	32.217
ATOM	7510	CG2	THR	M	73	35.702	-27.122	31.410
ATOM	7511	N	LEU	M	74	32.477	-26.823	30.402
ATOM	7512	CA	LEU	M	74	32.018	-25.897	29.393
ATOM	7513	C	LEU	M	74	33.012	-24.728	29.416
ATOM	7514	O	LEU	M	74	33.320	-24.185	30.493
ATOM	7515	CB	LEU	M	74	30.592	-25.391	29.671
ATOM	7516	CG	LEU	M	74	30.035	-24.377	28.657
ATOM	7517	CD1	LEU	M	74	29.501	-25.065	27.412
ATOM	7518	CD2	LEU	M	74	28.974	-23.548	29.265
ATOM	7519	N	THR	M	75	33.494	-24.337	28.225
ATOM	7520	CA	THR	M	75	34.451	-23.258	28.070
ATOM	7521	C	THR	M	75	33.885	-22.149	27.189
ATOM	7522	O	THR	M	75	33.246	-22.427	26.178
ATOM	7523	CB	THR	M	75	35.770	-23.822	27.515
ATOM	7524	OG1	THR	M	75	36.109	-25.026	28.211
ATOM	7525	CG2	THR	M	75	36.912	-22.840	27.620
ATOM	7526	N	ILE	M	76	34.114	-20.894	27.586
ATOM	7527	CA	ILE	M	76	33.754	-19.704	26.805
ATOM	7528	C	ILE	M	76	35.112	-19.000	26.628
ATOM	7529	O	ILE	M	76	35.613	-18.424	27.594
ATOM	7530	CB	ILE	M	76	32.644	-18.804	27.464
ATOM	7531	CG	ILE	M	76	31.408	-19.636	27.871
ATOM	7532	CG2	ILE	M	76	32.234	-17.667	26.524
ATOM	7533	CD1	ILE	M	76	30.645	-19.159	29.081
ATOM	7534	N	SER	M	77	35.766	-19.175	25.457
ATOM	7535	CA	SER	M	77	37.098	-18.643	25.141
ATOM	7536	C	SER	M	77	37.246	-17.105	25.336
ATOM	7537	O	SER	M	77	38.331	-16.644	25.713
ATOM	7538	CB	SER	M	77	37.534	-19.071	23.739
ATOM	7539	OG	SER	M	77	36.663	-18.657	22.695
ATOM	7540	N	ARG	M	78	36.162	-16.328	25.102
ATOM	7541	CA	ARG	M	78	36.112	-14.873	25.253
ATOM	7542	C	ARG	M	78	34.657	-14.479	25.610
ATOM	7543	O	ARG	M	78	33.754	-14.637	24.779
ATOM	7544	CB	ARG	M	78	36.630	-14.179	23.962
ATOM	7545	CG	ARG	M	78	36.221	-12.712	23.795
ATOM	7546	CD	ARG	M	78	36.926	-12.046	22.633
ATOM	7547	NE	ARG	M	78	37.655	-10.869	23.093
ATOM	7548	CZ	ARG	M	78	38.970	-10.818	23.290
ATOM	7549	NH1	ARG	M	78	39.730	-11.880	23.039
ATOM	7550	NH2	ARG	M	78	39.534	-9.707	23.743
ATOM	7551	N	LEU	M	79	34.433	-13.989	26.849
ATOM	7552	CA	LEU	M	79	33.093	-13.619	27.294
ATOM	7553	C	LEU	M	79	32.559	-12.351	26.652
ATOM	7554	O	LEU	M	79	33.186	-11.299	26.732
ATOM	7555	CB	LEU	M	79	33.009	-13.518	28.807
ATOM	7556	CG	LEU	M	79	33.087	-14.813	29.545
ATOM	7557	CD1	LEU	M	79	33.608	-14.585	30.913
ATOM	7558	CD2	LEU	M	79	31.737	-15.468	29.616
ATOM	7559	N	GLU	M	80	31.404	-12.459	25.994
ATOM	7560	CA	GLU	M	80	30.729	-11.323	25.388
ATOM	7561	C	GLU	M	80	29.671	-10.825	26.393
ATOM	7562	O	GLU	M	80	29.446	-11.514	27.391
ATOM	7563	CB	GLU	M	80	30.103	-11.724	24.049
ATOM	7564	CG	GLU	M	80	31.105	-12.053	22.948
ATOM	7565	CD	GLU	M	80	32.147	-11.004	22.595
ATOM	7566	OE1	GLU	M	80	31.765	-9.830	22.387
ATOM	7567	OE2	GLU	M	80	33.342	-11.370	22.485
ATOM	7568	N	PRO	M	81	29.039	-9.633	26.213
ATOM	7569	CA	PRO	M	81	28.042	-9.172	27.206
ATOM	7570	C	PRO	M	81	26.859	-10.129	27.376
ATOM	7571	O	PRO	M	81	26.402	-10.387	28.501
ATOM	7572	CB	PRO	M	81	27.593	-7.812	26.652
ATOM	7573	CG	PRO	M	81	28.692	-7.390	25.755
ATOM	7574	CD	PRO	M	81	29.187	-8.643	25.129
ATOM	7575	N	GLU	M	82	26.406	-10.693	26.244
ATOM	7576	CA	GLU	M	82	25.287	-11.627	26.155
ATOM	7577	C	GLU	M	82	25.509	-12.931	26.961
ATOM	7578	O	GLU	M	82	24.539	-13.481	27.489
ATOM	7579	CB	GLU	M	82	24.918	-11.907	24.682

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab - <i>C. difficile</i> toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	7580	CG	GLU	M	82	26.090	-12.192	23.736
ATOM	7581	CD	GLU	M	82	26.707	-11.041	22.946
ATOM	7582	OE1	GLU	M	82	26.514	-9.862	23.327
ATOM	7583	OE2	GLU	M	82	27.421	-11.329	21.957
ATOM	7584	N	ASP	M	83	26.787	-13.350	27.134
ATOM	7585	CA	ASP	M	83	27.232	-14.582	27.800
ATOM	7586	C	ASP	M	83	27.043	-14.634	29.333
ATOM	7587	O	ASP	M	83	27.217	-15.699	29.948
ATOM	7588	CB	ASP	M	83	28.697	-14.879	27.431
ATOM	7589	CG	ASP	M	83	28.931	-15.115	25.951
ATOM	7590	OD1	ASP	M	83	27.931	-15.248	25.198
ATOM	7591	OD2	ASP	M	83	30.107	-15.174	25.543
ATOM	7592	N	PHE	M	84	26.674	-13.511	29.950
ATOM	7593	CA	PHE	M	84	26.452	-13.518	31.393
ATOM	7594	C	PHE	M	84	25.029	-14.040	31.680
ATOM	7595	O	PHE	M	84	24.043	-13.377	31.336
ATOM	7596	CB	PHE	M	84	26.783	-12.151	31.994
ATOM	7597	CG	PHE	M	84	28.268	-11.844	31.856
ATOM	7598	CD1	PHE	M	84	29.187	-12.319	32.791
ATOM	7599	CD2	PHE	M	84	28.756	-11.131	30.758
ATOM	7600	CE1	PHE	M	84	30.563	-12.067	32.642
ATOM	7601	CE2	PHE	M	84	30.139	-10.887	30.609
ATOM	7602	CZ	PHE	M	84	31.027	-11.363	31.546
ATOM	7603	N	ALA	M	85	24.944	-15.304	32.192
ATOM	7604	CA	ALA	M	85	23.707	-16.048	32.468
ATOM	7605	C	ALA	M	85	23.960	-17.285	33.328
ATOM	7606	O	ALA	M	85	25.060	-17.460	33.841
ATOM	7607	CB	ALA	M	85	23.059	-16.465	31.155
ATOM	7608	N	VAL	M	86	22.939	-18.141	33.499
ATOM	7609	CA	VAL	M	86	23.061	-19.380	34.270
ATOM	7610	C	VAL	M	86	23.286	-20.530	33.302
ATOM	7611	O	VAL	M	86	22.768	-20.511	32.176
ATOM	7612	CB	VAL	M	86	21.883	-19.620	35.262
ATOM	7613	CG1	VAL	M	86	22.117	-20.865	36.126
ATOM	7614	CG2	VAL	M	86	21.670	-18.392	36.144
ATOM	7615	N	TYR	M	87	24.100	-21.501	33.728
ATOM	7616	CA	TYR	M	87	24.458	-22.629	32.911
ATOM	7617	C	TYR	M	87	24.204	-23.894	33.661
ATOM	7618	O	TYR	M	87	24.751	-24.092	34.754
ATOM	7619	CB	TYR	M	87	25.937	-22.537	32.486
ATOM	7620	CG	TYR	M	87	26.233	-21.385	31.551
ATOM	7621	CD2	TYR	M	87	26.116	-21.533	30.172
ATOM	7622	CD1	TYR	M	87	26.593	-20.135	32.044
ATOM	7623	CE2	TYR	M	87	26.361	-20.466	29.304
ATOM	7624	CE1	TYR	M	87	26.812	-19.053	31.186
ATOM	7625	CZ	TYR	M	87	26.708	-19.225	29.814
ATOM	7626	OH	TYR	M	87	26.951	-18.177	28.950
ATOM	7627	N	TYR	M	88	23.381	-24.776	33.060
ATOM	7628	CA	TYR	M	88	23.042	-26.073	33.648
ATOM	7629	C	TYR	M	88	23.606	-27.197	32.796
ATOM	7630	O	TYR	M	88	23.556	-27.119	31.567
ATOM	7631	CB	TYR	M	88	21.517	-26.263	33.795
ATOM	7632	CG	TYR	M	88	20.796	-25.190	34.575
ATOM	7633	CD1	TYR	M	88	20.561	-25.330	35.937
ATOM	7634	CD2	TYR	M	88	20.268	-24.078	33.937
ATOM	7635	CE1	TYR	M	88	19.888	-24.345	36.662
ATOM	7636	CE2	TYR	M	88	19.589	-23.093	34.645
ATOM	7637	CZ	TYR	M	88	19.400	-23.226	36.011
ATOM	7638	OH	TYR	M	88	18.750	-22.238	36.719
ATOM	7639	N	CYS	M	89	24.161	-28.228	33.438
ATOM	7640	CA	CYS	M	89	24.590	-29.389	32.708
ATOM	7641	C	CYS	M	89	23.500	-30.431	32.919
ATOM	7642	O	CYS	M	89	22.698	-30.279	33.832
ATOM	7643	CB	CYS	M	89	25.991	-29.875	33.085
ATOM	7644	SG	CYS	M	89	26.200	-30.375	34.816
ATOM	7645	N	GLN	M	90	23.336	-31.352	31.976
ATOM	7646	CA	GLN	M	90	22.272	-32.326	32.019
ATOM	7647	C	GLN	M	90	22.819	-33.665	31.630
ATOM	7648	O	GLN	M	90	23.790	-33.735	30.891
ATOM	7649	CB	GLN	M	90	21.168	-31.878	31.043
ATOM	7650	CG	GLN	M	90	19.965	-32.818	30.858
ATOM	7651	CD	GLN	M	90	20.035	-33.587	29.551
ATOM	7652	OE1	GLN	M	90	20.030	-33.021	28.456
ATOM	7653	NE2	GLN	M	90	20.081	-34.900	29.627
ATOM	7654	N	GLN	M	91	22.179	-34.734	32.093
ATOM	7655	CA	GLN	M	91	22.531	-36.110	31.746
ATOM	7656	C	GLN	M	91	21.244	-36.989	31.682

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	7657	O	GLN	M	91	20.224	-36.630	32.262	1.00	72.54	O
ATOM	7658	CB	GLN	M	91	23.573	-36.649	32.752	1.00	72.69	C
ATOM	7659	CG	GLN	M	91	23.878	-38.138	32.669	1.00	97.58	C
ATOM	7660	CD	GLN	M	91	23.012	-39.018	33.561	1.00	135.20	C
ATOM	7661	OE1	GLN	M	91	23.164	-40.247	33.577	1.00	137.74	O
ATOM	7662	NE2	GLN	M	91	22.093	-38.434	34.337	1.00	126.45	N
ATOM	7663	N	TYR	M	92	21.297	-38.100	30.941	1.00	69.01	N
ATOM	7664	CA	TYR	M	92	20.250	-39.110	30.871	1.00	68.58	C
ATOM	7665	C	TYR	M	92	20.888	-40.433	31.256	1.00	74.67	C
ATOM	7666	O	TYR	M	92	22.040	-40.692	30.910	1.00	74.91	O
ATOM	7667	CB	TYR	M	92	19.615	-39.214	29.464	1.00	68.96	C
ATOM	7668	CG	TYR	M	92	18.699	-40.415	29.302	1.00	68.08	C
ATOM	7669	CD1	TYR	M	92	17.406	-40.407	29.820	1.00	69.50	C
ATOM	7670	CD2	TYR	M	92	19.144	-41.574	28.679	1.00	68.06	C
ATOM	7671	CE1	TYR	M	92	16.568	-41.512	29.693	1.00	68.53	C
ATOM	7672	CE2	TYR	M	92	18.312	-42.682	28.535	1.00	68.69	C
ATOM	7673	CZ	TYR	M	92	17.026	-42.646	29.044	1.00	76.90	C
ATOM	7674	OH	TYR	M	92	16.216	-43.745	28.913	1.00	81.18	O
ATOM	7675	N	GLY	M	93	20.120	-41.264	31.935	1.00	73.23	N
ATOM	7676	CA	GLY	M	93	20.536	-42.586	32.384	1.00	74.06	C
ATOM	7677	C	GLY	M	93	19.415	-43.253	33.153	1.00	81.29	C
ATOM	7678	O	GLY	M	93	18.614	-42.563	33.805	1.00	81.98	O
ATOM	7679	N	SER	M	94	19.344	-44.598	33.073	1.00	78.50	N
ATOM	7680	CA	SER	M	94	18.331	-45.424	33.739	1.00	78.75	C
ATOM	7681	C	SER	M	94	16.920	-44.780	33.670	1.00	83.47	C
ATOM	7682	O	SER	M	94	16.310	-44.441	34.692	1.00	84.21	O
ATOM	7683	CB	SER	M	94	18.755	-45.796	35.164	1.00	81.92	C
ATOM	7684	OG	SER	M	94	19.016	-44.666	35.983	1.00	91.80	O
ATOM	7685	N	SER	M	95	16.461	-44.541	32.427	1.00	78.65	N
ATOM	7686	CA	SER	M	95	15.143	-44.000	32.065	1.00	77.45	C
ATOM	7687	C	SER	M	95	14.805	-42.604	32.657	1.00	79.83	C
ATOM	7688	O	SER	M	95	13.643	-42.179	32.555	1.00	80.57	O
ATOM	7689	CB	SER	M	95	14.044	-45.010	32.397	1.00	79.36	C
ATOM	7690	OG	SER	M	95	14.403	-46.313	31.960	1.00	85.33	O
ATOM	7691	N	THR	M	96	15.802	-41.873	33.239	1.00	72.62	N
ATOM	7692	CA	THR	M	96	15.531	-40.543	33.805	1.00	70.71	C
ATOM	7693	C	THR	M	96	16.577	-39.505	33.370	1.00	72.02	C
ATOM	7694	O	THR	M	96	17.734	-39.859	33.151	1.00	69.84	O
ATOM	7695	CB	THR	M	96	15.322	-40.575	35.353	1.00	75.36	C
ATOM	7696	OG1	THR	M	96	16.562	-40.515	36.039	1.00	79.81	O
ATOM	7697	CG2	THR	M	96	14.540	-41.797	35.852	1.00	72.56	C
ATOM	7698	N	TRP	M	97	16.144	-38.221	33.252	1.00	69.30	N
ATOM	7699	CA	TRP	M	97	16.927	-37.020	32.893	1.00	69.28	C
ATOM	7700	C	TRP	M	97	17.254	-36.203	34.169	1.00	74.52	C
ATOM	7701	O	TRP	M	97	16.347	-35.841	34.920	1.00	74.72	O
ATOM	7702	CB	TRP	M	97	16.139	-36.106	31.936	1.00	68.02	C
ATOM	7703	CG	TRP	M	97	16.170	-36.479	30.486	1.00	69.44	C
ATOM	7704	CD1	TRP	M	97	16.850	-35.838	29.493	1.00	72.45	C
ATOM	7705	CD2	TRP	M	97	15.391	-37.499	29.844	1.00	69.35	C
ATOM	7706	NE1	TRP	M	97	16.599	-36.442	28.281	1.00	71.60	N
ATOM	7707	CE2	TRP	M	97	15.696	-37.456	28.467	1.00	72.93	C
ATOM	7708	CE3	TRP	M	97	14.488	-38.471	30.302	1.00	70.69	C
ATOM	7709	CZ2	TRP	M	97	15.117	-38.335	27.546	1.00	72.21	C
ATOM	7710	CZ3	TRP	M	97	13.925	-39.350	29.388	1.00	71.77	C
ATOM	7711	CH2	TRP	M	97	14.244	-39.280	28.031	1.00	72.23	C
ATOM	7712	N	THR	M	98	18.539	-35.870	34.378	1.00	71.29	N
ATOM	7713	CA	THR	M	98	19.022	-35.128	35.546	1.00	70.49	C
ATOM	7714	C	THR	M	98	19.715	-33.835	35.135	1.00	73.37	C
ATOM	7715	O	THR	M	98	20.435	-33.820	34.141	1.00	73.23	O
ATOM	7716	CB	THR	M	98	19.926	-36.048	36.384	1.00	77.65	C
ATOM	7717	OG1	THR	M	98	19.269	-37.311	36.530	1.00	77.30	O
ATOM	7718	CG2	THR	M	98	20.263	-35.469	37.757	1.00	77.49	C
ATOM	7719	N	PHE	M	99	19.502	-32.763	35.911	1.00	69.52	N
ATOM	7720	CA	PHE	M	99	20.119	-31.458	35.691	1.00	69.85	C
ATOM	7721	C	PHE	M	99	21.062	-31.098	36.840	1.00	75.69	C
ATOM	7722	O	PHE	M	99	20.946	-31.638	37.946	1.00	76.62	O
ATOM	7723	CB	PHE	M	99	19.051	-30.363	35.554	1.00	71.64	C
ATOM	7724	CG	PHE	M	99	18.306	-30.357	34.241	1.00	72.97	C
ATOM	7725	CD2	PHE	M	99	18.681	-29.496	33.215	1.00	74.82	C
ATOM	7726	CD1	PHE	M	99	17.217	-31.200	34.035	1.00	75.20	C
ATOM	7727	CE2	PHE	M	99	17.994	-29.495	32.001	1.00	77.60	C
ATOM	7728	CE1	PHE	M	99	16.521	-31.188	32.825	1.00	75.89	C
ATOM	7729	CZ	PHE	M	99	16.909	-30.330	31.818	1.00	75.60	C
ATOM	7730	N	GLY	M	100	22.003	-30.200	36.550	1.00	71.75	N
ATOM	7731	CA	GLY	M	100	22.944	-29.648	37.516	1.00	70.80	C
ATOM	7732	C	GLY	M	100	22.253	-28.474	38.173	1.00	74.33	C
ATOM	7733	O	GLY	M	100	21.235	-27.986	37.648	1.00	74.17	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	7734	N	GLN	M	101	22.781	-28.009	39.321	1.00	69.25	N
ATOM	7735	CA	GLN	M	101	22.138	-26.919	40.050	1.00	68.83	C
ATOM	7736	C	GLN	M	101	22.396	-25.512	39.430	1.00	73.59	C
ATOM	7737	O	GLN	M	101	21.750	-24.534	39.825	1.00	73.35	O
ATOM	7738	CB	GLN	M	101	22.495	-26.982	41.538	1.00	70.35	C
ATOM	7739	CG	GLN	M	101	23.844	-26.355	41.937	1.00	103.67	C
ATOM	7740	CD	GLN	M	101	25.100	-27.087	41.502	1.00	124.67	C
ATOM	7741	OE1	GLN	M	101	25.134	-28.318	41.293	1.00	118.07	O
ATOM	7742	NE2	GLN	M	101	26.179	-26.320	41.417	1.00	116.30	N
ATOM	7743	N	GLY	M	102	23.300	-25.442	38.453	1.00	70.28	N
ATOM	7744	CA	GLY	M	102	23.651	-24.210	37.766	1.00	69.62	C
ATOM	7745	C	GLY	M	102	24.940	-23.567	38.242	1.00	73.46	C
ATOM	7746	O	GLY	M	102	25.466	-23.889	39.314	1.00	71.71	O
ATOM	7747	N	THR	M	103	25.458	-22.647	37.415	1.00	70.36	N
ATOM	7748	CA	THR	M	103	26.619	-21.804	37.673	1.00	69.17	C
ATOM	7749	C	THR	M	103	26.247	-20.437	37.064	1.00	71.30	C
ATOM	7750	O	THR	M	103	26.026	-20.359	35.847	1.00	70.58	O
ATOM	7751	CB	THR	M	103	27.943	-22.405	37.075	1.00	73.24	C
ATOM	7752	OG1	THR	M	103	28.313	-23.605	37.762	1.00	71.98	O
ATOM	7753	CG2	THR	M	103	29.137	-21.410	37.135	1.00	71.51	C
ATOM	7754	N	LYS	M	104	26.136	-19.376	37.906	1.00	66.33	N
ATOM	7755	CA	LYS	M	104	25.878	-18.028	37.383	1.00	65.48	C
ATOM	7756	C	LYS	M	104	27.226	-17.445	36.887	1.00	69.38	C
ATOM	7757	O	LYS	M	104	28.290	-17.746	37.448	1.00	67.87	O
ATOM	7758	CB	LYS	M	104	25.194	-17.099	38.416	1.00	66.47	C
ATOM	7759	N	VAL	M	105	27.185	-16.713	35.777	1.00	66.76	N
ATOM	7760	CA	VAL	M	105	28.370	-16.056	35.251	1.00	67.67	C
ATOM	7761	C	VAL	M	105	28.093	-14.574	35.377	1.00	76.97	C
ATOM	7762	O	VAL	M	105	27.282	-14.006	34.638	1.00	78.29	O
ATOM	7763	CB	VAL	M	105	28.837	-16.513	33.853	1.00	70.84	C
ATOM	7764	CG1	VAL	M	105	30.141	-15.815	33.470	1.00	70.79	C
ATOM	7765	CG2	VAL	M	105	29.032	-18.027	33.828	1.00	70.35	C
ATOM	7766	N	GLU	M	106	28.667	-14.000	36.427	1.00	74.45	N
ATOM	7767	CA	GLU	M	106	28.500	-12.622	36.841	1.00	74.93	C
ATOM	7768	C	GLU	M	106	29.615	-11.743	36.250	1.00	78.42	C
ATOM	7769	O	GLU	M	106	30.712	-12.246	35.990	1.00	78.99	O
ATOM	7770	CB	GLU	M	106	28.543	-12.604	38.373	1.00	76.65	C
ATOM	7771	CG	GLU	M	106	28.117	-11.300	39.012	1.00	87.72	C
ATOM	7772	CD	GLU	M	106	28.956	-10.966	40.221	1.00	120.65	C
ATOM	7773	OE1	GLU	M	106	30.166	-10.692	40.046	1.00	116.45	O
ATOM	7774	OE2	GLU	M	106	28.414	-11.024	41.347	1.00	122.66	O
ATOM	7775	N	ILE	M	107	29.339	-10.435	36.060	1.00	72.75	N
ATOM	7776	CA	ILE	M	107	30.301	-9.489	35.500	1.00	71.74	C
ATOM	7777	C	ILE	M	107	31.189	-8.954	36.605	1.00	75.97	C
ATOM	7778	O	ILE	M	107	30.676	-8.246	37.472	1.00	75.84	O
ATOM	7779	CB	ILE	M	107	29.597	-8.338	34.702	1.00	74.40	C
ATOM	7780	CG1	ILE	M	107	28.476	-8.889	33.775	1.00	75.02	C
ATOM	7781	CG2	ILE	M	107	30.611	-7.533	33.893	1.00	73.58	C
ATOM	7782	CD1	ILE	M	107	27.262	-8.003	33.477	1.00	80.17	C
ATOM	7783	N	LYS	M	108	32.516	-9.297	36.600	1.00	72.99	N
ATOM	7784	CA	LYS	M	108	33.474	-8.745	37.579	1.00	72.40	C
ATOM	7785	C	LYS	M	108	33.681	-7.266	37.237	1.00	76.18	C
ATOM	7786	O	LYS	M	108	33.777	-6.893	36.062	1.00	77.54	O
ATOM	7787	CB	LYS	M	108	34.830	-9.482	37.626	1.00	74.35	C
ATOM	7788	CG	LYS	M	108	35.739	-8.997	38.772	1.00	81.96	C
ATOM	7789	CD	LYS	M	108	36.424	-10.131	39.539	1.00	90.23	C
ATOM	7790	CE	LYS	M	108	35.729	-10.422	40.854	1.00	97.68	C
ATOM	7791	NZ	LYS	M	108	36.243	-11.664	41.498	1.00	99.88	N
ATOM	7792	N	ARG	M	109	33.666	-6.427	38.260	1.00	70.31	N
ATOM	7793	CA	ARG	M	109	33.884	-4.991	38.137	1.00	68.59	C
ATOM	7794	C	ARG	M	109	34.538	-4.513	39.446	1.00	73.22	C
ATOM	7795	O	ARG	M	109	34.675	-5.291	40.410	1.00	71.26	O
ATOM	7796	CB	ARG	M	109	32.580	-4.238	37.789	1.00	64.34	C
ATOM	7797	CG	ARG	M	109	31.578	-4.172	38.922	1.00	66.86	C
ATOM	7798	CD	ARG	M	109	30.890	-2.834	39.003	1.00	63.66	C
ATOM	7799	NE	ARG	M	109	31.745	-1.805	39.577	1.00	71.48	N
ATOM	7800	CZ	ARG	M	109	31.515	-0.502	39.483	1.00	90.80	C
ATOM	7801	NH1	ARG	M	109	30.459	-0.054	38.811	1.00	77.20	N
ATOM	7802	NH2	ARG	M	109	32.347	0.368	40.041	1.00	81.07	N
ATOM	7803	N	THR	M	110	34.985	-3.257	39.465	1.00	71.75	N
ATOM	7804	CA	THR	M	110	35.607	-2.700	40.657	1.00	72.07	C
ATOM	7805	C	THR	M	110	34.622	-2.633	41.810	1.00	76.56	C
ATOM	7806	O	THR	M	110	33.421	-2.436	41.603	1.00	75.40	O
ATOM	7807	CB	THR	M	110	36.228	-1.331	40.393	1.00	79.36	C
ATOM	7808	OG1	THR	M	110	35.264	-0.463	39.787	1.00	81.03	O
ATOM	7809	CG2	THR	M	110	37.486	-1.422	39.554	1.00	75.55	C
ATOM	7810	N	VAL	M	111	35.130	-2.822	43.031	1.00	73.53	N

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	7811	CA	VAL	M	111	34.311	-2.714	44.221	1.00	72.69	C
ATOM	7812	C	VAL	M	111	33.716	-1.292	44.201	1.00	78.73	C
ATOM	7813	O	VAL	M	111	34.392	-0.319	43.806	1.00	78.21	O
ATOM	7814	CB	VAL	M	111	35.136	-3.026	45.484	1.00	75.37	C
ATOM	7815	CG1	VAL	M	111	34.418	-2.565	46.744	1.00	74.82	C
ATOM	7816	CG2	VAL	M	111	35.486	-4.512	45.569	1.00	74.57	C
ATOM	7817	N	ALA	M	112	32.408	-1.229	44.478	1.00	76.54	N
ATOM	7818	CA	ALA	M	112	31.595	-0.019	44.560	1.00	76.55	C
ATOM	7819	C	ALA	M	112	30.810	-0.153	45.849	1.00	83.30	C
ATOM	7820	O	ALA	M	112	30.269	-1.223	46.138	1.00	84.71	O
ATOM	7821	CB	ALA	M	112	30.651	0.075	43.367	1.00	76.93	C
ATOM	7822	N	ALA	M	113	30.802	0.897	46.660	1.00	79.51	N
ATOM	7823	CA	ALA	M	113	30.112	0.868	47.936	1.00	78.03	C
ATOM	7824	C	ALA	M	113	28.659	1.336	47.764	1.00	80.12	C
ATOM	7825	O	ALA	M	113	28.365	2.190	46.906	1.00	79.06	O
ATOM	7826	CB	ALA	M	113	30.849	1.737	48.936	1.00	78.65	C
ATOM	7827	N	PRO	M	114	27.722	0.774	48.555	1.00	76.20	N
ATOM	7828	CA	PRO	M	114	26.328	1.211	48.421	1.00	75.42	C
ATOM	7829	C	PRO	M	114	26.092	2.609	48.981	1.00	79.26	C
ATOM	7830	O	PRO	M	114	26.776	3.026	49.923	1.00	80.78	O
ATOM	7831	CB	PRO	M	114	25.555	0.170	49.241	1.00	76.78	C
ATOM	7832	CG	PRO	M	114	26.523	-0.330	50.253	1.00	81.40	C
ATOM	7833	CD	PRO	M	114	27.878	-0.253	49.614	1.00	77.61	C
ATOM	7834	N	SER	M	115	25.123	3.325	48.400	1.00	73.02	N
ATOM	7835	CA	SER	M	115	24.641	4.596	48.928	1.00	71.66	C
ATOM	7836	C	SER	M	115	23.456	4.079	49.745	1.00	74.29	C
ATOM	7837	O	SER	M	115	22.580	3.428	49.172	1.00	74.33	O
ATOM	7838	CB	SER	M	115	24.141	5.526	47.820	1.00	74.11	C
ATOM	7839	OG	SER	M	115	24.658	5.224	46.533	1.00	84.18	O
ATOM	7840	N	VAL	M	116	23.484	4.240	51.080	1.00	68.90	N
ATOM	7841	CA	VAL	M	116	22.415	3.725	51.956	1.00	67.19	C
ATOM	7842	C	VAL	M	116	21.334	4.802	52.198	1.00	72.40	C
ATOM	7843	O	VAL	M	116	21.662	5.987	52.267	1.00	73.57	O
ATOM	7844	CB	VAL	M	116	22.998	3.098	53.266	1.00	69.08	C
ATOM	7845	CG1	VAL	M	116	21.910	2.466	54.125	1.00	68.56	C
ATOM	7846	CG2	VAL	M	116	24.087	2.071	52.939	1.00	68.16	C
ATOM	7847	N	PHE	M	117	20.044	4.392	52.259	1.00	68.71	N
ATOM	7848	CA	PHE	M	117	18.884	5.272	52.506	1.00	68.31	C
ATOM	7849	C	PHE	M	117	17.840	4.537	53.344	1.00	72.63	C
ATOM	7850	O	PHE	M	117	17.534	3.392	53.037	1.00	73.06	O
ATOM	7851	CB	PHE	M	117	18.210	5.727	51.193	1.00	69.76	C
ATOM	7852	CG	PHE	M	117	19.079	6.469	50.214	1.00	71.83	C
ATOM	7853	CD1	PHE	M	117	19.190	7.851	50.270	1.00	76.07	C
ATOM	7854	CD2	PHE	M	117	19.761	5.789	49.206	1.00	74.95	C
ATOM	7855	CE1	PHE	M	117	19.986	8.545	49.344	1.00	77.44	C
ATOM	7856	CE2	PHE	M	117	20.556	6.479	48.282	1.00	78.21	C
ATOM	7857	CZ	PHE	M	117	20.664	7.855	48.359	1.00	76.29	C
ATOM	7858	N	ILE	M	118	17.289	5.188	54.387	1.00	68.60	N
ATOM	7859	CA	ILE	M	118	16.218	4.641	55.229	1.00	68.31	C
ATOM	7860	C	ILE	M	118	14.925	5.442	54.985	1.00	74.55	C
ATOM	7861	O	ILE	M	118	14.982	6.668	54.804	1.00	75.09	O
ATOM	7862	CB	ILE	M	118	16.587	4.506	56.739	1.00	71.06	C
ATOM	7863	CG1	ILE	M	118	15.573	3.581	57.498	1.00	70.31	C
ATOM	7864	CG2	ILE	M	118	16.745	5.899	57.407	1.00	72.55	C
ATOM	7865	CD1	ILE	M	118	15.887	3.222	58.910	1.00	70.07	C
ATOM	7866	N	PHE	M	119	13.771	4.737	54.947	1.00	71.64	N
ATOM	7867	CA	PHE	M	119	12.454	5.329	54.736	1.00	71.38	C
ATOM	7868	C	PHE	M	119	11.512	4.897	55.856	1.00	78.77	C
ATOM	7869	O	PHE	M	119	11.369	3.695	56.120	1.00	79.48	O
ATOM	7870	CB	PHE	M	119	11.871	4.968	53.360	1.00	72.44	C
ATOM	7871	CG	PHE	M	119	12.731	5.365	52.183	1.00	73.57	C
ATOM	7872	CD1	PHE	M	119	12.650	6.644	51.641	1.00	76.47	C
ATOM	7873	CD2	PHE	M	119	13.628	4.460	51.612	1.00	74.60	C
ATOM	7874	CE1	PHE	M	119	13.460	7.020	50.552	1.00	76.76	C
ATOM	7875	CE2	PHE	M	119	14.439	4.837	50.529	1.00	77.12	C
ATOM	7876	CZ	PHE	M	119	14.342	6.113	49.998	1.00	75.24	C
ATOM	7877	N	PRO	M	120	10.886	5.870	56.549	1.00	76.16	N
ATOM	7878	CA	PRO	M	120	9.947	5.522	57.628	1.00	76.00	C
ATOM	7879	C	PRO	M	120	8.555	5.166	57.075	1.00	78.32	C
ATOM	7880	O	PRO	M	120	8.249	5.549	55.934	1.00	76.57	O
ATOM	7881	CB	PRO	M	120	9.895	6.814	58.469	1.00	77.89	C
ATOM	7882	CG	PRO	M	120	10.853	7.800	57.793	1.00	82.08	C
ATOM	7883	CD	PRO	M	120	10.977	7.332	56.392	1.00	77.83	C
ATOM	7884	N	PRO	M	121	7.681	4.472	57.856	1.00	75.39	N
ATOM	7885	CA	PRO	M	121	6.330	4.171	57.346	1.00	76.10	C
ATOM	7886	C	PRO	M	121	5.493	5.433	57.101	1.00	84.80	C
ATOM	7887	O	PRO	M	121	5.467	6.307	57.962	1.00	85.61	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TedB antibody beziotuxumab
Fab -C. difficile toxin B (TedB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	7888	CB	PRO	M	121	5.708	3.296	58.448	1.00	77.23	C
ATOM	7889	CG	PRO	M	121	6.483	3.564	59.639	1.00	81.02	C
ATOM	7890	CD	PRO	M	121	7.872	3.924	59.214	1.00	76.61	C
ATOM	7891	N	SER	M	122	4.810	5.530	55.938	1.00	84.30	N
ATOM	7892	CA	SER	M	122	3.952	6.675	55.594	1.00	85.59	C
ATOM	7893	C	SER	M	122	2.778	6.837	56.583	1.00	93.22	C
ATOM	7894	O	SER	M	122	2.452	5.884	57.311	1.00	92.20	O
ATOM	7895	CB	SER	M	122	3.429	6.554	54.164	1.00	88.65	C
ATOM	7896	OG	SER	M	122	2.751	5.323	53.983	1.00	98.43	O
ATOM	7897	N	ASP	M	123	2.171	8.054	56.634	1.00	92.40	N
ATOM	7898	CA	ASP	M	123	1.040	8.316	57.526	1.00	93.40	C
ATOM	7899	C	ASP	M	123	-0.174	7.486	57.099	1.00	98.68	C
ATOM	7900	O	ASP	M	123	-0.824	6.877	57.963	1.00	97.76	O
ATOM	7901	CB	ASP	M	123	0.710	9.815	57.611	1.00	95.72	C
ATOM	7902	CG	ASP	M	123	1.765	10.678	58.294	1.00	106.59	C
ATOM	7903	OD1	ASP	M	123	2.206	10.317	59.418	1.00	105.62	O
ATOM	7904	OD2	ASP	M	123	2.094	11.745	57.745	1.00	115.47	O
ATOM	7905	N	GLU	M	124	-0.410	7.392	55.754	1.00	96.41	N
ATOM	7906	CA	GLU	M	124	-1.479	6.585	55.143	1.00	96.83	C
ATOM	7907	C	GLU	M	124	-1.400	5.135	55.652	1.00	100.75	C
ATOM	7908	O	GLU	M	124	-2.416	4.576	56.075	1.00	101.26	O
ATOM	7909	CB	GLU	M	124	-1.369	6.539	53.603	1.00	98.53	C
ATOM	7910	CG	GLU	M	124	-1.117	7.841	52.865	1.00	113.72	C
ATOM	7911	CD	GLU	M	124	-1.021	7.679	51.352	1.00	143.08	C
ATOM	7912	OE1	GLU	M	124	-0.250	8.447	50.730	1.00	148.48	O
ATOM	7913	OE2	GLU	M	124	-1.721	6.803	50.785	1.00	128.78	O
ATOM	7914	N	GLN	M	125	-0.185	4.535	55.602	1.00	95.87	N
ATOM	7915	CA	GLN	M	125	0.077	3.163	56.028	1.00	94.83	C
ATOM	7916	C	GLN	M	125	-0.131	2.980	57.511	1.00	97.86	C
ATOM	7917	O	GLN	M	125	-0.597	1.921	57.927	1.00	96.81	O
ATOM	7918	CB	GLN	M	125	1.489	2.721	55.629	1.00	95.88	C
ATOM	7919	CG	GLN	M	125	1.641	1.210	55.603	1.00	99.10	C
ATOM	7920	CD	GLN	M	125	3.037	0.731	55.850	1.00	110.83	C
ATOM	7921	OE1	GLN	M	125	4.038	1.453	55.670	1.00	100.61	O
ATOM	7922	NE2	GLN	M	125	3.117	-0.528	56.253	1.00	104.86	N
ATOM	7923	N	LEU	M	126	0.219	3.999	58.305	1.00	95.29	N
ATOM	7924	CA	LEU	M	126	0.082	3.941	59.753	1.00	95.51	C
ATOM	7925	C	LEU	M	126	-1.379	3.980	60.227	1.00	100.64	C
ATOM	7926	O	LEU	M	126	-1.661	3.461	61.312	1.00	99.93	O
ATOM	7927	CB	LEU	M	126	0.941	5.010	60.430	1.00	95.44	C
ATOM	7928	CG	LEU	M	126	2.375	4.577	60.709	1.00	100.13	C
ATOM	7929	CD1	LEU	M	126	3.252	5.763	61.016	1.00	100.47	C
ATOM	7930	CD2	LEU	M	126	2.433	3.542	61.827	1.00	102.38	C
ATOM	7931	N	LYS	M	127	-2.310	4.544	59.399	1.00	97.62	N
ATOM	7932	CA	LYS	M	127	-3.759	4.589	59.668	1.00	96.98	C
ATOM	7933	C	LYS	M	127	-4.268	3.135	59.787	1.00	100.53	C
ATOM	7934	O	LYS	M	127	-4.966	2.807	60.755	1.00	100.35	O
ATOM	7935	CB	LYS	M	127	-4.511	5.384	58.583	1.00	98.80	C
ATOM	7936	N	SER	M	128	-3.841	2.250	58.849	1.00	96.28	N
ATOM	7937	CA	SER	M	128	-4.102	0.808	58.925	1.00	95.84	C
ATOM	7938	C	SER	M	128	-3.079	0.270	59.955	1.00	99.50	C
ATOM	7939	O	SER	M	128	-2.019	0.875	60.134	1.00	100.36	O
ATOM	7940	CB	SER	M	128	-3.925	0.146	57.561	1.00	99.00	C
ATOM	7941	OG	SER	M	128	-2.672	0.452	56.971	1.00	107.09	O
ATOM	7942	N	GLY	M	129	-3.409	-0.805	60.653	1.00	94.41	N
ATOM	7943	CA	GLY	M	129	-2.570	-1.331	61.731	1.00	93.97	C
ATOM	7944	C	GLY	M	129	-1.195	-1.910	61.433	1.00	97.27	C
ATOM	7945	O	GLY	M	129	-0.747	-2.781	62.186	1.00	96.78	O
ATOM	7946	N	THR	M	130	-0.488	-1.419	60.371	1.00	92.89	N
ATOM	7947	CA	THR	M	130	0.847	-1.919	59.984	1.00	91.42	C
ATOM	7948	C	THR	M	130	1.822	-0.779	59.597	1.00	92.85	C
ATOM	7949	O	THR	M	130	1.417	0.234	59.021	1.00	91.01	O
ATOM	7950	CB	THR	M	130	0.710	-3.022	58.898	1.00	90.13	C
ATOM	7951	OG1	THR	M	130	0.220	-4.208	59.535	1.00	83.52	O
ATOM	7952	CG2	THR	M	130	2.028	-3.342	58.173	1.00	84.47	C
ATOM	7953	N	ALA	M	131	3.118	-0.985	59.948	1.00	89.07	N
ATOM	7954	CA	ALA	M	131	4.281	-0.122	59.694	1.00	88.19	C
ATOM	7955	C	ALA	M	131	5.389	-0.889	58.953	1.00	89.81	C
ATOM	7956	O	ALA	M	131	5.852	-1.941	59.409	1.00	88.35	O
ATOM	7957	CB	ALA	M	131	4.827	0.431	61.000	1.00	88.88	C
ATOM	7958	N	SER	M	132	5.799	-0.346	57.802	1.00	85.66	N
ATOM	7959	CA	SER	M	132	6.844	-0.895	56.945	1.00	84.62	C
ATOM	7960	C	SER	M	132	8.003	0.094	56.828	1.00	83.81	C
ATOM	7961	O	SER	M	132	7.846	1.200	56.294	1.00	82.31	O
ATOM	7962	CB	SER	M	132	6.290	-1.265	55.566	1.00	89.81	C
ATOM	7963	OG	SER	M	132	5.374	-2.348	55.639	1.00	101.31	O
ATOM	7964	N	VAL	M	133	9.155	-0.303	57.375	1.00	78.33	N

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	7965	CA	VAL	M	133	10.387	0.485	57.357
ATOM	7966	C	VAL	M	133	11.276	-0.083	56.255
ATOM	7967	O	VAL	M	133	11.515	-1.287	56.226
ATOM	7968	CB	VAL	M	133	11.114	0.519	58.723
ATOM	7969	CG1	VAL	M	133	12.047	1.715	58.787
ATOM	7970	CG2	VAL	M	133	10.127	0.539	59.891
ATOM	7971	N	VAL	M	134	11.748	0.781	55.349
ATOM	7972	CA	VAL	M	134	12.537	0.374	54.180
ATOM	7973	C	VAL	M	134	13.994	0.895	54.179
ATOM	7974	O	VAL	M	134	14.226	2.100	54.197
ATOM	7975	CB	VAL	M	134	11.797	0.767	52.861
ATOM	7976	CG1	VAL	M	134	12.534	0.251	51.625
ATOM	7977	CG2	VAL	M	134	10.347	0.288	52.868
ATOM	7978	N	CYS	M	135	14.950	-0.026	54.042
ATOM	7979	CA	CYS	M	135	16.384	0.249	53.937
ATOM	7980	C	CYS	M	135	16.858	-0.042	52.493
ATOM	7981	O	CYS	M	135	16.818	-1.194	52.064
ATOM	7982	CB	CYS	M	135	17.154	-0.584	54.957
ATOM	7983	SG	CYS	M	135	18.895	-0.133	55.131
ATOM	7984	N	LEU	M	136	17.282	1.005	51.747
ATOM	7985	CA	LEU	M	136	17.770	0.929	50.358
ATOM	7986	C	LEU	M	136	19.306	1.002	50.262
ATOM	7987	O	LEU	M	136	19.906	1.929	50.811
ATOM	7988	CB	LEU	M	136	17.133	2.027	49.466
ATOM	7989	CG	LEU	M	136	17.769	2.238	48.080
ATOM	7990	CD1	LEU	M	136	17.524	1.038	47.158
ATOM	7991	CD2	LEU	M	136	17.281	3.514	47.440
ATOM	7992	N	LEU	M	137	19.918	0.034	49.520
ATOM	7993	CA	LEU	M	137	21.364	-0.067	49.220
ATOM	7994	C	LEU	M	137	21.500	0.180	47.700
ATOM	7995	O	LEU	M	137	21.305	-0.733	46.901
ATOM	7996	CB	LEU	M	137	21.929	-1.456	49.612
ATOM	7997	CG	LEU	M	137	22.134	-1.749	51.090
ATOM	7998	CD1	LEU	M	137	20.816	-1.898	51.829
ATOM	7999	CD2	LEU	M	137	22.952	-2.996	51.262
ATOM	8000	N	ASN	M	138	21.738	1.433	47.306
ATOM	8001	CA	ASN	M	138	21.787	1.793	45.893
ATOM	8002	C	ASN	M	138	23.155	1.494	45.243
ATOM	8003	O	ASN	M	138	24.209	1.688	45.856
ATOM	8004	CB	ASN	M	138	21.340	3.247	45.687
ATOM	8005	CG	ASN	M	138	21.177	3.637	44.250
ATOM	8006	OD1	ASN	M	138	20.156	3.363	43.618
ATOM	8007	ND2	ASN	M	138	22.196	4.278	43.694
ATOM	8008	N	ASN	M	139	23.097	0.981	44.001
ATOM	8009	CA	ASN	M	139	24.176	0.623	43.079
ATOM	8010	C	ASN	M	139	25.526	0.249	43.736
ATOM	8011	O	ASN	M	139	26.491	1.016	43.672
ATOM	8012	CB	ASN	M	139	24.354	1.726	42.040
ATOM	8013	CG	ASN	M	139	23.185	1.859	41.106
ATOM	8014	OD1	ASN	M	139	22.626	2.944	40.935
ATOM	8015	ND2	ASN	M	139	22.773	0.752	40.500
ATOM	8016	N	PHE	M	140	25.592	-0.957	44.320
ATOM	8017	CA	PHE	M	140	26.805	-1.503	44.938
ATOM	8018	C	PHE	M	140	27.355	-2.728	44.177
ATOM	8019	O	PHE	M	140	26.679	-3.270	43.312
ATOM	8020	CB	PHE	M	140	26.546	-1.857	46.408
ATOM	8021	CG	PHE	M	140	25.604	-3.013	46.657
ATOM	8022	CD1	PHE	M	140	26.077	-4.314	46.718
ATOM	8023	CD2	PHE	M	140	24.253	-2.796	46.864
ATOM	8024	CE1	PHE	M	140	25.207	-5.384	46.931
ATOM	8025	CE2	PHE	M	140	23.383	-3.869	47.079
ATOM	8026	CZ	PHE	M	140	23.871	-5.155	47.133
ATOM	8027	N	TYR	M	141	28.572	-3.176	44.536
ATOM	8028	CA	TYR	M	141	29.267	-4.343	43.975
ATOM	8029	C	TYR	M	141	30.456	-4.802	44.873
ATOM	8030	O	TYR	M	141	31.255	-3.949	45.259
ATOM	8031	CB	TYR	M	141	29.767	-4.082	42.531
ATOM	8032	CG	TYR	M	141	30.396	-5.321	41.951
ATOM	8033	CD1	TYR	M	141	29.631	-6.255	41.259
ATOM	8034	CD2	TYR	M	141	31.738	-5.615	42.178
ATOM	8035	CE1	TYR	M	141	30.181	-7.457	40.825
ATOM	8036	CE2	TYR	M	141	32.295	-6.818	41.761
ATOM	8037	CZ	TYR	M	141	31.519	-7.726	41.064

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	8038	OH	TYR	M	141	32.081	-8.904	40.650
ATOM	8039	N	PRO	M	142	30.659	-6.119	45.172
ATOM	8040	CA	PRO	M	142	29.855	-7.300	44.795
ATOM	8041	C	PRO	M	142	28.531	-7.401	45.531
ATOM	8042	O	PRO	M	142	28.262	-6.566	46.399
ATOM	8043	CB	PRO	M	142	30.798	-8.472	45.097
ATOM	8044	CG	PRO	M	142	31.643	-7.994	46.205
ATOM	8045	CD	PRO	M	142	31.824	-6.514	45.990
ATOM	8046	N	ARG	M	143	27.679	-8.416	45.158
ATOM	8047	CA	ARG	M	143	26.337	-8.669	45.737
ATOM	8048	C	ARG	M	143	26.355	-8.838	47.280
ATOM	8049	O	ARG	M	143	25.393	-8.413	47.933
ATOM	8050	CB	ARG	M	143	25.600	-9.847	45.045
ATOM	8051	N	GLU	M	144	27.460	-9.391	47.856
ATOM	8052	CA	GLU	M	144	27.602	-9.617	49.303
ATOM	8053	C	GLU	M	144	27.456	-8.331	50.134
ATOM	8054	O	GLU	M	144	28.291	-7.414	50.088
ATOM	8055	CB	GLU	M	144	28.885	-10.377	49.667
ATOM	8056	CG	GLU	M	144	29.018	-11.737	49.006
ATOM	8057	CD	GLU	M	144	29.595	-11.704	47.600
ATOM	8058	OE1	GLU	M	144	30.748	-11.237	47.433
ATOM	8059	OE2	GLU	M	144	28.890	-12.156	46.667
ATOM	8060	N	ALA	M	145	26.337	-8.285	50.865
ATOM	8061	CA	ALA	M	145	25.909	-7.195	51.734
ATOM	8062	C	ALA	M	145	25.105	-7.757	52.935
ATOM	8063	O	ALA	M	145	24.260	-8.638	52.747
ATOM	8064	CB	ALA	M	145	25.056	-6.209	50.941
ATOM	8065	N	LYS	M	146	25.408	-7.281	54.166
ATOM	8066	CA	LYS	M	146	24.698	-7.673	55.393
ATOM	8067	C	LYS	M	146	23.890	-6.468	55.846
ATOM	8068	O	LYS	M	146	24.462	-5.394	56.032
ATOM	8069	CB	LYS	M	146	25.646	-8.147	56.526
ATOM	8070	N	VAL	M	147	22.558	-6.623	55.955
ATOM	8071	CA	VAL	M	147	21.666	-5.548	56.404
ATOM	8072	C	VAL	M	147	21.040	-5.999	57.701
ATOM	8073	O	VAL	M	147	20.322	-7.003	57.744
ATOM	8074	CB	VAL	M	147	20.624	-5.086	55.354
ATOM	8075	CG1	VAL	M	147	19.755	-3.962	55.896
ATOM	8076	CG2	VAL	M	147	21.302	-4.647	54.065
ATOM	8077	N	GLN	M	148	21.370	-5.289	58.770
ATOM	8078	CA	GLN	M	148	20.863	-5.597	60.094
ATOM	8079	C	GLN	M	148	19.880	-4.508	60.512
ATOM	8080	O	GLN	M	148	20.116	-3.336	60.222
ATOM	8081	CB	GLN	M	148	22.024	-5.716	61.079
ATOM	8082	CG	GLN	M	148	21.846	-6.828	62.086
ATOM	8083	CD	GLN	M	148	22.937	-7.862	61.990
ATOM	8084	OE1	GLN	M	148	24.134	-7.579	62.180
ATOM	8085	NE2	GLN	M	148	22.544	-9.085	61.663
ATOM	8086	N	TRP	M	149	18.745	-4.897	61.114
ATOM	8087	CA	TRP	M	149	17.750	-3.938	61.596
ATOM	8088	C	TRP	M	149	17.906	-3.823	63.115
ATOM	8089	O	TRP	M	149	18.088	-4.831	63.803
ATOM	8090	CB	TRP	M	149	16.322	-4.340	61.192
ATOM	8091	CG	TRP	M	149	15.945	-3.966	59.779
ATOM	8092	CD1	TRP	M	149	15.859	-4.803	58.702
ATOM	8093	CD2	TRP	M	149	15.577	-2.657	59.298
ATOM	8094	NE1	TRP	M	149	15.497	-4.094	57.574
ATOM	8095	CE2	TRP	M	149	15.295	-2.781	57.915
ATOM	8096	CE3	TRP	M	149	15.461	-1.389	59.905
ATOM	8097	CZ2	TRP	M	149	14.871	-1.699	57.137
ATOM	8098	CZ3	TRP	M	149	15.065	-0.310	59.121
ATOM	8099	CH2	TRP	M	149	14.789	-0.469	57.751
ATOM	8100	N	LYS	M	150	17.935	-2.589	63.618
ATOM	8101	CA	LYS	M	150	18.075	-2.291	65.040
ATOM	8102	C	LYS	M	150	16.986	-1.289	65.450
ATOM	8103	O	LYS	M	150	16.830	-0.235	64.824
ATOM	8104	CB	LYS	M	150	19.505	-1.825	65.382
ATOM	8105	N	VAL	M	151	16.163	-1.679	66.436
ATOM	8106	CA	VAL	M	151	15.047	-0.869	66.948
ATOM	8107	C	VAL	M	151	15.367	-0.560	68.410
ATOM	8108	O	VAL	M	151	15.292	-1.457	69.262
ATOM	8109	CB	VAL	M	151	13.696	-1.596	66.761
ATOM	8110	CG1	VAL	M	151	12.561	-0.821	67.400

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	8111	CG2	VAL	M	151	13.405	-1.844	65.288	1.00	74.36	C
ATOM	8112	N	ASP	M	152	15.784	0.701	68.681	1.00	67.71	N
ATOM	8113	CA	ASP	M	152	16.269	1.176	69.976	1.00	67.55	C
ATOM	8114	C	ASP	M	152	17.441	0.278	70.439	1.00	73.84	C
ATOM	8115	O	ASP	M	152	17.386	-0.331	71.516	1.00	72.41	O
ATOM	8116	CB	ASP	M	152	15.149	1.287	71.032	1.00	69.36	C
ATOM	8117	CG	ASP	M	152	14.206	2.469	70.884	1.00	78.91	C
ATOM	8118	OD1	ASP	M	152	14.618	3.487	70.283	1.00	76.51	O
ATOM	8119	OD2	ASP	M	152	13.077	2.403	71.436	1.00	86.40	O
ATOM	8120	N	ASN	M	153	18.471	0.141	69.550	1.00	74.03	N
ATOM	8121	CA	ASN	M	153	19.719	-0.640	69.723	1.00	75.32	C
ATOM	8122	C	ASN	M	153	19.517	-2.176	69.904	1.00	81.40	C
ATOM	8123	O	ASN	M	153	20.469	-2.880	70.262	1.00	80.97	O
ATOM	8124	CB	ASN	M	153	20.597	-0.073	70.875	1.00	77.65	C
ATOM	8125	CG	ASN	M	153	20.659	1.431	70.959	1.00	102.77	C
ATOM	8126	OD1	ASN	M	153	20.869	2.128	69.966	1.00	94.59	O
ATOM	8127	ND2	ASN	M	153	20.469	1.966	72.156	1.00	98.76	N
ATOM	8128	N	ALA	M	154	18.298	-2.692	69.637	1.00	79.85	N
ATOM	8129	CA	ALA	M	154	17.985	-4.126	69.732	1.00	80.08	C
ATOM	8130	C	ALA	M	154	17.988	-4.753	68.322	1.00	83.48	C
ATOM	8131	O	ALA	M	154	17.270	-4.255	67.445	1.00	81.98	O
ATOM	8132	CB	ALA	M	154	16.628	-4.324	70.403	1.00	80.67	C
ATOM	8133	N	LEU	M	155	18.818	-5.819	68.095	1.00	80.27	N
ATOM	8134	CA	LEU	M	155	18.895	-6.491	66.784	1.00	80.17	C
ATOM	8135	C	LEU	M	155	17.621	-7.287	66.477	1.00	86.53	C
ATOM	8136	O	LEU	M	155	17.201	-8.146	67.265	1.00	85.42	O
ATOM	8137	CB	LEU	M	155	20.156	-7.356	66.603	1.00	79.72	C
ATOM	8138	N	GLN	M	156	16.996	-6.956	65.336	1.00	85.05	N
ATOM	8139	CA	GLN	M	156	15.763	-7.562	64.836	1.00	85.54	C
ATOM	8140	C	GLN	M	156	16.022	-8.836	64.023	1.00	91.85	C
ATOM	8141	O	GLN	M	156	16.954	-8.883	63.219	1.00	91.33	O
ATOM	8142	CB	GLN	M	156	14.965	-6.558	63.981	1.00	86.58	C
ATOM	8143	CG	GLN	M	156	14.616	-5.240	64.678	1.00	92.61	C
ATOM	8144	CD	GLN	M	156	13.900	-5.417	65.993	1.00	99.30	C
ATOM	8145	OE1	GLN	M	156	12.698	-5.667	66.037	1.00	91.94	O
ATOM	8146	NE2	GLN	M	156	14.626	-5.283	67.096	1.00	90.14	N
ATOM	8147	N	SER	M	157	15.166	-9.858	64.224	1.00	89.42	N
ATOM	8148	CA	SER	M	157	15.219	-11.141	63.521	1.00	88.49	C
ATOM	8149	C	SER	M	157	13.814	-11.699	63.178	1.00	89.03	C
ATOM	8150	O	SER	M	157	12.900	-11.642	64.005	1.00	88.12	O
ATOM	8151	CB	SER	M	157	16.049	-12.157	64.304	1.00	92.49	C
ATOM	8152	OG	SER	M	157	15.253	-12.999	65.123	1.00	103.25	O
ATOM	8153	N	GLY	M	158	13.686	-12.226	61.961	1.00	83.87	N
ATOM	8154	CA	GLY	M	158	12.475	-12.840	61.428	1.00	82.91	C
ATOM	8155	C	GLY	M	158	11.331	-11.885	61.168	1.00	85.06	C
ATOM	8156	O	GLY	M	158	10.166	-12.284	61.269	1.00	84.31	O
ATOM	8157	N	ASN	M	159	11.650	-10.620	60.834	1.00	80.28	N
ATOM	8158	CA	ASN	M	159	10.639	-9.589	60.587	1.00	79.42	C
ATOM	8159	C	ASN	M	159	11.006	-8.667	59.428	1.00	83.39	C
ATOM	8160	O	ASN	M	159	10.422	-7.581	59.284	1.00	82.20	O
ATOM	8161	CB	ASN	M	159	10.315	-8.807	61.867	1.00	77.63	C
ATOM	8162	CG	ASN	M	159	11.455	-8.036	62.489	1.00	95.96	C
ATOM	8163	OD1	ASN	M	159	12.632	-8.137	62.100	1.00	97.06	O
ATOM	8164	ND2	ASN	M	159	11.116	-7.230	63.480	1.00	81.54	N
ATOM	8165	N	SER	M	160	11.961	-9.124	58.583	1.00	80.32	N
ATOM	8166	CA	SER	M	160	12.403	-8.408	57.377	1.00	79.64	C
ATOM	8167	C	SER	M	160	12.543	-9.323	56.147	1.00	81.25	C
ATOM	8168	O	SER	M	160	12.659	-10.547	56.274	1.00	79.81	O
ATOM	8169	CB	SER	M	160	13.679	-7.599	57.624	1.00	82.15	C
ATOM	8170	OG	SER	M	160	14.703	-8.371	58.225	1.00	89.12	O
ATOM	8171	N	GLN	M	161	12.491	-8.711	54.962	1.00	76.55	N
ATOM	8172	CA	GLN	M	161	12.604	-9.402	53.694	1.00	75.90	C
ATOM	8173	C	GLN	M	161	13.447	-8.588	52.722	1.00	76.47	C
ATOM	8174	O	GLN	M	161	13.089	-7.445	52.420	1.00	74.44	O
ATOM	8175	CB	GLN	M	161	11.206	-9.613	53.092	1.00	77.70	C
ATOM	8176	CG	GLN	M	161	10.408	-10.800	53.664	1.00	85.75	C
ATOM	8177	CD	GLN	M	161	9.097	-10.975	52.920	1.00	96.85	C
ATOM	8178	OE1	GLN	M	161	8.247	-10.068	52.878	1.00	87.82	O
ATOM	8179	NE2	GLN	M	161	8.928	-12.124	52.270	1.00	90.29	N
ATOM	8180	N	GLU	M	162	14.546	-9.177	52.202	1.00	72.61	N
ATOM	8181	CA	GLU	M	162	15.369	-8.469	51.209	1.00	72.24	C
ATOM	8182	C	GLU	M	162	15.013	-8.899	49.751	1.00	75.88	C
ATOM	8183	O	GLU	M	162	14.512	-9.995	49.510	1.00	74.49	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody beziotoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	8184	CB	GLU	M	162	16.909	-8.486	51.468	1.00	73.26	C
ATOM	8185	CG	GLU	M	162	17.432	-9.348	52.607	1.00	81.65	C
ATOM	8186	CD	GLU	M	162	18.368	-8.648	53.577	1.00	104.38	C
ATOM	8187	OE1	GLU	M	162	17.885	-8.167	54.630	1.00	109.82	O
ATOM	8188	OE2	GLU	M	162	19.592	-8.632	53.314	1.00	89.31	O
ATOM	8189	N	SER	M	163	15.218	-7.973	48.810	1.00	73.21	N
ATOM	8190	CA	SER	M	163	14.956	-8.117	47.379	1.00	73.00	C
ATOM	8191	C	SER	M	163	16.108	-7.441	46.614	1.00	77.13	C
ATOM	8192	O	SER	M	163	16.427	-6.280	46.870	1.00	75.05	O
ATOM	8193	CB	SER	M	163	13.618	-7.477	47.014	1.00	75.67	C
ATOM	8194	OG	SER	M	163	13.373	-7.512	45.619	1.00	77.74	O
ATOM	8195	N	VAL	M	164	16.744	-8.198	45.705	1.00	75.65	N
ATOM	8196	CA	VAL	M	164	17.899	-7.770	44.915	1.00	75.67	C
ATOM	8197	C	VAL	M	164	17.531	-7.612	43.469	1.00	81.03	C
ATOM	8198	O	VAL	M	164	16.840	-8.473	42.923	1.00	81.74	O
ATOM	8199	CB	VAL	M	164	19.081	-8.768	45.013	1.00	79.45	C
ATOM	8200	CG1	VAL	M	164	20.405	-8.055	44.769	1.00	79.96	C
ATOM	8201	CG2	VAL	M	164	19.107	-9.504	46.346	1.00	79.05	C
ATOM	8202	N	THR	M	165	18.065	-6.569	42.819	1.00	77.80	N
ATOM	8203	CA	THR	M	165	17.880	-6.364	41.383	1.00	78.05	C
ATOM	8204	C	THR	M	165	18.891	-7.246	40.641	1.00	83.27	C
ATOM	8205	O	THR	M	165	19.841	-7.782	41.238	1.00	82.67	O
ATOM	8206	CB	THR	M	165	18.107	-4.892	40.985	1.00	84.35	C
ATOM	8207	OG1	THR	M	165	19.376	-4.451	41.470	1.00	83.40	O
ATOM	8208	CG2	THR	M	165	16.974	-3.971	41.426	1.00	81.73	C
ATOM	8209	N	GLU	M	166	18.697	-7.379	39.325	1.00	80.20	N
ATOM	8210	CA	GLU	M	166	19.663	-8.097	38.497	1.00	79.16	C
ATOM	8211	C	GLU	M	166	20.824	-7.122	38.236	1.00	81.68	C
ATOM	8212	O	GLU	M	166	20.639	-5.900	38.404	1.00	81.79	O
ATOM	8213	CB	GLU	M	166	19.012	-8.602	37.189	1.00	80.21	C
ATOM	8214	CG	GLU	M	166	18.112	-9.824	37.369	1.00	89.57	C
ATOM	8215	CD	GLU	M	166	18.720	-10.979	38.144	1.00	117.07	C
ATOM	8216	OE1	GLU	M	166	19.762	-11.518	37.705	1.00	118.90	O
ATOM	8217	OE2	GLU	M	166	18.171	-11.321	39.216	1.00	113.77	O
ATOM	8218	N	GLN	M	167	22.025	-7.654	37.914	1.00	76.65	N
ATOM	8219	CA	GLN	M	167	23.227	-6.845	37.650	1.00	75.46	C
ATOM	8220	C	GLN	M	167	22.906	-5.799	36.591	1.00	78.85	C
ATOM	8221	O	GLN	M	167	22.365	-6.163	35.550	1.00	79.01	O
ATOM	8222	CB	GLN	M	167	24.374	-7.753	37.209	1.00	76.31	C
ATOM	8223	CG	GLN	M	167	25.740	-7.157	37.463	1.00	87.41	C
ATOM	8224	CD	GLN	M	167	26.854	-8.162	37.439	1.00	109.02	C
ATOM	8225	OE1	GLN	M	167	26.831	-9.140	36.689	1.00	103.33	O
ATOM	8226	NE2	GLN	M	167	27.886	-7.904	38.229	1.00	107.72	N
ATOM	8227	N	ASP	M	168	23.131	-4.503	36.898	1.00	75.13	N
ATOM	8228	CA	ASP	M	168	22.818	-3.365	36.020	1.00	75.07	C
ATOM	8229	C	ASP	M	168	23.487	-3.432	34.655	1.00	78.28	C
ATOM	8230	O	ASP	M	168	24.676	-3.753	34.558	1.00	77.47	O
ATOM	8231	CB	ASP	M	168	23.126	-2.018	36.706	1.00	77.40	C
ATOM	8232	CG	ASP	M	168	22.395	-0.849	36.064	1.00	90.00	C
ATOM	8233	OD1	ASP	M	168	21.204	-0.641	36.396	1.00	92.12	O
ATOM	8234	OD2	ASP	M	168	22.993	-0.175	35.191	1.00	91.26	O
ATOM	8235	N	SER	M	169	22.710	-3.129	33.599	1.00	74.89	N
ATOM	8236	CA	SER	M	169	23.181	-3.130	32.207	1.00	74.63	C
ATOM	8237	C	SER	M	169	24.286	-2.073	31.931	1.00	78.65	C
ATOM	8238	O	SER	M	169	25.143	-2.296	31.075	1.00	78.77	O
ATOM	8239	CB	SER	M	169	22.011	-2.908	31.256	1.00	78.13	C
ATOM	8240	OG	SER	M	169	21.372	-1.663	31.498	1.00	91.08	O
ATOM	8241	N	LYS	M	170	24.259	-0.936	32.652	1.00	74.32	N
ATOM	8242	CA	LYS	M	170	25.207	0.162	32.468	1.00	73.05	C
ATOM	8243	C	LYS	M	170	26.489	0.023	33.309	1.00	76.92	C
ATOM	8244	O	LYS	M	170	27.592	-0.017	32.744	1.00	76.15	O
ATOM	8245	CB	LYS	M	170	24.510	1.523	32.725	1.00	73.88	C
ATOM	8246	CG	LYS	M	170	24.981	2.646	31.814	1.00	75.65	C
ATOM	8247	CD	LYS	M	170	24.488	4.010	32.303	1.00	88.07	C
ATOM	8248	CE	LYS	M	170	25.502	5.081	31.980	1.00	105.62	C
ATOM	8249	NZ	LYS	M	170	25.377	6.264	32.879	1.00	118.17	N
ATOM	8250	N	ASP	M	171	26.339	-0.046	34.658	1.00	73.20	N
ATOM	8251	CA	ASP	M	171	27.446	-0.036	35.606	1.00	71.75	C
ATOM	8252	C	ASP	M	171	27.722	-1.353	36.315	1.00	74.36	C
ATOM	8253	O	ASP	M	171	28.573	-1.369	37.202	1.00	75.03	O
ATOM	8254	CB	ASP	M	171	27.254	1.098	36.630	1.00	73.51	C
ATOM	8255	CG	ASP	M	171	25.875	1.181	37.266	1.00	85.40	C
ATOM	8256	OD2	ASP	M	171	25.789	1.092	38.503	1.00	83.18	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	8257	OD1	ASP	M	171	24.897	1.456	36.533	1.00	96.40	O
ATOM	8258	N	SER	M	172	27.080	-2.459	35.897	1.00	69.88	N
ATOM	8259	CA	SER	M	172	27.257	-3.817	36.453	1.00	69.38	C
ATOM	8260	C	SER	M	172	27.110	-3.911	37.985	1.00	74.38	C
ATOM	8261	O	SER	M	172	27.750	-4.747	38.633	1.00	73.95	O
ATOM	8262	CB	SER	M	172	28.577	-4.433	35.992	1.00	70.82	C
ATOM	8263	OG	SER	M	172	28.579	-4.608	34.586	1.00	74.37	O
ATOM	8264	N	THR	M	173	26.219	-3.100	38.549	1.00	72.80	N
ATOM	8265	CA	THR	M	173	25.975	-3.097	39.983	1.00	74.02	C
ATOM	8266	C	THR	M	173	24.619	-3.700	40.366	1.00	80.73	C
ATOM	8267	O	THR	M	173	23.730	-3.890	39.526	1.00	79.35	O
ATOM	8268	CB	THR	M	173	26.059	-1.678	40.541	1.00	83.15	C
ATOM	8269	OG1	THR	M	173	24.988	-0.909	39.992	1.00	86.55	O
ATOM	8270	CG2	THR	M	173	27.427	-1.027	40.337	1.00	78.18	C
ATOM	8271	N	TYR	M	174	24.469	-3.929	41.677	1.00	79.72	N
ATOM	8272	CA	TYR	M	174	23.267	-4.430	42.325	1.00	79.86	C
ATOM	8273	C	TYR	M	174	22.652	-3.378	43.230	1.00	81.16	C
ATOM	8274	O	TYR	M	174	23.349	-2.530	43.788	1.00	81.48	O
ATOM	8275	CB	TYR	M	174	23.600	-5.643	43.190	1.00	81.77	C
ATOM	8276	CG	TYR	M	174	24.181	-6.782	42.406	1.00	85.33	C
ATOM	8277	CD1	TYR	M	174	23.364	-7.631	41.661	1.00	88.14	C
ATOM	8278	CD2	TYR	M	174	25.548	-7.025	42.411	1.00	86.18	C
ATOM	8279	CE1	TYR	M	174	23.899	-8.687	40.928	1.00	88.53	C
ATOM	8280	CE2	TYR	M	174	26.090	-8.092	41.707	1.00	87.38	C
ATOM	8281	CZ	TYR	M	174	25.259	-8.923	40.968	1.00	93.52	C
ATOM	8282	OH	TYR	M	174	25.775	-9.973	40.262	1.00	93.26	O
ATOM	8283	N	SER	M	175	21.341	-3.468	43.399	1.00	74.13	N
ATOM	8284	CA	SER	M	175	20.604	-2.668	44.350	1.00	72.10	C
ATOM	8285	C	SER	M	175	19.813	-3.665	45.207	1.00	76.01	C
ATOM	8286	O	SER	M	175	19.541	-4.787	44.763	1.00	76.50	O
ATOM	8287	CB	SER	M	175	19.764	-1.602	43.665	1.00	72.12	C
ATOM	8288	OG	SER	M	175	20.660	-0.739	42.982	1.00	76.36	O
ATOM	8289	N	LEU	M	176	19.559	-3.308	46.464	1.00	70.96	N
ATOM	8290	CA	LEU	M	176	18.881	-4.162	47.430	1.00	69.48	C
ATOM	8291	C	LEU	M	176	17.965	-3.313	48.302	1.00	72.59	C
ATOM	8292	O	LEU	M	176	18.314	-2.184	48.659	1.00	71.26	O
ATOM	8293	CB	LEU	M	176	19.946	-4.902	48.274	1.00	69.33	C
ATOM	8294	CG	LEU	M	176	19.488	-5.927	49.307	1.00	73.25	C
ATOM	8295	CD1	LEU	M	176	20.415	-7.101	49.346	1.00	72.91	C
ATOM	8296	CD2	LEU	M	176	19.430	-5.317	50.684	1.00	75.90	C
ATOM	8297	N	SER	M	177	16.786	-3.859	48.631	1.00	70.00	N
ATOM	8298	CA	SER	M	177	15.806	-3.228	49.505	0.47	69.16	C
ATOM	8299	C	SER	M	177	15.523	-4.252	50.577	1.00	75.37	C
ATOM	8300	O	SER	M	177	15.239	-5.393	50.229	1.00	76.80	O
ATOM	8301	CB	SER	M	177	14.530	-2.884	48.737	0.47	69.51	C
ATOM	8302	OG	SER	M	177	13.723	-4.021	48.466	0.47	72.01	O
ATOM	8303	N	SER	M	178	15.682	-3.887	51.867	1.00	71.86	N
ATOM	8304	CA	SER	M	178	15.367	-4.753	53.022	1.00	71.31	C
ATOM	8305	C	SER	M	178	14.196	-4.105	53.760	1.00	76.37	C
ATOM	8306	O	SER	M	178	14.342	-2.987	54.253	1.00	76.36	O
ATOM	8307	CB	SER	M	178	16.562	-4.907	53.955	1.00	72.73	C
ATOM	8308	OG	SER	M	178	16.227	-5.677	55.098	1.00	77.92	O
ATOM	8309	N	THR	M	179	13.019	-4.764	53.775	1.00	73.37	N
ATOM	8310	CA	THR	M	179	11.818	-4.204	54.400	1.00	72.66	C
ATOM	8311	C	THR	M	179	11.510	-4.828	55.747	1.00	77.98	C
ATOM	8312	O	THR	M	179	11.276	-6.035	55.821	1.00	77.34	O
ATOM	8313	CB	THR	M	179	10.617	-4.264	53.445	1.00	72.27	C
ATOM	8314	OG1	THR	M	179	10.973	-3.681	52.189	1.00	70.75	O
ATOM	8315	CG2	THR	M	179	9.399	-3.564	54.001	1.00	68.20	C
ATOM	8316	N	LEU	M	180	11.477	-3.980	56.806	1.00	76.59	N
ATOM	8317	CA	LEU	M	180	11.113	-4.347	58.183	1.00	77.09	C
ATOM	8318	C	LEU	M	180	9.605	-4.142	58.348	1.00	81.91	C
ATOM	8319	O	LEU	M	180	9.109	-3.039	58.086	1.00	82.02	O
ATOM	8320	CB	LEU	M	180	11.879	-3.485	59.199	1.00	77.03	C
ATOM	8321	CG	LEU	M	180	11.631	-3.794	60.677	1.00	81.51	C
ATOM	8322	CD1	LEU	M	180	12.533	-4.910	61.162	1.00	82.20	C
ATOM	8323	CD2	LEU	M	180	11.871	-2.572	61.518	1.00	82.87	C
ATOM	8324	N	THR	M	181	8.867	-5.200	58.743	1.00	78.07	N
ATOM	8325	CA	THR	M	181	7.414	-5.079	58.893	1.00	77.34	C
ATOM	8326	C	THR	M	181	7.022	-5.335	60.349	1.00	78.91	C
ATOM	8327	O	THR	M	181	7.338	-6.372	60.938	1.00	76.84	O
ATOM	8328	CB	THR	M	181	6.626	-5.903	57.825	1.00	84.14	C
ATOM	8329	OG1	THR	M	181	6.972	-5.447	56.501	1.00	76.93	O

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	8330	CG2	THR	M	181	5.113	-5.776	57.988	1.00	84.81	C
ATOM	8331	N	LEU	M	182	6.336	-4.335	60.908	1.00	76.46	N
ATOM	8332	CA	LEU	M	182	5.858	-4.285	62.283	1.00	77.01	C
ATOM	8333	C	LEU	M	182	4.404	-3.853	62.345	1.00	82.00	C
ATOM	8334	O	LEU	M	182	3.955	-3.068	61.495	1.00	79.44	O
ATOM	8335	CB	LEU	M	182	6.674	-3.237	63.067	1.00	76.95	C
ATOM	8336	CG	LEU	M	182	8.082	-3.591	63.484	1.00	81.00	C
ATOM	8337	CD1	LEU	M	182	8.833	-2.343	63.868	1.00	79.89	C
ATOM	8338	CD2	LEU	M	182	8.069	-4.592	64.636	1.00	84.88	C
ATOM	8339	N	SER	M	183	3.687	-4.308	63.413	1.00	80.38	N
ATOM	8340	CA	SER	M	183	2.309	-3.887	63.681	1.00	80.20	C
ATOM	8341	C	SER	M	183	2.368	-2.454	64.258	1.00	84.38	C
ATOM	8342	O	SER	M	183	3.251	-2.181	65.088	1.00	83.93	O
ATOM	8343	CB	SER	M	183	1.650	-4.827	64.686	1.00	82.66	C
ATOM	8344	OG	SER	M	183	2.240	-4.721	65.972	1.00	90.34	O
ATOM	8345	N	LYS	M	184	1.440	-1.547	63.824	1.00	80.38	N
ATOM	8346	CA	LYS	M	184	1.333	-0.153	64.316	1.00	80.10	C
ATOM	8347	C	LYS	M	184	1.579	-0.057	65.848	1.00	82.17	C
ATOM	8348	O	LYS	M	184	2.252	0.867	66.293	1.00	81.53	O
ATOM	8349	CB	LYS	M	184	-0.036	0.462	63.951	1.00	82.88	C
ATOM	8350	CG	LYS	M	184	-0.154	1.959	64.242	1.00	97.25	C
ATOM	8351	CD	LYS	M	184	-1.597	2.393	64.446	1.00	108.18	C
ATOM	8352	CE	LYS	M	184	-1.677	3.849	64.848	1.00	118.26	C
ATOM	8353	NZ	LYS	M	184	-3.059	4.385	64.750	1.00	124.68	N
ATOM	8354	N	ALA	M	185	1.097	-1.061	66.617	1.00	77.26	N
ATOM	8355	CA	ALA	M	185	1.268	-1.196	68.058	1.00	76.71	C
ATOM	8356	C	ALA	M	185	2.744	-1.149	68.445	1.00	81.88	C
ATOM	8357	O	ALA	M	185	3.155	-0.203	69.112	1.00	79.67	O
ATOM	8358	CB	ALA	M	185	0.638	-2.502	68.529	1.00	77.30	C
ATOM	8359	N	ASP	M	186	3.546	-2.136	67.963	1.00	82.05	N
ATOM	8360	CA	ASP	M	186	4.991	-2.294	68.206	1.00	82.73	C
ATOM	8361	C	ASP	M	186	5.842	-1.164	67.634	1.00	86.05	C
ATOM	8362	O	ASP	M	186	6.894	-0.856	68.199	1.00	85.77	O
ATOM	8363	CB	ASP	M	186	5.476	-3.657	67.706	1.00	85.45	C
ATOM	8364	CG	ASP	M	186	4.880	-4.806	68.497	1.00	101.57	C
ATOM	8365	OD2	ASP	M	186	5.578	-5.333	69.388	1.00	110.59	O
ATOM	8366	OD1	ASP	M	186	3.693	-5.156	68.247	1.00	102.43	O
ATOM	8367	N	TYR	M	187	5.387	-0.535	66.536	1.00	81.83	N
ATOM	8368	CA	TYR	M	187	6.080	0.611	65.961	1.00	81.55	C
ATOM	8369	C	TYR	M	187	6.015	1.844	66.900	1.00	90.03	C
ATOM	8370	O	TYR	M	187	7.043	2.508	67.080	1.00	90.58	O
ATOM	8371	CB	TYR	M	187	5.552	0.945	64.566	1.00	80.86	C
ATOM	8372	CG	TYR	M	187	6.166	2.192	63.967	1.00	80.88	C
ATOM	8373	CD1	TYR	M	187	7.494	2.213	63.555	1.00	82.25	C
ATOM	8374	CD2	TYR	M	187	5.417	3.351	63.804	1.00	82.03	C
ATOM	8375	CE1	TYR	M	187	8.067	3.363	63.007	1.00	82.87	C
ATOM	8376	CE2	TYR	M	187	5.974	4.504	63.246	1.00	83.17	C
ATOM	8377	CZ	TYR	M	187	7.305	4.511	62.862	1.00	90.63	C
ATOM	8378	OH	TYR	M	187	7.848	5.639	62.284	1.00	92.21	O
ATOM	8379	N	GLU	M	188	4.817	2.137	67.502	1.00	87.70	N
ATOM	8380	CA	GLU	M	188	4.605	3.263	68.441	1.00	87.70	C
ATOM	8381	C	GLU	M	188	5.419	3.090	69.753	1.00	92.05	C
ATOM	8382	O	GLU	M	188	5.784	4.086	70.383	1.00	91.36	O
ATOM	8383	CB	GLU	M	188	3.110	3.457	68.791	1.00	89.12	C
ATOM	8384	CG	GLU	M	188	2.115	3.466	67.640	1.00	99.23	C
ATOM	8385	CD	GLU	M	188	1.855	4.772	66.918	1.00	114.10	C
ATOM	8386	OE1	GLU	M	188	2.826	5.368	66.395	1.00	97.56	O
ATOM	8387	OE2	GLU	M	188	0.665	5.146	66.790	1.00	104.41	O
ATOM	8388	N	LYS	M	189	5.682	1.822	70.150	1.00	89.49	N
ATOM	8389	CA	LYS	M	189	6.424	1.394	71.348	1.00	89.59	C
ATOM	8390	C	LYS	M	189	7.918	1.822	71.401	1.00	93.70	C
ATOM	8391	O	LYS	M	189	8.518	1.761	72.481	1.00	92.71	O
ATOM	8392	CB	LYS	M	189	6.355	-0.147	71.479	1.00	91.83	C
ATOM	8393	CG	LYS	M	189	5.128	-0.688	72.200	1.00	99.98	C
ATOM	8394	CD	LYS	M	189	5.277	-2.187	72.448	1.00	107.51	C
ATOM	8395	CE	LYS	M	189	4.078	-2.798	73.133	1.00	112.80	C
ATOM	8396	NZ	LYS	M	189	4.245	-4.260	73.346	1.00	116.11	N
ATOM	8397	N	HIS	M	190	8.530	2.182	70.243	1.00	90.56	N
ATOM	8398	CA	HIS	M	190	9.959	2.516	70.145	1.00	90.84	C
ATOM	8399	C	HIS	M	190	10.242	3.813	69.381	1.00	93.35	C
ATOM	8400	O	HIS	M	190	9.390	4.238	68.604	1.00	92.79	O
ATOM	8401	CB	HIS	M	190	10.710	1.339	69.514	1.00	92.43	C
ATOM	8402	CG	HIS	M	190	10.601	0.079	70.310	1.00	96.72	C
ATOM	8403	ND1	HIS	M	190	9.571	-0.820	70.094	1.00	98.94	N
ATOM	8404	CD2	HIS	M	190	11.372	-0.370	71.331	1.00	99.19	C
ATOM	8405	CE1	HIS	M	190	9.751	-1.792	70.978	1.00	98.82	C
ATOM	8406	NE2	HIS	M	190	10.824	-1.564	71.746	1.00	99.18	N

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab Fab -C. difficile toxin B (TcdB ⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.								
ATOM	8407 N	LYS M	191	11.455	4.418	69.577	1.00	88.84 N
ATOM	8408 CA	LYS M	191	11.872	5.701	68.978	1.00	88.17 C
ATOM	8409 C	LYS M	191	12.890	5.629	67.818	1.00	90.16 C
ATOM	8410 O	LYS M	191	12.628	6.200	66.755	1.00	88.77 O
ATOM	8411 CB	LYS M	191	12.418	6.653	70.064	1.00	90.84 C
ATOM	8412 N	VAL M	192	14.069	4.997	68.050	1.00	86.13 N
ATOM	8413 CA	VAL M	192	15.173	4.887	67.074	1.00	85.38 C
ATOM	8414 C	VAL M	192	15.081	3.627	66.208	1.00	85.70 C
ATOM	8415 O	VAL M	192	15.131	2.499	66.711	1.00	84.40 O
ATOM	8416 CB	VAL M	192	16.599	5.027	67.686	1.00	89.46 C
ATOM	8417 CG1	VAL M	192	17.566	5.648	66.679	1.00	88.94 C
ATOM	8418 CG2	VAL M	192	16.587	5.822	68.993	1.00	89.50 C
ATOM	8419 N	TYR M	193	14.993	3.848	64.896	1.00	80.82 N
ATOM	8420 CA	TYR M	193	14.904	2.804	63.883	1.00	80.16 C
ATOM	8421 C	TYR M	193	16.122	2.908	62.977	1.00	81.15 C
ATOM	8422 O	TYR M	193	16.270	3.902	62.275	1.00	80.57 O
ATOM	8423 CB	TYR M	193	13.571	2.935	63.104	1.00	81.30 C
ATOM	8424 CG	TYR M	193	12.379	2.450	63.905	1.00	83.20 C
ATOM	8425 CD1	TYR M	193	12.007	1.109	63.895	1.00	85.19 C
ATOM	8426 CD2	TYR M	193	11.670	3.315	64.734	1.00	83.80 C
ATOM	8427 CE1	TYR M	193	10.942	0.646	64.667	1.00	86.34 C
ATOM	8428 CE2	TYR M	193	10.613	2.858	65.527	1.00	84.39 C
ATOM	8429 CZ	TYR M	193	10.259	1.519	65.497	1.00	91.59 C
ATOM	8430 OH	TYR M	193	9.208	1.058	66.253	1.00	92.88 O
ATOM	8431 N	ALA M	194	17.012	1.909	63.022	1.00	76.20 N
ATOM	8432 CA	ALA M	194	18.242	1.953	62.241	1.00	76.13 C
ATOM	8433 C	ALA M	194	18.580	0.700	61.454	1.00	80.10 C
ATOM	8434 O	ALA M	194	18.419	-0.408	61.966	1.00	79.57 O
ATOM	8435 CB	ALA M	194	19.400	2.266	63.163	1.00	76.80 C
ATOM	8436 N	CYS M	195	19.133	0.877	60.239	1.00	76.36 N
ATOM	8437 CA	CYS M	195	19.657	-0.264	59.501	1.00	77.21 C
ATOM	8438 C	CYS M	195	21.161	-0.133	59.365	1.00	77.47 C
ATOM	8439 O	CYS M	195	21.646	0.962	59.123	1.00	75.83 O
ATOM	8440 CB	CYS M	195	18.952	-0.543	58.170	1.00	78.77 C
ATOM	8441 SG	CYS M	195	19.064	0.788	56.940	1.00	83.19 S
ATOM	8442 N	GLU M	196	21.893	-1.223	59.653	1.00	73.16 N
ATOM	8443 CA	GLU M	196	23.347	-1.278	59.638	1.00	73.13 C
ATOM	8444 C	GLU M	196	23.889	-2.174	58.486	1.00	78.56 C
ATOM	8445 O	GLU M	196	23.933	-3.413	58.593	1.00	75.88 O
ATOM	8446 CB	GLU M	196	23.870	-1.697	61.019	1.00	74.26 C
ATOM	8447 CG	GLU M	196	25.377	-1.655	61.141	1.00	88.40 C
ATOM	8448 CD	GLU M	196	25.902	-2.174	62.463	1.00	116.07 C
ATOM	8449 OE1	GLU M	196	25.830	-1.424	63.463	1.00	127.43 O
ATOM	8450 OE2	GLU M	196	26.391	-3.327	62.500	1.00	102.98 O
ATOM	8451 N	VAL M	197	24.318	-1.498	57.392	1.00	77.68 N
ATOM	8452 CA	VAL M	197	24.886	-2.060	56.161	1.00	78.35 C
ATOM	8453 C	VAL M	197	26.372	-2.438	56.350	1.00	87.18 C
ATOM	8454 O	VAL M	197	27.148	-1.648	56.883	1.00	88.16 O
ATOM	8455 CB	VAL M	197	24.638	-1.095	54.972	1.00	80.86 C
ATOM	8456 CG1	VAL M	197	25.433	-1.484	53.735	1.00	79.86 C
ATOM	8457 CG2	VAL M	197	23.156	-1.018	54.649	1.00	80.79 C
ATOM	8458 N	THR M	198	26.752	-3.653	55.919	1.00	85.19 N
ATOM	8459 CA	THR M	198	28.116	-4.180	56.009	1.00	85.28 C
ATOM	8460 C	THR M	198	28.553	-4.647	54.588	1.00	91.68 C
ATOM	8461 O	THR M	198	28.238	-5.764	54.158	1.00	90.48 O
ATOM	8462 CB	THR M	198	28.178	-5.285	57.086	1.00	85.80 C
ATOM	8463 OG1	THR M	198	27.590	-4.821	58.303	1.00	79.89 O
ATOM	8464 CG2	THR M	198	29.575	-5.797	57.329	1.00	83.55 C
ATOM	8465 N	HIS M	199	29.238	-3.765	53.857	1.00	90.30 N
ATOM	8466 CA	HIS M	199	29.733	-4.057	52.519	1.00	91.19 C
ATOM	8467 C	HIS M	199	31.251	-3.869	52.502	1.00	98.18 C
ATOM	8468 O	HIS M	199	31.774	-3.056	53.272	1.00	99.31 O
ATOM	8469 CB	HIS M	199	29.032	-3.166	51.467	1.00	91.81 C
ATOM	8470 CG	HIS M	199	29.314	-3.570	50.051	1.00	94.54 C
ATOM	8471 ND1	HIS M	199	30.418	-3.095	49.381	1.00	95.70 N
ATOM	8472 CD2	HIS M	199	28.633	-4.408	49.237	1.00	95.27 C
ATOM	8473 CE1	HIS M	199	30.386	-3.665	48.193	1.00	94.63 C
ATOM	8474 NE2	HIS M	199	29.321	-4.452	48.057	1.00	94.88 N
ATOM	8475 N	GLN M	200	31.957	-4.611	51.630	1.00	95.69 N
ATOM	8476 CA	GLN M	200	33.419	-4.524	51.513	1.00	96.16 C
ATOM	8477 C	GLN M	200	33.918	-3.227	50.841	1.00	101.29 C
ATOM	8478 O	GLN M	200	35.127	-3.002	50.789	1.00	101.98 O
ATOM	8479 CB	GLN M	200	34.016	-5.760	50.830	1.00	97.38 C
ATOM	8480 CG	GLN M	200	33.751	-5.854	49.341	1.00	110.20 C
ATOM	8481 CD	GLN M	200	33.833	-7.283	48.899	1.00	124.96 C
ATOM	8482 OE1	GLN M	200	34.806	-7.684	48.249	1.00	113.48 O
ATOM	8483 NE2	GLN M	200	32.813	-8.088	49.263	1.00	118.64 N

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezitoxumab
Fab - *C. difficile* toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	8484	N	GLY	M	201	32.994	-2.403	50.353	1.00	96.85	N
ATOM	8485	CA	GLY	M	201	33.309	-1.118	49.748	1.00	96.28	C
ATOM	8486	C	GLY	M	201	33.341	-0.025	50.783	1.00	99.10	C
ATOM	8487	O	GLY	M	201	33.828	1.076	50.510	1.00	98.75	O
ATOM	8488	N	LEU	M	202	32.802	-0.332	51.981	1.00	94.47	N
ATOM	8489	CA	LEU	M	202	32.707	0.572	53.127	1.00	93.54	C
ATOM	8490	C	LEU	M	202	33.778	0.250	54.170	1.00	99.77	C
ATOM	8491	O	LEU	M	202	33.980	-0.922	54.515	1.00	99.08	O
ATOM	8492	CB	LEU	M	202	31.317	0.489	53.769	1.00	92.62	C
ATOM	8493	CG	LEU	M	202	30.102	0.801	52.886	1.00	95.87	C
ATOM	8494	CD1	LEU	M	202	28.827	0.332	53.536	1.00	95.22	C
ATOM	8495	CD2	LEU	M	202	30.014	2.268	52.548	1.00	97.28	C
ATOM	8496	N	SER	M	203	34.457	1.300	54.677	1.00	97.91	N
ATOM	8497	CA	SER	M	203	35.544	1.239	55.674	1.00	98.07	C
ATOM	8498	C	SER	M	203	35.146	0.515	56.974	1.00	101.20	C
ATOM	8499	O	SER	M	203	35.944	-0.235	57.547	1.00	100.69	O
ATOM	8500	CB	SER	M	203	36.049	2.650	55.977	1.00	102.44	C
ATOM	8501	OG	SER	M	203	35.008	3.618	55.940	1.00	111.49	O
ATOM	8502	N	SER	M	204	33.891	0.741	57.410	1.00	96.40	N
ATOM	8503	CA	SER	M	204	33.280	0.167	58.604	1.00	95.18	C
ATOM	8504	C	SER	M	204	31.741	0.141	58.397	1.00	97.04	C
ATOM	8505	O	SER	M	204	31.247	0.888	57.531	1.00	95.97	O
ATOM	8506	CB	SER	M	204	33.655	0.996	59.835	1.00	97.87	C
ATOM	8507	OG	SER	M	204	32.832	2.141	59.998	1.00	106.11	O
ATOM	8508	N	PRO	M	205	30.966	-0.681	59.169	1.00	92.29	N
ATOM	8509	CA	PRO	M	205	29.508	-0.685	58.984	1.00	91.17	C
ATOM	8510	C	PRO	M	205	28.892	0.713	59.032	1.00	93.41	C
ATOM	8511	O	PRO	M	205	29.209	1.515	59.915	1.00	94.96	O
ATOM	8512	CB	PRO	M	205	28.991	-1.605	60.106	1.00	92.71	C
ATOM	8513	CG	PRO	M	205	30.111	-1.780	61.040	1.00	97.74	C
ATOM	8514	CD	PRO	M	205	31.364	-1.633	60.231	1.00	93.61	C
ATOM	8515	N	VAL	M	206	28.085	1.016	58.009	1.00	86.05	N
ATOM	8516	CA	VAL	M	206	27.356	2.272	57.818	1.00	84.00	C
ATOM	8517	C	VAL	M	206	25.959	2.113	58.402	1.00	86.35	C
ATOM	8518	O	VAL	M	206	25.280	1.136	58.094	1.00	86.65	O
ATOM	8519	CB	VAL	M	206	27.340	2.681	56.317	1.00	86.76	C
ATOM	8520	CG1	VAL	M	206	26.262	3.715	55.995	1.00	85.55	C
ATOM	8521	CG2	VAL	M	206	28.716	3.185	55.891	1.00	86.96	C
ATOM	8522	N	THR	M	207	25.545	3.055	59.262	1.00	81.12	N
ATOM	8523	CA	THR	M	207	24.225	3.062	59.888	1.00	79.79	C
ATOM	8524	C	THR	M	207	23.446	4.316	59.455	1.00	82.19	C
ATOM	8525	O	THR	M	207	23.958	5.430	59.589	1.00	82.00	O
ATOM	8526	CB	THR	M	207	24.346	2.864	61.420	1.00	82.94	C
ATOM	8527	OG1	THR	M	207	25.113	1.682	61.693	1.00	82.62	O
ATOM	8528	CG2	THR	M	207	22.993	2.781	62.112	1.00	76.15	C
ATOM	8529	N	LYS	M	208	22.241	4.113	58.879	1.00	77.66	N
ATOM	8530	CA	LYS	M	208	21.312	5.161	58.442	1.00	76.95	C
ATOM	8531	C	LYS	M	208	20.026	4.989	59.294	1.00	82.75	C
ATOM	8532	O	LYS	M	208	19.426	3.917	59.288	1.00	82.97	O
ATOM	8533	CB	LYS	M	208	21.064	5.081	56.920	1.00	77.87	C
ATOM	8534	N	SER	M	209	19.676	5.999	60.115	1.00	80.38	N
ATOM	8535	CA	SER	M	209	18.553	5.916	61.047	1.00	80.44	C
ATOM	8536	C	SER	M	209	17.607	7.124	61.061	1.00	86.58	C
ATOM	8537	O	SER	M	209	17.839	8.132	60.392	1.00	85.89	O
ATOM	8538	CB	SER	M	209	19.072	5.645	62.460	1.00	83.66	C
ATOM	8539	OG	SER	M	209	19.221	6.807	63.260	1.00	91.69	O
ATOM	8540	N	PHE	M	210	16.533	6.989	61.851	1.00	85.72	N
ATOM	8541	CA	PHE	M	210	15.513	7.991	62.102	1.00	86.96	C
ATOM	8542	C	PHE	M	210	14.885	7.788	63.493	1.00	91.32	C
ATOM	8543	O	PHE	M	210	15.051	6.739	64.133	1.00	91.33	O
ATOM	8544	CB	PHE	M	210	14.438	8.033	60.981	1.00	89.64	C
ATOM	8545	CG	PHE	M	210	13.435	6.892	60.947	1.00	92.29	C
ATOM	8546	CD1	PHE	M	210	12.318	6.893	61.783	1.00	95.74	C
ATOM	8547	CD2	PHE	M	210	13.584	5.842	60.053	1.00	94.61	C
ATOM	8548	CE1	PHE	M	210	11.400	5.829	61.761	1.00	96.33	C
ATOM	8549	CE2	PHE	M	210	12.658	4.791	60.024	1.00	97.19	C
ATOM	8550	CZ	PHE	M	210	11.571	4.793	60.873	1.00	94.96	C
ATOM	8551	N	ASN	M	211	14.174	8.823	63.940	1.00	87.36	N
ATOM	8552	CA	ASN	M	211	13.408	8.906	65.171	1.00	87.32	C
ATOM	8553	C	ASN	M	211	12.069	9.441	64.695	1.00	91.87	C
ATOM	8554	O	ASN	M	211	12.043	10.165	63.693	1.00	92.50	O
ATOM	8555	CB	ASN	M	211	14.077	9.873	66.150	1.00	90.21	C
ATOM	8556	CG	ASN	M	211	15.525	9.545	66.447	1.00	118.86	C
ATOM	8557	OD1	ASN	M	211	15.831	8.688	67.282	1.00	116.71	O
ATOM	8558	ND2	ASN	M	211	16.449	10.211	65.760	1.00	108.60	N
ATOM	8559	N	ARG	M	212	10.965	9.093	65.366	1.00	87.97	N
ATOM	8560	CA	ARG	M	212	9.620	9.498	64.941	1.00	87.97	C

TABLE1-continued

Three-dimensional crystal coordinate for anti-TcdB antibody bezlotoxumab
Fab -C. difficile toxin B (TcdB⁽¹⁸³⁴⁻²¹⁰¹⁾) complex.

ATOM	8561	C	ARG	M	212	9.273	11.032	65.069	1.00	93.22	C
ATOM	8562	O	ARG	M	212	8.432	11.418	65.892	1.00	93.64	O
ATOM	8563	CB	ARG	M	212	8.598	8.646	65.684	1.00	86.47	C
ATOM	8564	CG	ARG	M	212	8.447	7.264	65.091	1.00	88.28	C
ATOM	8565	CD	ARG	M	212	8.770	6.172	66.083	1.00	87.21	C
ATOM	8566	NE	ARG	M	212	8.171	6.368	67.410	1.00	91.76	N
ATOM	8567	CZ	ARG	M	212	6.881	6.214	67.705	1.00	100.71	C
ATOM	8568	NH1	ARG	M	212	6.004	5.920	66.751	1.00	95.66	N
ATOM	8569	NH2	ARG	M	212	6.451	6.403	68.946	1.00	72.84	N
ATOM	8570	N	GLY	M	213	9.873	11.860	64.209	1.00	88.76	N
ATOM	8571	CA	GLY	M	213	9.658	13.303	64.188	1.00	101.30	C
ATOM	8572	C	GLY	M	213	10.587	14.045	63.245	1.00	112.67	C
ATOM	8573	O	GLY	M	213	11.803	13.830	63.256	1.00	65.19	O
TER	8574		GLY	M	213						
HETATM	8575	O	HOH	W	1	26.307	-31.997	-2.011	1.00	48.73	O
HETATM	8576	O	HOH	W	2	22.526	-3.989	-23.853	1.00	48.16	O
HETATM	8577	O	HOH	W	3	14.644	-7.119	-27.035	1.00	66.79	O
HETATM	8578	O	HOH	W	4	19.424	-39.800	-5.896	1.00	52.99	O
HETATM	8579	O	HOH	W	5	23.260	15.691	-1.224	1.00	50.95	O
HETATM	8580	O	HOH	W	6	18.764	2.750	35.487	1.00	42.29	O
HETATM	8581	O	HOH	W	7	25.977	0.281	-32.052	1.00	45.46	O
HETATM	8582	O	HOH	W	8	18.861	-2.190	37.149	1.00	46.78	O
HETATM	8583	O	HOH	W	9	31.231	15.144	-17.678	1.00	48.84	O
HETATM	8584	O	HOH	W	10	9.450	-45.171	15.010	1.00	52.02	O
HETATM	8585	O	HOH	W	11	3.958	-31.748	11.822	1.00	58.88	O
HETATM	8586	O	HOH	W	12	-10.876	-63.982	33.588	1.00	59.28	O
HETATM	8587	O	HOH	W	13	-8.867	-60.172	31.826	1.00	45.54	O
HETATM	8588	O	HOH	W	14	15.215	-23.239	21.830	1.00	56.03	O
END											

Example 8

Binding Analysis of Toxin Fragments to Bezlotoxumab (Sandwich Assay Format)

Binding of TcdB and TcdB fragments to the antibodies was studied by surface plasmon resonance using ProteOn XPR36

tions in ProteOn Running Buffer (PBS pH 7.4, 0.005% Tween-20) and injected in horizontal orientation for 4 min (flow rate 25 ml/min). Association and dissociation were measured over time as changes in the refractive index. Data analyses were carried out using the ProteOn instrument software and data were fitted using a two site heterogeneous ligand model to determine k_{on} , k_{off} and K_d .

TABLE 2

Binding of toxin B fragments to bezlotoxumab

Toxin Fragment	High affinity binding site			Low affinity binding site		
	k_{on}^a (M ⁻¹ · sec ⁻¹)	k_{off} (sec ⁻¹)	K_d^* (pM)	k_{on} (M ⁻¹ · sec ⁻¹)	k_{off} (sec ⁻¹)	K_d^* (pM)
TcdB	$1.52 \times 10^6 \pm 0.45 \times 10^6$	$2.83 \times 10^{-5} \pm 0.11 \times 10^{-5}$	19 ± 5	$1.57 \times 10^7 \pm 0.14 \times 10^7$	$5.59 \times 10^{-3} \pm 4.36 \times 10^{-3}$	370 ± 310
B1	$3.64 \times 10^6 \pm 0.11 \times 10^6$	$1.41 \times 10^{-4} \pm 0.06 \times 10^{-4}$	41 ± 13	$2.09 \times 10^7 \pm 0.11 \times 10^7$	$1.37 \times 10^{-2} \pm 0.07 \times 10^{-2}$	660 ± 35
B2	$3.73 \times 10^6 \pm 0.11 \times 10^6$	$1.61 \times 10^{-4} \pm 0.28 \times 10^{-4}$	46 ± 21	$1.35 \times 10^7 \pm 0.13 \times 10^7$	$1.10 \times 10^{-2} \pm 0.18 \times 10^{-2}$	810 ± 56
B3	N/M ^b	N/M	N/M	$3.25 \times 10^6 \pm 1.52 \times 10^6$	$3.03 \times 10^{-2} \pm 0.36 \times 10^{-2}$	$11,000 \pm 6,000$
B4	N/M	N/M	N/M	N/M	N/M	N/M

instrument (BioRad, Hercules, Calif., USA). Bezlotoxumab was immobilized to the sensor chip surface using an antibody capture method. Briefly, a ProteOn GLC Sensor chip was docked to the system, and after standard cleaning according to the manufacturer's recommendations, a mixture of 1xEDC+sNHS was injected over the chip to activate the chip surface. A 25 mg/mL solution of Goat anti-Human IgG F(ab')₂ (ThermoScientific, Rockford, Ill., USA) in ProteOn immobilization buffer (10 mM Sodium Acetate, pH 5.5) was injected over 2 min. 1 M Ethanolamine HCl was then injected over 5 mins to block any unoccupied reactive sites on the chip surface. Twenty mg/mL Bezlotoxumab in ProteOn Running Buffer (PBS pH 7.4, 0.005% Tween-20) was injected over 2 mins. Toxins fragments were diluted at various concentra-

55
55
60
The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, the scope of the present invention includes embodiments specifically set forth herein and other embodiments not specifically set forth herein; the embodiments specifically set forth herein are not necessarily intended to be exhaustive. Various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the claims.

Patents, patent applications, publications, product descriptions, and protocols are cited throughout this application, the disclosures of which are incorporated herein by reference in their entireties for all purposes.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 14

<210> SEQ ID NO 1

<211> LENGTH: 2366

<212> TYPE: PRT

<213> ORGANISM: Clostridium difficile

<400> SEQUENCE: 1

Met	Ser	Leu	Val	Asn	Arg	Lys	Gln	Leu	Glu	Lys	Met	Ala	Asn	Val	Arg
1								10							15

Phe	Arg	Thr	Gln	Glu	Asp	Glu	Tyr	Val	Ala	Ile	Leu	Asp	Ala	Leu	Glu
			20				25							30	

Glu	Tyr	His	Asn	Met	Ser	Glu	Asn	Thr	Val	Val	Glu	Lys	Tyr	Leu	Lys
			35				40					45			

Leu	Lys	Asp	Ile	Asn	Ser	Leu	Thr	Asp	Ile	Tyr	Ile	Asp	Thr	Tyr	Lys
	50						55				60				

Lys	Ser	Gly	Arg	Asn	Lys	Ala	Leu	Lys	Lys	Phe	Glu	Tyr	Leu	Val
65							70			75			80	

Thr	Glu	Val	Leu	Glu	Leu	Lys	Asn	Asn	Asn	Leu	Thr	Pro	Val	Glu	Lys
			85				90				95				

Asn	Leu	His	Phe	Val	Trp	Ile	Gly	Gly	Gln	Ile	Asn	Asp	Thr	Ala	Ile
			100				105			110					

Asn	Tyr	Ile	Asn	Gln	Trp	Lys	Asp	Val	Asn	Ser	Asp	Tyr	Asn	Val	Asn
			115				120				125				

Val	Phe	Tyr	Asp	Ser	Asn	Ala	Phe	Leu	Ile	Asn	Thr	Leu	Lys	Lys	Thr
							130			135		140			

Val	Val	Glu	Ser	Ala	Ile	Asn	Asp	Thr	Leu	Glu	Ser	Phe	Arg	Glu	Asn
145							150			155			160		

Leu	Asn	Asp	Pro	Arg	Phe	Asp	Tyr	Asn	Lys	Phe	Phe	Arg	Lys	Arg	Met
			165				170					175			

Glu	Ile	Ile	Tyr	Asp	Lys	Gln	Lys	Asn	Phe	Ile	Asn	Tyr	Tyr	Lys	Ala
			180				185				190				

Gln	Arg	Glu	Glu	Asn	Pro	Glu	Leu	Ile	Ile	Asp	Asp	Ile	Val	Lys	Thr
			195			200				205					

Tyr	Leu	Ser	Asn	Glu	Tyr	Ser	Lys	Glu	Ile	Asp	Glu	Leu	Asn	Thr	Tyr
			210			215			220						

Ile	Glu	Glu	Ser	Leu	Asn	Lys	Ile	Thr	Gln	Asn	Ser	Gly	Asn	Asp	Val
225							230			235		240			

Arg	Asn	Phe	Glu	Glu	Phe	Lys	Asn	Gly	Glu	Ser	Phe	Asn	Leu	Tyr	Glu
			245			250			255					255	

Gln	Glu	Leu	Val	Glu	Arg	Trp	Asn	Leu	Ala	Ala	Ala	Ser	Asp	Ile	Leu
			260			265					270				

Arg	Ile	Ser	Ala	Leu	Lys	Glu	Ile	Gly	Gly	Met	Tyr	Leu	Asp	Val	Asp
			275			280				285					

Met	Leu	Pro	Gly	Ile	Gln	Pro	Asp	Leu	Phe	Glu	Ser	Ile	Glu	Lys	Pro
290							295			300					

Ser	Ser	Val	Thr	Val	Asp	Phe	Trp	Glu	Met	Thr	Lys	Leu	Glu	Ala	Ile
305							310			315		320			

Met	Lys	Tyr	Lys	Glu	Tyr	Ile	Pro	Glu	Tyr	Thr	Ser	Glu	His	Phe	Asp
			325			330			335					335	

Met	Leu	Asp	Glu	Glu	Val	Gln	Ser	Ser	Phe	Glu	Ser	Val	Leu	Ala	Ser
			340			345			350						

Lys	Ser	Asp	Lys	Ser	Glu	Ile	Phe	Ser	Ser	Leu	Gly	Asp	Met	Glu	Ala
			355			360				365					

-continued

Ser Pro Leu Glu Val Lys Ile Ala Phe Asn Ser Lys Gly Ile Ile Asn
 370 375 380
 Gln Gly Leu Ile Ser Val Lys Asp Ser Tyr Cys Ser Asn Leu Ile Val
 385 390 395 400
 Lys Gln Ile Glu Asn Arg Tyr Lys Ile Leu Asn Asn Ser Leu Asn Pro
 405 410 415
 Ala Ile Ser Glu Asp Asn Asp Phe Asn Thr Thr Thr Asn Thr Phe Ile
 420 425 430
 Asp Ser Ile Met Ala Glu Ala Asn Ala Asp Asn Gly Arg Phe Met Met
 435 440 445
 Glu Leu Gly Lys Tyr Leu Arg Val Gly Phe Phe Pro Asp Val Lys Thr
 450 455 460
 Thr Ile Asn Leu Ser Gly Pro Glu Ala Tyr Ala Ala Ala Tyr Gln Asp
 465 470 475 480
 Leu Leu Met Phe Lys Glu Gly Ser Met Asn Ile His Leu Ile Glu Ala
 485 490 495
 Asp Leu Arg Asn Phe Glu Ile Ser Lys Thr Asn Ile Ser Gln Ser Thr
 500 505 510
 Glu Gln Glu Met Ala Ser Leu Trp Ser Phe Asp Asp Ala Arg Ala Lys
 515 520 525
 Ala Gln Phe Glu Glu Tyr Lys Arg Asn Tyr Phe Glu Gly Ser Leu Gly
 530 535 540
 Glu Asp Asp Asn Leu Asp Phe Ser Gln Asn Ile Val Val Asp Lys Glu
 545 550 555 560
 Tyr Leu Leu Glu Lys Ile Ser Ser Leu Ala Arg Ser Ser Glu Arg Gly
 565 570 575
 Tyr Ile His Tyr Ile Val Gln Leu Gln Gly Asp Lys Ile Ser Tyr Glu
 580 585 590
 Ala Ala Cys Asn Leu Phe Ala Lys Thr Pro Tyr Asp Ser Val Leu Phe
 595 600 605
 Gln Lys Asn Ile Glu Asp Ser Glu Ile Ala Tyr Tyr Asn Pro Gly
 610 615 620
 Asp Gly Glu Ile Gln Glu Ile Asp Lys Tyr Lys Ile Pro Ser Ile Ile
 625 630 635 640
 Ser Asp Arg Pro Lys Ile Lys Leu Thr Phe Ile Gly His Gly Lys Asp
 645 650 655
 Glu Phe Asn Thr Asp Ile Phe Ala Gly Phe Asp Val Asp Ser Leu Ser
 660 665 670
 Thr Glu Ile Glu Ala Ala Ile Asp Leu Ala Lys Glu Asp Ile Ser Pro
 675 680 685
 Lys Ser Ile Glu Ile Asn Leu Leu Gly Cys Asn Met Phe Ser Tyr Ser
 690 695 700
 Ile Asn Val Glu Glu Thr Tyr Pro Gly Lys Leu Leu Leu Lys Val Lys
 705 710 715 720
 Asp Lys Ile Ser Glu Leu Met Pro Ser Ile Ser Gln Asp Ser Ile Ile
 725 730 735
 Val Ser Ala Asn Gln Tyr Glu Val Arg Ile Asn Ser Glu Gly Arg Arg
 740 745 750
 Glu Leu Leu Asp His Ser Gly Glu Trp Ile Asn Lys Glu Glu Ser Ile
 755 760 765
 Ile Lys Asp Ile Ser Ser Lys Glu Tyr Ile Ser Phe Asn Pro Lys Glu
 770 775 780
 Asn Lys Ile Thr Val Lys Ser Lys Asn Leu Pro Glu Leu Ser Thr Leu

US 9,181,632 B1

257

-continued

258

785	790	795	800
Leu Gln Glu Ile Arg Asn Asn Ser Ser Ser Asp Ile Glu Leu Glu			
805	810	815	
Glu Lys Val Met Leu Thr Glu Cys Glu Ile Asn Val Ile Ser Asn Ile			
820	825	830	
Asp Thr Gln Ile Val Glu Glu Arg Ile Glu Glu Ala Lys Asn Leu Thr			
835	840	845	
Ser Asp Ser Ile Asn Tyr Ile Lys Asp Glu Phe Lys Leu Ile Glu Ser			
850	855	860	
Ile Ser Asp Ala Leu Cys Asp Leu Lys Gln Gln Asn Glu Leu Glu Asp			
865	870	875	880
Ser His Phe Ile Ser Phe Glu Asp Ile Ser Glu Thr Asp Glu Gly Phe			
885	890	895	
Ser Ile Arg Phe Ile Asn Lys Glu Thr Gly Glu Ser Ile Phe Val Glu			
900	905	910	
Thr Glu Lys Thr Ile Phe Ser Glu Tyr Ala Asn His Ile Thr Glu Glu			
915	920	925	
Ile Ser Lys Ile Lys Gly Thr Ile Phe Asp Thr Val Asn Gly Lys Leu			
930	935	940	
Val Lys Lys Val Asn Leu Asp Thr Thr His Glu Val Asn Thr Leu Asn			
945	950	955	960
Ala Ala Phe Phe Ile Gln Ser Leu Ile Glu Tyr Asn Ser Ser Lys Glu			
965	970	975	
Ser Leu Ser Asn Leu Ser Val Ala Met Lys Val Gln Val Tyr Ala Gln			
980	985	990	
Leu Phe Ser Thr Gly Leu Asn Thr Ile Thr Asp Ala Ala Lys Val Val			
995	1000	1005	
Glu Leu Val Ser Thr Ala Leu Asp Glu Thr Ile Asp Leu Leu Pro			
1010	1015	1020	
Thr Leu Ser Glu Gly Leu Pro Ile Ile Ala Thr Ile Ile Asp Gly			
1025	1030	1035	
Val Ser Leu Gly Ala Ala Ile Lys Glu Leu Ser Glu Thr Ser Asp			
1040	1045	1050	
Pro Leu Leu Arg Gln Glu Ile Glu Ala Lys Ile Gly Ile Met Ala			
1055	1060	1065	
Val Asn Leu Thr Thr Ala Thr Thr Ala Ile Ile Thr Ser Ser Leu			
1070	1075	1080	
Gly Ile Ala Ser Gly Phe Ser Ile Leu Leu Val Pro Leu Ala Gly			
1085	1090	1095	
Ile Ser Ala Gly Ile Pro Ser Leu Val Asn Asn Glu Leu Val Leu			
1100	1105	1110	
Arg Asp Lys Ala Thr Lys Val Val Asp Tyr Phe Lys His Val Ser			
1115	1120	1125	
Leu Val Glu Thr Glu Gly Val Phe Thr Leu Leu Asp Asp Lys Ile			
1130	1135	1140	
Met Met Pro Gln Asp Asp Leu Val Ile Ser Glu Ile Asp Phe Asn			
1145	1150	1155	
Asn Asn Ser Ile Val Leu Gly Lys Cys Glu Ile Trp Arg Met Glu			
1160	1165	1170	
Gly Gly Ser Gly His Thr Val Thr Asp Asp Ile Asp His Phe Phe			
1175	1180	1185	
Ser Ala Pro Ser Ile Thr Tyr Arg Glu Pro His Leu Ser Ile Tyr			
1190	1195	1200	

US 9,181,632 B1

259

-continued

Asp	Val	Leu	Glu	Val	Gln	Lys	Glu	Glu	Leu	Asp	Leu	Ser	Lys	Asp
1205						1210					1215			
Leu	Met	Val	Leu	Pro	Asn	Ala	Pro	Asn	Arg	Val	Phe	Ala	Trp	Glu
1220						1225					1230			
Thr	Gly	Trp	Thr	Pro	Gly	Leu	Arg	Ser	Leu	Glu	Asn	Asp	Gly	Thr
1235						1240					1245			
Lys	Leu	Leu	Asp	Arg	Ile	Arg	Asp	Asn	Tyr	Glu	Gly	Glu	Phe	Tyr
1250						1255					1260			
Trp	Arg	Tyr	Phe	Ala	Phe	Ile	Ala	Asp	Ala	Leu	Ile	Thr	Thr	Leu
1265						1270					1275			
Lys	Pro	Arg	Tyr	Glu	Asp	Thr	Asn	Ile	Arg	Ile	Asn	Leu	Asp	Ser
1280						1285					1290			
Asn	Thr	Arg	Ser	Phe	Ile	Val	Pro	Ile	Ile	Thr	Thr	Glu	Tyr	Ile
1295						1300					1305			
Arg	Glu	Lys	Leu	Ser	Tyr	Ser	Phe	Tyr	Gly	Ser	Gly	Gly	Thr	Tyr
1310						1315					1320			
Ala	Leu	Ser	Leu	Ser	Gln	Tyr	Asn	Met	Gly	Ile	Asn	Ile	Glu	Leu
1325						1330					1335			
Ser	Glu	Ser	Asp	Val	Trp	Ile	Ile	Asp	Val	Asp	Asn	Val	Val	Arg
1340						1345					1350			
Asp	Val	Thr	Ile	Glu	Ser	Asp	Lys	Ile	Lys	Lys	Gly	Asp	Leu	Ile
1355						1360					1365			
Glu	Gly	Ile	Leu	Ser	Thr	Leu	Ser	Ile	Glu	Glu	Asn	Lys	Ile	Ile
1370						1375					1380			
Leu	Asn	Ser	His	Glu	Ile	Asn	Phe	Ser	Gly	Glu	Val	Asn	Gly	Ser
1385						1390					1395			
Asn	Gly	Phe	Val	Ser	Leu	Thr	Phe	Ser	Ile	Leu	Glu	Gly	Ile	Asn
1400						1405					1410			
Ala	Ile	Ile	Glu	Val	Asp	Leu	Leu	Ser	Lys	Ser	Tyr	Lys	Leu	Leu
1415						1420					1425			
Ile	Ser	Gly	Glu	Leu	Lys	Ile	Leu	Met	Leu	Asn	Ser	Asn	His	Ile
1430						1435					1440			
Gln	Gln	Lys	Ile	Asp	Tyr	Ile	Gly	Phe	Asn	Ser	Glu	Leu	Gln	Lys
1445						1450					1455			
Asn	Ile	Pro	Tyr	Ser	Phe	Val	Asp	Ser	Glu	Gly	Lys	Glu	Asn	Gly
1460						1465					1470			
Phe	Ile	Asn	Gly	Ser	Thr	Lys	Glu	Gly	Leu	Phe	Val	Ser	Glu	Leu
1475						1480					1485			
Pro	Asp	Val	Val	Leu	Ile	Ser	Lys	Val	Tyr	Met	Asp	Asp	Ser	Lys
1490						1495					1500			
Pro	Ser	Phe	Gly	Tyr	Tyr	Ser	Asn	Asn	Leu	Lys	Asp	Val	Lys	Val
1505						1510					1515			
Ile	Thr	Lys	Asp	Asn	Val	Asn	Ile	Leu	Thr	Gly	Tyr	Tyr	Leu	Lys
1520						1525					1530			
Asp	Asp	Ile	Lys	Ile	Ser	Leu	Ser	Leu	Thr	Leu	Gln	Asp	Glu	Lys
1535						1540					1545			
Thr	Ile	Lys	Leu	Asn	Ser	Val	His	Leu	Asp	Glu	Ser	Gly	Val	Ala
1550						1555					1560			
Glu	Ile	Leu	Lys	Phe	Met	Asn	Arg	Lys	Gly	Asn	Thr	Asn	Thr	Ser
1565						1570					1575			
Asp	Ser	Leu	Met	Ser	Phe	Leu	Glu	Ser	Met	Asn	Ile	Lys	Ser	Ile
1580						1585					1590			

260

-continued

Phe Val Asn Phe Leu Gln Ser Asn Ile Lys Phe Ile Leu Asp Ala
1595 1600 1605

Asn Phe Ile Ile Ser Gly Thr Thr Ser Ile Gly Gln Phe Glu Phe
1610 1615 1620

Ile Cys Asp Glu Asn Asp Asn Ile Gln Pro Tyr Phe Ile Lys Phe
1625 1630 1635

Asn Thr Leu Glu Thr Asn Tyr Thr Leu Tyr Val Gly Asn Arg Gln
1640 1645 1650

Asn Met Ile Val Glu Pro Asn Tyr Asp Leu Asp Asp Ser Gly Asp
1655 1660 1665

Ile Ser Ser Thr Val Ile Asn Phe Ser Gln Lys Tyr Leu Tyr Gly
1670 1675 1680

Ile Asp Ser Cys Val Asn Lys Val Val Ile Ser Pro Asn Ile Tyr
1685 1690 1695

Thr Asp Glu Ile Asn Ile Thr Pro Val Tyr Glu Thr Asn Asn Thr
1700 1705 1710

Tyr Pro Glu Val Ile Val Leu Asp Ala Asn Tyr Ile Asn Glu Lys
1715 1720 1725

Ile Asn Val Asn Ile Asn Asp Leu Ser Ile Arg Tyr Val Trp Ser
1730 1735 1740

Asn Asp Gly Asn Asp Phe Ile Leu Met Ser Thr Ser Glu Glu Asn
1745 1750 1755

Lys Val Ser Gln Val Lys Ile Arg Phe Val Asn Val Phe Lys Asp
1760 1765 1770

Lys Thr Leu Ala Asn Lys Leu Ser Phe Asn Phe Ser Asp Lys Gln
1775 1780 1785

Asp Val Pro Val Ser Glu Ile Ile Leu Ser Phe Thr Pro Ser Tyr
1790 1795 1800

Tyr Glu Asp Gly Leu Ile Gly Tyr Asp Leu Gly Leu Val Ser Leu
1805 1810 1815

Tyr Asn Glu Lys Phe Tyr Ile Asn Asn Phe Gly Met Met Val Ser
1820 1825 1830

Gly Leu Ile Tyr Ile Asn Asp Ser Leu Tyr Tyr Phe Lys Pro Pro
1835 1840 1845

Val Asn Asn Leu Ile Thr Gly Phe Val Thr Val Gly Asp Asp Lys
1850 1855 1860

Tyr Tyr Phe Asn Pro Ile Asn Gly Gly Ala Ala Ser Ile Gly Glu
1865 1870 1875

Thr Ile Ile Asp Asp Lys Asn Tyr Tyr Phe Asn Gln Ser Gly Val
1880 1885 1890

Leu Gln Thr Gly Val Phe Ser Thr Glu Asp Gly Phe Lys Tyr Phe
1895 1900 1905

Ala Pro Ala Asn Thr Leu Asp Glu Asn Leu Glu Gly Glu Ala Ile
1910 1915 1920

Asp Phe Thr Gly Lys Leu Ile Ile Asp Glu Asn Ile Tyr Tyr Phe
1925 1930 1935

Asp Asp Asn Tyr Arg Gly Ala Val Glu Trp Lys Glu Leu Asp Gly
1940 1945 1950

Glu Met His Tyr Phe Ser Pro Glu Thr Gly Lys Ala Phe Lys Gly
1955 1960 1965

Leu Asn Gln Ile Gly Asp Tyr Lys Tyr Tyr Phe Asn Ser Asp Gly
1970 1975 1980

Val Met Gln Lys Gly Phe Val Ser Ile Asn Asp Asn Lys His Tyr

-continued

1985	1990	1995
Phe Asp Asp Ser Gly Val Met Lys Val Gly Tyr Thr Glu Ile Asp		
2000 2005 2010		
Gly Lys His Phe Tyr Phe Ala Glu Asn Gly Glu Met Gln Ile Gly		
2015 2020 2025		
Val Phe Asn Thr Glu Asp Gly Phe Lys Tyr Phe Ala His His Asn		
2030 2035 2040		
Glu Asp Leu Gly Asn Glu Glu Gly Glu Glu Ile Ser Tyr Ser Gly		
2045 2050 2055		
Ile Leu Asn Phe Asn Asn Lys Ile Tyr Tyr Phe Asp Asp Ser Phe		
2060 2065 2070		
Thr Ala Val Val Gly Trp Lys Asp Leu Glu Asp Gly Ser Lys Tyr		
2075 2080 2085		
Tyr Phe Asp Glu Asp Thr Ala Glu Ala Tyr Ile Gly Leu Ser Leu		
2090 2095 2100		
Ile Asn Asp Gly Gln Tyr Tyr Phe Asn Asp Asp Gly Ile Met Gln		
2105 2110 2115		
Val Gly Phe Val Thr Ile Asn Asp Lys Val Phe Tyr Phe Ser Asp		
2120 2125 2130		
Ser Gly Ile Ile Glu Ser Gly Val Gln Asn Ile Asp Asp Asn Tyr		
2135 2140 2145		
Phe Tyr Ile Asp Asp Asn Gly Ile Val Gln Ile Gly Val Phe Asp		
2150 2155 2160		
Thr Ser Asp Gly Tyr Lys Tyr Phe Ala Pro Ala Asn Thr Val Asn		
2165 2170 2175		
Asp Asn Ile Tyr Gly Gln Ala Val Glu Tyr Ser Gly Leu Val Arg		
2180 2185 2190		
Val Gly Glu Asp Val Tyr Tyr Phe Gly Glu Thr Tyr Thr Ile Glu		
2195 2200 2205		
Thr Gly Trp Ile Tyr Asp Met Glu Asn Glu Ser Asp Lys Tyr Tyr		
2210 2215 2220		
Phe Asn Pro Glu Thr Lys Lys Ala Cys Lys Gly Ile Asn Leu Ile		
2225 2230 2235		
Asp Asp Ile Lys Tyr Tyr Phe Asp Glu Lys Gly Ile Met Arg Thr		
2240 2245 2250		
Gly Leu Ile Ser Phe Glu Asn Asn Asn Tyr Tyr Phe Asn Glu Asn		
2255 2260 2265		
Gly Glu Met Gln Phe Gly Tyr Ile Asn Ile Glu Asp Lys Met Phe		
2270 2275 2280		
Tyr Phe Gly Glu Asp Gly Val Met Gln Ile Gly Val Phe Asn Thr		
2285 2290 2295		
Pro Asp Gly Phe Lys Tyr Phe Ala His Gln Asn Thr Leu Asp Glu		
2300 2305 2310		
Asn Phe Glu Gly Glu Ser Ile Asn Tyr Thr Gly Trp Leu Asp Leu		
2315 2320 2325		
Asp Glu Lys Arg Tyr Tyr Phe Thr Asp Glu Tyr Ile Ala Ala Thr		
2330 2335 2340		
Gly Ser Val Ile Ile Asp Gly Glu Glu Tyr Tyr Phe Asp Pro Asp		
2345 2350 2355		
Thr Ala Gln Leu Val Ile Ser Glu		
2360 2365		

-continued

<211> LENGTH: 275
 <212> TYPE: PRT
 <213> ORGANISM: Clostridium difficile
 <400> SEQUENCE: 2

```

Met Gly Leu Ile Tyr Ile Asn Asp Ser Leu Tyr Tyr Phe Lys Pro Pro
1           5          10          15

Val Asn Asn Leu Ile Thr Gly Phe Val Thr Val Gly Asp Asp Lys Tyr
20          25          30

Tyr Phe Asn Pro Ile Asn Gly Gly Ala Ala Ser Ile Gly Glu Thr Ile
35          40          45

Ile Asp Asp Lys Asn Tyr Tyr Phe Asn Gln Ser Gly Val Leu Gln Thr
50          55          60

Gly Val Phe Ser Thr Glu Asp Gly Phe Lys Tyr Phe Ala Pro Ala Asn
65          70          75          80

Thr Leu Asp Glu Asn Leu Glu Gly Ala Ile Asp Phe Thr Gly Lys
85          90          95

Leu Ile Ile Asp Glu Asn Ile Tyr Tyr Phe Asp Asp Asn Tyr Arg Gly
100         105         110

Ala Val Glu Trp Lys Glu Leu Asp Gly Glu Met His Tyr Phe Ser Pro
115         120         125

Glu Thr Gly Lys Ala Phe Lys Gly Leu Asn Gln Ile Gly Asp Tyr Lys
130         135         140

Tyr Tyr Phe Asn Ser Asp Gly Val Met Gln Lys Gly Phe Val Ser Ile
145         150         155         160

Asn Asp Asn Lys His Tyr Phe Asp Asp Ser Gly Val Met Lys Val Gly
165         170         175

Tyr Thr Glu Ile Asp Gly Lys His Phe Tyr Phe Ala Glu Asn Gly Glu
180         185         190

Met Gln Ile Gly Val Phe Asn Thr Glu Asp Gly Phe Lys Tyr Phe Ala
195         200         205

His His Asn Glu Asp Leu Gly Asn Glu Glu Gly Glu Ile Ser Tyr
210         215         220

Ser Gly Ile Leu Asn Phe Asn Asn Lys Ile Tyr Tyr Phe Asp Asp Ser
225         230         235         240

Phe Thr Ala Val Val Gly Trp Lys Asp Leu Glu Asp Gly Ser Lys Tyr
245         250         255

Tyr Phe Asp Glu Asp Thr Ala Glu Ala Tyr Ile Leu Glu His His His
260         265         270

His His His
275
  
```

<210> SEQ ID NO 3
 <211> LENGTH: 13
 <212> TYPE: PRT
 <213> ORGANISM: Clostridium difficile

<400> SEQUENCE: 3

```

Glu Asp Gly Phe Lys Tyr Phe Ala Pro Ala Asn Thr Leu
1           5          10
  
```

<210> SEQ ID NO 4
 <211> LENGTH: 5
 <212> TYPE: PRT
 <213> ORGANISM: Clostridium difficile

<400> SEQUENCE: 4

-continued

Glu Asn Gly Glu Met
1 5

<210> SEQ ID NO 5
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Clostridium difficile
<400> SEQUENCE: 5

Glu Asp Gly Phe Lys Tyr
1 5

<210> SEQ ID NO 6
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Clostridium difficile
<400> SEQUENCE: 6

Glu Asn Gly Glu Met Gln Ile Gly Val Phe Asn Thr Glu Asp Gly Phe
1 5 10 15

Lys Tyr

<210> SEQ ID NO 7
<211> LENGTH: 117
<212> TYPE: PRT
<213> ORGANISM: Clostridium difficile
<400> SEQUENCE: 7

Gly Phe Val Thr Val Gly Asp Asp Lys Tyr Tyr Phe Asn Pro Ile Asn
1 5 10 15

Gly Gly Ala Ala Ser Ile Gly Glu Thr Ile Ile Asp Asp Lys Asn Tyr
20 25 30

Tyr Phe Asn Gln Ser Gly Val Leu Gln Thr Gly Val Phe Ser Thr Glu
35 40 45

Asp Gly Phe Lys Tyr Phe Ala Pro Ala Asn Thr Leu Asp Glu Asn Leu
50 55 60

Glu Gly Glu Ala Ile Asp Phe Thr Gly Lys Leu Ile Ile Asp Glu Asn
65 70 75 80

Ile Tyr Tyr Phe Asp Asp Asn Tyr Arg Gly Ala Val Glu Trp Lys Glu
85 90 95

Leu Asp Gly Glu Met His Tyr Phe Ser Pro Glu Thr Gly Lys Ala Phe
100 105 110

Lys Gly Leu Asn Gln
115

<210> SEQ ID NO 8
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Clostridium difficile
<400> SEQUENCE: 8

Gly Phe Val Ser Ile Asn Asp Asn Lys His Tyr Phe Asp Asp Ser Gly
1 5 10 15

Val Met Lys Val Gly Tyr Thr Glu Ile Asp Gly Lys His Phe Tyr Phe
20 25 30

Ala Glu Asn Gly Glu Met Gln Ile Gly Val Phe Asn Thr Glu Asp Gly
35 40 45

Phe Lys Tyr Phe Ala His His Asn Glu Asp Leu Gly Asn Glu Glu Gly
50 55 60

-continued

Glu Glu Ile Ser Tyr Ser Gly Ile Leu Asn Phe Asn Asn Lys Ile Tyr
 65 70 75 80
 Tyr Phe Asp Asp Ser Phe Thr Ala Val Val Gly Trp Lys Asp Leu Glu
 85 90 95
 Asp Gly Ser Lys Tyr Tyr Phe Asp Glu Asp Thr Ala Glu Ala Tyr Ile
 100 105 110
 Gly Leu Ser Leu
 115

<210> SEQ ID NO 9
<211> LENGTH: 118
<212> TYPE: PRT
<213> ORGANISM: Clostridium difficile
<400> SEQUENCE: 9
Gly Phe Val Thr Ile Asn Asp Lys Val Phe Tyr Phe Ser Asp Ser Gly
 1 5 10 15
Ile Ile Glu Ser Gly Val Gln Asn Ile Asp Asp Asn Tyr Phe Tyr Ile
 20 25 30
Asp Asp Asn Gly Ile Val Gln Ile Gly Val Phe Asp Thr Ser Asp Gly
 35 40 45
Tyr Lys Tyr Phe Ala Pro Ala Asn Thr Val Asn Asp Asn Ile Tyr Gly
 50 55 60
Gln Ala Val Glu Tyr Ser Gly Leu Val Arg Val Gly Glu Asp Val Tyr
 65 70 75 80
Tyr Phe Gly Glu Thr Tyr Thr Ile Glu Thr Gly Trp Ile Tyr Asp Met
 85 90 95
Glu Asn Glu Ser Asp Lys Tyr Tyr Phe Asn Pro Glu Thr Lys Ala
 100 105 110
Cys Lys Gly Ile Asn Leu
 115

<210> SEQ ID NO 10
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Clostridium difficile
<400> SEQUENCE: 10
Gly Leu Ile Ser Phe Glu Asn Asn Asn Tyr Tyr Phe Asn Glu Asn Gly
 1 5 10 15
Glu Met Gln Phe Gly Tyr Ile Asn Ile Glu Asp Lys Met Phe Tyr Phe
 20 25 30
Gly Glu Asp Gly Val Met Gln Ile Gly Val Phe Asn Thr Pro Asp Gly
 35 40 45
Phe Lys Tyr Phe Ala His Gln Asn Thr Leu Asp Glu Asn Phe Glu Gly
 50 55 60
Glu Ser Ile Asn Tyr Thr Gly Trp Leu Asp Leu Asp Glu Lys Arg Tyr
 65 70 75 80
Tyr Phe Thr Asp Glu Tyr Ile Ala Ala Thr Gly Ser Val Ile Ile Asp
 85 90 95
Gly Glu Glu Tyr Tyr Phe Asp Pro Asp Thr Ala Gln Leu Val Ile Ser
 100 105 110

Glu

<210> SEQ ID NO 11
<211> LENGTH: 213
<212> TYPE: PRT

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 11

Glu	Ile	Val	Leu	Thr	Gln	Ser	Pro	Gly	Thr	Leu	Ser	Leu	Ser	Pro	Gly
1					5				10					15	

Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Ser	Val	Ser	Ser	Ser
	20					25						30			

Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu
35				40					45						

Ile	Tyr	Gly	Ala	Ser	Ser	Arg	Ala	Thr	Gly	Ile	Pro	Asp	Arg	Phe	Ser
50					55				60						

Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Arg	Leu	Glu
65					70			75			80				

Pro	Glu	Asp	Phe	Ala	Val	Tyr	Tyr	Cys	Gln	Gln	Tyr	Gly	Ser	Ser	Thr
85					90				95						

Trp	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg	Thr	Val	Ala
	100					105				110					

Ala	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser
115					120				125						

Gly	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu
130					135				140						

Ala	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser
145					150			155		160					

Gln	Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu
165					170			175							

Ser	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val
180					185			190							

Tyr	Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys
195					200			205							

Ser	Phe	Asn	Arg	Gly											
210															

<210> SEQ_ID NO 12

<211> LENGTH: 221

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 12

Glu	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Ser	Gly	Glu
1					5			10		15					

Ser	Leu	Lys	Ile	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Ser	Phe	Thr	Ser	Tyr
20					25				30						

Trp	Ile	Gly	Trp	Val	Arg	Gln	Met	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Met
35					40				45						

Gly	Ile	Phe	Tyr	Pro	Gly	Asp	Ser	Ser	Thr	Arg	Tyr	Ser	Pro	Ser	Phe
50					55			60							

Gln	Gly	Gln	Val	Thr	Ile	Ser	Ala	Asp	Lys	Ser	Val	Asn	Thr	Ala	Tyr
65					70			75		80					

Leu	Gln	Trp	Ser	Ser	Leu	Lys	Ala	Ser	Asp	Thr	Ala	Met	Tyr	Tyr	Cys
85					90			95							

Ala	Arg	Arg	Arg	Asn	Trp	Gly	Asn	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly
100					105			110							

Thr	Met	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe
115					120			125							

Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

-continued

130	135	140
-----	-----	-----

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
 145 150 155 160

Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu
 165 170 175

Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
 180 185 190

Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro
 195 200 205

Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser
 210 215 220

<210> SEQ ID NO 13

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Hex-His tag

<400> SEQUENCE: 13

His His His His His His
 1 5

<210> SEQ ID NO 14

<211> LENGTH: 268

<212> TYPE: PRT

<213> ORGANISM: Clostridium difficile

<400> SEQUENCE: 14

Gly Leu Ile Tyr Ile Asn Asp Ser Leu Tyr Tyr Phe Lys Pro Pro Val
 1 5 10 15

Asn Asn Leu Ile Thr Gly Phe Val Thr Val Gly Asp Asp Lys Tyr Tyr
 20 25 30

Phe Asn Pro Ile Asn Gly Gly Ala Ala Ser Ile Gly Glu Thr Ile Ile
 35 40 45

Asp Asp Lys Asn Tyr Tyr Phe Asn Gln Ser Gly Val Leu Gln Thr Gly
 50 55 60

Val Phe Ser Thr Glu Asp Gly Phe Lys Tyr Phe Ala Pro Ala Asn Thr
 65 70 75 80

Leu Asp Glu Asn Leu Glu Gly Glu Ala Ile Asp Phe Thr Gly Lys Leu
 85 90 95

Ile Ile Asp Glu Asn Ile Tyr Tyr Phe Asp Asp Asn Tyr Arg Gly Ala
 100 105 110

Val Glu Trp Lys Glu Leu Asp Gly Glu Met His Tyr Phe Ser Pro Glu
 115 120 125

Thr Gly Lys Ala Phe Lys Gly Leu Asn Gln Ile Gly Asp Tyr Lys Tyr
 130 135 140

Tyr Phe Asn Ser Asp Gly Val Met Gln Lys Gly Phe Val Ser Ile Asn
 145 150 155 160

Asp Asn Lys His Tyr Phe Asp Asp Ser Gly Val Met Lys Val Gly Tyr
 165 170 175

Thr Glu Ile Asp Gly Lys His Phe Tyr Phe Ala Glu Asn Gly Glu Met
 180 185 190

Gln Ile Gly Val Phe Asn Thr Glu Asp Gly Phe Lys Tyr Phe Ala His
 195 200 205

His Asn Glu Asp Leu Gly Asn Glu Glu Gly Glu Ile Ser Tyr Ser
 210 215 220

-continued

Gly	Ile	Leu	Asn	Phe	Asn	Asn	Lys	Ile	Tyr	Tyr	Phe	Asp	Asp	Ser	Phe
225				230				235				240			
Thr	Ala	Val	Val	Gly	Trp	Lys	Asp	Leu	Glu	Asp	Gly	Ser	Lys	Tyr	Tyr
				245		250						255			
Phe	Asp	Glu	Asp	Thr	Ala	Glu	Ala	Tyr	Ile	Gly	Leu				
				260		265									

We claim:

1. An isolated crystal comprising a bezlotoxumab Fab fragment complexed to a polypeptide comprising SEQ ID NO: 14, wherein said polypeptide is *C. difficile* toxin B amino acids 1834-2101 and wherein the crystal is characterized by:
space group: P21; and
unit cell dimensions: a=79.413 Å, b=134.659 Å,
c=102.579 Å, $\alpha=\gamma=90^\circ$, $\beta=112.559^\circ$.
2. The crystal of claim 1, wherein said polypeptide is characterized by structure coordinates comprising a root mean square deviation (RMSD) of conserved residue back-

bone atoms of less than about 2.0 angstroms when superimposed on backbone atoms described by structural coordinates of Table 1.

15 3. A method for producing a crystalline complex of claim 1 comprising incubating a first solution comprising 10 mg/ml of the complex, 5 mM phosphate, pH 7.4, 68.5 mM sodium chloride, 1.35 mM potassium chloride and 2.2% polyethylene glycol 4000 in a sealed container in close proximity to a second solution comprising 4.4 polyethylene glycol 4000.

20 4. The method of claim 3 wherein the first solution is in the form of a drop which is hanging or sitting on a surface.

* * * * *